{
  "1000196":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Ventral view of extracorporeal vasculature of Botryllus schlosseri immediately following injection of 1 ??l of 0.1 ??g/ml recombinant GFP protein into the circulation and (A???) 24 hours post injection. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2067,
            "y2":751
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Ventral view of extracorporeal vasculature of Botryllus schlosseri immediately following injection of 1 ??l of 0.1 ??g/ml recombinant mCherry protein into the circulation and (B???) 24 hours post injection. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2067,
            "y2":751
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Ventral view of mCherry labeled vasculature within a single system of Botryllus schlosseri and (C???) vascular labeling during a takeover event with regressing zooids (rz) and the appearance of mCherry labeling in ventral island phagocytes (arrows). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2067,
            "y2":751
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Ventral view of Botryllus schlosseri colony co-injected with Alexa Fluor 488 conjugated BSA and Alexa Fluor 594 conjugated Bio-Particles showing labeled vessels and phagocytic island populations (arrows). (D???) Same co-injected Botryllus schlosseri colony following apoptotic clearance of regressing zooids showing double labeling of phagocytic island populations (arrows). Scale bars: A???B???=???200 ??m, C???=???800 ??m, C??????=???1 mm, D???=???800 ??m."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2067,
            "y2":751
          }
        ]
      }
    }
  },
  "1002182":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) E106 MAb binding to DENV-1 RVPs by bio-layer interferometry. E106 MAb binds with high apparent affinity to DENV-1 RVPs (KDapp of 13??2 nM) with a slow dissociation (t1/2>400 sec). Raw data is in red and fits are in gray. "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":919,
            "y2":565
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Direct binding of E106 Fab to DENV-1 RVPs. Results are representative of several independent experiments that showed low affinity binding (KD of >1 ??M) and fast off-rate kinetics (t1/2C) MAb and "
        ],
        "rois":[
          {
            "x":7,
            "y":610,
            "x2":2017,
            "y2":1201
          },
          {
            "x":1032,
            "y":7,
            "x2":1985,
            "y2":575
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Fab to DENV-1 RVPs. E103 MAb and Fab binding to DENV-1 RVPs are comparable, with a calculated apparent KDapp of 0.8??0.1 nM and KD of 7??1 nM, respectively, as expected for a predominantly monovalent interaction. Raw data is in blue (E103 MAb) and purple (E103 Fab) and fits are in gray. Results are representative of at least two independent experiments."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1003206":{
    
  },
  "1003207":{
    
  },
  "1003209":{
    
  },
  "1005730":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(E) did not have significant difference in plasma from controls and PTSD patients. The boxed data included 50% of measurements at medium level, the line in the box was the average value and the data beyond the upper line were the outliers. p values were presented."
        ],
        "rois":[
          {
            "x":22,
            "y":19,
            "x2":1679,
            "y2":4329
          },
          {
            "x":1914,
            "y":1470,
            "x2":3606,
            "y2":2799
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), IL-17 "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B), PDGF-bb "
        ],
        "rois":[
          {
            "x":1971,
            "y":19,
            "x2":3593,
            "y2":1356
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), and RANTES "
        ],
        "rois":[
          {
            "x":1971,
            "y":19,
            "x2":3593,
            "y2":1356
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) were found to be significantly different between controls and PTSD patients, whereas other cytokines such as IL-4 "
        ],
        "rois":[
          {
            "x":1971,
            "y":19,
            "x2":3593,
            "y2":1356
          }
        ]
      }
    }
  },
  "1005915":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A. Four siRNAs RET/PTC3 along with siRNA Control (for sequences see: Table S1 and Fig. S2) were transfected at 50 nM with Lipofectamine 2000 in RP3 cell line. After 24 h, 48 h and 72 h post-transfection, RNA was extracted and the RET/PTC3 mRNA expression was analyzed by RT-qPCR and recorded as relative mRNA expression of treated compared to non-treated "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1669,
            "y2":975
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and Western blot "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1669,
            "y2":975
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C, D). Quantification of Western blot was performed by scanning films with Gel Doc XR+ Systems images and analysing results by Bio-Rad Image Lab software scanning (Bio-Rad Laboratories). The results are expressed as relative RET protein expression compared to non-treated cells. All data were analysed by one-way ANOVA followed by LSD post-hoc test. Stars represent the significant difference between the treatment groups compared to non-treated cells. *???=???pp"
        ],
        "rois":[
          {
            "x":303,
            "y":980,
            "x2":1340,
            "y2":1542
          }
        ]
      },
      "NT":{
        "descriptions":[
          "(NT) cells. B, C and D. siRNA RET/PTC3 #2 was transfected with Lipofectamine (Lipo) at 10 nM, 25 nM, 50 nM and 100 nM concentrations in RP3 cells. After 24 h post-transfection, RNA and protein were extracted and RET/PTC3 mRNA and protein expressions were respectively analyzed by RT-qPCR "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(C, D). Quantification of Western blot was performed by scanning films with Gel Doc XR+ Systems images and analysing results by Bio-Rad Image Lab software scanning (Bio-Rad Laboratories). The results are expressed as relative RET protein expression compared to non-treated cells. All data were analysed by one-way ANOVA followed by LSD post-hoc test. Stars represent the significant difference between the treatment groups compared to non-treated cells. *???=???pp"
        ],
        "rois":[
          {
            "x":303,
            "y":980,
            "x2":1340,
            "y2":1542
          }
        ]
      }
    }
  },
  "1005916":{
    "Figure_2.tif":{
      "I":{
        "descriptions":[
          "(I) and BHP10-3 cells "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":2033,
            "y2":504
          }
        ]
      },
      "II":{
        "descriptions":[
          "(II). After 24 h, 48 h and 72 h post-transfection, RT-qPCR (IA, IIA) and Western blot (IC, IIC) were performed for relative mRNA and protein expressions. Quantification of relative RET protein expression (IB, IIB) was performed by Bio-Rad Image Lab software scanning, results are expressed as relative RET protein expression compared to non-treated cells. Data were analysed by one-way ANOVA followed by LSD Post-hoc test. Stars represent the significant difference between the treatment groups compared to non-treated cells. ***???=???p"
        ],
        "rois":[
          {
            "x":7,
            "y":488,
            "x2":2051,
            "y2":1299
          },
          {
            "x":7,
            "y":7,
            "x2":2033,
            "y2":504
          }
        ]
      }
    }
  },
  "1006831":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A). Representative flow cytometry dot plots showing binding of Alexafluor488-conjugated cercarial E/S products (0-3hRP), Alexafluor488-conjugated egg E/S products (ESP), Alexafluor488-conjugated zymosan-coated bio-particles, and Fluorescein-conjugated D-mannose, to SSChi monocytes following incubation for 60 mins. Populations of ligand+ cells were identified for each ligand via a ligand+ gate set relative to cells incubated without antigen (No ligand control). Plots of ligand binding are representative of data accrued from all study participants. Numerical values are the median for binding of each ligand ?? the range"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":915,
            "y2":1558
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B). Data shows the proportions of SSChi cells in the ligand+ gate for each participant relative to cells from the same individuals incubated without ligands (horizontal bars indicate the median value; Paired Wilcoxon test, ***p+versus no ligand control, n???=???41)."
        ],
        "rois":[
          {
            "x":12,
            "y":1597,
            "x2":857,
            "y2":2353
          }
        ]
      }
    }
  },
  "1006832":{
    "Figure_3.tif":{
      "B":{
        "descriptions":[
          ", B) Alexafluor488-conjugated egg E/S products"
        ],
        "rois":[
          {
            "x":14,
            "y":16,
            "x2":2829,
            "y2":1085
          }
        ]
      },
      "C":{
        "descriptions":[
          ", C) Alexafluor488-conjugated zymosan-coated bio-particles, and D) Fluorescein-conjugated D-mannose, to different monocyte sub-sets following incubation for 60 mins. Populations of ligand+ cells were identified for each ligand relative to cells incubated without antigen (Fig.2A). Data was accrued from all study participants (n???=???41; horizontal bars indicating the median value; Paired Wilcoxon test, ***p"
        ],
        "rois":[
          {
            "x":52,
            "y":1204,
            "x2":2829,
            "y2":2245
          }
        ]
      }
    }
  },
  "1006883":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) gmmdripa, "
        ],
        "rois":[
          {
            "x":163,
            "y":7,
            "x2":820,
            "y2":518
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) gmmdripb and "
        ],
        "rois":[
          {
            "x":7,
            "y":483,
            "x2":881,
            "y2":2062
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) gmmaqp5. Transcript levels were determined by qRT-PCR analysis. The data were analyzed with software version 3.1 (Bio-Rad). Data represent the mean ?? SE for four samples and was normalized to tubulin. * indicates that the expression is significantly higher (P"
        ],
        "rois":[
          {
            "x":7,
            "y":483,
            "x2":881,
            "y2":2062
          }
        ]
      }
    }
  },
  "1007067":{
    
  },
  "1007070":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) Tissue specific RT-PCR. Data represents three replicates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2381,
            "y2":1755
          }
        ]
      },
      "B":{
        "descriptions":[
          "( B) Time course of mgp1???10 and asmase1 expression during the first two tsetse gonotrophic cycles. Transcript levels were determined by qPCR using a CFX PCR detection system (Bio-Rad, Hercules) and data were analyzed with CFX manager software version 3.1 (Bio-Rad). Data represents the mean ?? SE of three replicates and was normalized to tubulin."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2381,
            "y2":1755
          },
          {
            "x":0,
            "y":1756,
            "x2":2381,
            "y2":2898
          }
        ]
      }
    }
  },
  "1015055":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A. Nuclear fractions from BEAS2B cells treated with SKI-II (1 ??M) at increasing times (10???120 min) were analysed for Keap1 and Nrf2 expression and normalized using TBP (nuclear). Keap1 bands at 140 kDa and 69 kDa were analysed as fold change over non-treatment of the 69 kDa band. *** pB. Cells were treated with cycloheximide (CXM) and SKI-II (1 ??M) at different time points (1 to 24 h) and whole cell extracts were analysed for Keap1 expression normalized against ??-actin. Keap1 bands at 140 kDa and 69 kDa were analysed as fold change over non-treatment of the 69 kDa band. *** pC. Whole-cell extracts from BEAS2B cells that were treated with SKI-II (1 ??M) for 2 and 4 h were immunoprecipitated "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP) using a Keap1 antibody. IP Keap1 was analysed by immunoblotting for ubiquitin modification, p62 and Keap1 expression. IgG: Mouse immunoglobulin control (no cell lysates). Ub: ubiquitin. Hmw: High molecular weight"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D. Whole-cell extracts from BEAS2B cells that were pre-treated with arachidonic acid (AA; 10 ??M) or biotynilated arachidonic acid (AA-Bio; 10 ??M) for 30 min were treated with SKI-II (1 ??M) for 2.5 h and immunoprecipitated using Neutravidin Agarose Resin (IP-NA). IP-NA was analysed by immunoblotting for Keap1 expression"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. Whole-cell extracts from BEAS2B cells treated with SKI-II (SK; 1 ??M), sulforaphane (SF; 5 ??M) or CDDO-Imidazolide (CD; 50 nM) for 4 h, 8 h and 24 h were analysed by immunoblotting for Nrf2, Keap1, NQO1, HO-1 and ??-actin. Results are representative of 3 independent experiments and are means and S.E. of triplicates."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      }
    }
  },
  "1015201":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) D283 cells engineered to express IL13R??2 (D283- IL13R??2) (blue histograms) and D283 parental (black histograms) cells were evaluated by flow cytometry for expression of constitutive IL13R??2 using the IL13R??2-specific antibody AF146, and biotinylated recombinant human IL-13 (IL13-bio) followed by PE-conjugated strepavidin (SA-PE). Data are representative of 2 separate experiments. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1043,
            "y2":336
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) U251T (grown in the absence of cytokines) were evaluated by flow cytometry for constitutive IL13R??2 expression using AF146, and for binding to IL13-bio/SA-PE in the presence and absence of 10-fold molar excess of recombinant human IL-4 or IL-13. Black histograms represent staining with istoype control antibody or SA-PE alone. Data are representative of 2 separate experiments. "
        ],
        "rois":[
          {
            "x":11,
            "y":381,
            "x2":1290,
            "y2":752
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) THP-1 and PBT008 grown in media alone (black histograms) or induced overnight with TNF and IL-4 (red histograms) were analyzed by flow cytometry for expression of constitutive IL13R??2 (AF146), for expression of the induced antigen (B-D13-PE), and for binding to IL13-bio/SA-PE. Data are representative of 3 separate experiments. "
        ],
        "rois":[
          {
            "x":703,
            "y":839,
            "x2":1212,
            "y2":1446
          },
          {
            "x":9,
            "y":809,
            "x2":395,
            "y2":1108
          },
          {
            "x":416,
            "y":842,
            "x2":689,
            "y2":1108
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IL13-zetakine+ CD8+ CTL recognize and kill U251T glioma targets expressing constitutive IL13R??2 (AF146-positive), but not cytokine-induced PBT003 cells (B-D13-positive). Percentage specific lysis (mean ?? S.D.) of triplicate wells is depicted. *, p???0.0002 using an unpaired Student's t-test to compare U251T vs. PBT003-4 targets. #, p>0.05 using an unpaired Student's t-test to compare PBT003-4 targets with and without overnight cytokine stimulation. Data are representative of at least 2 separate experiments."
        ],
        "rois":[
          {
            "x":10,
            "y":1132,
            "x2":1299,
            "y2":2678
          },
          {
            "x":416,
            "y":1132,
            "x2":689,
            "y2":1446
          }
        ]
      }
    }
  },
  "1016130":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) GI transit distribution histograms and calculated geometric center ",
          "(A, C, D) with Bonferroni correction for multiple comparison ",
          "(A)."
        ],
        "rois":[
          {
            "x":0,
            "y":502,
            "x2":2377,
            "y2":2520
          }
        ]
      },
      "GC":{
        "descriptions":[
          "(GC) values from the histograms. GC has been frequently and reliably used to estimate GI transit. Stom, stomach; S1???S10, small intestine segments 1???10; C, caecum; L1???2, Large intestine segments 1???2. Control (PBS-treated), day 1, 3 and 7 after ??CD3 injection (n???=???3 for each group of mice). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Carbachol (CCh)-stimulated dose-response curves of contractile response of SI strips prepared from day 7 with or without ??CD3 treatment (n???=???7). CCh was added cumulatively. "
        ],
        "rois":[
          {
            "x":0,
            "y":502,
            "x2":2377,
            "y2":2520
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CCh-stimulated dose-response curves of contractile response of SI longitudinal SMCs prepared from day 7 with or without ??CD3 treatment. The respective concentration of CCh was added separately (n???=???4). ",
          "(A, C, D) with Bonferroni correction for multiple comparison "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2377,
            "y2":501
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Time-dependent changes of mRNA and protein levels of various Th-cytokines in the intestinal tissue measured by quantitative RT-PCR and Bio-plex assay, respectively (n???=???4???8). Numerical data represent means ?? s.e.m. *PB), Student's t-test ",
          "(A, C, D) with Bonferroni correction for multiple comparison "
        ],
        "rois":[
          {
            "x":0,
            "y":502,
            "x2":2377,
            "y2":2520
          }
        ]
      }
    }
  },
  "1017578":{
    
  },
  "1017674":{
    
  },
  "1018902":{
    
  },
  "1018923":{
    
  },
  "1021811":{
    
  },
  "1022296":{
    
  },
  "1022420":{
    
  },
  "1022423":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          ". E. Quantitation of DNA binding by BirA (Quantity One software). The results show the average of three independent experiments, and the error bars denote standard error of the mean"
        ],
        "rois":[
          {
            "x":10,
            "y":255,
            "x2":750,
            "y2":862
          },
          {
            "x":823,
            "y":254,
            "x2":1580,
            "y2":1524
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. BirA binding to non-operator DNA (a 125 bp internal fragment of the yngHB gene that encodes BLAP)"
        ],
        "rois":[
          {
            "x":16,
            "y":1547,
            "x2":648,
            "y2":2113
          },
          {
            "x":10,
            "y":885,
            "x2":748,
            "y2":1507
          }
        ]
      },
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":830,
            "y2":233
          },
          {
            "x":832,
            "y":20,
            "x2":1136,
            "y2":233
          }
        ]
      },
      "I":{
        "descriptions":[
          ". I"
        ],
        "rois":[
          {
            "x":1111,
            "y":1547,
            "x2":1584,
            "y2":2116
          }
        ]
      },
      "G":{
        "descriptions":[
          ". G. BirA binding to bioO without hydroxylamine treatment. Bio-5???-AMP accumulates in the active site during expression in E. coli and survives purification of BirA"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":830,
            "y2":233
          },
          {
            "x":10,
            "y":885,
            "x2":748,
            "y2":1507
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. subtilis has three predicted BirA DNA binding sites: 5??? UTR of the bioWAFDBI operon, 5??? UTR of yuiG, and 5??? UTR of the yhfUTS operon. Conserved residues are highlighted in red and similar residues are highlighted in yellow. B C and D",
          ". B. subtilis BirA binding to bioO, the yuiG operator and the yhfU operator, respectively. Note that only in the presence of biotin and ATP is binding observed",
          ". B. subtilis BirA binding to a half site of the inverted repeat of B. subtilis bioO. Note lane 2 is positive control full-length bioO",
          ". B. subtilis BirA binding to E. coli bioO. A collection of all putative BirA binding sites in diverse bacteria can be found in the RegPrecise database (http://regprecise.lbl.gov/RegPrecise/)."
        ],
        "rois":[
          
        ]
      },
      "H":{
        "descriptions":[
          ". H"
        ],
        "rois":[
          {
            "x":659,
            "y":1545,
            "x2":1092,
            "y2":2115
          },
          {
            "x":10,
            "y":885,
            "x2":748,
            "y2":1507
          }
        ]
      }
    }
  },
  "1022424":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. Sequence alignment of the B. subtilis biotinylated proteins. Conserved residues are in white text and highlighted in red and similar residues are in red text and boxed in blue. The black arrow indicates the conserved lysine residue that becomes biotinylated"
        ],
        "rois":[
          {
            "x":12,
            "y":10,
            "x2":1667,
            "y2":266
          },
          {
            "x":12,
            "y":279,
            "x2":1134,
            "y2":455
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Mass spectrometry values for purified acceptor proteins AccB-86, PyC-77, and BLAP"
        ],
        "rois":[
          {
            "x":10,
            "y":307,
            "x2":1752,
            "y2":1287
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Thin layer chromatographic analysis of B. subtilis BirA ligase reaction: synthesis of Bio-5???-AMP and transfer of biotin to AccB-86, PyC-77, and BLAP."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1022435":{
    "Figure_8.tif":{
      "E":{
        "descriptions":[
          ", E. coli ??2-65 BirA, wild type B. subtilis BirA, and B. subtilis ??2-65 BirA",
          ". E. Quantitation of Bio-5???-AMP synthesis by wild type E. coli BirA",
          ", E. coli ??2-65 BirA, wild type B. subtilis BirA, and B. subtilis ??2-65 BirA. The results show the average of three independent experiments, and the error bars denote standard error of the mean",
          ", E. coli ??2-65 BirA, wild type B. subtilis BirA and B. subtilis ??2-65 BirA. The results show the average of three independent experiments, and the error bars denote standard error of the mean."
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":811,
            "y2":973
          },
          {
            "x":838,
            "y":10,
            "x2":1542,
            "y2":490
          },
          {
            "x":838,
            "y":1056,
            "x2":1542,
            "y2":1534
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. Quantitation of biotin transfer to E. coli AccB-87 or B. subtilis AccB-86 by wild type E. coli BirA"
        ],
        "rois":[
          {
            "x":848,
            "y":1578,
            "x2":1542,
            "y2":2055
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Thin layer chromatographic analysis of wild type B. subtilis BirA and B. subtilis BirA N-terminal deletions with and without the addition of acceptor protein AccB-86"
        ],
        "rois":[
          {
            "x":838,
            "y":10,
            "x2":1542,
            "y2":490
          },
          {
            "x":835,
            "y":533,
            "x2":1542,
            "y2":1011
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Quantitation of Bio-5???-AMP synthesis by wild type B. subtilis BirA and the B. subtilis BirA N-terminal deletion proteins. The results show the average of three independent experiments, and the error bars denote standard error of the mean"
        ],
        "rois":[
          {
            "x":835,
            "y":533,
            "x2":1542,
            "y2":1011
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Quantitation of biotin transfer to AccB-86 by wild type B. subtilis BirA and B. subtilis BirA N-terminal deletions. The results show the average of three independent experiments, and the error bars denote standard error of the mean"
        ],
        "rois":[
          {
            "x":838,
            "y":10,
            "x2":1542,
            "y2":490
          },
          {
            "x":838,
            "y":1056,
            "x2":1542,
            "y2":1534
          },
          {
            "x":835,
            "y":533,
            "x2":1542,
            "y2":1011
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Thin layer chromatographic analysis of wild type E. coli BirA"
        ],
        "rois":[
          {
            "x":838,
            "y":1056,
            "x2":1542,
            "y2":1534
          },
          {
            "x":101,
            "y":1058,
            "x2":800,
            "y2":2025
          }
        ]
      }
    }
  },
  "1022633":{
    
  },
  "1026968":{
    
  },
  "1027853":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) An aliquot of the purified LeIF was resolved by SDS polyacrylamide gel and stained with Coomassie brilliant blue. The positions of the Bio-Rad prestained marker (in kDa) are indicated at the left. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":279,
            "y2":498
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The identity of the protein LeIF was verified by using rabbit anti-LieIF primary polyclonal antibodies (1/1000 dilution)."
        ],
        "rois":[
          {
            "x":102,
            "y":109,
            "x2":279,
            "y2":498
          },
          {
            "x":280,
            "y":0,
            "x2":526,
            "y2":498
          }
        ]
      }
    }
  },
  "1032154":{
    
  },
  "1034218":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Anti-biofilm peptide 1018 at 5 ??g/ml directly prevented (p)ppGpp accumulation. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Treatment with peptide 1018 led to (p)ppGpp elimination within 30 min in P. aeruginosa PAO1 cells containing pre-accumulated (p)ppGpp due to SHX treatment. In panel A, bacteria were grown overnight in modified MOPS minimal medium containing 0.4% glucose, 2 mM phosphate (KH2PO4), and 0.2% CAA. For experiments evaluating the ability of the peptide to directly degrade (p)ppGpp in panel B, the cells were grown as described previously, induced with SHX and allowed to synthesize (p)ppGpp for 3 h prior to peptide treatment. After growth for both A and B, the cells were then diluted 1???20 in the same MOPS minimal medium except containing 0.4 mM phosphate (KH2PO4) and 500 ??M serine hydroxamate (SHX) to induce (p)ppGpp synthesis, in the presence or absence of peptide 1018 and cells were labelled with 10 ??Ci/ml 32P for 3 h. Samples were then extracted with frozen 13 M formic acid by three cycles of freeze-thaw. Aliquots of the supernatants were applied to 20??20 cm PEI cellulose TLC plates, resolved with 1.5 M KH2PO4, pH 3.4 for 4 h. After chromatography, nucleotides were visualized by autoradiography and quantified with a MolecularImager FX PhosphorImager and Quantity One software (Bio-Rad). Controls were performed to demonstrate that the ??relAspoT mutation also prevented (p)ppGpp formation."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1019,
            "y2":1586
          }
        ]
      }
    }
  },
  "1039259":{
    
  },
  "1039260":{
    
  },
  "1039261":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          "(a) weighted UniFrac algorithm and "
        ],
        "rois":[
          {
            "x":16,
            "y":101,
            "x2":1955,
            "y2":1498
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) unweighted UniFrac algorithm for treatments with bio-organic fertilizer (BIO), cattle manure compost (CM), Chinese medicine residue compost (CMR), general operation control (GCK) and pig manure compost (PM)."
        ],
        "rois":[
          {
            "x":2145,
            "y":15,
            "x2":4120,
            "y2":1589
          }
        ]
      }
    }
  },
  "1039263":{
    "Figure_5.tif":{
      "a":{
        "descriptions":[
          "(a), three of the most classified bacteria genera "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4133,
            "y2":1861
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) and banana Fusarium wilt disease incidence for treatments with bio-organic fertilizer (BIO), cattle manure compost (CM), Chinese medicine residue compost (CMR), general operation control (GCK) and pig manure compost (PM)."
        ],
        "rois":[
          {
            "x":0,
            "y":1862,
            "x2":4133,
            "y2":2273
          }
        ]
      }
    }
  },
  "1039264":{
    
  },
  "1040801":{
    
  },
  "1041039":{
    
  },
  "1044401":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) after the treatments shown at the top of each column. Postnatal day four (P4) IVDs were cultured for either five days (P4t5) or three days (P4t3), in either vehicle alone, BIO, or XAV939. The panels on the right of each row show quantitation of pixel intensity measurements from three independent experiments, each carried out in duplicate. F shows qPCR data from the same experiments. Scale bar in A-D???=???50 ??m, E???=???200 ??m. Nuclei are stained blue with POPO3-iodide. NP ???=??? nucleus pulposus, AF ???=??? annulus fibrosus, EP ???=??? end plate. (* p???0.05, ** p???0.01, *** p???0.001, NS???=??? not significant)."
        ],
        "rois":[
          {
            "x":15,
            "y":1741,
            "x2":479,
            "y2":2141
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), GLI1 "
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":475,
            "y2":465
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), BRA "
        ],
        "rois":[
          {
            "x":19,
            "y":2152,
            "x2":984,
            "y2":2654
          },
          {
            "x":885,
            "y":1741,
            "x2":1284,
            "y2":2168
          },
          {
            "x":1322,
            "y":1799,
            "x2":1911,
            "y2":2146
          },
          {
            "x":14,
            "y":12,
            "x2":1897,
            "y2":941
          },
          {
            "x":1358,
            "y":12,
            "x2":1882,
            "y2":489
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), SOX9 "
        ],
        "rois":[
          {
            "x":1036,
            "y":2166,
            "x2":1905,
            "y2":2655
          },
          {
            "x":885,
            "y":1741,
            "x2":1284,
            "y2":2168
          },
          {
            "x":483,
            "y":1741,
            "x2":883,
            "y2":2141
          },
          {
            "x":1374,
            "y":967,
            "x2":1904,
            "y2":1326
          },
          {
            "x":889,
            "y":945,
            "x2":1342,
            "y2":1345
          },
          {
            "x":15,
            "y":942,
            "x2":885,
            "y2":1342
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), and CHSO4 "
        ],
        "rois":[
          {
            "x":1036,
            "y":2166,
            "x2":1905,
            "y2":2655
          },
          {
            "x":16,
            "y":1343,
            "x2":1922,
            "y2":1740
          }
        ]
      }
    }
  },
  "1044402":{
    
  },
  "1044406":{
    "Figure_6.tif":{
      "B":{
        "descriptions":[
          "(B), BRA "
        ],
        "rois":[
          {
            "x":78,
            "y":481,
            "x2":628,
            "y2":1054
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), CHSO4 "
        ],
        "rois":[
          {
            "x":630,
            "y":482,
            "x2":1112,
            "y2":1053
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and ACAN "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2014,
            "y2":465
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E) after treatment of one-year-old IVDs with BIO. Right hand panels show quantitation of fluorescent intensities in control (blue bars) and BIO-treated (red bars) NP cells. The data represent three independent experiments, each carried out in duplicate. Scale bar in A and C ???=??? 50 ??m, and B, D and E ???=??? 200 ??m. In B - E nuclei are stained blue with POPO3-iodide. NP ???=??? nucleus pulposus, AF ???=??? annulus fibrosus, EP ???=??? end plate. (* p???0.05, ** p???0.01, *** p???0.001)."
        ],
        "rois":[
          {
            "x":1156,
            "y":560,
            "x2":1758,
            "y2":1543
          },
          {
            "x":632,
            "y":1054,
            "x2":1113,
            "y2":1536
          },
          {
            "x":69,
            "y":1057,
            "x2":1628,
            "y2":2508
          }
        ]
      }
    }
  },
  "1044407":{
    
  },
  "1044514":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A), Bio-Rad Avidity assay "
        ],
        "rois":[
          {
            "x":86,
            "y":52,
            "x2":4076,
            "y2":1859
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and LAg-Avidity enzyme immunoassay "
        ],
        "rois":[
          {
            "x":24,
            "y":1915,
            "x2":4151,
            "y2":5983
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Respective assay cut-offs are indicated by the black line. Data are shown for subsets of the evaluation panel."
        ],
        "rois":[
          {
            "x":24,
            "y":1915,
            "x2":4151,
            "y2":5983
          }
        ]
      }
    }
  },
  "1044515":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A). False recent ratios among long-term subtype B and ???non-B??? infected, ARV-na??ve individuals "
        ],
        "rois":[
          {
            "x":12,
            "y":16,
            "x2":3909,
            "y2":1777
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Misclassification in the ???challenge specimens??? set "
        ],
        "rois":[
          {
            "x":3999,
            "y":26,
            "x2":5968,
            "y2":1779
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Only significant p-values ("
        ],
        "rois":[
          {
            "x":3999,
            "y":26,
            "x2":5968,
            "y2":1779
          }
        ]
      }
    }
  },
  "1044864":{
    
  },
  "1047744":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A) TryS expression in L. donovani parasites in the presence of H2O2 (10???200 ??M) was analysed by western blot. H2O2 treated parasites showed increased expression level of LdTryS, whereas the ??-actin expression level did not change significantly. The experiments were repeated twice in duplicates and quantitation was done by densitometric analysis using Quantity One (Bio-Rad). Band intensity is presented as fold increase/decrease of LdTryS expression. "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":1638,
            "y2":1257
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) LdTryS expression level was analyzed by semiquantitative RT-PCR, and PCR product stained with ethidium bromide and photographed. PCR of ??-tubulin was used as housekeeping control that showed uniform expression pattern irrespective of H2O2 concentration."
        ],
        "rois":[
          {
            "x":49,
            "y":1444,
            "x2":1332,
            "y2":1977
          }
        ]
      }
    }
  },
  "1048647":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) ChIP and qPCR analysis on chromatin isolated from GSK3??+/+ MEFs and GSK3?????/??? MEFs synchronized in G1, untreated or treated with MG132, at the rRNA gene promoter with antibodies against NM1 and GSK3?? (CGR11). Significances p(???MG132)???=???2.2e-05 (***) and p(+MG132)???=???3.0e-05 (***) were respectively calculated against the NM1 values obtained in GSK3??+/+ MEFs not treated with MG132. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Immunoblots of total lysates from GSK3??+/+ MEFs untreated or treated with the kinase inhibitor BIO. Analysis was performed with antibodies to NM1, actin, and the GSK3?? antibodies 27C10 and CGR11 as indicated. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Cell cycle profile analyzed at the indicated time points, after release from a G1 arrest by serum starvation, on immunoblots of the corresponding lysates for NM1, cyclin A, cyclin E, p27 and ??-actin. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) ChIP and qPCR analysis on chromatin isolated from GSK3??+/+ MEFs at G1, untreated or treated with BIO, at the rRNA gene promoter with antibodies against NM1 and GSK3?? (CGR11). The significance p???=???0.009 (**) was calculated against the NM1 values obtained in GSK3??+/+ MEFs not treated with BIO."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Relative NM1 mRNA levels in GSK3??+/+ MEFs and GSK3?????/??? MEFs monitored by RT-qPCR using ??-tubulin mRNA as internal control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) rRNA synthesis in GSK3??+/+ MEFs and GSK3?????/??? MEFs arrested in G1 by serum starvation. For the analysis, relative 45S pre-rRNA levels were monitored from total RNA preparations by RT-qPCR using tubulin mRNA as internal control [p???=???3.2e-09 (***)]. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Lysates from GSK3?????/??? MEFs untreated or treated with the proteasome inhibitor MG132, released from a G1 block were collected at the indicated time points and analyzed on immunoblots for NM1 and ??-actin. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2606
          }
        ]
      }
    }
  },
  "1049239":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Visceral adipose tissues (VAT) weight and adiposity of mice after 12-week HFD feeding. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2755,
            "y2":1816
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Nuclear factor-??B (NF??B) activation in VAT of HFD mice. Western blotting was performed with antibodies against p65 and phosphorylated p65 (Pp65; n???=???3). C, control; T, IFNT. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2755,
            "y2":1816
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Activation of c-Jun N-terminal kinase (JNK) signaling pathway in VAT of HFD mice. Fluorescent-labeled beads conjugated with antibodies against total JNK (tJNK) and phosphorylated JNK (phospho JNK) in VAT were measured using the Bio-Plex?? MAGPIX??? multiplex reader. MFI, medium fluorescence intensity. Data are presented as mean ?? SEM. *P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2755,
            "y2":1816
          }
        ]
      }
    }
  },
  "1049240":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Gene expression of cytokines. Cytokines, chemokine (C-C motif) ligand 2 (CCL2) and adipokineadiponectin in VAT of HFD mice measured using quantitative reverse transcriptase-PCR (qRT-PCR; normalized to ??-actin). IL, interleukin; TNF-??, tumor necrosis factor-??. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2428,
            "y2":1040
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Concentration of IL-1??, IL-6, TNF-??, CCL2, and IL-10 in plasma of HFD mice were measured using the Bio-Plex???Cytokine Assay (Bio-Rad). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2428,
            "y2":1040
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Adipose tissue insulin signaling. After 16-h fasting, mature adipocytes were collected from VAT and treated with insulin (100 nM) for 15 min. Total AKT (tAKT) and phosphorylated AKT (pAKT) protein in adipocytes were measured using Bio-Plex Cell Signaling Magnetic Assays (Bio-Rad). Data are presented as mean ?? SEM. *P"
        ],
        "rois":[
          {
            "x":0,
            "y":1041,
            "x2":2428,
            "y2":1729
          }
        ]
      }
    }
  },
  "1049244":{
    
  },
  "1049278":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) T47D cells were infected with lentivirus particles that expressed Vav1-specific shRNA or shRNA with a scramble sequence (served as a control). The homogenous cells were first synchronized to G0/G1 phase and then treated with DMSO as control or E2 (10???7 mol/L) for 36 h before harvest. The expression of Vav1 and Cyclin D1 were analyzed by Western Blot with indicated antibodies respectively. The density of the bands was quantitated by Quantity One software (Bio-Rad, version 4.4.0, CA, USA). The bar chart represents the normalized protein level of Cyclin D1 to tubulin of three independent experiments. ???**??? indicates P2 treatment of Control by unpaired student T test. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1616,
            "y2":3698
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Another aliquots of above cells were stained by PI and analyzed by flow cytometer for DNA contents. The decrease in the percentage of cells in G0/G1-phase before and after the treatment by DMSO or E2 was calculated and plotted as y-axis and labeled on the bar graph. The differences between two T47D-Ctrl and T47D-ShVav1 cells were also marked. The data represented the mean ??S.D. of three independent experiments. ???**??? indicates P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1616,
            "y2":3698
          }
        ]
      }
    }
  },
  "1049641":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Bio flap."
        ],
        "rois":[
          {
            "x":12,
            "y":344,
            "x2":738,
            "y2":807
          },
          {
            "x":774,
            "y":388,
            "x2":1314,
            "y2":744
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) rectangular, "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":696,
            "y2":224
          }
        ]
      },
      "V":{
        "descriptions":[
          "(V) curved and tapered cross-section. Robojelly with "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) tapered and "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) no flap (0% flap) and "
        ],
        "rois":[
          {
            "x":774,
            "y":67,
            "x2":1306,
            "y2":351
          }
        ]
      }
    }
  },
  "1049654":{
    
  },
  "1049657":{
    
  },
  "1049661":{
    "Figure_13.tif":{
      "A":{
        "descriptions":[
          "(A) Non-dimensional circulation of the first peak as a function of flap length for ?????=???15. This does not include the bio flap. The normalize standard deviation is 0.23. "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1217,
            "y2":1085
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Normalized standard deviation of first peak circulation as a function of ??."
        ],
        "rois":[
          {
            "x":1286,
            "y":14,
            "x2":2503,
            "y2":1089
          }
        ]
      }
    }
  },
  "1053304":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1144,
            "y2":695
          },
          {
            "x":1233,
            "y":4,
            "x2":2048,
            "y2":857
          }
        ]
      },
      "S":{
        "descriptions":[
          ". S. enterica encodes a one-enzyme and a two-enzyme pathway for acetate activation. The one-enzyme pathway is composed of acetyl-CoA synthetase (Acs), whose activity is modulated post-translationally by the protein acetyltransferase (Pat) and sirtuin deacetylase (CobB) enzymes. The two-enzyme pathway is comprised of acetate kinase (Ack) and phosphotransacetylase (Pta)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. Growth behavior of ??acs ??pta S. enterica strain JE13238 as a function of SlAcsWT. Experiments were performed on NCE minimal medium supplemented with acetate (10 mM), at 37??C using a microtiter plate and a plate reader (Bio-Tek Instruments). Synthesis of SlAcsWT was ectopically encoded (plasmid pSlAcs6) and induced using L-(+)-arabinose (5 mM). Cloning vector (pBAD30) lacking S. lividans acs+ was used as negative control. All S.D. "
        ],
        "rois":[
          {
            "x":1233,
            "y":4,
            "x2":2048,
            "y2":857
          }
        ]
      }
    }
  },
  "1054887":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A), kidney "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1942,
            "y2":699
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), and spleen "
        ],
        "rois":[
          {
            "x":10,
            "y":791,
            "x2":892,
            "y2":1314
          },
          {
            "x":925,
            "y":792,
            "x2":1241,
            "y2":1314
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). All cytokine concentrations were normalized to the amount of the respective tissue that was homogenized in each sample. Error bars represent standard deviations. Statistical significance is indicated by * for p** for p"
        ],
        "rois":[
          {
            "x":9,
            "y":1351,
            "x2":526,
            "y2":2008
          },
          {
            "x":558,
            "y":1356,
            "x2":892,
            "y2":2008
          },
          {
            "x":923,
            "y":791,
            "x2":1942,
            "y2":2008
          }
        ]
      }
    }
  },
  "1054920":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) 133 genes that are up-regulated in the ??iscR mutant relative to the wild type and "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":995,
            "y2":678
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 92 that are down-regulated."
        ],
        "rois":[
          {
            "x":7,
            "y":686,
            "x2":995,
            "y2":1344
          }
        ]
      }
    }
  },
  "1055487":{
    "Figure_S1.tif":{
      "TL":{
        "descriptions":[
          "(TL) and visceral leishmaniasis "
        ],
        "rois":[
          
        ]
      },
      "VL":{
        "descriptions":[
          "(VL) and canine visceral leishmaniasis (CVL). Linear B-cell epitope mapping was performed to identify polymorphic epitopes when comparing orthologous sequences present in Trypanosoma cruzi, the agent for Chagas disease "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2990,
            "y2":1123
          }
        ]
      },
      "CD":{
        "descriptions":[
          "(CD), and the Homo sapiens and Canis familiaris hosts. The serological assay (ELISA) demonstrated that TL, VL and CVL individuals showed high levels of antibodies against rPeroxidoxin, allowing identification of infected ones with considerable sensitivity and great ability to discriminate (specificity) between non-infected and CD individuals (98.46% and 100%; 98.18% and 95.71%; 95.79% and 100%, respectively). An rPeroxidoxin ELISA also showed a greater ability to discriminate between vaccinated and infected animals, which is an important requirement for the public campaign control of CVL. A depletion ELISA assay using soluble peptides of this B-cell epitope confirmed the recognition of these sites only by Leishmania-infected individuals. Moreover, this work identifies two antigenic polymorphic linear B-cell epitopes of L. braziliensis. Specific recognition of TL and VL patients was confirmed by significantly decreased IgG reactivity against rPeroxidoxin after depletion of peptide-1- and peptide-2-specific antibodies (peptide 1: reduced by 32%, 42% and 5% for CL, ML and VL, respectively; peptide-2: reduced by 24%, 22% and 13% for CL, ML and VL, respectively) and only peptide-2 for CVL (reduced 9%). Overall, rPeroxidoxin may be a potential antigen for the immunodiagnosis of TL, VL or CVL, as it has a higher agreement with parasitological assays and is better than other reference tests that use soluble Leishmania antigens for diagnosing CVL in Brazil (EIE-LVC, Bio-manguinhos, FIOCRUZ)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2990,
            "y2":1123
          }
        ]
      }
    }
  },
  "1058802":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E), strain "
        ],
        "rois":[
          {
            "x":1985,
            "y":15,
            "x2":2781,
            "y2":392
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), and the major PC axes (PC 1???=???34.51% variance, PC 2???=???25.41% variance, PC 3???=???19.31% variance). Note that PC 1 in the unweighted analysis is dominated by variation in soil type ",
          "(F). Grey points (Fig. 2c, 2f) represent bulk soil samples that aren't associated with either strain. Abbreviations for strains are denoted by MW (Mauie Wowie) and WW (White Widow), and abbreviations for soil type are denoted by MB (Mo-Bio soil) and OC (Orange County soil)."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A), sample type ",
          "(A), but PC 1 in weighted analysis is dominated by strain "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1014,
            "y2":392
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), strain "
        ],
        "rois":[
          {
            "x":1102,
            "y":15,
            "x2":1899,
            "y2":392
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), and the major PC axes (PC 1???=???32.06% variance, PC 2???=???11.34% variance, PC 3???=???5.67% variance). Plots for weighted analysis are based on weighted UniFrac distances, and demonstrate relationship between soil type "
        ],
        "rois":[
          {
            "x":41,
            "y":416,
            "x2":1899,
            "y2":790
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), sample type "
        ],
        "rois":[
          {
            "x":1985,
            "y":416,
            "x2":2781,
            "y2":790
          }
        ]
      }
    }
  },
  "1058804":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E), strain "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1007,
            "y2":399
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), and the major PC axes (PC 1???=???37.69% variance, PC 2???=???13.95% variance, PC 3???=???11.07% variance). Abbreviations for strains are denoted by B (Burmese), BK (BooKoo Kush), D (Sour Diesel), MW (Mauie Wowie) and WW (White Widow). Abbreviations for soil type are denoted by MB1 (Mo-Bio soil from the first experiment), MB2 (Mo-Bio soil from the second experiment) and OC (Orange County soil)."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A), sample type "
        ],
        "rois":[
          {
            "x":46,
            "y":399,
            "x2":1007,
            "y2":798
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), strain "
        ],
        "rois":[
          {
            "x":1982,
            "y":422,
            "x2":2780,
            "y2":798
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), and the major PC axes (PC 1???=???13.27% variance, PC 2???=???10.15% variance, PC 3???=???6.15% variance). Plots for weighted analysis are based on weighted UniFrac distances, and demonstrate relationship between soil type "
        ],
        "rois":[
          {
            "x":1096,
            "y":422,
            "x2":1896,
            "y2":798
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) sample type "
        ],
        "rois":[
          {
            "x":1096,
            "y":7,
            "x2":2780,
            "y2":399
          }
        ]
      }
    }
  },
  "1058809":{
    
  },
  "1058883":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "A: A549 cells were transfected with siRNA oligos for 72 h or treated with 50 ??M 4-IPP overnight as indicated. Intracellular ROS levels were assessed by flow cytometry upon incubation with the fluorescent ROS detector, DCF-DA"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1803,
            "y2":2069
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B,C: A549 cells were transfected with siRNA oligos as indicated. 48 h later, increasing concentrations of NAC ",
          "(B) or MPG "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1803,
            "y2":2069
          }
        ]
      },
      "C":{
        "descriptions":[
          ". B,C: A549 cells were transfected with siRNA oligos as indicated. 48 h later, increasing concentrations of NAC ",
          "(C) were added to the cells for an additional 16 h. Lysates were analyzed by immunoblotting. Bio-Rad Quantity One software was used for densitometry and p53/GAPDH or p21/GAPDH densitometry values are depicted in the graph. Data shown are representative of four independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1803,
            "y2":2069
          }
        ]
      }
    }
  },
  "1059431":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) and Egypt ",
          "(A). In Egypt, the concentrated epidemic among MSM seems to have preceded the epidemic among PWID "
        ],
        "rois":[
          {
            "x":21,
            "y":817,
            "x2":1307,
            "y2":1425
          },
          {
            "x":21,
            "y":55,
            "x2":1307,
            "y2":763
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B); a pattern of established concentrated epidemic is observed in Iran ",
          "(B); and a pattern of low-level HIV epidemic is observed in Tunisia ",
          "(B). In Tunisia, the potential link between the MSM and PWID epidemics is not clear because the studies were conducted after the epidemics had already risen."
        ],
        "rois":[
          {
            "x":21,
            "y":817,
            "x2":1307,
            "y2":1425
          },
          {
            "x":1392,
            "y":72,
            "x2":2678,
            "y2":768
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). In Afghanistan "
        ],
        "rois":[
          {
            "x":21,
            "y":817,
            "x2":1307,
            "y2":1425
          },
          {
            "x":1380,
            "y":812,
            "x2":2667,
            "y2":1420
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E), there is an emerging epidemic among PWID in apparently only part of the country; the effect of which was diluted in the second round with the inclusion of new cities with still very limited prevalence. The potential overlap of the HIV epidemics among PWID and MSM is depicted in Pakistan and Egypt. In Pakistan, an emerging HIV epidemic among transgender sex workers is observed, but lags the epidemic among PWID "
        ],
        "rois":[
          {
            "x":21,
            "y":1457,
            "x2":1307,
            "y2":2004
          }
        ]
      }
    }
  },
  "1059558":{
    
  },
  "1059600":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Effect of Wnt3a, Wnt7a and BIO in the expression of ??-catenin (after 1 day) as well as in the paracellular permeability (at days 1 and 5) of monocultures of CD34+-derived ECs. Results are Mean ?? SEM (n???=???3???6). The dashed line represents the paracellular permeability of ECs in co-culture with pericytes for 6 days. For permeability results the concentrations of Wnt3a, Wnt7a and BIO were 6.25 ng/mL, 6.25 ng/mL, and 0.5 ??M. (B???C) Paracellular permeability of untreated ECs or ECs treated with different concentrations of human recombinant protein Wnt3a "
        ],
        "rois":[
          {
            "x":3,
            "y":4,
            "x2":418,
            "y2":327
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or Wnt7a "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) for 5 days. Results are Mean ?? SEM (n???=???4). "
        ],
        "rois":[
          {
            "x":857,
            "y":5,
            "x2":1327,
            "y2":580
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Expression and localization of claudin-1 (at day 6) and total ??-catenin (day 3) in monoculture of CD34+-derived ECs cultured in medium supplemented with BIO (0.5 ??M) or Wnt3a (6.25 ng/mL). Arrowheads indicate nuclear accumulation of ??-catenin. Bar corresponds to 50 ??m. *PPP"
        ],
        "rois":[
          {
            "x":1343,
            "y":5,
            "x2":2095,
            "y2":1074
          },
          {
            "x":397,
            "y":477,
            "x2":813,
            "y2":1108
          },
          {
            "x":858,
            "y":592,
            "x2":1326,
            "y2":1131
          },
          {
            "x":36,
            "y":47,
            "x2":754,
            "y2":1063
          }
        ]
      }
    }
  },
  "1060653":{
    "Figure_1.tif":{
      "4":{
        "descriptions":[
          "(4) Interior Mountains (adapted from "
        ],
        "rois":[
          {
            "x":4,
            "y":3,
            "x2":1140,
            "y2":865
          }
        ]
      },
      "46":{
        "descriptions":[
          "[46]; see also "
        ],
        "rois":[
          {
            "x":4,
            "y":885,
            "x2":1359,
            "y2":1753
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1) Atlantic, "
        ],
        "rois":[
          
        ]
      },
      "47":{
        "descriptions":[
          "[47])."
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          "(2) Northern Plateau, "
        ],
        "rois":[
          {
            "x":4,
            "y":3,
            "x2":1140,
            "y2":865
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3) South-Central, "
        ],
        "rois":[
          {
            "x":4,
            "y":3,
            "x2":1140,
            "y2":865
          }
        ]
      }
    }
  },
  "1060655":{
    
  },
  "1061158":{
    
  },
  "1064879":{
    
  },
  "1065234":{
    
  },
  "1065936":{
    
  },
  "1068714":{
    
  },
  "1071622":{
    
  },
  "1072419":{
    "Figure_11.tif":{
      "A":{
        "descriptions":[
          "(A), "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1268,
            "y2":1036
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), "
        ],
        "rois":[
          {
            "x":1281,
            "y":8,
            "x2":2406,
            "y2":1036
          },
          {
            "x":11,
            "y":1068,
            "x2":1239,
            "y2":2007
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and "
        ],
        "rois":[
          {
            "x":1254,
            "y":1066,
            "x2":2405,
            "y2":2007
          },
          {
            "x":11,
            "y":1068,
            "x2":1239,
            "y2":2007
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) shows the close-up docking view generated by Molegro Virtual Docker version 4.0.2 (CLC bio-Qiagen company) of ??-methoxybenzyl alcohol; m-methoxybenzyl alcohol; 3,4 dimethoxybenzyl alcohol and benzyl alcohol, respectively."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1072554":{
    
  },
  "1072876":{
    "Figure_2.tif":{
      "CA":{
        "descriptions":[
          ", CA) and quantified using a Nanodrop ND-1000 UV spectrophotometer (NanoDrop Technologies, Wilmington"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":988,
            "y2":1079
          }
        ]
      },
      "DE":{
        "descriptions":[
          ", DE). Each bar represents the mean DNA yield (??g/mg dust) ?? SEM from two independent dust samples."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1074791":{
    
  },
  "1074795":{
    
  },
  "1075581":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A: Fluorescence micrographs showing adherence of wild-type and ??Sgo0707 strains to protein-coated surfaces and to oral keratinocytes. In panels 1???3 bacteria were flowed over surfaces coated with type-1 collagen, 25% saliva or 10% serum for 2 h, as described, and adhered bacteria stained green using the LIVE/DEAD?? Baclight??? Bacterial Viability stain. Images were obtained using CLSM and the surface coverage determined by image analysis using the bioImage_L software package. In panel 4, bacteria were flowed over keratinocyte layers for 1 h, stained using the LIVE BacLight??? Bacterial Gram Stain Kit and viewed with CLSM. The mean number of bacteria (stained red)/1000 keratinocytes (stained green) was determined by manual image analysis"
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":2051,
            "y2":1031
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Graphs showing the adherence of the wild-type (grey bars) and ??Sgo0707 (white bars) strains to different surface coatings. For type-1 collagen, saliva and serum, adherence is expressed as surface coverage (arbitrary units) whereas for the keratinocytes, binding is expressed as number of bacteria/1000 keratinocytes. The mean and standard error of three independent experiments is shown (* indicates a significant difference p"
        ],
        "rois":[
          {
            "x":58,
            "y":1205,
            "x2":1976,
            "y2":1873
          }
        ]
      }
    }
  },
  "1075588":{
    
  },
  "1077490":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) Freshly isolated PBMCs were incubated with 9.6 ??M LabyA1 and 0.016 ??M PHA for 3 days and afterwards CD25 and CD69 expression was analyzed using anti-CD25-PE and anti-CD69-PE conjugated mAbs in combination with anti-CD4-conjugated PerCP. Mean ?? SEM out of 4 individual donor experiments are shown. The white bars represent untreated conditions, while the grey and black bars indicate, treatment of 9.6 ??M of LabyA1 and 0.016 ??M of PHA, respectively. p-values, according to unpaired T-test. "
        ],
        "rois":[
          {
            "x":8,
            "y":10,
            "x2":1069,
            "y2":640
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Freshly isolated PBMCs were pre-treated with various concentrations of LabyA1 and PHA for 24 h. After extensive washing, the cells were then infected with HIV-1 R5 BaL in the absence of compounds. The viral replication level at day 7 post-infection was measured using HIV-1 p24 Ag ELISA. Mean ?? SEM of 3 independent PBMC donors is shown. p-values, according to unpaired T-test "
        ],
        "rois":[
          {
            "x":8,
            "y":10,
            "x2":1069,
            "y2":640
          },
          {
            "x":1162,
            "y":9,
            "x2":2053,
            "y2":770
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Freshly isolated PBMCs from healthy donors were incubated for 24 h with medium only or LabyA1 or PHA. Supernatant was collected and cytokine/chemokine production was determined using the Bio-Plex system. The fold-increase of the cytokine/chemokine concentration in the supernatant of treated PBMCs with respect to the concentrations in the supernatant of untreated PBMCs was determined for 4 individual donors for LabyA1 and PHA. The fold-increase is divided in 5 subgroups: 1-fold increase (white), 2???5-fold increase (yellow), 5???10-fold increase (orange), 10???50-fold increase (dark red) and >50-fold increase (black bars). The amount of ???fold increase values for each cytokine/chemokine is given as a percentage in the total amount of donors."
        ],
        "rois":[
          {
            "x":10,
            "y":741,
            "x2":2084,
            "y2":2029
          }
        ]
      }
    }
  },
  "1078276":{
    
  },
  "1079853":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Cells left untreated (co), stimulated with NGF (25 ng/ml) or alternatively with NGF (25 ng/ml) and PD098059 (50 ??M) for 16 h and were stained with Phalloidin-TRITC and Hoechst 33342. Pictures were taken of 3???4 independent microscopic fields and are representative of 3 experiments. Scale bar???=???20 ??m. "
        ],
        "rois":[
          {
            "x":13,
            "y":12,
            "x2":1089,
            "y2":512
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, C) PC12 cells were stimulated with either NGF (25 ng/ml) or EGF (100 ng/ml) and activation of p42/44 MAPK was measured by Bio-Plex phosphoprotein detection assay at various time points (0 min ???20 min). Differences were analyzed using one-way ANOVA followed by Dunnett???s multiple comparison test: *p"
        ],
        "rois":[
          {
            "x":13,
            "y":12,
            "x2":1089,
            "y2":512
          },
          {
            "x":1054,
            "y":112,
            "x2":2325,
            "y2":792
          }
        ]
      },
      "C":{
        "descriptions":[
          "(B, C) PC12 cells were stimulated with either NGF (25 ng/ml) or EGF (100 ng/ml) and activation of p42/44 MAPK was measured by Bio-Plex phosphoprotein detection assay at various time points (0 min ???20 min). Differences were analyzed using one-way ANOVA followed by Dunnett???s multiple comparison test: *p"
        ],
        "rois":[
          {
            "x":13,
            "y":518,
            "x2":2198,
            "y2":2009
          }
        ]
      }
    }
  },
  "1079863":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A, B) PC12 cells were transfected with control or specific siRNA for LAMTOR2. After 24 h, cells were left untreated (co) or stimulated with either NGF (25 ng/ml) or EGF (100 ng/ml). After various time points (0, 2, 5, 10, 20 min), activation of p42/44 MAPK was measured with the Bio-Plex phosphoprotein detection assay. Values represent the mean ?? SEM, n???=???3. Differences were analyzed using unpaired two-tailed t-test: ***p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2269,
            "y2":1549
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) PC12 cells were transfected with control or specific siRNA for LAMTOR2. After 24 h, cells were left untreated (co) or stimulated with either NGF (25 ng/ml) or EGF (100 ng/ml). After various time points (0, 2, 5, 10, 20 min), activation of p42/44 MAPK was measured with the Bio-Plex phosphoprotein detection assay. Values represent the mean ?? SEM, n???=???3. Differences were analyzed using unpaired two-tailed t-test: ***p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2269,
            "y2":1549
          }
        ]
      }
    }
  },
  "1081535":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) A heat map delineating the expression of SNAI1 and epithelial???mesenchymal transition (EMT) correlated genes in 5 normal brain tissues and 220 glioma tissues (97 cases of WHO grade II, 34 cases of WHO grade III and 89 cases of WHO grade IV). "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1876,
            "y2":340
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SNAI1 is correlated with glioma WHO grade, as shown in the scatter diagram. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) and "
        ],
        "rois":[
          {
            "x":11,
            "y":363,
            "x2":1857,
            "y2":997
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) mRNA and protein levels of SNAI1 in normal and glioma samples, the western blot band was quantified using Image Lab 4.0 software (Bio-Rad) and shown as the ratio of SNAI1/??-actin band intensity."
        ],
        "rois":[
          {
            "x":11,
            "y":1034,
            "x2":1861,
            "y2":1355
          }
        ]
      }
    }
  },
  "1082330":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) A heat map delineating the expression of SNAI1 and epithelial???mesenchymal transition (EMT) correlated genes in 5 normal brain tissues and 220 glioma tissues (97 cases of WHO grade II, 34 cases of WHO grade III and 89 cases of WHO grade IV). "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1876,
            "y2":340
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SNAI1 is correlated with glioma WHO grade, as shown in the scatter diagram. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) and "
        ],
        "rois":[
          {
            "x":11,
            "y":363,
            "x2":1857,
            "y2":997
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) mRNA and protein levels of SNAI1 in normal and glioma samples, the western blot band was quantified using Image Lab 4.0 software (Bio-Rad) and shown as the ratio of SNAI1/??-actin band intensity."
        ],
        "rois":[
          {
            "x":11,
            "y":1034,
            "x2":1861,
            "y2":1355
          }
        ]
      }
    }
  },
  "1083104":{
    
  },
  "1089861":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) cells were harvested 24 hs after treatment with 2 ??M 6-bromoindirubin-3???-oxime (BIO) and 20 ??M SB216763 (SB2) GSK3 inhibitors; specificity of the inhibitor for GSK3A was assessed by checking GSK3A activation/inactivation checked by western blot using a mix of pSer21-GSK3A and pSer9-GSK3B antibodies and antibody cross-reacting with both pTyr279-GSK3A and pTyr216-GSK3B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      },
      "F":{
        "descriptions":[
          ". B, D, F) percentage of cell death of HCT116p53KO",
          "(F) treated with 200 ??M 5FU in presence and in absence of the indicated inhibitors (72 hrs)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and SW480 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B, D, F) percentage of cell death of HCT116p53KO",
          "(B), SW480 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) cells were harvested 24hs after treatment with 1 ??M 6-bromoindirubin-3???-oxime (BIO) and 20 ??M SB216763 (SB2) GSK3 inhibitors; lysates of HT-29 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      },
      "D":{
        "descriptions":[
          ". B, D, F) percentage of cell death of HCT116p53KO",
          "(D) and HT-29 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1765,
            "y2":2321
          }
        ]
      }
    }
  },
  "1091113":{
    
  },
  "1091116":{
    "Figure_3.tif":{
      "0":{
        "descriptions":[
          ": 0.0805 cm2; TGA"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":996,
            "y2":652
          }
        ]
      },
      "10":{
        "descriptions":[
          ": 10.0 mM/ethanol; EDC",
          ": 10.0 mM; ChOx",
          ": 10.0 mM."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1091117":{
    
  },
  "1091119":{
    "Figure_5.tif":{
      "0":{
        "descriptions":[
          ": 0.1 V/s; Concentration range of cholesterol"
        ],
        "rois":[
          {
            "x":923,
            "y":7,
            "x2":1875,
            "y2":807
          }
        ]
      },
      "1":{
        "descriptions":[
          ": 1.0 nM to 100.0 mM; Method: CV; Reference electrode: Ag/AgCl (sat. KCl)."
        ],
        "rois":[
          {
            "x":10,
            "y":12,
            "x2":918,
            "y2":805
          }
        ]
      }
    }
  },
  "1091950":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Fluorescence imaging of SKW-3 cells at 72 h after viral transduction with three different pLL 3.7-constructs (nonsense shRNA ??? NSO, antisense shRNAs???21 bp, 1 or 27 bp, 2) and Cell Sorting using the eGFP signal. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3670,
            "y2":5753
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The efficacy of the Rb-knockdown estimated by Western blot before and after selection. The Rb-knockdown on protein level was calculated as percentage of the respective nonsense-control cells after densitometric analysis of the protein bands using the Quantity One 4.6.6 Program (Bio-Rad Laboratories)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1091997":{
    
  },
  "1092002":{
    
  },
  "1093227":{
    
  },
  "1093252":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Chl, "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1776,
            "y2":1107
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) bbp, and "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1776,
            "y2":1107
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CDOM. Note difference in vertical axes for Chl (upper 200 m) versus bbp and CDOM (entire depth profile) to emphasize depth zones of maximum variability. For reference, the density layer ?????=???1023.6 is shown in panel A (black line) with sample times (black dots), and bottom depth is shown in panels B and C (shaded grey). The times corresponding to SSHA imagery in Fig. 2 are indicated in panel A (white dashed lines) to show float location relative to the LC boundary."
        ],
        "rois":[
          {
            "x":63,
            "y":1135,
            "x2":1709,
            "y2":1763
          }
        ]
      }
    }
  },
  "1093255":{
    
  }
,
  "392495":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A, B) Competitions were started with equal amounts of mutant and reference cells. The y-axis indicates the relative count of mutants over the reference strain following one round of the indicated experimental challenge (as explained in Materials and Methods). As cultures undergo different numbers of generations during each type of challenge, values from different challenges for the same mutant are not directly comparable. Error bars indicate the standard error of at least 8, 4, and 3 experiments for the Bio-TOB, Bio-ND, and Pla-ND conditions, respectively. Mutants in ",
          "(A) have an advantage over wild-type in the Bio-TOB competition; mutants in ",
          "(A) and "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":2029,
            "y2":706
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Competitions were started with equal amounts of mutant and reference cells. The y-axis indicates the relative count of mutants over the reference strain following one round of the indicated experimental challenge (as explained in Materials and Methods). As cultures undergo different numbers of generations during each type of challenge, values from different challenges for the same mutant are not directly comparable. Error bars indicate the standard error of at least 8, 4, and 3 experiments for the Bio-TOB, Bio-ND, and Pla-ND conditions, respectively. Mutants in ",
          "(B) have a disadvantage. Gene annotations, which were updated from the original genome annotation [48] by BLAST comparisons [14] against the NCBI non-redundant database, are in Table S3. ",
          "(B) with 4 ??g/ml tobramycin are shown."
        ],
        "rois":[
          {
            "x":9,
            "y":739,
            "x2":1004,
            "y2":1409
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Growth curves for representative strains from panels "
        ],
        "rois":[
          {
            "x":1074,
            "y":776,
            "x2":1953,
            "y2":1409
          }
        ]
      }
    }
  },
  "392503":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "; E: Atacama and Coquimbo"
        ],
        "rois":[
          {
            "x":1607,
            "y":1147,
            "x2":1984,
            "y2":1837
          }
        ]
      },
      "N":{
        "descriptions":[
          "; N: Central Patagonia (R??o Negro)"
        ],
        "rois":[
          {
            "x":828,
            "y":1130,
            "x2":1300,
            "y2":1832
          }
        ]
      },
      "T":{
        "descriptions":[
          "; T: Austral Patagonia. 2C: 9: Payunia and Central Chile"
        ],
        "rois":[
          
        ]
      },
      "J":{
        "descriptions":[
          "; J: Central Monte (La Rioja)"
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":538,
            "y2":893
          }
        ]
      },
      "U":{
        "descriptions":[
          "; U: Sierras Subandinas and Cumbres Calchaqu??es"
        ],
        "rois":[
          {
            "x":820,
            "y":14,
            "x2":1315,
            "y2":893
          }
        ]
      },
      "F":{
        "descriptions":[
          "; F: Maule"
        ],
        "rois":[
          {
            "x":60,
            "y":1131,
            "x2":558,
            "y2":1832
          }
        ]
      },
      "A":{
        "descriptions":[
          "; A: Prepuna of Salta and Jujuy"
        ],
        "rois":[
          {
            "x":828,
            "y":1130,
            "x2":1300,
            "y2":1832
          }
        ]
      },
      "M":{
        "descriptions":[
          "; M: Northern Patagonia. 2D"
        ],
        "rois":[
          {
            "x":1533,
            "y":17,
            "x2":2005,
            "y2":907
          }
        ]
      },
      "I":{
        "descriptions":[
          "- I: Los Lagos"
        ],
        "rois":[
          {
            "x":828,
            "y":1130,
            "x2":1300,
            "y2":1832
          }
        ]
      },
      "G":{
        "descriptions":[
          ": G: Atacama and Puna of Bolivia"
        ],
        "rois":[
          
        ]
      },
      "V":{
        "descriptions":[
          "; V: Prepuna and Monte Boreal"
        ],
        "rois":[
          {
            "x":1607,
            "y":1147,
            "x2":1984,
            "y2":1837
          }
        ]
      },
      "Q":{
        "descriptions":[
          ": Q: Payunia and Monte Central."
        ],
        "rois":[
          
        ]
      },
      "L":{
        "descriptions":[
          "; L: Central Patagonia (Santa Cruz)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "; B: Atacama (Chile)"
        ],
        "rois":[
          
        ]
      },
      "P":{
        "descriptions":[
          "; P: Central Chile. 2F"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "; C: Puna of Jujuy"
        ],
        "rois":[
          
        ]
      },
      "H":{
        "descriptions":[
          "; H: Northern Atacama (Chile)."
        ],
        "rois":[
          {
            "x":828,
            "y":1130,
            "x2":1300,
            "y2":1832
          }
        ]
      },
      "W":{
        "descriptions":[
          "; W: Coastal Central Peru. 2B: 4: Prepuna of Catamarca; 7: Payunia"
        ],
        "rois":[
          {
            "x":820,
            "y":14,
            "x2":1315,
            "y2":893
          }
        ]
      },
      "K":{
        "descriptions":[
          "; K: Central Chile (Metropolitana, O'Higgins)"
        ],
        "rois":[
          {
            "x":828,
            "y":1130,
            "x2":1300,
            "y2":1832
          }
        ]
      },
      "R":{
        "descriptions":[
          "; R: Central Monte (Mendoza). 2E"
        ],
        "rois":[
          {
            "x":1533,
            "y":17,
            "x2":2005,
            "y2":907
          }
        ]
      },
      "O":{
        "descriptions":[
          "; O: Coquimbo"
        ],
        "rois":[
          {
            "x":1607,
            "y":1147,
            "x2":1984,
            "y2":1837
          }
        ]
      },
      "D":{
        "descriptions":[
          "; D: Cuyo"
        ],
        "rois":[
          
        ]
      },
      "S":{
        "descriptions":[
          ": S: Prepuna (Jujuy and Bolivia)"
        ],
        "rois":[
          {
            "x":1607,
            "y":1147,
            "x2":1984,
            "y2":1837
          }
        ]
      }
    }
  },
  "3925935":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "A: Regular geometry of the printed tissue construct"
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":331,
            "y2":328
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Blueprint recognizable by 3D Bio-plotter"
        ],
        "rois":[
          {
            "x":341,
            "y":4,
            "x2":1003,
            "y2":328
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Diagram of the inner grid structure of 3D printed tissue construct: 0???90??."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3936795":{
    
  },
  "393805":{
    
  },
  "3938070":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) Venn diagram demonstrating overlap in the sets of genes found to be MDP-, MPLA- and/or MDP+MPLA-induced in THP-1 cells. Cells were treated with MDP (20??g/ml) and MPLA (1??g/ml) individually or in combination or left unstimulated. RNA was harvested after 3 h and analyzed by hybridization to Affymetrix Human Gene 1.0 ST genechip microarrays. Genes induced by MDP (white circle), MPLA (gray circle) or their combination (black circle) by at least 3-fold over untreated cells are shown. "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":1990,
            "y2":1175
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) List of MDP+MPLA-induced genes with potentiated expression in comparison to gene expression levels in untreated cells and cells treated with either MPLA or MDP alone. Cells were left untreated or treated with MDP (20??g/ml) and MPLA (1??g/ml) individually or in combination. RNA was harvested after 3 h and analyzed by hybridization to Affymetrix Human Gene 1.0 ST Genechip microarrays. The figure lists 72 genes that showed potentiated expression with MDP+MPLA treatment compared to MPLA or MDP alone (potentiated = fold induction of gene expression level with combined treatment over the untreated control was greater than the sum of the fold induction seen with MPLA alone and MDP alone). Statistical significance was determined by a random-variance t-test with P"
        ],
        "rois":[
          {
            "x":18,
            "y":12,
            "x2":1585,
            "y2":1209
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Multiplex analysis of molecular pathways activated via phosphorylation in THP-1 cells in response to individual or combined TLR4 and NOD2 stimulation. Cells were left untreated or treated for 20 min with MDP (20 ??g/ml) and MPLA (1 ??g/ml) alone or in combination. Phosphoprotein levels of p65 subunit NF-??B (Ser536), I??B (Ser32), IKK??/?? (Ser177/Ser181), p38 (Thr180/Tyr182), ERK/MAP kinase 1/2 (Thr185/Tyr187), JNK (Thr183/Tyr185), Akt (Ser473), CREB (Ser133), STAT3 (Ser727), p70 S6 kinase (Thr412), and STAT5A/B (Tyr694/699), as well as total protein levels of TNFR1 and c-Myc were evaluated using MILLIPLEX Magnetic Bead Signaling kits and a Bio-Plex MAGPIX multiplex reader (Bio-Rad). Data was collected from triplicate samples in two independent experiments and is presented as mean fluorescent intensity (MFI) ?? SD. * indicates significant difference (P???0.05) between formulations containing MDP or MPLA individually and the formulation without PRR agonists. # indicates significant difference (P???0.05) between group treated with Alum+OVA+MDP+MPLA and Alum+OVA+MPLA or Alum+OVA+MDP (Student???s t-test)."
        ],
        "rois":[
          {
            "x":18,
            "y":12,
            "x2":1585,
            "y2":1209
          }
        ]
      }
    }
  },
  "3938121":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "(A) Addition of the vaccine formulation containing both TLR4 and NOD2 agonists to THP1-XBlue???-CD14 cells leads to enhanced NF-??B/AP-1-dependent SEAP activity compared to formulations with individual PRR agonists. SEAP activity was measured in cell-free culture supernatants 18 h after vaccine formulation addition. Results are expressed as the fold-increase in SEAP activity relative to untreated (intact) cells; mean values ?? SD from three independent experiments, each performed in duplicate. * indicates significant difference (P???0.05) between formulations containing MDP or MPLA individually and the formulation without PRR agonists. # indicates significant difference (P???0.05) between Alum+OVA+MDP+MPLA treatment and Alum+OVA+MPLA or Alum+OVA+MDP (Student???s t-test). ",
          "(A)."
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":1990,
            "y2":2620
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Addition of the vaccine formulation containing both TLR4 and NOD2 agonists to THP1 cells leads to enhanced cytokine production in comparison to vaccine formulations with individual PRR agonists. Cells were left untreated or treated with Alum+OVA, Alum+OVA+MDP, Alum+OVA+MPLA, or Alum+OVA+MDP+MPLA formulations for 18 hrs. Cell-free supernatants were prepared and analyzed by multiplex-bead ELISA Bio-Plex Pro kit (BioRad, USA) for production of IL-1??, TNF-??, and IL-8. Results are representative of two separate experiments, each performed in triplicate. Mean ?? SD is shown for triplicate samples. * and # indicate significant differences as described for "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3938163":{
    "Fig 2.TIF":{
      "E":{
        "descriptions":[
          "(E) between Mtb- and Maf-infected patients at 6 month of treatment. ",
          "(E) and Rantes "
        ],
        "rois":[
          {
            "x":2242,
            "y":3505,
            "x2":3204,
            "y2":4290
          },
          {
            "x":33,
            "y":1242,
            "x2":991,
            "y2":2062
          }
        ]
      },
      "II":{
        "descriptions":[
          "(II) Only ESAT-6/CFP-10 stimulation induced significant differences in cytokine production between Mtb- and Maf-infected patients above the background level of IFN-?? "
        ],
        "rois":[
          
        ]
      },
      "F":{
        "descriptions":[
          "(F). Dot plots show log-2 transformed cytokine concentrations measured with Bio-Plex assay. Horizontal bars indicate median cytokine concentration by lineage groups, Maf-infected patients (closed circles, n = 26 and 20) and Mtb-infected patients (open circles, n = 49 and 31) respectively at 0 and 6 months of TB treatment. Log-2 transformed cytokine concentrations were compared between lineage groups using a random-intercept model adjusted for age, sex and ethnicity, and Sidak multiple comparison correction. Contrasts analysis was used after estimation to compute the difference in each cytokine concentration between lineage groups and used Wald test for assessing the significance at each time point. P-values of the differences are shown."
        ],
        "rois":[
          {
            "x":2234,
            "y":1151,
            "x2":3223,
            "y2":2075
          },
          {
            "x":4,
            "y":2240,
            "x2":3222,
            "y2":3447
          },
          {
            "x":33,
            "y":1242,
            "x2":991,
            "y2":2062
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), PDGF-???? ",
          "(A), IL-2 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2969,
            "y2":1197
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I), revealed differences in the concentrations of IL12p70 "
        ],
        "rois":[
          {
            "x":1151,
            "y":3483,
            "x2":2089,
            "y2":4291
          },
          {
            "x":33,
            "y":1242,
            "x2":991,
            "y2":2062
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), MIP-1?? ",
          "(B), IL-1ra "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2969,
            "y2":1197
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), IL-15 ",
          "(C), TNF-?? "
        ],
        "rois":[
          {
            "x":29,
            "y":3502,
            "x2":989,
            "y2":4286
          },
          {
            "x":0,
            "y":0,
            "x2":2969,
            "y2":1197
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and IL-8 ",
          "(D), GM-CSF "
        ],
        "rois":[
          {
            "x":1145,
            "y":1153,
            "x2":2108,
            "y2":2067
          },
          {
            "x":33,
            "y":1242,
            "x2":991,
            "y2":2062
          }
        ]
      }
    }
  },
  "394382":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Analysis of homogeneity for HCC and adjacent non-cancerous tissues using PCC values. The PCC values of gene expression between different samples were represented by different colors: bigger value corresponding to darker color. AVE: Average raw reads number for each gene from re-sequenced sample. The character C represents cancerous tissue sample and P for peri-cancerous tissue sample. "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":2510,
            "y2":2036
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Enrichment regions of up-regulated genes on Chromosome 8. "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":2510,
            "y2":2036
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C)Top 10 bio-function terms enriched by DEGs and "
        ],
        "rois":[
          {
            "x":1147,
            "y":13,
            "x2":2746,
            "y2":763
          },
          {
            "x":10,
            "y":10,
            "x2":2510,
            "y2":2036
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) top 10 canonical pathways enriched by DEGs. Percentage represents the ratio of the number of mapped genes to all genes in a pathway from IPA. Threshold was set (P1.3) by Fisher's Exact Test."
        ],
        "rois":[
          {
            "x":22,
            "y":2069,
            "x2":2592,
            "y2":3209
          }
        ]
      }
    }
  },
  "3949383":{
    
  },
  "39541":{
    
  },
  "3955257":{
    "Fig 3.TIF":{
      "E":{
        "descriptions":[
          ", E) lectins, respectively. Error bars represent standard deviations of three independent experiments (paired t-test, p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1319
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) SpaCBA pili are glycosylated on L. rhamnosus GG cells???Cell wall-associated proteins of L. rhamnosus GG wild type (1), the pilus-deficient ??spaCBA::TcR mutant (CMPG5357, 2) and the ??welE::TcR mutant on which the pili are overexposed (CMPG5351, 3), were probed with mannose- and fucose-specific lectins (HHA and AAL resp.). Pili content was visualized by probing with SpaC antiserum (SpaC, black arrow and HMW: high molecular weight pili). Interference of the Msp1 glycoprotein was ruled out (open arrow). Blots and gels were performed in triplicate. (LK = Precision Plus Protein??? Kaleidoscope??? Standard, Bio-Rad) "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1319
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Purified pili are glycosylated???SDS-PAGE separated pili (pool A) were stained with PAS glycostain and Sypro?? to visualize their protein content. Pili content was shown by probing of Western blotted samples with SpaC antiserum (HMW: high molecular weight pili). Purified Msp1 (open arrow) was used as a positive control. Representative gels are shown, experiment was carried out in triplicate. (LK = Precision Plus Protein??? Kaleidoscope??? Standard, Bio-Rad) "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1319
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) SpaCBA pili bind mannose-specific lectins???Purified pili fractions (PRM and pili pool B) were subjected to PAS glycostaining and both Sypro?? and Silver stain to visualize their protein content. Absence of 75 kDa signals on PAS and lectin blots rule out the interference Msp1 (cf. open arrow). Western blotted samples were probed with SpaC antiserum (HMW: high molecular weight pili) and the mannose-specific lectins HHA and GNA, visualizing the pili content of the samples and the presence of mannose, respectively. Representative gels and blots of in triplicate-repeated experiment. (LK = Precision Plus Protein??? Kaleidoscope??? Standard, Bio-Rad) (D&E) Mannose- and fucose-specific lectins bind SpaCBA pili???Binding of lectins to plate-coated pili was measured to ELISA. Wells coated with coating buffer served as a negative control. Mannan and Lewis X were coated as a positive control for the mannose-specific HHA (Hippeastrum hybrid"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ", D) and fucose-specific AAL (Aleuria aurantia"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1319
          }
        ]
      }
    }
  },
  "3956037":{
    
  },
  "3957762":{
    "Fig 4.TIF":{
      "SB":{
        "descriptions":[
          ", SB), PKA (10 ??M, H89), or STAT1 (20 ??M, EGCG) for 1 h, and subsequently co-incubated with IFN?? (30 ng/ml). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1005,
            "y2":2399
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Cells were harvested 10 h after IFN?? stimulation to evaluate IL-33 production by western blot analysis (loading control: ??-actin). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1005,
            "y2":2399
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Media from the basal compartment were harvested 24 h after IFN?? stimulation to analyze IL-6, IL-8, RANTES, and MCP-1 production using the Bio-Plex assay. Each value represents the mean ?? SD of 3 independent experiments. **P ## P "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1005,
            "y2":2399
          }
        ]
      }
    }
  },
  "3957888":{
    "Fig 6.TIF":{
      "E":{
        "descriptions":[
          "(E) IL-8 production was analyzed by ELISA after 24 h stimulation. "
        ],
        "rois":[
          {
            "x":948,
            "y":1879,
            "x2":1797,
            "y2":2387
          },
          {
            "x":15,
            "y":1897,
            "x2":851,
            "y2":2395
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) In the supernatant of negative siRNA and IL-33 siRNA-treated groups, the production of IL-6, RANTES, MCP-1, and GM-CSF 24 h after IFN?? or TNF-?? stimulation were assessed using the Bio-Plex assay. Each value represents the mean ?? SD of 3 independent experiments. *P P "
        ],
        "rois":[
          {
            "x":5,
            "y":1226,
            "x2":854,
            "y2":1817
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Monolayer HEECs were stimulated with IFN?? (30 ng/ml) or TNF-?? (20 ng/ml) for 6 h and IL-33 mRNA was subsequently analyzed by RT-qPCR. "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":642,
            "y2":483
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IL-33 siRNA and non-specific control siRNA (negative siRNA) were transfected into monolayer HEECs. IL-33 expression was evaluated by RT-qPCR 72 h after transfection. "
        ],
        "rois":[
          {
            "x":15,
            "y":1897,
            "x2":851,
            "y2":2395
          },
          {
            "x":4,
            "y":4,
            "x2":642,
            "y2":483
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Cell viability 72 h after transfection was examined by WST-1. (D-F) After 72 h transfection, monolayer HEECs were stimulated with IFN?? (30 ng/ml) or TNF-?? (20 ng/ml). "
        ],
        "rois":[
          {
            "x":15,
            "y":1897,
            "x2":851,
            "y2":2395
          },
          {
            "x":928,
            "y":673,
            "x2":1799,
            "y2":1816
          },
          {
            "x":622,
            "y":4,
            "x2":1814,
            "y2":601
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IL-8 expression was analyzed by RT-qPCR after 6 h stimulation. "
        ],
        "rois":[
          {
            "x":15,
            "y":1897,
            "x2":851,
            "y2":2395
          },
          {
            "x":32,
            "y":552,
            "x2":856,
            "y2":1206
          }
        ]
      }
    }
  },
  "3963534":{
    "Fig 1.TIF":{
      "e":{
        "descriptions":[
          "(e) hydrolytic amino acids and inoculum contents; "
        ],
        "rois":[
          {
            "x":17,
            "y":14,
            "x2":1632,
            "y2":1480
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f) composting temperature and inoculum contents."
        ],
        "rois":[
          
        ]
      },
      "a":{
        "descriptions":[
          "(a) maggot manure and hydrolytic amino acids; "
        ],
        "rois":[
          {
            "x":17,
            "y":14,
            "x2":1632,
            "y2":1480
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) maggot manure and composting temperature; "
        ],
        "rois":[
          {
            "x":17,
            "y":14,
            "x2":1632,
            "y2":1480
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) maggot manure and inoculum contents; "
        ],
        "rois":[
          {
            "x":17,
            "y":14,
            "x2":1632,
            "y2":1480
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) hydrolytic amino acids and composting temperature; "
        ],
        "rois":[
          {
            "x":17,
            "y":14,
            "x2":1632,
            "y2":1480
          }
        ]
      }
    }
  },
  "3963615":{
    "Fig 2.TIF":{
      "a":{
        "descriptions":[
          "(a) Temperature and T-E5 population; "
        ],
        "rois":[
          {
            "x":24,
            "y":0,
            "x2":2285,
            "y2":1296
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) C/N;"
        ],
        "rois":[
          {
            "x":2350,
            "y":1,
            "x2":4205,
            "y2":1299
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c)NH4+-N/NO3--N; "
        ],
        "rois":[
          {
            "x":0,
            "y":1372,
            "x2":1883,
            "y2":2921
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) pH and EC. Note: Error bars represent standard deviation of triplicates for temperature, C/N, pH, EC, NH4+-N/NO3???N and T-E5 population."
        ],
        "rois":[
          {
            "x":2305,
            "y":1374,
            "x2":4500,
            "y2":2921
          }
        ]
      }
    }
  },
  "3965040":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "(A) The top five entries in three aspects of biological impact: Disease and Disorders, Molecular and Cellular Functions, and Hepatotoxicity. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1637,
            "y2":560
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Top altered canonical pathways predicted by IPA (p"
        ],
        "rois":[
          {
            "x":0,
            "y":561,
            "x2":1637,
            "y2":1735
          }
        ]
      }
    }
  },
  "3975861":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "A. Colony morphology was observed with a BIO-RAD Gel DocTM XR+ imager. hfq deletion led to a colony morphology change from translucent and smooth to opaque and rugose"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3788,
            "y2":5100
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Amounts of extracellular polysaccharides of ZJ-T, ??hfq-T and hfq+-T were assayed in triplicates with alcian blue (top) and quantified by spectroscopy (bottom). Error bars correspond to standard deviations. Statistically significant differences are indicated (* p "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3976701":{
    
  },
  "39897":{
    
  },
  "3990795":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) Western blot analysis of Aip protein in GH3 and mutant GH3 clones (clones 1 and 2). Fifteen ??g of protein from cell lysates was subjected to SDS-PAGE and immunoblotted with antibodies against Aip and beta-actin. Each target protein was visualized using VersaDoc 5000 (BIO-RAD, Tokyo, Japan). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":944,
            "y2":2549
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, C) The relative expression of Gh mRNA and Prl mRNA to Actb mRNA is shown, respectively. Data were compared using the unpaired two-tailed t-test. **PD) The relative expression of Aip mRNA to Actb mRNA in cultured clone 1 (GH3-FTY cells) and clone 2 is shown. Data were compared using the unpaired two-tailed t-test. * P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(B, C) The relative expression of Gh mRNA and Prl mRNA to Actb mRNA is shown, respectively. Data were compared using the unpaired two-tailed t-test. **PD) The relative expression of Aip mRNA to Actb mRNA in cultured clone 1 (GH3-FTY cells) and clone 2 is shown. Data were compared using the unpaired two-tailed t-test. * P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3990861":{
    
  },
  "3990879":{
    "Fig 4.TIF":{
      "E":{
        "descriptions":[
          "(E) Statistical evaluation of p-Stat3. GFP and Aip indicate LV-GFP and LV-Aip, respectively. Data were compared using the unpaired two-tailed t-test. **PF) Il6r mRNA levels relative to Actb mRNA levels as determined by qPCR. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1569,
            "y2":2249
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Western blot analysis of p-Stat3 (Tyr705) and Stat3. Twenty ??g protein from cell lysates was separated by SDS-PAGE and immunoblotted with antibodies against p-Stat3, Stat3, and beta-actin. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1569,
            "y2":2249
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Il6r mRNA levels relative to Actb mRNA levels as determined by qPCR before and after lentivirus "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1569,
            "y2":2249
          }
        ]
      },
      "LV":{
        "descriptions":[
          "(LV)-mediated forced expression of exogenous Aip (LV-AIP) or gfp (LV-GFP) as a control on p-Stat3 expression was examined. Twenty ??g protein from cell lysates was subjected to SDS-PAGE and immunoblotted with antibodies against p-Stat3 and beta-actin. ",
          "(LV)-mediated exogenous expression of Aip (LV-Aip) or gfp (LV-GFP) as a control. GFP and Aip indicate LV-GFP and LV-Aip, respectively. Data were compared using the unpaired two-tailed t-test. *PP"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Statistical evaluation of Stat3/ beta-actin expression between cultured GH3 and GH3-FTY cells. Data were compared using the unpaired two-tailed t-test. ns, not significant. The intensity of each detected band was analyzed using the image analysis software Quantity One (BIO-RAD), and the Stat3/ beta-actin ratio was calculated. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1569,
            "y2":2249
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Statistical evaluation of p-Stat3/ beta-actin expression between cultured GH3 and GH3-FTY cells. Data were compared using the unpaired two-tailed t-test. **PD) Western blot analysis of p-Stat3 and Stat3. The effect of lentivirus "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1569,
            "y2":2249
          }
        ]
      }
    }
  },
  "399208":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) a GC content of 50% was preferred in the 12 bp sequences flanking the target position [14, Japan Bio Services Co.,LTD.(JAPAN) unpublished data]; "
        ],
        "rois":[
          {
            "x":0,
            "y":517,
            "x2":1301,
            "y2":787
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) presence more than 3 nt of A or U residues in a 7 nt sequence at the 5??? end of the antisense strand of siRNA [7]; "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) siRNAs with a GC content that ranged between 35% and 55%; "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) the 2 nt overhangs of the antisense strand at the 3??? end were UU [15]; and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) the 5???-sense end of siRNAs was G or C [7]; "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) the 5???-antisense end of siRNAs was A or U [7]; "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) the 2 nt overhangs of the sense strand at the 3??? end were UU, UN, NU, or AA [15, Japan Bio Services Co.,LTD.(JAPAN) unpublished data]."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) the target position selected was located 75 bp downstream of the initiation codon (AUG), to avoid binding sites for translational factors [13]; "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1301,
            "y2":516
          }
        ]
      }
    }
  },
  "4002429":{
    
  },
  "4012035":{
    
  },
  "4013187":{
    
  },
  "401424":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. HT-29 cells were transfected and treated as above (Figure 4). After thirty six hours of transfection, cells were stained with TUNEL reagent (BD biosciences, USA) as per the instruction of the manufacturer. The approximate percentages of cells that are positive for TUNEL are 41, 55, 58 and 28 for HT-29 cells, EVI1 specific siRNA transfected HT-29 cells, PCAF-wt or PCAF-DN transfected HT-29 cells respectively (p value???=???0.0036)"
        ],
        "rois":[
          {
            "x":9,
            "y":46,
            "x2":979,
            "y2":873
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. A part of the same transfected cells that were used for apoptosis assay was checked for the BCL-XL mRNA level through real time PCR. As shown Bcl-xL mRNA level was higher in HT-29 cells however it was reduced when EVI1 siRNA or PCAF was transfected in the HT-29 cells. Expression of PCAF-DN again increased the Bcl-xL mRNA level (p value???=???0.0016)"
        ],
        "rois":[
          {
            "x":1233,
            "y":9,
            "x2":2202,
            "y2":843
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Another part of the same transfected cells that were used for apoptosis assay was checked for the BCL-XL protein expression with Bcl-xL antibody (Imgenex India Pvt. Ltd.) and beta-actin antibody (Santa Cruz) through western blotting. As shown BCL-XL expression was higher in HT-29 cells however BCL-XL expression was reduced when EVI1 siRNA or PCAF was transfected in the HT-29 cells. Expression of PCAF-DN again increased the BCL-XL expression"
        ],
        "rois":[
          {
            "x":11,
            "y":1016,
            "x2":1040,
            "y2":1582
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. The same western blotting data was quantified by Bio-rad gel doc volume analysis method. Figure shows a quantification of Bcl-xL with respect to the beta actin (p value???=???0.0039)."
        ],
        "rois":[
          {
            "x":1184,
            "y":908,
            "x2":2199,
            "y2":1681
          }
        ]
      }
    }
  },
  "4015815":{
    
  },
  "4017420":{
    
  },
  "4017444":{
    
  },
  "4017456":{
    
  },
  "4019406":{
    
  },
  "4022343":{
    "Fig 2.TIF":{
      "E":{
        "descriptions":[
          "(E) Spontaneous release of the cytokines IL-1??, IL-10, GM-CSF, IFN-?? and TNF-?? from inflamed biopsies into the culture medium measured by Bio-Plex. Biopsies from the same patients were cultured on either T-disk or transwell as indicated. No difference in cytokine release was observed when comparing T-disk and transwell for all 5 cytokines in combination (P > 0.05, two-way ANOVA), but when analyzed alone, IL-10 and IFN-?? were significantly increased with T-disk (*P "
        ],
        "rois":[
          {
            "x":28,
            "y":581,
            "x2":622,
            "y2":883
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A, C) and inflamed ",
          "(A, B) or transwells "
        ],
        "rois":[
          {
            "x":660,
            "y":569,
            "x2":1029,
            "y2":889
          },
          {
            "x":18,
            "y":289,
            "x2":1033,
            "y2":554
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B,D) biopsies from the same patient were cultured on T-disks ",
          "(A, B) or transwells "
        ],
        "rois":[
          {
            "x":13,
            "y":0,
            "x2":519,
            "y2":266
          }
        ]
      },
      "C":{
        "descriptions":[
          "(A, C) and inflamed ",
          "(C,D) for 24 hours and processed for histology. Representative pictures of H&E-stained paraffin-sections (n = 5 patients). Bars = 600 ??m. "
        ],
        "rois":[
          {
            "x":531,
            "y":3,
            "x2":1039,
            "y2":266
          }
        ]
      },
      "D":{
        "descriptions":[
          "(B,D) biopsies from the same patient were cultured on T-disks ",
          "(C,D) for 24 hours and processed for histology. Representative pictures of H&E-stained paraffin-sections (n = 5 patients). Bars = 600 ??m. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4022346":{
    
  },
  "402899":{
    "Figure_8.tif":{
      "S":{
        "descriptions":[
          "(S) or pellet "
        ],
        "rois":[
          {
            "x":7,
            "y":35,
            "x2":981,
            "y2":655
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) phases. T are the fractions taken prior to centrifugation. All fractions were separated by SDS-PAGE and stained with SYPRO Ruby (Bio-Rad, Hercules CA)."
        ],
        "rois":[
          {
            "x":14,
            "y":659,
            "x2":1931,
            "y2":1161
          },
          {
            "x":1031,
            "y":7,
            "x2":1931,
            "y2":652
          }
        ]
      }
    }
  },
  "4030737":{
    "Fig 8.TIF":{
      "A":{
        "descriptions":[
          "(A) Protein elution profile of McES at 280 nm. "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":1031,
            "y2":565
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Protein concentration of eluted fractions of McES, as measured by Bicinchoninic acid assay. "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":1031,
            "y2":565
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) LPS-driven IL-12p70 release following BMDC pre-exposure to 5 ??g/ml of each McES fractions. Most active IEX fractions are indicated. "
        ],
        "rois":[
          {
            "x":4,
            "y":102,
            "x2":1797,
            "y2":1370
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) One-dimensional SDS-PAGE of 1 ??g of the most represented Ion-exchange-chromatography-based McES fractions."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4030785":{
    "Fig 9.TIF":{
      "A":{
        "descriptions":[
          "(A) Superdex 200 chromatogram of McES fractions. The fractions were monitored by recording the absorbance at 280 nm for protein content. "
        ],
        "rois":[
          {
            "x":23,
            "y":738,
            "x2":840,
            "y2":1337
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Protein concentration of eluted McES fractions, as measured by Bicinchoninic acid assay. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) LPS-driven IL-12p70 release following BMDC pre-exposure to 5 ??g/ml of each McES fractions. Most active GFX fractions are indicated. "
        ],
        "rois":[
          {
            "x":4,
            "y":3,
            "x2":883,
            "y2":724
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) One-dimensional SDS-PAGE of 1 ??g of the most represented gel-filtration-based McES fractions. Proteins are visually clustered on the gel into 3 groups of molecular weight i.e. group i) 25->130kda, group ii) "
        ],
        "rois":[
          {
            "x":881,
            "y":698,
            "x2":1797,
            "y2":1310
          },
          {
            "x":868,
            "y":75,
            "x2":1761,
            "y2":681
          }
        ]
      }
    }
  },
  "4031580":{
    
  },
  "4031613":{
    
  },
  "4031637":{
    
  },
  "4031673":{
    
  },
  "4031709":{
    
  },
  "4031745":{
    
  },
  "403556":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) PBMC were collected from 10 Caucasian (CAU), and 10 Gabonese (GAB) healthy donors, and 10 CHIKV-infected patients (CHIK) to determine intracellular production of IFN-?? after overnight treatment with IL-12 and IL-18. Horizontal bars indicate the median. ***: p-CD56+ NK-cell gate for flow cytometric analysis. Numbers denote the percentage of intracellular IFN-??+ production among CD3-CD56+ NK cells. "
        ],
        "rois":[
          {
            "x":776,
            "y":8,
            "x2":1423,
            "y2":1220
          },
          {
            "x":9,
            "y":8,
            "x2":726,
            "y2":548
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Correlation between NKG2C expression by CD3-CD56+ NK cells and IFN-?? production in the sera of CHIKV-infected patients determined with Luminex Technology (Bio-Rad), as recently published [14]."
        ],
        "rois":[
          {
            "x":7,
            "y":589,
            "x2":743,
            "y2":1204
          }
        ]
      }
    }
  },
  "4040535":{
    
  },
  "404222":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) TEL and MN1-TEL bind RAR and RXR whereas MN1 does not. In vitro generated, 35S-labeled proteins, as shown in the input lanes, were used for GST pulldowns with GST-RAR, GST-RXR and GST (as control). "
        ],
        "rois":[
          {
            "x":6,
            "y":6,
            "x2":1022,
            "y2":449
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) TEL binds the DBD domain of RAR??. Upper panel: Schematic overview of the RAR?? and RXR?? constructs. The domains within RAR?? and RXR?? are indicated with letters commenly used to indicate the domains within the nuclear receptor family. At the bottom the different regions are indicated with respect to their function. AF1, Activator function 1; DBD, DNA binding domain; CTE, C-terminal extension; LBD, ligand-binding domain; AF2, activator function 2. Lower panel: GST pulldowns with in vitro transcribed/translated TEL and TIF2. Binding of TEL to RAR and RXR differs from the binding of TIF2 to RAR?? and RXR??. Binding of TIF2 was detected for LB-containing RAR?? constructs whereas TEL bound to the DBD region of RAR??. No binding of TEL to the AF1 and first part of DBD was detected (GST-RAR-N2). "
        ],
        "rois":[
          {
            "x":1045,
            "y":6,
            "x2":2061,
            "y2":893
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HLH and DBD domains of TEL are crucial for binding to RAR??. Upper panel: Schematic overview of deletion constructs of TEL. Numbers indicate the amino acid positions. Middle left: ITT products were used for GST pulldown assays with GST-RAR-N3. Middle right: Only deletion constructs that contain both HLH and DBD domains were detected in the in vitro binding assay. Lower panel: WT TEL showed binding to GST-RAR??, whereas HLH, DBD or double mutant TEL proteins failed to bind GST-RAR??. "
        ],
        "rois":[
          {
            "x":1044,
            "y":923,
            "x2":2060,
            "y2":1537
          },
          {
            "x":7,
            "y":457,
            "x2":1023,
            "y2":1530
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) bio-precipitation of bioV5-tagged RAR-N3 proteins. Only in the presence of bioV5-tagged RARN3, TEL-HA proteins were detectable in the precipitations, showing the in vivo binding between TEL and RAR. Right panel shows input lysates. TEL proteins were detectable with both a-TEL and a-HA antibodies."
        ],
        "rois":[
          {
            "x":1045,
            "y":6,
            "x2":2061,
            "y2":893
          }
        ]
      }
    }
  },
  "4045446":{
    
  },
  "404574":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A), Nitrotyrosine "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1988,
            "y2":540
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and GFAP "
        ],
        "rois":[
          {
            "x":13,
            "y":544,
            "x2":1972,
            "y2":1040
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) in the cortex of sham operated animals and MCAO operated animals from the ischemic or contralateral side (24 hours after reperfusion). No differences were seen between genotypes (n???=???4). Protein levels were normalized to actin. D???F. Bio-Plex measurements of the cytokines IL-1??, TNF-?? and IL-6 in pg/mL in the cortex of CpKO and WT animals 3 hours after reperfusion (n???=???7 per group). No significant differences were seen between the two groups."
        ],
        "rois":[
          {
            "x":1174,
            "y":1110,
            "x2":1987,
            "y2":1515
          },
          {
            "x":15,
            "y":1005,
            "x2":1016,
            "y2":1517
          }
        ]
      }
    }
  },
  "4048332":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) An evaluation of the whole transcriptome was performed after direct injection of purified Saxitoxin in mussels, followed by RNA sequencing using the HiSeq2000 platform (Illumina, San Diego, USA) and bioinformatics analysis with the commercial CLC Genomic Workbench software (CLC Bio, Denmark). Complementary to this, "
        ],
        "rois":[
          {
            "x":0,
            "y":873,
            "x2":1944,
            "y2":1845
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) a validation assay was performed by exposing mussels to toxic Alexandrium catanella and Alexandrium tamarense, followed by evaluating the expression levels of selected transcripts through RT-qPCR."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1944,
            "y2":872
          }
        ]
      }
    }
  },
  "4048359":{
    "Fig 6.TIF":{
      "A":{
        "descriptions":[
          "A) sRecE was tagged with Alexa Fluor 647 and adsorbed to PLGA nanoparticles and inoculated into to footpad. At indicated time points, the draining popliteal lymph nodes (PLNs) were isolated and analyzed for total fluorescence. The upper panel comparing sRecE and 80??320 nm PLGA-RecE is representative for the measure of antigen presence in the PLNs. The comparison of all nanoparticle sizes is depicted in the lower panel"
        ],
        "rois":[
          {
            "x":4,
            "y":5,
            "x2":2146,
            "y2":1175
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The foot pads were analyzed at similar time points to analyze the bio-availability at the inoculation site. Statistical analysis was done by two-way ANOVA followed by Bonferroni posttests. * p"
        ],
        "rois":[
          {
            "x":1169,
            "y":6,
            "x2":1941,
            "y2":332
          }
        ]
      }
    }
  },
  "404949":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Coexpression of Pax6, SPBP and AR in mammalian cell lines. Approximately 50 ??g proteins from each of the whole cell extracts were separated on 6 and 12% SDS-polyacrylamide gels, followed by immunoblotting using anti-Pax6 (Chemicon), anti-AR (Santa Cruz), anti-SPBP [10] and anti-actin (Sigma) antibodies. Actin was used as a loading control. The cell lines used were HeLa (human epithelial), HEK293 (human embryonic kidney), MEF (mouse embryonic fibroblast), Kelly and SKNBe(2) (human neuroblastoma), and Du145, PC3 and LNCaP (human prostate cancer)."
        ],
        "rois":[
          {
            "x":818,
            "y":842,
            "x2":1591,
            "y2":1682
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Colocalization between GFP-AR and Cherry-Pax6 or Cherry-SPBP, respectively. The GFP-AR 3108 expressing cell line [30] was transiently transfected with 100 ng pDestCherry-Pax6 or 150 ng pDestCherry-SPBP using TransIT-LT1 (Mirus Bio). The cells were stimulated with synthetic androgen R1881 and live cell images obtained using a Zeiss LSM510 confocal laser scanning microscope. Scale bars: 10 ??m. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":287,
            "y2":528
          },
          {
            "x":294,
            "y":10,
            "x2":1547,
            "y2":298
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Colocalization between GFP- and Cherry-tagged SPBP and Pax6. HeLa cells were transiently cotransfected with either 175 ng pDestEGFP-SPBP and 25 ng pDestCherry-Pax6, or 25 ng pDestEGFP-Pax6 and 175 ng pDestCherry-SPBP using TransIT-LT1 (Mirus Bio). Live cell images were obtained as in A. Scale bars: 10 ??m. "
        ],
        "rois":[
          {
            "x":7,
            "y":541,
            "x2":523,
            "y2":822
          },
          {
            "x":294,
            "y":299,
            "x2":1547,
            "y2":534
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Pearson's correlation coefficients support the colocalization of GFP-AR with mCherry-SPBP and mCherry-Pax6 shown in A and B. The correlation is based on the average of 5???10 independent cells, with standard deviations shown. The nuclear correlation between mCherry-Pax6 and nuclear GFP, and GFP-Pax6 and nuclear mCherry, were used as negative controls. "
        ],
        "rois":[
          {
            "x":34,
            "y":829,
            "x2":759,
            "y2":1882
          },
          {
            "x":847,
            "y":567,
            "x2":1548,
            "y2":836
          },
          {
            "x":529,
            "y":554,
            "x2":759,
            "y2":822
          }
        ]
      }
    }
  },
  "4051293":{
    
  },
  "405704":{
    
  },
  "407324":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "(a) Expression of human delta-sarcoglycan assessed by WB analysis in the hearts respectively of a positive control of transduction (CRT+), negative control (CRT-), BIO14.6 AAV and BIO 14.6 AAV+DEF 6 weeks after AAV delivery (???8 weeks). "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":2879,
            "y2":1331
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Explanted hearts from BIO 14.6 AAV and BIO 14.6 AAV+DEF hamsters at 9 months of age. The heart dilation of a BIO14.6AAV+DEF hamster is evident if compared with a BIO14.6 AAV hamster. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) Hematoxylin-eosin staining on cryosections of the hearts of BIO14.6 AAV 6 weeks after AAV delivery, BIO 14.6 AAV at 9 months, BIO14.6 AAV+DEF at 9 months, the healthy control (GS hamsters) and the untreated BIO14.6 hamsters. "
        ],
        "rois":[
          {
            "x":11,
            "y":1393,
            "x2":694,
            "y2":1897
          }
        ]
      },
      "D":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":698,
            "y":1403,
            "x2":2879,
            "y2":1897
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) On the same groups of hamsters we performed Masson's trichrome staining on a cryosection of the heart. (10 ??m)."
        ],
        "rois":[
          {
            "x":11,
            "y":1393,
            "x2":694,
            "y2":1897
          }
        ]
      }
    }
  },
  "407572":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) ejection fraction (EF) "
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":1516,
            "y2":1040
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) LEVDd respectively in the BIO 14.6 AAV, BIO14.6 AAV+DEF, BIO14.6 +DEF and BIO14.6 hamsters at 9 months. Statistical significance is calculated in comparison with the BIO14.6 group."
        ],
        "rois":[
          {
            "x":7,
            "y":1063,
            "x2":1516,
            "y2":2162
          }
        ]
      }
    }
  },
  "407861":{
    
  },
  "4083957":{
    "Fig 10.TIF":{
      "E":{
        "descriptions":[
          "(E) were analyzed after 4 h. *P P "
        ],
        "rois":[
          {
            "x":14,
            "y":2282,
            "x2":783,
            "y2":3311
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Tln1 mRNA level in YAMC cells transduced with Ctrl, Slc7a2, or Tln1 shRNA, infected or not with C. rodentium (C. rod). **P n = 3 independent experiments. "
        ],
        "rois":[
          {
            "x":85,
            "y":14,
            "x2":962,
            "y2":1051
          },
          {
            "x":620,
            "y":1122,
            "x2":2022,
            "y2":2150
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Effect of L-Lys on Tln1 expression in YAMC cells. ***P n = 3 independent experiments. "
        ],
        "rois":[
          {
            "x":925,
            "y":2187,
            "x2":2616,
            "y2":3164
          },
          {
            "x":986,
            "y":110,
            "x2":1623,
            "y2":393
          },
          {
            "x":620,
            "y":1122,
            "x2":2022,
            "y2":2150
          },
          {
            "x":1708,
            "y":14,
            "x2":2522,
            "y2":1126
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Cells were L-Arg-depleted or not and treated with actinomycin D (ActD); total RNA was extracted at the indicated times and Tln1 mRNA was analyzed by real-time PCR. The combined results of two independent experiments are shown and depicted as the percent of the Tln1 expression compared to the level before addition of actinomycin D. (D-E) YAMC cells were transduced with Ctrl or Tln1 shRNA infected with C. rodentium; FAS test "
        ],
        "rois":[
          {
            "x":361,
            "y":3243,
            "x2":2247,
            "y2":4344
          },
          {
            "x":620,
            "y":1122,
            "x2":2022,
            "y2":2150
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and Cxcl1 and Cxcl2 mRNA levels "
        ],
        "rois":[
          {
            "x":14,
            "y":2282,
            "x2":783,
            "y2":3311
          }
        ]
      }
    }
  },
  "409370":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Binding of 100 nM radiolabeled CL4, prior incubated with 300 nM EC-EGFR or EC-ErbB3 for 15 min at 37??C, on A549 cells. In (B???E), the results are expressed relative to the background binding detected with the CL4sc used as a negative control. Error bars depict means ?? s.d. (n???=???3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Lysates from A549 cells untreated (lane 1) or treated with biotinylated CL4sc (CL4sc-bio, lane 2) or CL4 (CL4-bio, lane 3) were purified on streptavidin beads and immunoblotted with anti-EGFR antibodies. Lane 4, 10 ??g-cell lysates. In ",
          "(A, C, F), molecular weights of indicated proteins are reported."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Lysates from NIH3T3 or NIH/EGFR cells were immunoblotted with anti-EGFR antibodies. ??tubulin was used as an internal control. ",
          "(A, C, F), molecular weights of indicated proteins are reported."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Binding of radiolabeled CL4 on NIH3T3 or NIH/EGFR. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Lysates from A549 cells following 72 h-transfection with a specific EGFR shRNA (shRNAEGFR) or a non-related shRNA (shRNActrl) were immunoblotted with anti-EGFR antibodies. ??tubulin was used as an internal control. Values below the blot indicate signal levels relative to control non transfected, arbitrarily set to 1 (labeled with asterisk). Intensity of bands has been calculated using the NIH Image Program on at least two different expositions to assure the linearity of each acquisition. ",
          "(A, C, F), molecular weights of indicated proteins are reported."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Binding of 100 nM radiolabeled CL4 on A549 cells in the absence or in the presence of 1 ??M EGF or on A549 cells following 72 h-transfection with shRNAEGFR or shRNActrl. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2464
          }
        ]
      }
    }
  },
  "4095555":{
    
  },
  "4096890":{
    
  },
  "4107330":{
    "Fig 3.TIF":{
      "a":{
        "descriptions":[
          "(a) Sensitivity of TF for infection. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":770,
            "y2":862
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Specificity of TF for infection. "
        ],
        "rois":[
          {
            "x":879,
            "y":0,
            "x2":1649,
            "y2":859
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Positive Predictive Value (PPV) of TF for C. trachomatis infection. "
        ],
        "rois":[
          {
            "x":0,
            "y":926,
            "x2":769,
            "y2":1775
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Negative Predictive Value (NPV) of TF for C. trachomatis infection. Data from population-based studies, summarised in Table 1. The size of the circles reflects the sample size. Line fitted by linear regression, weighted by the size of the studies, except for the PPV which was fitted by polynomial."
        ],
        "rois":[
          {
            "x":878,
            "y":926,
            "x2":1650,
            "y2":1775
          }
        ]
      }
    }
  },
  "410758":{
    
  },
  "4108101":{
    
  },
  "4111":{
    
  },
  "411481":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) TOPflash reporter assay in MDCK cells (control, ???Tet) or MDCK cells depleted of E-cadherin (E-cadherin shRNA, +Tet). Cells transfected with TOPflash reporter were either treated with Wnt3a medium or co-transfected with ??-catenin. Treatment of cells with HGF enhances cells' response to Wnt3a or ??-catenin, as seen in Fig. 1E and 1F. In cells depleted of E-cadherin, HGF fails to enhance the response to Wnt3a and ??-catenin. "
        ],
        "rois":[
          {
            "x":13,
            "y":987,
            "x2":2510,
            "y2":2089
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Western blot analysis of membrane (upper two rows) and cytosolic (lower four rows) fractions of MDCK cells without or with induction of E-cadherin shRNA expression, without or with HGF. Some groups of cells were treated with Wnt3a conditioned medium or with 2 ??M BIO, a GSK3?? inhibitor, or transfected with myc-tagged ??-catenin, as indicated at the top. The membrane fraction analysis shows that E-cadherin shRNA completely abolishes E-cadherin protein. The cytosolic fraction was analysed with anti-Active-??-catenin (ABC) and anti-??-catenin (total) antibodies, along with anti-myc antibody to detect exogenous ??-catenin and with anti-??-tubulin for loading control. Cell lysate of A431 human carcinoma was used as a positive control for anti-active-??-catenin antibody. In all experimental groups, active-??-catenin is increased in response to HGF when E-cadherin expression is kept intact. In contrast, in the absence of E-cadherin the ability of HGF to increase active-??-catenin is abolished. Note that myc-tagged ??-catenin, larger than endogenous one in size, is also detected by ABC antibody, responding to HGF and to the loss of E-cadherin in a manner similar to endogenous ones treated with Wnt3a or BIO. "
        ],
        "rois":[
          {
            "x":55,
            "y":2263,
            "x2":2509,
            "y2":4492
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) TOPflash reporter assay in MDCK cells (control, ???Tet) or MDCK cells depleted of E-cadherin (E-cadherin shRNA, +Tet). Cells were transfected with TOPflash reporter along with ??-catenin (??-cat) or the stabilised form in which four serine and threonine residues of GSK3?? targets have been mutated to alanine (??4A) [45]. Similar to ??-catenin, ??4A construct does not show any significant activation of the reporter in E-cadherin-depleted cells, regardless of presence or absence of HGF."
        ],
        "rois":[
          {
            "x":13,
            "y":987,
            "x2":2510,
            "y2":2089
          },
          {
            "x":52,
            "y":13,
            "x2":2494,
            "y2":848
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and "
        ],
        "rois":[
          {
            "x":13,
            "y":987,
            "x2":2510,
            "y2":2089
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) (C???,D???) are exogenous ??-catenin detected by myc tag. For the exogenous ??-catenin in the presence of E-cadherin, see Fig. 3J,K. E-cadherin-depleted cells do not scatter by HGF and the majority of ??-catenin remains on the cell membrane, while the minority distributes in the cytoplasm in a punctuated manner. Transfected ??-catenin localises at the cell membrane in the absence of HGF (C???), while it distributes in the cytoplasm in the presence of HGF (D???), similar to E-cadherin-positive MDCK cells (see Fig. 3J,K). Scale bar, 20 ??m. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "411876":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Immunoblot analysis of recombinant proteins extraction from transgenic rice seeds by four different extraction buffers, B1, B2, B3 and To. Total protein samples extracted from equal amount of rice seed powder by different buffers (see Materials and Methods) were used for analysis. "
        ],
        "rois":[
          {
            "x":1195,
            "y":1870,
            "x2":1906,
            "y2":2741
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Relative accumulation levels of PAL in SP and SA rice seeds. gPAL, N-glycosylated PAL; and ePAL, relative amount of PAL derived from ELP-intein-PAL fusion protein. "
        ],
        "rois":[
          {
            "x":1195,
            "y":1870,
            "x2":1906,
            "y2":2741
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Analysis of total protein extracted from transgenic rice seeds by SDS-PAGE and by immunoblot using anti-PAL antibody, anti-PAL. WT, non-trangenic rice; and M, Precision plus protein Standards (Bio-Rad). Empty trangle denoted the band of synthesized EiP in SA seeds and black triangle denoted the immunoactive band of N-glycosylated PAL. Arrows denoted PAL and ELP-intein-PAL fusion protein (EiP). "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1420,
            "y2":995
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Accumulation levels of uncleaved EiP in T1 and T2 seeds of SA transformed rice. Error bars indicate standard deviation among different transgenic lines."
        ],
        "rois":[
          {
            "x":2013,
            "y":1869,
            "x2":2687,
            "y2":2741
          },
          {
            "x":34,
            "y":2018,
            "x2":1218,
            "y2":2683
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) N-Glycosylation analysis of PAL in SP (top panel) and EiP in SA seeds (bottom panel) by Endo H digestion. gPAL, N-glycosylated PAL and gEiP, N-glycosylated EiP. "
        ],
        "rois":[
          {
            "x":1622,
            "y":15,
            "x2":2514,
            "y2":817
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Detection of Ei tag in total protein extracted from SA seeds by immunoblot using anti-ELP antibody. Only EiP fusion protein was detected while free Ei tag was not observed. Arrows denoted N-glycosylated PAL (gPAL), PAL and ELP-intein-PAL fusion protein (EiP). "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1420,
            "y2":995
          },
          {
            "x":12,
            "y":1041,
            "x2":903,
            "y2":1928
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Immunoblot analysis on total protein extracted from SA seeds of different trnagenic lines (1???6) using anti-PAL antibody. "
        ],
        "rois":[
          {
            "x":1096,
            "y":952,
            "x2":2606,
            "y2":1741
          }
        ]
      }
    }
  },
  "412478":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Analysis of total protein by SDS-PAGE and by immunoblot using anti-ELP antibody, anti-ELP. Equal amount of total protein was loaded in all lanes. To, extracted by total protein extraction buffer; Bt, extracted by Bt buffer. "
        ],
        "rois":[
          {
            "x":15,
            "y":16,
            "x2":1721,
            "y2":1279
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Relative purification efficiency of EiP from transgenic rice seeds. Samples EX, EXF, DS, DSC, 1CS, 2CS, 3CS, FP and FS, as denoted in the Purification Scheme and Materials and Methods. Recovery percentage of EiP was counted relative to EiP extracted by total protein extraction buffer, and error bar was obtained from three independent experiments. (C???D) Purification of PAL from rice seeds by the ELP-intein system: "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) SDS-PAGE analysis; "
        ],
        "rois":[
          {
            "x":54,
            "y":15,
            "x2":3950,
            "y2":2444
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) immunoblot reacted with anti-ELP antibody, anti-ELP and anti-PAL antibody, anti-PAL. Lanes EX, EXF, DS, DSC, 1CS, 2CS, 3CS, FP and FS, as denoted in the Purification Scheme and Materials and Methods; and M, Precision Plus protein Standards (Bio-Rad). Arrows indicated ELP-intein-PAL fusion protein (EiP), cleaved ELP-intein tag (Ei), and purified PAL and N-glycosylated PAL (gPAL)."
        ],
        "rois":[
          {
            "x":1803,
            "y":1431,
            "x2":4118,
            "y2":2500
          }
        ]
      }
    }
  },
  "412906":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Frozen video frames (under infrared lighting) showing onset of a violent clonic seizure (E1) in a Brd2+/??? mouse and the end of status epilepticus (after more than an hour of clonic seizures) in the same mouse (E2)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4111,
            "y2":2856
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Scheme of head mounted electrodes with one reference (REF) in the nasal bone, one common ground in the occipital area, and active electrodes in the left and right frontal area (LF, RF, respectively) and in both occipital areas (BiO). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4111,
            "y2":2856
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) EEG recordings of interictal discharges (one indicated by an arrow) in a Brd2+/??? mouse associated with myoclonic jerks (twitches of body musculature). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4111,
            "y2":2856
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) EEG recordings from the same mouse showing a long EEG seizure consisting of spike-and-wave pattern. Onset of seizure is marked by an arrowhead. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4111,
            "y2":2856
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) EEG recordings of spindle-shaped sharp wave episodes associated with behavioral freezing in another Brd2+/??? mouse. Onset of two spindles (about 3 s and 1 s long) is marked by arrowheads. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4135908":{
    
  },
  "4141362":{
    
  },
  "415860":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Detection of endogenous RPS3a mRNA levels in the tumor and non-tumor regions of HBV-associated HCC tissues. Total RNA was extracted from tumor or non-tumor tissues of three HBV-caused HCC patients. Using total RNA extracts (2 ??g) and oligo dT primer, cDNA was synthesized. N and T represent the non-tumor tissues and tumor tissues, respectively. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1306
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Relative expression ratio of RPS3a mRNA between the tumor and non-tumor tissues of HBV-associated HCC. Data were calculated by three independent experiments (* PC) Representative immunohistochemistry data of endogenous RPS3a protein expression in the HBV-associated HCC tissues. The difference of RPS3a expression between non-tumor and tumor tissues was determined by visual inspection under microscope (magnification ??400) and assigned on the top of the panels. See Table 1 for full information. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2011,
            "y2":1306
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Generation and validation of human RPS3a antibody. Human RPS3a protein was produced in E. coli and the rabbit antibody was generated. The specificity of the generated antibody was validated by knock-down and over-expression of RPS3a in Huh7 cells. Huh7 cells were harvested at 72 hr after transfection."
        ],
        "rois":[
          {
            "x":0,
            "y":1307,
            "x2":2011,
            "y2":2830
          }
        ]
      }
    }
  },
  "4163007":{
    
  },
  "41670":{
    
  },
  "416764":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A. Purity of Thermus MTHFR (tMTHFR) with or without a His-tag was analyzed by 12% polyacrylamide gel electrophoresis under denaturing conditions. The gel was stained by Quick-CBB (Wako Pure Chemical, Osaka, Japan). The molecular markers were obtained from Bio-Rad. BPB, bromophenol blue"
        ],
        "rois":[
          {
            "x":97,
            "y":10,
            "x2":912,
            "y2":1450
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Measurement of the native molecular mass of the as-purified MTHFR by size exclusion column chromatography using the multi-angle light scattering detector. The red dots show the molecular weight at each point in the chromatogram, while the solid line shows the elution profile detected by the refractive index detector"
        ],
        "rois":[
          {
            "x":10,
            "y":1536,
            "x2":1215,
            "y2":2820
          },
          {
            "x":1260,
            "y":19,
            "x2":2399,
            "y2":1412
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Anaerobic titration of the as-purified MTHFR with NADH. Fifteen nmol of enzyme (based on FAD content) was prepared in the anaerobic cuvette, then titrated with NADH. The initial spectrum is shown in the red line, and the final one is blue. (inset) Changes in absorbance at 450 nm"
        ],
        "rois":[
          {
            "x":10,
            "y":1536,
            "x2":1215,
            "y2":2820
          },
          {
            "x":1277,
            "y":1538,
            "x2":2463,
            "y2":2830
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Anaerobic titration of the FAD-replete MTHFR with (6RS)- 5-CH3-H4folate. Fifteen nmol of enzyme was used. The initial spectrum is shown in the red line. The final spectrum, which is shown in blue, is resemble to the spectrum of the fully reduced FAD, indicating that (6S) - 5-CH3-H4folate could reduce all FAD to the fully reduced form of FAD. (inset) Changes in absorbance at 450 nm."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "417753":{
    
  },
  "41855":{
    
  },
  "419197":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Genomic structure of bro-1, showing the size and position of the CNE. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1511,
            "y2":372
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Alignment of the C. elegans bro-1 CNE with orthologues from C. briggsae and C. brenneri reveals high levels of sequence conservation at the 3??? end of intron 1. Conservation is still evident, though less pronounced, when C. remanei and C. japonica are included in the alignment (data not shown). Predicted GATA binding sites are labelled. Sequence alignments were performed using CLC Sequence Viewer v6.4 (CLC bio, Aarhus, Denmark). Red shading denotes that sequences are conserved across all 3 species of nematode; pink denotes conservation in 2 out of 3 species; blue denotes no conservation."
        ],
        "rois":[
          {
            "x":0,
            "y":373,
            "x2":1511,
            "y2":1268
          }
        ]
      }
    }
  },
  "419442":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic representation of the His6-tagged recombinant GAV N protein (QE10-N2) and truncated N protein constructs (QE10-N1, -N14, -N38, -N22, -N25) used in EMSAs, including amino acid length, deduced molecular weight, pI and their ability to bind ssRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1344,
            "y2":615
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) CBB-stained SDS-PAGE gel showing the purity of Ni2+-purified His6-tagged fusion proteins. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Western blot of a duplicate gel with protein detected using Ni2+-HRP. M1 ???=??? low range protein standards (Amersham Biosciences), M2 ???=??? pre-stained Precision Plus All-Blue molecular weight standards (Bio-Rad)."
        ],
        "rois":[
          {
            "x":0,
            "y":616,
            "x2":1344,
            "y2":1233
          }
        ]
      }
    }
  },
  "419664":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A) Chemiarray: Rat cytokine array membranes were incubated with 1 ml of 2-fold diluted fa+ or fa/fa rats plasma for 2 h. After removing unbound materials, membranes were incubated with a mixture of biotin-labeled antibodies and controls with TBS buffer only. Signals were detected with HRP-conjugated streptavidin and ECL. The relative expression levels of cytokines were determined by densitometry and plotted from 4 fa/+ and 4 fa/fa rats. The array membranes were scanned with a chemiluminescence imager. Signal densities were normalized and background corrected"
        ],
        "rois":[
          {
            "x":8,
            "y":17,
            "x2":913,
            "y2":819
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Bio-Plex rat cytokine analysis. Cytokines concentrations were calculated automatically with Bio-Plex Manager software, using a standard curve derived from a recombinant cytokine standard. Concentrations are given in picograms per milliliter."
        ],
        "rois":[
          {
            "x":1026,
            "y":8,
            "x2":2011,
            "y2":824
          }
        ]
      }
    }
  },
  "42021":{
    
  },
  "42022":{
    
  },
  "42023":{
    
  },
  "42024":{
    
  },
  "42025":{
    
  },
  "42027":{
    
  },
  "42028":{
    
  },
  "42029":{
    
  },
  "42030":{
    
  },
  "42031":{
    
  },
  "4203957":{
    "Fig 9.TIF":{
      "a":{
        "descriptions":[
          "(a) A bilayer made up of spruce veneer (active layer) glued to a thick paper (passive layer), bends upon anisotropic swelling of the spruce veneer in the direction perpendicular to the cellulose fibrils orientation. "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b) Two of such bilayers attached together, constructs a cell-like structure that can open/closes upon changes in the relative humidity. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) Scaling up the bilayer-cell concept into a hydro-actuated honeycomb prototype that expands up to 5 fold upon actuation (sequential images after 0, 2, 4 and 16 hours of exposure to 95%RH) [20]."
        ],
        "rois":[
          {
            "x":3,
            "y":1547,
            "x2":482,
            "y2":2316
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":504,
            "y":3,
            "x2":1997,
            "y2":2316
          },
          {
            "x":10,
            "y":9,
            "x2":729,
            "y2":724
          },
          {
            "x":10,
            "y":746,
            "x2":734,
            "y2":1447
          }
        ]
      }
    }
  },
  "4214214":{
    
  },
  "421490":{
    
  },
  "422332":{
    
  },
  "4225808":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "; A: antisaccade"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3648,
            "y2":1611
          }
        ]
      },
      "P":{
        "descriptions":[
          "; P: prosaccade."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4227866":{
    "Fig 3.TIF":{
      "A":{
        "descriptions":[
          "A) A fraction of the arrested K562 cells treated with 20 ??M of curcumin showed DNA damage as indicated by the presence of TUNEL-positive cells and FACS analysis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1915,
            "y2":1822
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The percentage of TUNEL-positive cells is represented by graphic bars, and C) production of a typical apoptotic DNA ladder is shown"
        ],
        "rois":[
          {
            "x":220,
            "y":1857,
            "x2":1636,
            "y2":2642
          },
          {
            "x":0,
            "y":0,
            "x2":1915,
            "y2":1822
          },
          {
            "x":2171,
            "y":0,
            "x2":3581,
            "y2":1790
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) Cell death was confirmed by death assays; FACS analysis, and E) the results are also shown as graphic bars. As positive controls of DNA fragmentation, we used cells treated with 100 nM nocodazole for 24 h. As a positive control of cell death, K562 cells were exposed to UV (40 mJ/cm2) for 2 min in a cross-linker GS Gene linker-UV chamber (Bio-Rad, Hercules CA, USA) and were recovered 24 h post-irradiation."
        ],
        "rois":[
          {
            "x":6,
            "y":2762,
            "x2":3637,
            "y2":4673
          }
        ]
      }
    }
  },
  "423351":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) A DMSO-treated (100 ??l/l) control froglet showed no regeneration. (B and C) BIO-treated (1 ??M) froglets regenerated a short spike "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":385,
            "y2":912
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or a long spike "
        ],
        "rois":[
          {
            "x":404,
            "y":9,
            "x2":1171,
            "y2":912
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Lines indicate the estimated amputation planes. Scale bar???=???500 ??m."
        ],
        "rois":[
          {
            "x":404,
            "y":9,
            "x2":1171,
            "y2":912
          }
        ]
      }
    }
  },
  "4236407":{
    
  },
  "4239497":{
    
  }
,
  "4240865":{
    
  },
  "424737":{
    
  },
  "424851":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A), IL-4 "
        ],
        "rois":[
          {
            "x":1194,
            "y":1137,
            "x2":2176,
            "y2":1879
          },
          {
            "x":12,
            "y":12,
            "x2":1124,
            "y2":920
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), and IL-10 "
        ],
        "rois":[
          {
            "x":1193,
            "y":207,
            "x2":2193,
            "y2":920
          },
          {
            "x":12,
            "y":12,
            "x2":1124,
            "y2":920
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) in lung homogenates were measured by Bio-Plex multiple immunassay. D, ratio of IFN-?? to IL-4. Data represents mean and SEM calculated from three independent experiments with a total of 6 - 7 mice per group (*different from BC7/PBS group at respective time points, p???ANOVA)."
        ],
        "rois":[
          {
            "x":18,
            "y":1028,
            "x2":1137,
            "y2":1879
          }
        ]
      }
    }
  },
  "4251425":{
    "Fig 9.tif":{
      "A":{
        "descriptions":[
          "(A) and ",
          "(A) and inside "
        ],
        "rois":[
          {
            "x":9,
            "y":7,
            "x2":3979,
            "y2":2195
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) in Fig 8. Two-dimensional electrograms calculated under strong remodeling conditions outside ",
          "(D) the fibrotic area (? = 0.72)."
        ],
        "rois":[
          {
            "x":7,
            "y":3567,
            "x2":3983,
            "y2":4773
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) the fibrotic area (? = 0.48) in comparison with three-dimensional electrograms calculated under intermediate remodeling conditions outside "
        ],
        "rois":[
          {
            "x":27,
            "y":2585,
            "x2":3989,
            "y2":3663
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and inside "
        ],
        "rois":[
          {
            "x":9,
            "y":7,
            "x2":3979,
            "y2":2195
          }
        ]
      }
    }
  },
  "425280":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic diagram of the E2F1 3???UTR, ARE region sequences, and locations. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2958,
            "y2":2236
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The E2F1 3???UTR sequences in different species "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2958,
            "y2":2236
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Sequences from the E2F1 3???UTR (ARE regions 1 to 3), IL-8 3???UTR (ARE control), and a control that lacks ARE were inserted in BamHI/XbaI sites in EGFP expression vector as shown. The Huh7 cell line (2.104 cells per well) in 96-well black clear-bottom microplates were transfected with the different 3???UTR constructs. The reporter activity was assessed after 24 hr using BD bio-imaging apparatus and software. The non-ARE 3???UTR was used as control and its fluorescence activity was taken as 100%. Data are presented as Mean??SEM (n???=???4) of % of the control. *** denote p values of p 4 cells per well) were seeded in 96-well black clear-bottom microplates and then transfected with the different 3???UTR constructs. Reporter activity was assessed as described in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2958,
            "y2":2236
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). ANOVA was performed to compare between U2OS and EH1 data groups."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2958,
            "y2":2236
          }
        ]
      }
    }
  },
  "425461":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Patient-derived PML/RAR??-positive NB4 cells treated with SSo (200 ??M), SSi (200 ??M) or 0.02% DMSO at 24 h and 48 h. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2225
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) PML/RAR??-expressing KG-1 cells treated at the cell type-specific IC50 (100 ??M - SSi, 360 ??M - SSo and 0.02% DMSO) at 72 h. Control - empty-vector-transfected cells; ??-??-tubulin-loading control. (C???D) protein quantification of western blots presented in panel A and B, the bars represent the band intensity relative to the intensity of the tubulin bands reveled with a S-800 Densitometer and the Quantity One software (Bio-Rad)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4255475":{
    
  },
  "426799":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) in wtD3 ES cells cultured in LIF-supplemented standard medium (blue bar), DMSO control (red bar), 1 ??M BIO (light green bar) and 2 ??M BIO (dark green bar)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. TOPflash and FOPflash reporter plasmid expression in Ecad-/- ES cells cultured in LIF-supplemented standard medium (blue bar), DMSO control (red bar), 1 ??M BIO (light green bar) and 2 ??M BIO (dark green bar)"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". C. RT-PCR expression of Brachyury "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1676,
            "y2":1066
          }
        ]
      },
      "T":{
        "descriptions":[
          "(T), a typical Wnt activity marker, in wtD3 and Ecad-/- ES cells grown in the presence (+) and absence (???) of 2 ??M BIO. ??t ???=??? ??-tubulin (loading control). Results present mean ?? SD of one single experiment. At least, three independent experiments were performed."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1676,
            "y2":1066
          }
        ]
      }
    }
  },
  "4268444":{
    "Fig 6.tif":{
      "C":{
        "descriptions":[
          "(C) NFATc2 expression after anti-CD3 Ab plus anti-CD28 Ab engagement. The densitometric analyses of the immunoblots for the relative protein expression levels are shown as ratios of NFATc2 or pNFATc2 to ??Tubulin. Lysates from three different donors were pooled. Results are representative of at least two independent experiments. IFN?? "
        ],
        "rois":[
          {
            "x":5,
            "y":3,
            "x2":943,
            "y2":823
          },
          {
            "x":16,
            "y":859,
            "x2":1081,
            "y2":1516
          },
          {
            "x":1037,
            "y":3,
            "x2":2072,
            "y2":823
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), IL-2 "
        ],
        "rois":[
          {
            "x":5,
            "y":3,
            "x2":943,
            "y2":823
          },
          {
            "x":1076,
            "y":848,
            "x2":1977,
            "y2":1581
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E), and TNF?? "
        ],
        "rois":[
          {
            "x":18,
            "y":1475,
            "x2":917,
            "y2":2396
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) concentrations in the supernatants of unstimulated (white), of soluble anti-CD3 Ab plus anti-CD28 Ab stimulated (dark gray), and of TCR/CD3 stimulated alone (light gray, with anti-CD28 Ab isotype) of naive T cells using a Bio-Plex cytokine assay (Bio-Rad). The mean value and SD are indicated for five independent experiments (two tailed ANOVA Tukey-Kramer post-hoc test * P0.05). n = number of individuals."
        ],
        "rois":[
          {
            "x":1052,
            "y":1652,
            "x2":1974,
            "y2":2396
          }
        ]
      }
    }
  },
  "4276145":{
    "Fig 8.tif":{
      "A":{
        "descriptions":[
          "(A), or co-transfected with TAP-tagged C6 or N1 and HA-STAT2 "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":797,
            "y2":512
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or infected with the viruses shown for 16 h at 2 PFU/cell ",
          "(B) were performed. Proteins were eluted and subjected to SDS-PAGE and immunoblotting with the stated antibodies. Immunoblots were performed at least twice and a representative figure is shown. Positions of molecular mass markers are shown to the left of the immunoblots."
        ],
        "rois":[
          {
            "x":903,
            "y":4,
            "x2":1934,
            "y2":542
          },
          {
            "x":87,
            "y":520,
            "x2":809,
            "y2":645
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) or co-transfected with TAP-tagged C6 or N1 and IRF9-S2C or HA-IRF9 expressing plasmids for 16 h "
        ],
        "rois":[
          {
            "x":4,
            "y":719,
            "x2":767,
            "y2":1113
          },
          {
            "x":917,
            "y":550,
            "x2":1544,
            "y2":685
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). In panel B, 16 h after transfection cells were stimulated with 100 units/ml IFN? for 1 h. (A-D) In all panels, cells were then lysed and immunoprecipitations against the FLAG- epitope (A, C and D) and the HA- epitope "
        ],
        "rois":[
          {
            "x":19,
            "y":1123,
            "x2":1888,
            "y2":1360
          },
          {
            "x":1392,
            "y":1090,
            "x2":1926,
            "y2":1170
          },
          {
            "x":898,
            "y":764,
            "x2":1942,
            "y2":1170
          }
        ]
      }
    }
  },
  "4279031":{
    
  },
  "4281428":{
    
  },
  "429761":{
    
  },
  "429954":{
    
  },
  "430053":{
    
  },
  "430220":{
    
  },
  "4303742":{
    
  },
  "4309613":{
    
  },
  "4313801":{
    "Fig 4.tif":{
      "A":{
        "descriptions":[
          "(A) Representative hepatic western blots of phosphorylated (Thr183/Tyr185), total JNK, and phosphorylated:total JNK, phosphorylated NF?B-p65 (Ser536), total NF?B-p65, and phosphorylated:total NF?B (n = 9), and "
        ],
        "rois":[
          {
            "x":0,
            "y":1315,
            "x2":2098,
            "y2":3045
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) hepatic gene expression of inflammatory markers (n = 10). Diets not sharing a common letter differ significantly from one another (P?.05)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2098,
            "y2":1314
          }
        ]
      }
    }
  },
  "431853":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Cell survival for in Caco-BR and Colo205 cells treated with TRAIL. The values are the average of three independent experiments and are presented as fold change of the absorbance of treated/ untreated cells, for each condition. The cytotoxic effects of TRAIL were assayed by SRB. Treatment conditions are provided along the top on each column. *Pvs Ctr-untreated. "
        ],
        "rois":[
          {
            "x":469,
            "y":1858,
            "x2":721,
            "y2":2164
          },
          {
            "x":190,
            "y":1576,
            "x2":977,
            "y2":2164
          },
          {
            "x":469,
            "y":1269,
            "x2":977,
            "y2":1855
          },
          {
            "x":7,
            "y":8,
            "x2":1213,
            "y2":705
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) DISC complex analysis of functional proteins bound to Bio-TRAIL at indicated time points. "
        ],
        "rois":[
          {
            "x":191,
            "y":2167,
            "x2":976,
            "y2":2482
          },
          {
            "x":724,
            "y":1886,
            "x2":976,
            "y2":2164
          },
          {
            "x":70,
            "y":754,
            "x2":909,
            "y2":1219
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Rapid induction of apoptosis within 30 minutes with respect to activation of apoptotic markers namely Tubulin, active caspase-3, cytochrome C and Bax were analysed by immunofluorescence after addition of TRAIL. Representative confocal immunofluorescence images, double labelled with Hoechst (blue), Mitotracker (Red) and indicated antibody (green). Original magnification 63x."
        ],
        "rois":[
          {
            "x":157,
            "y":1248,
            "x2":468,
            "y2":1573
          }
        ]
      }
    }
  },
  "432227":{
    
  },
  "4329089":{
    
  },
  "4335938":{
    
  },
  "4337057":{
    "13395_2016_111_MOESM3_ESM.pdf":{
      "A":{
        "descriptions":[
          ". A) Absolute maximal force (P0)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1714,
            "y2":1234
          }
        ]
      },
      "B":{
        "descriptions":[
          ", B) specific force (P0/weight), and C) fatigue resistance in mTGs and WT mice 16?days after CTX; n\u2009=\u20097\u20138 per group. Feret minimum measurements 19?days after injections in D) PBS- and E) CTX-injected TAs; n\u2009=\u20098\u201310 per group; Values are plotted as AV\u2009?\u2009SEM; * p\u2009?\u20090.05."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1714,
            "y2":1234
          }
        ]
      }
    }
  },
  "4337102":{
    
  },
  "434210":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) increased the levels of IL-6 differentially. Primary astrocytes from different donors were transfected with gp120 plasmid in order to compare the levels of IL-6 expression after 2 hours "
        ],
        "rois":[
          {
            "x":1160,
            "y":949,
            "x2":2287,
            "y2":1833
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and IL-6 protein expressions peaked at 6 hours "
        ],
        "rois":[
          {
            "x":2322,
            "y":949,
            "x2":3433,
            "y2":1833
          },
          {
            "x":18,
            "y":13,
            "x2":1124,
            "y2":993
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Monoclonal antibody for gp120 was used to negate the gp120 mediated response and thus served as another control. Heat inactivated gp120 was compared with untreated control to show gp120 specific IL-6 expression "
        ],
        "rois":[
          {
            "x":2322,
            "y":949,
            "x2":3433,
            "y2":1833
          },
          {
            "x":13,
            "y":1023,
            "x2":1119,
            "y2":1830
          },
          {
            "x":1159,
            "y":13,
            "x2":2287,
            "y2":898
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Different strains of gp120 "
        ],
        "rois":[
          {
            "x":2322,
            "y":949,
            "x2":3433,
            "y2":1833
          },
          {
            "x":13,
            "y":1023,
            "x2":1119,
            "y2":1830
          },
          {
            "x":2320,
            "y":19,
            "x2":3433,
            "y2":896
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and monomeric gp120 SF162 and trimeric gp140 SF162 ",
          "(D). Each bar represents mean ?? SE of 3 experiments with each experiment done in triplicates. The statistical significance was calculated using student's t test and * and ** denotes p value of ???0.05 and ???0.01, respectively."
        ],
        "rois":[
          {
            "x":2322,
            "y":949,
            "x2":3433,
            "y2":1833
          },
          {
            "x":18,
            "y":13,
            "x2":1124,
            "y2":993
          },
          {
            "x":13,
            "y":1023,
            "x2":1119,
            "y2":1830
          }
        ]
      }
    }
  },
  "434635":{
    
  },
  "434693":{
    
  },
  "4347950":{
    
  },
  "4351313":{
    
  },
  "4357712":{
    
  },
  "4360646":{
    
  },
  "4366088":{
    "12989_2016_176_MOESM8_ESM.pdf":{
      "67":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":246,
            "y":1672,
            "x2":1247,
            "y2":2202
          },
          {
            "x":1301,
            "y":1257,
            "x2":2224,
            "y2":1712
          }
        ]
      },
      "66":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":1301,
            "y":1257,
            "x2":2224,
            "y2":1712
          }
        ]
      },
      "77":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":1303,
            "y":1746,
            "x2":2224,
            "y2":2202
          }
        ]
      },
      "56":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":1301,
            "y":771,
            "x2":2228,
            "y2":1225
          },
          {
            "x":242,
            "y":1256,
            "x2":1247,
            "y2":1712
          }
        ]
      },
      "37":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":246,
            "y":769,
            "x2":1247,
            "y2":1225
          }
        ]
      },
      "87":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":243,
            "y":2233,
            "x2":2052,
            "y2":2935
          }
        ]
      },
      "76":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":246,
            "y":1672,
            "x2":1247,
            "y2":2202
          }
        ]
      },
      "57":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":242,
            "y":1256,
            "x2":1247,
            "y2":1712
          }
        ]
      },
      "17":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":246,
            "y":33,
            "x2":2225,
            "y2":731
          }
        ]
      },
      "47":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":1301,
            "y":771,
            "x2":2228,
            "y2":1225
          }
        ]
      },
      "96":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          
        ]
      },
      "27":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":246,
            "y":769,
            "x2":1247,
            "y2":1225
          },
          {
            "x":246,
            "y":33,
            "x2":2225,
            "y2":731
          }
        ]
      },
      "86":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          {
            "x":243,
            "y":2233,
            "x2":2052,
            "y2":2935
          },
          {
            "x":1303,
            "y":1746,
            "x2":2224,
            "y2":2202
          }
        ]
      },
      "07":{
        "descriptions":[
          "(a-n) represent sizes within Site significantly different from one another (p\u2009<\u20090.05). Two-way ANOVA (Standards): Particle (p\u2009=\u20090.002) and Dose (p\u2009<\u20090.001) main effects. Asterisks represent significant pairwise comparisons (Holm-Sidak) as follows: doses significantly different from 0??g/cm2, or particles significantly different from one another as indicated by brackets (*p\u2009<\u20090.05, **p\u2009<\u20090.001). Field blanks. Three-way ANOVA: Dose (p\u2009<\u20090.001) main effect. Letter (a) spanned by a line represents doses significantly different from 0??g/cm2 (p\u2009<\u20090.001). (PDF 55 kb)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4373495":{
    
  },
  "437378":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Ionizing radiation (10 Gy) induces co-localization of endogenous Bax with MCRMs in HeLa cells. Mitochondria were isolated from HeLa cells 34 h after irradiation and immunostained as described in Supporting Information Text S1. Data represent typical stainings from 1 of 4 similar studies in which 2000 mitochondria were analyzed each. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2750
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Addition of exogenous C16-ceramide induces co-localization of endogenous full-length Bax with MCRMs in HeLa cells. Mitochondria were isolated from HeLa cells using percoll gradient and treated with ceramide as Figure 3A. After 30 min incubation, mitochondria were fixed and stained with MitoTracker (blue), while ceramide and Bax were localized using anti-ceramide IgM (red) or anti-Bax IgG (green), respectively. Control IgM and IgG did not yield detectable signals (not shown). These data represent 1 of 3 similar studies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2750
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bax translocates into a radiation-generated HeLa MCRM. Upper panel: 34 h post-irradiation, HeLa mitochondria were isolated as in Materials and Methods and incubated with 0.15% Triton X-100 in MBS buffer for 30 min on ice. 40 ??l mitochondrial homogenate (3.3 ??g/??l) were subjected to 5???30% mini-discontinuous sucrose density gradient centrifugation as described in Materials and Methods. 20 ??l aliquots of 80 ??l fractions were analyzed by immunoblotting using the indicated antibodies. The protein level of each fraction was assessed using the Bio-Rad Dc protein assay kit (PE, Pellet). Data are from 1 of 4 studies, consisting of 2 independent gradients per study. The gradient shown displays our clearest example of Bax translocation into light membranes. Lower panel: Bax in each fraction, revealed by immunoblotting and quantified using NIH Image software, was normalized to protein content for all 8 gradients. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2750
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) MCRM Bax exists as high molecular weight oligomers. Mitochondria from 10 Gy-irradiated HeLa cells, disrupted by either (a) 1% CHAPS and sonication or (b) dounce homogenization in 0.15% Triton X-100, were subjected to 5???30% discontinuous sucrose gradient for MCRM isolation as in Experimental Procedures. Light (MCRM; fractions 6,7) and heavy fractions (solubilized proteins; fractions 11,12) were analyzed by gel filtration on Sephacryl S-200 column as in Figure 2C. 500 ??l of each eluted fraction were concentrated by 20% TCA precipitation for immunoblotting. Data are from 3 independent studies."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":2750
          }
        ]
      }
    }
  },
  "4376699":{
    
  },
  "437963":{
    "Figure 6.TIF":{
      "E":{
        "descriptions":[
          "(E) Quiescent MEFs were stimulated with PDGF for 5 min. The total cell lysates were subjected to Western blot using anti-phosphotyrosine antibody (4G10)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2811,
            "y2":1674
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) MEFs were grown in medium supplemented with either 0.2% or 10% serum and incubated with biotin-labeled transferrin (Bio-Tfn) for 5 min. Uptake of Bio-Tfn was measured as described in the Materials and Methods. ",
          "(A). All the error bars represent the mean ?? SEM of three independent experiments. P values (t test) refer to the difference between the samples as indicated. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cells were treated with Alexa Fluor 647 and incubated for the times as indicated. Internalization of the fluorescent dye was measured by flow cytometry. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) NIH3T3 cells infected by retroviruses encoding GFP-MIM or GFP only were incubated with Bio-Tfn for 5 min. The internalized Bio-Tfn was measured as described in "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) Quiescent MEFs were stimulated with PDGF (50 ng/ml) for the times as indicated. The cell surface (s) and total (t) PDGFR?? proteins were analyzed as described in the Materials and Methods. The data represents two-independent experiments. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "438309":{
    
  },
  "438735":{
    
  },
  "4392488":{
    
  },
  "4396967":{
    
  },
  "4399985":{
    "40478_2015_245_MOESM1_ESM.pdf":{
      "66":{
        "descriptions":[
          "(a-e) shown in Fig.?? 1 . (PDF 2079 kb)"
        ],
        "rois":[
          {
            "x":720,
            "y":862,
            "x2":1402,
            "y2":1625
          },
          {
            "x":0,
            "y":0,
            "x2":3507,
            "y2":1625
          }
        ]
      },
      "56":{
        "descriptions":[
          "(a-e) shown in Fig.?? 1 . (PDF 2079 kb)"
        ],
        "rois":[
          
        ]
      },
      "76":{
        "descriptions":[
          "(a-e) shown in Fig.?? 1 . (PDF 2079 kb)"
        ],
        "rois":[
          {
            "x":720,
            "y":862,
            "x2":1402,
            "y2":1625
          },
          {
            "x":1403,
            "y":862,
            "x2":2083,
            "y2":1625
          },
          {
            "x":2084,
            "y":862,
            "x2":2765,
            "y2":1625
          }
        ]
      },
      "96":{
        "descriptions":[
          "(a-e) shown in Fig.?? 1 . (PDF 2079 kb)"
        ],
        "rois":[
          
        ]
      },
      "86":{
        "descriptions":[
          "(a-e) shown in Fig.?? 1 . (PDF 2079 kb)"
        ],
        "rois":[
          {
            "x":2084,
            "y":862,
            "x2":2765,
            "y2":1625
          },
          {
            "x":2766,
            "y":862,
            "x2":3507,
            "y2":1625
          },
          {
            "x":0,
            "y":1626,
            "x2":3507,
            "y2":2479
          }
        ]
      }
    }
  },
  "440183":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) The spicule (sp) synthesis starts intracellularly in sclerocytes (scl). The primordial spicules are associated with filaments (fi) which are assumed to participate in the extrusion of the growing spicule. This phase is dominated by the expression of silicatein that ??? at the later stage ??? is required for the formation of both the core and the shell cylinder of the siliceous mantel of the spicule. The newly formed silicatein molecules undergo fractal organization. "
        ],
        "rois":[
          {
            "x":8,
            "y":992,
            "x2":1114,
            "y2":1470
          },
          {
            "x":8,
            "y":9,
            "x2":1114,
            "y2":446
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The primordial spicule is extruded and becomes associated in the extracellular space with sclerocytes (scl) which intracellularly form the silicasomes (sis). These organelles contain silicatein and silicate that are released into the extra-spicular space and cause bio-silica formation. "
        ],
        "rois":[
          {
            "x":8,
            "y":480,
            "x2":1114,
            "y2":958
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The growth of the spicule (sp) continues in two directions; axial elongation and appositional growth/thickening. The bio-silica formation is mediated by silicatein (sil) under the consumption of the substrate silicate (si). Growth of spicule is driven both longitudinally and (subsequently) radially along the cell protrusion. During this phase the cell extensions elongate by evagination. The core of the spicule mantel is formed by silicatein, existing in the axial canal, and the shell by silicatein layered onto the outer surface of the growing spicule. "
        ],
        "rois":[
          {
            "x":8,
            "y":992,
            "x2":1114,
            "y2":1470
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Final completion of the size and form of the spicule. After termination the spicule disconnects from the sclerocyte (not shown in the scheme) and the hole is closed by bio-silica formation. The direction of cell movement is indicated with an arrow."
        ],
        "rois":[
          {
            "x":8,
            "y":1503,
            "x2":1114,
            "y2":1981
          }
        ]
      }
    }
  },
  "440263":{
    
  },
  "4404113":{
    
  },
  "4404377":{
    
  },
  "440440":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) 106 HSAECs were maintained in serum-minus media for 48 h. Twenty four h later, they were treated with 10, 50 and 100 ng/ml of TNF??. Total cell extracts were obtained at 4 and 24 h post addition of TNF??. The extracts were run on 4???20% Tris glycine gels and transferred on to nitrocellulose membranes. The membranes were probed with anti-SOD1 antibody. Actin was used as a loading control"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":275
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) at 1, 2, 4, 6, 24 and 30 h post infection. RT-PCR was performed with primers to TNF??. GAPDH was used as a control"
        ],
        "rois":[
          {
            "x":0,
            "y":276,
            "x2":2066,
            "y2":1213
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I) and uninfected control cells "
        ],
        "rois":[
          {
            "x":0,
            "y":276,
            "x2":2066,
            "y2":1213
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The band intensities for all SOD1 bands were calculated using the quantity one software and Bio-Rad imaging system. All quantifications represented included normalization to actin band intensity. Quantification of SOD1 is shown for the 24-h time point and is the average of two independent experiments"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". C) Total RNA was extracted from MP12 infected "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D) Quantification of fold differences in TNF?? expression between uninfected control cells and MP12-infected cells over the indicated time course. * indicates p???=???0.01. Data comprises results from three experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":276,
            "x2":2066,
            "y2":1213
          }
        ]
      }
    }
  },
  "440742":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Expression of the 8 genes. Expression of the 8 genes had an inverse correlation with DNA methylation level. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Bisulfite sequencing analysis of the 8 genes in endometrial cells (UtE1104), UtE-iPS-11 and HUES-8 cells. (Top) Schematic diagram of the genes. Arrows, open boxes and open circles represent transcription start site, first exon and position of CpG sites, respectively. (Bottom) Open and closed circles indicate unmethylated and methylated sites, respectively. Red and blue arrowheads represent the position of CpG sites in Infinium assay and COBRA assay, respectively."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Venn-like diagram showing overlapping CpG sites among ESCs, iPSCs and their parent cells. The 220 overlapping sites are stem cell-specific differentially methylated regions (DMRs). Notably, neither overlapping iPSCs-specific DMRs nor inherited regions in iPSCs from the parent cells were observed. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Proportion of the hyper- and hypo-methylated stem cell-specific DMRs and GO analysis. Approximately 80% of the regions were hyper-methylated in iPSCs, compared with that of the parent cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Proportion of the regions associated with CpG islands and non-CpG islands in the hypo-methylated stem cell-specific DMRs. The hypo-methylated regions were biased to CpG islands, whereas the hyper-methylated regions were biased to non-CpG islands. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) DNA methylation levels in the 8 representative genes determined by Illumina Infinium HumanMethylation27 assay and Bio-COBRA. These 8 genes were defined as SS-DMRs with significant changes of expression and were described in Table S6. The relative amount of methylated and unmethylated DNA ratio is indicated as the black and white area, respectively, in the pie chart. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2044,
            "y2":2354
          }
        ]
      }
    }
  },
  "4409207":{
    
  },
  "442222":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(panel A), spleen "
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":2054,
            "y2":815
          }
        ]
      },
      "B":{
        "descriptions":[
          "(panel B) and serum samples "
        ],
        "rois":[
          {
            "x":14,
            "y":847,
            "x2":2058,
            "y2":2160
          }
        ]
      },
      "C":{
        "descriptions":[
          "(panel C) in groups of mice (n???=???5 per group) three days after challenge with C. albicans strain CAF2-1, in the absence (blue bars) or presence (red bars) of doxycycline in the animals' drinking water. Results are presented as averages and standard deviations. No statistically significant differences were detected between doxycycline-treated and untreated animals for any of the chemokines and cytokines analyzed."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4429571":{
    
  },
  "443069":{
    
  },
  "443582":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A. Hierarchical clustering of primary breast cancer cell lines as control monoculture, and in coculture with tumor-derived fibroblasts. Note independent clusters portraying distinctive stromally induced expression patterns in tumor cells reflected by 482 significant probe sets"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":869,
            "y2":1634
          }
        ]
      },
      "TF":{
        "descriptions":[
          "(TF) samples. Data represent ACTB normalized expression of test gene in cocultured tumor cells relative to control. Note range of expression for each test gene."
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. Enriched categories of bio-functions represented by 107 probe sets, with >2 fold change in gene expression, designated as FTExT. Bars are grouped and colored according to bio-function categories. Each bar represents an enrichment test p-value of a bio-function"
        ],
        "rois":[
          {
            "x":10,
            "y":1654,
            "x2":785,
            "y2":2390
          },
          {
            "x":895,
            "y":7,
            "x2":1835,
            "y2":1634
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Analysis of 482 significant probe sets averaged over multiple epithelial cell cultures derived from malignant (red) and nonmalignant breast tissue (green) in the presence (y-axis) or absence (x-axis) of stromal coculture. The black dotted line represents x???=???y. Tumor cells display greater deviation from this line, i.e. between control and coculture whereas the expression patterns of cocultured nonmalignant epithelial cells shows minimal deviation from control"
        ],
        "rois":[
          {
            "x":10,
            "y":1654,
            "x2":785,
            "y2":2390
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Scatter plot of relative transcript levels of 11 FTExT genes measured by QPCR in an independent set of 6 primary breast tumor cell lines cocultured with one of 4 tumor-derived fibroblast "
        ],
        "rois":[
          {
            "x":813,
            "y":1654,
            "x2":1840,
            "y2":2391
          },
          {
            "x":10,
            "y":1654,
            "x2":785,
            "y2":2390
          }
        ]
      }
    }
  },
  "4448120":{
    
  },
  "4456460":{
    "12931_2016_341_MOESM2_ESM.tif":{
      "A":{
        "descriptions":[
          "(A) BAL and "
        ],
        "rois":[
          {
            "x":24,
            "y":8,
            "x2":896,
            "y2":1113
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) LH cells from LFD (top rows) and HFD (bottom rows) mice were gated based on size (FSC) and granularity (SSC). CD45+ leukocytes were selected, and alveolar macrophages identified as CD11c+GR1? (black circle). Alveolar macrophages were also CD11blowSSChigh. PMNs were identified as GR1+F4/80?CD11b+ cells (grey box). Another population of myeloid cells in the lung was identified as GR1+F4/80+CD11b+ (blue box). (TIF 4080 kb)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "446134":{
    "Figure_1.tif":{
      "a":{
        "descriptions":[
          "(a) the IDEXX Herdchek assay "
        ],
        "rois":[
          {
            "x":9,
            "y":17,
            "x2":1063,
            "y2":774
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) the Bio-Rad TeSeE ELISA and "
        ],
        "rois":[
          {
            "x":1143,
            "y":8,
            "x2":2236,
            "y2":774
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) and the Bio-Rad TeSeE Sheep and Goat Western blot. Values are shown as the mean and standard deviations (n???=???4 or 6). The cut-off points for the assays are shown (dotted line). BM ???=??? biotinylated markers with molecular mass shown in kDa. Mesenteric lymph node (MLN) and brain (Br) from confirmed scrapie positive sheep are shown as positive controls. Liver from a negative sheep (Con) is also shown."
        ],
        "rois":[
          {
            "x":9,
            "y":914,
            "x2":1300,
            "y2":1343
          }
        ]
      }
    }
  },
  "4461821":{
    
  },
  "446268":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "(a) the IDEXX Herdchek assay "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b) the Bio-Rad TeSeE ELISA and "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":2252,
            "y2":779
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) the Bio-Rad TeSeE sheep and goat Western blot. Values are shown as the mean and standard deviations (n???=???4). The cut-off points of the assays are shown (dotted line). M ???=??? molecular mass markers (kDa). Mesenteric lymph node (MLN) and brain (Br) from confirmed scrapie positive sheep are shown as positive controls. Liver from a negative sheep (C) is also shown."
        ],
        "rois":[
          {
            "x":27,
            "y":914,
            "x2":1268,
            "y2":1361
          }
        ]
      }
    }
  },
  "4463210":{
    
  },
  "446501":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "A. MIN6 cells were treated with or without 11.6 nM MCP-1 for 2 h, the nuclear protein was extracted and applied for EMSA using biotin-labeled amylin AP1 probe (Bio-A-AP1 probe) or consensus AP1 probe (Bio-C-AP1 probe). 100-fold of unlabeled consensus AP1 probe (cold-C-AP1) or amylin AP1 probe (cold-A-AP1) was used as competitor. The experiments were performed at least three times and representative results are shown"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. MIN6 cells pretreated with 50 ??M SP600125 "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":988,
            "y2":935
          }
        ]
      },
      "SP":{
        "descriptions":[
          "(SP) or 30 ??M PD98059 "
        ],
        "rois":[
          {
            "x":9,
            "y":1656,
            "x2":976,
            "y2":2479
          },
          {
            "x":23,
            "y":987,
            "x2":850,
            "y2":1613
          }
        ]
      },
      "PD":{
        "descriptions":[
          "(PD) for 1 h were stimulated with 11.6 nM MCP-1 for another 2 h. The nuclear protein was extracted and applied for EMSA using biotin-labeled amylin AP1 probe. *p#pC. A representative gel of B is shown."
        ],
        "rois":[
          {
            "x":23,
            "y":987,
            "x2":850,
            "y2":1613
          }
        ]
      }
    }
  },
  "4466621":{
    
  },
  "447270":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Sequence alignment between miR-29a and the 3???UTR of human PTEN mRNA. Solid line, seed match region; dashed line, seed-deleted region. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3578,
            "y2":4626
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Luciferase reporter gene assay showed the effect of miR-29a on the activity of PTEN 3???UTR reporter. Co-transfection was performed using the plasmids, such as human PTEN 3???UTR (PTEN 3???UTR-1 or PTEN 3???UTR-2) or the miR-29a-binding site-deleted (del) PTEN 3???UTR (PTEN 3???UTR-1-del or PTEN 3???UTR-2-del), a miR-29a expression plasmid (50, 100, and 200 ng), in HepG2 cells. Empty pcDNA3.0 plasmid (200 ng) was used as a negative control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3578,
            "y2":4626
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Luciferase reporter gene assay showed that the decreased luciferase activities of PTEN 3???UTR reporter (PTEN 3???UTR-1 or PTEN 3???UTR-2) in HepG2 cells mediated by miR-29a overexpression (200 ng) was rescued by a miR-29a inhibitor in a dose dependent manner (30, 50, and 100 nM). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3578,
            "y2":4626
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Immunoblot and qRT-PCR showed that miR-29a (3 ??g, 6-cm plate) induced a decrease in endogenous human PTEN protein and mRNA in HepG2 and MHCC-97L cells, which was increased by transfection with a miR-29a inhibitor. GAPDH and ??-actin were used as internal controls. Protein bands were quantified using Quantity One software (Bio-Rad). The value under each lane indicates the relative expression level of the PTEN, which is represented by the intensity ratio between PTEN and ??-actin bands in each lane. Statistically significant differences are indicated: *Pt test."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3578,
            "y2":4626
          }
        ]
      }
    }
  },
  "447585":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A, B) The phosphorylation level of Akt (P-Akt) and the expression level of total Akt (Akt-tot) were detected by Western blot analysis in HepG2 and H7402 cell lines after transfection of miR-29a (or a specific inhibitor). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) The phosphorylation level of Akt (P-Akt) and the expression level of total Akt (Akt-tot) were detected by Western blot analysis in HepG2 and H7402 cell lines after transfection of miR-29a (or a specific inhibitor). "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Western blot analysis showed the phosphorylation of Akt (P-Akt) and the expression of total Akt (Akt-tot) in the cells treated by PTEN siRNA when the hepatoma cells were transfected with miR-29a inhibitor. Protein bands were quantified using Quantity One software (Bio-Rad). The value under each lane indicates the relative expression level of PTEN or phosphorylated Akt, which is represented by the intensity ratio between PTEN or phosphorylated Akt and ??-actin or total Akt bands in each lane. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3816,
            "y2":3249
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) A wound healing assay showed that enhanced cell migration by miR-29a was abolished by Akt siRNA. One representative experiment is shown. Black arrows indicate the wound edge."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4479080":{
    
  },
  "4479086":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "(A) Steps of RPE cell treatment in the in vitro model of phototoxicity. * indicates blue-light illumination "
        ],
        "rois":[
          {
            "x":5,
            "y":0,
            "x2":1519,
            "y2":534
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Representative pictures of RPE cell nuclei stained with Hoechst 33342 and ethidium homodimer 2 24 hours after illumination. In the controls (cont), cells were treated with DMSO instead of bixin and norbixin, then either treated or not with A2E. Bixin and norbixin treatments were performed 48 hours before illumination. A2E treatment was done 19 hours before illumination. Pictures were taken in the centre of a well (scale bar = 20 ??m). "
        ],
        "rois":[
          {
            "x":0,
            "y":698,
            "x2":1554,
            "y2":1448
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bixin and norbixin effects on RPE cell survival after A2E + illumination compared to non-treated cells (cont???A2E) or cells treated with A2E only (cont + A2E). Data in B and C are representative of five independent experiments with n = 4. Bars represent mean +/- s.e.m. ****p"
        ],
        "rois":[
          {
            "x":0,
            "y":1458,
            "x2":1554,
            "y2":3444
          }
        ]
      }
    }
  },
  "4479095":{
    
  },
  "4479104":{
    "Fig 4.tif":{
      "A":{
        "descriptions":[
          "(A) and norbixin ",
          "(A) bixin or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1723,
            "y2":2001
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) given orally. ",
          "(B) norbixin were given at 50 mg/kg. Plasma analyses???note that bixin is efficiently converted into norbixin (values are the mean of three different animals). "
        ],
        "rois":[
          {
            "x":1968,
            "y":14,
            "x2":3704,
            "y2":1995
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HPLC-MS/MS analysis of a mouse plasma sample following oral administration of 9???-cis-norbixin. Both norbixin isomers and glucuronide conjugates are observed. DAD: diode-array detector; MRM: multiple reaction monitoring."
        ],
        "rois":[
          {
            "x":127,
            "y":2204,
            "x2":3584,
            "y2":4994
          }
        ]
      }
    }
  },
  "4479116":{
    
  },
  "4479125":{
    "Fig 6.tif":{
      "A":{
        "descriptions":[
          "(A) ERG from Abca4-/- Rdh8-/- mice injected in one eye with either norbixin or vehicle and light-exposed were recorded after 7 days",
          ". A- and b-wave amplitudes are presented for the five groups studied. non-induced: non-injected and non-illuminated; i.e.: injected eye; n.i.e.: non-injected eye. ",
          "(A) and ",
          "(A): *pp# p##p###p####p"
        ],
        "rois":[
          {
            "x":34,
            "y":0,
            "x2":944,
            "y2":829
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Representative cryosection pictures showing Hoechst 33342 staining of the retinal cell nuclei one week after BLD in norbixin- or DMSO-injected or non-injected eyes and compared to non-induced eyes"
        ],
        "rois":[
          {
            "x":1048,
            "y":72,
            "x2":1879,
            "y2":833
          }
        ]
      },
      "OS":{
        "descriptions":[
          ". OS: outer segment; ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. Scale bars = 25 ??m. "
        ],
        "rois":[
          {
            "x":0,
            "y":882,
            "x2":417,
            "y2":1784
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Graph showing the number of photoreceptor layers measured along the retina each 200 ??m from the optic nerve. *: norbixin i.e. compared to norbixin n.i.e.; #: norbixin i.e. compared to DMSO i.e. Data from ",
          "(C) represent the mean ?? s.e.m. of four separate experiments with n = 3???4. "
        ],
        "rois":[
          {
            "x":36,
            "y":965,
            "x2":1973,
            "y2":2911
          }
        ]
      }
    }
  },
  "4479134":{
    "Fig 7.tif":{
      "A":{
        "descriptions":[
          "(A) A- and b-wave amplitudes are presented for the six groups studied. ",
          "(A) and "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":918,
            "y2":860
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Representative pictures of retinal sections stained with Trichrome-Masson showing cell nuclei one week after BLD. Scale bars = 30 ??m. "
        ],
        "rois":[
          {
            "x":4,
            "y":959,
            "x2":1821,
            "y2":1564
          },
          {
            "x":999,
            "y":33,
            "x2":1820,
            "y2":860
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Morphometric analysis of retina. Photoreceptor cell nuclei were measured from the optic nerve to the superior and inferior side of the retina. Data from ",
          "(C) represent the mean ?? s.e.m. of two separate experiments with n = 3. *pppp"
        ],
        "rois":[
          {
            "x":0,
            "y":1667,
            "x2":1855,
            "y2":2541
          }
        ]
      }
    }
  },
  "4479149":{
    
  },
  "4479167":{
    
  },
  "4484162":{
    
  },
  "4488416":{
    
  },
  "4488698":{
    "Fig 6.tif":{
      "A":{
        "descriptions":[
          "A: Electrophoretic profile of Ni-NTA affinity chromatography purification fractions of Bg10 under denatured conditions in an SDS-PAGE gel (10% polyacrylamide)"
        ],
        "rois":[
          {
            "x":1141,
            "y":0,
            "x2":2161,
            "y2":1418
          },
          {
            "x":659,
            "y":67,
            "x2":1091,
            "y2":607
          }
        ]
      },
      "M":{
        "descriptions":[
          ". M: molecular weight standards (Thermo Scientific). Lane 1: soluble extract of the induced cells. Lane 2: flow-through fraction from affinity chromatography. Lanes 3 to 5: eluted fractions with 20, 500 and 100 mM imidazole, respectively",
          ". M: molecular weight standards (Bio-Rad, Hercules, CA, USA)"
        ],
        "rois":[
          {
            "x":2,
            "y":0,
            "x2":679,
            "y2":602
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Zymogram of recombinant Bg10 under non-denaturing conditions. P1: Protein used as molecular weight standard, ???Bovine Serum Albumin??? (BSA, Sigma, St. Louis, MO, USA). Lane 1: purified protein. Lane 2: ??-1-4-glycosidic activity of purified Bg10 band using pNP-??-D-glucopyranoside as substrate (Sigma, St. Louis, MO, USA)"
        ],
        "rois":[
          {
            "x":659,
            "y":67,
            "x2":1091,
            "y2":607
          },
          {
            "x":0,
            "y":668,
            "x2":1108,
            "y2":1419
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Chromatographic profile of Bg10 by gel filtration using a Superdex 16.600.200 column (GE healthcare) at a flow rate of 0.5 mL/min. The internal image corresponds to the electrophoretic migration profile in an SDS-PAGE gel (10% polyacrylamide) for the analysed samples"
        ],
        "rois":[
          {
            "x":659,
            "y":67,
            "x2":1091,
            "y2":607
          },
          {
            "x":0,
            "y":668,
            "x2":1108,
            "y2":1419
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D: Estimation of Bg10 molecular size by gel filtration based on the linear correlation of the relative migration patterns of Bg10 and protein standards versus their log molecular size values. P2-P5: Proteins used as molecular weight standards, corresponding to thyroglobulin bovine, ??-globulin, albumin, ribonuclease A and P-aminobenzoic acid, respectively (Protein Standard Mix 15???600 kDa, Sigma, St. Louis, MO, USA)."
        ],
        "rois":[
          {
            "x":2,
            "y":0,
            "x2":679,
            "y2":602
          }
        ]
      },
      "S":{
        "descriptions":[
          ". S: Sample of Bg10 before the gel filtration chromatography assay. Lanes 1 to 7: eluted fractions from gel filtration for the enzyme Bg10"
        ],
        "rois":[
          {
            "x":1141,
            "y":0,
            "x2":2161,
            "y2":1418
          }
        ]
      }
    }
  },
  "448986":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Immunoblots (7% SDS-PAGE) of proteins from cell lysates from growing HeLa cells and WSTF KD cells probed with the antibodies indicated at the left."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2944,
            "y2":2284
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) DNAse digestion of cells for the times indicated, before preparing DNA and amplifying regions at the rRNA promoter, 4 kb into the gene, and in the IGS (at position 27 kb from transcription start site) with specific PCR primer pairs. The signal intensities of the products were quantified using Quantity One, Bio-RAD. Error bars represent standard deviation **: p-value of 0.0007, *: p-value of 0.04 (Student t-test, paired, n???=???4). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2944,
            "y2":2284
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) ChIP of WSTF KD cells and cells transfected with scrambled control SiRNA using primers over the rRNA promoter to detect DNA precipitated by the antibodies indicated below the bars. The values are presented as the percentage of the input signal for each primer pair. Error bars represent standard deviations from four separate experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2944,
            "y2":2284
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) ChIP of WSTF KD cells using PCR primers which detected the position along the rDNA repeat as indicated with the antibodies as indicated below the bars. The signals are the percentages of the input signal for each primer pair. One representative experiment of four. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2944,
            "y2":2284
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) ChIP of cells transfected with scrambled control SiRNA using PCR primers which detected the position along the rDNA repeat as indicated with the antibodies as indicated below the bars. The signals are the percentages of the input signal for each primer pair. One representative experiment of four. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2944,
            "y2":2284
          }
        ]
      }
    }
  },
  "44900":{
    
  },
  "44902":{
    
  },
  "449189":{
    
  },
  "449276":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) PhyloChip and "
        ],
        "rois":[
          {
            "x":7,
            "y":13,
            "x2":820,
            "y2":826
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SSU rRNA pyrosequencing of microbial communities detected in lignin-amended and unamended biosep beads over time. For PhyloChip analysis there were 537 distinct bacterial taxa detected; for pyrosequencing there were 4,684 bacterial, archaeal, and eukaryotic taxa detected. In both analyses, ordination performed was nonmetric multidimensional scaling using Bray-Curtis distance measure, and mean ordination scores plus or minus standard error are shown based on four randomly chosen of the six biological replicates."
        ],
        "rois":[
          {
            "x":874,
            "y":7,
            "x2":2059,
            "y2":826
          }
        ]
      }
    }
  },
  "449999":{
    
  },
  "4501106":{
    
  },
  "450271":{
    
  },
  "450773":{
    "Figure_5.tif":{
      "67":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "12":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "66":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-"
        ],
        "rois":[
          
        ]
      },
      "8":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "73":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "78":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-"
        ],
        "rois":[
          
        ]
      },
      "4":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":32,
            "y":32,
            "x2":3785,
            "y2":3248
          }
        ]
      },
      "77":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-"
        ],
        "rois":[
          
        ]
      },
      "15":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "11":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "9":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "68":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "13":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "16":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "79":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-"
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "72":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "10":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "76":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-"
        ],
        "rois":[
          
        ]
      },
      "71":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "80":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-"
        ],
        "rois":[
          
        ]
      },
      "6":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":32,
            "y":32,
            "x2":3785,
            "y2":3248
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)",
          ", 1.0 ??g each, to obtain 5- to 200-fold excess (by weight) of crystallins. The mixtures were incubated at 37??C for 24 h in 1 ml of 50 mM phosphate buffer, pH 7.2. The precipitate formed was collected by centrifugation and estimated as above. The results show that the presence of several peptides in low concentration is sufficient to induce lens crystallin precipitation when the crystallin concentration is high. Therefore, an in vivo lens protein concentration of 400 mg/ml is likely to aggregate and precipitate even when the peptide concentration is 100's of times lower than that of crystallins."
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "17":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "14":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "69":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "75":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "70":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":32,
            "y":32,
            "x2":3785,
            "y2":3248
          }
        ]
      },
      "18":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":38,
            "y":3401,
            "x2":3835,
            "y2":6592
          }
        ]
      },
      "7":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          "(1-18) and ??A3/A1-(102-117)"
        ],
        "rois":[
          {
            "x":32,
            "y":32,
            "x2":3785,
            "y2":3248
          }
        ]
      },
      "74":{
        "descriptions":[
          "(66-80) peptide in 1 ml buffer at 37??C. The amount of protein precipitated after 24 h was estimated using Bio-Rad protein assay reagent (n???=???3). The amount of precipitate formed increased when the reaction mixture contained increased amounts of peptide or lens extract. (B) Effect of a mixture of peptides on lens proteins. Different concentrations of dialyzed human lens extract were mixed with a mixture of peptides consisting of ??A-",
          "(66-80), ??A-",
          "(66-75), ??A-",
          "(67-75), ??B-"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4511507":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "(A) Body temperatures; the dotted horizontal line shows the cut-off value for fever (101.5??F); "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":919,
            "y2":703
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) clinical scores; "
        ],
        "rois":[
          {
            "x":1063,
            "y":0,
            "x2":1925,
            "y2":694
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) nasal shedding expressed as viral copy numbers of the EHV-1 gene gB per ml nasal secretion sample and "
        ],
        "rois":[
          {
            "x":0,
            "y":750,
            "x2":955,
            "y2":1401
          },
          {
            "x":0,
            "y":0,
            "x2":919,
            "y2":703
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) viremia (gB Ct-value) per 5 x 106 PBMC. Nasal shedding and viremia were evaluated by real-time PCR. The dotted horizontal line shows the positive PCR Ct-value cut-off value. All negative PCR values were set to this value. All graphs show means and standard errors per group. Significant differences between groups: a = groups 1 and 3; c = groups 1 and 2."
        ],
        "rois":[
          {
            "x":1063,
            "y":751,
            "x2":1888,
            "y2":1401
          }
        ]
      }
    }
  },
  "4511519":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "(A) total serum anti-EHV-1 gC antibodies and "
        ],
        "rois":[
          {
            "x":975,
            "y":0,
            "x2":2012,
            "y2":607
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) total serum anti-EHV-1 gD antibodies. The graphs represent means and standard errors by group. Significant differences between groups: a = groups 1 and 3; b = groups 2 and 3."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":876,
            "y2":607
          }
        ]
      }
    }
  },
  "4513931":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          ". A) Relative luciferase activity in wheat germ of a m7GpppG-capped and polyadenylated vector reporter in the presence of competing free RNAs in increasing molar excess A 0- to 20-fold molar excess of the competing free RNAs corresponding to the biotin-UTP labeled and unlabeled TriMV 5???UTR sequence (1???739) and the non-functional TriMV reverse sequence (739???1) were used. In B and C are shown the BLI sensograms revealing the binding curves for eIF4G/eIF4E "
        ],
        "rois":[
          {
            "x":51,
            "y":8,
            "x2":3291,
            "y2":1645
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and eIFiso4G/eIFiso4E "
        ],
        "rois":[
          {
            "x":8,
            "y":1794,
            "x2":1816,
            "y2":2842
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). A magnification of the binding curves for eIF4E and eIFiso4E is included. A table with their corresponding kinetics values is displayed below the appropriate graphs."
        ],
        "rois":[
          {
            "x":57,
            "y":1790,
            "x2":3797,
            "y2":4792
          }
        ]
      }
    }
  },
  "4514801":{
    
  },
  "4515845":{
    
  },
  "451986":{
    
  },
  "4526750":{
    "Fig 6.tif":{
      "A":{
        "descriptions":[
          "(A) or viability "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":618,
            "y2":453
          },
          {
            "x":733,
            "y":0,
            "x2":1353,
            "y2":459
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) according to each cancer cell line tested before or after live cell enrichment (n = 3 experiments). Error bars indicate standard error. Cells from human and mouse tumor cell lines were incubated 5 min with the Rarecells?? Live Cells Buffer with blood and recovered on standard (8 micron-pore) ISET?? filters. MMTV = MMTV-PyMT. Cell size and viability were analyzed using the TC20??? Automated Cell Counter (Bio Rad) and Trypan Blue stain."
        ],
        "rois":[
          {
            "x":733,
            "y":0,
            "x2":1353,
            "y2":459
          }
        ]
      }
    }
  },
  "4528310":{
    "Fig 6.tif":{
      "A":{
        "descriptions":[
          "(A) Wnt signaling cascade representing the mechanism of action of different Wnt antagonists and inhibitors: sFRP2 binds to Wnt ligand preventing the binding with the receptor; DKK1 binds to the co-receptor LRP6; ICG001 down-regulates ??-catenin/T cell factor signaling; and 6-BIO is a specific inhibitor of GSK-3??, thereby it activates the Wnt signaling. "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":946,
            "y2":1665
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) mPTP opening assay performed in the presence of Wnt inhibitors: sFRP2 (250 nM), DKK1 (100 ng/mL), ICG001 (20 ??M) and 6-BIO (10 nM). The graph represents the measurements of each condition at the end point (500 s) of the experiment, normalized to the basal average registered previous to A??os addition. mPTP opening is visualized as a decay in the fluorescence. ",
          "(B). Statistical analysis was performed using one-way ANOVA post hoc Bonferroni correction: *p"
        ],
        "rois":[
          {
            "x":1023,
            "y":4,
            "x2":2088,
            "y2":1701
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) m???? was evaluated in the same conditions described in "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4531310":{
    
  },
  "4533989":{
    
  },
  "4544956":{
    "pone.0169640.g001.tif":{
      "4":{
        "descriptions":[
          "[4, 14]. L: Liver; L1 to L5: Liver N?? 1 to Liver N?? 5. M1 to M4: Method 1 to method 4."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1259,
            "y2":970
          }
        ]
      },
      "14":{
        "descriptions":[
          "[4, 14]. L: Liver; L1 to L5: Liver N?? 1 to Liver N?? 5. M1 to M4: Method 1 to method 4."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "455814":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          ". A: For evaluation by IFA, sera from each treatment group were pooled for analysis. The results show serocoversion for each of the four treatment groups. In general, the titers increased progressively with time and with the VLP dose although by day 35, similar titers were seen with the three higher VLP doses"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1023,
            "y2":647
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Shows neutralizing antibody titers (PRNT50) in sera from each mouse collected on the stated days. Neutralizing antibodies were seen starting on day 28 after primary inoculation. The response was again clearly dose dependent; all mice in the two highest treatment groups (C and D) showed neutralizing response by day 35. Such response was seen in 3 of 5 and 1 of 5 mice in the two lower (B and A respectively) treatment groups."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1023,
            "y2":647
          },
          {
            "x":1091,
            "y":7,
            "x2":2060,
            "y2":650
          }
        ]
      }
    }
  },
  "4558264":{
    
  },
  "4561486":{
    
  },
  "4563085":{
    
  },
  "4568005":{
    
  }
,
  "4569445":{
    
  },
  "4571314":{
    "pone.0170233.g002.tif":{
      "a":{
        "descriptions":[
          "(a)Levels of UCK2 mRNA expression in cells treated with increasing concentration of crude hexane (IC25: 10.52, IC50: 21.05, and IC75:42.1 ??g/mL) and chloroform (IC25: 9.5, IC50: 19.09, and IC75:38.18 ??g/mL) extracts; ",
          "(a) Levels of UCK2 protein expression in cells treated with increasing concentration of crude hexane (IC25: 10.52, IC50: 21.05, and IC75:42.1 ??g/mL) and chloroform (IC25: 9.5, IC50: 19.09, and IC75:38.18 ??g/mL) extracts. ",
          "(a) Crude hexane and chloroform extract, and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2206
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Levels of UCK2 mRNA expressed in cells treated with FKB at 12.5 (3.55 ??g/mL), 25 (7.1 ??g/mL), and 50 ??M (14.2 ??g/mL); ",
          "(b) Levels of UCK2 protein expressed in cells treated with FKB at a concentration of 12.5 (3.55 ??g/mL), 25 (7.1 ??g/mL), and 50 ??M (14.2 ??g/mL). ",
          "(b) Bioactive compounds of FKB and APN;. DC: DMSO treated control at a final concentration of 0.1%. Data are expressed as Mean??SD"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2206
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Levels of UCK2 mRNA expressed in cells treated with APN at a concentration of 12.5 (3.37 ??g/mL), 25 (6.75 ??g/mL), and 50 ??M (13.5 ??g/mL). The housekeeping gene, GAPDH was used as loading control. C, Untreated control; D, DMSO used as negative control at a final concentration of 0.1%. (B) Western blot analysis of UCK2 protein expressed in HT-29 cells. ",
          "(c) Levels of UCK2 protein expressed in cells treated with APN at a concentration of 12.5 (3.37 ??g/mL), 25 (6.75 ??g/mL), and 50 ??M (13.5 ??g/mL). (C) Levels of UCK2 protein expression quantified from western blotting analysis using Bio-rad Image Lab software in HT-29 cells treated with "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2206
          }
        ]
      },
      "ns":{
        "descriptions":[
          "; ns: non-significant; *p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4571338":{
    "pone.0170233.g004.tif":{
      "a":{
        "descriptions":[
          "(a) crude hexane (IC25: 10.52, IC50: 21.05, and IC75:42.1 ??g/mL) and chloroform (IC25: 9.5, IC50: 19.09, and IC75:38.18 ??g/mL) extracts. ",
          "(a) Hexane and chloroform extracts "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":999
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) 25 ??M (7.1 ??g/ mL) of FKB at different time interval. ",
          "(b) FKB, and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":999
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) 25 ??M (6.75 ??g/mL) of APN at different time interval. (B) Level of MDM2 and p53 protein expression quantified from western blotting analysis using Bio-rad Image Lab software in HT 29 cells treated with ",
          "(c) APN. Data are expressed as Mean??SD"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":999
          }
        ]
      },
      "ns":{
        "descriptions":[
          "; ns: non-significant; *p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4571353":{
    "pone.0170233.g005.tif":{
      "a":{
        "descriptions":[
          "(a) crude hexane (IC25: 10.52, IC50: 21.05, and IC75:42.1 ??g/mL) and chloroform (IC25: 9.5, IC50: 19.09, and IC75:38.18 ??g/mL) extracts. ",
          "(a) Hexane and chloroform extracts "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":968
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) FKB at a concentration of 12.5 (3.55 ??g/mL), 25 (7.1 ??g/mL), and 50 ??M (14.2 ??g/mL) and ",
          "(b) FKB, and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":968
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) APN at a concentration of 12.5 (3.37 ??g/mL), 25 (6.75 ??g/mL), and 50 ??M (13.5 ??g/mL). (B) Levels of protein expression quantified from western blotting analysis using Bio-rad Image Lab software in HT-29 cells treated with ",
          "(c) APN. Data are expressed as Mean??SD"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1549,
            "y2":968
          }
        ]
      },
      "ns":{
        "descriptions":[
          "; ns: non-significant; *p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "457372":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E). Susceptibility to benzopyrene-induced lung carcinogenesis was compared between the wild type and AIMP2-DX2 transgenic mice by tumor incidence "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) and area "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) BPDE-transformed WI-26 cells with different expression ratio of AIMP2-DX2 to AIMP2-F were tested for their propensity to anchorage-independent colony formation. The relationship between the ratio of AIMP2-DX2 to AIMP2-F and the average numbers of the produced colonies with standard deviation in each colony were displayed as dot plot. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G). The area was represented by the numbers given in Bio-Image J 2.0. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) WI-26 cells stably expressing EV, AIMP2-F and -DX2 were also compared for anchorage-independent colony formation. The same numbers of the three cell lines (200 cells per plate) were spread on the testing medium and the resulting colonies were counted and shown as bar graph. The experiments were repeated three times. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Two independent 12.5d MEFs were obtained from the wild type and AIMP2-DX2 transgenic mice and compared for the expression levels of p53 and phosphorylation status of p53. Expression of AIMP2-DX2 was also determined by Western blot analysis. Tubulin was used as a loading control. 12.5d MEFs isolated from the wild type and AIMP2-DX2 transgenic mice were treated with adriamycin (1 ??M) for 24 h and the sub-G1 populations induced by adriamycin treatment were determined by flow cytometry "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Three lungs were isolated from the wild type and AIMP2-DX2 transgenic mice and subjected to hematoxylin and eosin staining."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). The cell growth in completed media was also monitored "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1566,
            "y2":1809
          }
        ]
      }
    }
  },
  "4576039":{
    "pone.0169932.g002.tif":{
      "J":{
        "descriptions":[
          " and IL-5 (J)"
        ],
        "rois":[
          {
            "x":699,
            "y":1501,
            "x2":1287,
            "y2":1859
          }
        ]
      },
      "A":{
        "descriptions":[
          "CFSE-labeled PBMCs isolated from healthy donors were pretreated for 24 hours without (white column, CTRL) or with GSC-derived exosomes (black column, GSC-EXO) and stimulated for 4 days with anti-CD3 and anti-CD28. (A)"
        ],
        "rois":[
          {
            "x":104,
            "y":8,
            "x2":348,
            "y2":502
          },
          {
            "x":730,
            "y":523,
            "x2":1287,
            "y2":843
          }
        ]
      },
      "I":{
        "descriptions":[
          ", TNF-?? (I)"
        ],
        "rois":[
          {
            "x":104,
            "y":8,
            "x2":348,
            "y2":502
          },
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          }
        ]
      },
      "G":{
        "descriptions":[
          " T cells. (E-F) CD3+ T-cell expression of CD25 and CD69 was measured by flow cytometry on day 2. (G-L) PBMC-derived supernatants were harvested after 48 hours and used for ELISA with the Bio-plex cytokine assay system. Cytokines that showed statistically significant differences with the exosome treatment are reported. Concentration of IL-2 (G)"
        ],
        "rois":[
          {
            "x":10,
            "y":1165,
            "x2":600,
            "y2":1516
          },
          {
            "x":351,
            "y":181,
            "x2":648,
            "y2":340
          },
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          }
        ]
      },
      "B":{
        "descriptions":[
          " Representative microscope images and respective cytometry CFSE histograms, showing the fraction of proliferative CD3+ T cells, in unstimulated PBMCs (i), stimulated PBMCs (ii) and exosomes-treated stimulated PBMCs (iii). (B-D) Histograms showing, within the PBMCs, the fraction of proliferating CD3+ (B)"
        ],
        "rois":[
          {
            "x":349,
            "y":10,
            "x2":722,
            "y2":178
          },
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          },
          {
            "x":710,
            "y":89,
            "x2":1291,
            "y2":442
          }
        ]
      },
      "C":{
        "descriptions":[
          ", CD4+ (C)"
        ],
        "rois":[
          {
            "x":10,
            "y":353,
            "x2":722,
            "y2":843
          },
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          },
          {
            "x":710,
            "y":89,
            "x2":1291,
            "y2":442
          }
        ]
      },
      "H":{
        "descriptions":[
          ", INF-?? (H)"
        ],
        "rois":[
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          },
          {
            "x":694,
            "y":1165,
            "x2":1287,
            "y2":1516
          }
        ]
      },
      "D":{
        "descriptions":[
          " and CD8+ (D)"
        ],
        "rois":[
          {
            "x":11,
            "y":828,
            "x2":600,
            "y2":1178
          },
          {
            "x":351,
            "y":181,
            "x2":648,
            "y2":340
          },
          {
            "x":11,
            "y":1501,
            "x2":600,
            "y2":1859
          },
          {
            "x":699,
            "y":828,
            "x2":1287,
            "y2":1178
          }
        ]
      }
    }
  },
  "4576090":{
    "pone.0169932.g005.tif":{
      "66":{
        "descriptions":[
          "Unstimulated PBMCs were incubated in the absence (white column, CTRL) or presence (black column, GSC-EXO) of GSC-derived exosomes. Incubation with LPS (square column) was used as monocyte stimulation positive control. Cells were surface stained with anti-CD14 and then stained to detect an intracellular level of IL-1??, IL-6 and IL-10 by flow cytometry. (A-C)"
        ],
        "rois":[
          {
            "x":549,
            "y":0,
            "x2":1012,
            "y2":280
          },
          {
            "x":1013,
            "y":0,
            "x2":1299,
            "y2":280
          }
        ]
      },
      "56":{
        "descriptions":[
          "Unstimulated PBMCs were incubated in the absence (white column, CTRL) or presence (black column, GSC-EXO) of GSC-derived exosomes. Incubation with LPS (square column) was used as monocyte stimulation positive control. Cells were surface stained with anti-CD14 and then stained to detect an intracellular level of IL-1??, IL-6 and IL-10 by flow cytometry. (A-C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":548,
            "y2":280
          },
          {
            "x":549,
            "y":0,
            "x2":1012,
            "y2":280
          }
        ]
      },
      "76":{
        "descriptions":[
          "Unstimulated PBMCs were incubated in the absence (white column, CTRL) or presence (black column, GSC-EXO) of GSC-derived exosomes. Incubation with LPS (square column) was used as monocyte stimulation positive control. Cells were surface stained with anti-CD14 and then stained to detect an intracellular level of IL-1??, IL-6 and IL-10 by flow cytometry. (A-C)"
        ],
        "rois":[
          {
            "x":1013,
            "y":0,
            "x2":1299,
            "y2":280
          },
          {
            "x":0,
            "y":281,
            "x2":1299,
            "y2":613
          }
        ]
      },
      "96":{
        "descriptions":[
          " Representative FACS plot of the intracellular staining is shown by the indicated percentage of CD14+/IL-1??+, CD14+/IL-6+ and CD14+/IL-10+ positive cells, respectively. (D-F)"
        ],
        "rois":[
          
        ]
      },
      "86":{
        "descriptions":[
          " Representative FACS plot of the intracellular staining is shown by the indicated percentage of CD14+/IL-1??+, CD14+/IL-6+ and CD14+/IL-10+ positive cells, respectively. (D-F)"
        ],
        "rois":[
          {
            "x":0,
            "y":614,
            "x2":1299,
            "y2":1400
          },
          {
            "x":0,
            "y":281,
            "x2":1299,
            "y2":613
          }
        ]
      },
      "07":{
        "descriptions":[
          " Representative FACS plot of the intracellular staining is shown by the indicated percentage of CD14+/IL-1??+, CD14+/IL-6+ and CD14+/IL-10+ positive cells, respectively. (D-F)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4577098":{
    "pone.0170409.g007.tif":{
      "A":{
        "descriptions":[
          "(A) Top panel: Representative western blot analysis of phosphorylated and total ERK2 in the stroma and walls of prehierarchical (P PRLR "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3096,
            "y2":3111
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and StAR "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3096,
            "y2":3111
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) in granulosa cells treated without or with 10 ng/ml FSH, or together with the MEK inhibitor (1 ??M PD0325901) after a 4-h culture. Relative mRNA expression level was normalized to 18S rRNA. Data are expressed as fold differences ?? SEM of three independent experiments using tissues from different hens and are compared to control cells. *, P #, P "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3096,
            "y2":3111
          }
        ]
      }
    }
  },
  "4577107":{
    
  },
  "45815":{
    
  },
  "4585579":{
    "pone.0170481.g001.tif":{
      "A":{
        "descriptions":[
          "(A) Trace a1, to 2 mL of SR vesicles suspended at 0.04 mg protein/mL (together with 0.02 mg endogenous lipid/mL) in buffer A at 20?C, 0.6 mM EGTA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1645,
            "y2":2206
          }
        ]
      },
      "EG":{
        "descriptions":[
          "(EG) followed by 0.6 mM CaCl2 (Ca) were first added as controls, to illustrate the classical Ca2+-dependent changes in SERCA1a intrinsic fluorescence as well as the usual down-drift in fluorescence intensity accompanying such measurements (see Materials and Methods). SERCA1a was then solubilized by adding mixed DDM/egg PC micelles (D/L, containing the unbrominated lipid at a ratio of 5 g detergent/g lipid, i.e. ~7 mol/mol) at final concentrations of 0.4 and 0.08 mg/mL for DDM and egg PC, respectively. Mixed micelles with brominated lipids (D/BrL) were then added and this was followed by addition of excess DDM (to reach a final total DDM concentration of 4 mg/mL). For Trace a2, additions were performed first with brominated (D/BrL) and then with unbrominated (D/L) lipid. Traces a3 and a4 correspond to experiments similar to those in a1 and a2, respectively, but now measuring light scattering at 290 nm. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1645,
            "y2":2206
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) In Traces b1 and b2, unbrominated lipid was used but DDM was replaced by 5,6-brominated DDM (BrD) at the same molar concentration. Traces here have not been corrected for dilution effects. This dilution effect only becomes somewhat significant when adding excess DDM at 3.2 mg/mL (32 ?L of a 200 mg/mL stock solution resulting in a 1.6% dilution). Numbers indicate the concentrations of detergent and lipid added at each step to the cuvette, in mg/mL. The cartoon on top depicts the principle of the experiment. Lipids are represented with a grey headgroup, detergent molecules are represented with a white headgroup and bromine ions are displayed as black dots. Each trace corresponds to one experiment representative of three independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1645,
            "y2":2206
          }
        ]
      }
    }
  },
  "4586221":{
    
  },
  "458750":{
    
  },
  "458816":{
    
  },
  "458888":{
    
  },
  "4589521":{
    "pone.0170512.g003.tif":{
      "E":{
        "descriptions":[
          "(E). (n = 10/genotype, means ? SEM, 2-way ANOVA for locomotor assessment, unpaired Student's t-test for inclined grid, *p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2619,
            "y2":2656
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and PAR-1 null mice "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2619,
            "y2":2656
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 42 days post injury as well as that of the uninjured PAR-1 null mice "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2619,
            "y2":2656
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). After spinal cord injury, dragging of the hindlimbs with poor coordination is evident in the wild-type mice, whereas considerable improvement with weight-bearing stepping and slight external rotation of the hindpaws is consistent in the PAR-1 null mice. Injured PAR-1 null mice also show significant locomotor recovery, assessed by the Basso Mouse Scale, as compared to the wild-type mice "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2619,
            "y2":2656
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). This result parallels the better performance of PAR-1 null mice on the inclined grid "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2619,
            "y2":2656
          }
        ]
      }
    }
  },
  "458956":{
    
  },
  "459048":{
    
  },
  "459183":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) NIR fluorescence imaging (Kodak 8000) revealed that ProCA1-Affi is able to target to the HER2 positive tumor (SKOV-3, right) 24 hr after injection from tail vein. No significant near IR signal was detected in the HER2 negative tumor (MDA-MB-231, left) (n???=???6"
        ],
        "rois":[
          {
            "x":7,
            "y":20,
            "x2":419,
            "y2":587
          }
        ]
      },
      "PB":{
        "descriptions":[
          ", PB) Fast spin echo and "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) gradient echo transversal MR images collected prior to injection and at various time points post injection of 3.0 mM of ProCA1-affi-m in HEPES saline via tail vein. The MRI signal on the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and reaches maximum enhancement at 24 hours post injection (n???=???6, PMethods). "
        ],
        "rois":[
          {
            "x":156,
            "y":914,
            "x2":840,
            "y2":1212
          },
          {
            "x":423,
            "y":23,
            "x2":754,
            "y2":587
          },
          {
            "x":1115,
            "y":14,
            "x2":2058,
            "y2":687
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). NIR images of the dissected mouse organs. General bio-distribution was obtained based on the NIR signal and western blot assay. The ProCA1-affi-m mainly distributed in the positive tumor, liver and kidney."
        ],
        "rois":[
          {
            "x":15,
            "y":1274,
            "x2":2036,
            "y2":2250
          },
          {
            "x":1091,
            "y":728,
            "x2":2034,
            "y2":1212
          },
          {
            "x":775,
            "y":8,
            "x2":1194,
            "y2":587
          }
        ]
      }
    }
  },
  "459325":{
    
  },
  "459509":{
    
  },
  "459598":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "(a) Representative microphotographs showing MCP-induced reactive oxygen species (ROS) generation in PC12 cells. ROS generation was studied using dichlorofluorescin diacetate (DCFH-DA) dye. Images were captured by Nikon phase contrast cum fluorescence microscope (model 80i) attached with 12.7 Megapixel Nikon DS-Ri1 digital CCD cool camera. "
        ],
        "rois":[
          {
            "x":583,
            "y":71,
            "x2":865,
            "y2":331
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Percent change in ROS generation following 6, 12 and 24 h exposure of various concentrations of MCP in PC12 cells assessed by spectrofluorometric analysis. In brief, cells (1??104 per well) were seeded in poly L-lysine pre-coated 96 well black bottom culture plates and allowed to adhere for 24 h in 5% CO2???95% atmosphere at 37??C. Cells were exposed to MCP (10???4 to 10???8 M) for 6, 12 and 24 h. Following the exposure, cells were re-incubated with 2???, 7??? dichlorodihydrofluorescein-diacetate (DCFH-DA) (20 ??M) for 30 min at 37??C and fluorescence intensity was measured using multiwall micro plate reader (Synergy HT, Bio-Tek, USA) on excitation wavelength at 485 nm and emission wavelength at 528 nm. The data are expressed in mean of percent of the unexposed control ?? SEM, n???=???8. * ???=???P"
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":292,
            "y2":439
          },
          {
            "x":297,
            "y":71,
            "x2":581,
            "y2":331
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":175,
            "y":424,
            "x2":1320,
            "y2":1291
          },
          {
            "x":872,
            "y":71,
            "x2":1448,
            "y2":331
          }
        ]
      }
    }
  },
  "4596211":{
    
  },
  "4599":{
    
  },
  "4599298":{
    
  },
  "460012":{
    
  },
  "460172":{
    
  },
  "460294":{
    
  },
  "4603261":{
    "pone.0170938.g003.tif":{
      "A":{
        "descriptions":[
          "(A) and normalized by the length of the VZ "
        ],
        "rois":[
          
        ]
      },
      "M":{
        "descriptions":[
          ". M: male-alone, M-M: male housed with another male, M-F: male housed with female, F-M: female housed with a male. The figures on the bars indicate the numbers of available data points. * = p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2250,
            "y2":1052
          }
        ]
      },
      "VZ":{
        "descriptions":[
          "(VZ) dorsal to HVC as an absolute number per section "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2250,
            "y2":1052
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Density (number per mm2) of BrdU+cells in HVC "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) and number of BrdU+cells estimated for the entire HVC "
        ],
        "rois":[
          {
            "x":3,
            "y":1077,
            "x2":1088,
            "y2":1903
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D)"
        ],
        "rois":[
          {
            "x":1126,
            "y":1079,
            "x2":2247,
            "y2":1900
          }
        ]
      }
    }
  },
  "4605277":{
    "pone.0170709.g003.tif":{
      "A":{
        "descriptions":[
          "(A) Chemical structure of Bio-BENDA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1599,
            "y2":1178
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Pull-down assay using Bio-BENDA. MDA-MB-468 cells were treated with Bio-BENDA in the presence or absence of excess free BENDA for 4 h. Cellular STAT3 was immunoprecipitated with anti-STAT3 or anti-STAT1 antibody and Bio-BENDA binding to STAT3 was detected with streptavidin-HRP. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Pull-down assay using Bio-BENDA. MDA-MB-468 cells were treated with Bio-BENDA in the presence or absence of excess free BENDA or HP2 for 4 h. Cellular STAT3 was immunoprecipitated with anti-STAT3 antibody and Bio-BENDA binding to STAT3 was detected with streptavidin-HRP."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4605847":{
    "pone.0170321.g003.tif":{
      "B":{
        "descriptions":[
          "(B) and a sample of the cells were cultured as suspension for five days in serum-free medium containing 1??M BIO and 5 ??M REPSOX then seeded in fibronectin-coated plate ",
          "(B); (b)???flow cytometry evaluation of the SHED populations expressing mesenchymal (CD73), epithelialization (E-cadherin) and neural-crest (p75) genes. (c) immunofluoresence assay of Sox10 in ",
          "(B); (d) RT-qPCR-determined relative transcription levels of E-cadherin, ZEB1, TWIST, ZO-1, SNAIL1 and SOX10 genes."
        ],
        "rois":[
          {
            "x":43,
            "y":77,
            "x2":2086,
            "y2":745
          },
          {
            "x":401,
            "y":79,
            "x2":1209,
            "y2":386
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). The properties of the cells grown in the two conditions were determined. (a)???bright field images comparing the morphology of the cells on ",
          "(A) and ",
          "(A) and "
        ],
        "rois":[
          {
            "x":58,
            "y":77,
            "x2":395,
            "y2":381
          }
        ]
      }
    }
  },
  "4605862":{
    "pone.0170321.g004.tif":{
      "e":{
        "descriptions":[
          "(e)- RT-PCR assay of the expression of FABP4 and PPAR genes. D. Neuronal lineage potential. "
        ],
        "rois":[
          {
            "x":39,
            "y":37,
            "x2":1657,
            "y2":1669
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) and neural crest migratory ",
          "(a); ACTB gene and (RT-) served as reaction controls. Immunofluorescence assay of pluripotency markers of SHED ",
          "(a), and clonogenicity ",
          "(a)- calcium deposits detected by staining with Alizarin Red S; ",
          "(a)???morphological changes, expression of SOX2, MASH-1 at day 5 and ??III-tubulin at day 14 determined by immunofluorescence analysis; "
        ],
        "rois":[
          {
            "x":39,
            "y":37,
            "x2":1657,
            "y2":1669
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) genes; RNA of NCCIT, an embryocarcinoma line (ATCC), was included as a pluripotency control in ",
          "(b, c) of the cells. C. Osteogenic and adipogenic differentiation potentials of the cells. Osteogenic potential: ",
          "(b)- quantitative evaluation of the Alizarin Red S intensity by spectrophotometry (Epoch, Biotek)) in control and in differentiated (diff.) cultures; ",
          "(b)???RT-PCR analysis of transcription of SOX2 and MASH-1 genes. GAPDH and RT- were positive and negative controls, respectively."
        ],
        "rois":[
          {
            "x":491,
            "y":1411,
            "x2":1640,
            "y2":1871
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c), cells from the human ESC line (ESI-BIO, US) were included as positive control ",
          "(b, c) of the cells. C. Osteogenic and adipogenic differentiation potentials of the cells. Osteogenic potential: ",
          "(c)- RT-PCR analysis of the transcription of ALP and BGLAP genes. GAPDH and RT- were positive and negative controls, respectively. Adipogenic potential: "
        ],
        "rois":[
          {
            "x":39,
            "y":37,
            "x2":1657,
            "y2":1669
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d). B. Proliferation rate of SHED measured during five passages ",
          "(d)???lipid droplets in adipocytes; "
        ],
        "rois":[
          {
            "x":148,
            "y":1669,
            "x2":490,
            "y2":1873
          }
        ]
      }
    }
  },
  "461060":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Plasma membrane proteins were isolated from MCF10A cells cultured with insulin (5 ??g/ml) and MCF10HER2 cells cultured without insulin. Isolated membrane proteins were probed for GLUT1, GLUT3 and GLUT4. Transferrin receptor was used as a plasma membrane loading control. Amounts of plasma membrane-localized GLUT1 and GLUT3 appeared to be similar in both samples. Although levels of the insulin-responsive transporter GLUT4 were higher in membrane preparations from MCF10A cells cultured in the presence of insulin, GLUT4 was readily detectable at the plasma membrane in MCF10HER2 cells maintained long-term in the absence of insulin in serum-free media. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1744,
            "y2":774
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MCF10HER2 cells were maintained in serum-free media with out insulin and MCF10A cells were incubated for 18 hours in the absence of insulin in serum-free media, then both cell lines were cultured with or without insulin for 30 minutes. Plasma membrane localized proteins were harvested and probed for GLUT4. In MCF10HER2 cells cultured without insulin basal levels of plasma membrane localized GLUT4 were calculated to be 44% higher than basal GLUT4 plasma membrane levels in MCF10A cells cultured without insulin. In both cell types, insulin induced an increase in GLUT4 at the plasma membrane. The highest levels were observed in the MCF10HER2 cells plus insulin condition. ",
          "(B) were quantified (optical density) by Quantity One software from Bio-Rad Laboratories. Levels of GLUT4 were normalized to transferrin receptor levels in each context and expressed as a ratio. Relative normalized expression is compared to MCF10A minus-insulin results."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1744,
            "y2":774
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) bands in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1744,
            "y2":774
          }
        ]
      }
    }
  },
  "461251":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":21,
            "y":21,
            "x2":4672,
            "y2":2420
          }
        ]
      },
      "B":{
        "descriptions":[
          " Scatter plot of the raw Ct values obtained from the 9 aging-related cDNA samples. Each gene has an average of 54 Ct values and the order of genes has been sorted by the mean Ct values. The Ct values were adjusted to the same baseline using IQ5 software (Bio-Rad) for construction of this plot and are thus not exactly the same as those used in other statistical analyses. (B)"
        ],
        "rois":[
          
        ]
      },
      "P":{
        "descriptions":[
          " The reported mRNA levels from FlyAtlas for the 20 candidate reference genes. The FlyAtlas microarray signals are negatively correlated to the Ct values (Ct vs. FlyAtlas brain: Pearson's R???=??????0.905, P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4613080":{
    
  },
  "4613107":{
    "Fig 5.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-imaging cellomics analysis of lysosome number and size, and HaCat cell count. Numbers in brackets indicate the fold variation relative to DMSO treated cells. Only significant decrease or increase are shown, and were obtained from 6 replicates (p-value Fig 3. "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":2547,
            "y2":1821
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunofluorescence was performed using DAPI to detect the cell nucleus and anti-LAMP1 antibody to detect lysosomes. Methyl benzethonium chloride was tested at 5 ??M and monensin at 50 ??M."
        ],
        "rois":[
          {
            "x":6,
            "y":1887,
            "x2":2594,
            "y2":2628
          }
        ]
      }
    }
  },
  "4613632":{
    "Fig 5.tif":{
      "66":{
        "descriptions":[
          "(b-d)."
        ],
        "rois":[
          
        ]
      },
      "76":{
        "descriptions":[
          "(b-d)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":1212
          }
        ]
      },
      "86":{
        "descriptions":[
          "(b-d)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4614244":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "(A, B) Steady-state expression levels of GFP-tagged wt GluA1 and GluA1 C893S in HEK293T cells. ",
          "(A) Immunoreactive GluA1 protein levels relative to tubulin (control for cellular protein) are shown for total cell extracts prepared from cells transfected for the expression of GluA1 or GluA1/Bio-SAP97. Equal amounts (10 ??g) of GFP-GluA1 wt, GFP-GluA1 C893S, and Bio-SAP97 plasmids were used in the transfections; for single transfections, 10 ??g of empty pcDNA3.1 plasmid was added to make the total amount of plasmid DNA 20 ??g in all transfections. The data are expressed as mean ?? SEM (n = 6), and were analyzed by one-way ANOVA with Bonferroni??s multiple comparison test. One asterisk (*) indicates P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":1284
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Steady-state expression levels of GFP-tagged wt GluA1 and GluA1 C893S in HEK293T cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":1284
          }
        ]
      }
    }
  },
  "4614256":{
    
  },
  "4615627":{
    "13045_2017_410_MOESM6_ESM.pdf":{
      "a":{
        "descriptions":[
          "(a) DNMT3A mutation status and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":964
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) TP53 mutation status. Log-rank test was used to determine significance. +, censored data. (PDF 424 kb)"
        ],
        "rois":[
          {
            "x":0,
            "y":965,
            "x2":1434,
            "y2":1926
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1435,
            "y":965,
            "x2":2549,
            "y2":1926
          },
          {
            "x":0,
            "y":1927,
            "x2":2549,
            "y2":3299
          }
        ]
      }
    }
  },
  "462058":{
    
  },
  "4624087":{
    "Fig 11.tif":{
      "A":{
        "descriptions":[
          "(A,B) Time courses of the cell length L ",
          "(A) and the rate change L???(t) of the cell length "
        ],
        "rois":[
          {
            "x":1036,
            "y":1395,
            "x2":2025,
            "y2":1663
          },
          {
            "x":1085,
            "y":4,
            "x2":2025,
            "y2":801
          },
          {
            "x":44,
            "y":4,
            "x2":986,
            "y2":801
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A,B) Time courses of the cell length L ",
          "(B) in wild type and MYOII-KD. "
        ],
        "rois":[
          {
            "x":1085,
            "y":4,
            "x2":2025,
            "y2":801
          },
          {
            "x":1045,
            "y":1142,
            "x2":2000,
            "y2":1334
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Time courses of deformation  of the nucleus in wild type and MYOII-KD. "
        ],
        "rois":[
          {
            "x":4,
            "y":844,
            "x2":984,
            "y2":1658
          },
          {
            "x":1085,
            "y":4,
            "x2":2025,
            "y2":801
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Time courses of the average sensing pressure (ps; top panel), myosin II level ([mb]; middle panel), and the stiffening rate (r[mb]; bottom panel) in wild type and MYOII-KD."
        ],
        "rois":[
          {
            "x":1039,
            "y":844,
            "x2":2000,
            "y2":1091
          }
        ]
      }
    }
  },
  "462471":{
    
  },
  "4626580":{
    
  },
  "4626595":{
    
  },
  "4626613":{
    
  },
  "4626619":{
    
  },
  "4632544":{
    "Fig 6.tif":{
      "E":{
        "descriptions":[
          "(E) were measured. The designation \u201824F\u2019 in the x-axis represents 24h post MBP filtrate exposure. The box-whisker plots show the following: The horizontal line within each box represents the median from six animal treatments. Lower and upper boundaries of the boxes represent the 25th and 75th percentiles, respectively. The whiskers represent the 10th and 90th percentiles. Asterisks indicate statistically different values compared to saline-treated controls (p"
        ],
        "rois":[
          {
            "x":1151,
            "y":627,
            "x2":1855,
            "y2":1202
          },
          {
            "x":373,
            "y":629,
            "x2":1134,
            "y2":1194
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), IL-6 "
        ],
        "rois":[
          {
            "x":2,
            "y":2,
            "x2":866,
            "y2":580
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), TNF-? "
        ],
        "rois":[
          {
            "x":2,
            "y":2,
            "x2":866,
            "y2":580
          },
          {
            "x":1510,
            "y":11,
            "x2":2197,
            "y2":579
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), KC "
        ],
        "rois":[
          {
            "x":799,
            "y":4,
            "x2":1493,
            "y2":582
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), and MCP-1 "
        ],
        "rois":[
          {
            "x":373,
            "y":629,
            "x2":1134,
            "y2":1194
          }
        ]
      }
    }
  },
  "4638847":{
    
  },
  "4642219":{
    "Fig 4.tif":{
      "E":{
        "descriptions":[
          ". E. Proportion of trials with reverse saccade."
        ],
        "rois":[
          {
            "x":9,
            "y":1422,
            "x2":1460,
            "y2":2778
          }
        ]
      },
      "A":{
        "descriptions":[
          ". A. Eye velocity latency (ms)"
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":1458,
            "y2":1363
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Eye velocity gain"
        ],
        "rois":[
          {
            "x":9,
            "y":1422,
            "x2":1460,
            "y2":2778
          },
          {
            "x":1473,
            "y":102,
            "x2":2704,
            "y2":1359
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Minimum position error (deg)"
        ],
        "rois":[
          {
            "x":1473,
            "y":9,
            "x2":4081,
            "y2":2778
          },
          {
            "x":1473,
            "y":102,
            "x2":2704,
            "y2":1359
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Cumulative saccade amplitude (deg)"
        ],
        "rois":[
          {
            "x":1473,
            "y":102,
            "x2":2704,
            "y2":1359
          }
        ]
      }
    }
  },
  "464224":{
    "Figure_6.tif":{
      "8":{
        "descriptions":[
          "(8)\n                            BPL+bio-5???AMP. (b) The percentage of digestion during a\n                            period of 2 h. MtBPL was pre-incubated with substrates\n                            500 ??M biotin, 3 mM ATP, biotin+ATP, 10 ??M\n                            bio-5???AMP for 30 min and then subjected to proteolysis by\n                            incubating with trypsin for 20 min."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          },
          {
            "x":1695,
            "y":0,
            "x2":2762,
            "y2":1174
          }
        ]
      },
      "4":{
        "descriptions":[
          "(4) BPL+ATP "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      },
      "5":{
        "descriptions":[
          "(5) BPL+biotin "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      },
      "6":{
        "descriptions":[
          "(6) BPL+biotin+ATP\n                            "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) BPL, no trypsin "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      },
      "7":{
        "descriptions":[
          "(7) BPL+biotin+non-hydrolyzable AMP pNPP "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3)\n                            BPL "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1694,
            "y2":1174
          }
        ]
      }
    }
  },
  "4644211":{
    
  },
  "4647409":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "A: In the Bio 3D group, an 8-mm Bio 3D conduit was interposed into the nerve defect, and the proximal and distal nerve stumps were secured 1.5 mm into the tube to create a 5-mm interstump gap in the conduit"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3660,
            "y2":1417
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: In the silicone group, the silicone tube with 8 mm length was interposed in the same procedure."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4647421":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          "A: The photographs demonstrate drag toe "
        ],
        "rois":[
          {
            "x":2412,
            "y":0,
            "x2":4498,
            "y2":1740
          }
        ]
      },
      "DT":{
        "descriptions":[
          "(DT) and angle of attack (AoA) in both Bio 3D and silicone groups. In the silicone group, the rat???s toe was not off the ground. The red curved arrows represent the AoA"
        ],
        "rois":[
          {
            "x":0,
            "y":34,
            "x2":2435,
            "y2":1765
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Regarding the DT, there was no significant difference among two groups"
        ],
        "rois":[
          {
            "x":0,
            "y":34,
            "x2":2435,
            "y2":1765
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: AoA was significantly different between the two groups (p "
        ],
        "rois":[
          {
            "x":2412,
            "y":0,
            "x2":4498,
            "y2":1740
          }
        ]
      }
    }
  },
  "4647430":{
    
  },
  "4648987":{
    
  },
  "465725":{
    
  },
  "4658212":{
    
  },
  "465937":{
    
  },
  "465994":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A), Phonon Plasmon peak (207???297 cm???1) originating from gold depicting the presence of Cr-AuNps "
        ],
        "rois":[
          {
            "x":12,
            "y":24,
            "x2":536,
            "y2":562
          },
          {
            "x":1113,
            "y":15,
            "x2":2449,
            "y2":1190
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), Cr"
        ],
        "rois":[
          {
            "x":577,
            "y":21,
            "x2":1102,
            "y2":559
          }
        ]
      },
      "VI":{
        "descriptions":[
          "(VI) - hexavalent chromium (C, 837???873 cm???1), reduced non-toxic trivalent Cr(III) (D, 531???567 cm???1). Raman images in grid format, Fig. 6E and 6F are representations of 6B and 6C respectively. 6-E* and F* represent magnified pixel plots to demonstrate the overlap in signal of Au and Cr",
          "(VI) peaks within cells."
        ],
        "rois":[
          {
            "x":11,
            "y":586,
            "x2":1104,
            "y2":1128
          },
          {
            "x":1113,
            "y":15,
            "x2":2449,
            "y2":1190
          }
        ]
      }
    }
  },
  "465996":{
    
  },
  "4661761":{
    "Fig 10.tif":{
      "A":{
        "descriptions":[
          "(A), dlx5a "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":764,
            "y2":379
          },
          {
            "x":789,
            "y":6,
            "x2":1396,
            "y2":517
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), aldh1a2 "
        ],
        "rois":[
          {
            "x":5,
            "y":487,
            "x2":1396,
            "y2":955
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), and junbb "
        ],
        "rois":[
          {
            "x":1138,
            "y":971,
            "x2":1747,
            "y2":1483
          },
          {
            "x":4,
            "y":967,
            "x2":1103,
            "y2":1345
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) expression in 1-dpa (3-dpf) larval tails."
        ],
        "rois":[
          {
            "x":1138,
            "y":1457,
            "x2":1747,
            "y2":1923
          },
          {
            "x":5,
            "y":1449,
            "x2":1103,
            "y2":1828
          }
        ]
      }
    }
  },
  "4662379":{
    
  },
  "4666090":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "(A), MO group "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":518,
            "y2":403
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and HO group "
        ],
        "rois":[
          {
            "x":519,
            "y":0,
            "x2":1549,
            "y2":403
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "4668298":{
    "rsif20160940_si_005.pdf":{
      "EO":{
        "descriptions":[
          "(EO) and eyes-closed "
        ],
        "rois":[
          
        ]
      },
      "EC":{
        "descriptions":[
          "(EC) resting-state conditions. Results showed that the tendency to form triangles and stars, reflecting clustering and node centrality, better explained the global properties of the EEG connectomes as compared to other combinations of graph metrics. In particular, the synthetic networks generated by this model configuration replicated the characteristic differences found in the real brain networks, with EO eliciting significantly higher segregation in the alpha frequency band (8\u201313\u2009Hz) as compared to EC. Furthermore, the fitted ERGM parameter values provided complementary information showing that clustering connections are significantly more represented from EC to EO in the alpha range, but also in the beta band (14\u201329\u2009Hz), which is known to play a crucial role in cortical processing of visual input and externally oriented attention. Taken together, these findings support the current view of the brain functional segregation and integration in terms of modules and hubs, and provide a statistical approach to extract new information on the (re)organizational mechanisms in healthy and diseased brains."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2479,
            "y2":3507
          }
        ]
      }
    }
  },
  "467019":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A) Phage peptide library against C. albicans hyphal cells after 3 rounds of bio panning. Gradual increase in phage titres was observed during first (6.8??102 pfu), second (1??107 pfu) and third round (1??109 pfu) of bio panning"
        ],
        "rois":[
          {
            "x":9,
            "y":7,
            "x2":556,
            "y2":564
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Plaque assay to determine binding specificity of clones to yeast (black bars) or hyphal (grey bars) form cells. Y axis represents the number of phages bound to 5??106 cells. M13 phage without peptide served as a negative control."
        ],
        "rois":[
          {
            "x":8,
            "y":543,
            "x2":2051,
            "y2":1362
          }
        ]
      }
    }
  },
  "4673854":{
    
  },
  "4674571":{
    
  },
  "4681603":{
    
  },
  "4684993":{
    
  },
  "46859":{
    
  },
  "468850":{
    
  },
  "470473":{
    
  },
  "470927":{
    
  },
  "471227":{
    
  },
  "471327":{
    
  },
  "471620":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic diagram of the Xvent-1B, Xvent-2B, AmphiVent1 and AmphiVent2 promoter-luciferase constructs with putative Tcf/Lef binding sites depicted by black rectangles. Nucleotide changes within Tcf/Lef binding site introduced into mutant luciferase reporter genes used in "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1130,
            "y2":486
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) are indicated. ",
          "(B, C) Wild-type ",
          "(C) luciferase reporter plasmids were cotransfected with expression plasmid encoding a stabilized form of ??-catenin (??-catenin??N) into 293T cells. Please, note that fold induction of individual reporter genes was normalized to activation of the promoter-less construct pGL3-basic. "
        ],
        "rois":[
          {
            "x":11,
            "y":1178,
            "x2":1505,
            "y2":2367
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, C) Wild-type ",
          "(B) or mutant "
        ],
        "rois":[
          {
            "x":1440,
            "y":25,
            "x2":3091,
            "y2":2338
          },
          {
            "x":242,
            "y":600,
            "x2":1090,
            "y2":1066
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Quantitative RT-PCR expression analysis of AmphiAxin, AmphiFoxQ2, AmphiVent1 and AmphiVent2 in control embryos (DMSO) and in embryos treated with canonical Wnt signaling activator (BIO) [23]. *P"
        ],
        "rois":[
          {
            "x":11,
            "y":1178,
            "x2":1505,
            "y2":2367
          }
        ]
      }
    }
  },
  "473164":{
    "Figure_1.tif":{
      "I":{
        "descriptions":[
          "(I) the perfusion inlet of constant height , (E) the expansion chamber of spatially varying height , and "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1296,
            "y2":419
          }
        ]
      },
      "II":{
        "descriptions":[
          "(II) the main reactor area of constant height . The perfusion flow, driven by the pressure drop , is indicated by arrows."
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1296,
            "y2":419
          }
        ]
      }
    }
  },
  "473479":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) M. tb lysates (15 ??g protein) were immunoblotted using rabbit anti-HspX or anti-SigA polyclonal sera and the blots were analyzed using Quantity One software (Bio-Rad, USA). The normalised intensities of the HspX-derived signals (with respect to those of SigA) are denoted as Arbitrary Signal Intensities (ASI) with respect to those obtained in 5 days hypoxic WT cultures (H5). ???Aer???, aerobic; H1 H3 and H5 refer to 1, 3 and 5 days hypoxic cultures, respectively; ND, not detected. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1864,
            "y2":347
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Relative Quantity "
        ],
        "rois":[
          {
            "x":0,
            "y":348,
            "x2":1864,
            "y2":2490
          }
        ]
      },
      "RQ":{
        "descriptions":[
          "(RQ) of devRC transcripts in different Comp strains determined by real time RT-PCR analysis. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Real time RT-PCR analysis of DevR regulon transcripts. Fold change in the relative quantity of transcripts under ???hypoxic??? vs. ???aerobic??? conditions (fold decrease in Comp5 and fold increase in Comp13) is shown."
        ],
        "rois":[
          {
            "x":0,
            "y":348,
            "x2":1864,
            "y2":2490
          }
        ]
      }
    }
  },
  "474691":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A) Viability of encapsulated cells, as assessed by a LIVE/DEAD assay. Results are average ?? SD, n???=???3"
        ],
        "rois":[
          {
            "x":43,
            "y":22,
            "x2":1900,
            "y2":1252
          },
          {
            "x":1988,
            "y":16,
            "x2":3960,
            "y2":1244
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Mitochondrial metabolic activity of encapsulated cells. Results are average ?? SD, n???=???6. Each absorbance at 540 nm was normalized by day 2 absorbance"
        ],
        "rois":[
          {
            "x":1988,
            "y":16,
            "x2":3960,
            "y2":1244
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Viability of encapsulated cells, as quantified by a LIVE/DEAD assay. Results are average ?? SD, n???=???3. In all figures, * denote statistical significance within time group: * PPPPPn???=???3."
        ],
        "rois":[
          {
            "x":15,
            "y":1349,
            "x2":3969,
            "y2":2738
          }
        ]
      }
    }
  },
  "474989":{
    "Figure_1.tif":{
      "e":{
        "descriptions":[
          "(e) and DTME "
        ],
        "rois":[
          {
            "x":190,
            "y":982,
            "x2":842,
            "y2":1326
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f) are shown, images were constructed with the DrawIt application in KnowItAll Informatics System v. 4.1 (Bio-Rad)."
        ],
        "rois":[
          {
            "x":927,
            "y":969,
            "x2":1440,
            "y2":1326
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a, b) or DTME ",
          "(a, c) and reducing conditions "
        ],
        "rois":[
          {
            "x":7,
            "y":19,
            "x2":507,
            "y2":545
          }
        ]
      },
      "b":{
        "descriptions":[
          "(a, b) or DTME ",
          "(b, d) as indicated. Arrowheads indicate monomeric E-cadherin and p120, large cross-linked species are indicated with arrows, smaller crosslinked E-cadherin species are indicated with a diamond (???), and a possible cysteine-induced E-cadherin dimer is indicated with an asterisk (*). The chemical structures of DSP "
        ],
        "rois":[
          {
            "x":536,
            "y":7,
            "x2":810,
            "y2":545
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c, d) between 0.01 mM and 1.0 mM. Samples were prepared under non-reducing ",
          "(a, c) and reducing conditions "
        ],
        "rois":[
          {
            "x":125,
            "y":19,
            "x2":1499,
            "y2":934
          },
          {
            "x":1223,
            "y":7,
            "x2":1503,
            "y2":543
          }
        ]
      },
      "d":{
        "descriptions":[
          "(c, d) between 0.01 mM and 1.0 mM. Samples were prepared under non-reducing ",
          "(b, d) as indicated. Arrowheads indicate monomeric E-cadherin and p120, large cross-linked species are indicated with arrows, smaller crosslinked E-cadherin species are indicated with a diamond (???), and a possible cysteine-induced E-cadherin dimer is indicated with an asterisk (*). The chemical structures of DSP "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "475188":{
    
  },
  "478197":{
    
  },
  "479237":{
    
  },
  "479517":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) After the glycosylation reaction, the samples were separated by SDS-PAGE, and the gel was stained with Coomassie Blue. "
        ],
        "rois":[
          {
            "x":17,
            "y":17,
            "x2":2672,
            "y2":1478
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) A duplicate gel was transferred to a PVDF membrane and subjected to a detection reaction using the GlycoProfile III Fluorescent Glycoprotein Detection kit (Sigma). The lanes labeled ???Native??? and ???His-HMW1ct only??? are control reaction samples with and without ApHMW1C, respectively. M1 is a pre-staining protein marker (Precision Plus Protein Standards, Bio-Rad), and M2 is a glycosylated protein marker (ProteoProfile PTM Marker, Sigma)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "480631":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A",
          ". Kinase reactions described in (A)",
          ". DU145 cells were starved for 24 h prior to stimulation as described in (A)",
          ". Kinase assays and immunoblots were performed as in (A)"
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1203,
            "y2":604
          }
        ]
      },
      "B":{
        "descriptions":[
          ". HEK293 cells were transfected with empty vector or the indicated FGFR4 constructs, then starved for 16 h. Cells were then either stimulated with vehicle for 10 min or FGF19 for 10 min prior to the addition of TNF?? for an additional 10 min. The IKK complex was then immunoprecipitated from cytoplasmic extracts and subjected to an in vitro kinase assay utilizing GST-I??B(1???54) as substrate. The top panel shows phosphorylation to produce 32P-GST-I??B(1???54) during the in vitro kinase reaction, as visualized by autoradiography. The second panel shows the substrate GST-I??B(1???54) present in each reaction, as determined by Coomassie staining. The lower panels show immunoblots of whole cell lysates from which immune complexes were prepared for the GST-I??B in vitro phosphorylation assays. These cell lysates were separated by SDS-PAGE, transferred to Immobilon-P, and probed with the indicated antibodies. B",
          ". Quantification of 32P incorporation into GST-I??B(1???54) was performed as in (B)"
        ],
        "rois":[
          {
            "x":47,
            "y":687,
            "x2":2112,
            "y2":2483
          }
        ]
      },
      "P":{
        "descriptions":[
          ". The average 32P incorporation from three independent experiments, normalized to mock-transfected cells stimulated with TNF??, is shown +/??? std. dev. *, P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          " were exposed to a Phosphorimager (Bio-Rad). Quantification of 32P incorporation into GST-I??B was performed using the Quantity One software (Bio-Rad). The average 32P incorporation from three independent experiments, normalized to mock-transfected cells stimulated with TNF??, is shown +/??? std. dev. *, P???0.0002; **, P???=???0.004. C"
        ],
        "rois":[
          {
            "x":1412,
            "y":291,
            "x2":2112,
            "y2":622
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D"
        ],
        "rois":[
          {
            "x":1466,
            "y":1307,
            "x2":2112,
            "y2":2473
          }
        ]
      }
    }
  },
  "480757":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          ". The experiment from (E)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      },
      "F":{
        "descriptions":[
          ". DU145 cells were treated with TSA, FGF19 and TNF?? as indicated. Cell lysates were separated by SDS-PAGE and transferred to Immobilon-P. The membrane was cut and the top was incubated with antibody against cleaved-PARP (top panel). The lower portion was probed with ??-tubulin antibody (bottom panel). F"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      },
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      },
      "B":{
        "descriptions":[
          " antibody was added during the immunoprecipitation for the ???No antibody??? control (lane 1), whereas an equal amount of normal mouse IgG was added for the ???IgG??? control (lane 3). B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      },
      "P":{
        "descriptions":[
          " was performed in triplicate and quantitated, with the amount of cleaved PARP normalized to the TNF sample, shown +/??? sem. *, P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          " antibody (top panel). Membranes were stripped and reprobed with ??-tubulin and mSin3A antibodies to confirm cytoplasmic and nuclear fractions (lower panels). Quantitation of cytoplasmic NF??B in Lanes 1???3, for 3 independent experiments, was normalized relative to tubulin in lower blot, with NF??B in Lane 1 set to 100%: Lane 1, 100%; Lane 2, 79%??7%; Lane 3, 76%??9%. Quantitation of nuclear NF??B in Lanes 4???6, for 3 independent experiments, was normalized relative to Sin3A in lower blot, with NF??B in Lane 5 set to 100%: Lane 4, 16%??10%; Lane 5, 100%; Lane 6, 56%??18%. C",
          ". Samples from (C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      },
      "PE":{
        "descriptions":[
          " were exposed to a phosphorimager (Bio-Rad). Quantification of NF-??B binding to the probe was performed using the Quantity One software (Bio-Rad). The average NF-??B binding from three independent experiments, normalized to mock-transfected cells stimulated with TNF??, is shown +/??? std. dev. *, PE"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". DU145 cells were stimulated with vehicle for 30 min, TNF?? for 30 min, or FGF19 for 10 min prior to the addition of TNF?? for an additional 30 min. Nuclear extracts were prepared and equal amounts of protein (2 ??g) were subjected to EMSA with 32P-labeled 30 bp double-stranded oligonucleotide containing a consensus ??B-site. D"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1669,
            "y2":2669
          }
        ]
      }
    }
  },
  "486480":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Structure diagrams of recombinant TMV CP and GFP proteins. Foreign peptides were fused in frame to the site S154-G155 near the C-terminus of TMV CP to generate recombinant CP proteins. GFP was inserted in frame downstream of the N-terminal 18 amino acid residues to replace CP. Foreign peptides were then fused to the C-terminus of GFP to generate recombinant GFP proteins. CP, coat protein. GFP, Green fluorescent protein. FE, foreign epitope. Total proteins were extracted from tobacco seedlings at 4 dpi with wt TMV, TMV??cpGFP, TMV??cpGFPFN20, TMV??cpGFPSC1754 "
        ],
        "rois":[
          {
            "x":12,
            "y":11,
            "x2":1878,
            "y2":413
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), TMVFN20 and TMVSC1754 "
        ],
        "rois":[
          {
            "x":12,
            "y":468,
            "x2":1454,
            "y2":1986
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) at 25??C, respectively. Expressed recombinant proteins were separated on 12% SDS-PAGE and visualized by using anti-GFP antibody or anti-CP antibody in western analysis. A protein standard marker (Precision Plus Protein??? standards, Bio-Rad"
        ],
        "rois":[
          {
            "x":12,
            "y":468,
            "x2":1454,
            "y2":1986
          }
        ]
      },
      "U":{
        "descriptions":[
          ", U.S.A.) was used to measure the sizes of recombinant proteins. Phenotypes of inoculated leaves of Samsun nn were photographed at the same time. Infection buffer was used as negative control."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "491240":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A), each plot represents one individual, with the donor number noted at the top. The limits of detection of each analyte are shown in gray bars, and are listed in the materials and methods. A significant level of analyte (as defined in the materials and methods) from either unstimulated and/or stimulated culture supernatants is noted with an asterisk. Symbols on the Y axis represent values to low to be given a numerical value. Note that the scale is different for the donor 1 graph (0.1???11,000). "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":1587,
            "y2":2845
          },
          {
            "x":1689,
            "y":232,
            "x2":2392,
            "y2":1416
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The percentage of the five subjects whose culture supernatants (either unstimulated, stimulated, or both) gave a significant signal for each analyte."
        ],
        "rois":[
          {
            "x":1674,
            "y":1525,
            "x2":2389,
            "y2":2873
          }
        ]
      }
    }
  },
  "494286":{
    
  },
  "495875":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) PGN from S. aureus SA113 ??lgt lacks lipoproteins. Covalently coupled proteins and non-covalently associated proteins, WTA, LTA, and O-acetylation were removed from PGN during purification. Oxidation by NaIO4 only occurs between C3 and C4 of the terminal GlcNAc at the non-reducing end of the glycan strand. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1406,
            "y2":1182
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The oxidation reaction cleaved the GlcNAc ring and led to two free aldehyde groups, which were used for biotinylation with biotin-hydrazide. In the figure, one biotin-hydrazide reacted with one of the two aldehyde groups. The remaining free aldehyde group may also react with a biotin-hydrazide. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1406,
            "y2":1182
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Verification of biotinylation by dot blot analysis. Biotin (1), non-oxidized PGNpol incubated with 10 ??g of biotin-hydrazide (2) 1, 2 and 10 ??g of PGN-Bio (3???5) were dropped onto a nitrocellulose membrane. Biotin was detected via streptavidin-HRP and visualized by ECL. Only the oxidized PGNpol was biotinylated. PGN without free aldehyde groups remained unlabeled. GlcNAc: N-acetyl glucosamine; MurNAc: N-acetyl muramic acid; R1: [GlcNAc-MurNAc]n; R2: L-Lys-D-Ala-D-Ala linked by [Gyl]5 to another PGN strand."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1406,
            "y2":1182
          }
        ]
      }
    }
  },
  "495957":{
    "Figure_2.tif":{
      "4":{
        "descriptions":[
          "(4) and 1 ??g/ml LPS "
        ],
        "rois":[
          {
            "x":20,
            "y":536,
            "x2":982,
            "y2":1118
          }
        ]
      },
      "5":{
        "descriptions":[
          "(5). "
        ],
        "rois":[
          {
            "x":20,
            "y":536,
            "x2":982,
            "y2":1118
          }
        ]
      },
      "6":{
        "descriptions":[
          "(6): Non-stimulated MonoMac 6. Supernatant was analyzed by ELISA. Untreated PGNpol, oxidized PGNpol, and PGN-Bio induced the release of TNF-?? after 4h (A) and the release of IL-6 after 24 h of stimulation (B), respectively. No significant change in the signaling activity of PGNpol after oxidation/biotinylation was detectable."
        ],
        "rois":[
          {
            "x":20,
            "y":536,
            "x2":982,
            "y2":1118
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1), oxidized PGNpol "
        ],
        "rois":[
          {
            "x":13,
            "y":5,
            "x2":977,
            "y2":587
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2), biotinylated PGNpol from S. aureus 113 ?? lgt (PGN-Bio) "
        ],
        "rois":[
          {
            "x":13,
            "y":5,
            "x2":977,
            "y2":587
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3), 1 ??g/ml Pam3Cys "
        ],
        "rois":[
          {
            "x":13,
            "y":5,
            "x2":977,
            "y2":587
          }
        ]
      }
    }
  },
  "496050":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) In TLR2-deficient MK PGN-Bio was internalized, elicited accumulation of Nod2 and co-localized with Nod2. "
        ],
        "rois":[
          {
            "x":19,
            "y":1550,
            "x2":393,
            "y2":2027
          },
          {
            "x":385,
            "y":1550,
            "x2":858,
            "y2":2027
          },
          {
            "x":1663,
            "y":178,
            "x2":2056,
            "y2":1094
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Biotin did not affect Nod2. "
        ],
        "rois":[
          {
            "x":9,
            "y":1102,
            "x2":405,
            "y2":1549
          },
          {
            "x":385,
            "y":1550,
            "x2":858,
            "y2":2027
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) PBS control. "
        ],
        "rois":[
          {
            "x":14,
            "y":175,
            "x2":407,
            "y2":1094
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Nod2 was not detected after stimulation with Cy2-SitC-his. Images of cells shown are representative of the cells observed in each dish and are representative of three experiments."
        ],
        "rois":[
          {
            "x":422,
            "y":1100,
            "x2":817,
            "y2":1549
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Stimulation with non-biotinylated PGNpol from S. aureus SA113 ??lgt led to Nod2 accumulation. "
        ],
        "rois":[
          {
            "x":19,
            "y":1550,
            "x2":393,
            "y2":2027
          },
          {
            "x":12,
            "y":22,
            "x2":2055,
            "y2":153
          },
          {
            "x":426,
            "y":174,
            "x2":818,
            "y2":1094
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) PGN-Bio was incorporated into Nod2-deficient MK, but co-localization was not detectable as Nod2 was not present. "
        ],
        "rois":[
          {
            "x":19,
            "y":1550,
            "x2":393,
            "y2":2027
          },
          {
            "x":12,
            "y":22,
            "x2":2055,
            "y2":153
          },
          {
            "x":836,
            "y":174,
            "x2":1229,
            "y2":1094
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) PGN-Bio elicited Nod2 accumulation and co-localized with Nod2. "
        ],
        "rois":[
          {
            "x":19,
            "y":1550,
            "x2":393,
            "y2":2027
          },
          {
            "x":385,
            "y":1550,
            "x2":858,
            "y2":2027
          },
          {
            "x":12,
            "y":22,
            "x2":2055,
            "y2":153
          },
          {
            "x":1250,
            "y":178,
            "x2":1644,
            "y2":1094
          }
        ]
      }
    }
  },
  "496492":{
    
  },
  "496759":{
    
  },
  "496859":{
    
  },
  "497231":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Staining of total thymocytes or splenocytes with biotinylated WTH-2 or isotype control antibodies and SA-PE. Gray and black lines correspond to C57BL/6 and LEW cells, respectively. Filled histograms are control stainings. "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":955,
            "y2":449
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Co-expression of CD1d and TCR on thymocytes was analyzed by two-color flow cytometry. CD1d was stained using the WTH-2 mAb and PE-labeled donkey anti-mouse IgG. For staining of mouse and rat TCRs, H57-597-APCy and R73-bio + SA-APCy were used respectively. Numbers indicate the MFI of anti-CD1d mAb for the gated populations. "
        ],
        "rois":[
          {
            "x":434,
            "y":396,
            "x2":963,
            "y2":928
          },
          {
            "x":7,
            "y":479,
            "x2":424,
            "y2":926
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CD1d expression by B and T cells in the spleen. In C57BL/6 mice, CD1d was analyzed with the biotinylated WTH-2 mAb followed by SA-PE and in LEW rats, since biotinylated mAbs were used for B and T cell identification, CD1d was stained with unconjugated WTH-2 mAb followed by PE-labeled donkey anti-mouse IgG. Filled histograms are control stainings carried out as WTH-2 stainings but with an isotype control antibody. (Upper row) Relative CD1d expression by B and T cells. Histograms show separate multicolor experiments with same overall CD1d staining intensity (Fig. S2), since both, T and B cells, were identified using APCy visualized antibodies in order to avoid unspecific signal due to fluorescence spectral overlap into the PE channel. The gating strategy and the antibodies used are explained in detail in figure S2. Gray and black lines correspond to B and T cells, respectively. (Lower row) Histograms show CD1d expression by CD4 and CD8 positive T cells. The gating strategy and used antibodies are explained in detail in the figure S3. Gray and black lines represent CD4+ and CD8+ T cells, respectively."
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":955,
            "y2":449
          }
        ]
      }
    }
  },
  "497823":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Principal component analysis (PCA) for DNA methylation states of 24,949 CpG sites with 16 human cell lines. The PC1 axis clearly distinguish iPS/ES cell group from differentiated cells, while human iPS cells are very close to human ES cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1422,
            "y2":2545
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Stem cell-specific differently methylated regions (SS-DMRs) were defined by PC1. In the pluripotent stem cells, 60.5% of the SS-DMRs are located outside of CpG islands and 87.6% of the SS-DMRs are hyper-methylated. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1422,
            "y2":2545
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) DNA methylation levels at promoter regions in 12 representative genes determined by Illumina Infinium HumanMethylation27 assay and Bio-COBRA. Details of these genes are described in Table S6B. The promoter regions of these genes were defined as the SS-DMRs. The relative amount of methylated DNA ratio is indicated as the black area in the pie chart. The same methylation patterns in 12 regions were detected both by Infinium assay and COBRA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1422,
            "y2":2545
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Bisulfite sequencing analysis of the same regions that were analyzed by Infinium assay and COBRA assay in SOX15, SALL4, SP100 and GBP3. (Top) Schematic diagram of the genes. Arrows, open boxes and open circles represent transcription start site, first exon and position of CpG sites, respectively. (Bottom) Open and closed circles indicate unmethylated and methylated states, respectively. Red and blue arrowheads represent the position of CpG sites in Infinium assay and COBRA, respectively."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1422,
            "y2":2545
          }
        ]
      }
    }
  },
  "499880":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Primary human T cells were left unstimulated (lane 1) or stimulated for 18 hours with plate bound anti-CD3 and anti-CD28 antibodies (lane 2), or with increasing concentrations of LiCl (0, 0.2, 2 or 20 mM, indicated by black triangles, lanes 3???6), or with anti-CD3/CD28 and increasing LiCl concentrations together (lanes 7???10). Total cell lysates were immunoblotted with antibodies specific for ??-catenin, phospho-??-catenin (Ser33/37/Thr41, herein referred to as p-??-catenin), phospho-GSK3??/?? (Ser21/9, herein referred to as p-GSK3??/??) and GSK3. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":953,
            "y2":1208
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) T cells were stimulated for 18 hours with plate-bound anti-CD3 as indicated, either in the absence or presence of the GSK3 inhibitor Bio-ac at 1 ??M. Total cell lysates were analysed by Western blot with anti-??-catenin. An anti-tubulin blot is shown as a control for protein loading. This experiment was repeated twice with similar results."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":953,
            "y2":1208
          }
        ]
      }
    }
  }
,
  "502224":{
    "Figure_1.tif":{
      "F":{
        "descriptions":[
          "(F) at 520 nm was determined using excitation wavelengths of 450 and 405 nm. The ratio of F450/405 is presented as a function of pH. Dotted lines represent the linear range. "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) Western blot of the cytosolic extract (3k Sup), heavy membrane fraction (3k Pellet) and light membrane fraction (120k pellet) showing that FLAG-p7 (left panel) and FLAG-p7KR (right panel) were present in whole cell extracts as well as in the heavy membrane and light membrane fractions. Marker proteins were LAMP-2 (lysosomal/late endosomal protein), PDI (ER chaperone) and GRP75 (mitochondrial chaperone). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1436,
            "y2":1740
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HPTS (100 nM solution) was titrated to varying pH values from 4.5 to 10.5 and fluorescence emission "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1436,
            "y2":1740
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Frozen 120k vesicle pellet was thawed in the presence of HPTS and re-homogenized as described in Materials and Methods. The mixture was applied to a Bio-Gel P-10 size exclusion column and eluted with constant flow. The column void volume eluted at approximately fraction 28. The right panel shows both fluorescence and protein content of fractions over the whole column profile while the left panel shows results around the void volume only with a magnified ordinate. Solid symbols (???) represent fluorescence; bars indicate protein concentration. "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) Protocol was similar to that shown in C except that the vesicle prep was first exposed to Triton X-100 prior to gel filtration. In this experiment the void volume eluted approximately at fraction 15. Note the absence of a fluorescence peak associated with the eluted protein."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1436,
            "y2":1740
          }
        ]
      }
    }
  },
  "502656":{
    
  },
  "503378":{
    
  },
  "504003":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Quantitative RT-PCR confirms early overexpression of MDM2 RNA by CD34+ cells transduced with AML1-ETO. Fold change shown is the average of 3 independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1761,
            "y2":1447
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunoblotting shows increased MDM2 protein levels in cells transduced with AML1-ETO. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1761,
            "y2":1447
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) MDM2 protein was quantified by using the ChemiDoc XRS imaging system (Bio-Rad) with Quantity One 1-D software and fold change over control was calculated. Fold change shown is the average of 3 independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1761,
            "y2":1447
          }
        ]
      }
    }
  },
  "504897":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. 2.5 ??g of cytoplasmic protein lysate from the cortex of 3 alanine- and 3 NAC-treated PDGFb-SNCA mice was run on a 10-well 4???15% SDS-PAGE gel (Bio-Rad). After transfer, the membrane was cut around the 50 kD marker and probed with anti- NF??B p65 antibody (Santa Cruz) and anti-??-actin antibody (Santa Cruz). 2.5 ??g of nuclear protein lysate was run on a separate 10-well 4???15% SDS-PAGE gel and the treated in the manner outlined above. In both cases a single 65 kDa band was observed for NF??B and a single 43 kDa band was observed for ??-actin"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":923,
            "y2":1014
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Band quantification of cytoplasmic NF??B normalized to ??-actin levels"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":923,
            "y2":1014
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Band quantification of nuclear NF??B normalized to Histone H3 levels. Data were analyzed using a 2-tailed Student's t-test. All relevant statistically significant comparisons are indicated on the graphs. The experiment was repeated three times; representative results from a 1 minute exposure of both blots are shown."
        ],
        "rois":[
          {
            "x":15,
            "y":995,
            "x2":882,
            "y2":1577
          }
        ]
      }
    }
  },
  "504971":{
    
  },
  "506032":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) HCT116 cells were treated with purified recombinant Wnt3a (150 ng/ml) for the indicated times, and the lysates were immunoprecipitated and immunoblotted with antibody to PLD. ??-catenin was analyzed by Western blotting using nuclear lysates (upper panel). Histograms show relative protein levels of PLD1 and PLD2, which are normalized to the corresponding ??-tubulin values (lower panel). (B-C) HCT116 cells were treated with Wnt3a (150 ng/ml), LiCl (20 mM), or BIO (1 ??M) for 24 h. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1717,
            "y2":2092
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Protein level of PLDs was analyzed by immunoprecipitation and immunoblotting. c-Myc and NOS2 expression was analyzed by Western blotting (upper panel). Histograms show relative protein levels of PLD1 and PLD2, which are normalized to the corresponding ??-tubulin values (lower panel). Data are representative of three independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1717,
            "y2":2092
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) mRNA levels of the indicated genes were analyzed by Q-RT-PCR. *Pversus vehicle. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1717,
            "y2":2092
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The indicated promoter reporter plasmids were transfected and treated with Wnt3a, LiCl, or BIO for 12 h; luciferase activity was then determined. *Pversus vehicle. Data represent the mean ?? S.D. of three independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1717,
            "y2":2092
          }
        ]
      }
    }
  },
  "506374":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(E) Arrows indicate position of primers used in the ChIP experiment. The ChIP assay was performed using preimmune IgG, anti-??-catenin, or anti-HDAC1 antibody and analyzed by Q-RT-PCR. As a positive control, ChIP analysis of the NOS2 promoter containing TBE was performed. *Pversus ??-catenin/vehicle; ???Pversus HDAC1/vehicle. Data are representative of four independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":3027,
            "x2":1700,
            "y2":3374
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Schematic diagram for comparison of TBEs on PLD2 promoter regions from various species. TCF-4 binding elements in 5??? flanking regions of the human PLD2 transcriptional start site (TSS) were compared with those of the genomes from 4 different species. A core motif, CTTTG(A/T)(A/T) [or the complementary sequence (A/T)(A/T)CAAAG] of TCF binding sequences on PLD2 promoter is highly conserved across species."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1700,
            "y2":3026
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Deletion analysis of pGL4-PLD2 in HCT116 cells. A schematic representation of pGL4-PLD2 reporter constructs is shown. Cells were cotransfected with pGL4-PLD2 and the indicated expression vectors, followed by determination of luciferase activity. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1700,
            "y2":3026
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Diagrammatic representation of the ???2180 to +491 region of the human PLD2 promoter. Numbers above the lines refer to the transcription start site of the PLD2 gene (+1). Two putative binding sites for TCF-4 are indicated on the sequence (the arrows indicate the direction). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1700,
            "y2":3026
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HCT 116 cells were transfected with the luciferase reporter plasmid containing the wild type (wt) PLD2 promoter, one or double TBE mutant forms (mt) of PLD2 promoter, and treated with Wnt3a (150 ng/ml) or BIO (1 ??M). Luciferase activities were measured. *Pversus wtTBE/Wnt3a; ???Pversus wtTBE/BIO. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1700,
            "y2":3026
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cells were co-transfected with the indicated expression vectors, along with the wt or TBE mutant forms of the PLD2 promoter. Luciferase activities were measured. *Pversus transfected with wtTBE/??-catenin; ???Pversus wtTBE/TCF4; **Pversus transfected with wtTBE/??-catenin/TCF4. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1700,
            "y2":3026
          }
        ]
      }
    }
  },
  "507030":{
    
  },
  "507184":{
    "Figure_5.tif":{
      "65":{
        "descriptions":[
          "[65]. Second, a contractile ring is formed by contractile forces acting on the opposite sites of the cell boundary in the cytokinesis process ",
          "[65]. This results in the formation of a contractile furrow and causes division of the cell into two daughter cells. The cell points can therefore be divided into two groups, A and B, where group A consists of membrane points from  to  and nucleus points from  to  and the remaining points belong to group B. To model the first mechanical force, the points of the nucleus in A and B are pulled apart, in the orthogonal direction to the division axis with force  (Eq."
        ],
        "rois":[
          
        ]
      },
      "8":{
        "descriptions":[
          "(8) ). During the nucleus separation, the contractile force, , acts on boundary points of A and B groups to model the second mechanical force(Eq. "
        ],
        "rois":[
          
        ]
      },
      "9":{
        "descriptions":[
          "(9)). b) The main phases of cell growth and division. (I) Cell growth. To implement cell growth in the proposed model, the number of membrane points, i.e. the number of viscoelastic compartments, is allowed to increase. When we add two points on each the cell and nuclear membranes, four subunits are added to the system, with the parameters of these new subunits calculated from the average of the first neighbor's homogeneous subunit parameters. With the additional ???growth??? point, the circumferential length of the membrane increases in proportion to . Hence, the rest volume i. e. the volume of the cell when it grows freely without any inner or outer constraint, must increase proportional to . Therefore, the rest length of radial springs is increased in proportion to . When the area (or volume) of cell doubles, the number of defining membrane points increases to , where  is the number of membrane points on the initial cell. (II,III) Mitotic process: two types of forces act on points to divide the cell. Due to these forces the cell elongates and prepares for division. (IV) Two new daughter nuclei are then placed orthogonal to the axis of cell division. After the nucleus separates, i.e. the distance between the center of the mass of nuclear points exceeds a certain value, , the cell will divide into two daughter cells, i.e. the subunits which join the boundary points will be eliminated and will bind to a new first neighbor point in the same group with a new subunit. V) After division takes place, each daughter cell will only have  points, and as a result it is possible to simultaneously add  points to each cell. To add membrane points, two consecutive points in the membrane are found that have the longest distance and a new point is inserted between them, and this process is repeated until the number of cell points becomes . f) Adhesion of the two daughter cells."
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1809,
            "y2":1613
          }
        ]
      }
    }
  },
  "509400":{
    
  },
  "510925":{
    "Figure_1.tif":{
      "12":{
        "descriptions":[
          "[12], "
        ],
        "rois":[
          
        ]
      },
      "26":{
        "descriptions":[
          "[26], "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":2667,
            "y2":1804
          }
        ]
      },
      "24":{
        "descriptions":[
          "[24], "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":2667,
            "y2":1804
          }
        ]
      },
      "35":{
        "descriptions":[
          "[35]."
        ],
        "rois":[
          
        ]
      },
      "25":{
        "descriptions":[
          "[25], "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":2667,
            "y2":1804
          }
        ]
      },
      "27":{
        "descriptions":[
          "[27], "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":2667,
            "y2":1804
          }
        ]
      }
    }
  },
  "511065":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "(a) Areal extent of GHG-neutral SRC system under 1991???2000 [CO2] and climate conditions. Under current conditions the minimal biomass production to obtain a GHG-neutral bio-energy system was estimated at 2.0??0.1 ton DM ha???1 yr???1 (production indicated as red). "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b) Areal extent of GHG-neutral SRC system under future [CO2] and climate conditions (IPCC scenario A1B in 2059???2068). Under these conditions the minimal biomass production to obtain a GHG-neutral bio-energy system was estimated at 3.2??0.1 ton DM ha???1 yr???1 (production indicated as red plus orange)."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2963,
            "y2":1346
          }
        ]
      }
    }
  },
  "512239":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) Levels of Cdk1 inhibitory phosphorylation after mkk1DD expression. Protein extracts from FB1 wild-type cells (control) or UMA20 (mkk1DDcrg1) growing in inducing conditions (YPA) for the indicated time (hours) were separated by SDS-PAGE. Immunoblots were incubated successively with an antibody that recognizes the Cdk1 phosphorylated form (anti-Cdc2-Y15P) and anti-PSTAIRE, which recognizes Cdk1 as well as Cdk5. "
        ],
        "rois":[
          {
            "x":10,
            "y":1762,
            "x2":1979,
            "y2":2392
          },
          {
            "x":780,
            "y":28,
            "x2":1120,
            "y2":290
          },
          {
            "x":8,
            "y":8,
            "x2":776,
            "y2":291
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Levels of Cdk1 phosphorylation were determined by quantifying the level of antibody signal using a ChemiDoc (Bio-Rad). Signal from the phosphopeptide-specific antibodies was normalized to the amount of phosphorylation of control strain at time zero. Differences in loading of samples were corrected by dividing each phosphopeptide-specific antibody signal by the Cdk1 (anti-PSTAIRE) antibody signal. Mean and s.d. are shown (n???=???2 exp.)."
        ],
        "rois":[
          {
            "x":10,
            "y":1762,
            "x2":1979,
            "y2":2392
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Time-course of morphological changes induced after mkk1DD expression. UMA54 cells carrying a NLS-GFP fusion to detect nuclei as well as a HA-tagged mpk1 allele, were incubated in YPA at 22??C along 12 h. Samples were withdrawn at different times and submitted, after WGA-TRITC staining, to microscopic observation. Bar 15 ??m. "
        ],
        "rois":[
          {
            "x":95,
            "y":1329,
            "x2":836,
            "y2":1502
          },
          {
            "x":1008,
            "y":954,
            "x2":1894,
            "y2":1710
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantification of the number of cell compartments per cell aggregate at different time points. At least 50 cell aggregates were counted at each time point (2 independent experiments). "
        ],
        "rois":[
          {
            "x":20,
            "y":963,
            "x2":836,
            "y2":1327
          },
          {
            "x":1008,
            "y":954,
            "x2":1894,
            "y2":1710
          },
          {
            "x":1190,
            "y":9,
            "x2":1946,
            "y2":805
          },
          {
            "x":780,
            "y":556,
            "x2":1121,
            "y2":819
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Time-course of T-loop phosphorylation of Mpk1 after mkk1DD induction. "
        ],
        "rois":[
          {
            "x":10,
            "y":1762,
            "x2":1979,
            "y2":2392
          },
          {
            "x":1008,
            "y":954,
            "x2":1894,
            "y2":1710
          },
          {
            "x":780,
            "y":556,
            "x2":1121,
            "y2":819
          },
          {
            "x":781,
            "y":293,
            "x2":1121,
            "y2":554
          },
          {
            "x":93,
            "y":558,
            "x2":778,
            "y2":819
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Size of cell compartments decreases after each mitosis. Volume of each cell compartment (assuming each cell compartment was a cylinder) was obtained after measurement of length and wide of 30 cell compartments in each cell type (2 independent experiments). At the top, cell images at same magnification (Bar 5 ??m) of the four cell types measured. Cells were stained with WGA-TRITC to detect septa. Mean and s.d. are shown. "
        ],
        "rois":[
          {
            "x":1008,
            "y":954,
            "x2":1894,
            "y2":1710
          },
          {
            "x":780,
            "y":28,
            "x2":1120,
            "y2":290
          },
          {
            "x":781,
            "y":293,
            "x2":1121,
            "y2":554
          },
          {
            "x":93,
            "y":293,
            "x2":779,
            "y2":554
          }
        ]
      }
    }
  },
  "512921":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A: CFUs-spleen assay. Lethally irradiated CD45.2 mice (10.5 Gy) were injected with whole marrow cells from CD45.1 mice (1??105 marrow cells per mouse). The recipient mice were injected subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. At day +9, the mice were sacrificed and CFUs-spleen measured (n???=???5???10 mice per group)"
        ],
        "rois":[
          {
            "x":34,
            "y":7,
            "x2":572,
            "y2":679
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Plasma cytokine/chemokine measurement. Lethally irradiated CD45.2 mice (10.5 Gy) were injected with sorted KTLS stem cell from CD45.1 mice (7000 KTLS cells per mouse). The recipient mice were injected subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. The mice were bled at Day +7 and plasma prepared. Plasma cytokines and chemokines (pg/ml) were measured as per manufacturer's instruction (Bioplex, Bio-Rad Laboratories) (n???=???5 mice per group). G-CSF level was shown in a separate panel"
        ],
        "rois":[
          {
            "x":693,
            "y":7,
            "x2":2059,
            "y2":919
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: 9 cytokines/chemokines that were significantly reduced in AMD3100-treated mice"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D: Survival rate in lethally irradiated mice without HCT. CD45.2 mice were lethally irradiated (10.5 Gy) but not transplanted with HSCs. The mice were then administered subcutaneously with PBS or AMD3100 at 5 mg/kg every other day beginning at day +2 post irradiation until the end of experiments. Animal survival was monitored daily (data representative of 3 separate sets of experiments with 10 mice in each group of each experiment)."
        ],
        "rois":[
          {
            "x":8,
            "y":885,
            "x2":2014,
            "y2":1711
          },
          {
            "x":693,
            "y":7,
            "x2":2059,
            "y2":919
          }
        ]
      }
    }
  },
  "515294":{
    "Figure_5.tif":{
      "a":{
        "descriptions":[
          "(a). Two distinct component peaks (peak 1 and peak 2) were obtained from the bispecific serum. A control, which consisted exclusively of IgG monomers, was separated on the same column with the same chromatographic conditions "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":2017,
            "y2":1077
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b). The elution curves of bispecific serum and control overlapped after fractionation. (B) All 500 ??L fractions of peak 1 and peak 2 were analyzed by bispecific antibody ELISA and their IgG nature was confirmed using a HRP conjugated goat anti-rabbit IgG antibody. The results were expressed as ELISA end point titers and plotted against the elution time."
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":11,
            "y":1197,
            "x2":1827,
            "y2":2453
          }
        ]
      }
    }
  },
  "515510":{
    
  },
  "516757":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "A) raw data recorded from Bio-MEMS device showing TPT and ?? RT"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1024,
            "y2":162
          },
          {
            "x":1025,
            "y":0,
            "x2":2067,
            "y2":658
          }
        ]
      },
      "B":{
        "descriptions":[
          ", B) Stress values calculated using the modified Stoney's equation."
        ],
        "rois":[
          {
            "x":0,
            "y":163,
            "x2":1024,
            "y2":742
          },
          {
            "x":1025,
            "y":0,
            "x2":2067,
            "y2":658
          },
          {
            "x":1025,
            "y":659,
            "x2":2067,
            "y2":742
          }
        ]
      }
    }
  },
  "520246":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "A. BAEC cells were transiently transfected with a P-selectin promoter-reporter construct with the addition of a blank expression vector, an expression vector for HMGA1, and/or expression vectors for NF-??B family members (p50/p65). Transfected cells were harvested and assessed for luciferase activity (normalized for ??-galactosidase content). Results are expressed as fold-change in luciferase activity relative to transfection with the P-selectin promoter and a blank expression vector"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2313,
            "y2":3017
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. BAEC cells were transiently transfected with a P-selectin promoter-reporter construct and increasing concentrations of a vector expressing a dominant-negative form of HMGA1 (DN-HMGA1). Transfected cells were stimulated with TNF-??, then harvested and assessed for luciferase activity (normalized for ??-galactosidase content). Results are expressed for each transfection condition as fold-change in luciferase activity as a result of TNF-?? stimulation. (*pC. An electrophoretic mobility shift assay (EMSA) was performed using the HMGA1 peptide and a radiolabeled probe spanning the AT-rich region of the P-selectin promoter (basepairs ???542 to ???521) without (Lane 2) or with Dist A (10 ??M, Lane 3). Lane 1 represents the radiolabeled probe in the absence of incubation with protein. (* represents the HMGA1-DNA complex in Lane 2 which is diminished in intensity following addition of Dist A in Lane 3). Binding studies were repeated at least two separate times"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2313,
            "y2":3017
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Chromatin Immunoprecipitation (ChIP) was performed on murine bEnd.3 endothelial cells without (Lane 1) or with 3 hours of exposure to Vehicle (Veh, Upper Panel and Lanes 2???3 Lower Panel), mTNF-?? (TNF, Lane 4), Distamycin A (Dist A, Lane 5), mTNF-??/Vehicle (T+V, Lane 6), and mTNF-??/Dist A (T+D, Lane 7). Immunoprecipitation of crosslinked, sonicated cell lysates was carried out with an affinity-purified HMGA1 antibody (Upper panel and Lanes 3???7 Lower Panel) or IgG rabbit control antibody (Lanes 1???2 Lower Panel), with PCR amplification using primers spanning a 246-basepair AT-rich region of the P-selectin promoter (including basepairs ???542 to ???521; ???Promoter??? in Upper Panel and all lanes in Lower Panel) or 200-basepair fragments spanning a coding region or upstream promoter region of P-selectin (???Exon??? and ???Upstream Promoter???, respectively in Upper Panel; see sequences in Methods section). PCR amplification was undertaken for immunoprecipitated DNA as well as for ???input??? DNA as an additional control for each condition. Quantitation of precipitated DNA relative to input DNA was undertaken using Quantity One 1-D Analysis Software (Bio-Rad). This experiment was performed two separate times. (*p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2313,
            "y2":3017
          }
        ]
      }
    }
  },
  "520489":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) HFF monolayers were mock infected or infected with gradient-purified KSHV virions. At one hour post-infection, these cells were subjected to an immunoflorescence (IFA) by staining with mouse monoclonal antibody (2D4A5) against ORF45 followed by subsequent treatment with Alexa-488 conjugated anti-mouse secondary antibody and counterstaining with DAPI. The DAPI panel shows the nucleus counterstained with DAPI. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1327,
            "y2":1214
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 293T cells were infected with gradient-purified KSHV virions in the absence (lanes 3, 4) or the presence of cycloheximide (CHX) (lanes 5 and 6) or heparin (lanes 7 and 8). After 1 or 2 h post-infection, the unbound viruses were washed away with low pH buffer. Cell extracts were made and protein concentration was measured using a Bradford assay kit (Bio-Rad). About 50 ??g of the protein extract was run on 4???12% Bis-Tris gels and expression levels of ORF45 were detected by a western blot using a specific mouse monoclonal anti-ORF45 antibody. The viral inoculum lysate (lane 1) and mock-infected cell lysate (lane 2) served as controls."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1327,
            "y2":1214
          },
          {
            "x":0,
            "y":1215,
            "x2":1327,
            "y2":1553
          }
        ]
      }
    }
  },
  "523193":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A. The data show increased expression of known immune suppressive factors by TLR3-primed hMSCs (MSC2) but not by TLR4-primed hMSCs (MSC1).. Methods: MSCs were pre-treated for 1 hr with TLR agonists (LPS for MSC1 or poly(I???C) for MSC2), washed and cultured for an additional 48 hr prior to harvesting the spent medium and analysis with Bio-Plex Cytokine Assays (Human Group I & II; Bio-Rad, Hercules"
        ],
        "rois":[
          {
            "x":22,
            "y":10,
            "x2":593,
            "y2":481
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA) following the manufacturer's instructions. Data are presented by the quantitative comparative CT (threshold value) method [46]. Error bars indicate SEM. Data are representative of triplicate measurements with 5 MSC donors"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. The data implicate direct TLR3 induction of IP10 (CCL10) and RANTES (CCL5) secretion.. Methods: hMSCs were transfected with pZERO-hTLR3 and pZERO-hTLR4 (Invivogen), using 250 ng plasmid/1??106 cells (nucleofector). Cells from each transfection were left untreated or stimulated with TLR3 and TLR4 agonists for 1 hr washed and incubated for 48 hr. Conditioned medium was harvested and analyzed as in A. Transfection efficiency was determined by these methods to be 30???35%. Data are representative of triplicate measurements with 3 MSC donors."
        ],
        "rois":[
          {
            "x":10,
            "y":511,
            "x2":2399,
            "y2":1228
          },
          {
            "x":1840,
            "y":147,
            "x2":2399,
            "y2":483
          },
          {
            "x":621,
            "y":147,
            "x2":1164,
            "y2":483
          },
          {
            "x":1213,
            "y":18,
            "x2":1792,
            "y2":483
          }
        ]
      }
    }
  },
  "524671":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(Panel A) and western-blotting with labeled human IgA "
        ],
        "rois":[
          {
            "x":7,
            "y":10,
            "x2":1012,
            "y2":689
          }
        ]
      },
      "B":{
        "descriptions":[
          "(Panel B). Lanes 1 and 4???strain 168/00; lanes 2 and 5???sak188 mutant strain; lanes 3 and 6???sak189/sak188 double mutant strain; lane 7???protein ladder (Bio-Rad Laboratories). bac gene transcription levels "
        ],
        "rois":[
          {
            "x":1054,
            "y":10,
            "x2":1586,
            "y2":678
          }
        ]
      },
      "C":{
        "descriptions":[
          "(Panel C) were assessed by quantitative reverse transcriptase "
        ],
        "rois":[
          {
            "x":1662,
            "y":12,
            "x2":2057,
            "y2":704
          }
        ]
      },
      "RT":{
        "descriptions":[
          "(RT)-PCR. Numbers indicate relative differences (%) in transcription levels of bac gene in mutant strains compared to transcription level of bac gene in wild-type strain. The bac gene transcription level was normalized to the cpn60 gene transcription level in each strain. Mean values and standard errors are shown as results of two independent experiments."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "525091":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) Diagram of the expression levels of various bio-markers. Lavender bars indicate the percentage of cells expressing basal levels of the various markers in parental SAOS-2 cells cultured in normal 1-G gravity condition (control). Purple bars indicate the percentage of cells expressing the various markers in CD133(+) MACSorted SAOS-2 cells that were isolated from parental SAOS-2 cells cultured in normal 1-G gravity condition. Yellow bars indicate the percentage of cells expressing the various markers in CD133(+) MACSorted SAOS-2 cells that were cultured in hypogravity condition. Light blue bars indicate the percentage of cells expressing the various markers in parental SAOS-2 cells that were cultured in hypogravity condition for 5-days, resulting in a population of selected and proliferated CD133(+) SAOS-2 cells"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":2036,
            "y2":3244
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Immunofluorescence staining (40??) and positivity of SAOS-2 cells to CD133, Sox-9, SPARC, and CD117/c-Kit following growth in the bioreactor for 5-days."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "529427":{
    
  },
  "533741":{
    
  },
  "534009":{
    
  },
  "534511":{
    
  },
  "536294":{
    "Figure 1.TIF":{
      "E":{
        "descriptions":[
          "(E) Coimmunoprecipitation analysis of extracts derived from HEK 293T cells overexpressing 3XFlag-SATB1 and its functional domains using anti-Flag antibody followed by WB with anti-??-catenin (lanes 1???3). Expression levels of the 3XFlag-fused domains of SATB1 were monitored by WB using anti-Flag (lanes 4???6). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Mammalian two hybrid assay was performed to score for protein-protein interactions in HEK 293T cells essentially as described [23]. The C-terminus of ??-catenin and the PDZ-like domain of SATB1 were expressed as fusions with VP-16 and GAL4-DBD using the pACT and pBIND vectors of the CheckMate mammalian two-hybrid system (Promega). pBIND and pACT fusion constructs were transfected along with a reporter vector pG5-Luc containing 4?? GAL4 responsive element and luciferase activity was compared with the control. Error bars represent standard deviation calculated from triplicates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) SATB1 and ??-catenin colocalize in the thymocyte nuclei. Indirect immunofluorescence staining of thymocytes using antibodies to SATB1 (red) and ??-catenin (green) was performed as described in Materials and Methods. DNA counterstaining was performed using DAPI (blue). The cut view panel depicts two perpendicular transverse sections of a triple-stained thymocyte as indicated by white lines, intersecting at the point of the brightest fluorescence signal. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) The C-terminus and not the N-terminus of ??-catenin is involved in its interaction with SATB1. VP-16 fused C-terminal (aa 666???780, lane 1) and N-terminal (aa 1???137, lane 2) regions of ??-catenin were overexpressed in HEK 293T cells. Co-immunoprecipitation was performed as described in Materials and Methods using anti-SATB1 followed by WB using anti-??-catenin."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Direct interaction between SATB1 and ??-catenin was monitored by in vitro pulldown assays performed as described in Materials and Methods. 35S-labeled SATB1 was specifically pulled down after incubation with immobilized GST-??-catenin (lane 3) and not with control immobilized GST (lane 2). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) In vivo interaction of SATB1 and ??-catenin was assessed by performing coimmunoprecipitation analysis as described in Materials and Methods. Nuclear extracts derived from BIO treated (+) and control (???) human thymocytes were immunoprecipitated using anti-??-catenin followed by WB with anti-SATB1. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The interacting regions of SATB1 and ??-catenin were mapped by in vitro pulldown assay. GST pulldowns of SATB1 and ??-catenin were performed by passing Jurkat nuclear extract on immobilized domains of GST-??-catenin (lanes 1???6) and SW480 nuclear extract on immobilized domains of SATB1 (lanes 7???11) including both full-length proteins followed by WB with anti-SATB1 and anti-??-catenin. SATB1 and ??-catenin truncations used are depicted schematically on the left. Solid black bars depict the respective interacting regions. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2493,
            "y2":3477
          }
        ]
      }
    }
  },
  "536843":{
    "Figure 5.TIF":{
      "A":{
        "descriptions":[
          "(A) Deacetylation of SATB1 is a functional consequence of Wnt/??-catenin signalling. SATB1 was immunoprecipitated using nuclear extracts from LiCl treated HEK 293T and Jurkat cells and BIO treated human thymocytes at indicated time points, followed by WB with anti-pan-acetyl antibody. Lower panels indicate expression levels of SATB1 and ??-catenin during the time course. While levels of SATB1 did not change much during this time course, ??-catenin was progressively stabilized indicating that Wnt/??-catenin signalling is active in all three cell types. Immunoblot analysis of these extracts with anti-PCAF revealed downregulation of PCAF upon induction of Wnt signalling in human thymocytes. Immunoblot with anti-??-tubulin served as a loading control for thymocyte extracts. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2347,
            "y2":2870
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MAR-linked reporter activity is upregulated upon induction of Wnt signalling. The activity of IgH-MAR and IL-2 reporter during the time course of LiCl treatment in HEK-293T cells or that of IgH-MAR reporter in Wnt3a treated human thymocytes was monitored as described in Materials and Methods. Each error bar represents standard deviation calculated from triplicates, and the p values are less than 0.001. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2347,
            "y2":2870
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) ChIP analysis was performed to monitor the occupancy of SATB1, ??-catenin, and H3K9Ac at the SBSs within the IL-2 and c-Myc loci as described in Materials and Methods. Change in occupancy was calculated from real-time PCR analysis of respective SBSs using anti-SATB1, anti-??-catenin, and anti-H3K9Ac immunoprecipitated chromatin from Jurkat cells treated with LiCl over 24 h. Occupancy at zero time was considered as base line control and the change in occupancy at other time points was calculated as relative occupancy with respect to the control."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2347,
            "y2":2870
          }
        ]
      }
    }
  },
  "536974":{
    "Figure 6.TIF":{
      "A":{
        "descriptions":[
          "(A) Na??ve CD4+ T cells were isolated from cord blood as described in Materials and Methods. Wnt signalling activity was measured by performing transactivation assay using TOPFlash and FOPFlash reporter constructs. TCF reporter activity was measured after 48 h in untreated control cells (bar 1), cells treated with Wnt inhibitor Dkk1 (bar 2), and upon cotransfections of si-??-catenin (bar 3) and ??-catenin (T41A) (bar 4) as indicated. In all samples the reporter activity was measured without adding any Wnt agonist. The ratio of luciferase activities in TOPFlash transfected versus FOPFlash-transfected cells was determined and plotted as the relative TCF activity. Each error bar indicates standard deviation calculated from triplicates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2003,
            "y2":4913
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Expression of Wnts in CD4+ T cells. Na??ve CD4+ T cells were isolated from cord blood as described in Materials and Methods. The mRNA levels of indicated Wnts were determined by RT-PCR analysis of total RNA extracted from these cells (top panel). Wnt expression was also monitored by quantitative RT-PCR analysis of RNAs from two biological replicates (lower graph). Expression level of Wnt 5b was considered as one unit for calculating relative fold expression of other Wnts after normalizing with GAPDH expression in the same sample. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2003,
            "y2":4913
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Immunoblot analysis was performed to monitor stabilization of ??-catenin in differentiating TH cells. Na??ve CD4+ cells were activated using plate-bound anti-CD3 and soluble anti-CD28 and differentiated by adding IL-4 or IL-12 as described in Materials and Methods. Nuclear extracts were prepared from control cells and cells polarized to TH1 and TH2 and were treated with Wnt agonist BIO or Wnt inhibitor Dkk1, followed by immunoblot analysis using anti-??-catenin (upper panel) and anti-??-tubulin (lower panel). Each lane represents protein isolated from 5??106 differentiated and treated cells. The numbers below the ??-catenin panel represent fold change in ??-catenin expression in the indicated lanes of the immunoblot upon normalization with that of ??-tubulin as loading control. Fold change values were calculated from densitometric quantitation of respective bands. Numbers below the ??-tubulin panel denote individual lanes of the immunoblot."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2003,
            "y2":4913
          }
        ]
      }
    }
  },
  "540074":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Myotubes cultured in 5 mM glucose (G5) or in 25 mM glucose (G25) for 48 hours were transfected with a mouse Wnt10b cDNA or treated with 1 ??M BIO. 2-deoxyglucose "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":1477,
            "y2":1591
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantification of GLUT4 and GLUT1 translocation. Data are expressed as mean??SE from 4 independent experiments. Significant difference from G5, (***) p"
        ],
        "rois":[
          {
            "x":89,
            "y":1681,
            "x2":1539,
            "y2":2422
          }
        ]
      }
    }
  },
  "540206":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) BIO decreased within 30 minutes GSK-3??Y216 phosphorylation in myotubes cultured either in G5 or G25, but had no effect on GSK-3??S9 phosphorylation. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2110,
            "y2":174
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) BIO induced PDK1S241, Akt1T308 and AS160S588 phosphorylations, but had no effect on Akt2S473 phosphorylation in myotubes cultured either in G5 or G25. "
        ],
        "rois":[
          {
            "x":0,
            "y":175,
            "x2":2110,
            "y2":650
          },
          {
            "x":0,
            "y":651,
            "x2":2110,
            "y2":950
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) BIO increased AMPK-??1S485 phosphorylation, but had no effect on AMPK-??T172 phosphorylation in myotubes cultured in G5 (left panels). In contrast, BIO had a biphasic effect in myotubes cultured in G25: AMPK-??1S485 phosphorylation was decreased to a basal level within 30 minutes, then increased with a time-course similar to that observed in myotubes cultured in G5 (right panels). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2110,
            "y2":174
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) BIO decreased Erk1/2 phosphorylation with a similar time-course in myotubes cultured either in G5 or G25. Data are expressed as mean??SE from 3 independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":651,
            "x2":2110,
            "y2":950
          },
          {
            "x":0,
            "y":951,
            "x2":2110,
            "y2":1531
          }
        ]
      }
    }
  },
  "540374":{
    "Figure_7.tif":{
      "E":{
        "descriptions":[
          "(E) Insulin increased Erk1/2 phosphorylation only in myotubes cultured in G5, whereas BIO diminished Erk1/2 phosphorylation in myotubes whatever the glucose concentration. Lower panels show quantifications of 3 independent experiments. Data are expressed as mean??SE. Significant difference between BIO and insulin, (###) p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1419,
            "y2":2408
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Insulin increased GSK-3??S9 phosphorylation in myotubes cultured in G5 or G25, whereas BIO had no effect. In contrast, BIO decreased GSK-3??Y216 phosphorylation, whereas insulin had no effect. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1419,
            "y2":2408
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Insulin increased Akt2S473 phosphorylation in myotubes cultured in G5, whereas myotubes cultured in G25 were resistant to insulin. BIO increased Akt1T308 phosphorylation in myotubes cultured in G5, and had a biphasic effect in myotubes cultured in G25. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1419,
            "y2":2408
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) BIO stimulated AMPK-??1S485 but not AMPK-??2T172 phosphorylation whatever the glucose concentration, whereas insulin had no effect on AMPK phosphorylation. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1419,
            "y2":2408
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) In contrast to BIO, insulin failed to increase AS160S588 phosphorylation. BIO showed a biphasic effect in myotubes cultured in G25. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1419,
            "y2":2408
          }
        ]
      }
    }
  },
  "540496":{
    "Figure_8.tif":{
      "e":{
        "descriptions":[
          "(e). In contrast, insulin stimulates GLUT4 translocation through the PI3K/Akt2S473/AS160 pathway ",
          "(e). These results strongly suggest that Wnt signaling, in contrast to insulin signaling, increases glucose transport in both insulin-sensitive and insulin-resistant myotubes through the activation of AMPK-??1 and Akt2/AS160 pathways."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f). Insulin-induced Srebp-1c transcription is mediated by the MAPK pathway in muscle cells. BIO inhibits the MAPK pathway, which could explain the down-regulation of Srebp-1c gene expression "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) and BIO "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) activate the Wnt/??-catenin pathway through the inactivation of GSK-3??Y216 phosphorylation, which results in the nuclear translocation of active ??-catenin, stimulation of myogenic genes transcription such as myoD, and inhibition of Srebp-1c transcription "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c). In parallel, inactivation of GSK-3??Y216 is followed by autophosphorylation of PDK1S241 which phosphorylates Akt1T308 (but not Akt2S473), then the subsequent phosphorylation of AS160S588 induces GLUT4 translocation "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d). BIO activates the AMP kinase pathway by phosphorylating AMPK-??1S485, which also induces GLUT4 translocation "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2318,
            "y2":1690
          }
        ]
      }
    }
  },
  "540609":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) with a monoclonal antibody against cortactin (IP: cort) or an unrelated protein (IP: ctl). When these samples were immuno-blotted for cortactin (IB: cort) and total phosphotyrosine (IB: PY; mAb4G10), cortactin was found to be captured only by the anti-cortactin antibody (upper lanes), and anti-phosphotyrosine staining showed that cortactin from extracts of agrin-treated cells was tyrosine phosphorylated significantly more than that captured from control extracts (lower lanes). This increase in cortactin phosphorylation was quantified from four experiments (A, graph) by measuring band densities, normalizing for cortactin loading (see Methods), and calculating the phosphotyrosine level change relative to control"
        ],
        "rois":[
          {
            "x":11,
            "y":8,
            "x2":787,
            "y2":400
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. To test whether the src-target sites in cortactin were phosphorylated in response to agrin-treatment, myotube extracts were blotted with antibodies against total cortactin and cortactin phosphorylated on Y421. Agrin-treatment did not alter the amount of cortactin present in extracts (upper lanes) but the staining of cortactin by the anti-Y421-phospho-cortactin antibody (IB: pCort) was enhanced by agrin-treatment more than two-fold, as shown by quantification from three experiments (B, graph). Positions of pre-stained MW markers (Bio-Rad) are indicated on the right side of blots, and in the graphs * represents P"
        ],
        "rois":[
          {
            "x":8,
            "y":85,
            "x2":1396,
            "y2":854
          },
          {
            "x":11,
            "y":8,
            "x2":787,
            "y2":400
          }
        ]
      }
    }
  },
  "540674":{
    
  },
  "540887":{
    
  },
  "542459":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Mutated dASF1 proteins fused to HA-tag were co-expressed with wild-type bio-tagged dASF1 in S2 cells and revealed by immunoblotting. Mutated Serines within dASF1 protein are indicated. "
        ],
        "rois":[
          {
            "x":26,
            "y":27,
            "x2":3057,
            "y2":1236
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Levels of mutant HA-dASF1 proteins were quantified and normalized to bio-dASF1wt protein level and compared to the same ratio obtained for HA-dASF1wt. The graph shows the mean for three experiments and error bars show standard errors of the mean (SEM). Mutated Serines are indicated (S-A mutations ??? blue bars, S-D ??? yellow bars). "
        ],
        "rois":[
          {
            "x":37,
            "y":1382,
            "x2":2793,
            "y2":3296
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C, D) Mutated HA-hASF1 proteins were co-expressed with GFP in HEK293T cells. Representative immunoblots are shown ",
          "(C) and HA-hASF1 protein levels were analyzed as above "
        ],
        "rois":[
          {
            "x":33,
            "y":3383,
            "x2":1613,
            "y2":4485
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C, D) Mutated HA-hASF1 proteins were co-expressed with GFP in HEK293T cells. Representative immunoblots are shown ",
          "(D) using GFP levels as a reference. The graph shows the mean for three experiments and error bars show SEM. Mutated Serines are indicated (S-A mutations ??? blue bars, S-D ??? yellow bars)."
        ],
        "rois":[
          {
            "x":102,
            "y":3385,
            "x2":3059,
            "y2":4936
          }
        ]
      }
    }
  },
  "543876":{
    
  },
  "545140":{
    
  },
  "549458":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) glpFK mRNA levels in wt, crp and crp Glp+ cells. "
        ],
        "rois":[
          {
            "x":23,
            "y":9,
            "x2":988,
            "y2":582
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) glpFK mRNA levels in glpR, crp glpR and crp glpR Glp+ cells. "
        ],
        "rois":[
          {
            "x":22,
            "y":641,
            "x2":989,
            "y2":1203
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Glycerol kinase (GlpK) activities in wt, crp, and crp Glp+ cells. Cells were grown in LB with or without 1% glycerol (Gly). Radioactivity was measured by scintillation counting with 10 ml of Bio-safe II fluid."
        ],
        "rois":[
          {
            "x":8,
            "y":1297,
            "x2":986,
            "y2":1868
          }
        ]
      }
    }
  },
  "551379":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) Minichromosomes assembled with increasing amounts of H1.2 and H1.5 corresponding to the NRL indicated below, were purified as in ",
          "(E) were quantitated, normalised according to their different staining ability shown in "
        ],
        "rois":[
          {
            "x":23,
            "y":2163,
            "x2":1526,
            "y2":2967
          },
          {
            "x":1799,
            "y":1309,
            "x2":2687,
            "y2":2051
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N) and with H1 is indicated on the right margin. "
        ],
        "rois":[
          {
            "x":16,
            "y":3031,
            "x2":1483,
            "y2":3870
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) The intensity of the bands corresponding to H3, H1.2 and H1.5 in "
        ],
        "rois":[
          {
            "x":1539,
            "y":2161,
            "x2":2735,
            "y2":2971
          },
          {
            "x":1799,
            "y":1309,
            "x2":2687,
            "y2":2051
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Nucleosome ladders obtained after micrococcal nuclease (MNase) digestion of minichromosomes assembled in preblastodermic Drosophila embryo extracts (DREX) with increasing amounts of histone H1 subtypes. Results with H1.1 and H1.5 are shown as an example. DNA size markers are shown on both sides of the MNase digested samples. Numbers on the left indicate fragment length in base pairs. ",
          "(A) with the amount of each H1 subtype indicated in nanograms. "
        ],
        "rois":[
          {
            "x":16,
            "y":3031,
            "x2":1483,
            "y2":3870
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Mononucleosomes assembled by salt dialysis on 100 ng of a 220 bp DNA fragment were incubated for 20 minutes with increasing amounts of H1.1 and H1.4 and analysed on a 0.7% agarose gel. The position of the mononucleosome without H1 ",
          "(G)."
        ],
        "rois":[
          {
            "x":32,
            "y":23,
            "x2":1302,
            "y2":1100
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Graphic representation of the Nucleosomal Repeat Length (NRL) calculated from experiments similar to that shown in "
        ],
        "rois":[
          {
            "x":1370,
            "y":18,
            "x2":2829,
            "y2":1297
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Minichromosomes, assembled with each H1 subtype to yield a NRL of 200 bp, were precipitated with buffer containing 20 mM MgCl2, and their proteins were electrophoresed on a 16% SDS-Polyacrylamide gel (SDS-PAGE), and visualized by Coomassie G-250 staining. The bands were quantified using Quantity One software (Bio-Rad) and the ratio between each H1 and H3 is shown below the corresponding gel lane. H1.4 runs slower than the other H1 subtypes as it contains a FLAG tag. Abbreviation and Symbol: M, Marker; -, without H1. ",
          "(C). Proteins were separated by electrophoresis and stained with Coomassie G-250. "
        ],
        "rois":[
          {
            "x":25,
            "y":1236,
            "x2":1610,
            "y2":2029
          },
          {
            "x":1799,
            "y":1309,
            "x2":2687,
            "y2":2051
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Graphic representation of the extent of H1.0, H1.1, H1.2 and H1.4 binding, calculated from the band shift experiments as shown in "
        ],
        "rois":[
          {
            "x":1532,
            "y":3031,
            "x2":2845,
            "y2":3965
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Staining of 2 ??g of each purified H1 subtypes (H1.0 to H1.5) with Coomassie G-250. The lower panel is from a separate experiment that included H1x and a subset of the other subtypes for comparison. ",
          "(D), and the NRL plotted against the H1/H3 ratio. "
        ],
        "rois":[
          {
            "x":1799,
            "y":1309,
            "x2":2687,
            "y2":2051
          },
          {
            "x":1370,
            "y":18,
            "x2":2829,
            "y2":1297
          }
        ]
      }
    }
  },
  "551624":{
    
  },
  "553354":{
    
  },
  "553376":{
    
  },
  "553451":{
    
  },
  "555335":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic of the screening assay using the BAR reporter. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2002,
            "y2":2012
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Establishment of the optimal dose of BIO for the enhancer screen using RKO-BAR cells. RKO-BAR cells were mock infected (No LV-shRNA), or were infected with lentiviral vectors that expressed no shRNA (LV-control) or shRNAs targeting either GSK3?? or Axin1. Forty eight hours after transduction, cells were exposed to a titration of BIO (GSK3i), and luciferase activity was measured after 24 hr of exposure to drug. Silencing of GSK3?? or Axin1 enhanced luciferase activity at doses of BIO that showed no detectable luciferase activity in mock and control vector infected cells (green box). This optimized dose range of BIO (300???500 nM) was used in our screen and follow up studies. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Volcano plot of the screen using a lentiviral shRNA library targeting the druggable genome. Samples were screened in triplicate in the presence of 312 nM BIO. shRNA vectors that increased luciferase activity by 3-fold or greater with a P value less than 0.01 are highlighted as top hits. Among this set of hits, known members of the ??-catenin destruction complex (including GSK3??) are colored and labeled in orange, whereas potentially novel GSK3 modulators including the two DHFR shRNAs are colored maroon. The two PSMD7 shRNAs are colored maroon with an orange outline. An expanded hit list with full statistical analysis is provided in Table S1."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2002,
            "y2":2012
          }
        ]
      }
    }
  },
  "555429":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Hit confirmation by the BAR assay. Fresh virus generated for DHFR shRNAs, GSK3?? shRNAs, and empty vector controls was used to transduce RKO-BAR cells. 48 hours following transduction cells were exposed to a sub-optimal (non-activating) dose of GSK3i (312 nM) for another 24 hours before measuring pathway activation by luciferase activity. Importantly, all three vectors targeting DHFR (red bars) induced similar levels of activation as shRNAs targeting GSK3??. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":995,
            "y2":1626
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Examination of the effect of the DHFR inhibitor methotrexate on BAR activation by BIO. RKO-BAR cells were exposed to a titration of methotrexate in the presence (red) or absence (blue) of a non-activating dose of BIO and luciferase activity was measured. In confirmation of the enhancement of BIO activity in cells transduced with shRNA targeting DHFR, inhibition by methotrexate is synergistic with GSK3 inhibition for activation BAR."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "555505":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) The experiment was performed as described for BIO in figure legend 2 with the substitution of an alternative GSK3 inhibitor. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1437
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) RKO-BAR cells were exposed to multiple activators of ??-catenin signaling (GSK3 specific inhibitors BIO and GSK3i VIII, lithium chloride (LiCL), and Wnt3A conditioned medium (3ACM)) or controls (DMSO, NaCL, and control conditioned medium (LCM)). Protein lysates were harvested and subjected to Western Blot analysis with a GSK3?? phospho-serine 9 specific antibody. The enhancement of BAR activity by DHFR inhibition correlated with agents that induced phosphorylation of GSK3 at inhibitory residue serine 9. The result is representative of two separate experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1437
          }
        ]
      }
    }
  },
  "555607":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(E) RKO-BAR cells were subjected to DNMT inhibition (DNMTi) with 5??? Aza-2???-deoxycytidine (750 nM), BIO (312 nM), or both inhibitors in combination. Luciferase activity was measured 16 h following drug addition. Data represent the mean??SD of 4 replicate wells for each sample."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2571
          }
        ]
      },
      "SD":{
        "descriptions":[
          "(SD) of 8 replicate wells for each sample. Addition of purines (adenosine, Ad., or hypoxanthine, Hypo.) or s-adenosylmethionine (SAM), but not thymidine (Thy.) blocked the synergistic effect of dual inhibition. "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) RKO-BAR cells were transduced with a lentiviral vector control lacking an shRNA (U6-TERM), with vectors encoding shRNAs targeting ??-catenin or GSK3??, or with vectors encoding three distinct shRNAs targeting DHFR and then exposed to BIO (right lanes) or vehicle control (left lanes) 48 hours following transduction. Protein lysates were harvested and subjected to Western Blot analysis with a ??-catenin specific antibody. Whereas none of the vectors had an effect in the absence of drug, silencing of GSK3?? or DHFR synergized with BIO to induce accumulation of ??-catenin (CTNNB1, blot is representative of three separate experiments). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) RKO-BAR cells were exposed to methotrexate (MTX), BIO (312 nM), or the combination of the two drugs and stained with the nuclear dye Hoechst and with an antibody recognizing ??-catenin. Images were collected on an InCELL 1000 high content imager. A synergistic increase in ??-catenin expression and nuclear localization was observed upon dual inhibition of GSK3 and DHFR. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) RKO-BAR cells were exposed to a titration of methotrexate in the presence of 312 nM BIO and stained for ??-catenin. ??-catenin expression was quantified on an Acumen Explorer laser scanning microplate reader. As shown in the graph, a methotrexate dose-dependent increase in ??-catenin levels was observed (red curve, each point represents the average of six replicate samples). The effect of a BAR-activating dose of BIO alone (1 ??M) is provided as a reference (blue). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2571
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) RKO-BAR cells were subjected to DHFR, GSK3 (BIO 312 nM), or dual inhibition in the absence or presence of products of the folate metabolism pathway. ??-catenin accumulation was analyzed as in panel C. Data represent the mean and standard deviation "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2571
          }
        ]
      }
    }
  },
  "555751":{
    
  },
  "555827":{
    
  },
  "555900":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A), IL-6 "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B), IL-12 "
        ],
        "rois":[
          {
            "x":12,
            "y":11,
            "x2":1957,
            "y2":1693
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), or IL-10 "
        ],
        "rois":[
          {
            "x":1064,
            "y":92,
            "x2":1958,
            "y2":822
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). *, PPP"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "556232":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A) Western blot analyses performed with protein extracts from hemocytes (from 6 to 72 hours post infection)"
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":987,
            "y2":775
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Comparison of Spod-11-tox content in hemocytes and plasma early post infection. Proteins were loaded (10 ??g/lane) on a Tris-Tricine 10???20% gradient gel. The western blot was realized as in figure 1. Numbers on the right sides of the blots indicate the molecular weight (kDa) estimated using Precision Plus ProteinTM Standards from Bio-Rad. Un; unchallenged."
        ],
        "rois":[
          {
            "x":9,
            "y":777,
            "x2":977,
            "y2":1884
          }
        ]
      }
    }
  },
  "55631":{
    
  },
  "55632":{
    
  },
  "556320":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A) Schematic representation of the protocol used for the purification of the insect hemolymph. Proteins were eluted from the Sep-Pack C18 cartridge with 10, 40, and 80% ac??tonitrile prepared in acidified water (TFA 0.05%), lyophilizated and reconstituted with MilliQ water"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":881,
            "y2":1122
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Western blot analysis of Spod-11-tox content in the elution fractions of Sep-Pack C18 cartridge. Protein extracts were loaded (15 ??g/lane) on a Tris-Tricine 16.5% gel and blotted on a PVDF membrane. The blot was Coomassie stained (upper panel) and probed with polyclonal anti-Spod-11-tox antibody (lower panel). Numbers on the right sides of the blots indicate the molecular weight (kDa) estimated using Precision Plus ProteinTM Standards from Bio-Rad"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":881,
            "y2":1122
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) The eluted Sep-Pack fractions were tested for their antimicrobial activities by liquid growth inhibition assay against E. coli (CIP7624). Results are representative of three independents experiments."
        ],
        "rois":[
          {
            "x":933,
            "y":8,
            "x2":1549,
            "y2":946
          }
        ]
      }
    }
  },
  "55634":{
    
  },
  "557580":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) or BIO-Acetoxime "
        ],
        "rois":[
          {
            "x":8,
            "y":905,
            "x2":988,
            "y2":1735
          },
          {
            "x":19,
            "y":8,
            "x2":988,
            "y2":837
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Negative controls included untreated cells and cells treated only with z-FAD-fmk. After 24 hours, all cells were collected and stained with Annexin-V-FITC and propidium iodide and quadrant analysis after flow cytometry was performed. Shown are the mean??SD of the living, early and late apoptotic cell fractions from 3 independent experiments, ***???=???p"
        ],
        "rois":[
          {
            "x":8,
            "y":905,
            "x2":988,
            "y2":1735
          }
        ]
      }
    }
  },
  "558337":{
    
  },
  "560540":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Kinase inhibitor screen: A2780 cells were transfected with hTERT-luciferase reporter. 32 h later cells were treated for 16 h with DMSO or 10 ??M kinase inhibitors prior to luciferase assay. Hits are shown outside the shaded area. 38: Ro-31-8220; 69: indirubin-3???-monoxime; 79: kenpaullone. Mean of 3 experiments. "
        ],
        "rois":[
          {
            "x":83,
            "y":18,
            "x2":2085,
            "y2":1290
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) hTERT promoter inhibition and toxicity of GSK3 inhibitors. A2780 cells were transfected with hTERT-luciferase reporter. 32 h later cells were treated for 16 h with compounds at 20 ??M, 10 ??M, 5 ??M, 2.5 ??M and 1.25 ??M or DMSO for 16 h prior to luciferase assay. Parallel MTT assays of compound toxicity were performed. Mean??SEM of 3 experiments. ",
          "(B) prior to luciferase assay. Mean??SEM of 3 experiments."
        ],
        "rois":[
          {
            "x":116,
            "y":1407,
            "x2":2953,
            "y2":3342
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) BIO suppresses the hTERT promoter in multiple cell lines. Cells were transfected with hTERT-luciferase reporter. 32 h later cells were treated for 16 h with inhibitor titrations as in "
        ],
        "rois":[
          {
            "x":16,
            "y":3402,
            "x2":3576,
            "y2":4863
          }
        ]
      }
    }
  },
  "560761":{
    
  },
  "560951":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) expression and "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1999,
            "y2":1382
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) phosphorylation of indicated proteins. Band intensity changes were assessed by densitometry relative to DMSO. Phosphospecific bands are normalised with expression. Mean??SEM of 2 experiments. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) BIO schedule in 5 week treatments. Cells were treated twice weekly on days 1 and 4 with DMSO or BIO (A2780, 2.5 ??M; HCT116, 1 ??M; 5637, 500 nM). BIO was not removed between treatments. Counting and harvesting was on treatment day 1 of each week. "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1999,
            "y2":1382
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) GSK3 inhibition over 5 week BIO treatment. 20 ??g protein samples from each time point were analysed by western blotting (C, Control; B, BIO). Two independent treatments were analysed. Representative blots are shown."
        ],
        "rois":[
          {
            "x":52,
            "y":1545,
            "x2":1988,
            "y2":2537
          }
        ]
      }
    }
  },
  "561121":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":10,
            "y":892,
            "x2":984,
            "y2":1764
          },
          {
            "x":455,
            "y":9,
            "x2":1443,
            "y2":756
          }
        ]
      },
      "PD":{
        "descriptions":[
          " 5 week cell growth curves under BIO treatment. Cells were counted weekly to determine cumulative population doublings (PD)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". Mean??SEM of three experiments. (B)"
        ],
        "rois":[
          {
            "x":237,
            "y":892,
            "x2":2000,
            "y2":2680
          },
          {
            "x":10,
            "y":892,
            "x2":984,
            "y2":1764
          }
        ]
      }
    }
  },
  "561338":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A)",
          " Transcriptional network of GSK3 inhibition. Differentially expressed genes from day 21 BIO treated cells were identified using Agilent whole genome expression arrays (n???=???3; mean fold change>5; phTERT. Shortest paths linking transcription factors from (A)"
        ],
        "rois":[
          {
            "x":235,
            "y":11,
            "x2":1461,
            "y2":846
          }
        ]
      },
      "C":{
        "descriptions":[
          " and GSK3 were identified in MetaCore. Green arrows: activation; red: inhibition; reaction mechanisms not shown. (C)"
        ],
        "rois":[
          {
            "x":269,
            "y":906,
            "x2":1491,
            "y2":1751
          },
          {
            "x":10,
            "y":1799,
            "x2":1274,
            "y2":2706
          },
          {
            "x":235,
            "y":11,
            "x2":1461,
            "y2":846
          }
        ]
      },
      "D":{
        "descriptions":[
          " Multiplex consensus oligonucleotide binding in A2780 nuclear extracts. 16 h DMSO or BIO treated cell nuclear extracts were incubated with labelled consensus oligonucleotide probe mix prior to column purification and hybridisation of eluted bound probes to oligonucleotide array. Mean??SEM of duplicate spots. (D)"
        ],
        "rois":[
          {
            "x":1309,
            "y":1818,
            "x2":1995,
            "y2":2600
          }
        ]
      }
    }
  },
  "561523":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":10,
            "y":17,
            "x2":1038,
            "y2":1721
          }
        ]
      },
      "B":{
        "descriptions":[
          " Growth delay of A2780 xenografts. Athymic mice (n???=???6/group) with established A2780 xenografts were treated intraperitoneally with BIO (2 mg/kg every two days, or 6 mg/kg twice weekly on days 1 and 4). Mean??SEM of calliper estimated tumour volumes relative to treatment day 0. (B)"
        ],
        "rois":[
          {
            "x":1147,
            "y":10,
            "x2":1947,
            "y2":772
          }
        ]
      },
      "C":{
        "descriptions":[
          " hTERT expression in A2780 xenografts. Tumours from vehicle or treated animals were excised and Q-RTPCR was performed. hTERT expression normalised to RPS15 in each tumour is shown. Bars show median expression (control???=???100%). (C)"
        ],
        "rois":[
          {
            "x":10,
            "y":1787,
            "x2":1955,
            "y2":2689
          },
          {
            "x":10,
            "y":17,
            "x2":1038,
            "y2":1721
          },
          {
            "x":973,
            "y":899,
            "x2":1958,
            "y2":1751
          }
        ]
      },
      "D":{
        "descriptions":[
          " GSK3 inhibition during prolonged BIO treatment. A2780 cells were treated twice weekly on days 1 and 4 with 2.5 ??M BIO or DMSO for 25 weeks. Analysis samples were taken every 4 weeks on treatment day 1. 20 ??g protein samples were analysed by western blotting. Two experiments were analysed. Representative blots are shown. (D)"
        ],
        "rois":[
          {
            "x":10,
            "y":17,
            "x2":1038,
            "y2":1721
          }
        ]
      }
    }
  },
  "561693":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":10,
            "y":17,
            "x2":1074,
            "y2":1766
          },
          {
            "x":625,
            "y":14,
            "x2":1510,
            "y2":485
          },
          {
            "x":1157,
            "y":523,
            "x2":1510,
            "y2":917
          }
        ]
      },
      "B":{
        "descriptions":[
          " Network motif analysis. Motifs in figure 5(B)",
          " were identified in MetaCore. Representative examples are shown. Green arrows: positive regulation; red arrows: negative regulation (reaction mechanisms not shown). (B)"
        ],
        "rois":[
          {
            "x":9,
            "y":1886,
            "x2":1884,
            "y2":2723
          },
          {
            "x":1097,
            "y":981,
            "x2":1928,
            "y2":1732
          }
        ]
      }
    }
  },
  "563301":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Pretreatment with Bili or Axin1 siRNA leads to a 2-fold greater activation of a ??-catenin responsive reporter after treatment with WNT3A conditioned media (black bars) in RKO-BAR cells compared to control siRNA. ??-catenin (??-cat) siRNA ablated Wnt 3A mediated reporter activation. Error bars represent STDEV. "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":821,
            "y2":605
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) hBili overexpression inhibits Wnt3A mediated ??-catenin responsive reporter activation in HEK293T cells. "
        ],
        "rois":[
          {
            "x":864,
            "y":11,
            "x2":1421,
            "y2":608
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) hBili overexpression inhibits WNT1, ??NLRP6, and DVl, but not BIO, or ??-catenin mediated ??-catenin responsive reporter activation in HEK293T cells. HEK293T cells stably expressing a ??-catenin responsive luciferase reporter were transfected or treated with WNT1, ??NLRP6, DVL, BIO, or ??-catenin along with GFP or Bili. Error bars represent STDEV. "
        ],
        "rois":[
          {
            "x":864,
            "y":11,
            "x2":1421,
            "y2":608
          },
          {
            "x":1453,
            "y":10,
            "x2":2205,
            "y2":640
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Bili colocalizes with LRP6. HEK293T cells were transfected with flag-hBili and hLRP6-eGFP and imaged. (*p"
        ],
        "rois":[
          {
            "x":15,
            "y":674,
            "x2":1525,
            "y2":1242
          }
        ]
      }
    }
  },
  "563422":{
    
  },
  "566384":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) sponge explants, showing changes in epithelium morphology. Note increased number and ovoid shape of epithelial cells in treated samples. Higher-magnification views of sequential sections of ectopic ostia forming by epithelial invagination from placode-like structures are shown on the right panels in E. Similar results were obtained with LiCl-treated sponges (data not shown). Ostia existing before treatment are shown by arrows and ectopic ostia are shown by asterisks. (Ch"
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), treated for 72 h with 40 mM LiCl "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) Mesohyl"
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), or treated for 48 h with 0.5 ??M BIO "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Both LiCl-treated and BIO-treated samples have more ostia than controls. Ostia pre-existing before treatment are shown by arrows and ectopic ostia by asterisks. D???E: Semi-thin sections of untreated ",
          ". C) Choanocyte chamber. (Ex) Exopinacodem. (Ex",
          ". C) Exhalant channel. "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and BIO-treated "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2895,
            "y2":2276
          }
        ]
      }
    }
  },
  "566537":{
    
  },
  "566839":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(E) Outgrowths generated in NOD/SCID mice from PTEN shRNA lentivirus-infected cells displayed increased phospho-Akt expression as well as increased nuclear ??-catenin localization as compared to control outgrowths. Scale bars???=???100 ??m. Data represent the mean??SD of three independent experiments."
        ],
        "rois":[
          {
            "x":954,
            "y":918,
            "x2":1641,
            "y2":1569
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Effects of the GSK3-?? inhibitor (Bio) and the Akt inhibitor (perifosine) on activation of Akt/GSK3-??/??-catenin signaling as assessed by Western blotting using phospho-specific antibodies. Perifosine inhibits pAkt, pGSK3-??, and activated ??-catenin expression. The GSK3-?? inhibitor Bio restores ??-catenin activation even in the presence of perifosine. "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":945,
            "y2":560
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) After 5 d treatment of primary mammospheres with either 10 ??M perifosine or 0.5 ??M Bio alone or in combination, cells were dissociated and passaged to form secondary mammospheres. Bio treatment increased the number of secondary mammospheres more than 2-fold, whereas perifosine treatment or down-regulation of ??-catenin via infection with an shRNA lentivirus decreased the number of secondary mammospheres by more than 50%. Bio reversed the inhibitory effect of perifosine. "
        ],
        "rois":[
          {
            "x":950,
            "y":3,
            "x2":2063,
            "y2":911
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) To monitor ??-catenin activity, TOP-GFP reporter lentivirus-infected mammospheres were treated with Bio or co-transfected with PTEN shRNA. Control mammospheres cultured for 7 d contained one???four GFP-positive cells. The proportion of GFP-positive cells was increased more than 2-fold by Bio treatment. Knockdown of PTEN also resulted in more than a 2-fold increase in the proportion of GFP-positive cells. "
        ],
        "rois":[
          {
            "x":950,
            "y":3,
            "x2":2063,
            "y2":911
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) TOP-GFP infected mammospheres were treated for 5 d with indicated compounds either alone or in combination and analyzed by flow cytometry. Perifosine treatment decreased the proportion of GFP-positive cells by more than 50%, whereas Bio treatment increased them more than 2-fold. The inhibition produced by perifosine was abrogated when the mammospheres were also treated with Bio. "
        ],
        "rois":[
          {
            "x":6,
            "y":561,
            "x2":950,
            "y2":1571
          }
        ]
      }
    }
  },
  "566954":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) PTEN knockdown in MCF7 or SUM159 cells resulted in increased Akt phosphorylation as assessed by Western blotting. "
        ],
        "rois":[
          {
            "x":7,
            "y":6,
            "x2":985,
            "y2":610
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) PTEN knockdown resulted in increased secondary tumorsphere formation in MCF7 and SUM159 cells. "
        ],
        "rois":[
          {
            "x":7,
            "y":6,
            "x2":985,
            "y2":610
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) PTEN knockdown secondary tumorspheres contained an increased proportion of Aldefluor-positive cells as compared with the tumorspheres from parental lines. "
        ],
        "rois":[
          {
            "x":972,
            "y":578,
            "x2":2040,
            "y2":1119
          },
          {
            "x":7,
            "y":6,
            "x2":985,
            "y2":610
          },
          {
            "x":21,
            "y":585,
            "x2":919,
            "y2":1078
          },
          {
            "x":1011,
            "y":39,
            "x2":2026,
            "y2":539
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Flow cytometry analyses of TOP-GFP-infected SUM159 tumorspheres treated with indicated inhibitors. Perifosine treatment decreased the proportion of GFP-positive cells by more than 50%, whereas Bio treatment increased the proportion of GFP-positive cells more than 2-fold and reversed the inhibitory effect of perifosine. Data represent the mean??SD of three independent experiments."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "56754":{
    
  },
  "567738":{
    
  },
  "569354":{
    
  },
  "570082":{
    "Figure_4.tif":{
      "5608":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "98":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "67":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5647":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "08":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "78":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "88":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "77":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5618":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5697":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          
        ]
      },
      "37":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "68":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5627":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5686":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5696":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "87":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "48":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5617":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "57":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5637":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5676":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5687":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "17":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "47":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "96":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "58":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "27":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "38":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5657":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "07":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          
        ]
      },
      "5677":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5609":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "18":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5666":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5607":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "97":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5667":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "5656":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      },
      "28":{
        "descriptions":[
          "(E-FL) and two ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [35S]-labeled proteins. The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [35S]-labeled proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-Myc and anti-??-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and ??-Actin band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of ??-actin (right graph)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2023,
            "y2":2542
          }
        ]
      }
    }
  },
  "570200":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. Pulse-chase assay was conducted with MDA-MB-231 cells transfected with either an empty vector or an expression vector for ENC1-Myc. Cells were incubated for 30 minutes with medium containing [35S]-methionine and [35S]-cysteine to label proteins. Cells were then washed and incubated in normal complete medium for the indicated time periods prior to cell lysis. Cell lysates were subjected to immunoprecipitation with anti-Nrf2 antibodies and immunoprecipitates were resolved in SDS-PAGE gel and detected by autoradiography"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":539
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Nrf2 band intensities were quantified using Quantity One (BIO-RAD) and the half-life was plotted and calculated"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":539
          },
          {
            "x":0,
            "y":540,
            "x2":1501,
            "y2":923
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Pulse-chase assay was conducted in the same way, except that cells were treated with 100 ??M tBHQ for 4 hr"
        ],
        "rois":[
          {
            "x":0,
            "y":924,
            "x2":1501,
            "y2":1752
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Quantified data of Fig. 5C."
        ],
        "rois":[
          {
            "x":0,
            "y":924,
            "x2":1501,
            "y2":1752
          },
          {
            "x":0,
            "y":1753,
            "x2":1501,
            "y2":2260
          }
        ]
      }
    }
  },
  "573333":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) RT-PCR analysis of endogenous, ectopic and total Myc expression in embryos of four different genotypes, which are indicated above each lane (Gal4???=???arm-Gal4, Gal4-Myc???=???armGal4; UAS dmyc, Gal4-Su(z)2???=???armGal4; Su(z)2XP, Gal4-Myc-Su(z)2???=???armGal4; Su(z)2XP; UAS dmyc). A 0???21 hour collection of embryos was used for RNA isolation and for all subsequent assays. Ras64B was used as a loading control"
        ],
        "rois":[
          {
            "x":10,
            "y":4,
            "x2":894,
            "y2":413
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) A chart showing endogenous dmyc expression, the average of biological triplicates is plotted with standard deviations indicated for four genotypes of embryos. Expression was quantified using Quantity 1 (Bio-Rad). The blue line denotes a statistically significant change in endogenous dmyc levels from Gal4-Myc to Gal4-Myc-Su(z)2"
        ],
        "rois":[
          {
            "x":12,
            "y":414,
            "x2":993,
            "y2":1418
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Living larvae of the genotypes shown, all grown at low density, aged 4 days after egg laying at room temperature, and photographed simultaneously."
        ],
        "rois":[
          {
            "x":3,
            "y":1427,
            "x2":964,
            "y2":2105
          }
        ]
      }
    }
  },
  "57346":{
    
  },
  "57347":{
    
  },
  "57349":{
    
  },
  "57351":{
    
  },
  "573511":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A) A representative gel of RT-PCR data showing the expression of six Myc targets of repression in four genotypes, as indicated above each column of bands. Total dmyc expression and Ras64B expression, a loading and RNA level control, are shown in the bottom two panels"
        ],
        "rois":[
          {
            "x":3,
            "y":4,
            "x2":1499,
            "y2":932
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The average band intensities indicating levels of expression and relative standard deviation are plotted for the 8 genes shown in A. Genotypes are indicated along the X axis, and the Y axis shows band intensities as quantified by Quantity 1 (Bio-Rad)"
        ],
        "rois":[
          {
            "x":24,
            "y":1040,
            "x2":1105,
            "y2":1841
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) ChIP results showing H3K27 tri-methylation of three of the 8 genes shown in A, in the 4 genotypes of the experiment. Ras64B is a negative control. These data show a representative picture of biological triplicates for all 8 genes."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "574198":{
    "Figure_2.tif":{
      "J":{
        "descriptions":[
          "(J). Monoclonal antibody against alpha-SG, beta-SG or gamma-SG together with polyclonal antibody against delta-SG were used to test the co-expression of the proteins on the sarcolemma. They were stained respectively using secondary antibodies conjugated with Cy3 or FITC fluorochrome. On the left of the figure the merge shows the co-localization of ??-SG with ??-, ??- or ??-SG. Original magnification, 20??. "
        ],
        "rois":[
          {
            "x":1540,
            "y":1652,
            "x2":1711,
            "y2":1823
          },
          {
            "x":7,
            "y":1652,
            "x2":368,
            "y2":1894
          },
          {
            "x":694,
            "y":1875,
            "x2":902,
            "y2":2105
          },
          {
            "x":1649,
            "y":1902,
            "x2":1820,
            "y2":2105
          },
          {
            "x":1171,
            "y":831,
            "x2":1368,
            "y2":1002
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Expression of ??-SG assessed by WB analysis in heart "
        ],
        "rois":[
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          },
          {
            "x":4,
            "y":1004,
            "x2":220,
            "y2":1175
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G), Liver (Li) and lung (Lu) respectively of 2w 2/1, 2w 2/9, 2w 2/8 and 2/8+2/1 groups of hamsters. "
        ],
        "rois":[
          {
            "x":3,
            "y":2118,
            "x2":199,
            "y2":2288
          },
          {
            "x":1540,
            "y":1271,
            "x2":1710,
            "y2":1478
          },
          {
            "x":1369,
            "y":1005,
            "x2":1710,
            "y2":1175
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          },
          {
            "x":474,
            "y":1004,
            "x2":670,
            "y2":1247
          }
        ]
      },
      "Q":{
        "descriptions":[
          "(Q), diaphragm "
        ],
        "rois":[
          {
            "x":3,
            "y":1922,
            "x2":199,
            "y2":2116
          },
          {
            "x":5,
            "y":3,
            "x2":843,
            "y2":830
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) WB performed using a polyclonal antibody against ??-SG and a monoclonal antibody against human ??-SG, respectively on heart and quadriceps of 2w 2/8, WT BIO14.6 hamsters. The expression and the localization, as well as the restoration of the SG complex was assessed through immunofluorescence "
        ],
        "rois":[
          {
            "x":636,
            "y":2106,
            "x2":1667,
            "y2":2786
          },
          {
            "x":1171,
            "y":1652,
            "x2":1539,
            "y2":1823
          },
          {
            "x":202,
            "y":1859,
            "x2":542,
            "y2":2116
          },
          {
            "x":1476,
            "y":1902,
            "x2":1646,
            "y2":2105
          },
          {
            "x":1369,
            "y":831,
            "x2":1710,
            "y2":1002
          },
          {
            "x":845,
            "y":92,
            "x2":1710,
            "y2":830
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          }
        ]
      },
      "IF":{
        "descriptions":[
          "(IF) staining respectively on heart, gastrocnemius and tongue of WT and BIO 14.6 not treated (C and D), compared with BIO14.6 hamsters that received alternative treatment protocols (E???I). IF were carried out by monoclonal antibodies against ??-, ??-, and human ??-SG respectively on 7w 2/1; 2w 2/1, 2w 2/8 and 2w 2/9; 2/8+2/1. The co-expression of SGs was determined with co-IF staining on several muscles of injected hamsters. Examples of co-IF staining on double injected hamsters (2/8+2/1) and 2w 2/9 hamsters are reported "
        ],
        "rois":[
          {
            "x":202,
            "y":2118,
            "x2":542,
            "y2":2288
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H), quadriceps "
        ],
        "rois":[
          {
            "x":5,
            "y":1480,
            "x2":368,
            "y2":1650
          },
          {
            "x":369,
            "y":1480,
            "x2":539,
            "y2":1650
          },
          {
            "x":369,
            "y":1652,
            "x2":539,
            "y2":1823
          },
          {
            "x":3,
            "y":2118,
            "x2":199,
            "y2":2288
          },
          {
            "x":1540,
            "y":1480,
            "x2":1711,
            "y2":1650
          },
          {
            "x":1540,
            "y":1652,
            "x2":1711,
            "y2":1823
          },
          {
            "x":904,
            "y":2106,
            "x2":1074,
            "y2":2276
          },
          {
            "x":7,
            "y":1652,
            "x2":368,
            "y2":1894
          },
          {
            "x":904,
            "y":1902,
            "x2":1074,
            "y2":2105
          },
          {
            "x":1170,
            "y":1004,
            "x2":1539,
            "y2":1478
          },
          {
            "x":1171,
            "y":831,
            "x2":1368,
            "y2":1002
          },
          {
            "x":5,
            "y":1213,
            "x2":368,
            "y2":1477
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          },
          {
            "x":224,
            "y":832,
            "x2":410,
            "y2":1175
          },
          {
            "x":369,
            "y":1271,
            "x2":539,
            "y2":1477
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K) We calculated the percentage of fibers expressing ??-SG in the differently injected groups of hamsters. The percentages were evaluated estimating the number of expressing fibers in cryosections of gastrocnemius, quadriceps and tongue of each group of treated hamsters compared with BIO14.6. The number of the analysed hamsters are indicated in the figure. The bars represent the mean??the standard error of the analysed animals."
        ],
        "rois":[
          {
            "x":636,
            "y":2106,
            "x2":1667,
            "y2":2786
          },
          {
            "x":3,
            "y":1922,
            "x2":199,
            "y2":2116
          },
          {
            "x":7,
            "y":1652,
            "x2":368,
            "y2":1894
          },
          {
            "x":1650,
            "y":2106,
            "x2":1820,
            "y2":2276
          },
          {
            "x":1649,
            "y":1902,
            "x2":1820,
            "y2":2105
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), Gastrocnemius "
        ],
        "rois":[
          {
            "x":3,
            "y":2118,
            "x2":199,
            "y2":2288
          },
          {
            "x":3,
            "y":1480,
            "x2":1539,
            "y2":2461
          },
          {
            "x":1171,
            "y":1652,
            "x2":1539,
            "y2":1823
          },
          {
            "x":202,
            "y":1859,
            "x2":542,
            "y2":2116
          },
          {
            "x":1476,
            "y":2106,
            "x2":1646,
            "y2":2276
          },
          {
            "x":1079,
            "y":2106,
            "x2":1250,
            "y2":2276
          },
          {
            "x":1271,
            "y":1902,
            "x2":1474,
            "y2":2105
          },
          {
            "x":1079,
            "y":1902,
            "x2":1250,
            "y2":2105
          },
          {
            "x":1369,
            "y":831,
            "x2":1710,
            "y2":1002
          },
          {
            "x":1369,
            "y":1005,
            "x2":1710,
            "y2":1175
          },
          {
            "x":5,
            "y":832,
            "x2":220,
            "y2":1003
          },
          {
            "x":586,
            "y":1275,
            "x2":778,
            "y2":1477
          },
          {
            "x":781,
            "y":1215,
            "x2":1120,
            "y2":1477
          },
          {
            "x":672,
            "y":833,
            "x2":1016,
            "y2":1175
          },
          {
            "x":475,
            "y":833,
            "x2":670,
            "y2":1003
          }
        ]
      }
    }
  },
  "575584":{
    "Figure_3.tif":{
      "WT":{
        "descriptions":[
          "(WT) or RING mutant "
        ],
        "rois":[
          
        ]
      },
      "RM":{
        "descriptions":[
          "(RM)), API2 and empty vector were transiently expressed together with HA-Ub in HEK-293T. Protein complexes were precipitated with streptavidin-coated paramagnetic beads and analyzed with ??-Flag, ??-HA (after stripping of ??-Flag) and ??-BCL10. A, Mono- and di-ubiquitinated bands of WT MALT1-API2 and API2 are indicated with asterisks in the ??-Flag and ??-HA panel. B, Where indicated, the precipitated protein complex was treated with ??-PPase to remove phosphorylation. C???D, BCL10 ubiquitination by M4A8 becomes more pronounced after inhibition of the proteasome. HA-bio-tagged BCL10 was transiently overexpressed in HEK-293T together with Flag-tagged M4A8 (WT or RM) or empty vector. Where indicated, cells were pretreated with MG132 to inhibit to proteasome. C, Cell lysates were immunodetected with ??-BCL10 and ??-HA (both for HA-BCL10), ??-Flag and ??-??-actin. BCL10 ubiquitination is indicated with asterisks. D, Following denaturation of the cell lysates, HA-bio-tagged BCL10 was precipitated via streptavidin pull-down and where indicated, treated with ??-PPase to remove phosphorylation. The bio-IPs were then immunodetected with ??-BCL10, ??-Flag (to check if the denaturation was complete) and ??-Ub. BCL10 ubiquitination is indicated with asterisks. Molecular weight standards are in kDa."
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":1499,
            "y2":2122
          }
        ]
      }
    }
  },
  "576007":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) QRT-PCR analysis of pluripotent cell markers OCT3/4 and REX-1, or differentiated cell markers NESTIN, T and GATA4. hESCs were incubated in CM, or UM in the absence or presence of cocktail inhibitors as indicated (25 ??M DCA, 25 ??M PD and 0.5 ??M Bio) for 6 days (Mean??SEM, n???=???3). "
        ],
        "rois":[
          {
            "x":999,
            "y":8,
            "x2":1741,
            "y2":616
          },
          {
            "x":1097,
            "y":1447,
            "x2":1440,
            "y2":1742
          },
          {
            "x":1443,
            "y":2163,
            "x2":1742,
            "y2":2447
          },
          {
            "x":1443,
            "y":1447,
            "x2":1748,
            "y2":1742
          },
          {
            "x":1443,
            "y":810,
            "x2":1745,
            "y2":1141
          },
          {
            "x":1443,
            "y":1867,
            "x2":1745,
            "y2":2163
          },
          {
            "x":100,
            "y":1464,
            "x2":511,
            "y2":1748
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Morphological analysis of hESCs performed by immunostaining of OCT3/4, and SSEA-4. Scale bar, 10 ??m. "
        ],
        "rois":[
          {
            "x":1007,
            "y":784,
            "x2":1440,
            "y2":1141
          },
          {
            "x":1097,
            "y":1447,
            "x2":1440,
            "y2":1742
          },
          {
            "x":1443,
            "y":2163,
            "x2":1742,
            "y2":2447
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) DCA partially inhibits differentiation in both mESCs (left panel) and hESCs (right panel) monitored by qRT-PCR analysis of Oct3/4 expression. "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":476,
            "y2":536
          },
          {
            "x":497,
            "y":74,
            "x2":828,
            "y2":521
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Removal of cocktail inhibitors restored differentiation capacity. hESC cells maintained with the cocktail inhibitors were incubated in UM without inhibitors for 8 days and allowed for differentiation under standard procedures. Cells were immunostained for TUJ1+ neurons, GATA4+ endoderm cell lineage or T+ mesoderm cell lineage, and hES cells incubated in CM were immunostained for OCT3/4. Scale bar, 5 ??m."
        ],
        "rois":[
          {
            "x":528,
            "y":1467,
            "x2":1026,
            "y2":1876
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) qRT-PCR analysis of pluripotent cell markers Nanog and Sox2. mESCs were incubated in feeder-free and LIF-free medium in the absence or presence of 50 ??M DCA for 6 days and total RNAs were extracted for analysis (Mean??SEM, n???=???3). "
        ],
        "rois":[
          {
            "x":1095,
            "y":1145,
            "x2":1745,
            "y2":1443
          },
          {
            "x":1443,
            "y":810,
            "x2":1745,
            "y2":1141
          },
          {
            "x":531,
            "y":1104,
            "x2":918,
            "y2":1456
          },
          {
            "x":7,
            "y":570,
            "x2":752,
            "y2":1033
          },
          {
            "x":497,
            "y":74,
            "x2":828,
            "y2":521
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) AP staining (left panel) and Ssea-1 flow cytometry (right panel) of mESCs treated with or without cocktail inhibitors. Scale bars, 50 ??m. "
        ],
        "rois":[
          {
            "x":1443,
            "y":810,
            "x2":1745,
            "y2":1141
          },
          {
            "x":8,
            "y":1108,
            "x2":518,
            "y2":1437
          },
          {
            "x":497,
            "y":74,
            "x2":828,
            "y2":521
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) mESCs cultured in feeder-free and LIF-free medium with cocktail inhibitors exhibited comparable proliferation rate as cells cultured in standard mESC medium (+LIF). "
        ],
        "rois":[
          {
            "x":1134,
            "y":1867,
            "x2":1440,
            "y2":2447
          },
          {
            "x":1443,
            "y":1447,
            "x2":1748,
            "y2":1742
          },
          {
            "x":1443,
            "y":810,
            "x2":1745,
            "y2":1141
          },
          {
            "x":1443,
            "y":1867,
            "x2":1745,
            "y2":2163
          },
          {
            "x":12,
            "y":1830,
            "x2":856,
            "y2":2441
          }
        ]
      }
    }
  },
  "576160":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) or protein ",
          "(E) and Western blot analysis "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N) or 20 mM LiCl "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) was collected at the designated times and analyzed using real-time PCR ",
          "(F)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and Western "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "G":{
        "descriptions":[
          ". G: MDA-MB-231 and PC-3 cells were transfected with either non-specific scrambled siRNA (siScramble), or siRNA directed against GSK3?? (si GSK3). 48 hours after transfection protein was isolated for Western blot analysis."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L). 24 hours after treatment, RNA and protein were collected for real-time PCR "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) analysis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Cancer cells BT549, Hs578T, PC-3, and Kato-III were plated at a medium density and allowed to adhere. Cells were then treated with 20 mM LiCl or NaCl control. 48 hours after transfection protein was collected for Western blot analysis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D: MDA-MB-231 cells were plated at a medium density, serum starved overnight, and treated with 20 mM NaCl or 20 mM LiCl. 24 hours after treatment, the cells were washed once with PBS and maintained in serum-free medium containing only 20 mM NaCl. RNA was collected at the times indicated for real-time PCR analysis. E and F: MDA-MB-231 cells were plated at a medium density and serum starved overnight. 16 hours after plating, the cells were treated with 1 ??M meBIO (control), 1 ??M BIO, or 20 mM LiCl. RNA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1501,
            "y2":1853
          }
        ]
      }
    }
  },
  "576543":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A: PC-3 cells were transfected with pGL3-CDH11-3???UTR NCBI or pGL3-CDH11-3???UTR Ensembl and pCMV-Renilla and along with either non-specific siRNA or siRNA directed against CTNNB1. 48 hours after transfection cells were were lysed using passive lysis buffer and luciferase activity was analyzed. Luciferase activity was normalized to renilla activity. (** indicates a p-value >0.001)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B: MDA-MB-231 and PC-3 cells were transfected with either non-specific scrambled siRNA (siScramble) or siRNA directed against CTNNB1 (si ??-cat). 24 hours after transfection cells were treated with 1 ??M BIO or meBIO (control). 48 hours after transfection protein was isolated for Western blot analysis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":995,
            "y2":2022
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: MDA-MB-231 and PC-3 cells were transfected with either non-specific scrambled siRNA (siScramble) or siRNA directed against CTNNB1 (si ??-cat). 24 hours after transfection cells were treated with 1 ??M BIO or meBIO (control). 48 hours after transfection RNA was isolated for real-time PCR analysis. (* indicates a p-value >0.05; ** indicates a p-value >0.005)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":995,
            "y2":2022
          }
        ]
      }
    }
  },
  "578065":{
    
  },
  "578132":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Immunoblotting of carbonate-insoluble pellet integral membrane proteins of schizont extracts of clones 5A, 5B, 3.2C, and 5.2A. A protein band of approximately 35 kDa was detected by anti-S1 serum in clones 5A and 3.2C (upper left panel) and by anti-S2 serum in clones 5A and 5.2A (upper right panel). Mouse anti-glycophorin C antibody recognizing a protein band of 25 kDa was used as loading control. Molecular weight comparison of detected STEVOR proteins by anti-S1 (lower left panel) and anti-S2 (lower right panel) is also shown. Secondary anti-rabbit (or mouse) IgG horseradish peroxydase-conjugated antibodies (Bio-Rad) and West Pico chemiluminescence (Pierce) were used to visualize the detected proteins in photographic film. Molecular marker (MM, Biorad) used for protein size comparison is shown. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1770,
            "y2":2091
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Microarray analysis of the expression profile of transcribed stevor genes at mid-trophozoite stage (22???28 hours post invasion) of each clone. Level of transcription was determined in relation to a pool of RNA as described in Materials and Methods. Individual stevor genes with regulated transcription are shown by their accession number."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1770,
            "y2":2091
          }
        ]
      }
    }
  },
  "581505":{
    "Figure_1.tif":{
      "0":{
        "descriptions":[
          "; 0.92"
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":464,
            "y2":941
          }
        ]
      },
      "1":{
        "descriptions":[
          ", 1.0",
          ", 1.06 Mb) were estimated using the MCID 3.0 software (Imaging Research Inc., St. Catharines, Canada). Based on densitometry analysis (ImageQuant TL 1-D analysis software; GE Healthcare Bio-Sciences Corp., Piscataway, NJ), the ratios of the bands were estimated to be 1???4???1. Using these ratios, the genome was estimated to be ???6 Mb. S. cerevisiae chromosomal size standards (Bio-Rad) were included (lane 1) and their sizes (Mb) are shown."
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":464,
            "y2":941
          }
        ]
      }
    }
  },
  "58203":{
    
  },
  "583827":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A, B) Bioinformatic analysis of Gata3 and Ret genomic loci 50 kb upstream of the translational start site. Conserved regions between mouse and human sequences are depicted as thick black lines. Conserved TCF/Lef binding sites (consensus sequence (C/G)TTG(A/T)(A/T)) [69] ",
          "(A) and Gata3 binding sites (consensus sequence (A/T)GATA(A/T)) [70] "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":978,
            "y2":109
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Bioinformatic analysis of Gata3 and Ret genomic loci 50 kb upstream of the translational start site. Conserved regions between mouse and human sequences are depicted as thick black lines. Conserved TCF/Lef binding sites (consensus sequence (C/G)TTG(A/T)(A/T)) [69] ",
          "(B), are represented as asterisks. ",
          "(B) A putative Gata3 binding site located in a previously reported RET regulatory element [50] and the mutated version used in "
        ],
        "rois":[
          {
            "x":0,
            "y":110,
            "x2":978,
            "y2":261
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) are indicated in brackets. "
        ],
        "rois":[
          {
            "x":0,
            "y":262,
            "x2":978,
            "y2":929
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantitative RT-PCR analysis of Gata3 expression in mIMCD3 reveals a marked increase in endogenous Gata3 expression upon treatment with 3 ??M BIO versus DMSO control. Results are expressed as ratios relative to control (n???=???3, ** P"
        ],
        "rois":[
          {
            "x":0,
            "y":262,
            "x2":978,
            "y2":929
          }
        ]
      }
    }
  },
  "584028":{
    
  },
  "584393":{
    
  },
  "586317":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "; E: 5-day treatment by the four Halomonas isolates."
        ],
        "rois":[
          {
            "x":0,
            "y":2063,
            "x2":1883,
            "y2":3225
          }
        ]
      },
      "A":{
        "descriptions":[
          "A: Control"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1879,
            "y2":993
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B: 2-day treatment by the four Halomonas isolates"
        ],
        "rois":[
          {
            "x":2027,
            "y":0,
            "x2":3902,
            "y2":993
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C: 3-day treatment after supplied with the seven Bacillus isolates"
        ],
        "rois":[
          {
            "x":0,
            "y":1034,
            "x2":1877,
            "y2":2028
          }
        ]
      },
      "D":{
        "descriptions":[
          "; D: sterilized and treated for 3 days after supplied with the seven Bacillus isolates"
        ],
        "rois":[
          {
            "x":2027,
            "y":1034,
            "x2":3904,
            "y2":3192
          }
        ]
      }
    }
  },
  "587986":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Primer-templates used for photo-cross-linking studies. ???B??? indicates a BrdU residue and * shows the position of an ??-32P-labeled dC residue in the template. Dashes indicate that the sequence is the same as the line above. Subscript ???H??? indicates a dideoxynucleotide residue introduced at the 3??? end of an oligodeoxynucleotide primer. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2988,
            "y2":2266
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Primer-templates used for SA binding and SA-biotin barrier experiments. ???Bio??? indicates the position of the internal Biotin-ON structure (shown in panel "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2988,
            "y2":2266
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C)). WL50 has the same sequence as WL50-Bio39 with the Biotin-ON structure replaced by T."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2988,
            "y2":2266
          }
        ]
      }
    }
  },
  "588364":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A,C) or L36-ddA/WL50-Bio39 ",
          "(A,B) or dNTP???RT???P/T ternary complexes "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3984,
            "y2":1371
          }
        ]
      },
      "C":{
        "descriptions":[
          "(A,C) or L36-ddA/WL50-Bio39 ",
          "(C,D). A portion of each P/T sequence is shown. ???Bio??? indicates the biotin-ON linkage. Subscript ???H??? denotes a dideoxyribonucleotide residue."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3984,
            "y2":1371
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B,D) were incubated without or with 100 nM RT in the absence of ligands or with 0.8, 3.2 or 6.4 mM dNTP. In A and B, SA (50 nM) was added for 5 min at 37??C, and 0.6 ??M biotin was added to bind excess SA. Then RT was dissociated with SDS and urea, and SA-biotin-DNA complexes were separated from free DNA by electrophoresis on nondenaturing gels. For C and D, complexes formed with dNTP were transferred to ice, treated with heparin to dissociate RT???P/T binary complexes and fractionated by nondenaturing gel electrophoresis. Arrows to the right of each panel indicate positions of free DNA (P/T) and SA-biotin-DNA complexes ",
          "(A,B) or dNTP???RT???P/T ternary complexes "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3984,
            "y2":1371
          }
        ]
      },
      "D":{
        "descriptions":[
          "(B,D) were incubated without or with 100 nM RT in the absence of ligands or with 0.8, 3.2 or 6.4 mM dNTP. In A and B, SA (50 nM) was added for 5 min at 37??C, and 0.6 ??M biotin was added to bind excess SA. Then RT was dissociated with SDS and urea, and SA-biotin-DNA complexes were separated from free DNA by electrophoresis on nondenaturing gels. For C and D, complexes formed with dNTP were transferred to ice, treated with heparin to dissociate RT???P/T binary complexes and fractionated by nondenaturing gel electrophoresis. Arrows to the right of each panel indicate positions of free DNA (P/T) and SA-biotin-DNA complexes ",
          "(C,D). A portion of each P/T sequence is shown. ???Bio??? indicates the biotin-ON linkage. Subscript ???H??? denotes a dideoxyribonucleotide residue."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3984,
            "y2":1371
          }
        ]
      }
    }
  },
  "588555":{
    
  }
,
  "588626":{
    
  },
  "589088":{
    
  },
  "589221":{
    "Figure_5.tif":{
      "UK":{
        "descriptions":[
          ", UK) and SYBR Green I chemistry according to manufacturer's instructions. Briefly, real-time PCR parameters included 40 cycles, fluorescent reading after each cycle and melt curve analysis of individual products at the end of the 40 cycles. Unique oligonucleotide identification number is shown along with BLASTx annotation and gender association. Significant similarity is defined as "
        ],
        "rois":[
          
        ]
      },
      "E":{
        "descriptions":[
          "(E) value???10???05. Fold-difference was calculated as described in Methods. Primer characteristics (Tm, annealing temperature and sequence) along with amplicon size are included in the Dataset S1 (RT-PCR Primers). Underlined unique IDs represent gender-associated transcripts identified by the indirect hybridization strategy (parasite cDNA versus parasite gDNA). The italicized unique ID represents a gender-associated transcript identified by the direct hybridization strategy (female cDNA versus male cDNA). Plain text unique IDs represent gender-associated transcripts identified by both hybridization strategies."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5493,
            "y2":4405
          }
        ]
      }
    }
  },
  "589883":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) FACS analysis of exosomes derived from control transfected (wt) or BAT3-transfected (BAT3) 293T cells revealed over-expression of BAT3 on the exosomal surface. Specific binding of anti-BAT3, NKp30-Ig and NKp46-Ig was detectable. Grey histograms: background (secondary antibody) staining of beads coated with exosomes. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Western blot analysis demonstrates that the enhanced secretion of BAT3 into the supernatant obtained from tumor cells (293T) when treated with heat shock (HS, lane: 3) or left untreated (UT, lane: 2). Lanes 4 and 5 demonstrate the co-immunoprecipitation of BAT3 by using either a polyclonal BAT3 antibody (4th lane) or a monoclonal Ab against Hsp70 (5th lane). The western blot is stained for BAT3. Lane 1 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Detection of BAT3 expression on exosomes by electron microscopy {left panel: gold antibody control (140000??) and right panel: exosomes stained with anti-BAT3 antibody (140000??)}. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) indicates the marker."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blotting to detect BAT3, Hsp70, Lamp-2 and CD9 in exosomal fractions (30 ??g) and lysate (10 ??g) of 293T cells and iDCs. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C,D) FACS analysis to detect BAT3 and various surface markers on exosomes, that were purified from iDCs ",
          "(C) or 293T cells "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C,D) FACS analysis to detect BAT3 and various surface markers on exosomes, that were purified from iDCs ",
          "(D) that were immobilized to latex beads. Grey background represents isotype control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2549,
            "y2":3299
          }
        ]
      }
    }
  },
  "590734":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic structures of biotin (bio)- and digoxigenin (dig)-labeled DNA constructs with one (O-539 and O-349) or two (O-153-O and O-158-O) ideal lac operator sequences (white bars) [82]. Numerals are DNA segment lengths (base pairs) measured from the center(s) of the operator(s).\n          "
        ],
        "rois":[
          {
            "x":0,
            "y":3,
            "x2":1525,
            "y2":2642
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) AFM image of molecules adsorbed to a mica surface (see Materials and Methods) from a mixture of repressor and di-operator DNA O-153-O (183-nm contour length). R, repressor; R-DNA, repressor???DNA complex. The color scale corresponds to a 3-nm range of heights.\n          "
        ],
        "rois":[
          {
            "x":1501,
            "y":0,
            "x2":2749,
            "y2":1116
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Scatter plot of the DNA arm contour lengths in repressor???DNA complexes. Measurements were made on images of complexes (n = 364) that had a single repressor molecule with two well-resolved protruding DNA arms; complexes with only one arm or with an arm that was too short for accurate measurement were excluded. In this graph, the data from each complex are plotted twice: the length of the longer arm (on the vertical axis) is plotted against the length of the shorter arm (horizontal axis); the same data are then replotted in a different color with the two axes interchanged. This produces a representation of the data that is symmetrical across a line (not shown) extending from the lower left to upper right corner. Data from both O-158-O (red and black) and O-153-O (green and blue) containing samples are included. The region between the dashed lines is that in which the sum of the arms lengths is 169 ?? 16 nm, the image contour length mean ?? 2 ?? S.D. measured for the uncomplexed DNAs. Green and red squares enclose the ranges of arm lengths predicted for operator-specific linear and looped repressor???DNA complexes, respectively.\n          (D and E) Left: projection images of two alternative three-dimensional structural models of looped complexes between Lac repressor (gray) and DNA (black) with two operators spaced approximately 50 nm apart. Right: the corresponding AFM images produced by numerical simulation of the AFM imaging process (see Materials and Methods).\n          "
        ],
        "rois":[
          {
            "x":1668,
            "y":1329,
            "x2":2807,
            "y2":2643
          },
          {
            "x":0,
            "y":3,
            "x2":1525,
            "y2":2642
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Representative images (120 ?? 120 nm) of looped complexes with O-158-O or O-153-O DNA."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "591487":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(D, E, F) Western immunoblot analysis of supernatants and cell extracts from cultures grown to stationary or mid-exponential phase. Proteins were detected with rabbit polyclonal antibodies specific for LukF-PV, Hla (??-toxin), or Spa. The immunoblots in panel E were exposed on the same film for equal times or using a longer exposure for MW2 (inset), which produced less Spa. Protein samples for SDS-PAGE presented in panels B and C were prepared in a manner identical to those shown in panels E and F."
        ],
        "rois":[
          {
            "x":1527,
            "y":45,
            "x2":2060,
            "y2":808
          },
          {
            "x":1087,
            "y":855,
            "x2":2063,
            "y2":1838
          }
        ]
      },
      "F":{
        "descriptions":[
          "(D, E, F) Western immunoblot analysis of supernatants and cell extracts from cultures grown to stationary or mid-exponential phase. Proteins were detected with rabbit polyclonal antibodies specific for LukF-PV, Hla (??-toxin), or Spa. The immunoblots in panel E were exposed on the same film for equal times or using a longer exposure for MW2 (inset), which produced less Spa. Protein samples for SDS-PAGE presented in panels B and C were prepared in a manner identical to those shown in panels E and F."
        ],
        "rois":[
          {
            "x":1087,
            "y":855,
            "x2":2063,
            "y2":1838
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) TaqMan real-time RT-PCR for comparison of fold changes in transcript levels of selected Agr-regulated genes in wild type and ??pvl mutant strains. See also Table 2 for additional data derived from in vitro growth to exponential phase and stationary phase in CCY or TSB media. agrA, accessory global regulator; hla, alpha-toxin; hlgA, gamma-haemolysin component A; splA, serine protease; spa, protein A; sdrD, serine aspartate repeat protein; clfB, clumping factor B. "
        ],
        "rois":[
          {
            "x":1081,
            "y":0,
            "x2":1514,
            "y2":788
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cell extracts separated by 12% SDS-PAGE (Protean II gel, Bio-Rad) using cultures grown to stationary phase. "
        ],
        "rois":[
          {
            "x":1527,
            "y":45,
            "x2":2060,
            "y2":808
          },
          {
            "x":35,
            "y":717,
            "x2":1134,
            "y2":1693
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Culture supernatants, prepared from growth in TSB or CCY media, were separated by gradient 10-20% SDS-PAGE. PVL subunits were identified by automated-direct infusion tandem mass spectrometry [32]. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1016,
            "y2":528
          },
          {
            "x":1527,
            "y":45,
            "x2":2060,
            "y2":808
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D, E, F) Western immunoblot analysis of supernatants and cell extracts from cultures grown to stationary or mid-exponential phase. Proteins were detected with rabbit polyclonal antibodies specific for LukF-PV, Hla (??-toxin), or Spa. The immunoblots in panel E were exposed on the same film for equal times or using a longer exposure for MW2 (inset), which produced less Spa. Protein samples for SDS-PAGE presented in panels B and C were prepared in a manner identical to those shown in panels E and F."
        ],
        "rois":[
          {
            "x":1527,
            "y":45,
            "x2":2060,
            "y2":808
          },
          {
            "x":1087,
            "y":855,
            "x2":2063,
            "y2":1838
          }
        ]
      }
    }
  },
  "592811":{
    
  },
  "59617":{
    
  },
  "5969383":{
    
  },
  "597030":{
    "Figure_6.tif":{
      "HM":{
        "descriptions":[
          "(HM) A: 20 ??g of protein from each fraction were separated in 12.5% SDS-PAGE and blotted for the presence of TfR (early endosomal marker), V0d and V1B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":699,
            "y2":524
          }
        ]
      },
      "EE":{
        "descriptions":[
          "(EE) from late endosomes "
        ],
        "rois":[
          {
            "x":856,
            "y":0,
            "x2":1328,
            "y2":948
          }
        ]
      },
      "LE":{
        "descriptions":[
          "(LE) and heavy membranes "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":699,
            "y2":524
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: The late endosomal lipid LBPA was used to follow the distribution of late endosomes on the gradient. An equal amount of protein was used for LBPA detection by ELISA with the LBPA antibody (6C4)"
        ],
        "rois":[
          {
            "x":4,
            "y":567,
            "x2":724,
            "y2":921
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Western blot was quantified using a Phosphoimager (Bio-Rad Laboratories) and the ratio V1/V0 was plotted. Note that the ratio LE/EE is higher for the V1B subunit than for the V0d subunit suggesting a higher assembly of the V-ATPase in the late endosomes compared to early endosomes."
        ],
        "rois":[
          {
            "x":856,
            "y":0,
            "x2":1328,
            "y2":948
          }
        ]
      }
    }
  },
  "597869":{
    
  },
  "597941":{
    
  },
  "598011":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Un-stimulated whole blood culture supernatant samples from a healthy donor were spiked at different concentrations (14???19000 pg/ml) with the standards from RnD-System Fluorokine-MAP base kits A and B. Samples were assayed in duplicate, read at a low RP1 target on the Bio-plex system instrument and recoveries calculated for each of the cytokines in the panel. The figure shows the individual cytokine's best recovery obtained. "
        ],
        "rois":[
          {
            "x":5,
            "y":1421,
            "x2":1909,
            "y2":2441
          },
          {
            "x":3,
            "y":10,
            "x2":1957,
            "y2":1333
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Serum samples from a healthy donor were spiked at concentrations (43.8???19000 pg/ml) with the standards from RnD-System's Fluorokine-MAP base kits A and B. Samples were assayed in duplicate, read at a low RP1 target on the Bio-plex system instrument and recoveries calculated for each of the cytokines in the panel. The figure shows the individual cytokine's recoveries obtained. The experiment was repeated for IFN-??, ????F-?? and IL-4 only."
        ],
        "rois":[
          {
            "x":5,
            "y":1421,
            "x2":1909,
            "y2":2441
          }
        ]
      }
    }
  },
  "599239":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Mobility frequencies. Donor plasmid pACD2X containing an Ll.LtrB-??ORF intron retargeted to insert at a site in the E. coli lacZ gene (between nucleotide residues 1062 and 1063, antisense strand; Figure S5) was transformed into the indicated strains and induced with 500 ??M IPTG for 0.5 h at 30 ??C (black bars) or 100 ??M IPTG for 1 h at 37 ??C (gray bars). The cells were then plated on LB medium containing X-Gal, and the lacZ integration frequency was calculated as the percentage of white colonies. The bar graphs show the mean for three independent assays, with the error bars indicating the standard deviation.\n            "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1355,
            "y2":924
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) LtrA expression levels in the cultures used for mobility assays after induction with IPTG at 30 ??C. Top, immunoblot probed with an anti-LtrA antibody preparation. Bottom, a parallel gel stained with Coomassie blue. Arrows to the left of the gel indicate positions of size markers (Kaleidoscope Prestained Standard; Bio-Rad)."
        ],
        "rois":[
          {
            "x":45,
            "y":924,
            "x2":1370,
            "y2":1560
          },
          {
            "x":0,
            "y":0,
            "x2":1355,
            "y2":924
          }
        ]
      }
    }
  },
  "600087":{
    "Figure_6.tif":{
      "2":{
        "descriptions":[
          ", panel 2) or with 5 ??g of pcDNA3-hFUS-DDIT3 (hFUS-DDIT3 expression vector",
          "(panel 2) or with 5 ??g of a vector expressing the DDIT3 domain "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1992,
            "y2":1627
          }
        ]
      },
      "3":{
        "descriptions":[
          ", panel 3). The data represent the fold activation with respect to a sample where reporter alone was transfected ",
          "(panel 3). The data represent the fold activation with respect to a sample where reporter alone was transfected "
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          "(panel 1). Data represent an average obtained from three separated experiments. A representative thin layer chromatograph is shown on the right. (C) Transactivation of the CAT reporter gene linked to mouse eIF4E promoter by FUS and DDIT3 domains of FUS-DDIT3 fusion protein. C3H10T1/2 cells were transiently cotransfected with 1 ??g of pm4ECAT together with 5 ??g of a vector expressing the FUS domain ",
          "(panel 1). Data represent an average obtained from three separated experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1992,
            "y2":1627
          }
        ]
      }
    }
  },
  "600587":{
    
  },
  "600703":{
    
  },
  "600757":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":951,
            "y":673,
            "x2":1494,
            "y2":1251
          }
        ]
      },
      "e":{
        "descriptions":[
          "(e) Twenty nine injections of 10 ??l each from a 50 ??M solution of bio-5???AMP were injected into 5 ??M MtBPL. The lower panel shows the least squares fit of the data in the upper panels of ",
          "(e) to obtain the binding parameters of the interactions of MtBPL with biotin + ATP and Bio-5???-AMP respectively."
        ],
        "rois":[
          {
            "x":45,
            "y":663,
            "x2":573,
            "y2":1249
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) biotin ",
          "(a) to obtain the binding parameters of the interactions of MtBPL with biotin.The fit of the data is not provided for reactions where interaction between MtBPL and a given ligand was not observed viz "
        ],
        "rois":[
          {
            "x":951,
            "y":0,
            "x2":1455,
            "y2":292
          },
          {
            "x":0,
            "y":20,
            "x2":575,
            "y2":616
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) desthiobiotin ",
          "(b) desthiobiotin or "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) ATP were used for the titrations. The lower panel shows the least squares fit of the data in the upper panel in ",
          "(c) ATP. "
        ],
        "rois":[
          {
            "x":951,
            "y":306,
            "x2":1460,
            "y2":618
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) MtBPL was incubated with 100 ??M biotin for 30 min in the ITC cell and then titrated against twenty nine injections of 10 ??l aliquots from 100 ??M ATP solution. ",
          "(d) and "
        ],
        "rois":[
          {
            "x":45,
            "y":663,
            "x2":573,
            "y2":1249
          }
        ]
      }
    }
  },
  "600788":{
    
  },
  "600913":{
    
  },
  "600990":{
    
  },
  "601696":{
    
  },
  "601792":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) C57 mice in acquisition at 1 mg/kg/infusion (left panel) and dose-response curve (right panel) "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1493,
            "y2":614
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) DBA mice in acquisition at 0.5 mg/kg/infusion (left panel) and dose-response curve (right panel). The symbols in the dose-response graph represent the last two days of stable intake on a dose. Behavior of the reference groups (-bio) is shown with grey lines and symbols. Horizontal lines show the data submitted to statistical analysis. Symbols represent mean??SEM. C57-AKR (white circles) n???=???5, C57-C3H (black circles) n???=???8, C57-bio (grey circles) n???=???8, DBA-AKR (white circles) n???=???8, DBA-C3H (black circles) n???=???11, DBA-bio (grey circles) n???=???10. * pC3H."
        ],
        "rois":[
          {
            "x":0,
            "y":615,
            "x2":868,
            "y2":1535
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":869,
            "y":613,
            "x2":1493,
            "y2":1535
          }
        ]
      }
    }
  },
  "601910":{
    
  },
  "603756":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Differential expression of the FOS and MYC networks and enriched disease classes. The Ingenuity Pathways Knowledge Base (IPKB) was used to generate networks of interacting genes that are overrepresented in the set of transcripts differentially expressed (based on a 1% FDR cutoff) between the urban and rural samples. The top two networks are focused on the FOS and MYC transcription factors, and every one of the genes that the IPKB indicate as interacting either genetically or biochemically are differentially expressed in this comparison. Network connectivity is indicated as solid edges for direct interactions, and dashed edges for indirect interactions. Transcripts are displayed in green for down-regulated and red for up-regulated, while cellular compartments in which the gene products are localized are also indicated. Gold edges highlight shared interactions. The list of genes, their fold change and P values are listed in Table S3. "
        ],
        "rois":[
          {
            "x":0,
            "y":9,
            "x2":2983,
            "y2":3405
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Overrepresentation of disease classes affected by differentially expressed genes. Some of the Ingenuity Knowledge Database disease bio-function categories enriched (Pvs. rural; blue, nomadic vs. urban; green, nomadic vs. rural). Fisher's exact test was used to calculate the P value associated with the probability that the number of genes in each biological function and/or disease assigned to that data set is greater or less than expected by chance given the numbers of genes expressed in leukocytes."
        ],
        "rois":[
          {
            "x":257,
            "y":3387,
            "x2":2892,
            "y2":4720
          },
          {
            "x":0,
            "y":9,
            "x2":2983,
            "y2":3405
          }
        ]
      }
    }
  },
  "605709":{
    
  },
  "605826":{
    
  },
  "606430":{
    
  },
  "606489":{
    
  },
  "607899":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E). Detection of endogenous JIP1 protein in HeLa and Cos1 cells by immunoblot using a polyclonal antibody against JIP1."
        ],
        "rois":[
          {
            "x":2070,
            "y":1348,
            "x2":2567,
            "y2":2067
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). Association of endogenous JIP1 with the endoplasmic reticulum. JIP1 was detected with a rabbit polyclonal antibody and as secondary a Cy3-labeled anti-rabbit antibody was used (red). Calnexin was detected with a monoclonal antibody and a Cy-2-labeled anti-mouse antibody (green). "
        ],
        "rois":[
          {
            "x":15,
            "y":20,
            "x2":906,
            "y2":524
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Association of endogenous JIP1 with mitochondria. JIP1 was detected with a rabbit polyclonal antibody and as secondary antibody a Cy2-labeled anti-rabbit antibody was used (green). Mitochondria were detected with the MitoTracker Red CMXRos reagent (red). Nuclei were identified with DAPI staining. The bar indicates 50 ??m. "
        ],
        "rois":[
          {
            "x":970,
            "y":25,
            "x2":1461,
            "y2":525
          },
          {
            "x":1463,
            "y":45,
            "x2":1869,
            "y2":525
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Colocalization of endogenous JIP1 and transfected HA-VRK2A. The Cos1 cell line was transfected with plasmid, pCEFL-HA-VRK2A and pCEFL-HA-VRK2B, expressing each of the VRK2 isoforms. The endogenous JIP1 protein was detected with a rabbit polyclonal antibody (red) and the transfected VRK2 proteins with a monoclonal antibody specific for HA epitope (green). Nuclei were identified with DAPI staining. The bar indicates 50 ??m. "
        ],
        "rois":[
          {
            "x":2063,
            "y":11,
            "x2":2567,
            "y2":1347
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). The expression of the four human JIP (1???4) genes was determined by quantitative RT-PCR in RNA extracted from HeLa cells as described in Material and Methods. The profile of amplification (upper panel) as well as the quantification (lower panel) by the Bio-Rad iCycler iQ5 Software is shown. "
        ],
        "rois":[
          {
            "x":14,
            "y":529,
            "x2":2884,
            "y2":3621
          },
          {
            "x":969,
            "y":520,
            "x2":1461,
            "y2":957
          },
          {
            "x":2569,
            "y":31,
            "x2":2985,
            "y2":1766
          }
        ]
      }
    }
  },
  "607959":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-IEk-MCC, bio-IEk-ER60, bio-IEk-HSP70, or bio-IEk-99A at the indicated concentrations were added to 96-well plates precoated with streptavidin and incubated for 18 h at 37 ??C. AD10 CD4+ T cells were added to the wells and stimulated for 7 h prior to IL2 assay.\n            ",
          "(A) was determined by ELISA using anti-IEk 14-4-4s antibody followed by HRP-conjugated goat anti-mouse antibody. ABTS substrate color development was monitored at 405 nm.\n            ",
          "(A).\n            (E and F) Same as "
        ],
        "rois":[
          {
            "x":7,
            "y":0,
            "x2":1727,
            "y2":1629
          },
          {
            "x":1715,
            "y":80,
            "x2":3272,
            "y2":1629
          },
          {
            "x":1686,
            "y":1675,
            "x2":3370,
            "y2":3305
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The level of IEk proteins on streptavidin plates coated as in "
        ],
        "rois":[
          {
            "x":7,
            "y":0,
            "x2":1727,
            "y2":1629
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Streptavidin plates coated with bio-IEk-MCC at the indicated concentrations were subsequently saturated with 10 ??g/ml bio-IEk-ER60, bio-IEk-HSP70, bio-IEk-99A, or buffer for 1 h at room temperature before being used to stimulate AD10 T cells.\n            ",
          "(C) and "
        ],
        "rois":[
          {
            "x":3,
            "y":1672,
            "x2":1694,
            "y2":3306
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The 96-well ELISA plates were coated with bio-IEk-MCC at the indicated concentrations overnight at 4 ??C. The wells were then saturated with 10 ??g/ml BSA, IEk-ER60, IEk-HSP70, IEk-99A, or IAk-CA for 4 h at room temperature. Stimulation of AD10 and measurement of IL2 measurements were done as described in ",
          "(D), respectively, except that 5C.C7 cells were used."
        ],
        "rois":[
          {
            "x":0,
            "y":3389,
            "x2":3372,
            "y2":5009
          },
          {
            "x":1686,
            "y":1675,
            "x2":3370,
            "y2":3305
          }
        ]
      }
    }
  },
  "608078":{
    
  },
  "608203":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A. Distribution (%) of the bio-pathological factors ??4 integrin subunit, ErbB-3, P-Akt(ser473), ER??1 and ErbB-2 in 232 TAM treated breast cancers"
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":1986,
            "y2":1229
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Representative immunohistochemically positive cases for ??4, ErbB-3, P-Akt(ser473), ER??1 and ErbB-2 protein detection and control tissue sections."
        ],
        "rois":[
          {
            "x":78,
            "y":1374,
            "x2":1794,
            "y2":3050
          }
        ]
      }
    }
  },
  "608230":{
    
  },
  "608237":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) Similar to "
        ],
        "rois":[
          {
            "x":2594,
            "y":21,
            "x2":3995,
            "y2":1058
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) or were further anchored with (ICAM-1)2-SA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1251,
            "y2":972
          },
          {
            "x":1279,
            "y":0,
            "x2":2519,
            "y2":961
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) before adding T cells. Bilayers anchored with only (ICAM-1-bio)2-SA did not induce T cell calcium flux.\n            (C and D) A layer of CH27 cells pulsed for 1 h with 1 ??M MCC-FITC was attached on cover glasses coated with poly-l-lysine. Fura-2 AM???pulsed AD10 T cells treated with 10 ??M cytochalasin D for 1 h "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1251,
            "y2":972
          },
          {
            "x":1279,
            "y":0,
            "x2":2519,
            "y2":961
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) were introduced, and calcium flux was monitored.\n            ",
          "(C), except that 10 ??M cytochalasin D (or DMSO as control) was introduced after T cell calcium flux reached peak levels."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1251,
            "y2":972
          },
          {
            "x":2,
            "y":1103,
            "x2":2519,
            "y2":2124
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), or untreated AD10 T cells "
        ],
        "rois":[
          {
            "x":2610,
            "y":1112,
            "x2":3994,
            "y2":2180
          }
        ]
      }
    }
  },
  "608330":{
    
  },
  "608973":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Enzyme-linked immunosorbent assay (ELISA) to detect PA5369-like protein on cell surfaces of MPAO1 and MDR clinical P. aeruginosa strains. Data are mean ?? SD (n = 3)."
        ],
        "rois":[
          {
            "x":1579,
            "y":0,
            "x2":4106,
            "y2":2521
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J) Immuno-electron microscopy of strain MDR25. Gold spots identified with arrows indicate the protein recognized by anti-PA5369 antibody on cell surface structures."
        ],
        "rois":[
          {
            "x":1282,
            "y":2487,
            "x2":3987,
            "y2":5333
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F, G) TEM images of strain MDR25 grown on ",
          "(F) PIA supplemented with 1 mM K-phosphate buffer and "
        ],
        "rois":[
          {
            "x":1579,
            "y":0,
            "x2":4106,
            "y2":2521
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A, B) Fractionation of sheared cell surface proteins by 10% Tris-Glycine SDS-PAGE and identification of abundant proteins by N-terminal sequencing.",
          "(A), Lane 1, molecular weight standards (Bio-Rad, broad range, pre-stained); lane 2, strain MDR25; lane 3, strain MDR1. Black arrows show proteins of strain MDR1 subjected to N-terminal sequencing."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1736,
            "y2":948
          }
        ]
      },
      "I":{
        "descriptions":[
          "(H, I) Immunoblot of ",
          "(I) cell pellet proteins in strain MDR25 grown on PIA (low phosphate) versus PIA supplemented with 1 mM K-phosphate buffer (high phosphate)."
        ],
        "rois":[
          {
            "x":93,
            "y":1096,
            "x2":1398,
            "y2":3704
          }
        ]
      },
      "G":{
        "descriptions":[
          "(F, G) TEM images of strain MDR25 grown on ",
          "(G) on PIA."
        ],
        "rois":[
          {
            "x":1579,
            "y":0,
            "x2":4106,
            "y2":2521
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Fractionation of sheared cell surface proteins by 10% Tris-Glycine SDS-PAGE and identification of abundant proteins by N-terminal sequencing.",
          "(B) Lane 1, molecular weight standards (Invitrogen, SeeBlue Plus 2 pre-stained); lane 2, strain 13. Black arrow shows protein subjected to N-terminal sequencing."
        ],
        "rois":[
          {
            "x":93,
            "y":1096,
            "x2":1398,
            "y2":3704
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Immunoblot analysis of cell surface sheared proteins isolated from strains MDR1, MDR13, MDR25, and MPAO1 by using affinity purified polyclonal anti-PA5369 antibody."
        ],
        "rois":[
          {
            "x":1282,
            "y":2487,
            "x2":3987,
            "y2":5333
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H, I) Immunoblot of ",
          "(H) sheared surface proteins and "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) Immunoblot analysis of pellet and sheared surface proteins from strains MPAO1, MPAO1 derivative PA5369 mutant, and clinical strain MDR25. Colonies were collected and suspended in 200 ??l PBS up to final density of 5.0 (600 nm) followed by vortexing for 2 min and centrifuging at 5,000g, 5 min. Sheared material in 10 ??l of supernatant was denatured by boiling with 10 ??l sample buffer and 10 ??l was loaded on gel wells to be separated by 10% glycine SDS-PAGE. The remaining pellet was resuspended in 50 ??l of sample buffer, boiled, and 2 ??l were loaded on gel wells. PstS protein was identified by immunoblot using anti-PA5369 antibody."
        ],
        "rois":[
          {
            "x":1579,
            "y":0,
            "x2":4106,
            "y2":2521
          }
        ]
      }
    }
  },
  "610397":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) PrPres electrophoretic pattern in spleen (sp, circle) and brain (br, square) of mice euthanised healthy in triplicates up to 550 days post-infection (broken line) or at end of life time. vCJD- and sCJD-associated PrPres pattern are represented as brown and grey color, respectively. Empty symbols indicate PrPres negative tissue. Mock-infected mice (mock) were intraperitoneally inoculated with human brain without any TSE. "
        ],
        "rois":[
          {
            "x":5,
            "y":2,
            "x2":1237,
            "y2":1204
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantification of PrPres levels in the spleens on secondary transmission of vCJD (late brain). Spleen tissue was collected from healthy mice euthanised in triplicates at regular time points or individually at the end of life (see above). PrPres was extracted, detected by western blot and quantified with a bio-imaging system for chemiluminescence applications (see Methods). Results are expressed in arbitrary units (logarithmic scale). The standard deviations for triplicates without error bars were too small to be represented. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Electrophoretic pattern of PrPres in brain (Br) spleen (Sp) at various times after inoculation of the indicated brain materials."
        ],
        "rois":[
          {
            "x":18,
            "y":1240,
            "x2":1237,
            "y2":2431
          }
        ]
      }
    }
  },
  "613927":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          ". E. Cellular distribution of VT680 assessed microscopically"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":23,
            "y":19,
            "x2":1978,
            "y2":993
          },
          {
            "x":830,
            "y":1159,
            "x2":2085,
            "y2":1874
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "J":{
        "descriptions":[
          ". J. CD25 and CD44 expression. Thy1.2 splenocytes were labeled with VT680 and injected to Thy1.1 mice. At indicated times recipient spleens were harvested and CD25 and CD44 expression was measured on VT680-labeled, Thy1.2 donor splenocytes and unlabeled, Thy1.1 cells of recipient mice. Mean and SEM are shown, n???=???3???5."
        ],
        "rois":[
          {
            "x":2105,
            "y":1158,
            "x2":2723,
            "y2":1874
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. Cellular distribution of VT680 in resting and dividing cells assessed with a bio-cellular assay"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":12,
            "y":2088,
            "x2":932,
            "y2":3040
          },
          {
            "x":32,
            "y":1043,
            "x2":811,
            "y2":1874
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Splenocytes were incubated with increasing doses of VT680 and mean fluorescent intensity (MFI) for each dose is shown"
        ],
        "rois":[
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":1269,
            "y":3388,
            "x2":2507,
            "y2":4178
          }
        ]
      },
      "I":{
        "descriptions":[
          ". I. Retention of VT680 in vivo. Thy1.2 splenocytes were labeled with VT680 or CFSE ex vivo and injected to Thy1.1 mice. At indicated times recipient spleens (Thy1.1) were harvested and retention of label on donor cells (Thy1.2) was calculated"
        ],
        "rois":[
          {
            "x":2867,
            "y":1247,
            "x2":3973,
            "y2":2030
          },
          {
            "x":32,
            "y":1043,
            "x2":811,
            "y2":1874
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "G":{
        "descriptions":[
          ". G. VT680-labeled Thy1.1 cells were mixed in a 1???1 ratio with unlabeled Thy1.2 cells and cultured together. A different group was cultured separately. 24 h later VT680 retention was assessed in Thy1.1+ (Gate i) and Thy1.2+ (Gate ii) cells"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":51,
            "y":3140,
            "x2":1105,
            "y2":4178
          },
          {
            "x":32,
            "y":1043,
            "x2":811,
            "y2":1874
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Viability of splenocytes after labeling with increasing doses of VT680"
        ],
        "rois":[
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. In vitro retention of VT680 and CFSE in resting cells for three days after labeling (log scale)"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":51,
            "y":3140,
            "x2":1105,
            "y2":4178
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "H":{
        "descriptions":[
          ". H. Expression of IFN-?? on na??ve cells (thick-line histogram) and cells stimulated with PMA/Ionomycin (shaded histogram) that were either unlabeled or labeled with VT680"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":32,
            "y":1043,
            "x2":811,
            "y2":1874
          },
          {
            "x":2503,
            "y":2091,
            "x2":3923,
            "y2":3031
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. In vitro retention of VT680 and CFSE in dividing cells for three days after labeling (log scale)"
        ],
        "rois":[
          {
            "x":2035,
            "y":16,
            "x2":2950,
            "y2":1154
          },
          {
            "x":3017,
            "y":25,
            "x2":3927,
            "y2":992
          },
          {
            "x":2704,
            "y":3388,
            "x2":3948,
            "y2":4178
          },
          {
            "x":991,
            "y":2202,
            "x2":2358,
            "y2":3252
          }
        ]
      }
    }
  },
  "617319":{
    "Figure_8.tif":{
      "E":{
        "descriptions":[
          ". E) Cytokine secretion by activated T cells. T cells were purified by MACS and left unstimulated or treated with plate-bound anti-CD3 for 2 days. Thereafter, supernatant were harvested and cytokine secreted in the media were measured using Bio-Plex technology. There were no significant difference (p>0.05) between any genotypes in any of these graphs."
        ],
        "rois":[
          {
            "x":16,
            "y":1362,
            "x2":990,
            "y2":2131
          }
        ]
      },
      "A":{
        "descriptions":[
          "A) Growth curves of wild type, CSRNP-1???/???, CSRNP-2???/??? and CSRNP-1???/???/CSRNP-2???/??? T cells. Splenocytes were seeded a density of 106 cells/ml and stimulated with anti-CD3 and IL-2, thereafter, the cultures were kept in IL-2-containing media. Viable cell counts were determined by trypan blue staining every 2???3 days and the cells were split back to 106 cells/ml. The data shown represent the average of three animals per genotype"
        ],
        "rois":[
          {
            "x":9,
            "y":12,
            "x2":1038,
            "y2":708
          }
        ]
      },
      "IR":{
        "descriptions":[
          "(IR) with 500 rad or treated with 1 ??M of dexamethasone (DEX) or 1 ??g/mL anti-FAS, 20 hours later viability was determined by propidium iodine exclusion using flow cytometry"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B) Activated T cells grown in the presence of IL-2 for 7 days were IL-2-depreived overnight and then stimulated with increasing amounts of IL-2 for 48 hours, then DNA synthesis was determined by pulsing with [3H]thymidine for 16 hours"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". C) Activated T cells grown in the presence of IL-2 for 5 days were then stimulated overnight with plate-bound anti-CD3, viability was determined by trypan blue staining"
        ],
        "rois":[
          {
            "x":13,
            "y":661,
            "x2":2024,
            "y2":1314
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) Thymocytes were either gamma-irradiated "
        ],
        "rois":[
          {
            "x":1072,
            "y":12,
            "x2":2045,
            "y2":709
          }
        ]
      }
    }
  },
  "617520":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Western blot analysis of schizonts extracts (Sch.) or culture supernatants (S.n.) probed with rat anti-EBA-140 antibodies. The same membrane was re-probed with rabbit anti-EBA-175 antibodies to control for the amount of stage-specific material. The position of SeeBlue Plus2 pre-stained standards (Invitrogen) is shown (kDa)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":697,
            "y2":823
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunoprecipitation of NP-40-extracted schizonts and culture supernatants with anti-EBA-140 antibodies. The position of Precision Plus All Blue pre-stained standards (Bio-Rad, http://www.bio-rad.com/) is shown."
        ],
        "rois":[
          {
            "x":729,
            "y":0,
            "x2":1283,
            "y2":923
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Erythrocyte binding assay with radiolabelled supernatants from 3D7-A and 3D7-B. The lane IP corresponds to 3D7-B supernatant immunoprecipitated with anti-EBA-140 antibodies."
        ],
        "rois":[
          {
            "x":1308,
            "y":0,
            "x2":1688,
            "y2":1097
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IFA of 3D7-A and 3D7-B schizonts with rabbit anti-EBA-140 and mouse anti-EBA-175 antibodies. Middle and lower panels are representative of 93% and 7% of EBA-175-positive 3D7-A schizonts, respectively. Scale bar = 5 ??m."
        ],
        "rois":[
          {
            "x":1009,
            "y":1085,
            "x2":1311,
            "y2":1507
          },
          {
            "x":18,
            "y":1148,
            "x2":1666,
            "y2":2216
          },
          {
            "x":654,
            "y":1085,
            "x2":956,
            "y2":1507
          },
          {
            "x":36,
            "y":1027,
            "x2":602,
            "y2":1507
          }
        ]
      }
    }
  },
  "619031":{
    "Figure_2.tif":{
      "5608":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "98":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "67":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":11,
            "y":582,
            "x2":521,
            "y2":1115
          }
        ]
      },
      "5647":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          },
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "08":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":7,
            "y":16,
            "x2":475,
            "y2":536
          }
        ]
      },
      "6686":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          
        ]
      },
      "78":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":516,
            "y":1157,
            "x2":974,
            "y2":1702
          }
        ]
      },
      "88":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "77":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":516,
            "y":1157,
            "x2":974,
            "y2":1702
          },
          {
            "x":987,
            "y":579,
            "x2":1505,
            "y2":1117
          }
        ]
      },
      "5618":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "5697":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "5638":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "37":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":485,
            "y":7,
            "x2":974,
            "y2":536
          },
          {
            "x":978,
            "y":10,
            "x2":1470,
            "y2":538
          }
        ]
      },
      "68":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":11,
            "y":582,
            "x2":521,
            "y2":1115
          },
          {
            "x":987,
            "y":579,
            "x2":1505,
            "y2":1117
          }
        ]
      },
      "5627":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "5686":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "5696":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          },
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "87":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":988,
            "y":1163,
            "x2":1460,
            "y2":1698
          },
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "48":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":491,
            "y":576,
            "x2":1018,
            "y2":1117
          },
          {
            "x":1474,
            "y":7,
            "x2":1944,
            "y2":536
          }
        ]
      },
      "5658":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "5617":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          },
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "5628":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "57":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":491,
            "y":576,
            "x2":1018,
            "y2":1117
          },
          {
            "x":1474,
            "y":576,
            "x2":1950,
            "y2":1115
          }
        ]
      },
      "6676":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "5678":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "5637":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":17,
            "y":1160,
            "x2":524,
            "y2":1693
          }
        ]
      },
      "5648":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "5676":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "5687":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "47":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1474,
            "y":7,
            "x2":1944,
            "y2":536
          }
        ]
      },
      "58":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":11,
            "y":582,
            "x2":521,
            "y2":1115
          },
          {
            "x":1474,
            "y":576,
            "x2":1950,
            "y2":1115
          }
        ]
      },
      "38":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":978,
            "y":10,
            "x2":1470,
            "y2":538
          },
          {
            "x":1474,
            "y":7,
            "x2":1944,
            "y2":536
          }
        ]
      },
      "5668":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          },
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "5657":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "6609":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "5688":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "5677":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":219,
            "y":2157,
            "x2":742,
            "y2":2461
          }
        ]
      },
      "6656":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "5609":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "18":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":7,
            "y":16,
            "x2":475,
            "y2":536
          },
          {
            "x":485,
            "y":7,
            "x2":974,
            "y2":536
          }
        ]
      },
      "5666":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "5607":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "97":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":1470,
            "y":1160,
            "x2":1945,
            "y2":1706
          }
        ]
      },
      "5667":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "6666":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "5656":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":81,
            "y":1758,
            "x2":817,
            "y2":2152
          }
        ]
      },
      "5698":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":184,
            "y":2481,
            "x2":767,
            "y2":2785
          }
        ]
      },
      "28":{
        "descriptions":[
          "(i-iv) and C",
          "(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events >290 nm290 nm"
        ],
        "rois":[
          {
            "x":485,
            "y":7,
            "x2":974,
            "y2":536
          }
        ]
      }
    }
  },
  "619920":{
    "Figure_3.tif":{
      "LG":{
        "descriptions":[
          "(LG) and cells with high granularity "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":6023,
            "y2":3615
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Akata-GFP cells were cultured in medium alone, with GST (4 ??M), with CIDR1?? (0,12???4 ??M), or with anti-Ig (10 ??g/mL). After 48 h of incubation, a FACS analysis was performed. Cell populations were divided into cells with low granularity "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":6023,
            "y2":3615
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Akata-GFP cells were cultured with GST (2 ??M), with CIDR1?? (0???2 ??M), and with anti-Ig (10 ??g/mL). After 48 h of incubation, the proportion of GFP-positive cells was quantified by FACS analysis (circles), and the EBV DNA load was assessed by real-time PCR (diamonds). The left y-axis denotes the proportion of Akata-GFP???positive cells in lytic cycle, the right y-axis denotes the number of EBV genomes. Controls included GST-stimulated (empty diamonds/circles) and anti-Ig???stimulated cells (filled diamonds/circles). Data show the mean of three independent experiments."
        ],
        "rois":[
          {
            "x":785,
            "y":3616,
            "x2":6023,
            "y2":5161
          },
          {
            "x":0,
            "y":5162,
            "x2":6023,
            "y2":9244
          }
        ]
      },
      "HG":{
        "descriptions":[
          "(HG) on the basis of side scatter (SSC). The proportion of cells in lytic cycle (GFP-positive) was then quantified in the HG subpopulation. The figure shows one representative experiment. FSC, forward scatter."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":6023,
            "y2":3615
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Akata cells up-regulate BZLF1 upon stimulation with CIDR1??. Akata-GFP cells were cultured with GST (1,5 ??M) or with CIDR1?? (0,25???1,5 ??M). After 48 h of incubation, the expression of BZLF1 was analyzed by Western blot. Increased BZLF1 expression in CIDR1?? stimulated samples was confirmed by relative quantitative analysis with Quantity One software (Bio-Rad)."
        ],
        "rois":[
          {
            "x":0,
            "y":3616,
            "x2":784,
            "y2":5161
          },
          {
            "x":0,
            "y":5162,
            "x2":6023,
            "y2":9244
          }
        ]
      }
    }
  },
  "620860":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A), KC "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4133,
            "y2":3055
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and HMGB1 (C and D) was measured in sham-operated animals (n???=???6) and after I/R of either saline-treated animals (black bars, n???=???8) or nicotine-treated animals (white bars, n???=???8). TNF-?? and KC levels were measured by ELISA in kidney homogenates harvested 24 hours after reperfusion. All samples were corrected for total protein amounts measured by Bio-Rad protein assay. HMGB1 specific blots "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4133,
            "y2":3055
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) were performed on cytoplasmic renal extracts. From left to the right: saline treated sham-operated animals, nicotine-treated sham-operated animals, nicotine treated I/R animals and saline treated I/R animals. Blots are representative of 6 to 8 individual mice in each group. Quantification was assessed by the densitometry index "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4133,
            "y2":3055
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Similar results were observed in two separate experiments. Data are expressed as mean?? SEM and (*) p???0.05."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4133,
            "y2":3055
          }
        ]
      }
    }
  },
  "622505":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) The Dis3 protein contains the PINc, RNB and S1 domains. PINc belongs to a large family of protein domains associated with exonuclease or nucleotide binding activity. S1 is an RNA binding domain [65]. The RNaseII RNB domain contains four high consensus regions, Motif I, II, III and IV [30]. Amino acid sequences from Motifs I and IV of E. coli (EcRNaseII)"
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":1425,
            "y2":373
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) In vitro RNase activity of WT, P509L and T808A mutant Dis3-GST proteins at 37??C (top panel) and 20??C (bottom panel). Wild-type and mutant Dis3-GST proteins (1 pmol/lane) purified from S. pombe cells were incubated with total S. pombe RNA (1 ??g/lane) as described in Materials and Methods. Reactions were stopped at the indicated time points and subject to denatured agarose gel electrophoresis. RNA was detected by ethidium bromide staining. 25S and 18S rRNA bands are indicated. "
        ],
        "rois":[
          {
            "x":3,
            "y":398,
            "x2":1413,
            "y2":848
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantitation of three independent experiments represented in Fig. 5B. Total ethidium bromide signal intensities for the major 25S and 18S rRNA bands were measured using an Image Analyzer (Bio-Rad) and normalized against the intensities for the 0 min time points. "
        ],
        "rois":[
          {
            "x":1455,
            "y":403,
            "x2":2061,
            "y2":1452
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) A multicopy plasmid carrying the wild-type dis3 gene is able to complement the cold sensitivity of dis3-54 mutant at 20??C on YPD media, whereas equivalent plasmids carrying either the dis3-54 (P509L) or dis3-T808A RNase mutant genes are unable to complement the cold sensitivity."
        ],
        "rois":[
          {
            "x":3,
            "y":942,
            "x2":1419,
            "y2":1747
          }
        ]
      },
      "S":{
        "descriptions":[
          ", S. pombe (SpDis3), Saccharomyces cerevisiae (ScDis3) and Human (Hs) are compared. Identity and similarity are indicated as black and gray boxes, respectively. The dis3-54 mutation alter the Pro509 residue to Leu (P509L) in Motif I, while another mutation affecting RNase activity (T808A) is located in Motif IV. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "62286":{
    
  },
  "62291":{
    
  },
  "624571":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) Turnover of cyclin D1 is mediated by the ubiquitin-proteasome pathway. NIH3T3 and HCT 116 cells were released from quiescence by serum stimulation and treated in the presence (+) or absence (???) of MG132 for 2 hrs prior to harvesting at each time point. Western blot was performed with cyclin D1 and ??-actin antibodies. (F???H) Polyubiquitination of cyclin D1. "
        ],
        "rois":[
          {
            "x":0,
            "y":1790,
            "x2":2818,
            "y2":3876
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N) and cytoplasmic "
        ],
        "rois":[
          {
            "x":0,
            "y":1790,
            "x2":2818,
            "y2":3876
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) HCT 116 colon cancer cells were transfected with HA-tagged ubiquitin cDNA (lanes 1???3) or without it (lane 4) and then synchronized to S phase through the sequential manipulation of serum starvation and stimulation. Cells were treated with 25 ??M MG132 (lanes 3 and 4) or without it (lanes 1 and 2) for one hour. Lysates were immunoprecipitated with antibodies to cyclin D1 antibody (lanes 2???4) or control IgG (lane 1) and immunoblotted with a HA antibody (upper panel) or a cyclin D1 antibody (lower panel). Asterisks indicate background non-specific bands (F???G). "
        ],
        "rois":[
          {
            "x":0,
            "y":1790,
            "x2":2818,
            "y2":3876
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A, B) Expression profile of cyclin D1 during cell cycle progression in cells released from quiescence. Normal cells ",
          "(A) and cancer cells ",
          "(A) NIH 3T3 mouse fibroblasts and CCD841 CoN normal colon epithelium. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2818,
            "y2":1789
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Nuclear "
        ],
        "rois":[
          {
            "x":0,
            "y":1790,
            "x2":2818,
            "y2":3876
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Expression profile of cyclin D1 during cell cycle progression in cells released from quiescence. Normal cells ",
          "(B) were tested. ",
          "(B) HCT 116 and SW480 cells. CCD841 CoN cells were synchronized at G0/G1 phase by treatment with ACL-4 media without EGF for 24 hrs, and then stimulated with complete ACL-4 media containing EGF. Other cells were released from quiescence by serum stimulation. Samples were collected at indicated time points. Cell cycle distributions were determined by flow-cytometry and percentages of each phase are indicated. Western-blots were performed with cyclin D1 and ??-actin antibodies, respectively. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C, D) Pulse-chase analysis of cyclin D1 in NIH 3T3 cells ",
          "(C) and HCT 116 cells ",
          "(C) proteins were fractionated (Fr.) from cell lysates collected in Panel F, lane 3. Nuclear and cytoplasmic extracts were immunoprecipitated with antibodies to cyclin D1 (lanes 1 and 2) or IgG (lane 3) and immunoblotted with a HA antibody (upper panel) or a cyclin D1 antibody (lower panel). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2818,
            "y2":1789
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Cell cycle distributions."
        ],
        "rois":[
          {
            "x":0,
            "y":1790,
            "x2":2818,
            "y2":3876
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C, D) Pulse-chase analysis of cyclin D1 in NIH 3T3 cells ",
          "(D). Cells were released from quiescence and labeled with 35S-methionine for 1 hour when most of the populations were in G1 phase (9 hrs for NIH3T3 and 6 hrs for HCT 116) or in S phase (21 hrs for NIH3T3 and 15 hrs for HCT 116). The cells were chased with cold methionine for the indicated times and then lysed. Cyclin D1 was immunoprecipitated and analyzed with SDS-PAGE. Autoradiography was performed. Levels of metabolically labeled-cyclin D1 were estimated by quantitative scanning using Quantity One software (Bio-Rad) and blotted on the graph to determine the half-life of cyclin D1. Cell cycle distribution is indicated below the figures. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2818,
            "y2":1789
          }
        ]
      }
    }
  },
  "625762":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) The HA/SCAP-Gelfoam/PDLSC implant was sutured for 3 months.\n                  "
        ],
        "rois":[
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          },
          {
            "x":1476,
            "y":0,
            "x2":1941,
            "y2":383
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N) Compressive strength measurement showed that newly formed bio-roots have much higher compressive strength than original HA/TCP carrier (*P???=???0.0002), but lower than that in natural swine root dentin (*P???=???0.003) (NR: natural minipig root"
        ],
        "rois":[
          {
            "x":1400,
            "y":779,
            "x2":1982,
            "y2":1172
          },
          {
            "x":542,
            "y":779,
            "x2":903,
            "y2":1172
          },
          {
            "x":538,
            "y":390,
            "x2":1004,
            "y2":775
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) The HA/SCAP-Gelfoam/PDLSC implant (arrow) was re-exposed and the temporary filling was removed to expose the post channel.\n                  "
        ],
        "rois":[
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Extracted minipig lower incisor and root-shaped HA/TCP carrier loaded with SCAP.\n                  "
        ],
        "rois":[
          {
            "x":1400,
            "y":779,
            "x2":1982,
            "y2":1172
          },
          {
            "x":1476,
            "y":390,
            "x2":1941,
            "y2":775
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M).\n                  "
        ],
        "rois":[
          {
            "x":538,
            "y":0,
            "x2":1004,
            "y2":383
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) A pre-made porcelain crown was cemented to the HA/SCAP-Gelfoam/PDLSC structure.\n                  "
        ],
        "rois":[
          {
            "x":1007,
            "y":0,
            "x2":1472,
            "y2":383
          },
          {
            "x":1007,
            "y":390,
            "x2":1472,
            "y2":775
          },
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L) and PDL tissue (PDL) on the outside of the implant "
        ],
        "rois":[
          {
            "x":907,
            "y":779,
            "x2":1396,
            "y2":1172
          },
          {
            "x":1007,
            "y":0,
            "x2":1472,
            "y2":383
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gelfoam containing 10??106 PDLSCs (open arrow) was used to cover the HA/SCAP (black arrow) and implanted into the lower incisor socket (open triangle).\n                  "
        ],
        "rois":[
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          },
          {
            "x":1476,
            "y":390,
            "x2":1941,
            "y2":775
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HA/SCAP-Gelfoam/PDLSCs were implanted into a newly extracted incisor socket.\n                  A post channel was pre-created inside the root shape HA carrier (arrow).\n                  "
        ],
        "rois":[
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          },
          {
            "x":1476,
            "y":390,
            "x2":1941,
            "y2":775
          }
        ]
      },
      "BR":{
        "descriptions":[
          ", BR: newly formed bio-root"
        ],
        "rois":[
          {
            "x":1997,
            "y":815,
            "x2":2406,
            "y2":1174
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) The exposed section was sutured.\n                  (I and J) Four weeks after fixation, the porcelain crown was retained in the swine after normal tooth use as shown by open arrows.\n                  "
        ],
        "rois":[
          {
            "x":907,
            "y":779,
            "x2":1396,
            "y2":1172
          },
          {
            "x":1007,
            "y":0,
            "x2":1472,
            "y2":383
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K) After 3 months implantation, the HA/SCAP-Gelfoam/PDLSC implant had formed a hard root structure (open arrows) in the mandibular incisor area as shown by CT scan image.\n                  A clear PDL space was found between the implant and surrounding bony tissue (triangle arrows).\n                  (L and M) H&E staining showed that implanted HA/SCAP-Gelfoam/PDLSC contains newly regenerated dentin "
        ],
        "rois":[
          {
            "x":907,
            "y":779,
            "x2":1396,
            "y2":1172
          },
          {
            "x":1007,
            "y":0,
            "x2":1472,
            "y2":383
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The post channel was sealed with a temporary filling for affixing a porcelain crown in the next step.\n                  ",
          "(D) inside the implant "
        ],
        "rois":[
          {
            "x":1945,
            "y":0,
            "x2":2410,
            "y2":383
          },
          {
            "x":1476,
            "y":390,
            "x2":1941,
            "y2":775
          }
        ]
      },
      "HA":{
        "descriptions":[
          ", HA: original HA carrier)."
        ],
        "rois":[
          {
            "x":1997,
            "y":815,
            "x2":2406,
            "y2":1174
          },
          {
            "x":0,
            "y":779,
            "x2":539,
            "y2":1172
          },
          {
            "x":0,
            "y":0,
            "x2":535,
            "y2":775
          },
          {
            "x":1945,
            "y":390,
            "x2":2410,
            "y2":775
          }
        ]
      }
    }
  },
  "626341":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Coomassie-stained gel (10% acrylamide) of aliquots from limited proteolysis of PSD-95 by Subtilisin proteinase: panels 1 and 3, Precision Plus Protein molecular weight marker (Bio-Rad, http://www.bio-rad.com); panel 2, starting sample prior to proteinase addition; panels 4, Lanes 4???9, Aliquots at 5, 30, 60, 90, 120 min, and 8 h after protease addition (as labeled). Arrows point to stable fragments that were excised from the gel and analyzed by mass spectrometry as described in Methods."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2799,
            "y2":2111
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Sequence of Rat PSD-95: underlined are the peptide sequences identified by mass spectrometry from the ???34 kDa stable fragment corresponding to residues 429???721 (33,944 kDa). In bold are the sequences derived from the ???48 kDa stable fragment comprising residues 300???721 (47,796 kDa)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2799,
            "y2":2111
          },
          {
            "x":0,
            "y":2112,
            "x2":2799,
            "y2":2499
          }
        ]
      }
    }
  },
  "626710":{
    
  },
  "627635":{
    
  },
  "63062":{
    
  },
  "631115":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Native RAW 264.7 macrophages or RAW 264.7 over-expressing murine dectin-1 were pretreated with isotype or 2A11 and co-cultured for 24 h with live A. fumigatus. Supernatant cytokine and chemokine levels were determined by Bio-Plex or ELISA. ",
          "(A) illustrates cumulative results from five separate experiments. Asterisks, double asterisks, and the hash sign represent significant differences between RAW and RAW + 2A11, RAW and RAW-Dect, and RAW-Dect and RAW-Dect + 2A11, respectively (p (B???D) Identical experimental design with alveolar macrophages. (B???D) illustrate cumulative results from five separate experiments. Asterisks represent significant differences between isotype and 2A11 (p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3178,
            "y2":4871
          },
          {
            "x":2141,
            "y":1838,
            "x2":4184,
            "y2":3206
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E) Alveolar macrophages were pre-treated with 10-??M cytochalasin D and co-cultured with live A. fumigatus for 16 h. Supernatant cytokine and chemokine levels were determined by Bio-Plex or ELISA. ",
          "(E) illustrates cumulative results from three separate experiments. Data are expressed as mean pg/ml + SEM."
        ],
        "rois":[
          {
            "x":2189,
            "y":3514,
            "x2":4131,
            "y2":4865
          }
        ]
      }
    }
  },
  "631282":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) were calculated by dividing the pg/ml cytokine/chemokine level in 12-h samples by that in 24-h samples. Asterisks represent significant differences between isotype (rat IgG) and 2A11 (p "
        ],
        "rois":[
          {
            "x":2118,
            "y":1908,
            "x2":4184,
            "y2":3490
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) live A. fumigatus RC and incubated for 4 h and 8 h, "
        ],
        "rois":[
          {
            "x":56,
            "y":0,
            "x2":2017,
            "y2":1622
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) live RC or SC and incubated for 4 h in the presence of isotype or 2A11, or "
        ],
        "rois":[
          {
            "x":1111,
            "y":3708,
            "x2":3073,
            "y2":5337
          },
          {
            "x":2139,
            "y":0,
            "x2":4104,
            "y2":1607
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) live A. fumigatus hyphae and incubated for 4 h, 8 h, and 24 h. (D and E) Alveolar macrophages were added to A. fumigatus RC and incubated for 24 h. Samples for cytokine analysis were taken between 9 h and 12 h, and at 24 h, as indicated. Also shown in "
        ],
        "rois":[
          {
            "x":1111,
            "y":3708,
            "x2":3073,
            "y2":5337
          },
          {
            "x":0,
            "y":1847,
            "x2":2091,
            "y2":3491
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) is a representative 4-h response to pre-generated SC, and inhibition of this response by 2A11. Thereafter, cytokine and chemokine levels were determined in supernatants by Bio-Plex or ELISA. Percentage data expressed in "
        ],
        "rois":[
          {
            "x":1111,
            "y":3708,
            "x2":3073,
            "y2":5337
          }
        ]
      }
    }
  },
  "631426":{
    
  },
  "631530":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) or RAW 264.7 macrophages over-expressing dectin-1 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2012,
            "y2":1154
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were pretreated with 250 ??g/ml S. cerevisiae-derived mannan or 100 ??g/ml glucan phosphate and then added to RC or SC. Thereafter, cytokine and chemokine levels were determined in supernatants by Bio-Plex or ELISA. Each graph illustrates cumulative results from four separate experiments. Asterisks represent significant differences between untreated and glucan-phosphate treated (p "
        ],
        "rois":[
          {
            "x":205,
            "y":1340,
            "x2":1803,
            "y2":2522
          }
        ]
      }
    }
  },
  "631695":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-Linux is a Linux distribution customized to be user-friendly that contains approximately 60 popular bioinformatics packages. The Bio-Linux system is freely available, though researchers not supported by the EGTDC must provide their own hardware. Software developed at the EGTDC is included on the Bio-Linux system, making it easy for researchers not well versed in computing to try out these packages. The graphical menus and wide range of bioinformatics software installed on Bio-Linux makes it an ideal system for all levels of users, including beginners, power users, and developers.\n          "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1045,
            "y2":798
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MaxdLoad2, one of the tools installed on Bio-Linux, provides an intuitive interface to annotate experiments to MIAME standards. When completed, the experiment annotation can be exported in MAGE-ML for submission to ArrayExpress. MaxdLoad2 has been recently engineered to capture data from the ???ENV??? extension to MIAME."
        ],
        "rois":[
          {
            "x":0,
            "y":767,
            "x2":1245,
            "y2":1709
          },
          {
            "x":0,
            "y":0,
            "x2":1045,
            "y2":798
          }
        ]
      }
    }
  },
  "631723":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Alveolar macrophages were co-cultured for 24 h with live A. fumigatus in the presence or absence of s-dectin-hFc (10 ??g/ml). Supernatant cytokine and chemokine levels were determined by Bio-Plex or ELISA. ",
          "(A) illustrates cumulative results from four separate experiments. Asterisks represent significant differences between untreated and s-dectin-1???containing wells (p "
        ],
        "rois":[
          {
            "x":1108,
            "y":0,
            "x2":3144,
            "y2":1354
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cytokine and chemokine levels in clarified BAL fluid from untreated and soluble (s-dect)???treated mice was measured by Bio-Plex. ",
          "(B) illustrates representative results from three independent experiments (n = 5???7 mice per group). Asterisks represent significant differences between untreated and s-dectin-1???treated mice (p "
        ],
        "rois":[
          {
            "x":0,
            "y":1673,
            "x2":2050,
            "y2":3030
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Total cell counts (Total) in BALF fluid as enumerated on a hemacytometer. Neutrophil (PMN) concentrations were determined by calculating the percentages of neutrophils in three to five sets of 100 cells and multiplying the percentage with the total BALF cell number."
        ],
        "rois":[
          {
            "x":2147,
            "y":1668,
            "x2":4184,
            "y2":3027
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Lungs were excised from non-lavaged???untreated and s-dectin-hFc???treated mice, homogenized, followed by serial 1:10 dilutions, and plated onto potato dextrose agar. CFU/lung were determined after incubating the plates for 24 h at 37 ??C. ",
          "(D) illustrates representative results from three independent experiments (n = 5???7 mice per group)."
        ],
        "rois":[
          {
            "x":1112,
            "y":3349,
            "x2":3125,
            "y2":4694
          }
        ]
      }
    }
  },
  "638124":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          ". A: CPT"
        ],
        "rois":[
          {
            "x":103,
            "y":1469,
            "x2":1978,
            "y2":2087
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B: HCPT; Sc: supercoiled DNA"
        ],
        "rois":[
          {
            "x":34,
            "y":412,
            "x2":1976,
            "y2":1444
          }
        ]
      },
      "R":{
        "descriptions":[
          "; R: relaxed DNA"
        ],
        "rois":[
          
        ]
      },
      "N":{
        "descriptions":[
          "; N: nicked DNA; pBR322: pBR322+0.50% DMSO; Topo1: Topo1+pBR322+0.50% DMSO."
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2010,
            "y2":382
          }
        ]
      }
    }
  },
  "638130":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          ". A: CPT"
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":2002,
            "y2":416
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B: HCPT; Sc: supercoiled DNA"
        ],
        "rois":[
          {
            "x":15,
            "y":387,
            "x2":2007,
            "y2":1401
          }
        ]
      },
      "R":{
        "descriptions":[
          "; R: relaxed DNA"
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":2002,
            "y2":416
          }
        ]
      },
      "N":{
        "descriptions":[
          "; N: nicked DNA; pBR322: pBR322+0.50% DMSO; Topo1: Topo1+pBR322+0.50% DMSO."
        ],
        "rois":[
          {
            "x":15,
            "y":387,
            "x2":2007,
            "y2":1401
          },
          {
            "x":37,
            "y":1424,
            "x2":1973,
            "y2":2104
          }
        ]
      }
    }
  },
  "638141":{
    "Figure_11.tif":{
      "A":{
        "descriptions":[
          "(A), or 10 ??M CPT "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2035,
            "y2":1703
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or HCPT "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2035,
            "y2":1703
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) were harvested and lysed at different time points post treatment (0, 2, 4, 6, 12, 24 and 48 h). The cytosolic and nuclear fractions of cells were prepared as described in Materials and Methods. Equal amounts of protein from each fraction (40 ??g for nuclear fraction and 80 ??g for cytosolic fraction) were subject to electrophoresis in denaturing gels, and immunoblotted with indicated antibodies. Beta-actin was used as a loading control. The protein bands were densitometrically quantified with Quantity One (Gel Doc XR, Bio-Rad, USA). The corrected Topo1 protein was calculated as the ratio of nuclear (gray) or cytosolic (dark) fraction over beta-actin. Each bar represents the mean ??SD."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2035,
            "y2":1703
          }
        ]
      }
    }
  },
  "638600":{
    
  },
  "640722":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) TNF-??; "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":874,
            "y2":537
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IL-6 (light grey bars), CCL2 (open bars), CCL3 (dark grey bars) and CCL4 (black bars); "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":874,
            "y2":537
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) IL-2 (light grey bars), GM-CSF (dark grey bars) and CCL5 (open bars); "
        ],
        "rois":[
          {
            "x":9,
            "y":562,
            "x2":874,
            "y2":1088
          },
          {
            "x":880,
            "y":68,
            "x2":1664,
            "y2":533
          }
        ]
      },
      "ND":{
        "descriptions":[
          "(ND). Data are mean +/- SEM for 4 independent experiments."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":874,
            "y2":537
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) the mediators indicated at 2 h and 24 h in media alone (light grey bars and dark grey bars, respectively) or with Listeria (open bars and black bars, respectively). Undetectable levels are indicated "
        ],
        "rois":[
          {
            "x":886,
            "y":613,
            "x2":1670,
            "y2":1154
          },
          {
            "x":9,
            "y":562,
            "x2":874,
            "y2":1088
          }
        ]
      }
    }
  },
  "644851":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Cell surface expression of disulfide-linked p75NTR dimers (dim) and monomers (mon) in transfected HEK 293T cells by probing of p75NTR immunoprecipitates treated with or without DTT. An unspecific band of MW???130 k Da was observed in all samples and controls. "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1455,
            "y2":465
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The binding of p75CTD monomer and symmetric dimer with the RIP2 CARD domain were analyzed by bio-layer interferometry (BLI). Binding kinetics of p75CTD monomer with the RIP2 CARD domain of different concentrations were further recorded. "
        ],
        "rois":[
          {
            "x":12,
            "y":557,
            "x2":1427,
            "y2":1192
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Proposed model of p75NTR activation. Different oligomerization patterns of p75NTR such as monomers, non-symmetric dimers and symmetric dimers may exist simultaneously on the cell surface (based on the relative position of the intracellular domains). Regulation may result from turnover between non-symmetric dimer and symmetric dimer. An oxidation-reduction equilibrium may exist between the covalent symmetric dimer (Cys379-Cys379 disulfide bond) and the non-covalent symmetric dimer, which might confer another level of regulation through oxidative stress."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "645088":{
    
  },
  "645477":{
    
  },
  "645758":{
    
  },
  "645932":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E), and CCL9 "
        ],
        "rois":[
          {
            "x":1398,
            "y":105,
            "x2":2007,
            "y2":622
          },
          {
            "x":727,
            "y":666,
            "x2":1405,
            "y2":1197
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) production by STXBP1+/+ and STXBP1???/??? Fc??RI-activated mast cells was assessed by ELISA in cell-free culture media following stimulation. (n???=???4 separate experiments). G, Cytokines and chemokines were detected using a Bio-Plex Pro Mouse 23-plex Group 1 Cytokine Assay (Bio-Rad, Hercules"
        ],
        "rois":[
          {
            "x":1398,
            "y":105,
            "x2":2007,
            "y2":622
          },
          {
            "x":727,
            "y":666,
            "x2":1405,
            "y2":1197
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), TNF "
        ],
        "rois":[
          {
            "x":1398,
            "y":680,
            "x2":2007,
            "y2":1197
          },
          {
            "x":29,
            "y":7,
            "x2":661,
            "y2":622
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), CCL1 "
        ],
        "rois":[
          {
            "x":1398,
            "y":680,
            "x2":2007,
            "y2":1197
          },
          {
            "x":7,
            "y":1258,
            "x2":1380,
            "y2":1840
          },
          {
            "x":727,
            "y":60,
            "x2":1411,
            "y2":622
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), CCL2 "
        ],
        "rois":[
          {
            "x":1398,
            "y":680,
            "x2":2007,
            "y2":1197
          },
          {
            "x":1446,
            "y":1305,
            "x2":2051,
            "y2":1822
          },
          {
            "x":727,
            "y":60,
            "x2":1411,
            "y2":622
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA) according to the manufacturer???s protocol. This assay detected 23 cytokines and chemokines including IL-1??, IL-1??, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, TNF, Eotaxin, G-CSF, GM-CSF, IFN??, KC, CCL2, CCL3, CCL4, and CCL5. H, PGD2 production by STXBP1+/+ and STXBP1???/??? Fc??RI-activated mast cells was measured using enzyme immunoassay kit. (n???=???4 separate experiments)."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D), CCL3 "
        ],
        "rois":[
          {
            "x":1398,
            "y":105,
            "x2":2007,
            "y2":622
          },
          {
            "x":1398,
            "y":680,
            "x2":2007,
            "y2":1197
          },
          {
            "x":33,
            "y":666,
            "x2":659,
            "y2":1199
          }
        ]
      }
    }
  },
  "646574":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) and un-cleaved form "
        ],
        "rois":[
          {
            "x":7,
            "y":15,
            "x2":977,
            "y2":561
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). The increase in mean fluorescence intensity (MFI) has been blotted as a function of antibody concentration. Control antibodies include b12, b6, b12-Bio (biotinylated version of B12) and 4E10. The lack of significant b6 interaction with the cells expressing cleaved Env indicates that most Env has been processed."
        ],
        "rois":[
          {
            "x":7,
            "y":618,
            "x2":979,
            "y2":1170
          }
        ]
      }
    }
  },
  "649135":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          ". E) PKC?? inhibitor increases the transcriptional activity of ??-catenin induced dose-dependently by Wnt3a. RKO cells were transfected with TOPFlash reporter plasmid. 24 h post-transfection, cells were serum starved for 8 h and incubated in the absence or presence of increasing concentrations of Wnt3a for a total 8 h period. During the last 3 h, cells were also incubated in the absence or presence of rottlerin 6 ??M. Then, cells were washed, homogenized and luciferase activity was measured and normalized with respect to the total protein content in the cell lysate. The results represent the means ?? S.E.M. of three independent experiments. *p"
        ],
        "rois":[
          {
            "x":0,
            "y":1040,
            "x2":1997,
            "y2":2449
          }
        ]
      },
      "A":{
        "descriptions":[
          "A) Over-expression of wild type PKC?? or expression of a dominant-negative form of PKC?? does not affect the constitutive active ??-catenin transcriptional activity of SW480 cells (expressing truncated APC) and of HCT116 cells (expressing a ??-catenin degradation-resistant mutant). Cells were co-transfected with 1 ??g of dominant-negative HA-tagged K376R PKC?? plasmid and with the TOPFlash/FOPFlash reporter or with 1 ??g of HA- wild type PKC?? plasmid and with the TOPFlash/FOPFlash reporter. Control cells were co-transfected with void plasmids and with the reporter. After 24 h post-transfection, the reporter activity was assayed and normalized with respect to the total protein content in the cell lysate. The Western blot analysis of the expression of endogenous and transfected proteins is shown at the right of the figure. The results represent the means ?? S.E.M. of at least three independent experiments and differences found were not statistically significant"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1997,
            "y2":1039
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Expression of a dominant negative form of PKC?? in non-malignant IEC-18 cells also induces an increase in ??-catenin transcriptional activity. Cells were co-transfected with 1 ??g of dominant-negative HA-tagged K376R PKC?? plasmid and with the TOPFlash/FOPFlash reporter Control cells were co-transfected with void plasmids (pV) and with the reporter. After 24 h post-transfection, the cells were incubated 16 h in the absence or presence of 5 ??M BIO. Cells were lysed and the reporter activity was assayed and normalized with respect to the total protein content in the cell lysate. The Western blot analysis of the expression of endogenous and HA-transfected PKC?? is shown at the right of the figure. The results represent the means ?? S.E.M. of at least three independent experiments"
        ],
        "rois":[
          {
            "x":0,
            "y":1040,
            "x2":1997,
            "y2":2449
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) PKC?? inhibition induces ??-catenin protein stabilization. RKO cells were incubated in the absence or presence of Wnt 3a conditioned medium for a total 8 h period and in the absence or presence of rottlerin (6 ??M) during the last 3 hours. Cytoplasmic and nuclear fractions were then obtained from the cell extracts employing a nuclear isolation kit (Sigma) and the presence of ??-catenin analyzed in each fraction by Western blot. ??-tubulin was employed as cytoplasmic marker and the transcription factor TCF4 as nuclear marker to confirm no contamination and thus, successful fractionation. The data are representative of three independent experiments"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1997,
            "y2":1039
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) The PKC?? inhibition increased ??-catenin immunoreactive signal particularly at the cell nuclei. RKO cells were incubated in the absence (basal) or presence of 6 ??M rottlerin for 3 h, and in the absence or presence of 100 ng/ml Wnt3a for 6 h. Cells were fixed, permeabilized and coimmunostained with antibodies against PKC?? and ??-catenin. Fluorescence was analyzed by laser confocal microscopy as described under ???Materials and Methods???. PKC?? was visualized with FITC-conjugated goat anti-rabbit antibody and ??-catenin with TRITC-conjugated goat anti-mouse antibody. Data are representative of four independent experiments"
        ],
        "rois":[
          {
            "x":0,
            "y":1040,
            "x2":1997,
            "y2":2449
          }
        ]
      }
    }
  },
  "649710":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) HE stained section with multiple tumors at 100x and 400x magnification. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) PCR analysis of DNA isolated from cell lines derived from tumor of RASLO and RASLO??KIIf/d mice show a PCR product of 240 bp indicating that the Stop cassette has been successfully removed by CRE recombinase in the tumor. The vector used to generate the mouse strain (pRASLO) prior to CRE treatment shows a 1200 bp fragment. The same vector following Cre treatment in vitro serves as a positive control for the CRE mediated excision and shows the expected 240 bp band after recombination."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schematic construct showing the strategy used to generate the inducible KRAS driven lung cancer model (RASLO). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-Luminescence image taken with an IVIS-200 (Xenogen) camera of tail fibroblasts cultures of the RASLO founder mice after treatment with 2 ??M TAT-CRE protein and addition of luciferin right before imaging, showing strong signals in 5 founder mice. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Luciferase imaging (IVIS-200) for 1 min at medium sensitivity of RASLO mice 6 weeks after induction with 2??107 PFU of Adeno-CRE i.n.(+) or breeding controls (???). Mice were injected i.p. with luciferin in 200 ??l PBS and anesthetized by isoflurane inhalation. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Macroscopic image of the lung of a RASLO mouse 6 weeks after of AdCre administration, and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2014,
            "y2":2739
          }
        ]
      }
    }
  },
  "650068":{
    
  },
  "650633":{
    "Figure_2.tif":{
      "U":{
        "descriptions":[
          "; U. may. for Ustilago maydis. Left tree: the enzyme families are represented by their class (GH for glycoside hydrolase; PL for polysaccharide lyase; CE for carbohydrate esterase) and family number according to the carbohydrate-active enzyme database [23]. Right side: known substrate of CAZy families. Abundance of the different enzymes within a family is represented by a colour scale from 0 (black) to >20 (red) occurrences per species."
        ],
        "rois":[
          
        ]
      },
      "V":{
        "descriptions":[
          "; V. vol. for Volvariella volvacea"
        ],
        "rois":[
          {
            "x":453,
            "y":288,
            "x2":1889,
            "y2":2150
          }
        ]
      },
      "L":{
        "descriptions":[
          "; L. bio. for Laccaria bicolor"
        ],
        "rois":[
          {
            "x":513,
            "y":7,
            "x2":1363,
            "y2":286
          }
        ]
      },
      "P":{
        "descriptions":[
          "; P. chr. for Phanerochaete chrysosporium",
          "; P. pla. for Postia placenta"
        ],
        "rois":[
          {
            "x":453,
            "y":288,
            "x2":1889,
            "y2":2150
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C. cin. for Coprinopsis cinerea",
          "; C. neo. for Cryptococcus neoformans"
        ],
        "rois":[
          {
            "x":7,
            "y":341,
            "x2":443,
            "y2":1886
          }
        ]
      },
      "S":{
        "descriptions":[
          ": S. com. for Schizophyllum commune"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "651284":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A. Origin of nucleotide metabolism ???3.8 Gy ago; ndFF ???=???0)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2049,
            "y2":1941
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Emergence of the nucleotide interconversion (INT), catabolism and salvage (CAT) and biosynthetic (BIO) pathways ???3.5 Gy ago (ndFF ???=???0.061???0.073)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2049,
            "y2":1941
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Fully connected INT, BIO and CAT pathways ???3 Gy ago (ndFF ???=???0.187). Pathways mediated by prebiotic chemistries that are plausible and most parsimonious are depicted in red and enable the growth of the emergent protein enzyme-mediated pathways of purine metabolism by structural and functional innovation and piecemeal recruitment (recruited FFs are indicated with numbers). Unknown candidate or withering prebiotic pathways are indicated with dashed lines. We note that primordial reactions of the BIO pathway (top of metabolic diagram) in B could have been non-operational in the absence of suitable prebiotic chemistries until later in evolution. FF structures associated with individual enzymatic activities (described in EC nomenclature) are painted according to their age, in a scale of node distance (ndFF) that ranges from 0 (the oldest enzymes; ???3.8 Gy ago) to 0.2 (???3.0 Gy ago)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2049,
            "y2":1941
          }
        ]
      }
    }
  },
  "65134":{
    
  },
  "652872":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) ",
          "(A) Representative trace from the RTCA-DP software of 4??105 Bio-Gel elicited macrophages from C57BL/6J male mice in the top chamber with murine CCL5 (5 nM) (red) or no chemokine (green) in the bottom chamber. A control of no macrophages and no chemokine was also run (blue). By 70 mins max CI had been reached, the plate was removed and membranes were cut and fixed with 2.5% gluteraldehyde and processed for scanning electron microscopy (SEM). Representative images are shown of macrophages adhered to the underside of filters in response to 5 nM murine CCL5 (C & D) no chemokine (E & F) or control where no cells or chemokine were added (G & H). Pores in the membrane are clearly visible in panel H. The number of cells adhered to individual gold discs on the underside of the membrane (seen as light grey regions in the SEM images) were quantitated (n???=???1 experiment with technical replicates of each condition analysed) "
        ],
        "rois":[
          {
            "x":7,
            "y":17,
            "x2":1773,
            "y2":670
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B)."
        ],
        "rois":[
          {
            "x":27,
            "y":818,
            "x2":1797,
            "y2":1998
          },
          {
            "x":7,
            "y":17,
            "x2":1773,
            "y2":670
          }
        ]
      }
    }
  },
  "652875":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          " Injection with 4% Thioglycollate generates 70% F4/80+ 7/4??? macrophages which were harvested 4 days post injection. (E)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "J":{
        "descriptions":[
          " Migration was measured for each curve of each concentration using slope analysis. (J)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "F":{
        "descriptions":[
          ". (F)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "A":{
        "descriptions":[
          "Panels A, D, G & J are representative FACS plots of the four different murine macrophage populations tested in the RTCA-DP system chemotaxis assay. (A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "I":{
        "descriptions":[
          " 4??105 Resident peritoneal macrophages were allowed to migrate toward indicated concentrations of murine CCL3 for 3 h. (I)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "G":{
        "descriptions":[
          " 4??105 Thioglycollate-elicited peritoneal macrophages were allowed to migrate toward indicated concentrations of murine CCL3 for 3 h (G)",
          " Migration was measured for each curve of each concentration using slope analysis. (G)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "L":{
        "descriptions":[
          " 0.5??105 BMDM were allowed to migrate toward indicated concentrations of murine CCL3 for 3 h. (L)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "B":{
        "descriptions":[
          " Injection with 2% Bio-Gel (polyacrylamide beads) typically yields 60???70% monocyte/macrophages which are collected after 4 days following the initial injection (assessed by staining with F4/80, 7/4 & CD11b antibodies). (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "C":{
        "descriptions":[
          " 4??105 Bio-Gel elicited peritoneal macrophages were allowed to migrate toward indicated concentrations of murine CCL3 for 3 h. (C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "H":{
        "descriptions":[
          " Lavage of the peritoneal cavity in non-elicited conditions yields ???30% F4/80hi resident peritoneal macrophages. (H)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "K":{
        "descriptions":[
          " Bone marrow cells cultured over 7 days in the presence of L929 conditioned media +10% FBS generated a 92% pure population of macrophages which expressed both CD11b and F4/80. (K)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      },
      "D":{
        "descriptions":[
          " Migration was measured for each curve of each concentration using slope (set between 15???60 mins) analysis. (D)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1848,
            "y2":2430
          }
        ]
      }
    }
  },
  "652877":{
    
  },
  "652880":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          " Max-min CI and (E)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "F":{
        "descriptions":[
          " AUC. Data are the mean ?? SEM of three independent experiments with 3???4 technical replicates per experiment. Vehicle alone was omitted in these sets of experiments in order to have all five conditions on a single CIM-16 plate. (F)",
          " Bio-Gel elicited macrophages were pre-incubated for 90 mins with either 200 nM cytochalasin D, an inhibitor of F-actin polymerisation. A representative trace is shown (F)"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "To test that the assay was detecting true macrophage chemotaxis, rather than chemokinesis or fugetaxis, the following three conditions were tested; CCL5 added to the bottom well alone (test chemotaxis), equal concentrations (5 nM) of murine CCL5 added to both top and bottom wells (test chemokinesis) or CCL5 added to the top well alone (test fugetaxis) (A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "I":{
        "descriptions":[
          " Max-min CI and (I)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "G":{
        "descriptions":[
          ". Data are shown as a percentage of 5 nM CCL2 induced migration for (G)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "B":{
        "descriptions":[
          " Single trace of a single experiment with four technical replicates shows Bio-Gel elicited macrophages migrate towards murine CCL5 (green), but display no chemokinesis (red) or fugetaxis (blue). Control (pink) had chemotaxis buffer alone in the bottom well. Bio-Gel elicited macrophages were pre-incubated for 90 mins at 37??C with PTX (200 ng/ml). (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "C":{
        "descriptions":[
          " A representative trace shows that pre-treatment of Bio-gel elicited macrophages with PTX significantly inhibits chemotaxis toward both murine CCL2 and CCL5. Data are shown as a percentage of 10 nM CCL2 or CCL5 induced migration for (C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "H":{
        "descriptions":[
          " Slope (H)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      },
      "D":{
        "descriptions":[
          " Slope (D)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2052,
            "y2":1939
          }
        ]
      }
    }
  },
  "652883":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          ", max-min (B, E, H)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "N":{
        "descriptions":[
          " and Max-min CI (N)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "F":{
        "descriptions":[
          " and AUC (C, F, I)"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "Bio-Gel elicited macrophages from C57BL/6J (4??105 total) were allowed to migrate toward indicated concentrations of murine C5a, chemerin and LTB4 for 4 h. Migration was measured for each curve of each concentration using slope (A, D, G)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1991
          }
        ]
      },
      "M":{
        "descriptions":[
          " CCL5 are shown. Migration was measured for each curve using slope (M)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "I":{
        "descriptions":[
          " and AUC (C, F, I)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "G":{
        "descriptions":[
          "Bio-Gel elicited macrophages from C57BL/6J (4??105 total) were allowed to migrate toward indicated concentrations of murine C5a, chemerin and LTB4 for 4 h. Migration was measured for each curve of each concentration using slope (A, D, G)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "L":{
        "descriptions":[
          " chemerin and (L)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "B":{
        "descriptions":[
          ", max-min (B, E, H)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1991
          }
        ]
      },
      "C":{
        "descriptions":[
          " and AUC (C, F, I)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1991
          }
        ]
      },
      "H":{
        "descriptions":[
          ", max-min (B, E, H)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      },
      "K":{
        "descriptions":[
          " analysis. Data are shown as migration index (i.e. fold change over media alone) for each parameter of analysis. Data are expressed as mean ?? SEM of 3???5 independent experiments, each concentration with two technical replicates per experiment. Statistical analysis performed by one-way ANOVA and Dunnett's multiple comparison post-test. *, pJ) A schematic representation of the plate designed used to test whether the chemotactic effects of chemerin are ChemR23 dependent. Representative traces of Bio-Gel elicited macrophages from ChemR23-/- and WT controls in response to (K)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1991
          }
        ]
      },
      "D":{
        "descriptions":[
          "Bio-Gel elicited macrophages from C57BL/6J (4??105 total) were allowed to migrate toward indicated concentrations of murine C5a, chemerin and LTB4 for 4 h. Migration was measured for each curve of each concentration using slope (A, D, G)"
        ],
        "rois":[
          {
            "x":0,
            "y":1992,
            "x2":2048,
            "y2":2782
          }
        ]
      }
    }
  },
  "653957":{
    
  },
  "656099":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          "(a) and the numbers of cells recovered relative to input at the indicated times points "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1519,
            "y2":2985
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) were analyzed. The graph shows the mean and standard deviation of two biological replicates conducted on two different days."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1519,
            "y2":2985
          }
        ]
      }
    }
  },
  "658103":{
    "Figure_8.tif":{
      "E":{
        "descriptions":[
          "(E), a component of the class I antigen complex. Negative controls from non-injected sheep hearts as well as human mesenchymal stem cells used as a positive control clearly confirmed the human specificity of the staining for human ??-2 microglobulin within the fetal heart: Agarose gel analysis of human ??-2 microglobulin (left panel"
        ],
        "rois":[
          {
            "x":6,
            "y":540,
            "x2":426,
            "y2":1094
          },
          {
            "x":561,
            "y":540,
            "x2":980,
            "y2":1735
          },
          {
            "x":106,
            "y":1056,
            "x2":627,
            "y2":1735
          }
        ]
      },
      "A":{
        "descriptions":[
          ", A) and ?? -actin (right panel"
        ],
        "rois":[
          {
            "x":20,
            "y":6,
            "x2":983,
            "y2":490
          }
        ]
      },
      "B":{
        "descriptions":[
          ", B) PCR products. Lane 1: molecular size marker (100 bp DNA ladder, Genecraft, Germany). Lane 2: human mesenchymal stem cells as a positive control. Lane 3: ovine fetal heart after human ATMSCs injection. Lane 4: tissue from sheep heart as a negative control for the human ??-2 microglobulin sequence."
        ],
        "rois":[
          {
            "x":6,
            "y":540,
            "x2":426,
            "y2":1094
          }
        ]
      }
    }
  },
  "658107":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(Panel A) poor differentiated tumor (p???=???0.039), "
        ],
        "rois":[
          {
            "x":25,
            "y":11,
            "x2":1918,
            "y2":874
          }
        ]
      },
      "B":{
        "descriptions":[
          "(Panel B) high proliferation index (p???=???0.028) and "
        ],
        "rois":[
          {
            "x":14,
            "y":1064,
            "x2":2059,
            "y2":1945
          }
        ]
      },
      "C":{
        "descriptions":[
          "(Panel C) presence of lymphovascular invasion (LVI p"
        ],
        "rois":[
          {
            "x":26,
            "y":2117,
            "x2":2082,
            "y2":3041
          }
        ]
      }
    }
  },
  "658108":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "Panel A: The MCA graph demonstrates that ALND (+) is located in the quadrant containing the most aggressive phenotypes (T2 tumors, positive LVI, HER2 subtype, OSNA++) in contrast to ALND (???) which is associated to more favourable bio-pathological parameters (T1 tumors, absence of LVI, LA subtype). *LA: Luminal A"
        ],
        "rois":[
          {
            "x":15,
            "y":11,
            "x2":1446,
            "y2":1301
          }
        ]
      },
      "LB":{
        "descriptions":[
          "; LB: Luminal B"
        ],
        "rois":[
          {
            "x":28,
            "y":1395,
            "x2":1853,
            "y2":2143
          }
        ]
      },
      "HS":{
        "descriptions":[
          "; HS: HER2 subtype"
        ],
        "rois":[
          {
            "x":27,
            "y":2222,
            "x2":1853,
            "y2":2959
          }
        ]
      },
      "TN":{
        "descriptions":[
          "; TN: Triple Negative Panel B : The histograms report the distribution of molecular subtypes in the 72 OSNA+ cases with ALND negative and CK19 mRNA Panel C : The histograms report the distribution of molecular subtypes in the 19 OSNA+ cases with ALND positive and CK19 mRNA >2000 copies/??l (range 2100???4600)."
        ],
        "rois":[
          {
            "x":27,
            "y":2222,
            "x2":1853,
            "y2":2959
          }
        ]
      }
    }
  },
  "660021":{
    "Figure_6.tif":{
      "34":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "12":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "8":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":1016,
            "y":7,
            "x2":2051,
            "y2":805
          }
        ]
      },
      "19":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "23":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "4":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "40":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "15":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":9,
            "y":818,
            "x2":974,
            "y2":1350
          }
        ]
      },
      "11":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "9":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":1016,
            "y":7,
            "x2":2051,
            "y2":805
          }
        ]
      },
      "33":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "22":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "26":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "37":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "13":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "24":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "35":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "16":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":1016,
            "y":7,
            "x2":2051,
            "y2":805
          }
        ]
      },
      "10":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":9,
            "y":818,
            "x2":974,
            "y2":1350
          }
        ]
      },
      "21":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "32":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "6":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "36":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          ".75, 1",
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "39":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "17":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "25":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "14":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "31":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "42":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "20":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "27":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":1016,
            "y":7,
            "x2":2051,
            "y2":805
          }
        ]
      },
      "38":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "18":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "30":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "7":{
        "descriptions":[
          "(A). ScFv-IC16 was added in concentrations of: 7",
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":7,
            "y":18,
            "x2":954,
            "y2":795
          }
        ]
      },
      "29":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "41":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ".5, 3",
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          {
            "x":7,
            "y":18,
            "x2":954,
            "y2":795
          }
        ]
      },
      "28":{
        "descriptions":[
          ".5 and 0 ??M (positive control) to 7.5 ??M A??(1-42)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "660981":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) pro-inflammatory cytokines "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1775,
            "y2":2756
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) anti-inflammatory cytokines, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1775,
            "y2":2756
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) lymphocyte growth factor."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1775,
            "y2":2756
          }
        ]
      }
    }
  },
  "661123":{
    
  },
  "662145":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Western blot analyses showing a cleaved fragment of the ANDV nucleocapsid protein (ANDV-N) after incubation with recombinant caspase 3 in the presence or absence of the caspase 3-inhibitor DEVD-CHO. Full-length and cleaved ANDV-N was visualized with the mAb 7B3/F7. One representative experiment out of three is shown. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1383,
            "y2":1826
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) ANDV-infected A549 cells were left untreated or treated with staurosporine, in the presence or absence of the caspase-inhibitor Z-VAD-fmk. Lysed cells were then subjected to Western blot analyses to visualize cleavage of the viral ANDV nucleocapsid protein (ANDV-N) after staurosporine-treatment. Full-length and cleaved ANDV-N was visualized with the mAb 7B3/F7. One representative experiment out of three is shown. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1383,
            "y2":1826
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Caspase 3-activity was measured after pre-incubation of recombinant caspase 3 with recombinant ANDV nucleocapsid protein (rANDV-N) or with control protein (rDHFR) for 30 minutes. Level of caspase 3-activity after co-incubation with rDHFRS represent maximal caspase 3 activity. Level of caspase 3-activity after co-incubation of caspase 3 with rANDV-N was compared with caspase 3-activity after co-incubation with rDHFRS. Data shown are mean ?? SEM of three independent experiments carried out in duplicate. Two-tailed Student's t test was used for statistical evaluation; * pD) Caspase 3-activity after pre-incubation for 30 minutes with increasing amount of recombinant ANDV nucleocapsid protein (rANDV-N). Data shown are mean ?? SEM of three independent experiments carried out in duplicate. One-way ANOVA was used for statistical evaluation; pE) Percentage of TUNEL-positive A549 cells transfected with PCMV-bios (control), PCMV-bios-ANDV-N-wt (ANDV-N-wt), or PCMV-bios-ANDV-N Asp285 to Ala285 mutant (ANDV-N-mut) for 20 hours, and then treated with staurosporine for four hours. TUNEL-positive cells were identified using fluorescence microscopy. Staurosporine-treated cells transfected with empty plasmid represent maximal level of TUNEL-positive cells. Data shown are mean ?? SEM of three independent experiments carried out in duplicate. One-way ANOVA was used for statistical evaluation; * pF) Percentage of caspase 3-positive A549 cells transfected with PCMV-bios (control), PCMV-bios-ANDV-N-wt (ANDV-N-wt), or PCMV-bios-ANDV-N Asp285 to Ala285 mutant (ANDV-N-mut) for 20 hours, and then treated with staurosporine for four hours. Caspase 3-positive cells, positive for FLICA-staining, were identified using fluorescence microscopy. Staurosporine-treated cells transfected with empty plasmid represent maximal level of caspase 3-positive cells. Data shown are mean ?? SEM of three independent experiments carried out in duplicate. One-way ANOVA was used for statistical evaluation; *** p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1383,
            "y2":1826
          }
        ]
      }
    }
  },
  "664813":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) MCF7 cells were treated with 1 ??mol/L CG0009 and analyzed by immunoblotting with anti-pAKTser473 and AKT antibodies. A densitometric analysis of pAKTser473 was done with Quantity One software (BIO-RAD). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2380,
            "y2":1443
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MCF7 cells were treated with 1 ??mol/L CG0009 for the indicated times and whole cell lysates were prepared for in vitro AKT kinase assay. Purified recombinant AKT proteins were used as a positive control. Columns represent means of three independent experiments; bars denote SD (* P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2380,
            "y2":1443
          },
          {
            "x":0,
            "y":1444,
            "x2":2380,
            "y2":3020
          }
        ]
      }
    }
  },
  "66639":{
    
  },
  "6693305":{
    
  },
  "670005":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) The inset shows the 13% SDS-PAGE of MjTX-I collected in different positions of the obtained peak. Lane I: unstained SDS-PAGE Standard from Bio-Rad Laboratories, Inc.; Lane II: MjTX-I collected at the elution volumes correspondent to points 1 and 2 in the chromatogram; Lane III: MjTX-I collected at the elution volume correspondent to point 3 in the chromatogram. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2301,
            "y2":935
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Calibration curve obtained using standard proteins shows the different oligomeric assemblies of MjTX-I in 20 mM Tris-HCl pH 8.0. The protein standards were obtained from a low molecular weight gel filtration calibration kit (Sigma-Aldrich) containing: blue dextran (2000 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.4 kDa) and aprotinin (6.5 kDa)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "670496":{
    "Figure 3.TIF":{
      "A":{
        "descriptions":[
          "(A) Initiation of operator intension (as signaled by the finger movement; top), the raw EEG data (the 2nd row), the filtered EEG data at 15 Hz (the 3rd row), and the detected rat tail movement (the last row). The threshold condition for the filtered EEG is shown in dotted line. ",
          "(A)."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1891,
            "y2":866
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The time resolved plot of the box shown in "
        ],
        "rois":[
          {
            "x":12,
            "y":980,
            "x2":1883,
            "y2":1805
          }
        ]
      }
    }
  },
  "677366":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          ". A) Lane 1: Kaleidoscope; Lane 2: Classical scrapie +ve; Lane 3: Atypical scrapie +ve; Lanes 4 to 15: C2 to C7 classical scrapie +ve in duplicate lanes; Lanes 16 and 17: Scrapie ???ve; Lane 18: MagicMark XP western standard"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1515,
            "y2":956
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Lane 1: Kaleidoscope; Lane 2: Classical scrapie +ve; Lanes 3, 6 and 7: Atypical scrapie +ve; Lanes 4 and 5: C8 classical scrapie +ve; Lanes 8 and 9: C9 classical scrapie +ve; Lanes 10 to 17: Empty; Lane 18: MagicMark XP western standard."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1515,
            "y2":956
          }
        ]
      }
    }
  },
  "678529":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E). Ovcar 8- ECFP- DEVD-EYFP cells were stained with Hoechst and TMRM, treated with Zerumbone 50 ??M. Imaging for Hoechst, TMRM, ECFP, and EYFP FRET were carried out using a 96 well plate Bio-imager as described at the indicated time points. The contrasts of ECFP and EYFP FRET images are linearly adjusted for visual purpose. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F). MCF-7 cells were transfected with vector alone or pc DNA3 Caspase 3 vector. The caspase 3 expression was analysed by western blot and shown. The stable clones were treated with zerumbone 50 ??M. After 24 h chromatin condensation was analysed as described. The right panel represents SiHa cells treated with zerumbone 50 ??M alone or after pretreatment with caspase inhibitor z VAD-FMK (50 ??M) followed by zerumbone 50 ??M for 24 h. The chromatin condensation data from three independent experiments were used for generating the graph."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). Schematic representation of live cell caspase probe employed to detect caspase activation. The cells express ECFP-DEVD-VENUS fusion protein. DEVD is the preferred amino acid sequence of activated caspase 3 and caspase 7 that is linked in between the donor fluorophore, ECFP and acceptor fluorophore, EYFP. If caspases are not activated, when ECFP is excited energy is transferred to EYFP because of the FRET between the donor and acceptor pairs leading to decrease in ECFP fluorescence and increase in EYFP fluorescence. Upon caspase activation, DEVD is cleaved with loss of FRET that changes the ratio of ECFP/EYFP. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Cervical cancer cell line SiHa expressing ECFP-DEVD-EYFP were stained with 50 nm TMRM for 10 min. Then the cells were treated with zerumbone 50 ??M in medium containing 10 nm TMRM. The images were taken at 0h, 6 h, 12 h and 24 h using the filter combinations described in the materials and methods under live cell incubation on stage. ECFP channel, EYFP FRET channel, ratio image and TMRM channels are shown. Caspase activation is reflected in ratio change and loss of ????m in TMRM fluorescence intensity by decrease, diffuse or loss. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Breast cancer cell line MCF-7 expressing ECFP-DEVD-EYFP were stained with 50 nm TMRM for 10 min. Then the cells were treated with zerumbone 50 ??M in medium containing 10 nm TMRM. The images were taken at 0 h, 6 h, 12 h and 24 h using the filter combinations described in the materials and methods under live cell incubation on stage. ECFP channel, EYFP FRET channel, ratio image and TMRM channels are shown. Caspase activation is reflected in ratio change and loss of ????m in TMRM fluorescence by decrease, diffuse or loss. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). SiHa cells and MCF-7 cells expressing FRET probe were treated with zerumbone 50 ??M and ratio imaging was carried out as described. The cells with FRET loss were calculated and represented as graph (n???=???4). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2061,
            "y2":2796
          }
        ]
      }
    }
  },
  "679187":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A). Consequently, high densities RBSDV-infected planthoppers migrated into the fields after planting of the test plants in the summer ",
          "(A) and June 12 "
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":1529,
            "y2":1042
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). After maize was planted, high levels of infection were observed in the control non-transgenic plants and in the highly susceptible maize variety, and high densities of RBSDV-infected planthoppers were detected in all plants. To mediate bio-safety protection, an isolation belt consisting of surrounding pear trees was considered in the initial design to provide protection against pollen flow and spread of transgenic maize [74]. The photographs were taken on May 15 ",
          "(B), 2010 respectively."
        ],
        "rois":[
          {
            "x":7,
            "y":1068,
            "x2":1529,
            "y2":2103
          }
        ]
      }
    }
  },
  "679524":{
    
  },
  "680712":{
    "Figure_10.tif":{
      "A":{
        "descriptions":[
          "(A) H. pylori enhances binding of SREBP1 to one of the three sterol-responsive elements (SRE3) [24], [62] in the proximal human Cav1 promoter. ChIP: MKN45 cells were infected with H. pylori G27 (MOI???=???100) for 16 h, and IP was performed in total cell lysates with rabbit polyclonal acetyl-H4-histone, SREBP1 or control IgG. CT-values from qPCR of IP-ed DNA were normalized to the CT-values of input DNA and were calculated as mean ?? S.E. (n???=???3) of protein-DNA complex pull-down by H. pylori compared to empty bead and uninfected controls; *p???=???0.0093 for SREBP1 and p???=???0.0478 for acetyl-H4-histone"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3191,
            "y2":5133
          }
        ]
      },
      "H":{
        "descriptions":[
          ", H. pylori versus mock. Insert: Representative WBs of nuclear extracts showing mature 68 kDa SREBP1 in the nucleus of H. pylori G27-infected MKN45 cells. ",
          ", H. pylori versus mock."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3191,
            "y2":5133
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) EMSA: MKN45 cells were infected with H. pylori G27 for 16 h, and nuclear extracts were incubated with biotin (BIO)-labelled oligonucleotide (SRE3) [62] from the human Cav1 promoter and an excess of unlabelled competitor oligonucleotides (SRE3-WT???=???wild-type; SRE3-MUT???=???mutant). Insert: Representative WBs of whole cell lysates showing accumulation of active 68 kDa SREBP1 in H. pylori G27-infected MKN45 cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3191,
            "y2":5133
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) H. pylori also regulates mRNA expression of other cognate SREBP1 target genes. CT-values from RT-qPCRs on total RNA extracted from cells infected with CagA-delivery competent G27 wt, CagA-deleted G27 Delta cagA or CagA-delivery deficient SS1 H. pylori strains were normalized to b2M and presented as % ?? S.E. (n???=???15 per group); *p???=???0.0137 to 0.0196"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3191,
            "y2":5133
          }
        ]
      }
    }
  }
,
  "680926":{
    
  },
  "682790":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A) Sequences of RNAIp and RNAIIp probes. ",
          "(A), were used to analyze exchange of RNA polymerase from DR region to RNAIp and RNAIIp. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Purified RNA polymerase "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2035,
            "y2":1366
          }
        ]
      },
      "RP":{
        "descriptions":[
          "(RP) was added to 32P-labeled-DR probe (Fig. 7A). Unlabeled RNAIIp and RNAIp probes, which contained sequences shown in "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) DNA-protein complexes that contained a biotinylated-DR probe (Bio-DR) and RNA polymerase (Bio-DR/RP) were captured using streptavidin-coated magnetic beads. After unbound RNA polymerase had been removed, 32P-labeled RNAIIp and RNAIp probes were added to RNA polymerase-DR complex to analyze exchange of RNA polymerase from repeats to RNAIp and RNAIIp. Probe 167 was used as a negative control."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2035,
            "y2":1366
          }
        ]
      }
    }
  },
  "687629":{
    
  },
  "689579":{
    
  },
  "692822":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) The tool contains three logical levels: the interface level, explanation level and calculation level. The interface level is an editor to build biological models and integrate necessary information and parameters. The explanation level is a complier to understand the user???s biological model and translate it into the mathematical model. The calculation level is a computational element to calculate the model and return the results. "
        ],
        "rois":[
          {
            "x":18,
            "y":18,
            "x2":1697,
            "y2":4145
          },
          {
            "x":1894,
            "y":210,
            "x2":4849,
            "y2":3189
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The interface of building the model and setting parameters. With a user-friendly interface, the tool provides an instant visual bio-model building environment. For user convenience, GeneCircuits chose standard icons to present biological elements. For example, a gene icon is represented by a set of standard sub-symbols, including two regulatory domains (white square), one mRNA (hollow parallelogram) and one corresponding protein (solid red rounded quadrilateral). Users can define the various roles of each element in the system. Based on the Petri net representation, each reaction has a horizontal line, which is a representation of the reaction. By double-clicking this horizontal line, users can set up parameters of the reaction. "
        ],
        "rois":[
          {
            "x":1894,
            "y":210,
            "x2":4849,
            "y2":3189
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The user interface for setting parameters."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "694253":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "EGFP+ cells from male donors were injected into liver-injured female mice. (A)"
        ],
        "rois":[
          {
            "x":2121,
            "y":3997,
            "x2":2940,
            "y2":4902
          },
          {
            "x":1822,
            "y":2921,
            "x2":2652,
            "y2":3750
          },
          {
            "x":15,
            "y":47,
            "x2":604,
            "y2":871
          }
        ]
      },
      "B":{
        "descriptions":[
          " After transplantation of stem cells, the EGFP fluorescence in the lung, liver, spleen and kidney was examined using bio- imaging system. A luminescent image from red (least intense) to yellow (most intense) represents the spatial distribution of the detected photons emitted from EGFP+ cells within the organs. The EGFP signal was not detected in the control mice. (B)"
        ],
        "rois":[
          {
            "x":25,
            "y":1843,
            "x2":3741,
            "y2":2805
          },
          {
            "x":2152,
            "y":16,
            "x2":3901,
            "y2":1785
          },
          {
            "x":654,
            "y":15,
            "x2":2106,
            "y2":871
          },
          {
            "x":398,
            "y":925,
            "x2":2109,
            "y2":1920
          }
        ]
      },
      "P":{
        "descriptions":[
          " mRNA levels of CXCR4 on MSCs and HSCs. P"
        ],
        "rois":[
          {
            "x":34,
            "y":2816,
            "x2":2031,
            "y2":4962
          }
        ]
      },
      "C":{
        "descriptions":[
          " Average radiance was quantified in the liver after stem cells transplantation. (C)"
        ],
        "rois":[
          {
            "x":2709,
            "y":2804,
            "x2":3749,
            "y2":3808
          },
          {
            "x":25,
            "y":1843,
            "x2":3741,
            "y2":2805
          },
          {
            "x":398,
            "y":925,
            "x2":2109,
            "y2":1920
          }
        ]
      },
      "H":{
        "descriptions":[
          " PCR-based detection of donor-derived cells in the livers of different recipients. (D and E) Liver sections were stained with DAPI, and the distribution of EGFP+ cells in the portal lobe was quantified in the different groups at 4 weeks. White arrows show the stem cells in the sinusoids (i, MSCs group; ii, HSCs group; and iii, MSCs+HSCs group). (F and G) FACS analyses of CXCR4 expression on MSCs and HSCs. (H)"
        ],
        "rois":[
          {
            "x":3015,
            "y":3999,
            "x2":3918,
            "y2":4896
          },
          {
            "x":398,
            "y":925,
            "x2":2109,
            "y2":1920
          }
        ]
      }
    }
  },
  "697108":{
    
  },
  "697113":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) Concentration-response curve between bio-MTX and AlBj obtained from SPR analysis. Rmax???=???66. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2059,
            "y2":1322
          }
        ]
      },
      "RU":{
        "descriptions":[
          ". RU: resonance unit. 1 RU???=???1 pg/mm2."
        ],
        "rois":[
          {
            "x":0,
            "y":1323,
            "x2":2059,
            "y2":2126
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Scatchard-plot analysis of AlBj binding to MTX. "
        ],
        "rois":[
          {
            "x":0,
            "y":1323,
            "x2":2059,
            "y2":2126
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Full length map of HMGB1 and truncated recombinant versions of the protein engineered in E. coli. The displayed sequence of the MTX-binding T7 phage particle (K86-V175) includes the Box B domain (K89-Y161), TLR4-binding domain (F88-E107) and part of the RAGE-binding domain (K149-V175). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2059,
            "y2":1322
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Hill-plot analysis of AlBj binding. Hill coefficients n???=???1.1"
        ],
        "rois":[
          {
            "x":0,
            "y":1323,
            "x2":2059,
            "y2":2126
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SDS-PAGE of AlBj, Al and Bj proteins after purification by affinity chromatography. The bands were stained with CBB. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2059,
            "y2":1322
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C, D) Representative SPR sensorgram with a global fitting curve between bio-MTX and Al ",
          "(C) or Bj "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2059,
            "y2":1322
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C, D) Representative SPR sensorgram with a global fitting curve between bio-MTX and Al ",
          "(D). Solutions containing various concentrations of Al (0.31???5 ??M) or Bj protein (0.16???2.5 ??M) were injected over the immobilized MTX-biotin on a SA sensor chip for 120 s and then dissociation was monitored for a further 120 s at a flow rate of 30 ??l/min. Response curves were generated by subtraction of the background signals generated simultaneously on the control flow cell (bio-MTX-non-immobilized cell) and the injection of vehicle (0 ??M analyte). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2059,
            "y2":1322
          }
        ]
      }
    }
  },
  "698423":{
    
  },
  "700228":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Dendritic cells were exposed to the indicated concentrations of NPs for 24 hrs and assessed for viability using 7-AAD and apoptosis by Po-Pro staining. As negative and positive controls, DCs were left untouched (mock) or treated with 1 ??g/ml Fas ligand (FAS), respectively. Bar graph data are plotted as mean ??SD. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2050,
            "y2":1289
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Dendritic cells were exposed to the indicated concentrations of NPs for 24 hours and assessed for phenotypic expression of human DC markers, as indicated, by flow cytometric analysis. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Supernatants from DCs stimulated with 1 ??M of either NPs were examined for soluble cytokines by Bio-Plex assay. Each dot on the scatter plot represents the signal for an individual donor; Data are mean+/???SD, n???=???10. A paired t-test was performed: **p2 or CeO2 group; ????p"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2050,
            "y2":1289
          }
        ]
      }
    }
  },
  "700233":{
    
  },
  "7007153":{
    
  },
  "70102":{
    
  },
  "70104":{
    
  },
  "706268":{
    
  },
  "706521":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) HCMV transcriptome 5 days post infection. "
        ],
        "rois":[
          {
            "x":31,
            "y":17,
            "x2":4069,
            "y2":981
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HCMV transcriptome 18 days post infection. Transcript analysis was performed using CLC Bio Genomics Workbench software. Peaks were calculated and determined based on 4 independent experiments and using a minimum of 20 read cut off and pValue of Inset: RT-PCR evaluation of identified ORFs during lytic or latent infection. Negative controls for latent infection: IE2, UL13 and US21. CycloA???=???cyclophillin A. "
        ],
        "rois":[
          {
            "x":15,
            "y":1014,
            "x2":4088,
            "y2":4485
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HCMV transcriptome upon reactivation of latently infected CD14 (+) monocytes with treatment of IL-6 and culturing cells on a surface that allows for cell attachment."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "71279":{
    
  },
  "71365":{
    
  },
  "71373":{
    
  },
  "71624":{
    
  },
  "717060":{
    
  },
  "718825":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) Relative fold induction of TOP-flash, IFNB1, ISG56"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2265,
            "y2":2710
          }
        ]
      },
      "NF":{
        "descriptions":[
          ", NF-??B and EF1??-driven reporter activity in HEK 293T cells subjected to GSK3 inhibition with BIO (5 ??M), TCF/LEF interaction inhibition with PNU74654 (6 ??M) or both inhibitors prior to SeV infection for 16 hours."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) and fold induction of CTNNB1-TCF/LEF dependent reporter activity TOP-flash "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) in HEK 293T cells transduced with lentivirus-expressing shRNA NT (control) or shRNA 45 targeting CTNNB1 for four days and subjected to GSK3 inhibition with BIO (5 ??M) or BIO-acetoxime (10 ??M) and SeV infection for 16 hours. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Immunoblot analysis of autophosphorylated GSK3??/?? at Tyr279/216, dephosphorylated active CTNNB1 at Ser37/Thr41 and IFIT1 in HEK 293T cells treated with GSK3 inhibitors BIO (5 ??M) or BIO-acetoxime (10 ??M) and infected with SeV for 16 hours. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2265,
            "y2":2710
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Immunoblot analysis of dephosphorylated active CTNNB1 at Ser37/Thr41, IFIT1 and phosphorylated NFKBIA (I??B??) at Ser32 in SeV-infected HEK 293T cells treated as described in (A???B) and treated with BIO (5 ??M) or BIO-acetoxime (10 ??M). "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "718826":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E) Immunoblot analysis of dephosphorylated active CTNNB1 at Ser37/Thr41, IFIT1 and HCV NS3 protease in primary human hepatocytes either transduced with lentivirus-expressing shRNA 45 targeting CTNNB1 for four days and/or subjected to GSK3 inhibition with BIO (5 ??M) and infected with Hepatitis C virus (HCV) strain JFH1 for 48 hours. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Huh7 cells transduced with shRNAs NT, WNT2B 76, WNT2B 77, WNT9B 69, WNT9B 70, WLS 58, WLS 99, CTNNB1 45 or YB1 48 (positive control) were infected with HCV J6/JFH-1(p7-Rluc2A) reporter virus. Following 96 hours of infection, Rluc was measure to assess HCV viral replication and results are represented as relative viral infection with shRNA NT treated cells arbitrarily set to 1. P values"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and TNF "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) mRNA levels in NHBE cells transduced with lentivirus-expressing shRNA 77 targeting WNT2B, shRNA 69 targeting WNT9B, shRNA 58 targeting WLS, shRNA 45 targeting CTNNB1 and NT shRNA in control cells for four days and infected with SeV for 16 hours. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Fold induction of IFNB1, IFIT1 and TNF mRNA levels in human monocyte-derived macrophages subjected to GSK3 inhibition with BIO (5 ??M) and SeV infection for 4 hours. qRT-PCR determination represents the average mRNA RQ normalized versus ACTIN and HPRT1 mRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Fold induction of IFIT1 mRNA in primary human hepatocytes transduced with lentivirus-expressing shRNA NT or shRNA 45 targeting CTNNB1 for four days and subjected to GSK3 inhibition with BIO (5 ??M) and SeV infection for 5 hours. qRT-PCR determination represents the average mRNA RQ normalized versus ACTIN and HPRT1 mRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2283,
            "y2":1388
          }
        ]
      }
    }
  },
  "72812":{
    
  },
  "728124":{
    "Figure_5.tif":{
      "a":{
        "descriptions":[
          "(a) Microscopic images of ES cells on day 4 of induction. ES cells were cultured with lignin (50 ??g/mL) and various concentrations of 6-BIO (1, 2 and 4 ??M). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2058,
            "y2":523
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Gene expression analysis by real-time PCR. Changes in the expressions of differentiation marker genes associated with the addition of lignin and 6-BIO were analyzed on day 4 of culture. The expression level of each marker gene was normalized to control. Scale bar: a???=???200 ??m Data are expressed as the mean ?? SD of the three experiments. *P"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":0,
            "y":524,
            "x2":2058,
            "y2":2300
          }
        ]
      }
    }
  },
  "728127":{
    
  },
  "729226":{
    
  },
  "730795":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) STAT1 expression was detected by Western blotting. Band intensities were quantified using Quantity One 4.4.0 software (Bio-Rad) and then normalized to the amount of GAPDH in each sample. All samples were compared with the signal detected in Non-target shRNA transduced cells. The data are representative of three independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3403,
            "y2":2275
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) NBT reduction assay was performed as described. The percentage of NBT-positive cells was calculated by counting at least 200 cells under a light microscope. Data presented are the mean ?? SD of three independent experiments. *** P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3403,
            "y2":2275
          }
        ]
      }
    }
  },
  "73892":{
    
  },
  "73893":{
    
  },
  "73894":{
    
  },
  "740321":{
    "Figure_6.tif":{
      "4":{
        "descriptions":[
          "(4), SP Sephadex C-25 "
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          "(5), Sephacryl S-200 beads "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2871,
            "y2":1901
          }
        ]
      },
      "6":{
        "descriptions":[
          "(6), or DEAE-Sephadex "
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          "(1), Dynabeads M-280 Streptavidin "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2871,
            "y2":1901
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2), Biorex 70 Resin "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2871,
            "y2":1901
          }
        ]
      },
      "7":{
        "descriptions":[
          "(7) for 30 minutes at room temperature. The sample was washed 4 times with water and then particles were tested in plaque assays to determine how much virus was bound by the particles. B) NT53 or HTP was incubated with purified RNA at 1.0E+7 genomic copies for 30 minutes at room temperature. Following water washes, the samples were resuspended in water and treated with 380 Units/ml of RNase A. Samples with no RNase A treatment were processed in parallel. The viral RNA was extracted from isolated particles and quantitated by qRT-PCR (black bars). Samples without NT53 were processed in parallel (gray bars). C) NT53 and HTP beads were incubated with viral supernatants containing RVFV at 1.7E+8 pfu/ml for 30 minutes at room temperature. Samples were then inactivated by incubation at 57??C for one hour or incubating in the presence of 1% NP-40 at room temperature for 1 hour. A ???no bead??? control processed in parallel was included for each condition. Viral RNA was extracted from the particles and quantitated by qRT-PCR."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2871,
            "y2":1901
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3), Bio-gel HTP Hydroxyapatite "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2871,
            "y2":1901
          }
        ]
      }
    }
  },
  "741365":{
    
  },
  "742603":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A). Increased IL-6 producing JAWSII cells and elevated IL-6 levels in lymphocytes culture media upon mMSLN-VLP treatment. JAWSII cells were stimulated with MSLN-VLP (5 ??g/ml) for 12 h and intracellular IL-6 staining was performed. Lymphocytes were prepared from spleen of na??ve B6 mice. After incubation with MSLN-VLP for 24 h, supernatant was collected to determine IL-6 concentrations by Bio-Plex"
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2723,
            "y2":2111
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B). Partial rescue of suppressive effect of mMSLN-VLP stimulation on foxp3+ Treg cells by IL-6 neutralization. MSLN-VLP with or without IL-6 neutralizing Ab or isotype control Ab were added to lymphocytes culture for 3 days. The foxp3+ cells were stained by using foxp3 intracellular staining kit. Data was acquired for flow cytometry analysis gated on CD3+ and CD4+ T cells. Shown were representative data from three to five independent experiments. (Statistically significances are shown, ** indicate p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "743190":{
    "Figure_1.tif":{
      "N":{
        "descriptions":[
          "(N) assayed at each timepoint. Urine samples of different genotypes but from the same month were tested in all possible cases on the same ELISA plate. There were no statistically significant differences by ANOVA (In-Stat3) for all groups and all time points with the exception of some 16 week and 28 week time points, which fit a pattern suggestive of plate-plate variation rather than progressive glomerulosclerosis. For instance, the 16 week KO is significantly lower than the KO at 24 weeks (by ANOVA with Tukey-Kramer post test 0.05 for all combinations of 24 week KO versus DH versus ff). It is simply that all 16 week values were atypically low, due either to aberrancy in the ELISA plate or to an unknown confounder at the time of that urine collection. Similarly, the 28 week DH and ff groups are significantly different than the KO 24 week time point (pMyh9 KO mice is not significantly different from control littermates within the same month, and podocyte-specific Myh9 KO mice do not show progressive albuminuria with aging from 8 weeks to 28 weeks."
        ],
        "rois":[
          {
            "x":9,
            "y":1908,
            "x2":1135,
            "y2":2080
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Urine from all mice was screened for albuminuria every 4 weeks by SDS-PAGE with Coomassie stain. Shown here is one of 2 gels from 28 week old mice. M???=???marker (Precision-Plus Dual Color, Bio-Rad), BSA???=???bovine serum albumin diluted from 1 mg/mL stock to the indicated amounts per lane (ug). Sample lanes contain 10 uL of mouse urine of the indicated genotype: "
        ],
        "rois":[
          
        ]
      },
      "FF":{
        "descriptions":[
          "(FF)???=???cre???; Myh9flox/flox. As an internal control, we observed low molecular weight (tubular) proteinuria from each urine sample lane but no significant albuminuria at this time or at any other time point. These urine samples are not normalized for concentration but provide an initial screen for albuminuria. "
        ],
        "rois":[
          {
            "x":17,
            "y":9,
            "x2":1136,
            "y2":779
          }
        ]
      },
      "DH":{
        "descriptions":[
          "(DH)???=???Podocin::Cre/+; Myh9flox/+, "
        ],
        "rois":[
          {
            "x":9,
            "y":1908,
            "x2":1135,
            "y2":2080
          },
          {
            "x":18,
            "y":915,
            "x2":1254,
            "y2":1883
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantification of albuminuria by urine albumin::creatinine ratio (ACR). Albuminuria was measured by plate ELISA (albuwell-M kit, Exocell/Glycadia) and creatinine was measured by endpoint-assay (Teco Diagnostics). For both assays, every plate included 8 standards and only plates for which the standards fit a straight line (r2>0.98) were accepted for analysis. All results from mouse urine that fell outside the linear range were repeated using additional urine dilutions. Legend???=???mouse genotypes as described above. Y-axis???=???urine to creatinine ratio (in ug/mg) +/??? standard deviation. X-axis???=???urine collections every four weeks from week 8 onwards. The table below the X axis shows the number of animals "
        ],
        "rois":[
          
        ]
      },
      "KO":{
        "descriptions":[
          "(KO)???=???Podocin::Cre/+; Myh9flox/flox, "
        ],
        "rois":[
          {
            "x":9,
            "y":1908,
            "x2":1135,
            "y2":2080
          }
        ]
      }
    }
  },
  "743195":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) SDS-PAGE with Coomassie stain of urine 4 days after injection to screen for albuminuria. M???=???marker (Precision Plus Dual Color, Bio-Rad); BSA???=???bovine serum albumin in ug/lane. Sample lanes of the indicated genotype contain 2.5 microliters of urine in sample buffer. "
        ],
        "rois":[
          {
            "x":11,
            "y":1109,
            "x2":1752,
            "y2":2217
          }
        ]
      },
      "KO":{
        "descriptions":[
          "(KO)???=???Podocin::Cre/+; Myh9flox/flox and "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1513,
            "y2":1008
          }
        ]
      },
      "FF":{
        "descriptions":[
          "(FF)???=???cre???; Myh9flox/flox. "
        ],
        "rois":[
          {
            "x":84,
            "y":2257,
            "x2":1517,
            "y2":2531
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantification of albuminuria normalized to urine concentration. Y axis is the ACR (ratio of albuminuria to urine creatinine), similar to Figures 1 and 3. Numbers of animals for each timepoint and each genotype are indicated below the abscissa. Data were analyzed by unpaired T-test with Welch correction. On one hand, as intended, KO mice had significantly more albuminuria after receiving NTS: (*) ACR on day1 after NTS was 239+/???44 ug/mg versus day 0 ACR of 0.2 ug/mg+/???0.0007, p???=???0.01, and albuminuria after NTS injection persisted through day 14. Similarly (**), the ACR on day1 after NTS was 239+/???44 ug/mg versus 0.4+/???0.3 ug/mg on day 1 after control sheep IgG, p???=???.012). However, (??????) for each day after injection with NTS, there is no difference in the magnitude of albuminuria between KO and control mice: day 1 p???=???0.58; day 2 p???=???0.31; day 3 p???=???0.20; day 4 p???=???0.396; day 7 p???=???0.37. At day 14, there is a trend towards a difference between KO and control mice injected with NTS, p???=???0.06, but in addition to the low N, this late timepoint is confounded by the contribution of an Fc dependent response from the immune system."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "743716":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) Immunostaining of N-MVECs with anti-desmoglein-2 and anti-integrin-beta8 antibodies (nuclei stained with DAPI) in a single N-MVEC (upper row) and in a group of N-MVECs (lower row). The results shown are indicative of experiments performed on 3 different N-MVEC cell lines. Original magnification: ??60 (Bio-Rad MRC 1024 ES Confocal Laser Scanning Microscope)"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1801,
            "y2":853
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Co-immunoprecipitation of integrin-beta8 and desmoglein-2. The lanes 1, 2 and 3 of each blot represent 1) input: total lysate, 2) protein A beads alone, 3) protein A beads + anti-Desmoglein-2 or anti-Integrin-beta8 antibody, respectively. Left side: immuno-blotting with anti-desmoglein-2 (upper part) and anti-integrin-beta8 (lower part) antibodies of the immuno-precipitates obtained with the same antibodies. Right side: immuno-blotting with anti-integrin-beta8 antibodies of the immuno-precipitate obtained with anti-desmoglein-2 antibodies (upper part), and immuno-blotting with anti-desmoglein-2 antibodies of the immuno-precipitate obtained with anti-integrin-beta8 antibodies (lower part). Numbers on the left indicate molecular weight (kDa) of the revealed bands"
        ],
        "rois":[
          {
            "x":7,
            "y":860,
            "x2":1801,
            "y2":1338
          }
        ]
      },
      "IP":{
        "descriptions":[
          ". IP: immuno-precipitate"
        ],
        "rois":[
          {
            "x":7,
            "y":860,
            "x2":1801,
            "y2":1338
          }
        ]
      },
      "IB":{
        "descriptions":[
          "; IB: immuno-blotting. The data shown represent a typical experiment out of three experiments on each N-MVEC line, all of which gave similar results."
        ],
        "rois":[
          {
            "x":7,
            "y":860,
            "x2":1801,
            "y2":1338
          }
        ]
      }
    }
  },
  "743721":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          ". Panel A: RT-PCR of the relevant transcripts in SSc-MVECs, relative to N-MVECs. Data are expressed as log2 of fold change. Negative values indicate decreased expression levels"
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":1493,
            "y2":611
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B: Immunostaining of SSc-MVECs with anti-desmoglein-2 and anti-integrin-beta8 antibodies (nuclei stained with DAPI) after transient transfection with control vector (upper pictures) or DSG2 transfection (lower pictures). The results shown are indicative of experiments performed on 3 SSc-MVEC cell lines. Original magnification: X60 (Bio-Rad MRC 1024 ES Confocal Laser Scanning Microscope)"
        ],
        "rois":[
          {
            "x":19,
            "y":641,
            "x2":1502,
            "y2":1037
          }
        ]
      },
      "C":{
        "descriptions":[
          ". Panel C: Capillary morphogenesis in control and DSG2-transfected SSc-MVECs. Pictures show the results of a typical experiment out of 3 experiments performed in triplicate in each one of the different SSc-MVEC lines (SSc-MVEC 1, 2 and 3)."
        ],
        "rois":[
          {
            "x":17,
            "y":1063,
            "x2":1500,
            "y2":2035
          }
        ]
      }
    }
  },
  "748172":{
    
  },
  "751860":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A), PcrAsFH "
        ],
        "rois":[
          {
            "x":22,
            "y":22,
            "x2":5831,
            "y2":2018
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), PcrAMpn "
        ],
        "rois":[
          {
            "x":22,
            "y":22,
            "x2":5831,
            "y2":2018
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) or PcrAMge "
        ],
        "rois":[
          {
            "x":30,
            "y":2165,
            "x2":2859,
            "y2":4146
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). The protein concentrations tested were 0 pM, 50 pM, 0.2 nM, 0.8 nM, 3.2 nM, 12.5 nM, 25 nM, 50 nM and 100 nM. DNA unwinding was quantified by determination of the percentage of free (labeled) oligonucleotide that was displaced from the DNA substrates. Quantification was performed using Quantity One software (Bio-Rad), after separation of reaction products on polyacrylamide gels. Data shown are the average of two independent experiments. Error bars indicate the standard deviation of the mean. In the inset at the right-hand corner of each graph, a detail is shown of the DNA helicase activity (%) at the lowest protein concentrations tested."
        ],
        "rois":[
          {
            "x":3005,
            "y":2166,
            "x2":5831,
            "y2":4146
          }
        ]
      }
    }
  },
  "752542":{
    "Figure_1.tif":{
      "R":{
        "descriptions":[
          "R. heilongjiangensis biotinylated proteins isolated by biotin-streptavidin affinity purification were separated using a pH 3???10 NL IPG strip (Bio-Rad, Richmond"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2027,
            "y2":2056
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA) in the first dimension followed by 12% SDS-PAGE. Numbers with arrowheads refer to the protein spots in the silver-stained gel. Protein spots excised from the gel were digested and subjected to ESI-MS/MS analysis. The relative molecular masses of the marker proteins are indicated in kDa on the left side of the figure and the protein spots identified by ESI-MS/MS analysis are listed in Table S2."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "755046":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "Panel A: Production of CC-chemokines by PBMC and the effects of adefovir, tenofovir, and PMEO-DAPym on the expression of the CCR5 receptor. Freshly isolated PBMCs from four healthy donors were incubated for 24 h with medium only "
        ],
        "rois":[
          {
            "x":343,
            "y":15,
            "x2":3453,
            "y2":2886
          }
        ]
      },
      "NC":{
        "descriptions":[
          "(NC) or with adefovir, tenofovir, or PMEO-DAPym. We collected the supernatants and measured the concentrations of MIP-1?? (???), MIP-1?? (???), and RANTES (???) using a Bioplex system (Bio-Rad, Hercules"
        ],
        "rois":[
          
        ]
      },
      "CA":{
        "descriptions":[
          ", CA). Shown are means ?? SEM. The cells were also collected, and the expression of the CCR5 receptor (???) was measured with flow cytometry using the PE-labeled CCR5 (clone 2D7) mAb; it is shown as percentage of control (?? SEM) from four independent representative experiments"
        ],
        "rois":[
          {
            "x":651,
            "y":2816,
            "x2":2965,
            "y2":5013
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B: Chemokine mRNA expression upon PMEO-DAPym exposure to PBMC. RT-PCR analysis of MIP-1??, MIP-1??, RANTES, and GAPDH (control) expression in PBMC treated with 100-??g/ml PMEO-DAPym for 4 h. Similar results were obtained with PBMC from three different donors. Results from one representative donor are shown."
        ],
        "rois":[
          {
            "x":343,
            "y":15,
            "x2":3453,
            "y2":2886
          }
        ]
      }
    }
  },
  "756407":{
    
  },
  "756412":{
    
  },
  "757003":{
    
  },
  "759300":{
    "Figure_6.tif":{
      "LN":{
        "descriptions":[
          "(LN) and obese "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":2044,
            "y2":928
          }
        ]
      },
      "OB":{
        "descriptions":[
          "(OB) were treated with Thbs1 inhibitor LSKL, or with Arg1 inhibitor ABH ammonium salt, immediately before the exposure to P. gingivalis (P.g). After 4 h incubation, cytokines in the cell culture supernatants were measured by Bio-Plex cytokine array. The data presented are means of 3 replicates. *PP"
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":2044,
            "y2":928
          }
        ]
      }
    }
  },
  "759350":{
    
  },
  "760012":{
    
  },
  "760898":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A). The short variant (Pol?? ?? Ex 8) presents a 103 bp deletion corresponding to exon 8. This deletion removes one part of the active site of the protein. The BRCT (breast cancer suppressor protein carboxy-terminal) and the Pol X domain, which contains the active site, are required for Pol?? function. Pol?? variants were amplified using primers indicated by horizontal arrows "
        ],
        "rois":[
          {
            "x":11,
            "y":9,
            "x2":1852,
            "y2":2521
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Quantification of the obtained PCR products using a Gel Doc 2000 and the Quantity One v.4.3.1 software (Bio-Rad, Hercules, CA, USA) indicates that the short isoform represents 16% and 6% of the Pol?? transcripts in the spleen and testis of P. waltl, respectively. Ctl??????=???negative control. MW???=???100 bp DNA ladder. A cladogram was then constructed by neighbor joining "
        ],
        "rois":[
          {
            "x":11,
            "y":9,
            "x2":1852,
            "y2":2521
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) supported with 1000 bootstrap replications using the MEGA4 software (http://www.megasoftware.net/) and the following sequences: Terminal deoxynucleotidyl transferase (TdT); Bos taurus (DAA14763), Homo sapiens (BAB72001), Mus musculus (NP_001036693), Gallus gallus (NP_990720), Ambystoma mexicanum (AA092254), Xenopus laevis (NP_001079251), Danio rerio (AAS89780). Polymerase beta; Mus musculus (NP_035260), Homo sapiens (NP_002681), Xenopus laevis (NP_001081643), Xenopus tropicalis (AAH74537), Xiphophorus maculatus (AAU11319). Polymerase lambda; Danio rerio (NP_998408), Xenopus tropicalis (NP_001093716), Mus musculus (NP_064416), Homo sapiens (NP_001167555). Polymerase mu; Homo sapiens (NP_037416), Mus musculus (NP_059097), Danio rerio (NP_956542), Xenopus tropicalis (NP_001164987), Pleurodeles waltl (HE583591). The scale bar corresponds to the evolutionary distance."
        ],
        "rois":[
          {
            "x":11,
            "y":9,
            "x2":1852,
            "y2":2521
          }
        ]
      }
    }
  },
  "763778":{
    
  },
  "763779":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          ". E. bEnd5 cells co-cultured with astrocytes (+AC) in comparison to bEnd5 cell monocultures (???AC)."
        ],
        "rois":[
          {
            "x":1113,
            "y":1646,
            "x2":2109,
            "y2":2365
          }
        ]
      },
      "A":{
        "descriptions":[
          ". A. Representative TEER/Ccl measurement comparing MBMECs, bEnd5 and bEnd5 infected with LEF??N-??CTA (??CTA-bEnd5), indicating that ??-catenin transcriptional activation leads to increased electrical resistance in bEnd5 cells. Vertical line at 125 hours indicates media exchange and boxed insert shows magnification of the Ccl curves after the media exchange, highlighting pronounced lower values for the ??CTA-bEnd5 compared to bEnd5 controls"
        ],
        "rois":[
          {
            "x":14,
            "y":14,
            "x2":2696,
            "y2":1593
          },
          {
            "x":2814,
            "y":17,
            "x2":3852,
            "y2":727
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Parental bEnd5 cells in comparison to the primary mouse MBMECs cells (n???=???3)"
        ],
        "rois":[
          {
            "x":1152,
            "y":2502,
            "x2":2069,
            "y2":3268
          },
          {
            "x":72,
            "y":2480,
            "x2":995,
            "y2":3268
          },
          {
            "x":2814,
            "y":17,
            "x2":3852,
            "y2":727
          },
          {
            "x":1729,
            "y":14,
            "x2":2745,
            "y2":730
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. bEnd5 cells infected with lenti-LEF??N-??CTA in comparison to the lenti-GFP control"
        ],
        "rois":[
          {
            "x":1152,
            "y":2502,
            "x2":2069,
            "y2":3268
          },
          {
            "x":2814,
            "y":17,
            "x2":3852,
            "y2":727
          },
          {
            "x":2881,
            "y":815,
            "x2":3781,
            "y2":1592
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. bEnd5 cells treated with the GSK3??/?? inhibitor 6-BIO (2.5 ??M) in comparison to the DMSO-treated cells"
        ],
        "rois":[
          {
            "x":17,
            "y":1646,
            "x2":1046,
            "y2":2372
          }
        ]
      }
    }
  },
  "765028":{
    
  },
  "770544":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) SDS-PAGE analysis: Lane 1: Rhodococcus T104 pHPNV culture broth; lane 2???1 ??g protein after octyl FF sepharose purification step; lane 3???0.89 ??g of purified protein after phenyl HP sepharose purification step; lane 4: Bio-Rad broad range molecular weight standards. Bands corresponding to PhaZSa are marked with an arrow"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2038,
            "y2":578
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Spot test activity assay: Rhodococcus T104 pNV19 culture broth (negative control), Rhodococcus T104 pHPNV culture broth, pooled fractions after octyl FF sepharose purification step and pooled fractions after phenyl HP sepharose."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "774835":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A). The relative intensity of the HA bands compared to each of the control (PBS i.n. and s.c.) samples was obtained using Image Lab version 3.0 (BIO RAD) "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":1999,
            "y2":1233
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Experiments were performed 3 times, and averages and standard deviations are shown. Student t-test was used for statistical analysis."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "774903":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) rectal tissue."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":506,
            "y2":532
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) modified balance; "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) weights; "
        ],
        "rois":[
          {
            "x":507,
            "y":0,
            "x2":987,
            "y2":532
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) metal plate; "
        ],
        "rois":[
          {
            "x":507,
            "y":0,
            "x2":987,
            "y2":532
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) in situ gelling enema; "
        ],
        "rois":[
          {
            "x":507,
            "y":0,
            "x2":987,
            "y2":532
          }
        ]
      }
    }
  },
  "774909":{
    
  },
  "777378":{
    "Figure_1.tif":{
      "PC":{
        "descriptions":[
          "(PC) and negative control "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3917,
            "y2":2909
          }
        ]
      },
      "NC":{
        "descriptions":[
          "(NC) were included in each plate during phage ELISA. The strongest positive clones were selected for subsequent cloning and expression as monomer and multimer (combody) in E.coli."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3917,
            "y2":2909
          }
        ]
      }
    }
  },
  "777443":{
    
  },
  "780234":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) PRC1 complexes catalyze monoubiquitylation of histone H2A lysine 119 (H2AK119ub1). The catalytic subunits are RING1A/B and one of six PCGF protein homologues, PCGF1???6. PRC1 exists in canonical and noncanonical forms. Canonical PRC1 complexes comprise RING1A/B, PCGF2/4, the CBX protein subunit that has a chromodomain "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1359,
            "y2":2207
          }
        ]
      },
      "CD":{
        "descriptions":[
          "(CD) that binds specifically to PRC2-mediated H3K27me3, and the PH subunit. In noncanonical PRC1, CBX proteins are substituted by the RYBP/YAF2 subunit and the PH subunit is absent. Association of additional subunits with noncanonical PRC1 occurs in a manner dependent on the associated PCGF protein. Thus, PCGF1 complexes, discussed extensively herein, include the additional subunits BCOR and KDM2B. KDM2B has a zinc finger CxxC domain (CXXC) that mediates binding to unmethylated CpG dinucleotides. PRC2 complexes methylate histone H3 lysine 27 (H3K27me1/2/3) and comprise the catalytic EZH2 protein and the core subunits EED, SUZ12, and RBAP48. JARID2 is a substoichiometric subunit that has been implicated in PRC2 targeting. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) PcG complexes occupy CpG islands at target gene promoters: an example from genome-wide ChIP-seq analysis of mouse embryonic stem cells illustrating a PcG target gene, Lhx4. The Bio-CAP procedure provides a molecular readout of the density of unmethylated CpG dinucleotides with peaks corresponding to CpG islands. ChIP-seq for PRC1 (RING1B) and PRC2 (EZH2) subunits illustrates that PcG protein occupancy closely mirrors unmethylated CpG density."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1359,
            "y2":2207
          }
        ]
      }
    }
  },
  "781821":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) Serum levels of pro-inflammatory cytokines were increased in ApcMin/+ mice after H. hepaticus infection. Eotaxin, IL-3, TNF-?? and IL-1?? were significantly elevated in comparison with age-matched uninfected ApcMin/+ controls. When compared with H. hepaticus infected wt mice, infected ApcMin/+ mice had significantly higher IL-17, IL-1??, IL-3, eotaxin and IL-9 concentration in their blood serum. Bio-Plex Cytokine Assay used sera of n=5 mice per group. ***pB) Paracortical areas in mesenteric lymph nodes"
        ],
        "rois":[
          {
            "x":38,
            "y":46,
            "x2":2009,
            "y2":1049
          }
        ]
      },
      "H":{
        "descriptions":[
          ". H. hepaticus infected ApcMin/+ mice at high risk of prostate cancer had large amounts of cytoplasmic and extracellular IL-17 that significantly decreased after depletion of TNF-??"
        ],
        "rois":[
          {
            "x":32,
            "y":1078,
            "x2":2010,
            "y2":1968
          },
          {
            "x":38,
            "y":46,
            "x2":2009,
            "y2":1049
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Morphometric assessment of IL-17 in immunohistochemically stained sections of mesenteric lymph nodes. Both ApcMin/+ genetic status and intestinal infection by H. hepaticus significantly correlate with a TNF-??-mediated increase of IL-17 expression in the mesenteric lymph nodes. ***p"
        ],
        "rois":[
          {
            "x":38,
            "y":46,
            "x2":2009,
            "y2":1049
          }
        ]
      }
    }
  },
  "78267":{
    
  },
  "78268":{
    
  },
  "78269":{
    
  },
  "78270":{
    
  },
  "783075":{
    
  },
  "783097":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) MCF-7, Cd7 and Cd12 cells were harvested for chromatin immunoprecititation (ChIP) analysis. ChIP analysis was done with ??-ER??, ??-c-fos, ??-c-jun, and ??-Sp1, and recruitment of proteins to the SDF-1, cyclin D1 and c-myc promoters was determined using promoter specific primers and semi-quantitative PCR. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2151,
            "y2":214
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Band intensities of PCR products for SDF-1, cycD, and c-myc were quantified and normalized to input using Quantity One (Bio-Rad) "
        ],
        "rois":[
          {
            "x":0,
            "y":215,
            "x2":2151,
            "y2":435
          },
          {
            "x":0,
            "y":436,
            "x2":267,
            "y2":675
          }
        ]
      },
      "PC":{
        "descriptions":[
          "(PC) In the ChIP re-ChIP assay, DNA/protein complexes from the first ChIP assay were extracted and re-ChIPed with a second antibody. The occupancy of ER??/c-jun or c-Jun/ER?? complexes on the SDF-1 promoter was analyzed as in B "
        ],
        "rois":[
          {
            "x":0,
            "y":436,
            "x2":267,
            "y2":675
          },
          {
            "x":0,
            "y":676,
            "x2":2151,
            "y2":2033
          },
          {
            "x":268,
            "y":436,
            "x2":2151,
            "y2":675
          }
        ]
      },
      "PD":{
        "descriptions":[
          "(PD) To confirm the presence of c-fos in the ER??/c-jun complex, reChIPed DNA containing ER??/c-jun complexes were immunoprecipitated with a third antibody, ??-c-fos, and the resulting DNA fragments were analyzed as in B (P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "783295":{
    "Figure_3.tif":{
      "1":{
        "descriptions":[
          ": 1. rLaSota"
        ],
        "rois":[
          {
            "x":11,
            "y":423,
            "x2":969,
            "y2":1267
          },
          {
            "x":9,
            "y":9,
            "x2":955,
            "y2":368
          }
        ]
      },
      "2":{
        "descriptions":[
          ", 2. rBan/AF"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":955,
            "y2":368
          }
        ]
      },
      "3":{
        "descriptions":[
          ", 3. rLaSota-Ban/AF F"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":955,
            "y2":368
          }
        ]
      },
      "4":{
        "descriptions":[
          ", 4. rLaSota-Ban/AF HN, and 5. rLaSota-Ban/AF F HN (B) The relative levels of the F0 and F1 proteins in the Western blot experiment in part C were measured by Bio-Rad Gel Image analysis, and the efficiency of cleavage was determined by dividing the amount of F1 by the amount of F1 plus F0. Each bar represents mean and standard error of the mean of triplicate samples."
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":955,
            "y2":368
          }
        ]
      }
    }
  },
  "78438":{
    
  },
  "78439":{
    "Emi0010-0978-f5.jpg":{
      "A":{
        "descriptions":[
          "(A) Xyn-RC(LNA-Even); or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":799,
            "y2":325
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Xyn-RC(LNA-5???)] was used in the RCA reaction. Products were analysed with an Agilent 2100 Bioanalyser with a DNA 7500 LabChip?? kit (TaKaRa-Bio).Copyright information:Taken from \"Retrieval of entire genes from environmental DNA by inverse PCR with pre-amplification of target genes using primers containing locked nucleic acids\"Environmental Microbiology 2008;10(4):978-987.Published online 01 Apr 2008PMCID:PMC2327201.?? 2007 The Authors Journal compilation ?? 2007 Society for Applied Microbiology and Blackwell Publishing Ltd"
        ],
        "rois":[
          {
            "x":0,
            "y":326,
            "x2":799,
            "y2":882
          }
        ]
      }
    }
  },
  "784678":{
    
  },
  "787007":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) High levels of CD147 expression in hypopharyngeal squamous cell carcinoma: diffuse cytoplasmic staining. "
        ],
        "rois":[
          {
            "x":855,
            "y":1371,
            "x2":1685,
            "y2":2035
          },
          {
            "x":9,
            "y":9,
            "x2":838,
            "y2":673
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Low level of CD147 expression in epithelium adjacent to carcinoma."
        ],
        "rois":[
          {
            "x":855,
            "y":9,
            "x2":1685,
            "y2":673
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) High levels of COX-2 expression in hypopharyngeal squamous cell carcinoma: diffuse cytoplasmic staining. "
        ],
        "rois":[
          {
            "x":9,
            "y":1371,
            "x2":838,
            "y2":2035
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Low levels of COX-2 expression in epithelium adjacent to carcinoma. "
        ],
        "rois":[
          {
            "x":855,
            "y":1371,
            "x2":1685,
            "y2":2035
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) High levels of CD44v6 expression in hypopharyngeal squamous cell carcinoma: cell membrane staining. "
        ],
        "rois":[
          {
            "x":855,
            "y":1371,
            "x2":1685,
            "y2":2035
          },
          {
            "x":9,
            "y":691,
            "x2":1684,
            "y2":1355
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) High levels of CD44v6 expression in epithelium adjacent to carcinoma as well as staining in carcinoma tissues. "
        ],
        "rois":[
          {
            "x":855,
            "y":1371,
            "x2":1685,
            "y2":2035
          },
          {
            "x":9,
            "y":691,
            "x2":1684,
            "y2":1355
          }
        ]
      }
    }
  },
  "787012":{
    "Figure_2.tif":{
      "T":{
        "descriptions":[
          "(T) High levels of CD147 expression in tumor tissue with lymph node metastasis. "
        ],
        "rois":[
          {
            "x":718,
            "y":7,
            "x2":1404,
            "y2":556
          }
        ]
      },
      "U":{
        "descriptions":[
          "(U) Low levels of CD147 expression in tumor tissue without lymph node metastasis."
        ],
        "rois":[
          {
            "x":718,
            "y":567,
            "x2":1404,
            "y2":1117
          }
        ]
      },
      "Q":{
        "descriptions":[
          "(Q) Low levels of COX-2 expression in tumor tissue without lymph node metastasis. "
        ],
        "rois":[
          {
            "x":7,
            "y":1138,
            "x2":694,
            "y2":1688
          },
          {
            "x":717,
            "y":1137,
            "x2":1404,
            "y2":1687
          },
          {
            "x":718,
            "y":7,
            "x2":1404,
            "y2":556
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) High levels of COX-2 expression in tumor tissue with lymph node metastasis. "
        ],
        "rois":[
          {
            "x":717,
            "y":1137,
            "x2":1404,
            "y2":1687
          },
          {
            "x":7,
            "y":7,
            "x2":694,
            "y2":1118
          }
        ]
      },
      "R":{
        "descriptions":[
          "(R) High levels of CD44v6 expression in tumor tissue with lymph node metastasis. "
        ],
        "rois":[
          {
            "x":7,
            "y":1138,
            "x2":694,
            "y2":1688
          },
          {
            "x":717,
            "y":1137,
            "x2":1404,
            "y2":1687
          },
          {
            "x":718,
            "y":7,
            "x2":1404,
            "y2":556
          }
        ]
      },
      "S":{
        "descriptions":[
          "(S) Low levels of CD44v6 expression in tumor tissue without lymph node metastasis. "
        ],
        "rois":[
          {
            "x":717,
            "y":1137,
            "x2":1404,
            "y2":1687
          },
          {
            "x":718,
            "y":7,
            "x2":1404,
            "y2":556
          }
        ]
      }
    }
  },
  "787019":{
    "Figure_3.tif":{
      "N":{
        "descriptions":[
          "(N) CD147 expression in moderate differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":1365,
            "y":7,
            "x2":1998,
            "y2":513
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J) CD44v6 expression in well differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":692,
            "y":1096,
            "x2":1325,
            "y2":1605
          },
          {
            "x":692,
            "y":7,
            "x2":1325,
            "y2":513
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) CD147 expression in well differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":692,
            "y":7,
            "x2":1325,
            "y2":513
          },
          {
            "x":691,
            "y":547,
            "x2":1325,
            "y2":1056
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I) COX-2 expression in poorly differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":1365,
            "y":1096,
            "x2":1998,
            "y2":1605
          },
          {
            "x":692,
            "y":7,
            "x2":1325,
            "y2":513
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) COX-2 expression in well differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":7,
            "y":547,
            "x2":640,
            "y2":1056
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L) CD44v6 expression in poorly differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":692,
            "y":7,
            "x2":1325,
            "y2":513
          },
          {
            "x":1367,
            "y":547,
            "x2":2002,
            "y2":1056
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) COX-2 expression in moderate differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":640,
            "y2":515
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K) CD44v6 expression in moderate differentiated tumor tissues. "
        ],
        "rois":[
          {
            "x":692,
            "y":7,
            "x2":1325,
            "y2":513
          },
          {
            "x":7,
            "y":547,
            "x2":640,
            "y2":1056
          }
        ]
      },
      "O":{
        "descriptions":[
          "(O) CD147 expression in poorly differentiated tumor tissues."
        ],
        "rois":[
          {
            "x":7,
            "y":1096,
            "x2":640,
            "y2":1605
          }
        ]
      }
    }
  },
  "787111":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E,G) BIO. Asterisks: dental lamina, White arrows: tooth germs; yellow arrowhead: successional lamina. "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":603,
            "y":1914,
            "x2":1129,
            "y2":2470
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N) LiCl treatment. "
        ],
        "rois":[
          {
            "x":1100,
            "y":7,
            "x2":2037,
            "y2":342
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J) percentage of the number of tooth germs in 3-day snake cultures after treatment, n???=???number of slices analyzed. "
        ],
        "rois":[
          {
            "x":1100,
            "y":7,
            "x2":2037,
            "y2":342
          },
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          }
        ]
      },
      "F":{
        "descriptions":[
          "(D,F) LiCl, "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":8,
            "y":1340,
            "x2":971,
            "y2":1810
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) RT-PCR analysis of Axin2 and Lunatic fringe (Lnfg) mRNA levels of the dental organ indicating Axin2 and Lnfg are up-regulated after LiCl treatment. EF1?? was used as a loading control. (B???G) F-Actin detection after 3 days of culture in "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":971,
            "y2":867
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) control, "
        ],
        "rois":[
          {
            "x":1127,
            "y":894,
            "x2":2054,
            "y2":1354
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I) Number of new tooth germs that appeared during 3 days of treatment and "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":603,
            "y":1914,
            "x2":1129,
            "y2":2470
          }
        ]
      },
      "G":{
        "descriptions":[
          "(E,G) BIO. Asterisks: dental lamina, White arrows: tooth germs; yellow arrowhead: successional lamina. "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":8,
            "y":1340,
            "x2":971,
            "y2":1810
          }
        ]
      },
      "Q":{
        "descriptions":[
          "(P,Q) BIO treatment. White arrows: tooth germs and epithelial projections. Yellow arrow: dysmorphic tooth germ. White asterisks: dental lamina. Yellow asterisks: acanthosis in dental lamina. Scale bars: 100 ??m."
        ],
        "rois":[
          
        ]
      },
      "L":{
        "descriptions":[
          "(K,L) Morphology of dental organs after 7 days of control culture ",
          "(L). Asterisks: dental lamina, Black arrows: tooth germs. (M???Q) Histology of explanted dental organs after 10 days in culture: "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":1592,
            "y":1974,
            "x2":2054,
            "y2":2432
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Control, "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":971,
            "y2":867
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P,Q) BIO treatment. White arrows: tooth germs and epithelial projections. Yellow arrow: dysmorphic tooth germ. White asterisks: dental lamina. Yellow asterisks: acanthosis in dental lamina. Scale bars: 100 ??m."
        ],
        "rois":[
          {
            "x":8,
            "y":1340,
            "x2":971,
            "y2":1810
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) DMSO and "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":971,
            "y2":867
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) The volume of the dental organ does not change after GSK3?? inhibitor treatment. "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          },
          {
            "x":29,
            "y":1907,
            "x2":518,
            "y2":2468
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K,L) Morphology of dental organs after 7 days of control culture ",
          "(K) and LiCl culture "
        ],
        "rois":[
          {
            "x":500,
            "y":868,
            "x2":971,
            "y2":1338
          },
          {
            "x":1128,
            "y":394,
            "x2":2057,
            "y2":864
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          }
        ]
      },
      "O":{
        "descriptions":[
          "(O) DMSO control and "
        ],
        "rois":[
          {
            "x":29,
            "y":1907,
            "x2":518,
            "y2":2468
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D,F) LiCl, "
        ],
        "rois":[
          {
            "x":8,
            "y":868,
            "x2":478,
            "y2":1338
          },
          {
            "x":1127,
            "y":1356,
            "x2":2054,
            "y2":1971
          }
        ]
      }
    }
  },
  "787119":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E, F) Quantification of the samples represented in A???D showing ",
          "(E) increase of pH3+ cells and "
        ],
        "rois":[
          {
            "x":1358,
            "y":30,
            "x2":1985,
            "y2":666
          },
          {
            "x":216,
            "y":1424,
            "x2":1337,
            "y2":2295
          },
          {
            "x":7,
            "y":7,
            "x2":1283,
            "y2":1377
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E, F) Quantification of the samples represented in A???D showing ",
          "(F) increase in mitotic index after LiCl and BIO treatment, n???=???number of slices analyzed. "
        ],
        "rois":[
          {
            "x":1359,
            "y":728,
            "x2":1985,
            "y2":1401
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Distribution of the number of pH3+ cells along the different regions of the dental organ represented in the scheme. Significant differences were found in the dental lamina after LiCl and BIO treatment. Scale bar: 100 ??m."
        ],
        "rois":[
          {
            "x":1393,
            "y":1661,
            "x2":1862,
            "y2":2119
          },
          {
            "x":216,
            "y":1424,
            "x2":1337,
            "y2":2295
          }
        ]
      }
    }
  },
  "788388":{
    "Figure_S1.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":64,
            "y":26,
            "x2":2692,
            "y2":1523
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    },
    "Figure_S2.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":39,
            "y":17,
            "x2":2684,
            "y2":1512
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    },
    "Figure_S3.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":89,
            "y":26,
            "x2":2666,
            "y2":1521
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    },
    "Figure_S4.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":78,
            "y":25,
            "x2":2652,
            "y2":1510
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    },
    "Figure_S5.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":32,
            "y":32,
            "x2":2728,
            "y2":1507
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    },
    "Figure_S6.tif":{
      "Z":{
        "descriptions":[
          ". Z. bailii grew at acetic acid concentrations above 24 g L???1, while limited growth of S. cerevisiae was observed after 11 h when cultured with only 12 g L???1 acetic acid. Detailed lipidomic profiling using electrospray ionization, multiple-reaction-monitoring mass spectrometry (ESI-MRM-MS) showed remarkable changes in the glycerophospholipid composition of Z. bailii, including an increase in saturated glycerophospholipids and considerable increases in complex sphingolipids in both S. cerevisiae (IPC 6.2??, MIPC 9.1??, M"
        ],
        "rois":[
          {
            "x":16,
            "y":27,
            "x2":2737,
            "y2":1503
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP)2C 2.2??) and Z. bailii (IPC 4.9??, MIPC 2.7??, M",
          "(IP)2C 2.7??), when cultured with acetic acid. In addition, the basal level of complex sphingolipids was significantly higher in Z. bailii than in S. cerevisiae, further emphasizing the proposed link between lipid saturation, high sphingolipid levels and acetic acid tolerance. The results also suggest that acetic acid tolerance is associated with the ability of a given strain to generate large rearrangements in its lipid profile."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "789807":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "M14 cell line (104 cells) was cultured and lysed with the Trizol reagent, in-house and Bio-Rad cell-to-Ct reagents. After reverse transcription, the cDNA samples were amplified by RPS8, ZNF706, RNF167, hsa-miR-29a, hsa-miR-197, hsa-miR-297 PCR assays. Graph bars represent (A)"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2212,
            "y2":904
          }
        ]
      },
      "B":{
        "descriptions":[
          " CVs and (B)"
        ],
        "rois":[
          {
            "x":76,
            "y":991,
            "x2":2255,
            "y2":1923
          }
        ]
      }
    }
  },
  "789809":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) in-house or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1166,
            "y2":1321
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-Rad lysis buffer. The cDNA samples generated from cell lysates were amplified by PCR assays from set 2. Standard curves for isolated RNAs were plotted as Ct versus Log (cells per RT). The experiments were conducted with biological duplicates."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1166,
            "y2":1321
          },
          {
            "x":1167,
            "y":0,
            "x2":2136,
            "y2":1321
          }
        ]
      }
    }
  },
  "789812":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) in-house or "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1114,
            "y2":780
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-Rad lysis buffers and incubated at room temperature across various durations (5, 10, 30, 60, 120, 240 min). The cDNA samples generated from cell lysates were amplified by PCR assays from set 2. Ct was plotted against duration of incubation to examine the stability of RNA in room temperature. The experiments were conducted with biological duplicates."
        ],
        "rois":[
          {
            "x":18,
            "y":11,
            "x2":2255,
            "y2":1457
          }
        ]
      }
    }
  },
  "789813":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) in-house or "
        ],
        "rois":[
          {
            "x":12,
            "y":12,
            "x2":1157,
            "y2":766
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-Rad lysis buffers. Cell lysates were collected and aliquoted. The lysates were then frozen at ???70??C, thawed in a temperature-controlled water bath at 25??C, and the freeze-thaw cycles repeated. The miRNA and mRNA expressions were quantified following 1, 3, 5, 10 freeze-thaw cycles. The qPCR assays from set 2 were used for quantifications. Ct was plotted against freeze-thaw cycles to examine the stability of RNA. The experiments were conducted in biological duplicates."
        ],
        "rois":[
          {
            "x":18,
            "y":12,
            "x2":2330,
            "y2":1473
          }
        ]
      }
    }
  },
  "790551":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) SDS-PAGE gel for C. neoformans recombinant (His)6-Bwc2. Left to right, lane 1 is the low molecular weight Bio-Rad protein ladder, lane 2, 3, 4 are purified recombinant Bwc2 eluted fractions. Lane 5 is crude unpurified protein extract. "
        ],
        "rois":[
          {
            "x":19,
            "y":14,
            "x2":1014,
            "y2":694
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gel mobility shift assay for a fragment of the JEC21 UVE1 promoter with purified Bwc2. Left to right, lane 1 contains just the UVE1 promoter P1 (PUVE1), lane 2, 3 and 4 contains P1+Bwc2 20 ??g, 50 ??g and 20 ??g+Zn2+ respectively. Lane 5 is loaded with the non-specific radiolabeled probe P2. Lane 6, 7 are P1+Bwc2 20 ??g and 50 ??g. Lane 8, 9 are competition with the increasing amount of specific probe cold P1 to negate any binding observed in lane 7. Lane 10 is Bwc2 and P2 with Zn2+."
        ],
        "rois":[
          {
            "x":15,
            "y":792,
            "x2":1120,
            "y2":1962
          }
        ]
      }
    }
  },
  "791323":{
    
  },
  "791451":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          "(a) The dimer structure of subunits A (red) and B (green) shows no disulfide bond formation between the Cys61 residues of the two monomers (Insets). Density maps superimposed with atomic models of two helices from the boxed region, showing no density that can be attributed to disulfide bond formation between the two interacting monomers in this region. The density maps are contoured at 4.5?? (left inset) and 3?? (right inset) above the mean. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":2242
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) The dimer structure of subunits C (yellow) and B (blue) also show no disulfide bond formation between the Cys61 residues of the two monomers based on the cryoEM density map (Bottom insets). Density maps superimposed with atomic models of two helices from the boxed region, showing no density that can be attributed to disulfide bond formation between the two interacting monomers in this region. The density maps are contoured at 4.5?? (left inset) and 3?? (right inset) above the mean. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) SDS-PAGE analysis of freshly-purified HBV core reveal no disulfide bond formation between core subunits. Lane 1: molecular-weight standards from Bio-Rad. Lane 2: HBV core boiled for 5 minutes under non-reducing condition; no dimer band was observed. Lane 3: HBV core boiled for 5 minutes under reducing condition with 5% (v/v) ??-mercaptoethanol. A 10??g protein sample per lane was loaded and visualized by Coomassie Blue staining."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":2242
          }
        ]
      }
    }
  },
  "793880":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Flow cytometry analysis of intracellular IL-12p40 in MGL2+ dDCs, MGL2???CD103??? skin-derived DCs, and CD103+ dDCs in skin-draining LNs under na??ve or sensitized conditions. MGL2+ dDCs are shown as ???MGL2,??? MGL2???CD103??? DCs are shown as ???DN??? and CD103+ dDCs are shown as ???CD103.??? Cells from na??ve mice are shown as ???Na??ve,??? and cells from sensitized mice are shown as ???Sensitized.??? Areas shaded in gray indicate the staining pattern with an isotype control antibody. The numbers represent the mean fluorescence intensity (MFI) of each skin-derived DC subset. "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":970,
            "y2":642
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The MFI of IL-12p40 for each skin-derived DC subset is shown in panel A in bar graphs. Data are shown as the mean ?? SD of three biological replicates (n???=???3); n.s. indicates that the difference is not statistically significant. (A???B) The experiments were independently performed three times. "
        ],
        "rois":[
          {
            "x":11,
            "y":679,
            "x2":913,
            "y2":1150
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Concentrations of IL-12p40 and IL-12p70 in culture supernatant of MHCIIhighMGL2+ dDCs, MHCIIhighCD103+ dDCs, FITC+MGL2+ dDCs, and FITC+CD103+ dDCs were measured by the Bio-Plex Suspension Array System and are shown in the panels as ???Naive MGL2,??? ???Na??ve CD103,??? ???Sensitized MGL2,??? and ???Sensitized CD103,??? respectively. The experiments were independently performed two times."
        ],
        "rois":[
          {
            "x":9,
            "y":1160,
            "x2":913,
            "y2":1688
          }
        ]
      }
    }
  },
  "79616":{
    
  },
  "79617":{
    
  },
  "79618":{
    
  },
  "79619":{
    
  },
  "79621":{
    
  },
  "79622":{
    
  },
  "79623":{
    
  },
  "79624":{
    
  },
  "79625":{
    
  },
  "79626":{
    
  },
  "79627":{
    
  },
  "79653":{
    
  },
  "79654":{
    
  },
  "79655":{
    
  },
  "79656":{
    
  },
  "796603":{
    "Figure_11.tif":{
      "A":{
        "descriptions":[
          "(A) or subcutaneous "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1144,
            "y2":2254
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) adipose tissue were obtained from Zen-Bio and differentiated as per their instructions for 14 days. A subset of cells were left untreated (control"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1144,
            "y2":2254
          }
        ]
      },
      "C":{
        "descriptions":[
          ", C) or were incubated in media supplemented with macrophage conditioned media (MCM, 5% v/v) or with 100 ng/ml of Tumor necrosis factor alpha (TNF??), Total RNA was isolated and FIP1 and adiponectin mRNA was quantitated by real time PCR as indicated in the methods section. Relative quantification was carried out using the ??????Ct method using PPIA gene expression as an internal control. Statistical analysis: One way ANOVA. * indicates statistical significance pC) Fully differentiated 3T3L1 adipocytes were incubated in the absence (control",
          ", C) or presence of TNF?? (TNF??) or Interleukin 6 (IL6) at 50 ng/ml for 24 hours, Total RNA was isolated and the amount of mRNA for FIP1, or Glut4 was determined by real time PCR. Quantification was carried out using the ??????Ct method using cyclophyllin A as internal control. The graph shows data from a representative experiment of two independent experiments each carried out with triplicate cell dishes for each group. Statistical analysis: One way ANOVA, ** indicates p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1144,
            "y2":2254
          }
        ]
      }
    }
  }
,
  "796858":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Myocardial infarction "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":2692
          }
        ]
      },
      "MI":{
        "descriptions":[
          "(MI) was induced by ligation of left coronary artery (LAC) in mice for 1 week. The mRNA expression of IL-6, IL-8 and CXCL1 was examined by qPCR analysis in the heart. Bar graphs show the relative mRNA levels in p53 KO mice compared with WT mice. Data expressed as mean??SEM (n=5 per group). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cardiac fibroblasts were treated as in Figure 4A. The protein levels of IL-6, IL-11, CXCL1, MCP-1, GCP-2, M-CSF and CXCL2 were measured by Bio-Plex assay kit. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":2692
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cardiac fibroblasts were treated as in Figure 5A. The protein levels of IL-6, IL-11, CXCL1, MCP-1, GCP-2, M-CSF and CXCL2 were measured as in B. Data expressed as mean??SEM (n=3). ***P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":2692
          }
        ]
      }
    }
  },
  "797681":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Secretome comparison of several factors of responders (n=27) and non-responders (n=14) CLI patients; For detection of cytokines, chemokines and growth factors Bio-Plex Pro Human Cytokine 27-plex Assay from Bio-Rad was used. The concentration of each factor was calculated per mg of total proteins in 24 hour conditioned medium. The values of growth factors detected in control medium were deducted from values found in conditioned medium. "
        ],
        "rois":[
          {
            "x":15,
            "y":16,
            "x2":1630,
            "y2":2205
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Relative expression of 15 genes typical for MSCs on the level of proteins. Cell extracts of MSCs in early passage of seven non-responders and eight responders were examined by Proteome Profiler Human Pluripotent Stem Cell Array."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "797798":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          ". E. Effects of the mutations L372R, L375R, and the double mutation L372R/L375R on NR2E3 repression activity (top). Below: Expression levels of wildtype and mutant Gal4DBD???NR2E3LBD determined by immunoblotting."
        ],
        "rois":[
          {
            "x":22,
            "y":1532,
            "x2":968,
            "y2":2159
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Top view of the NR2E3 LBD dimer, showing the close interaction of L372 and L375 (red and orange stick models, resp.) from the helices 10 (cyan) in the dimer interface"
        ],
        "rois":[
          {
            "x":19,
            "y":18,
            "x2":828,
            "y2":875
          },
          {
            "x":1032,
            "y":918,
            "x2":1954,
            "y2":2621
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. A close-up view of the helices 10 in the dimer interface"
        ],
        "rois":[
          {
            "x":1030,
            "y":151,
            "x2":1707,
            "y2":824
          },
          {
            "x":21,
            "y":2171,
            "x2":929,
            "y2":2737
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Size Exclusion Chromatography for Bio-rad Protein Standard (left) and MBP-NR2E3 LBD (right)"
        ],
        "rois":[
          {
            "x":1030,
            "y":151,
            "x2":1707,
            "y2":824
          },
          {
            "x":21,
            "y":2171,
            "x2":929,
            "y2":2737
          },
          {
            "x":18,
            "y":860,
            "x2":935,
            "y2":1459
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Mutation of helix 10 coiled coil interface residues abolished LBD dimerization in a mammalian two hybrid assay. Reporter gene activation by Gal4DBD???NR2E3LBD and VP16AD???NR2E3LBD wildtype and mutant expression plasmids is shown as bar graph. Cells cotransfected with pBIND-Id and pACT-MyoD were used as positive controls"
        ],
        "rois":[
          {
            "x":1030,
            "y":151,
            "x2":1707,
            "y2":824
          },
          {
            "x":21,
            "y":2171,
            "x2":929,
            "y2":2737
          }
        ]
      }
    }
  },
  "797901":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) mRNA were determined by semi-quantitative RT-PCR assay. pgRNA, pregenomic RNA; sRNA, mRNAs encoding envelope proteins; 28S and 18S, 28S and 18S rRNA, respectively; RC, relaxed circular DNA; DSL, double-stranded linear DNA."
        ],
        "rois":[
          {
            "x":10,
            "y":1644,
            "x2":1862,
            "y2":1755
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and cccDNA ",
          "(panel A). The levels of Mx1 "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1864,
            "y2":1090
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were determined by Northern and Southern blot hybridization, respectively. Ribosomal RNAs served as loading controls for the Northern blot hybridization. The amount of DHBV pgRNA was quantified by phosphoimager Quantity One (Bio-Rad) and presented as percentage of pgRNA on day 0 "
        ],
        "rois":[
          {
            "x":10,
            "y":1112,
            "x2":1816,
            "y2":1373
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), OAS1 "
        ],
        "rois":[
          {
            "x":9,
            "y":1394,
            "x2":1806,
            "y2":1505
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and ??-actin "
        ],
        "rois":[
          {
            "x":10,
            "y":1519,
            "x2":1841,
            "y2":1630
          }
        ]
      }
    }
  },
  "797904":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) and cccDNA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1750,
            "y2":2096
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were determined by Northern and Southern blot hybridization, respectively. Ribosomal RNAs served as loading controls for the Northern blot hybridization. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1750,
            "y2":2096
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The amounts of DHBV pgRNA were quantified by phosphoimager Quantity One (Bio-Rad) and plotted as the percentage of mock-treated controls. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1750,
            "y2":2096
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Dstet5 cells were cultured in the presence or absence of tet and mock-treated or treated with the indicated concentrations of apicidin, or TSA for 48 h. Intracellular DHBV mRNAs were analyzed by Northern blot hybridization. Ribosomal RNAs served as loading controls. pgRNA, pregenomic RNA; sRNA, mRNAs encoding envelope proteins; 28S and 18S, 28S and 18S rRNA, respectively; RC, relaxed circular DNA; DSL, double-stranded linear DNA."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1750,
            "y2":2096
          }
        ]
      }
    }
  },
  "798764":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A) Orb expression is downregulated in rin3 ovaries. Confocal analysis of wild type (wt) and homozygous rin3 egg chambers at different stages of oogenesis. Samples were processed in parallel and microscopy was carried out under identical settings. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":373,
            "y2":441
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot analysis of ovarian protein extracts derived from the indicated genotypes and probed with antibodies against Orb, Rin, and ??-tubulin (control). ",
          "(B) using the Quantity One software (Bio-Rad)."
        ],
        "rois":[
          {
            "x":15,
            "y":1059,
            "x2":372,
            "y2":1365
          },
          {
            "x":374,
            "y":1059,
            "x2":681,
            "y2":1365
          },
          {
            "x":15,
            "y":12,
            "x2":1725,
            "y2":748
          },
          {
            "x":812,
            "y":638,
            "x2":1702,
            "y2":1097
          },
          {
            "x":15,
            "y":750,
            "x2":681,
            "y2":1057
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantitation of Orb protein levels shown in "
        ],
        "rois":[
          {
            "x":15,
            "y":1171,
            "x2":1635,
            "y2":1710
          },
          {
            "x":375,
            "y":1367,
            "x2":681,
            "y2":1673
          }
        ]
      }
    }
  },
  "804793":{
    
  },
  "805044":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) determined by 3H-thymidine incorporation (CPM = counts per minute). Cytokines secreted by MOMP-stimulated cells "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":930,
            "y2":2559
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were measured by Bio-Plex assay as described in methods. Dotted bar represents p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":930,
            "y2":2559
          }
        ]
      }
    }
  },
  "807656":{
    
  },
  "808894":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A. Bio-analyzer qualitative analysis of total RNA extracted 72 hours after activation with Phytohemagglutinin (PHA) from CD4+ T lymphocytes (upper panel) and released nanovesicles purified by ExoMir (lower panel). A representative sample is reported"
        ],
        "rois":[
          {
            "x":18,
            "y":18,
            "x2":1332,
            "y2":1458
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Fold change (96 hours compared to 6 hours upon activation with PHA) and SEM of miRNome relative quantities of nanovesicle samples (in biological triplicate) released by CD4+ T lymphocyte. Two profiling platforms were used (as indicated, Applied Biosystems Stem-loop RT-qPCR and Exiqon Locked Nucleic Acid (LNA)-based RT-qPCR) and only miRNAs with a Ct+ T cellular and nanovesicular compartments "
        ],
        "rois":[
          {
            "x":1284,
            "y":47,
            "x2":1954,
            "y2":1435
          }
        ]
      },
      "NV":{
        "descriptions":[
          "(NV) at the indicated time points upon activation with PHA in vitro. Biological triplicates are reported. Distance for hierarchical clustering on significant miRNA: Pearson correlation with average linkage"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D. Hierarchical clustering of Z score values for normalized relative quantities of miRNome from CD4+ T and B lymphocytes and their relative released extracellular nanovesicles. Only the 101 co-expressed miRNAs with a Ct"
        ],
        "rois":[
          {
            "x":18,
            "y":18,
            "x2":1332,
            "y2":1458
          }
        ]
      }
    }
  },
  "8161":{
    "Gkl286f8.jpg":{
      "9":{
        "descriptions":[
          "(9):2536-2549.Published online 10 May 2006PMCID:PMC1459413.?? The Author 2006. Published by Oxford University Press. All rights reserved () EMSA showing that P-labelled mouse NHPPE duplex (5 nM) binds to three nuclear proteins from a mouse NIH 3T3 cell extract (M1???M3) (lane 1). The competitors are: quadruplex 28Rm (lanes 2???4"
        ],
        "rois":[
          
        ]
      },
      "10":{
        "descriptions":[
          ", 10-/50-/100-fold over the labelled duplex probe); quadruplex 32Rh (lanes 5???7",
          ", 10-/50-/100-fold), 4-base mutant 28Rmut (lanes 8???10",
          ", 10-/50-/100-fold), target duplex (10-/50-/100-fold) (lanes 11???13); quadruplex Q1 (for sequences see ) (lane 14, 100-fold excess over probe) (lane 14). The autoradiography was analysed with a Gel Doc 2000 Imager System (Bio-Rad) and the percent OD in bands M1 and M2 respect to total OD in the lane was calculated. Set to 100 the value obtained in lane 1 (control), the values of M1+M2 in lanes 1???14 are 100, 92, 63, 29, 73, 46, 24, 88, 81, 99, 1, 0, 0 and 82, respectively. These values provide a quantitative estimate of the competition capacity of the tested oligonucleotides; () EMSA showing the P-labelled mouse NHPPE duplex (5 nM) binds to two nuclear proteins from human Panc-1 cells (H1 and H2) (lane 1). The competitors are quadruplex 28Rm (lanes 2???5",
          ", 10-/20-/50-/100-fold over the probe); quadruplex 32Rh (lanes 9???10",
          ", 10-/50-/100-fold); quadruplexes Q1 and Q2 (for sequences see ) (lanes 11 and 12, 100-fold excess over probe); quadruplex  (sequence in ) (lanes 13"
        ],
        "rois":[
          {
            "x":3,
            "y":0,
            "x2":480,
            "y2":578
          }
        ]
      },
      "50":{
        "descriptions":[
          ", 50-/100-fold); 4-base mutants 28Rmut (lanes 6???8",
          ", 14, 50-/100-fold); Percent OD in H1 respect to total OD, measured in the lanes 1???14 are 100, 94, 77, 60, 41, 79, 77, 77, 46, 27, 83, 87, 68 and 69; () Southwestern blots showing that 28Rm, but not the 4-base mutant 28Rmut, binds to nuclear proteins of 32, 75 and 115 kDa. The letters H and M on the top panels indicate human and mouse nuclear extracts, respectively. The mobilities of marker proteins are shown on the left."
        ],
        "rois":[
          
        ]
      },
      "14":{
        "descriptions":[
          ", 14, 50-/100-fold); Percent OD in H1 respect to total OD, measured in the lanes 1???14 are 100, 94, 77, 60, 41, 79, 77, 77, 46, 27, 83, 87, 68 and 69; () Southwestern blots showing that 28Rm, but not the 4-base mutant 28Rmut, binds to nuclear proteins of 32, 75 and 115 kDa. The letters H and M on the top panels indicate human and mouse nuclear extracts, respectively. The mobilities of marker proteins are shown on the left."
        ],
        "rois":[
          {
            "x":3,
            "y":0,
            "x2":480,
            "y2":578
          }
        ]
      }
    }
  },
  "816213":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Protein purification by Ni-NTA chromatography of 13 constructs expressed in E. coli BL21 Star. SDS-PAGE (top panel) and Western blot (bottom panel) of purified protein. MW - Bio-rad precision plus protein standards. "
        ],
        "rois":[
          {
            "x":19,
            "y":20,
            "x2":2030,
            "y2":1103
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Estimated protein yield per litre of cell culture after initial Ni-NTA affinity chromatography. N/D - not determined."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "817001":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) and by ELISA in two independent experiments "
        ],
        "rois":[
          {
            "x":19,
            "y":19,
            "x2":781,
            "y2":559
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) ; Results represent the mean and SEM, one-way ANOVA with Bonferroni???s multiple comparison test; **Ppks+ and pks- groups."
        ],
        "rois":[
          {
            "x":27,
            "y":600,
            "x2":2030,
            "y2":2277
          },
          {
            "x":1024,
            "y":19,
            "x2":2030,
            "y2":727
          }
        ]
      }
    }
  },
  "818695":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          "(a) A. indica and "
        ],
        "rois":[
          {
            "x":19,
            "y":27,
            "x2":1005,
            "y2":808
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) pectin Ag NPs."
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1044,
            "y":19,
            "x2":2030,
            "y2":813
          }
        ]
      }
    }
  },
  "818696":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) UV-Vis absorbance spectra, and "
        ],
        "rois":[
          {
            "x":19,
            "y":19,
            "x2":1000,
            "y2":901
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) HDD and ?? potential values of A. indica Ag NPs. "
        ],
        "rois":[
          {
            "x":1047,
            "y":55,
            "x2":2028,
            "y2":826
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) UV-Vis absorbance spectra and "
        ],
        "rois":[
          {
            "x":19,
            "y":961,
            "x2":1001,
            "y2":1843
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) HDD and ?? potential values pectin Ag NPs."
        ],
        "rois":[
          {
            "x":1045,
            "y":997,
            "x2":2029,
            "y2":1790
          }
        ]
      }
    }
  },
  "819531":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1234,
            "y2":471
          }
        ]
      },
      "B":{
        "descriptions":[
          " 20E-induced increase in cAMP levels in MB neurons, as monitored by the cAMP bio-indicator Epac1-camps. Time courses of averaged YFP/CFP ratios in response to vehicle control (blue, N???=???24), 1 mM 20E (orange, N???=???25) and 3 mM 20E (red, N???=???17) are shown, with s.e.m. (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1234,
            "y2":471
          }
        ]
      },
      "P":{
        "descriptions":[
          ", for control (red, N???=???20) and MB-specific DopEcR knockdown (blue, N???=???22) lines. Student's t-test. **; P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1234,
            "y2":471
          }
        ]
      },
      "C":{
        "descriptions":[
          " Averaged YFP/CFP ratios 30 minutes after 20E or vehicle feeding. One-Way ANOVA followed by post-hoc comparisons. ***; PDopEcR RNAi suppressed the 20E-induced increase in cAMP levels in MB neurons. Time courses of averaged YFP/CFP ratios (C)"
        ],
        "rois":[
          {
            "x":1235,
            "y":0,
            "x2":1530,
            "y2":471
          },
          {
            "x":0,
            "y":472,
            "x2":1530,
            "y2":1136
          }
        ]
      },
      "D":{
        "descriptions":[
          ", and the ratios 30 minutes after 20E feeding (D)"
        ],
        "rois":[
          {
            "x":0,
            "y":472,
            "x2":1530,
            "y2":1136
          },
          {
            "x":0,
            "y":1137,
            "x2":1530,
            "y2":1483
          }
        ]
      }
    }
  },
  "819990":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A). The fluorescence emission spectrum was used to determine the origin of each colony. Statistical analysis was performed using a two-tailed t-test. Infected middle ear inferior bullae were analyzed by hematoxylin and eosin staining of thin sections with biofilm (Bio) as well as mucosa "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":894,
            "y2":673
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) and bone "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":894,
            "y2":673
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) highlighted ",
          "(B). 86-028NP that was restricted "
        ],
        "rois":[
          {
            "x":1052,
            "y":7,
            "x2":2012,
            "y2":698
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) for heme-iron was individually inoculated into the chinchilla middle ears. Four days post inoculation, infected middle ear bullae were fixed and processed for histological examination. Scale bar???=???50 ??m."
        ],
        "rois":[
          {
            "x":11,
            "y":798,
            "x2":967,
            "y2":1487
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) or replete "
        ],
        "rois":[
          {
            "x":1052,
            "y":799,
            "x2":2008,
            "y2":1488
          }
        ]
      }
    }
  },
  "819993":{
    "Figure_7.tif":{
      "E":{
        "descriptions":[
          "(E, F) NTHI. Scale bar???=???25 ??m ",
          "(C, D, E). Abbreviations???=???Bone "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":623,
            "y2":450
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E, F) NTHI. Scale bar???=???25 ??m ",
          "(F), 100 ??m "
        ],
        "rois":[
          {
            "x":706,
            "y":7,
            "x2":1342,
            "y2":1438
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). Histopathology was assessed by examination of hematoxylin and eosin stained thin sections of na??ve "
        ],
        "rois":[
          {
            "x":14,
            "y":974,
            "x2":654,
            "y2":1438
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M), biofilm (Bio). Arrows denote capillaries."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":623,
            "y2":450
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or infected middle ear bullae 7 days following introduction of heme-iron replete ",
          "(B), 50 ??m ",
          "(B), mucosa "
        ],
        "rois":[
          {
            "x":14,
            "y":974,
            "x2":654,
            "y2":1438
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C, D) or restricted ",
          "(C, D, E). Abbreviations???=???Bone "
        ],
        "rois":[
          {
            "x":11,
            "y":484,
            "x2":654,
            "y2":950
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C, D) or restricted ",
          "(C, D, E). Abbreviations???=???Bone "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "820326":{
    
  },
  "820327":{
    
  },
  "820328":{
    
  },
  "820418":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) P1 from CT-intoxicated cells was incubated with buffer, CE, or CE heat-inactivated (h.i.) at 65 or 95 degrees. The resulting S2??? were analyzed by immunoblotting with the indicated antibodies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2472,
            "y2":1674
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 1 ml CE was subjected to size exclusion chromatography by passage through a Bio-Sil SEC 250 column. The indicated even fractions were collected and used to generate S2??? from CT-intoxicated P1. Fractions were also directly analyzed for protein content by immunoblotting with the indicated antibodies (bottom panels). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2472,
            "y2":1674
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) As in A, except P1 derived from epoxomicin-treated cells expressing TCR??-HA was used. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2472,
            "y2":1674
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) 1 ml CE was subjected to size exclusion chromatography by passage through a Bio-Sil SEC 250 column. The indicated odd fractions were collected and used to generate S2??? from P1 derived from epoxomicin-treated cells expressing TCR??-HA. S2??? were treated with PNGase F prior to SDS-PAGE. Fractions were also directly analyzed for protein content by immunoblotting with the indicated antibodies (bottom panels)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2472,
            "y2":1674
          }
        ]
      }
    }
  },
  "820495":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "Panel A:  Amino acid sequences of the native STa toxin and the STaA14Q toxoid"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":979,
            "y2":187
          }
        ]
      },
      "NE":{
        "descriptions":[
          ", NE)",
          ", NE).  Extracted 6xHis-tagged protein form fusion strain 9164 and total protein extracts from negative control strain 8955 were examined in the SDS-PAGE.  Lane M is the protein marker (Precision Plus Protein Pre-stained standards, Bio-Rad, Hercules"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ".   Panel B: Construction of the 3xSTaA14Q-tmLT toxoid fusion gene with 3 copies of the STaA14Q toxoid gene genetically fused at the 5??? end, within LTA, and the 3??? end of the tmLT toxoid gene (LTS63K/R192G/L211A).  The numbers and arrows indicated primers used in PCRs to mutate the genes and to amplify fragments to be overlapped for a single open reading frame encoding the 3xSTaA14Q-tmLT toxoid fusion.  This chimeric toxoid fusion gene was cloned in vector pET28?? and expressed in E. coli BL21 as a 6xHis-tagged fusion protein.  The drawing scale is not in proportion to nucleotide fragment sizes"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":979,
            "y2":187
          }
        ]
      },
      "C":{
        "descriptions":[
          ".  Panel C: Detection of 6xHis-tagged 3xSTaA14Q-tmLT toxoid fusion protein in Western blot using 12% PAGE gel, with rabbit anti-CT antiserum (1:3300; Sigma) and IRDye-labeled goat anti-rabbit IgG (1:5000; LI-COR, Lincoln"
        ],
        "rois":[
          {
            "x":0,
            "y":188,
            "x2":979,
            "y2":553
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA)."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ".  Panel D: Detection of the toxoid fusion protein with purified rabbit anti-STa antiserum (1:5000) and IRDye-labeled goat anti-rabbit IgG (1:5000; LI-COR, Lincoln"
        ],
        "rois":[
          {
            "x":0,
            "y":188,
            "x2":979,
            "y2":553
          }
        ]
      }
    }
  },
  "820716":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          ". E) Flag-tagged Smad3 and Smad1 proteins were specifically bound by a 14 aa-long sequence represented by the A6 aptamer (sequence in red in panel A), and comprehending the tandem repeat (QxVx)2 (for details, see main text). The activation of the TGF?? family pathway was assessed using p-p38MAPK or pAKT levels; Tubulin detection was used as loading control. Panel B was acquired using a Digital Chemiluminescence System (Bio-Rad; see Materials and Methods)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2449,
            "y2":2937
          }
        ]
      },
      "A":{
        "descriptions":[
          "A) Sip1 SBD sequence conservation in five different vertebrates, and schematic representation of the peptide aptamers used in this study. The numbering shown for the aptamers at the right applies to the mouse protein sequence; the histograms reflect strong versus weaker conservation amongst the animal species. The aptamer A1 represents the insert in the Trx protein scaffold of the entire 51 aa-long SBD, as defined previously [12]; the aptamers A2???A8 are C- and/or N- terminal truncations of A1. B???D) Co-IP experiments in extracts from transfected HEK293T cells show that both TGF?? "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2449,
            "y2":2937
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and BMP "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2449,
            "y2":2937
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,D) activated (Flag-tagged) Smads bind only to the aptamers A1, A3 and A4, indicating that the shared region shared between A3 and A4 is responsible for the interaction"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2449,
            "y2":2937
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C,D) activated (Flag-tagged) Smads bind only to the aptamers A1, A3 and A4, indicating that the shared region shared between A3 and A4 is responsible for the interaction"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2449,
            "y2":2937
          }
        ]
      }
    }
  },
  "820723":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(panel A) or c.a.Alk4 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1610,
            "y2":3129
          }
        ]
      },
      "B":{
        "descriptions":[
          "(panel B) receptor. Increasing concentrations of Sip1 WT plasmid result in a down regulation of BMP or TGF?? induced gene response, effect that is attenuated by co-transfection of the c.a.Alk3/Alk4 encoding plasmids. On the other hand, the Smad binding mutant Sip1(AxAx)2 is no longer able to repress such gene response. Blots show the expression levels of the Sip1 (WT and mutant) encoding plasmids transfected. Images were acquired using a Digital Chemiluminescence System (Bio-Rad)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "824611":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E), TNF-?? "
        ],
        "rois":[
          {
            "x":26,
            "y":1111,
            "x2":400,
            "y2":1399
          },
          {
            "x":718,
            "y":1111,
            "x2":1345,
            "y2":1399
          },
          {
            "x":392,
            "y":1187,
            "x2":654,
            "y2":1399
          },
          {
            "x":700,
            "y":381,
            "x2":1331,
            "y2":708
          },
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), IL-5 "
        ],
        "rois":[
          {
            "x":718,
            "y":1111,
            "x2":1345,
            "y2":1399
          },
          {
            "x":392,
            "y":1187,
            "x2":654,
            "y2":1399
          },
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          },
          {
            "x":14,
            "y":719,
            "x2":654,
            "y2":1089
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), IL-1?? "
        ],
        "rois":[
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          },
          {
            "x":13,
            "y":12,
            "x2":655,
            "y2":303
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) and IL-6 "
        ],
        "rois":[
          {
            "x":392,
            "y":1187,
            "x2":654,
            "y2":1399
          },
          {
            "x":1010,
            "y":719,
            "x2":1336,
            "y2":983
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), IL-8 "
        ],
        "rois":[
          {
            "x":26,
            "y":1111,
            "x2":400,
            "y2":1399
          },
          {
            "x":718,
            "y":1111,
            "x2":1345,
            "y2":1399
          },
          {
            "x":698,
            "y":12,
            "x2":1327,
            "y2":364
          },
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), IL-9 "
        ],
        "rois":[
          {
            "x":26,
            "y":1111,
            "x2":400,
            "y2":1399
          },
          {
            "x":718,
            "y":1111,
            "x2":1345,
            "y2":1399
          },
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) by using the Bio-Plex 27-plex human cytokine kit from BioRad according to the manufacturer???s protocol. Measurements were performed on individual hFF samples diluted (1:2) using the standard curves optimization and the calculation of analyte concentrations of the Bio-Plex Manager software. Data are reported as scatter plots and average concentrations. * p-value ??? 0.1; ** p-value??? 0.05; *** p-value ??? 0.01  FF+ versus FF- dataset."
        ],
        "rois":[
          {
            "x":699,
            "y":783,
            "x2":1015,
            "y2":1089
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), IL-12 "
        ],
        "rois":[
          {
            "x":26,
            "y":1111,
            "x2":400,
            "y2":1399
          },
          {
            "x":718,
            "y":1111,
            "x2":1345,
            "y2":1399
          },
          {
            "x":698,
            "y":12,
            "x2":1327,
            "y2":364
          },
          {
            "x":14,
            "y":332,
            "x2":650,
            "y2":708
          }
        ]
      }
    }
  },
  "824612":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E) and RANTES "
        ],
        "rois":[
          {
            "x":314,
            "y":53,
            "x2":651,
            "y2":303
          },
          {
            "x":15,
            "y":676,
            "x2":331,
            "y2":985
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) by using the Bio-Plex 27-plex human cytokine kit from BioRad according to the manufacturer???s protocol. Measurements were performed on individual hFF samples diluted (1:2) using the standard curves optimization and the calculation of analyte concentrations of the Bio-Plex Manager software. Data are reported as scatter plots and average concentrations. ** p-value??? 0.05 FF+ versus FF- dataset."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A), IP-10 "
        ],
        "rois":[
          {
            "x":13,
            "y":12,
            "x2":334,
            "y2":364
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), MIP-1?? "
        ],
        "rois":[
          {
            "x":699,
            "y":12,
            "x2":1335,
            "y2":305
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), MIP-1?? "
        ],
        "rois":[
          {
            "x":13,
            "y":12,
            "x2":334,
            "y2":364
          },
          {
            "x":314,
            "y":53,
            "x2":651,
            "y2":303
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), MCP-1 "
        ],
        "rois":[
          {
            "x":26,
            "y":426,
            "x2":329,
            "y2":637
          },
          {
            "x":314,
            "y":53,
            "x2":651,
            "y2":303
          },
          {
            "x":327,
            "y":713,
            "x2":654,
            "y2":985
          },
          {
            "x":700,
            "y":676,
            "x2":1335,
            "y2":983
          },
          {
            "x":698,
            "y":332,
            "x2":1334,
            "y2":635
          },
          {
            "x":320,
            "y":363,
            "x2":658,
            "y2":637
          }
        ]
      }
    }
  },
  "825293":{
    
  },
  "827048":{
    
  },
  "827121":{
    
  },
  "830756":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) NIH3T3 cells were plated on COL I-coated glass slides and cultured in DMEM at 31??C, 37??C, and 43??C and in CO2-independent medium (CO2-IDM) at 31??C and 37??C. The results were expressed as the mean ?? SEM by scatter dot plot. Gray symbols represent the detailed experimental data. ***ppp"
        ],
        "rois":[
          {
            "x":0,
            "y":694,
            "x2":2590,
            "y2":1803
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) flat tip, and "
        ],
        "rois":[
          {
            "x":0,
            "y":694,
            "x2":2590,
            "y2":1803
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) NIH3T3 cells and 7-4 cells were plated on type I collagen (COL I)-coated glass slides overnight. The effective Young's moduli (Eeff) of cells were measured by Bio-AFM with a pyramidal tip (labeled as P in ",
          "(A)), flat tip (labeled as F in ",
          "(A)), and 5 ??m-bead-modified tip (labeled as B in ",
          "(A)) with a 1 nN indenting force at 1 ??m/sec approach velocity. To determine the effect of the indenting force at the same loading rate, cells were plated on COL I-coated glass slides overnight. The Eeff of cells were measured by Bio-AFM with a "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2590,
            "y2":693
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 5 ??m-bead-modified tip with different indenting force (0.2, 0.5 or 1 nN). To evaluate the effect of operating temperatures, "
        ],
        "rois":[
          {
            "x":0,
            "y":694,
            "x2":2590,
            "y2":1803
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) pyramidal tip, "
        ],
        "rois":[
          {
            "x":0,
            "y":694,
            "x2":2590,
            "y2":1803
          }
        ]
      }
    }
  },
  "830757":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) The cells were cultured in DMEM or CO2-IDM supplemented with or without 10% FBS at 37??C, respectively. The effective Young???s moduli (Eeff) of cells were assessed by the Bio-AFM. The results are showed in scatter dot plot by mean with standard error "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":2608,
            "y2":1420
          }
        ]
      },
      "SE":{
        "descriptions":[
          "(SE). **p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "830758":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) NIH3T3 cells were plated onto glass slides coated with various substrates (PLL, poly-L-Lysine; FN, fibronectin; COL I, type I collagen; COL IV, type IV collagen; GEL; gelatin) overnight. "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":927,
            "y2":881
          },
          {
            "x":1066,
            "y":9,
            "x2":2624,
            "y2":466
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) To evaluate the effect of substrate concentration on the effective Young???s moduli (Eeff) of cells, cells were plated onto glass slides coated with COL I of various concentrations (50, 100, or 1000 ??g/ml). "
        ],
        "rois":[
          {
            "x":16,
            "y":832,
            "x2":612,
            "y2":1516
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) To evaluate the effect of substrate compliance, cells were plated onto culture dish ",
          "(C), collagen gel-coated dish (Co), and collagen gel "
        ],
        "rois":[
          {
            "x":630,
            "y":875,
            "x2":992,
            "y2":1407
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G). The Eeff of cells were assessed by Bio-AFM. The results were expressed as the mean ?? SEM by scatter dot plot. Gray symbols represent the detailed experimental data. ***pp"
        ],
        "rois":[
          {
            "x":630,
            "y":875,
            "x2":992,
            "y2":1407
          },
          {
            "x":1062,
            "y":477,
            "x2":2624,
            "y2":1518
          }
        ]
      }
    }
  },
  "830765":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) NIH3T3 cells and "
        ],
        "rois":[
          {
            "x":10,
            "y":12,
            "x2":841,
            "y2":763
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MDCK cells were plated onto COL I-coated glass slides at densities of 5, 50, or 500 cells/mm2 overnight. The effective Young???s moduli (Eeff) of cells were assessed by Bio-AFM. The results were expressed as the mean ?? SEM by scatter dot plot. Gray symbols represent the detailed experimental data. (***p2. The immunofluorescence results are represented as F-actin (red) and nuclei (blue). "
        ],
        "rois":[
          {
            "x":837,
            "y":28,
            "x2":1434,
            "y2":644
          },
          {
            "x":15,
            "y":927,
            "x2":696,
            "y2":1680
          },
          {
            "x":788,
            "y":680,
            "x2":2556,
            "y2":1323
          },
          {
            "x":721,
            "y":1334,
            "x2":1433,
            "y2":1880
          },
          {
            "x":1444,
            "y":1334,
            "x2":2553,
            "y2":1940
          },
          {
            "x":1440,
            "y":9,
            "x2":2555,
            "y2":664
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) AFM surface topological images in living MDCK cells and confocal immunofluorescence images of F-actin (red), ??-tubulin (green), and the nucleus (blue) in stained MDCK cells that were cultured at densities of 5, 50, or 500 cells/mm2, respectively. (Scale bar???=???10 ??m)."
        ],
        "rois":[
          {
            "x":10,
            "y":12,
            "x2":841,
            "y2":763
          }
        ]
      }
    }
  },
  "831408":{
    
  },
  "833427":{
    
  },
  "834532":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A). Levels of IFN-??/?? (left panel) were measured by ELISA on day 1 p.i., while IFN-?? (right panel) was measured by Bio-Plex at various days p.i. "
        ],
        "rois":[
          {
            "x":33,
            "y":1459,
            "x2":839,
            "y2":2070
          },
          {
            "x":1679,
            "y":85,
            "x2":2489,
            "y2":711
          },
          {
            "x":16,
            "y":742,
            "x2":2506,
            "y2":2074
          },
          {
            "x":828,
            "y":90,
            "x2":1629,
            "y2":709
          },
          {
            "x":9,
            "y":9,
            "x2":789,
            "y2":706
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Data are expressed as mean ?? SEM of four to six animals/group and represents one of two independent experiments. *P???/??? mice to infected WT mice."
        ],
        "rois":[
          {
            "x":14,
            "y":2070,
            "x2":812,
            "y2":2781
          },
          {
            "x":841,
            "y":2155,
            "x2":1633,
            "y2":2783
          }
        ]
      }
    }
  },
  "838111":{
    "Figure 3.tif":{
      "A":{
        "descriptions":[
          "(A) and NF-kB "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1601,
            "y2":1132
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) activation after 12 min stimulation with TNF?? (10 ng/ml), with or without BXL-01-0029 (10???8 M). TNF?? induced JNK and NF-kB phosphorylation; BXL-01-0029 impaired JNK activation and prevented NF-kB phosphorylation (upper A and B); total JNK and NF-kB were used as loading control (middle A and B). Lower A and B report densitometric analysis (*P#P???8 M). TNF?? and BXL-01-0029 induced ERK1/2 phosphorylation (*P#P???8 M) after 24 h incubation; *P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1601,
            "y2":1132
          }
        ]
      }
    }
  },
  "838114":{
    
  },
  "840926":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) NgBR knockdown diminished estradiol-induced survivin expression in MCF-7 breast tumor cells. MCF-7 cells were treated with 10 nM estradiol for 6 and 48 hours. Protein levels of NgBR and survivin were determined by Western blot analysis. Beta-Actin is applied as a housekeeping protein. The density of each band was measured using NIH ImageJ and presented as relative intensity of survivin after normalized with beta-actin housekeeping protein. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2098,
            "y2":2921
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Folds of survivin increase were determined by measuring relative western blot intensity of survivin. Data is presented as fold changes of estradiol treatment group as compared to the non-treatment group (n???=???3; 6 hrs estradiol treatment, NS vs siNgBR p???=???0.178; * 48 hrs estradiol treatment, NS vs siNgBR ppp"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2098,
            "y2":2921
          }
        ]
      }
    }
  },
  "842881":{
    "Figure_3.tif":{
      "SE":{
        "descriptions":[
          "(SE) of A) browsers"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ", B) grazers/detritivores"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ", C) large excavators/bio-eroders and D) scrapers/small excavators per island. Mean biomass per groups was calculated by pooling all sites surveyed per island. Ofu & Olo???=???Ofu & Olosega."
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":1951,
            "y2":1954
          }
        ]
      }
    }
  },
  "842882":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) encrusting algae and grazers/detritivores (solid points, solid line), "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":687,
            "y2":675
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) fleshy macroalgae and grazers/detritivores (solid points, solid line), "
        ],
        "rois":[
          {
            "x":745,
            "y":9,
            "x2":1218,
            "y2":675
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) hard coral and large excavators/bio-eroders (hollow points, dashed line), and "
        ],
        "rois":[
          {
            "x":10,
            "y":766,
            "x2":1218,
            "y2":1532
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) turf algae and grazers/detritivores (solid points, solid line) and large excavators/bioeroders (hollow points, dashed line)."
        ],
        "rois":[
          {
            "x":10,
            "y":766,
            "x2":1218,
            "y2":1532
          }
        ]
      }
    }
  },
  "843705":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Tissue-specific gene expression pattern of daw. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":329,
            "y2":738
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Tissue-specific distribution of transcription factor Smox using 7-day-old Oregon R females. (C???E) Lifespan analysis of Activin signaling using muscle-specific Gal4 driver (MHC-Gal4). Lifespan was extended by inactivating Activin genes (daw, Smox and babo) in muscle (Log-rank test, pdaw and Smox) shortens lifespan (Log-rank test, pTable S4 for survival analysis. "
        ],
        "rois":[
          {
            "x":330,
            "y":0,
            "x2":2897,
            "y2":738
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I, J) mRNA expression of daw and phosphorylation of Smox are down-regulated by chico mutation and rescued by mutation of dFOXO. Muscle and fat body were dissected from 7-day-old female wildtype, chico???/??? and chico;foxo double mutants. Band intensity was quantified using Bio-Rad Image Lab software. The average band intensity from four independent experiments is shown. Asterisk indicates significant difference between treatment and control (p"
        ],
        "rois":[
          {
            "x":0,
            "y":739,
            "x2":2897,
            "y2":4809
          }
        ]
      },
      "J":{
        "descriptions":[
          "(I, J) mRNA expression of daw and phosphorylation of Smox are down-regulated by chico mutation and rescued by mutation of dFOXO. Muscle and fat body were dissected from 7-day-old female wildtype, chico???/??? and chico;foxo double mutants. Band intensity was quantified using Bio-Rad Image Lab software. The average band intensity from four independent experiments is shown. Asterisk indicates significant difference between treatment and control (p"
        ],
        "rois":[
          {
            "x":0,
            "y":739,
            "x2":2897,
            "y2":4809
          }
        ]
      }
    }
  },
  "843861":{
    
  },
  "843965":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. Coprecipitation of catalytic subunit of protein phosphatase 1 (PP1) and RGS18 in platelets. Washed human platelets were incubated without or with forskolin (10 ??M, 30min) or thrombin (0.1 U/ml, 30sec). Platelets were lysed and endogenous RGS18 was precipitated with rabbit anti-RGS18 antibody (LS-Bio). After SDS-PAGE and Western blotting, blots of precipitates were incubated with mouse anti-PP1 (upper panel, PP1) and subsequently with mouse anti-RGS18 (middle panel). Lysate blots were incubated with mouse anti-PP1 (lower panel, total PP1)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1931,
            "y2":3176
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Quantitation of results shown in A. Relative intensities of PP1 bands were normalized to the non-stimulated value. To control for loading, these values were divided by corresponding total PP1 and RGS18 values, which had also been normalized to the non-stimulated value. Shown are means +SEM of three independent experiments. Statistical significance was assessed using paired Students t-test comparing non-stimulated and thrombin treated samples, *p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1931,
            "y2":3176
          }
        ]
      }
    }
  },
  "844918":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A) Schematic representation of the human HMGB1 structure showing Box A, Box B and the acidic tail motifs. Both boxes are rich in positive amino acid residues (+), whereas the acidic tail is exclusively composed of acidic amino acid residues (-) (residues 186-215). The removal of the acidic tail generated a truncated construct (HMGB1??C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1616,
            "y2":1327
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Two micrograms of HMGB1 and HMGB1??C were separately applied onto a 15% SDS-PAGE. In a third lane, 5 ??L the pre-stained molecular weight standards (Bio-Rad) were applied. The gel was stained by Coomassie Blue G-250 dye and"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1616,
            "y2":1327
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Western blotting with anti-human HMGB1 to confirm the recombinant protein identity. The 6His-Tag was not removed."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1616,
            "y2":1327
          }
        ]
      }
    }
  },
  "846368":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          ". E. Expression profiles of SMCP variant 1 and variant 2 in the testis and cancer cells. SMCP mRNA expression was investigated by RT-PCR using an F1 and F2 mixture primer as a forward primer and R1 primer as a reverse primer in testis and cancer cells. Variant 1 was a 152-bp PCR product, and variant 2 was a 624-bp PCR product"
        ],
        "rois":[
          {
            "x":0,
            "y":878,
            "x2":2235,
            "y2":2927
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. Expression of SMCP protein. Detection of SMCP protein in HEK293T cells transfected with expression vectors of variant1 CDS and variant2 as assessed by Western blot analysis with polyclonal SMCP antibody. Beta-actin was used as a protein loading control."
        ],
        "rois":[
          {
            "x":0,
            "y":878,
            "x2":2235,
            "y2":2927
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. SMCP expression profiles in normal human organs. SMCP mRNA expression in normal tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, leukocyte, colon, stomach and bone marrow) was investigated by RT-PCR. cDNAs were obtained from TAKARA BIO INC. (Human Multiple Tissue cDNA Panels I and II). GAPDH was used as an internal positive control"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2235,
            "y2":353
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. SMCP expression profiles in human cancer cells. SMCP mRNA expression in lung cancer line cells (Sq-1, Lc817, 86-2, Lu99, 1-87, A549), renal cancer line cells (Caki-1, ACHN, SMKTR1, SMKTR2, SMKTR3, SMKTR4) and pancreas cancer line cell (HPC3) was investigated by RT-PCR. cDNAs were generated by total RNAs derived from cell lines. GAPDH was used as an internal positive control"
        ],
        "rois":[
          {
            "x":0,
            "y":354,
            "x2":2235,
            "y2":877
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. SMCP expression profiles in human lung cancer tissues. SMCP mRNA expression in human lung cancer tissues was investigated by RT-PCR. #1 and #2 are adenocarcinoma cases. #3 and #4 are squamous cell carcinoma cases. #5 is a large cell carcinoma case. T indicates lung cancer tissue. N indicates adjacent lung normal tissue. GAPDH was used as an internal positive control"
        ],
        "rois":[
          {
            "x":0,
            "y":878,
            "x2":2235,
            "y2":2927
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Schema of novel variant form of SMCP. SMCP wild type (variant 1) is composed of exon 1 and exon 2. The novel isoform of SMCP (variant 2) has only one exon with a 5??? terminal additional extension"
        ],
        "rois":[
          {
            "x":0,
            "y":878,
            "x2":2235,
            "y2":2927
          }
        ]
      }
    }
  },
  "847534":{
    
  },
  "847551":{
    
  },
  "850517":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A). Expression ratio of SRSF11???s three isoforms in seven disease sample and control: uc009wbj.1 (light green), uc001deu.2 (light blue) and uc001.dev.3 (light red). They have almost the same total expression levels but very different ratios in MDS (four ) and control (average of five controls), which means the splicing patterns of SRSF11 are switched. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2734,
            "y2":1902
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). This figure demonstrates motifs in SRSF11???s isoforms and classical SR proteins. Different motifs have different bio-function. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2734,
            "y2":1902
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Three isoforms that are over-expressed in our disease samples are picked up for RT-PCR validation. They are isoforms of three splicing factor, one isoform (uc001deu.2, refseq ID: NM_001190987) of SRSF11, one isoform (uc001xlp.3, refseq ID: NM_006925) of SRSF5 and one isoform (uc003jun.2, refseq ID:NM_080743) of SRSF12. Validation demonstrated that their expression levels in MDS disease are higher than in control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2734,
            "y2":1902
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Isofrom uc001deu.2 is translated into protein Q05519 and Q05519 is highly expressed in blood disease according to the Model Organism Protein Expression Database (MOPED); COPD: Chronic obstructive pulmonary disease."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2734,
            "y2":1902
          }
        ]
      }
    }
  },
  "850720":{
    
  },
  "858532":{
    
  },
  "860019":{
    
  },
  "860023":{
    
  },
  "862250":{
    "Figure_6.tif":{
      "B":{
        "descriptions":[
          ", B,) GCPs were treated with WNT3 for 24 h and lysates analyzed by Western blot analysis. ",
          "(B) Immunoblotting using anti-Phospho"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1582,
            "y2":793
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Immunoblotting of GCP lysates with anti-active-??-catenin (Ac-??-cat) antibody showed that WNT3 did not induce  ??-catenin activation. The GSK-3 inhibitor BIO was used as positive control to increase activated ??-catenin and activated ??-catenin levels were compared to total ??-catenin levels, using anti-??-catenin antibody (n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1582,
            "y2":793
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P)-216-GSK-3??, anti-GSK-3?? and anti-MYCN antibodies showed that WNT3 does not regulate ??-catenin signaling. GAPDH was used as loading control. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Using a Luciferase assay, WNT3 fails to activate ??-catenin signaling, which is reported by the expression of pTOPflash luciferase driven by the TCF/LEF promoter. LiCl was used as a positive control to activate ??-catenin signaling. Data represent the mean ?? s.e.m.: *p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1582,
            "y2":793
          },
          {
            "x":1583,
            "y":0,
            "x2":1867,
            "y2":793
          }
        ]
      }
    }
  },
  "862294":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Protein extracts were immunoblotted for key signaling proteins involved in the Wnt pathway regulation; GSK-3, Active and total ??-catenin with GAPDH used as a loading control, (Representative gel images shown, n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":979,
            "y2":1469
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Self-renewal potential was assessed by the percentage of colonies staining positive for alkaline phosphatase "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":979,
            "y2":1469
          }
        ]
      },
      "AP":{
        "descriptions":[
          "(AP) is given (Mean + SEMs, n=3 * p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "862296":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Relative gene expression profile TaqMan?? Mouse Stem Cell Pluripotency Array of mRNA harvested from DP-??C (+/- Tet) or E14 ES cells (+/- 5 ??M BIO) following 72 and 96 hours without LIF. Relative expression of each gene calibrated to untreated controls (-DP-??C or -BIO) using the 2 ???????CT method, plotted on a log scale with a relative expression of 1 representing no change to gene expression (Mean + SEMs, n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1594,
            "y2":875
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Semi-quantitative RT-PCR for DP-??C (+/- Tet) and E14 ES cells (+/- 5 ??M BIO, +/- 5 ??M & 10 ??M XAV) following 72 and 96 hours without LIF. (Representative gel images shown, n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":876,
            "x2":1594,
            "y2":2075
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) FACS plots confirming higher levels of Sox2, Oct3/4, Nanog or Brachyury over 72 and 96 hours following DP-??C or BIO treatment without LIF for 96 hours compared to control cells (Representative images shown, n=2)."
        ],
        "rois":[
          {
            "x":0,
            "y":876,
            "x2":1594,
            "y2":2075
          }
        ]
      }
    }
  },
  "862297":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) In addition IP was performed using Brachyury or Stat3 antibody on the sonicated chromatin material. The primer sets were designed on regions flanking the Brachyury binding sites (Start -4875 to Start -4476) and Stat 3 binding sites (Start -4875 to Start -4668) on the Nanog enhancer region. Quantitative PCR was performed to measure the relative enrichment (Mean fold enrichment, +/- SEM, n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Flow cytometry analysis indicating short-term activation of ??-catenin signalling (DP-??C or BIO) rapidly up-regulates Brachyury prior to any significant changes in Nanog levels (Representative images shown, n=2)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Protein extracts from DP-??C (+/- Tet) and E14 ES cells +/- BIO) following 96 hour culture in no LIF were immunoblotted to measure levels of active and total ??-catenin, TCF/LEF, Brachyury, pStat3, total Stat3 and Nanog with GAPDH used as the loading control.  Representative gel images shown, n=3. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Flow cytometry showing higher percentage of cells were positive for both Nanog and Brachyury following DP-??C or BIO treatment without LIF for 96 hours compared to control cells (Representative images shown, n=2). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Immunofluorescence to show up regulation of self-renewal markers Nanog or Stat3 and mesodermal marker Brachyury following DP-??C expression or BIO treatment. Representative images shown, n=3. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Chromatin Immunoprecipitation was performed on DP-??C (+/- Tet) and E14 ES cells (-/+ BIO) cultured in the absence of LIF for 96 hours. The cells were harvested and IP was performed on the sonicated chromatin material using the TCF/LEF antibody sampler kit. The primer sets were designed on regions flanking the TCF/LEF binding sites (Start -597 to Start -368 on the Brachyury promoter). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":1275
          }
        ]
      }
    }
  },
  "862298":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic diagram of the different differentiation stages examined. CONDITION 1 early differentiation, CONDITION 2 Hemangioblast/Early hematopoietic progenitors, CONDITION 3 MPP, MEP and GMP differentiation, CONDITION 4 Myeloid colony formation. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1280,
            "y2":979
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) QRT-PCR demonstrating activation of the canonical Wnt signaling (DP-??C or E14 ES cells + BIO) up-regulates key genes important for establishing early hematopoietic commitment, primitive erythroid specification and embryonic/fetal globin genes during differentiation induction in the absence of LIF (CONDITION 1). Control cells (DP-??C + tet or E14 ES cells -BIO) were used as calibrators and the fold change was calculated using the 2 ???????CT method (Mean of fold change +/- SEM, n=3). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1280,
            "y2":979
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Cells were directed to form EB???s and then cultured in M3434 to promote primitive erythroid colony formation and colonies scored. Active ??-catenin signalling (DP-??C or BIO) resulted in a significant increase in primitive erythroid colonies (Mean %, +/- SEM, n=3)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "862300":{
    "Figure__5.tif":{
      "i":{
        "descriptions":[
          "(i) Scoring of the number of BL-CFC compared to the number of EB???s for each condition by day 8 of differentiation shows activation of the canonical Wnt pathway (DP-??C or BIO) results in higher percentage of BL-CFC compared to control cultures (Mean %, +/- SEM, n=3). ",
          "(i) Total cell population from CONDITION 2 were analyzed for key HSC markers Sca1 and c-Kit by flow cytometry. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2048,
            "y2":964
          }
        ]
      },
      "ii":{
        "descriptions":[
          "(ii) Hemangioblasts/Early hematopoietic progenitors (CONDITION 2) were analysis for expression of mesodermal markers Flk1 and Brachyury by flow cytometry. (iii) RT-PCR analysis of key self-renewal and differentiation genes. (B) Flow cytometry analysis was performed on the hemangioblast/early hematopoietic progenitors to determine the percentage of cells expressing CD41, CD45, c-Kit, Sca1 and Flt3. Gating on the CD41+, CD45+ population revealed that these early hematopoietic progenitors also expressed the HSC markers Sca1 and c-Kit (Representative images shown, n=3). (C) ",
          "(ii) The early hematopoietic progenitor populations (Sca1+c-Kit+ cells) were sorted and Immunofluorescence performed to confirm higher levels of total and active ??-catenin in DP-??C ???tet and E14 cells + BIO. (iii) RT-PCR analysis of key hematopoietic genes within the Sca-1+c-kit+ hematopoietic progenitor cells and "
        ],
        "rois":[
          
        ]
      },
      "iv":{
        "descriptions":[
          "(iv) erythroid/globin genes.  The control cells (DP-??C + tet or E14 ES cells -BIO) were used as calibrators and the fold change was calculated using the 2 -????CT method (Mean of fold change +/- SEM, n=3). "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "862301":{
    "Figure__6.tif":{
      "A":{
        "descriptions":[
          "(A) Cells from CONDITION 2 of the differentiation, (DP-??C +/- Tet and E14 ES cells +/- BIO) were cultured in a MPP cocktail for 7 days prior to multi-parameter flow cytometry analysis of total cell population from CONDITION 3.  Live cells from CONDITION 3 of the differentiation were gated and the expression of the hematopoietic progenitor markers, Sca1hic-Kitlo and Sca1loc-Kithi were profiled along with the megakaryocytic marker CD41 and transferrin receptor CD71. ",
          "(A). Images are representative of 3 independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1406,
            "y2":750
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MPP population (CONDITION 3) were then replated for an additional 7 days and analyzed for the same panel of markers outlined in "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "862304":{
    "Figure__7.tif":{
      "A":{
        "descriptions":[
          "(A) Cells from CONDITION 2 of the differentiation, were directed to undergo myeloid colony formation and the number of GM-CFU, GEMM, and BFU-E colonies counted-CONDITION 4. Graph represents the Mean % +/- SEM, n=3. Representative pictures of hematopoietic colonies x 10 magnification, scale bar 100 ??M. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":964,
            "y2":912
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gene expression profiling of erythroid and myeloid genes. The control cells (DP-??C +Tet or E14 ES cells -BIO) were used as calibrators and the fold change was calculated using the 2 ???????CT method (Mean of fold change +/- SEM, n=3). "
        ],
        "rois":[
          {
            "x":141,
            "y":1025,
            "x2":971,
            "y2":1622
          }
        ]
      }
    }
  },
  "865250":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) SDS-PAGE analysis (Any-kD TGX gel, Bio-Rad) of small-scale expression and affinity purification of His6???tagged proteins: lanes 1???3, EsxGHms complex; lanes 4???6, EsxOPmt complex; lanes 7???9, EsxTUmt complex; and lanes 10???12, EsxEFmt complex. The first lane for each complex is expression of the complex from the pMA507 vector with the His6 tag alone on the N-terminus of the CFP-10 homolog, the second lane is the complex expressed from pMA510 which expresses the CFP-10 homolog with an N-terminal MBP-His6 fusion (indicated by an asterisk), and the third lane is the complex expressed from the pMAPLe3 vector which allows proteolytic cleavage of the MBP moiety in vivo and purification of the complex via a C-terminal His6 tag on the ESAT-6 homolog. Arrows indicate the presence of Esx complex subunits. "
        ],
        "rois":[
          {
            "x":22,
            "y":15,
            "x2":2674,
            "y2":1446
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SDS-PAGE analysis (Any-kD TGX gel, Bio-Rad) of concentrated Esx complex samples from large-scale purification (???3 ??g per lane): 1, EsxOPmt; 2, EsxEFmt; 3, EsxGHms; 4, EsxGHma; 5, EsxEFma; and 6, EsxTUma."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "868104":{
    "Figure_4.tif":{
      "5":{
        "descriptions":[
          ", 20, 10, 5, 2.5"
        ],
        "rois":[
          {
            "x":22,
            "y":16,
            "x2":1673,
            "y2":1143
          }
        ]
      },
      "10":{
        "descriptions":[
          ", 20, 10, 5, 2.5"
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          ", 1.25, and 0.625 ??M APP-E2_JMR binding to APP-E1_ED_AcD loaded on Streptavidin biosensors. Triplicate measurements were performed at each concentration in a 2-fold dilution series. (b) Plot of the concentration dependent APP-E2_JMR binding responses at the end of the association phase (150 seconds). "
        ],
        "rois":[
          {
            "x":19,
            "y":1136,
            "x2":1673,
            "y2":2220
          }
        ]
      },
      "20":{
        "descriptions":[
          ", 20, 10, 5, 2.5"
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          ", 20, 10, 5, 2.5"
        ],
        "rois":[
          {
            "x":19,
            "y":1136,
            "x2":1673,
            "y2":2220
          }
        ]
      }
    }
  },
  "868114":{
    
  },
  "871765":{
    
  },
  "871766":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Replicative DNA polymerases were inhibited with aphidicolin (aph) during Xenopus laevis egg extracts "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":866,
            "y2":1664
          }
        ]
      },
      "FE":{
        "descriptions":[
          "(FE) incubation. Supercoiled DNA (scDNA) was added to FE (with bio-dC) in the presence or absence of aph, and biotinylated DNA isolated and quantitated by qPCR. The bars represent fold change as the difference between the qPCR Ct value of each sample normalised to the treated (+ aph) sample, which was set to 1. Error bars indicate ?? SD (n???=???3). Time line of experiment shown above the graph indicates the order of addition of substrates/proteins/nucleotides/extract/etc. or treatments. "
        ],
        "rois":[
          {
            "x":841,
            "y":24,
            "x2":2351,
            "y2":1756
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) AID-induced lesions are repaired in Xenopus laevis egg extracts. scDNA plasmids were treated (or not - bar 1) with the indicated proteins and then incubated in FE (or not - bar 2), isolated, and quantified by qPCR. The blue bars represent the ratio (fold change) of the amount of recovered plasmids from reactions carried out in the presence of G-AID (bar 3), untagged AID (AID; bar 4), GAL4 DNA binding domain (G-DBD; bar 5), or mutant GAL4-AID C87R (G-AIDmt; bar 6) versus levels of plasmids recovered from reactions that did not contain G-AID (FE alone, set to 1; bar 1). Open pink bars represent the absolute recovery of each treated sample in relation to its input. Error bars indicate ?? SD (n???=???3). Statistical analysis (t-test) was performed on differences of indicated fold change (brackets), with p values shown. Time line of the experiment is shown above the graph."
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":866,
            "y2":1664
          }
        ]
      }
    }
  },
  "871768":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Incorporation of 1 or 2 biotinylated dCTP molecules is sufficient to recover the targeted plasmid by streptavidin purification. Schematic of the experiment is depicted at the top of the figure. Plasmids were untreated (scDNA) or nicked at one position with Nt.BsmAI (nicked DNA), followed by treatment with Klenow for 30 min at 25??C in the presence or absence of dTTP (dT) and varying ratios of biotinylated (bio-dC) and normal dCTP (dC). As indicated in the schematic, the lack of dGTP and dATP only allowed for the incorporation of 1 or 2 bio-dC molecules per plasmid. The bars (fold change) represent the difference between the qPCR Ct value for each sample before and after the streptavidin purification, normalised to the sample (scDNA or nicked DNA) treated with the Klenow and bio-dC (no dT and set to 1). Error bars indicate ?? SD (n???=???3). Time line of the experiment is shown above the graph. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":1532,
            "y2":727
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Patch length of incorporated bio-dC does not bias the recovery of plasmids from IVR. The amount of bio-dC incorporation depending on the presence of other dNTPs was monitored by an AID-induced IVR assay. The fold change represents the difference between the qPCR Ct value of each sample normalised to the FE-treated sample (no G-AID) that was set to 1."
        ],
        "rois":[
          {
            "x":13,
            "y":761,
            "x2":1511,
            "y2":3287
          }
        ]
      }
    }
  },
  "871774":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E) The incorporation of bio-dC or bio-dA from a nick by FE is equivalent. FE DNA repair activity was monitored by incorporation of bio-dC or bio-dA after incubation of either a supercoiled (scDNA) or nicked (Nt.BsmAI) plasmid. Analysis was performed as in Figure 2 with untreated sample (no FE - not shown) set to 1. Error bars indicate ?? SD (n???=???3). "
        ],
        "rois":[
          {
            "x":50,
            "y":2216,
            "x2":817,
            "y2":3190
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Time course of FE activity on a nicked damaged plasmid. DNase I (0.001 U) treated scDNA was incubated with FE for 0 to 60 min (23??C) in the presence of bio-dC or bio-dA. Analysis was performed as in Figure 2 with untreated sample (no FE - not shown) set to 1. Error bars indicate ?? SD (n???=???3)."
        ],
        "rois":[
          {
            "x":915,
            "y":2216,
            "x2":1924,
            "y2":3192
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) DNA topology changes upon FE treatment. scDNA was treated with G-AID, followed by incubation with FE for 0 to 60 min before deproteinisation with SDS and proteinase K at 56??C overnight. Deproteinised DNA was analysed as in Figure 3A. Various topoisomers of the DNA are indicated on the left; oc/rc (open circular/relaxed circular); sc (supercoiled). "
        ],
        "rois":[
          {
            "x":8,
            "y":32,
            "x2":951,
            "y2":859
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Time course of DNA repair activity during an IVR. G-AID was incubated with scDNA for 30 min 37??C before addition of the FE and incubation for the indicated time (23??C). Analysis was performed as in Figure 2 with untreated sample (no AID) set to 1. Error bars indicate ?? SD (n???=???3). "
        ],
        "rois":[
          {
            "x":48,
            "y":985,
            "x2":783,
            "y2":2096
          },
          {
            "x":1071,
            "y":8,
            "x2":1940,
            "y2":987
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bio-dC incorporation by FE quantitatively correlates with the number of DNA damages (nicks). FE repair activity was monitored by incorporation of bio-dC after incubation with damaged plasmid (nicked with Nt.AlwI or Nt.BsmAI, which cut the plasmid 15 or 1 times, respectively). Analysis was performed as in Figure 2 with untreated sample (no FE - not shown) set to 1. "
        ],
        "rois":[
          {
            "x":48,
            "y":985,
            "x2":783,
            "y2":2096
          },
          {
            "x":859,
            "y":982,
            "x2":1933,
            "y2":2115
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Repair specificity in FE. Repair activity was monitored by the incorporation of bio-dC after incubation of the nicked (Nt.AlwI or Nt.BsmAI) or re-ligated nicked (Lig - T4 ligase) plasmid with FE. The effect of T4 ligase on a G-AID-treated scDNA plasmid sample was also tested. Analysis was performed as in Figure 2 with untreated sample (no ligation) set to 1. Error bars indicate ?? SD (n???=???3). "
        ],
        "rois":[
          {
            "x":48,
            "y":985,
            "x2":783,
            "y2":2096
          },
          {
            "x":859,
            "y":982,
            "x2":1933,
            "y2":2115
          }
        ]
      }
    }
  },
  "872779":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) IL-6, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1080,
            "y2":767
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MCP-1, and "
        ],
        "rois":[
          {
            "x":0,
            "y":768,
            "x2":1080,
            "y2":1786
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) MIP-1?? levels from supernatants of infected CD14+ monocytes and MSCs monoculture and 1???5 ratio of MSCs/CD14+ monocytes cocultures at MOI 0.04 were measured by using Bio-plex Cytokine assay. Data was analyzed via Bio-plex 5.0 Software. The two different cell types used in the experiment were derived from different donors. The results represent the means and SD of two independent experiments. Single asterisk indicates statistically significant differences between mock and infected cells with P values of P values of "
        ],
        "rois":[
          {
            "x":0,
            "y":1787,
            "x2":1080,
            "y2":2981
          }
        ]
      }
    }
  },
  "8732":{
    
  },
  "8733":{
    
  },
  "876143":{
    "Figure_7.tif":{
      "E":{
        "descriptions":[
          "(E) Secreted cytokine protein expression in macrophages stimulated with a higher concentration of immuno-purified hCLCA1 was analyzed using Bio-plex Suspension Array System. The fold difference of each sample was compared against the corresponding control. Results were the means of 3 samples ?? SEM. Significant fold differences from corresponding control values are indicated by * (p??p??p??"
        ],
        "rois":[
          {
            "x":20,
            "y":1808,
            "x2":1117,
            "y2":2719
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Representative silver stained SDS-PAGE gel showing immuno-purified hCLCA1 and a 2-fold dilution series of lysozyme. "
        ],
        "rois":[
          {
            "x":19,
            "y":18,
            "x2":431,
            "y2":301
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Densitometry analysis using lysozyme standard curve demonstrated a higher concentration of pure hCLCA1 (9.425 ?? 0.335 pg/??L) was immunoprecipitated with an optimized protocol. Result was presented as the mean of 3 samples ?? SEM. "
        ],
        "rois":[
          {
            "x":469,
            "y":42,
            "x2":1785,
            "y2":304
          },
          {
            "x":18,
            "y":348,
            "x2":1878,
            "y2":1211
          },
          {
            "x":914,
            "y":1167,
            "x2":1883,
            "y2":1904
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The mRNA expression of cytokines in macrophages stimulated with a higher concentration of hCLCA1 for 48 h was quantified using RT-qPCR. The fold difference was calculated against the corresponding control (immunoprecipitation of eGFP using hCLCA1-N14 antibody). Results were presented as the means of 4 samples ?? SEM. "
        ],
        "rois":[
          {
            "x":32,
            "y":1280,
            "x2":856,
            "y2":1630
          },
          {
            "x":469,
            "y":42,
            "x2":1785,
            "y2":304
          },
          {
            "x":18,
            "y":348,
            "x2":1878,
            "y2":1211
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Representative Western blots showing intracellular IL-1?? and GAPDH levels in immuno-purified eGFP or hCLCA1-stimulated macrophages. GAPDH was used as a loading control for densitometry analysis. Immuno-purified hCLCA1-stimulated macrophages had a 2.38 ?? 0.21 folds increase in IL-1?? protein levels over immuno-purified eGFP-stimulated macrophages (the hCLCA1-induced IL-1?? was normalized to the eGFP-induced IL-1?? in each sample). Results were presented as the means of 7 samples ?? SEM. "
        ],
        "rois":[
          {
            "x":20,
            "y":1808,
            "x2":1117,
            "y2":2719
          },
          {
            "x":469,
            "y":42,
            "x2":1785,
            "y2":304
          }
        ]
      }
    }
  },
  "879282":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A.\tSeminal vesicle fluid was separated by 2-D electrophoresis\\ and was stained overnight with 0.01% Bio-Rad R-250 Coomassie in 10% acetic acid"
        ],
        "rois":[
          {
            "x":33,
            "y":14,
            "x2":1341,
            "y2":1382
          }
        ]
      },
      "B":{
        "descriptions":[
          ".\n\t\t\t\t\t\tB.\tFar Western blot: Incubate the membrane with 6-His-Eppin protein and probed with anti-His. We can see the positive spot molecular weight 55-72KDa on the blot (arrowhead)."
        ],
        "rois":[
          {
            "x":33,
            "y":14,
            "x2":1341,
            "y2":1382
          }
        ]
      }
    }
  },
  "881571":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          ", a) shows the Regularized Training Gain under 100 Jackknife turns (green: without variable; blue: with only one variable; and red: with all variables)"
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":2263,
            "y2":1455
          }
        ]
      },
      "b":{
        "descriptions":[
          "; b) shows the response curves of BIO 15, the variable that contributes most to these models."
        ],
        "rois":[
          {
            "x":1809,
            "y":1009,
            "x2":2264,
            "y2":1431
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":14,
            "y":1608,
            "x2":2268,
            "y2":3024
          }
        ]
      }
    }
  },
  "882297":{
    "Figure_6.tif":{
      "T":{
        "descriptions":[
          "(T) and blood "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "A) SEC analysis of 125I-L19-UG (Superdex 200). The retention volume of about 14.5 ml is in accordance with the molecular mass of dimeric L19-UG. B???D) Biodistribution of 125I-L19-UG in F9 tumor-bearing mice"
        ],
        "rois":[
          {
            "x":250,
            "y":8,
            "x2":1758,
            "y2":1203
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The percentage of injected dose per gram of tissue (%ID/g) in the various organs 48 hours post i.v. administration of 125I-L19-UG. The means ?? S.E. are indicated",
          "(B) of L19???UG and of the currently used L19 format SIP (data from reference 19) presently used in clinical"
        ],
        "rois":[
          {
            "x":250,
            "y":8,
            "x2":1758,
            "y2":1203
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) The ratios of the %ID/g in tumor "
        ],
        "rois":[
          {
            "x":7,
            "y":1170,
            "x2":957,
            "y2":1732
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) %ID/g in the blood at 24 and 48 hours after radio-labelled proteins injections using L19-SIP (data from reference 19), L19-UG produced in mammalian cells (data from reference 26) and L19-UG from E. coli. %ID/g and standard errors are shown."
        ],
        "rois":[
          {
            "x":250,
            "y":8,
            "x2":1758,
            "y2":1203
          },
          {
            "x":1191,
            "y":1176,
            "x2":2090,
            "y2":1760
          }
        ]
      }
    }
  },
  "883628":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Time course of the diffusional water permeability at 15??C in ghost from AQP1null phenotype, in the presence or absence of HgCl2 (10 mM) or DMU (0.5 mM). Smooth lines are exponential fits to the data using the simplex procedure of the Biokine (Bio-logic), providing rate constant of water permeability k (s???1). "
        ],
        "rois":[
          {
            "x":12,
            "y":12,
            "x2":933,
            "y2":740
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Coefficients of diffusional water permeability (Pd) at 15??C in the absence or the presence of inhibitors (Blue, DMU; red, HgCl2). Three experiments for each individual were averaged and the means of the rate constants k (s???1) for 3 controls, 3 UT-Bnull and AQP1null were reported (?? SD). "
        ],
        "rois":[
          {
            "x":1013,
            "y":12,
            "x2":2011,
            "y2":825
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Arrhenius activation energies (which correspond to the slope of the plot) of diffusional water permeation across RBC membranes (circles, control; squares, UT-Bnull; triangles, AQP1null)."
        ],
        "rois":[
          {
            "x":2045,
            "y":11,
            "x2":3032,
            "y2":789
          }
        ]
      }
    }
  },
  "886380":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) The r-Tp15-17-47 antigen is a chimeric in-frame fusion construct containing thioredoxin, 6x His tag (indicated by the asterisk), followed by the membrane proteins (Tp15, Tp17 and Tp47) of Tp stitched together with flexible tetra-glycyl (G4) linkers (presented with zig-zag lines). In r-Bio-Tp15-17-47, the BAP is inserted in-frame to generate the in vivo biotinylated version of the antigen. "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2025,
            "y2":1011
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SDS-PAGE analysis of r-Tp15-17-47 and r-Bio-Tp15-17-47 antigens. Aliquots of total cell lysates of E. coli harboring the r-p15-17-47 and r-Bio-p15-17-47 antigen constructs (uninduced: lanes marked ???U???; induced: lanes marked ???I???), and aliquots of the affinity-purified dialyzed and soluble antigens (lanes marked ???P???), were electrophoresed on denaturing gels and visualized by Coomassie staining. Protein size markers were run in lane ???M???; their sizes (in kDa) are shown on the left. The arrows shown denote the bands of purified proteins. The asterisk denotes the position of biotin ligase enzyme."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "886382":{
    "Figure_2.tif":{
      "4":{
        "descriptions":[
          "(4) serum anti-Tp IgG antibody, "
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          "(5) serum anti-Tp IgM antibody, and "
        ],
        "rois":[
          {
            "x":913,
            "y":10,
            "x2":2021,
            "y2":1262
          }
        ]
      },
      "6":{
        "descriptions":[
          "(6) r-p15-17-47 coated on Eu3+ chelate-doped nanoparticles. (B) Scatter plot with the S/Co values of all serum samples (n???=???311) analyzed in this study, using the in-house TRF immunoassays with 1 h (x axis) and 10 min (y axis) incubation times. Different symbols represent positive (+) or negative (-) serum samples, either from commercial panels based on the results provided by the panel supplier, or from six different categories (#1 ??? #6) of the in-house samples based on their reactivities with the reference assays as described in Table 1. Symbols for different kind of samples are as the following: PSS202 (+), filled blue triangles; PSS202 (-), empty blue triangles; QSS701 (+), filled cyan triangles; QSS701 (-), empty cyan triangle; samples of category #1, filled red circles; samples of category #2, filled green circles; samples of category #3, filled blue circles; samples of category #4, filled magenta circles; sample of category #5, filled olive square; samples of category #6 (except one sample), empty red circles; and exceptional sample of category #6 which gave positive results with in-house TRF immunoassays, black star. Dashed vertical and horizontal lines represent the cutoffs (at S/Co???=???1) for the two TRF immunoassays."
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          "(1) microtiter well surface, "
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":730,
            "y2":1110
          },
          {
            "x":913,
            "y":10,
            "x2":2021,
            "y2":1262
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) streptavidin, "
        ],
        "rois":[
          {
            "x":913,
            "y":10,
            "x2":2021,
            "y2":1262
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3) r-Bio-p15-17-47, "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "887791":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A). The activation of MAPKs (ERK1/2, JNK, and p38) was determined using the Bio-Plex luminescence assay in HCAECs treated with resistin (80 ??g/mL) for different time periods (0, 5, 10, 20, 30, 45, 60, and 90 minutes). The phosphorylated and the total protein for each MAPK were determined. "
        ],
        "rois":[
          {
            "x":17,
            "y":17,
            "x2":2190,
            "y2":3925
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). HCAECs were incubated with or without resistin, or pretreated with MnTBAP before treating them with resistin (80 ng/mL) for 45 minutes. The protein levels of MAPK (total and phosphorylated proteins) were determined by Western Blot. ??-actin was used as a loading control."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "888163":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) from parent strains and "
        ],
        "rois":[
          {
            "x":19,
            "y":19,
            "x2":1998,
            "y2":598
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) from mlrA mutant strains complemented with pUC19::mlrA plasmid (+). Strain 43894OR was used as positive control"
        ],
        "rois":[
          {
            "x":24,
            "y":740,
            "x2":1541,
            "y2":1317
          }
        ]
      },
      "MW":{
        "descriptions":[
          ".  MW: Precision Plus dual color protein standards (Bio-Rad)."
        ],
        "rois":[
          {
            "x":24,
            "y":740,
            "x2":1541,
            "y2":1317
          }
        ]
      }
    }
  },
  "891231":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A). Protein analysis was performed with SDS-PAGE on purified material from the E.coli expression system and concentrations were determined using the Bio-Rad DC protein assay, according to the manufacturer's instructions. Western blot analysis using HRP-labelled anti-DD antibodies "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1767,
            "y2":2816
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). The ADP-ribosylating ability of CTA1-UreB3T-DD, but not the mutant inactive CTA1R7K-UreB3T-DD protein, was comparable to that of CT at a molar level, as shown in the NAD-agmatine assay diagram "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1767,
            "y2":2816
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). These are representive data from at least 5 identical experiments giving similar results."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "891572":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E,F) group 3: BL107 and CC9902; "
        ],
        "rois":[
          {
            "x":12,
            "y":929,
            "x2":654,
            "y2":1358
          },
          {
            "x":693,
            "y":473,
            "x2":1293,
            "y2":903
          },
          {
            "x":693,
            "y":929,
            "x2":1293,
            "y2":1358
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E,F) group 3: BL107 and CC9902; "
        ],
        "rois":[
          {
            "x":693,
            "y":929,
            "x2":1293,
            "y2":1358
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A,B) Group 1 strains: MINOS11, A15-62, PROS-U-1, M11.1 and RS9915; "
        ],
        "rois":[
          {
            "x":14,
            "y":14,
            "x2":656,
            "y2":442
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G,H): group 4 : RCC307. Note the different x-axis scale for BL107. "
        ],
        "rois":[
          {
            "x":12,
            "y":1399,
            "x2":654,
            "y2":1929
          },
          {
            "x":693,
            "y":929,
            "x2":1293,
            "y2":1358
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A,B) Group 1 strains: MINOS11, A15-62, PROS-U-1, M11.1 and RS9915; "
        ],
        "rois":[
          {
            "x":696,
            "y":14,
            "x2":1295,
            "y2":442
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,D) group 2: BIOS-U3-1, CC9311, WH8020, CC9902 and RS9916; "
        ],
        "rois":[
          {
            "x":12,
            "y":473,
            "x2":654,
            "y2":903
          },
          {
            "x":693,
            "y":473,
            "x2":1293,
            "y2":903
          }
        ]
      },
      "H":{
        "descriptions":[
          "(G,H): group 4 : RCC307. Note the different x-axis scale for BL107. "
        ],
        "rois":[
          {
            "x":693,
            "y":1399,
            "x2":1293,
            "y2":1876
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C,D) group 2: BIOS-U3-1, CC9311, WH8020, CC9902 and RS9916; "
        ],
        "rois":[
          {
            "x":12,
            "y":1399,
            "x2":654,
            "y2":1929
          },
          {
            "x":693,
            "y":473,
            "x2":1293,
            "y2":903
          }
        ]
      }
    }
  },
  "891794":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) LPS-treated microglia produce more TNF-??, IL-1??, RANTES and MIP-2 than control microglia, while treatment with conditioned medium significantly inhibited production of these factors. "
        ],
        "rois":[
          {
            "x":16,
            "y":15,
            "x2":4085,
            "y2":1666
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Microglia in the LPS-treated groups produced more IL-6, IL-10 and MCP-1 compared to control groups. The supernatant derived from conditioned medium-treated groups contained more IL-6, IL-10, MCP-1 and VEGF compared to control groups. A P value of less than 0.05 (*), less than 0.01 (**), and less than 0.001 (***) was considered statistically significant."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "898790":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A), GadX "
        ],
        "rois":[
          {
            "x":15,
            "y":16,
            "x2":2681,
            "y2":1239
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), NsrR "
        ],
        "rois":[
          {
            "x":22,
            "y":1327,
            "x2":3280,
            "y2":2554
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Values higher than 20 (twice the values obtained for the strain EDL933 containing the empty pBADmycHisA vector) indicate protein binding to the promoters of interest"
        ],
        "rois":[
          {
            "x":19,
            "y":2631,
            "x2":3661,
            "y2":4067
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D: Bio-informatics analyses of NsrR-binding sites. Sequence logo determined from seven putative NsrR-binding sites in EDL933 (upper panel), and sequences with the best matches for the entire or one of the half sites are shown with their statistical scores (lower panel)."
        ],
        "rois":[
          {
            "x":19,
            "y":2631,
            "x2":3661,
            "y2":4067
          },
          {
            "x":306,
            "y":4010,
            "x2":3361,
            "y2":5466
          }
        ]
      }
    }
  },
  "901583":{
    
  },
  "901587":{
    
  },
  "902998":{
    
  },
  "903007":{
    
  },
  "903010":{
    
  },
  "903011":{
    
  },
  "904313":{
    "Figure_S1.tif":{
      "IL":{
        "descriptions":[
          "(IL)-4. We identified demethylation of H3K27me3 at the ALOX15 promoter after IL-4 treatment. Furthermore, we found that the H3K27me2/3-specific demethylase, ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), mediates the H3K27me3 demethylation during ALOX15 transcriptional activation. When UTX expression was knocked down using siRNA"
        ],
        "rois":[
          
        ]
      },
      "HL":{
        "descriptions":[
          "(HL) cell line L1236, but was in these cells not related to H3K27me3-demethylase activity. These results demonstrate that UTX is implicated in IL-4 mediated transcriptional activation of the ALOX15 gene."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2231,
            "y2":2646
          }
        ]
      }
    }
  },
  "904542":{
    
  },
  "906227":{
    
  },
  "906456":{
    
  },
  "907801":{
    
  },
  "908508":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Synthesis of biotinylated curcumin derivative. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2904,
            "y2":2019
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Comparison of the effects of unmodified curcumin (CUR) and biotinylated curcumin (BIO-CUR) in equimolar concentrations (50 ??M) on pTyr421-CTTN in HCT116 cells treated for 15 min. GAPDH served as a loading control. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Western blot analysis (left panel) and quantitative densitometry of the PTPN1 protein from pull-down experiment with biotinylated crcumin. HCT116 cell lysates were prepared with RIPA buffer and combined with curcumin (CUR), biotin linker (compound 3), or biotinylated curcumin (BIO-CUR; compound 4; all at 50 ??M) for 30 min at room temperature. Protein fraction recovered with streptavidin agarose beads was analyzed by western blotting for the presence of PTPN1. The data in the summary graph are expressed as fold change compared to linker treated samples from more extended exposures to visualize background PTPN1 signal (mean ?? SD). * p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2904,
            "y2":2019
          }
        ]
      }
    }
  },
  "908987":{
    
  },
  "909683":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) The template, (???)-RNA11???201 with its 3???-end blocked, was incubated with the MBP-Pro A and different concentrations specific RNA primer. Reaction products were analyzed on denaturing formaldehyde-agarose gel and detected as described in ???Materials and Methods???. Lane 1, synthesized DIG-labeled RNA at the designated size (200 nt) generated by T7 polymerase-mediated in vitro transcription. ",
          "(A) were measured via Bio-Rad Quantity One software, and the relative RdRP activities were determined by comparing the RNA product level in the presence of the indicated concentration of primer with the RNA product level without the primer. Error bars represent the standard deviation (S.D.) values from at least three independently repeated experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4853,
            "y2":1206
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The synthesized RNA products from the experiments in "
        ],
        "rois":[
          
        ]
      }
    }
  }
,
  "909684":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) The template, (???)-RNA11???201 with its 3???-end blocked, was incubated with the MBP-Pro A and different concentrations of Mn2+. Reaction products were analyzed on denaturing formaldehyde-agarose gel and detected as described in ???Materials and Methods???. Lane 1, synthesized DIG-labeled RNA at the designated size (200 nt) generated by T7 polymerase-mediated in vitro transcription. ",
          "(E) were measured via Bio-Rad Quantity One software Error bars represent the standard deviation (S.D.) values from at least three independently repeated experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) The synthesized RNA products from the experiments in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) The template, (???)-RNA11???201 with its 3???-end blocked, was incubated with the MBP-Pro A at different temperature. Reaction products were analyzed on denaturing formaldehyde-agarose gel and detected as described in ???Materials and Methods???. Lane 1, synthesized DIG-labeled RNA at the designated size (200 nt) generated by T7 polymerase-mediated in vitro transcription. ",
          "(A) were measured via Bio-Rad Quantity One software Error bars represent the standard deviation (S.D.) values from at least three independently repeated experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The synthesized RNA products from the experiments in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The template (???)-RNA11???201 with its 3???-end blocked, was incubated with the MBP-Pro A at the different pH. Reaction products were analyzed on denaturing formaldehyde-agarose gel and detected as described in ???Materials and Methods???. Lane 1, synthesized DIG-labeled RNA at the designated size (200 nt) generated by T7 polymerase-mediated in vitro transcription. ",
          "(C) were measured via Bio-Rad Quantity One software Error bars represent the standard deviation (S.D.) values from at least three independently repeated experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The synthesized RNA products from the experiments in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5561,
            "y2":5352
          }
        ]
      }
    }
  },
  "910433":{
    "Figure_S1.tif":{
      "1":{
        "descriptions":[
          ": 1) spatial models of fishing effort, environmental characteristics and distribution of demersal resources"
        ],
        "rois":[
          {
            "x":0,
            "y":961,
            "x2":2361,
            "y2":2635
          }
        ]
      },
      "2":{
        "descriptions":[
          "; 2) an Artificial Neural Network which captures the relationships among these aspects in a spatially explicit way and uses them to predict resources abundances"
        ],
        "rois":[
          {
            "x":0,
            "y":403,
            "x2":2361,
            "y2":960
          },
          {
            "x":0,
            "y":2636,
            "x2":2361,
            "y2":3267
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3) a deterministic module which analyzes the size structure of catches and the associated revenues, according to different spatially-based management scenarios. SMART is applied to demersal fishery in the Strait of Sicily, one of the most productive fisheries of the Mediterranean Sea. Three of the main target species are used as proxies for the whole range exploited by trawlers. After training, SMART is used to evaluate different management scenarios, including spatial closures, using a simulation approach that mimics the recent exploitation patterns. Results evidence good model performance, with a noteworthy coherence and reliability of outputs for the different components. Among others, the main finding is that a partial improvement in resource conditions can be achieved by means of nursery closures, even if the overall fishing effort in the area remains stable. Accordingly, a series of strategically designed areas of trawling closures could significantly improve the resource conditions of demersal fisheries in the Strait of Sicily, also supporting sustainable economic returns for fishermen if not applied simultaneously for different species."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2361,
            "y2":402
          }
        ]
      }
    },
    "Figure_S2.tif":{
      "1":{
        "descriptions":[
          ": 1) spatial models of fishing effort, environmental characteristics and distribution of demersal resources"
        ],
        "rois":[
          {
            "x":0,
            "y":2093,
            "x2":2361,
            "y2":2650
          }
        ]
      },
      "2":{
        "descriptions":[
          "; 2) an Artificial Neural Network which captures the relationships among these aspects in a spatially explicit way and uses them to predict resources abundances"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2361,
            "y2":1533
          },
          {
            "x":0,
            "y":2093,
            "x2":2361,
            "y2":2650
          },
          {
            "x":0,
            "y":2651,
            "x2":2361,
            "y2":3267
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3) a deterministic module which analyzes the size structure of catches and the associated revenues, according to different spatially-based management scenarios. SMART is applied to demersal fishery in the Strait of Sicily, one of the most productive fisheries of the Mediterranean Sea. Three of the main target species are used as proxies for the whole range exploited by trawlers. After training, SMART is used to evaluate different management scenarios, including spatial closures, using a simulation approach that mimics the recent exploitation patterns. Results evidence good model performance, with a noteworthy coherence and reliability of outputs for the different components. Among others, the main finding is that a partial improvement in resource conditions can be achieved by means of nursery closures, even if the overall fishing effort in the area remains stable. Accordingly, a series of strategically designed areas of trawling closures could significantly improve the resource conditions of demersal fisheries in the Strait of Sicily, also supporting sustainable economic returns for fishermen if not applied simultaneously for different species."
        ],
        "rois":[
          {
            "x":0,
            "y":1534,
            "x2":2361,
            "y2":2092
          }
        ]
      }
    },
    "Figure_S3.tif":{
      "1":{
        "descriptions":[
          ": 1) spatial models of fishing effort, environmental characteristics and distribution of demersal resources"
        ],
        "rois":[
          {
            "x":0,
            "y":1011,
            "x2":2361,
            "y2":1568
          }
        ]
      },
      "2":{
        "descriptions":[
          "; 2) an Artificial Neural Network which captures the relationships among these aspects in a spatially explicit way and uses them to predict resources abundances"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2361,
            "y2":452
          },
          {
            "x":0,
            "y":1569,
            "x2":2361,
            "y2":3267
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3) a deterministic module which analyzes the size structure of catches and the associated revenues, according to different spatially-based management scenarios. SMART is applied to demersal fishery in the Strait of Sicily, one of the most productive fisheries of the Mediterranean Sea. Three of the main target species are used as proxies for the whole range exploited by trawlers. After training, SMART is used to evaluate different management scenarios, including spatial closures, using a simulation approach that mimics the recent exploitation patterns. Results evidence good model performance, with a noteworthy coherence and reliability of outputs for the different components. Among others, the main finding is that a partial improvement in resource conditions can be achieved by means of nursery closures, even if the overall fishing effort in the area remains stable. Accordingly, a series of strategically designed areas of trawling closures could significantly improve the resource conditions of demersal fisheries in the Strait of Sicily, also supporting sustainable economic returns for fishermen if not applied simultaneously for different species."
        ],
        "rois":[
          {
            "x":0,
            "y":453,
            "x2":2361,
            "y2":1010
          }
        ]
      }
    },
    "Figure_S4.tif":{
      "1":{
        "descriptions":[
          ": 1) spatial models of fishing effort, environmental characteristics and distribution of demersal resources"
        ],
        "rois":[
          {
            "x":42,
            "y":29,
            "x2":1385,
            "y2":891
          }
        ]
      },
      "2":{
        "descriptions":[
          "; 2) an Artificial Neural Network which captures the relationships among these aspects in a spatially explicit way and uses them to predict resources abundances"
        ],
        "rois":[
          {
            "x":42,
            "y":29,
            "x2":1385,
            "y2":891
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3) a deterministic module which analyzes the size structure of catches and the associated revenues, according to different spatially-based management scenarios. SMART is applied to demersal fishery in the Strait of Sicily, one of the most productive fisheries of the Mediterranean Sea. Three of the main target species are used as proxies for the whole range exploited by trawlers. After training, SMART is used to evaluate different management scenarios, including spatial closures, using a simulation approach that mimics the recent exploitation patterns. Results evidence good model performance, with a noteworthy coherence and reliability of outputs for the different components. Among others, the main finding is that a partial improvement in resource conditions can be achieved by means of nursery closures, even if the overall fishing effort in the area remains stable. Accordingly, a series of strategically designed areas of trawling closures could significantly improve the resource conditions of demersal fisheries in the Strait of Sicily, also supporting sustainable economic returns for fishermen if not applied simultaneously for different species."
        ],
        "rois":[
          {
            "x":42,
            "y":29,
            "x2":1385,
            "y2":891
          }
        ]
      }
    }
  },
  "914816":{
    
  },
  "917037":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Effect of shRNA-mediated depletion of Eng on VEGF-induced endothelial cell sprouting. HUVECs were transduced with lentivirus expressing endoglin shRNA overnight. HUVEC spheroids with deficient endoglin expression were embedded in collagen and stimulated with VEGF (50 ng/ml). A representative experiment is shown. ",
          "(A). "
        ],
        "rois":[
          {
            "x":2064,
            "y":405,
            "x2":3829,
            "y2":2067
          },
          {
            "x":27,
            "y":25,
            "x2":1010,
            "y2":1183
          },
          {
            "x":43,
            "y":1219,
            "x2":1018,
            "y2":1992
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantitation of effects seen in "
        ],
        "rois":[
          {
            "x":2031,
            "y":3548,
            "x2":3963,
            "y2":4232
          },
          {
            "x":2064,
            "y":405,
            "x2":3829,
            "y2":2067
          },
          {
            "x":1057,
            "y":26,
            "x2":2183,
            "y2":1181
          },
          {
            "x":43,
            "y":1219,
            "x2":1018,
            "y2":1992
          },
          {
            "x":1057,
            "y":1219,
            "x2":1919,
            "y2":1992
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Effect of TRC105 ENG antibody on VEGF-induced endothelial cell sprouting. HUVEC spheroids were embedded in collagen and stimulated with VEGF (50 ng/ml), TRC105 (10 ??g/ml), or both overnight. As control antibody for experiments using TRC105, the Fc domain (MOPC-21) from Bio Express, West Lebanon, NH, was used. Pictures were taken by phase-contrast microscopy. Quantitative analysis of the mean total sprout length was performed on 10 spheroids per experimental group. P???0.05. "
        ],
        "rois":[
          {
            "x":25,
            "y":2420,
            "x2":1652,
            "y2":4352
          },
          {
            "x":2064,
            "y":405,
            "x2":3829,
            "y2":2067
          },
          {
            "x":43,
            "y":1219,
            "x2":1018,
            "y2":1992
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) VEGF-induced VEGFR2 phosphorylation at site 1175 and extracellular regulated kinase (ERK) mitogen activated protein (MAP) kinase phosphorylation was examined in shRNA-mediated Eng knockdown cells. Two bands were detected with the phosphor ERK MAPK antibodies with a molecular weight of 44 and 42 kDa; they represent ERK1 and ERK2 isoforms, respectively. Number sign (#) represents a background band, indicating the even loading for the experiment. Asterisks indicate the protein bands with expected size."
        ],
        "rois":[
          {
            "x":1983,
            "y":2423,
            "x2":3969,
            "y2":3532
          }
        ]
      }
    }
  },
  "917950":{
    
  },
  "919105":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A), with engraved microchannels. The two microchannels simulated the lumen area in which the apical portion of cells is exposed (upper channel) and the interstitial area in contact with basolateral membranes (lower channel). The channels were physically separated by a microporous PC membrane and were continuously fed in counter-current modality. Once assembled "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":1426,
            "y2":684
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), the device presented two inlet and two outlet ports, each connected to plastic tubes and syringe pumps for fluid control. "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":1426,
            "y2":684
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Photograph of the bioartificial proximal tubule microfluidic device. "
        ],
        "rois":[
          {
            "x":1441,
            "y":12,
            "x2":1902,
            "y2":579
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Complete experimental set-up including the chip and distinct bubble traps for the inlet ports."
        ],
        "rois":[
          {
            "x":7,
            "y":688,
            "x2":1902,
            "y2":1475
          }
        ]
      }
    }
  },
  "919113":{
    
  },
  "922745":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) 12% SDS/PAGE of the purified protein after Ni-TED chromatography. "
        ],
        "rois":[
          {
            "x":9,
            "y":16,
            "x2":1787,
            "y2":1313
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Size exclusion chromatography of PaoD. Freshly purified PaoD was analyzed by analytical size exclusion chromatography in 50 mM Tris-HCl, 300 mM NaCl, pH 8.0 using a Superdex 75 column. Inset: plot of the standard proteins. Size exclusion chromatography markers (Bio-Rad): gamma-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin B12 (1.3 kDa)."
        ],
        "rois":[
          {
            "x":9,
            "y":16,
            "x2":1787,
            "y2":1313
          }
        ]
      }
    }
  },
  "925190":{
    
  },
  "926556":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A. Nuclear fractions from BEAS2B cells treated with SKI-II (1 ??M) at increasing times (10???120 min) were analysed for Keap1 and Nrf2 expression and normalized using TBP (nuclear). Keap1 bands at 140 kDa and 69 kDa were analysed as fold change over non-treatment of the 69 kDa band. *** pB. Cells were treated with cycloheximide (CXM) and SKI-II (1 ??M) at different time points (1 to 24 h) and whole cell extracts were analysed for Keap1 expression normalized against ??-actin. Keap1 bands at 140 kDa and 69 kDa were analysed as fold change over non-treatment of the 69 kDa band. *** pC. Whole-cell extracts from BEAS2B cells that were treated with SKI-II (1 ??M) for 2 and 4 h were immunoprecipitated "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP) using a Keap1 antibody. IP Keap1 was analysed by immunoblotting for ubiquitin modification, p62 and Keap1 expression. IgG: Mouse immunoglobulin control (no cell lysates). Ub: ubiquitin. Hmw: High molecular weight"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D. Whole-cell extracts from BEAS2B cells that were pre-treated with arachidonic acid (AA; 10 ??M) or biotynilated arachidonic acid (AA-Bio; 10 ??M) for 30 min were treated with SKI-II (1 ??M) for 2.5 h and immunoprecipitated using Neutravidin Agarose Resin (IP-NA). IP-NA was analysed by immunoblotting for Keap1 expression"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. Whole-cell extracts from BEAS2B cells treated with SKI-II (SK; 1 ??M), sulforaphane (SF; 5 ??M) or CDDO-Imidazolide (CD; 50 nM) for 4 h, 8 h and 24 h were analysed by immunoblotting for Nrf2, Keap1, NQO1, HO-1 and ??-actin. Results are representative of 3 independent experiments and are means and S.E. of triplicates."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1558
          }
        ]
      }
    }
  },
  "927411":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) SDS-PAGE analysis of expressed and isolated GST-??29pol, and purified Phi29 DNA polymerase. Lane; M, molecular mass markers (Bio-Rad); 1, whole cell lysate; 2, supernatant after PEI precipitation; 3, supernatant after dilution; 4, GS4B resin before digestion by PreScission; 5, GS4B resin after digestion by PreScission; 6, purified Phi29 DNA polymerase (before addition of glycerol); 7, purified Phi29 DNA polymerase (after addition of glycerol); 8, commercially available Phi29 DNA polymerase (1 ??g, Epicentre, Lot No. RPH-61004). The arrowhead indicates the GST-??29pol (calculated size, approximately 94 kDa) and the arrow indicates the purified Phi29 DNA polymerase and commercially available polymerase (calculated size, approximately 67 kDa). "
        ],
        "rois":[
          {
            "x":17,
            "y":17,
            "x2":2917,
            "y2":1403
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Agarose gel analysis of the removal of host DNA by PEI precipitation. Lane; M, AccuRuler 1-kb DNA ladder (Maestrogen); 1, whole cell lysate; 2, supernatant after PEI precipitation."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "928643":{
    
  },
  "934545":{
    
  },
  "935024":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A), Effect of BIO on the transcription factor promoter panel and simulation in the model. Top panel: A2780 cells were transfected with each luciferase reporter. 32 h later transfectants were treated for 16 h prior to luciferase assay with DMSO or 5 ??M BIO. Luciferase assay results meeting model cut-off of FC>1.5, pSTAT3) were modelled as rule table modifications. Lower panel: heat-map representation of new steady states obtained by setting Fos to be constitutively suppressed and STAT3 to be constitutively active. Red colour indicates the node is on, green colour indicates the node is off. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":898,
            "y2":2083
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), noise simulation by the bit-flip method under basal or BIO modified rules in the model. State coherence [73] of each attractor under the model basal rule-set (top) or BIO simulation (bottom) was evaluated as described in the text. Heat-maps of both attractors under either rule-set are shown, with colouration as above. Horizontal arrows between attractor states indicate that a transient state change of the adjacent node caused a shift to the alternate steady state. Vertical and diagonal arrows indicate the state changes resulting from the rule-set change (basal ??? BIO, or the reverse)."
        ],
        "rois":[
          {
            "x":552,
            "y":520,
            "x2":647,
            "y2":778
          },
          {
            "x":552,
            "y":779,
            "x2":647,
            "y2":1012
          },
          {
            "x":552,
            "y":1013,
            "x2":647,
            "y2":1243
          },
          {
            "x":552,
            "y":1244,
            "x2":647,
            "y2":1458
          },
          {
            "x":552,
            "y":1459,
            "x2":647,
            "y2":1690
          },
          {
            "x":552,
            "y":1691,
            "x2":647,
            "y2":2083
          },
          {
            "x":648,
            "y":520,
            "x2":788,
            "y2":763
          },
          {
            "x":648,
            "y":764,
            "x2":788,
            "y2":1000
          },
          {
            "x":648,
            "y":1001,
            "x2":788,
            "y2":1302
          },
          {
            "x":648,
            "y":1796,
            "x2":788,
            "y2":2083
          },
          {
            "x":648,
            "y":1303,
            "x2":788,
            "y2":1795
          },
          {
            "x":789,
            "y":820,
            "x2":898,
            "y2":1051
          },
          {
            "x":789,
            "y":1052,
            "x2":898,
            "y2":1281
          },
          {
            "x":789,
            "y":1282,
            "x2":898,
            "y2":1498
          },
          {
            "x":789,
            "y":520,
            "x2":898,
            "y2":819
          },
          {
            "x":789,
            "y":1499,
            "x2":898,
            "y2":1730
          },
          {
            "x":789,
            "y":1731,
            "x2":898,
            "y2":2083
          }
        ]
      }
    }
  },
  "935878":{
    
  },
  "938472":{
    
  },
  "941947":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Heatmap representation of ChIP-Seq binding for BioMyc, Myc, and Max around transcriptional start sites (TSSs) ??5 kb for all genes rank ordered from the lowest to the most highly expressed according to thee mRNA expression levels obtained from RNA-Seq analysis. "
        ],
        "rois":[
          {
            "x":1034,
            "y":100,
            "x2":2284,
            "y2":1488
          },
          {
            "x":8,
            "y":8,
            "x2":1615,
            "y2":2261
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Venn diagram showing the exact number of promoters bound in the indicated ChIP-Seq analyses. Bio-Myc ChIP-Seq found many more genes bound on TSSs in comparison with the endogenous Myc ChIP-Seq (4325 TSS vs. 1682 TSSs, respectively), and Bio-Myc ChIP-Seq shows more overlapping genes with Max ChIP-Seq (2306 vs. 1418, respectively). "
        ],
        "rois":[
          {
            "x":1662,
            "y":1593,
            "x2":2285,
            "y2":2216
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Genomic occupancy profiles of the indicated Chip-Seq show a well-defined peak of enrichment on the E-Box at the Suz12 promoter (???570 bp from TSS) and the Ezh2 TSS, while there is no binding at the promoters of the negative control genes (H19 and Kdr)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "941948":{
    
  },
  "941949":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Venn diagram showing the number of gene promoters bound in the indicated ChIP-Seq analyses and their overlap. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2452,
            "y2":2599
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-Myc ChIP-Seq was able to identify many more bound regions in comparison with Myc ChIP-Seq as shown by the number of peaks found at each p-value indicated. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) The genomic colocalization of Bio-Myc peaks with Max, H3K4me3-only promoters, and active enhancers at different p-values. Bio-Myc ChIP-Seq always reveals a major number of peaks overlapping with the indicated genomic features and shows a similar distribution to the NMyc dataset. "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) About 50% of the newly identified Myc-bound promoters show overlap with NMyc targets and an enrichment in the motif sequence corresponding to the perfect Myc E-Box (p-value 1E-142). (E???F) Gene ontology analysis reveals that the newly identified Myc target genes are enriched for genes associated with the cell cycle and cell metabolism as well as genes with molecular functions involved in the metabolism of nucleic acid and chromatin structure."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "941951":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) while the second group is composed of the genes that are bound only by Bio-Myc "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2121,
            "y2":332
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). "
        ],
        "rois":[
          {
            "x":0,
            "y":333,
            "x2":2121,
            "y2":1077
          },
          {
            "x":0,
            "y":1078,
            "x2":2121,
            "y2":2916
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) RT-qPCR analysis of endogenous Myc ChIP samples at the promoters of the indicated genes. The Suz12 and Ezh2 genes were used as positive controls, and the H19 and Kdr genes were used as negative controls. The results are shown as the percentage (1/100) of the input. "
        ],
        "rois":[
          {
            "x":0,
            "y":1078,
            "x2":2121,
            "y2":2916
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) RT-qPCR analysis of endogenous NMyc and Max ChIP reveals their binding to the promoters of the second group of genes. The Suz12 and Ezh2 genes were used as positive controls, the H19 and Kdr genes were used as negative controls. The results are shown as the percentage (1/100) of the input."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2121,
            "y2":332
          }
        ]
      }
    }
  },
  "941961":{
    
  },
  "9426":{
    "Gkl547f6.jpg":{
      "13":{
        "descriptions":[
          "(13):e98-e98.Published online 7 Aug 2006PMCID:PMC1540742.?? 2006 The Author(s) () The sensitivity to the template amount of cHDA was tested. The amount of the pREP plasmid DNA (6 kb) used in each cHDA reaction is indicated on the top. Lane M, 2-log DNA maker (NEB). () Time course of cHDA product formation. A series of cHDA reactions containing different amounts of the pREP plasmid template (6 kb"
        ],
        "rois":[
          {
            "x":247,
            "y":10,
            "x2":453,
            "y2":142
          }
        ]
      },
      "50":{
        "descriptions":[
          "; 50, 5, 0.5 or 0.1 ng) was incubated at 25??C for upto 24 h and the incubation was stopped at various time points. The product formation was visualized by agarose gel electrophoresis, and analyzed with a GelDoc system (Bio-Rad). The relative yield (%) of the 2.3 kb specific product was calculated."
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          "; 50, 5, 0.5 or 0.1 ng) was incubated at 25??C for upto 24 h and the incubation was stopped at various time points. The product formation was visualized by agarose gel electrophoresis, and analyzed with a GelDoc system (Bio-Rad). The relative yield (%) of the 2.3 kb specific product was calculated."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":247,
            "y2":142
          }
        ]
      },
      "0":{
        "descriptions":[
          "; 50, 5, 0.5 or 0.1 ng) was incubated at 25??C for upto 24 h and the incubation was stopped at various time points. The product formation was visualized by agarose gel electrophoresis, and analyzed with a GelDoc system (Bio-Rad). The relative yield (%) of the 2.3 kb specific product was calculated."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "942670":{
    
  },
  "942812":{
    
  },
  "942821":{
    
  },
  "946805":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. Schematic representation of the different phosphorylation forms of GSK3?? and their activity status"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4801,
            "y2":4340
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B. Analysis of the phosphorylated forms of GSK3?? by western blot. Representative blots are shown. Expression levels of GSK3?? isoforms, ??1 and ??2, are presented and quantified individually or together. (n???=???3 independent studies, average ?? SD)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4801,
            "y2":4340
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C. Morphology of neurons (immunostained for TAU in green and nuclei counterstained in blue) cultured for 24 hours in the presence of DMSO (control) or in the presence of 6-bromoindirubin-3???-acetoxime (BIO) at 30 and 300 nM. Quantifications of the longest neurite, average neurite length and the number of neurites per cell are shown (n???=???130 cells, mean ?? SD, * for pD. Determination of CRMP4 phosphorylation levels in cortical neurons plated for 4 days on control or P(TMC-CL). Representative western blot is shown and below the quantification (n???=???3 independent studies, average ?? SD)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4801,
            "y2":4340
          }
        ]
      }
    }
  },
  "946989":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Functional diversity within four major plankton groups: phytoplankton (Phy), ciliates (Cil), rotifers (Rot), and all crustaceans (HerbCru + CarnCru), and system functional diversity Hbio of all 20 plankton guilds (cf. Table 1). Functional diversity of Rot is only shown when Rot biomass exceeded 1% of total biomass. "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":869,
            "y2":941
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Succession rate ?? of the 20 functional plankton guilds peaked twice shortly before and after the CWP. "
        ],
        "rois":[
          {
            "x":963,
            "y":12,
            "x2":1805,
            "y2":831
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) C:P ratios of algal and bacterial biomass and food quality of the food ingested by different consumer groups (average across 1987???1993) in relation to phosphorus concentrations (SRP from 1995, dashed line) and cellular levels of polyunsaturated fatty acids (PUFA average 2008???2009, dotted line) within the sestonic size fraction [92]. Food quality for herbivores decreased with increasing C:P ratios during succession. "
        ],
        "rois":[
          {
            "x":13,
            "y":1006,
            "x2":906,
            "y2":1890
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) System residence times for carbon (SRTC) and phosphorus (SRTP). SRTC and SRTP were maximal during the CWP due to the dominance of larger crustaceans with slower metabolism and in autumn-winter due to decreasing temperature and on average lower metabolic activity (Fig. 5D)."
        ],
        "rois":[
          {
            "x":963,
            "y":1000,
            "x2":1709,
            "y2":1815
          }
        ]
      }
    }
  },
  "946996":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) Correlogram of four system-level key indices: Ptot/Btot ???=??? system's mass-specific metabolic activity, Hbio ???=??? functional diversity, Cw ???=??? weighted connectance, SSS ???=??? Slope of the normalized biomass size spectrum. Blue (red) ellipsoids indicate positive (negative), and narrow (wide) ones indicate strong (weak) Spearman correlation coefficients. Note that the correlation coefficients between Ptot/Btot and Hbio (corr. ???=??????0.17) as well as between SSS and Hbio (corr. ???=??????0.07) were comparatively weak. B???E) Detailed trajectory of pairs of indices with comparatively strong correlations shown in ",
          "(A). The dashed arrows indicate the direction of the successional trajectory. The distance between the data points increases with the rate of change of the dynamics (approx. 1 data point per week). "
        ],
        "rois":[
          {
            "x":52,
            "y":7,
            "x2":765,
            "y2":738
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) During early succession, Ptot/Btot was maximal and SSS minimal due to the fast and density-independent growth of small producers and grazers. Towards intermediate succession, Ptot/Btot decreased with increasing body mass, leading to the maximal (shallowest) SSS. In late succession, SSS decreased again with more evenly distributed biomasses along the size gradient, accompanied by decreasing P/B due to aggravating abiotic conditions. "
        ],
        "rois":[
          {
            "x":827,
            "y":7,
            "x2":1703,
            "y2":727
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The correlation between Hbio and Cw was mostly positive along sections of the successional trajectory, but temporarily interrupted by a short phase of low functional diversity during intermediate succession (clear water phase). "
        ],
        "rois":[
          {
            "x":7,
            "y":823,
            "x2":811,
            "y2":1425
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cw increased while SSS became shallower (less negative) with the enhanced energy transfer from small to large organisms during succession. Note that Cw continued to increase in summer and autumn when the slope approached ???1 due to the more evenly distributed size classes along the size gradient."
        ],
        "rois":[
          {
            "x":827,
            "y":699,
            "x2":1674,
            "y2":1429
          }
        ]
      }
    }
  },
  "946997":{
    
  },
  "946998":{
    
  },
  "947650":{
    "Figure_2.tif":{
      "e":{
        "descriptions":[
          "(e, f): To compare the effect of RNA extraction methods on bio-analytical assay sensitivity, rat lung tissue was spiked with 372u ",
          "(e) or 372m "
        ],
        "rois":[
          {
            "x":9,
            "y":1639,
            "x2":859,
            "y2":2302
          }
        ]
      },
      "f":{
        "descriptions":[
          "(e, f): To compare the effect of RNA extraction methods on bio-analytical assay sensitivity, rat lung tissue was spiked with 372u ",
          "(f) (125 ng) and homogenised in 4M guanidine isothiocyanate (GITC) or Tri-reagent. Tri-reagent homogenised tissue was processed through the manufacturer???s recommended procedure for the extraction of RNA, either up to the chloroform phase separation step (TR-AQ) or through the entire process (TR-F). Recovery of siRNA from TR-AQ processed tissue was comparable to GITC, recovery from TR-F processed tissue was significantly lower. Values presented are mean ?? S.E.M (n???=???3), and represent % siRNA recovered in comparison to GITC."
        ],
        "rois":[
          {
            "x":948,
            "y":1639,
            "x2":1798,
            "y2":2302
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a, b) and anti-sense "
        ],
        "rois":[
          {
            "x":974,
            "y":8,
            "x2":1804,
            "y2":679
          }
        ]
      },
      "b":{
        "descriptions":[
          "(a, b) and anti-sense "
        ],
        "rois":[
          {
            "x":974,
            "y":8,
            "x2":1804,
            "y2":679
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c, d) strand measurement. Values presented are mean (n???=???3) with errors bars omitted for clarity. Percent PCR efficiency for 372u (sense) in TE buffer, plasma, or lung extract ???=??? 94.2%, 86.3% and 102.8% respectively. Percent PCR efficiency for 372 m (sense) ???=??? 124.2%, 101.5%, 114.8% respectively. "
        ],
        "rois":[
          {
            "x":9,
            "y":825,
            "x2":839,
            "y2":1496
          }
        ]
      },
      "d":{
        "descriptions":[
          "(c, d) strand measurement. Values presented are mean (n???=???3) with errors bars omitted for clarity. Percent PCR efficiency for 372u (sense) in TE buffer, plasma, or lung extract ???=??? 94.2%, 86.3% and 102.8% respectively. Percent PCR efficiency for 372 m (sense) ???=??? 124.2%, 101.5%, 114.8% respectively. "
        ],
        "rois":[
          {
            "x":10,
            "y":8,
            "x2":1804,
            "y2":1496
          }
        ]
      }
    }
  },
  "947655":{
    "Figure_4.tif":{
      "e":{
        "descriptions":[
          "(e). 1 ???=??? right accessory lobe, 2 ???=??? right cranial lobe, 3 ???=??? right middle lobe, 4 ???=??? upper left lobe, 5 ???=??? mid left lobe, 6 ???=??? lower left lobe, 7 ???=??? upper right caudal lobe, 8 ???=??? mid right caudal lobe and 9 ???=??? lower right caudal lobe. Values presented are mean ?? S.E.M (n???=???3), and P-value represents comparison between 372m and 372u."
        ],
        "rois":[
          {
            "x":26,
            "y":3609,
            "x2":3567,
            "y2":5174
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f) were significantly higher and persisted for longer than 372u "
        ],
        "rois":[
          {
            "x":26,
            "y":3609,
            "x2":3567,
            "y2":5174
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b). 372u "
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":3582,
            "y2":1763
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) and 372m "
        ],
        "rois":[
          {
            "x":28,
            "y":2068,
            "x2":1687,
            "y2":3408
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) were both distributed throughout the lung 5 minutes after intra-tracheal administration. In addition, plasma concentrations of 372m "
        ],
        "rois":[
          {
            "x":1923,
            "y":2040,
            "x2":3567,
            "y2":3408
          }
        ]
      }
    }
  },
  "947660":{
    "Figure_6.tif":{
      "f":{
        "descriptions":[
          "(f) followed by mRNA and protein analysis, revealed that STAT6 expression within the nasal cavity of Brown Norway rats was invariant "
        ],
        "rois":[
          
        ]
      },
      "a":{
        "descriptions":[
          "(a, b). Anaesthetised animals were administered 2mg/kg of siRNA in sterile saline and bioanalytical analysis performed 72 hours later on fine-dissected tissue samples and plasma. Small interfering RNA was detectable throughout the nasal cavities ("
        ],
        "rois":[
          {
            "x":17,
            "y":16,
            "x2":1684,
            "y2":1437
          }
        ]
      },
      "b":{
        "descriptions":[
          "(a, b). Anaesthetised animals were administered 2mg/kg of siRNA in sterile saline and bioanalytical analysis performed 72 hours later on fine-dissected tissue samples and plasma. Small interfering RNA was detectable throughout the nasal cavities ("
        ],
        "rois":[
          {
            "x":1956,
            "y":16,
            "x2":3698,
            "y2":1437
          }
        ]
      },
      "F":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":22,
            "y":1658,
            "x2":3827,
            "y2":4619
          }
        ]
      }
    }
  },
  "948575":{
    
  },
  "950792":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Malt agar plate with 2 mM ethyl vanillin after 14 d of incubation, "
        ],
        "rois":[
          {
            "x":7,
            "y":744,
            "x2":1468,
            "y2":1454
          },
          {
            "x":7,
            "y":7,
            "x2":724,
            "y2":720
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) a similar plate after pyrogallol and naphthol drop test for detection of secreted peroxidase (1) and laccase (2), "
        ],
        "rois":[
          {
            "x":750,
            "y":7,
            "x2":1468,
            "y2":720
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) malt agar plate with 2 mM iodo-ethyl vanillin after 14 d of incubation, note the brownish halo around the inoculated disc which indicates iodine release, "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) a similar plate after pyrogallol and naphthol drop test."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "954109":{
    
  },
  "954270":{
    
  },
  "955119":{
    
  },
  "955238":{
    "Figure_3.tif":{
      "NS":{
        "descriptions":[
          ".A.). TnT RRLs containing empty vector were used as controls for non-specific binding (NS)"
        ],
        "rois":[
          
        ]
      },
      "N":{
        "descriptions":[
          " [35S]- Flag-tagged DBC2 and C??210 were synthesized by TnT in the absence of any additions (no additions, N"
        ],
        "rois":[
          {
            "x":12,
            "y":939,
            "x2":1320,
            "y2":2065
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1276,
            "y2":906
          }
        ]
      },
      "B":{
        "descriptions":[
          " Homology model of the DBC2 Rho domain was built using Swiss-model and the crystal structure of Rnd1 (2CLS) as a template. The 46 residues which are deleted when DBC2's Rho-domain is truncated to a Ras domain including the loss of the G5 loop [32] are colored in magenta. The switch II region is colored yellow with the R99 residue in green. GTPgammaS is shown as spheres with V191 colored in cyan and K27 in light blue. The image was rendered by PyMol, Delano scientific. (B)"
        ],
        "rois":[
          {
            "x":12,
            "y":939,
            "x2":1320,
            "y2":2065
          }
        ]
      },
      "P":{
        "descriptions":[
          " [35S]-Labeled wild-type DBC2, DBC2 Rho domain (C??210), DBC2??Rho (N??258), and the DBC2/R99G (R99G) mutant were synthesized by TnT, pulled down from RRL with GTP-linked agarose, and washed with P100T as described under Materials and methods. The amount of bound [35S]-DBC2 constructs were quantified by scintillation counting and normalized for the number of Met present in each construct, and for [35S]-Met non-specifically bound to the GTP-agarose. The data represent three independent bio-replicates including three technical replicates. The (***) denotes a significant difference based on a 95% confidence interval, P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". [35S]DBC2 was pulled down from RRL with GMP or GTP-linked agarose, washed with P100T and analyzed by SDS-PAGE, and autoradiography, as described under Materials and methods. (C)"
        ],
        "rois":[
          {
            "x":12,
            "y":939,
            "x2":1320,
            "y2":2065
          }
        ]
      },
      "D":{
        "descriptions":[
          " [35S]-Flag-tagged DBC2 was synthesized by TnT in the absence of any additions. The samples were diluted with 5 volumes of TBS (buffer) or TBS containing GTP (GTP) to give a final concentration of 20 mM GTP. After 45 min of incubation with GTP-agarose at 4??C, the samples were washed and the amount of [35S]-DBC2 was determined by scintillation counting. The experiment was carried out in triplicate. (D)"
        ],
        "rois":[
          {
            "x":12,
            "y":939,
            "x2":1320,
            "y2":2065
          }
        ]
      }
    }
  },
  "955240":{
    "Figure_4.tif":{
      "NS":{
        "descriptions":[
          " or DMSO, pulled down from RRL with GTP-agarose, washed with buffer containing low (100 mM) or high (500 mM) NaCl, and analyzed by SDS-PAGE and autoradiography, as described under Materials and methods. Na??ve RRL containing no template DNA was used as the control for nonspecific binding (A and B: NS)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":996,
            "y2":182
          }
        ]
      },
      "NA":{
        "descriptions":[
          ", molybdate (MoO4), or the vehicle controls water (NA)"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A)",
          " GTP-agarose pull-downs of [35S]-labeled Flag-tagged DBC2 Rho domain (C??210) was carried out in the presence of geldanamycin, molybdate, or vehicle controls as described above in (A)",
          " GTP-agarose pull downs of [35S]-labeled Flag-tagged DBC2 was carried out in the presence of geldanamycin, molybdate or vehicle controls as described in (A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":996,
            "y2":182
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Input: control for amounts of protein that was present in samples used for GTP-agarose pull downs. (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":183,
            "x2":996,
            "y2":457
          }
        ]
      },
      "P":{
        "descriptions":[
          " above. The amount of bound [35S]-DBC2 constructs were quantified by scintillation counting and normalized for [35S]-Met non-specifically bound to the GTP-agarose. The data represent three independent bio-replicates including three technical replicates. The (***) denotes a significant difference based on a 95% confidence interval, P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          " for full length DBC2. (C)"
        ],
        "rois":[
          {
            "x":0,
            "y":458,
            "x2":996,
            "y2":1210
          }
        ]
      },
      "GA":{
        "descriptions":[
          " [35S]-Labeled Flag-tagged DBC2 was synthesized in the presence geldanamycin (GA)"
        ],
        "rois":[
          {
            "x":0,
            "y":183,
            "x2":996,
            "y2":457
          }
        ]
      }
    }
  },
  "955939":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Scheme of the developed bio-assay model system. "
        ],
        "rois":[
          {
            "x":7,
            "y":462,
            "x2":391,
            "y2":884
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) HE-staining of brain endothelial cell monolayers grown on top of the filter membranes. Scale bar: 50 ??m. "
        ],
        "rois":[
          {
            "x":1552,
            "y":2491,
            "x2":2017,
            "y2":2707
          },
          {
            "x":18,
            "y":1618,
            "x2":434,
            "y2":2151
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunofluorescence staining of different tight junction proteins expressed in PBEC mono- and co-culture with SH-SY5Y cells. Scale bars: 40 ??m. "
        ],
        "rois":[
          {
            "x":1552,
            "y":2491,
            "x2":2017,
            "y2":2707
          },
          {
            "x":35,
            "y":7,
            "x2":804,
            "y2":421
          },
          {
            "x":783,
            "y":50,
            "x2":1226,
            "y2":482
          },
          {
            "x":396,
            "y":509,
            "x2":740,
            "y2":884
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Immunofluorescent staining of zonula occludens protein "
        ],
        "rois":[
          {
            "x":1552,
            "y":2491,
            "x2":2017,
            "y2":2707
          },
          {
            "x":783,
            "y":50,
            "x2":1226,
            "y2":482
          },
          {
            "x":782,
            "y":487,
            "x2":1226,
            "y2":887
          },
          {
            "x":1644,
            "y":51,
            "x2":2048,
            "y2":887
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Electron microscopy images (a: SEM; b: TEM) of PBEC grown on top of the filter membranes. Arrows indicate the cell-cell connections. Scale bars: 20 ??m (a) and 1 ??m (b)."
        ],
        "rois":[
          {
            "x":853,
            "y":1708,
            "x2":2051,
            "y2":2149
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cell viability and caspase 3/7 activity of brain endothelial cells cultured with or without SH-SY5Y cells. Values obtained for mono-cultures were set to 100%, data represent mean ?? standard deviation of three experiments (n ???8; One Way Anova; Bonferroni post-test; ns: p>0.05; ***: papp) of hCMEC/D3 and PBECs grown with or without SH-SY5Y cells. At day eight SH-SY5Y cells were seeded on the bottom of the 24-well plate. Papp of sodium fluorescein was determined 3 hours and 48 hours after seeding of SH-SY5Y cells. "
        ],
        "rois":[
          {
            "x":1552,
            "y":2491,
            "x2":2017,
            "y2":2707
          },
          {
            "x":106,
            "y":2192,
            "x2":694,
            "y2":2714
          },
          {
            "x":981,
            "y":2194,
            "x2":1540,
            "y2":2707
          },
          {
            "x":464,
            "y":1684,
            "x2":818,
            "y2":2076
          },
          {
            "x":37,
            "y":942,
            "x2":918,
            "y2":1656
          },
          {
            "x":1193,
            "y":993,
            "x2":2043,
            "y2":1582
          },
          {
            "x":1233,
            "y":51,
            "x2":1638,
            "y2":887
          }
        ]
      }
    }
  },
  "957800":{
    
  },
  "957801":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A), as well as IFN "
        ],
        "rois":[
          {
            "x":708,
            "y":31,
            "x2":2040,
            "y2":821
          },
          {
            "x":7,
            "y":7,
            "x2":1263,
            "y2":1238
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), by Bio-Plex or ELISA. Results shown are representative of three separate experiments."
        ],
        "rois":[
          {
            "x":1424,
            "y":869,
            "x2":2043,
            "y2":1261
          }
        ]
      }
    }
  },
  "959574":{
    
  },
  "960466":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E, F) The protein levels of ZEB2, E-cadherin or vimentin was examined by Western blot in cells transfected with different plasmids. Figure F shows the relative gray values of each band (normalized to ??-actin). Protein bands from three independent Western blot assays were quantified using Quantity One software (Bio-Rad, USA). Data are reported as mean ??SD (**Pt- test)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E, F) The protein levels of ZEB2, E-cadherin or vimentin was examined by Western blot in cells transfected with different plasmids. Figure F shows the relative gray values of each band (normalized to ??-actin). Protein bands from three independent Western blot assays were quantified using Quantity One software (Bio-Rad, USA). Data are reported as mean ??SD (**Pt- test)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) The miR-132 binding site predicted in the 3???UTR of ZEB2 mRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Mutant was generated at the seed region of ZEB2 3??? UTR as indicated by the underline. A 3??? UTR fragment of ZEB2 mRNA containing wild-type or mutant of the miR-132 binding sequence was cloned into the downstream of the luciferase gene in pMIR vector. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) L9981 cells were transfected with pMIR reporter vectors containing either wild-type or mutant ZEB2 3???UTR (indicated as pMIR-ZEB2-3??? UTR-wt and pMIR-ZEB2-3??? UTR-mut) with either pcDNA3.1 (indicated as NC) or pcDNA3.1-miR-132 vector (indicated as miR-132). Luciferase activity was determined 48 h after transfection. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) ZEB2 mRNA was detected by qRT-PCR in cell lines transfected with pcDNA3.1 (indicated as NC) or pcDNA3.1-miR-132 vector (indicated as miR-132). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2834,
            "y2":2224
          }
        ]
      }
    }
  },
  "962840":{
    
  },
  "964445":{
    "Figure_1.tif":{
      "4":{
        "descriptions":[
          "(4) were dried onto the working carbon cloth electrode "
        ],
        "rois":[
          {
            "x":607,
            "y":8,
            "x2":1047,
            "y2":556
          }
        ]
      },
      "5":{
        "descriptions":[
          "(5) with illumination provided by a red LED light source "
        ],
        "rois":[
          
        ]
      },
      "6":{
        "descriptions":[
          "(6). (B) Scanning electron micrograph of wild type Synechocystis cells immobilized on a carbon cloth electrode."
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":498,
            "y2":594
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1) and electrochemical measurements were performed using a CHI 1200A (CH instruments, Inc. Austin, Texas) potentiostat "
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          "(2) and platinum wire as the counter electrode "
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          "(3). Synechocystis cells "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "964634":{
    
  },
  "973872":{
    
  },
  "973884":{
    
  },
  "976937":{
    
  },
  "985318":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(a) Concentration dependent ligand displacement of three odorants predicted as ligands for the PPAR?? receptor. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2051,
            "y2":1678
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Transcriptional activation of PPAR?? by three odorants. Results are shown as the average ?? standard deviation of 2 individual experiments with each of the experiments performed with 8 replicas. Activation is given as fold activation relative to the DMSO vehicle. Rosiglitazone (not shown) was used as positive control."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "988972":{
    
  },
  "989786":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          ". a) The growth of IgR39 (non-metastatic) cells is not affected by pressure after 3 days"
        ],
        "rois":[
          {
            "x":13,
            "y":10,
            "x2":1382,
            "y2":1039
          }
        ]
      },
      "b":{
        "descriptions":[
          ", b) but cells grow significantly less after 6 days"
        ],
        "rois":[
          {
            "x":1393,
            "y":10,
            "x2":2734,
            "y2":1039
          }
        ]
      },
      "c":{
        "descriptions":[
          ". c) IgR37 (metastatic) cells are unaffected by pressure both after c) 3 or d) 6 days. Statistically significant results according to the KS test () are denoted with *."
        ],
        "rois":[
          {
            "x":42,
            "y":1169,
            "x2":1368,
            "y2":2276
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1369,
            "y":1169,
            "x2":2740,
            "y2":2276
          }
        ]
      }
    }
  }
,
  "1093302":{
    
  },
  "10953":{
    
  },
  "1100957":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          ". A) Cells were pulsed with medium alone, PL at 25 ug/ml, LPS at 10 ng/ml, or PL before the addition of LPS to the medium"
        ],
        "rois":[
          {
            "x":79,
            "y":17,
            "x2":526,
            "y2":333
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Cells were pulsed with medium alone, PL at 25 ug/ml, Tg at 2 ??M, or PL before the addition of Tg to the medium. Immunoprecipitation of TRPC1-STIM1 complex from cell was prepared by using Anti-STIM1 Ab. Anti-TRPC1 was used for western blot detection in both Fig. 8 A and B. The average pixel intensity of the respective bands from three independent experiments was measured. This was done using the imaging software Quality One-4.6.7 (Bio-Rad)."
        ],
        "rois":[
          {
            "x":19,
            "y":647,
            "x2":2671,
            "y2":1685
          },
          {
            "x":1398,
            "y":29,
            "x2":2619,
            "y2":540
          },
          {
            "x":526,
            "y":105,
            "x2":1384,
            "y2":348
          },
          {
            "x":290,
            "y":374,
            "x2":1396,
            "y2":517
          }
        ]
      }
    }
  },
  "1103956":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) AID-induced lesions result in bio-dC incorporation. G-AID was incubated with a pre-methylated substrate (M.SssI - Figure S2) for 30 min and then added to FE. Repaired plasmids (bio-dC labelled) were isolated and quantified by qPCR. The bars represent the ratio (Fold change) of the amount of recovered plasmids from reactions carried out in the presence of G-AID, untagged AID (AID), the GAL4 DNA binding domain (G-DBD), or the mutant G-AID C87R versus levels of plasmids recovered from reactions that did not contain G-AID (FE, set to 1). Error bars indicate ?? standard deviation (SD, n???=???3). Line schematics for all IVR assays are shown above the graphs, and they indicate the order of addition of substrates/proteins/nucleotides/extract/etc. or treatments. ",
          "(A), containing either bio-dC or bio-dA during the resolution phase of the IVR. Where indicated, FE was treated with Ugi prior to addition of the plasmids (FE (Ugi)). The bars depict the levels of plasmids (bio-dC or bio-dA labelled) that were recovered from the individual reactions. Samples were normalized to FE reactions without G-AID "
        ],
        "rois":[
          {
            "x":51,
            "y":7,
            "x2":1219,
            "y2":1249
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) AID-induced lesion resolution on methylated targets involves BER and processive DNA polymerases-dependent repair. IVR reactions were performed as in "
        ],
        "rois":[
          {
            "x":8,
            "y":1359,
            "x2":1221,
            "y2":2673
          }
        ]
      },
      "FE":{
        "descriptions":[
          "(FE) and were set to 1. Error bars indicate ?? standard deviation (SD, n???=???3)."
        ],
        "rois":[
          {
            "x":51,
            "y":7,
            "x2":1219,
            "y2":1249
          }
        ]
      }
    }
  },
  "1107095":{
    
  },
  "1107515":{
    
  },
  "1108317":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) Scores plot obtained from OPLS-DA model of T1 and T2 in positive ionization mode shows inter-group separation B) OPLS-DA loadings S-plot comparing features from T1 and T2 in positive ionization mode"
        ],
        "rois":[
          {
            "x":906,
            "y":7,
            "x2":1795,
            "y2":535
          },
          {
            "x":9,
            "y":32,
            "x2":878,
            "y2":533
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Score plot obtained from OPLS-DA model of T1 and T2 in negative ionization mode shows inter-group separation"
        ],
        "rois":[
          {
            "x":23,
            "y":511,
            "x2":885,
            "y2":1032
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) OPLS-DA loadings S-plot comparing features from t1 and t2 in negative ionization mode. Each spot in S-plot corresponds to a feature with characteristic m/z ratio and retention time. The metabolites marked in red were treated as putative bio-markers for the therapy and characterized later."
        ],
        "rois":[
          {
            "x":912,
            "y":520,
            "x2":1804,
            "y2":1036
          }
        ]
      }
    }
  },
  "1109036":{
    "Figure_3.tif":{
      "12":{
        "descriptions":[
          "(12), Marginal Plateau "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "8":{
        "descriptions":[
          "(8), Island Arc "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          }
        ]
      },
      "19":{
        "descriptions":[
          "(19), Seamount Ridges "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "23":{
        "descriptions":[
          "(23), Structural Slope Region "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "4":{
        "descriptions":[
          "(4), Coastal (rugged) Terrane "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":3,
            "y":3,
            "x2":1062,
            "y2":920
          }
        ]
      },
      "15":{
        "descriptions":[
          "(15), Plateau "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "11":{
        "descriptions":[
          "(11), Marginal Ridge "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "9":{
        "descriptions":[
          "(9), Island Coastal Terrane "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          }
        ]
      },
      "22":{
        "descriptions":[
          "(22), Shelf Deep (Depressions) "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "26":{
        "descriptions":[
          "(26), Upper (Continental) Slope "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "13":{
        "descriptions":[
          "(13), Mid-Ocean Ridge Rift Valley "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "24":{
        "descriptions":[
          "(24), Trench "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "16":{
        "descriptions":[
          "(16), Plateau Slope "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "5":{
        "descriptions":[
          "(5), Contourite Drift "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":3,
            "y":3,
            "x2":1062,
            "y2":920
          }
        ]
      },
      "10":{
        "descriptions":[
          "(10), Lower Slope "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "21":{
        "descriptions":[
          "(21), Shelf "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "6":{
        "descriptions":[
          "(6), Cross Shelf Valley "
        ],
        "rois":[
          {
            "x":1025,
            "y":6,
            "x2":2042,
            "y2":897
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1), Bank "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          }
        ]
      },
      "17":{
        "descriptions":[
          "(17), Ridge "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "25":{
        "descriptions":[
          "(25), Trough Mouth Fans "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "14":{
        "descriptions":[
          "(14), Ocean Trough "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "20":{
        "descriptions":[
          "(20), Seamount "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "27":{
        "descriptions":[
          "(27), Volcano "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2), Canyon "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":3,
            "y":3,
            "x2":1062,
            "y2":920
          }
        ]
      },
      "18":{
        "descriptions":[
          "(18), Rugose Ocean Floor "
        ],
        "rois":[
          {
            "x":23,
            "y":1760,
            "x2":2042,
            "y2":2745
          }
        ]
      },
      "7":{
        "descriptions":[
          "(7), Fracture Zone "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3), Cliff "
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          },
          {
            "x":3,
            "y":3,
            "x2":1062,
            "y2":920
          }
        ]
      },
      "28":{
        "descriptions":[
          "(28) D) Seabed temperature E) Duration of the year where more than 85% of the region is covered by sea ice F) High positive and negative values indicate areas of consistently high and low summer productivity respectively. Values approaching zero indicate areas that vary greatly between years."
        ],
        "rois":[
          {
            "x":9,
            "y":858,
            "x2":2031,
            "y2":1741
          }
        ]
      }
    }
  },
  "11106":{
    
  },
  "1113479":{
    
  },
  "1114078":{
    
  },
  "1114081":{
    
  },
  "1114083":{
    
  },
  "1114085":{
    
  },
  "1116778":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A.. In vitro, Ca2+-free bGCAP2 is phosphorylated more efficiently than Ca2+-bound bGCAP2. Upper panel shows an autoradiograph of 33P phosphorylation products from an in vitro phosphorylation reaction of recombinant wildtype bGCAP2 or bEF???GCAP2 with protein kinase G (PKG), in the presence or absence of free Ca2+. The 20 ??l reaction mixture contained 8.5 ??g of purified recombinant wildtype bGCAP2 or bEF???GCAP2, purified PKGI?? (100 units, Calbiochem) and 3 ??Ci of 33P- ??ATP in phosphorylation reaction buffer, containing either CaCl2 or EGTA (see Methods). After incubation, reaction mixtures were resolved by 15% SDS-PAGE and transferred to a nitrocellulose membrane. Lower panel shows immunostained GCAP2. Recombinant bGCAP2 or bEF???GCAP2 protein were present to similar amounts in all reaction tubes"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1435,
            "y2":1665
          }
        ]
      },
      "MW":{
        "descriptions":[
          "(MW) markers (Precision Plus Protein Standards, BioRad) are 20, 25, 37, 50, 75, 100 and 150 kDa. Experiment shown in duplicate"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B.. In vitro phosphorylated or mock-treated bGCAP2 and bEF???GCAP2 were generated for pull-down assays. Phosphorylation reactions were performed as above, in the presence of EGTA, except that cGMP was added to 500 ??M (+ lanes) or not added (??? lanes). Immunostaining of GCAP2 in the same nitrocellulose membrane shows the GCAP2 monomer at 25 kDa and upper bands corresponding to dimers and multimers of GCAP2, observed to a higher extent in the EF???GCAP2 lanes. Molecular mass "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1435,
            "y2":1665
          }
        ]
      },
      "UK":{
        "descriptions":[
          ", UK), an IRDye 800CW Goat Anti-rabbit IgG and a IRDye 680CW Goat Anti-mouse IgG (Tebu-Bio, Offenbach, Germany). Image was acquired at the Odyssey Imaging System (LI-COR). Therefore 14-3-3pan isoforms (30 kDa) are shown in green, while 14-3-3?? (33 kDa) is shown in red. Experiment shown in duplicate."
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". C. The 14-3-3 protein isoforms bind more efficiently to phosphorylated bGCAP2 and bEF???GCAP2 than to unphosphorylated counterparts. Phosphorylated or mock- proteins were cross-liked to magnetic beads and pull-down assays were performed with whole bovine retinal extracts obtained in 1% Triton-X100. Panels show the input and bound fractions for the indicated phospho- or mock-proteins, resolved by 15% SDS-PAGE. Membrane was sequentially incubated with a pAb to 14-3-3pan (IBL International, Hamburg, Germany), a mAb to 14-3-3?? (abcam, Cambridge"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1435,
            "y2":1665
          }
        ]
      }
    }
  },
  "1117247":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) were analyzed by qRT-PCR. *pF and G. miR-361 prevents the processing of pri-miR-484 by Drosha into pre-miR-484. Cardiomyocytes were coinfected with the adenoviral Drosha and miR-361, transfected with anta-361 or anta-NC. 48 h after transfection, cells were harvested. pri-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) and pre-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. The miR-361 targeting site in pri-miR-484 is shown. B and C. Enforced expression of miR-361 increases the levels of pri-miR-484 and reduces the levels of pre-miR-484. Cardiomyocytes were infected with adenoviral miR-361 or ??-gal at indicated time, the expression of pri-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) were analyzed by qRT-PCR. *pH. miR-361 can directly bind to pri-miR-484 in vivo. Cardiomyocytes were transfected with biotinylated wild type miR-361 (Bio-wt-361), biotinylated mutant miR-361 (Bio-mut-361) and biotinylated negative control (Bio-NC). 48 h after transfection, cells were harvested for biotin-based pull-down assay. Only ???seed??? region of wt and mutant miR-361 were shown (upper panel). Pri-miR-484 were analyzed by qRT-PCR (low panel). *pI. miR-361 is associated with pri-miR-484 in vivo. pri-miR-484 probe-coated magnetic bead was incubated with cardiomyocyte nulear lysate. After washing and enrichment of beads/RNA complex, RNA was eluted from the streptavidin beads and was analyzed by northern blot. I, input (10% samples were loaded); P, pellet (100% samples were loaded)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and pre-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) were analyzed by qRT-PCR. *pD and E. Knockdown of miR-361 induces a reduction in pri-miR-484 levels and an increase in pre-miR-484. Cardiomyocytes were transfected with miR-361 antagomir (anta-361) or the antagomir negative control (anta-NC). 24 h after transfection, the expression of pri-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and pre-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2040,
            "y2":2309
          }
        ]
      }
    }
  },
  "1117257":{
    "Figure_5.tif":{
      "F":{
        "descriptions":[
          "(F) and pre-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1914,
            "y2":2336
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. MDRL RNA contains a site complementary to miR-361"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1914,
            "y2":2336
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) were analyzed by qRT-PCR. *pH. Knockdown of miR-361 attenuated the inhibitory effects of MDRL knockdown on the processing of pri-miR-484 induced by Drosha. Cardiomyocytes were coinfected with the adenoviral Drosha, MDRL-siRNA and MDRL-sc, transfected with anta-361 or anta-NC. 48 h after transfection, cells were harvested. pri-miR-484 expression levels were analyzed by qRT-PCR. *p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1914,
            "y2":2336
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Luciferase assay. miR-361 binding site in MDRL RNA wild type form (Luc-MDRL-wt) and the mutated form (Luc-MDRL-mut) are shown in upper panel. HEK293 cells were infected with adenoviral miR-361 or ??-gal, then transfected with the luciferase constructs of Luc-MDRL-wt or Luc-MDRL-mut. The luciferase activity was analyzed. *pC. Wild type and the mutated form of biotin-labeled miR-361 sequence are shown"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1914,
            "y2":2336
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. miR-361 can bind directly to MDRL in vivo. Cardiomyocytes were transfected with biotinylated wild type miR-361 (Bio-wt-361) or biotinylated mutant miR-361 (Bio-mut-361). A biotinylated miRNA that is not complementary to MDRL was used as a negative control (Bio-NC). 48 h after transfection, cells were harvested for biotin-based pull-down assay. MDRL expression levels were analyzed by real time PCR. *pE. MDRL can bind to miR-361 in vivo. Cardiomyocyte nuclear lysate was incubated with MDRL probe or random probe-coated magnetic bead. After washing and enrichment of beads/RNA complex, RNA was eluted from the streptavidin beads and was analyzed by northern blot. I, input (10% samples were loaded); P, pellet (100% samples were loaded). F and G. Enforced expression of MDRL induces the decreases of pri-miR-484 expression levels and the increases pre-miR-484 expression levels. Cardiomyocytes were infected with adenoviral MDRL or ??-gal, the expression of pri-miR-484 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1914,
            "y2":2336
          }
        ]
      }
    }
  },
  "1121066":{
    
  },
  "1121068":{
    
  },
  "1121431":{
    
  },
  "1121638":{
    
  },
  "1126750":{
    
  },
  "1126915":{
    "Figure_7.tif":{
      "IP":{
        "descriptions":[
          "(IP) cell lysate corresponded with the molecular weight "
        ],
        "rois":[
          {
            "x":15,
            "y":16,
            "x2":3959,
            "y2":2675
          }
        ]
      },
      "MW":{
        "descriptions":[
          "(MW) of 17 kDa for ID3. IP was performed to isolate ID3 from cell lysate using a monoclonal anti-ID3 antibody. Magnetic bead-based separation was then used to extract the bound ID3 protein via Protein G coupled to superparamagnetic Dynabeads. P-Tyr was detected by immunoblotting using the anti-phospho-Tyr antibody. Electrochemiluminescence (ECL) band intensity for phospho-Tyr was imaged with a Bio-Rad Versa Doc instrument."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1127176":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Western blot of FLAG-tagged PLAT1 at the N-terminal (FLAG-PLAT1). FLAG-PLAT1, expressed in yeast, was detected on 10% SDS-PAGE using the anti-FLAG mouse monoclonal antibody as the primary antibody, followed by HRP-conjugated anti-mouse IgG antibody as the secondary antibody. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":976,
            "y2":885
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The localization of PLAT1 was estimated by Western blot using the microsomal and cytosolic fractions of FLAG-PLAT1-expressing yeast cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":976,
            "y2":885
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) LPCAT activity was measured based on the incorporation of 16???0 from 16:0-CoA into [1-14C]palmitoyl-LPC. The reaction mixture contained 25 ??M 16:0-CoA and 1 ??M [1-14C]palmitoyl-LPC, and 10 ??g of cell protein (cell lysate) in 100 ??l of reaction buffer (100 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.01% sodium cholate). Mock represents the experiment using the enzyme prepared from the lysate of yeast cells harboring the empty vector. The reaction was conducted at 30??C for 20 min and terminated by the addition of 500 ??l of CHCl3/CH3OH (2???1, v/v). The reaction mixture was loaded on the TLC plate, developed with CHCl3/CH3OH/H2O (65/25/4, v/v/v), and analyzed with a FLA 5100 Bio-imaging analyzer. ",
          "(C), while the reaction mixture contained 1 mM EGTA (center column) or 1 mM CaCl2 (right column) instead of EDTA. The radioactivity of the band corresponding to PC on the TLC plate was quantified by a FLA 5100 Bio-imaging analyzer. Data represent the mean ?? SD (n???=???3). Blue and red bars represent the FLAG-PLAT1 and mock, respectively."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":976,
            "y2":885
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) LPCAT activity (left column) was measured by the method described in the legend "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":976,
            "y2":885
          }
        ]
      }
    }
  },
  "1127179":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) FLAG-PLAT1 was purified using the ANTI-FLAG M2 Affinity Gel and 3X FLAG peptide to remove the endogenous LPLs as described in Materials and Methods. Each assay contained 25 ??M acyl-CoA, 1 ??M [1-14C]palmitoyl-LPC, and purified enzyme (10 ??l of gel suspension) in 100 ??l of 100 mM Tris-HCl, pH 7.5, containing 1 mM EDTA and 0.01% sodium cholate. The reaction was conducted at 30??C for 20 min and terminated by the addition of 500 ??l of CHCl3/CH3OH (2???1, v/v). The reaction mixture was loaded on the TLC plate and developed with CHCl3/CH3OH/H2O (65/25/4, v/v/v). The radioactivity of the band corresponding to PC on the TLC plate was quantified by a FLA 5100 Bio-imaging analyzer. Data represent the mean ?? SD (n???=???3). "
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":831,
            "y2":511
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Each assay contained 1 ??M of LPLs, 1 ??M [1-14C]palmitoyl-CoA, and the purified enzyme (10 ??l of gel suspension) in 100 ??l of 100 mM Tris-HCl, pH 7.5, containing 1 mM EDTA and 0.01% sodium cholate. Mock represents the experiment using the enzyme prepared from the lysate of yeast cells harboring the empty vector. The assay was conducted at 30??C for 20 min and terminated by the addition of 500 ??l of CHCl3/CH3OH (2???1, v/v). The reaction mixture was loaded on the TLC plate, developed with CHCl3/CH3OH/H2O (65/25/4, v/v/v), and analyzed with a FLA 5100 Bio-imaging analyzer. The typical TLC is presented here. ",
          "(B). The reaction products were applied on TLC plates and the radioactivity of the band corresponding to each PL was quantified by a FLA 5100 Bio-imaging analyzer (n???=???3). Data represent the mean ?? SD."
        ],
        "rois":[
          {
            "x":10,
            "y":538,
            "x2":946,
            "y2":996
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The enzyme reaction was performed by the same procedure as shown in "
        ],
        "rois":[
          {
            "x":9,
            "y":1044,
            "x2":845,
            "y2":1503
          }
        ]
      }
    }
  },
  "11287":{
    
  },
  "1133262":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) Immunoblot of lysates of 293T cells transiently expressing MALT1 alone or in combination with BCL10 with antibodies against MALT1 [31], BCL10 and tubulin"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":913,
            "y2":663
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Immunoblot of streptavidin pull-downs (bio-IPs) of Avi-tagged MALT1 and its mutants co-expressed with BCL10 in 293T cells as specified"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":913,
            "y2":663
          }
        ]
      },
      "AS":{
        "descriptions":[
          ". AS: a-specific band. Arrows indicate the N-terminal p19 cleavage fragment. All molecular mass standards are in kDa."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":913,
            "y2":663
          }
        ]
      }
    }
  },
  "1133268":{
    "Figure_4.tif":{
      "NF":{
        "descriptions":[
          ". NF-??B-dependent luciferase activity is shown as fold induction of vector-transfected cells and represents the mean +/"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "A) Features of Flag-tagged MALT1, p76, MALT1-C and MALT1-p19. Numbers indicate the start and stop AA position for p76, MALT1-C and MALT1-p19 relative to the MALT1 protein sequence (Refseq NP_006776.1, 824 AA). B-C) NF-??B-reporter assays of 293T cells transiently expressing MALT1, mp-MALT1, MALT1-p19, p76 and mutants or MALT1-C"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2030,
            "y2":1218
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and a-MALT1-C "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2030,
            "y2":1218
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) shows equal expression of the different MALT1 constructs. Bottom ",
          "(C): streptavidin pull-down (bio-IP) of MALT1, p76 or MALT1-C, transiently expressed in 293T cells, and immunoblotted with a-MALT1C, a-TRAF6 and a-BCL10 antibodies. e-MALT1, e-TRAF6, e-BCL10: endogenous MALT1, TRAF6 and BCL10"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2030,
            "y2":1218
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) immunoblot of bio-IPs of Avi-tagged Ub-p76 expressed together with Flag-p76 or Flag MALT1 with a-MALT1-C, a-Flag and a-TRAF6. * indicate non-specific bands."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2030,
            "y2":1218
          }
        ]
      },
      "S":{
        "descriptions":[
          "- S.D. (n???=???3). Immunoblot of cell lysates with a-Flag ??? a-??-actin shows equal expression/loading of the different MALT1 constructs "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2030,
            "y2":1218
          }
        ]
      }
    }
  },
  "1133274":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "A) Jurkat T cells were left untreated or stimulated with P/I for 30 min, with or without pre min, with or without pre-treatment with 50 ??M z-VRPR-fmk for 30 min. Lysates were analysed for the presence of the cleavage fragments for BCL10 and MALT1 p19, for p min. Lysates were analysed for the presence of the cleavage fragments for BCL10 and MALT1 p19, for p-ERK (activation control) and tubulin (loading control)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":750,
            "y2":846
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) IL-2 production (ELISA) of Jurkat T cells stably expressing MALT1, MALT1-R149A, MALT1-C464A or MALT1-RACA, either untreated (-) or stimulated for 18 hrs with PMA hrs with PMA/ionomycin (P/I). Data shown as mean +/"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":750,
            "y2":846
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Immunoblot of cell lysates (top) and bio-IPs (bottom) from Jurkat T cells and Jurkat T cells with stable expression of Avi-tagged MALT1 or MALT1 mutants R149A, C464A and RACA with indicated antibodies."
        ],
        "rois":[
          {
            "x":751,
            "y":0,
            "x2":950,
            "y2":756
          },
          {
            "x":951,
            "y":0,
            "x2":1970,
            "y2":846
          }
        ]
      },
      "AS":{
        "descriptions":[
          ". AS: a-specific band obtained with a-Flag that serves as loading control"
        ],
        "rois":[
          {
            "x":951,
            "y":0,
            "x2":1970,
            "y2":846
          }
        ]
      },
      "S":{
        "descriptions":[
          "- S.D. (n???=???3). Inset: Immunoblot with a-MALT1-C and a-Flag showing expression of ectopic MALT1 and mutants relative to endogenous MALT1 (lane 1). Numbers indicate fold overexpression relative to endogenous MALT1"
        ],
        "rois":[
          {
            "x":751,
            "y":0,
            "x2":950,
            "y2":756
          },
          {
            "x":751,
            "y":757,
            "x2":950,
            "y2":846
          }
        ]
      }
    }
  },
  "1135335":{
    
  },
  "1135336":{
    
  },
  "1135337":{
    
  },
  "1140789":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A: Manhattan plot of p-values for all 528 miRNAs 18 samples. The AB-line (i.e. horizontal line in the middle of Figure) represents P-value cut off, p???=???0.00065. Relative location of 528 miRNAs (along the horizontal axis) across the human genome and their corresponding ???log10 transformed p-value (along the vertical axis) was plotted"
        ],
        "rois":[
          {
            "x":29,
            "y":2651,
            "x2":4167,
            "y2":5267
          },
          {
            "x":17,
            "y":16,
            "x2":4075,
            "y2":2603
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Heat map diagram of ????Ct values. Two-way unsupervised hierarchical clustering of 7 miRNAs whose expression was significantly deregulated samples. Each row represents expression of a miRNA and each column represents a sample. Sky-blue colored cells stand for failed assay i.e. no data in those cells. Red and green colors signify up- and down-regulation, respectively. Dendogram along the vertical axis represents hierarchical classification of miRNAs on the basis of expressions similarity. Distance metrics of hierarchical clustering was Euclidean distance. Heat map was constructed using Heatmap 2 of R's ???gplot??? package"
        ],
        "rois":[
          {
            "x":29,
            "y":2651,
            "x2":4167,
            "y2":5267
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Highly correlated expression of miR-206 and miR-1."
        ],
        "rois":[
          {
            "x":29,
            "y":2651,
            "x2":4167,
            "y2":5267
          }
        ]
      }
    }
  },
  "1140791":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A: Manhattan plot of p-values for 520 miRNAs from the cluster of 13 samples. The plot of relative location of 520 miRNAs (along the horizontal axis) across the human chromosome and their corresponding ???log10 transformed p-value (along the vertical axis). Benjamini-Hochberg corrected P-value cut off was 0.00298 (Horizontal line in the middle of figure)"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2950,
            "y2":1978
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Heat map diagram of ????Ct values of 30 miRNAs. Expression of these miRNAs was significantly deregulated in the cluster of 13 samples. Each row represents a miRNA and each column represents a sample. Sky-blue colored cells stand for failed assay (i.e.no data in those cells). Red and green colors signify up- and down-regulation of expression, respectively. Heat map was constructed using Heatmap 2 of R's ???gplot??? package"
        ],
        "rois":[
          {
            "x":19,
            "y":2009,
            "x2":3148,
            "y2":3372
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Highly correlated expression of miR-411* and miR-411."
        ],
        "rois":[
          {
            "x":15,
            "y":3469,
            "x2":3153,
            "y2":4085
          }
        ]
      }
    }
  },
  "1143100":{
    
  },
  "1145129":{
    "Figure_1.tif":{
      "X":{
        "descriptions":[
          "(X), a C-terminal FLAG tag and the HIV Rev NES (black box). In bio-cCE the NLS is deleted and a sequence that is biotinylated in vivo is added upstream of Myc tag and Rev NES. In bio-cCE??25C the C-terminal 25 amino acids of this protein were deleted. cCE-bio is similar to CE??NLS+NES except that the C-terminal FLAG tag is replaced with the biotinylation sequence. "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) The organization of vertebrate CE is shown with the N-terminal triphosphatase domain indicated in white, the guanylyltransferase domain indicated in grey, and the proline-rich C-terminus indicated by the black oval. The proximity of the proline-rich sequence to the C-terminus is indicated by the sequence of the last 12 amino acids of human CE. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3784
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The forms of CE used to analyze the impact of C-terminal modifications is shown. In the nomenclature used here CE corresponds to full-length protein with an N-terminal Myc tag. CE??25C is the same protein missing the C-terminal 25 amino acids. This deletion includes the NLS. CE??NLS+NES was described in Otsuka and colleagues [11] and consists of Myc-tagged CE with the NLS deleted ",
          "(B) or a plasmid expressing Myc-tagged GFP were transfected into HEK293 cells. GFP or CE and its associated proteins were recovered with anti-Myc beads (CE, CE??25C, cCE-bio, and CE??NLS+NES) or streptavidin beads (bio-cCE and bio-cCE??25C). The recovered protein was incubated with ??-[32P]GTP and analyzed for the covalent binding of [32P]GMP (guanylylation) [11], and for [32P]GMP labeling of 5???-monophosphate RNA (capping). The products were separated by denaturing gel electrophoresis and visualized by autoradiography. The amount of capping activity relative to guanylylation activity is shown at the bottom of the figure, with results normalized to either CE or to bio-cCE as indicated by the vertical line. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3784
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The plasmids shown in ",
          "(C) was repeated with an additional assay for 5???-kinase activity. The vertical line in the Western blot and guanylylation assay is to indicate that CE and CE??25C were separated by empty lanes on each of these gels. In (C and D) the mean ?? standard deviation (n???=???3) for recovered kinase and capping activity normalized to guanylylation activity is shown beneath each autoradiogram. In each case comparison to matching controls yielded p-valuet test."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3784
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The experiment in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3784
          }
        ]
      }
    }
  },
  "1145134":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Cytoplasmic extract was immunoprecipitated with control IgG or anti-Nck1 antibody. 2.5% of input sample and 20% of the immunoprecipitated sample was used for Western blotting to determine Nck1 recovery, and 2.5% of input sample and 70% of the immunoprecipitated sample was assayed by guanylylation to determine CE recovery. The weak guanylylation signal seen in the input sample is due to the presence of a previously described [11] inhibitory activity in cytoplasmic extract."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":4170
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) HEK293 cells were co-transfected with plasmids expressing HA-Nck1 and bio-cCE (lanes 1 and 4), bio-cCE??25C (lanes 2 and 5), and bio-cCE??pro in which the five C-terminal prolines shown in Figure 1A were deleted (bio-cCE??pro, lanes 3 and 6). Protein recovered on streptavidin beads was analyzed by Western blotting with anti-Myc (cCE) and anti-HA (Nck1) antibodies (upper two panels). In the lower two panels the bound complexes were assayed as in Figure 1 for guanylylation and capping activity. The quantified capping activity (mean ?? standard deviation, n???=???3) for capping assay is shown beneath that autoradiogram. The same results were obtained for each of the modified forms of CE, with p-valuet test. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":4170
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cytoplasmic extract from cells expressing bio-cCE (cCE) and HA-Nck1 was treated ?? micrococcal nuclease (MNase) prior to recovery of CE and associated proteins with streptavidin beads. Proteins were analyzed by Western blotting with anti-Myc (cCE) and anti-HA (Nck1) antibodies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":4170
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) HEK293 cells were transfected with plasmids expressing bio-cCE or a protein consisting of two MS2 binding sites fused to the biotinylation sequence present in bio-cCE (MS2-bio) [19]. Proteins recovered on streptavidin beads were analyzed by Western blotting with HRP-streptavidin (bio-cCE and MS2-bio), and with an antibody to endogenous Nck1. ",
          "(C) was repeated except Western blots of recovered proteins were probed with antibodies to Nck2 and Grb2. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":4170
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The experiment in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":4170
          }
        ]
      }
    }
  },
  "1145136":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Cytoplasmic extract from cells expressing bio-cCE was separated on a 10%???50% glycerol gradient. Fractions containing each of these proteins were identified by Western blotting of input fractions with antibodies to the Myc tag on bio-cCE and to Nck1 (upper 2 panels). Streptavidin beads were used to recover bio-cCE from individual fractions and bound proteins were again analyzed by Western blotting with anti-Myc and anti-Nck1 antibodies (lower two panels). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":449
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cytoplasmic extract from non-transfected cells was separated on a calibrated Sephacryl S-200 column. Starting with the void volume individual fractions were collected and analyzed by Western blotting with anti-CE and anti-Nck1 antibodies. The missing CE band in fraction 3 was due to sample loss during loading. ",
          "(B) were pooled and immunoprecipitated with anti-Nck1 or control IgG. 20% of the immunoprecipitated sample was used for Western blotting with anti-Nck1 antibody and 70% of the immunoprecipitated sample was used for Western blotting with anti-CE antibody. "
        ],
        "rois":[
          {
            "x":0,
            "y":450,
            "x2":1960,
            "y2":1819
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The fractions indicated with a box at the bottom of "
        ],
        "rois":[
          {
            "x":0,
            "y":1820,
            "x2":1960,
            "y2":2833
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cytoplasmic extract from non-transfected cells was immunoprecipitated with anti-CE antibody or control IgG, and the recovered proteins were analyzed by Western blotting with anti-Nck1 antibody."
        ],
        "rois":[
          {
            "x":0,
            "y":1820,
            "x2":1960,
            "y2":2833
          }
        ]
      }
    }
  },
  "1145138":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Gst and Gst-Nck1 were expressed in E. coli and protein purified on glutathione agarose was analyzed by SDS-PAGE stained with Coomassie Blue (left panel). The middle panel is a Western blot using HRP-streptavidin of cytoplasmic extracts of cells that were transfected with plasmids expressing bio-cCE or MS2-bio. Gst- or Gst-Nck1 bound glutathione beads were added to each of these extracts (right panels) and bound proteins were analyzed by Western blotting with HRP-streptavidin (top panel), for guanylylation activity (middle panel), and for capping activity (bottom panel). The single band in guanylylation assay of MS2-bio expressing cells is endogenous CE, the two bands in bio-cCE expressing cells correspond to endogenous CE and bio-cCE. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3468
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 293 cells were transfected with Nck1 siRNA or a scrambled control and plasmid expressing bio-cCE. The effectiveness of Nck1 knockdown was determined by Western blotting with anti-Nck1 and anti-GAPDH antibodies, and the expression of bio-cCE and its recovery on streptavidin beads was monitored by Western blotting with anti-Myc antibody. The recovery of Nck1 with bio-cCE was determined by Western blotting with anti-Nck1 antibody (upper panels). In the bottom two panels the recovered complexes were assayed for recovery of 5???-kinase activity and capping activity, normalized to bio-cCE recovery, with the mean ?? standard deviation (n???=???3) shown beneath each autoradiogram. For each of these p-value was t test."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1960,
            "y2":3468
          }
        ]
      }
    }
  },
  "1145141":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) The organization of Nck1 (wild type "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2917,
            "y2":2412
          }
        ]
      },
      "WT":{
        "descriptions":[
          "[WT]) is shown together with a series of plasmids expressing HA-tagged forms with inactivating mutations (black box) in each of the functional domains. ",
          "(WT) or Nck1 with inactivating mutations in the third SH3 domain (M3) or all 3 SH3 domains (3SH3M). Protein recovered on streptavidin beads was analyzed by Western blotting with Alexafluor800-coupled streptavidin (cCE) and anti-HA (Nck1) antibody. Kinase activity was assayed by incubating the recovered proteins with a 23 nt 5???-monophosphate RNA and ??-[32P]ATP, and capping activity was assayed by incubating recovered proteins with with ATP and ??-[32P]GTP. The products of each reaction were separated on a denaturing polyacrylamide/urea gel and visualized by autoradiography. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2917,
            "y2":2412
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HEK293 cells were co-transfected with plasmids expressing the indicated forms of Nck1 and bio-cCE. Protein recovered on streptavidin beads was analyzed by Western blotting with antibodies to the Myc tag on bio-cCE and the HA tag on Nck1. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2917,
            "y2":2412
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Cells were co-transfected with plasmids expressing bio-cCE and HA-tagged wild type Nck1 ",
          "(C)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2917,
            "y2":2412
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) HEK293 cells were transfected with the plasmids expressing HA-tagged forms of wild-type Nck1, or Nck1 with inactivating mutations in the first (M1) and second (M2) SH3 domains. Complexes recovered on anti-HA beads were analyzed by Western blotting (upper panels), and for 5???-kinase activity as in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2917,
            "y2":2412
          }
        ]
      }
    }
  },
  "114621":{
    
  },
  "1149344":{
    "Figure_1.tif":{
      "1":{
        "descriptions":[
          "(1) Gene expression data consisting of normal and cancer samples (1A) and the PPI network (1B) are used as inputs. "
        ],
        "rois":[
          {
            "x":1679,
            "y":787,
            "x2":3302,
            "y2":1253
          },
          {
            "x":0,
            "y":1254,
            "x2":3302,
            "y2":2250
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) We begin by constructing two responsive networks under the investigated condition: In (2A), we use two statistic measurements to construct a bio-molecular network. For each gene,  is used to measure activity of gene  (a node score) and for each pair of genes  is used to measure connectivity relationship between gene  and gene  (an edge score). In (2B), for each interaction in PPI network,  is used to measure activity of interaction behavior between gene  and gene  (an edge contribution score from PPI) and for each gene,  is used to measure the weighted degree of gene  (a node contribution score from PPI) under the condition. "
        ],
        "rois":[
          {
            "x":1679,
            "y":0,
            "x2":3302,
            "y2":786
          },
          {
            "x":0,
            "y":787,
            "x2":1678,
            "y2":1253
          },
          {
            "x":1679,
            "y":2251,
            "x2":3302,
            "y2":2609
          },
          {
            "x":0,
            "y":2251,
            "x2":1678,
            "y2":3349
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3) We then combine the two responsive networks to construct the background network by assigning node and edge scores to a set of genes. Orange edges represent gene-gene co-expression estimated from only gene expression data and green edges represent activity of interactions in the PPI network. In the process of combining two networks, new edges are included to (2A) although they are not in the existing PPI network. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1678,
            "y2":786
          },
          {
            "x":1679,
            "y":2251,
            "x2":3302,
            "y2":2609
          },
          {
            "x":1679,
            "y":2610,
            "x2":3302,
            "y2":3349
          }
        ]
      },
      "4":{
        "descriptions":[
          "(4) Finally, we solve the constrained optimization problem to obtain the single optimal sub-network."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1151001":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A) robot's biological (BIO, continuous line) and non-biological (NBIO, dashed line) velocity profiles are represented for the three movement velocities. While in BIO the deceleration phase started when the maximum of velocity was reached, in NBIO, after the initial acceleration phase, the velocity profile reached a maximum that was kept approximately constant for a minimum of 1 s, followed by a deceleration phase"
        ],
        "rois":[
          {
            "x":19,
            "y":15,
            "x2":1210,
            "y2":533
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Participants' mean velocity (VP, y-axis) as function of the robot's velocities (VR, x-axis) (mean??SE). Full and empty triangles refer to BIO and NBIO robot movement kinematics, respectively. Continuous and dashed traces are the regression lines which model VP and VR relationships in BIO and NBIO, respectively."
        ],
        "rois":[
          {
            "x":15,
            "y":676,
            "x2":1612,
            "y2":2649
          },
          {
            "x":2020,
            "y":16,
            "x2":3816,
            "y2":2656
          }
        ]
      }
    }
  },
  "1154377":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          ". E. Cas9-mediated knockin of a longer insert"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. PCR genotyping of pooled ESC genomic DNA. The band is diagnostic of knockin"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Mef2c traditional targeting vector containing long homology arms, fl-bio epitope tag, and positive selection cassette. Efficiency of traditional and Cas9-mediated targeting strategies is shown"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "G":{
        "descriptions":[
          ". G. GFP expression after EB differentiation of a targeted clone."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Cas9-mediated targeting using a 50 bp homology arms and no selectable marker"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. PCR genotyping of pooled ESC genomic DNA. Upper band is diagnostic of knockin"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1377,
            "y2":2116
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Confirmation of knockin and effective epitope tagging by streptavidin pulldown of in vivo biotinylated Mef2c"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1155710":{
    
  },
  "1158375":{
    
  },
  "1163113":{
    
  },
  "1163115":{
    
  },
  "1166372":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A) Denaturing gel analysis of the purified PAP fractions from Affigel Blue column by SDS-PAGE and stained by silver nitrate. Lanes 1 and 11, Bio-Rad Precision plus protein standards; lanes 2???4, 0.28, 0.55 and 0.83 ??g of fraction #4; lanes 5???7, 0.19, 0.37 and 0.56 ??g of fraction #5; lanes 8???10, 0.30, 0.60 and 0.90 ??g of the pooled fractions 11???17. "
        ],
        "rois":[
          {
            "x":1361,
            "y":56,
            "x2":3475,
            "y2":2129
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) PAP activity determined by in-gel phosphatase assay with DiFMUP. Lanes 1 and 8, positive control B-phycoerythrin; lanes 2???7, 0.5, 1, 3, 6, 10 and 12 ??g of PAP from the pooled fraction. "
        ],
        "rois":[
          {
            "x":70,
            "y":2275,
            "x2":2158,
            "y2":4576
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Native gel analysis of the purified PAP fractions stained with Coomassie Blue. Lanes 1 and 8, native marker unstained protein standards; lanes 2???7, 0.5, 1, 3, 6, 10 and 12 ??g of PAP from the pooled fraction."
        ],
        "rois":[
          {
            "x":2226,
            "y":2277,
            "x2":4695,
            "y2":4583
          }
        ]
      }
    }
  },
  "1169361":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-process associated with the twenty identified proteins was indicated by Pubgene. "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":2057,
            "y2":631
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B)The ORM1 protein function partner network was indicated by String analysis."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1175590":{
    
  },
  "1175739":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) USF2 was immunoprecipitated from GSK3??+/+ and GSK3?????/??? cells and phospho-USF2 protein levels were detected with phospho-threonine or phospho-serine antibodies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":795,
            "y2":2784
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) USF2 was immunoprecipitated from HeLa cells transfected with pcDNA3-GSK3??-WT-HA. Following SDS-PAGE phosphoproteins were visualized with the Pro-Q Diamond Phosphoprotein Gel Stain. The total protein amount was detected by silver staining and GSK3?? expression was verified by Western blotting. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":795,
            "y2":2784
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Where indicated, HeLa cells transfected as above were treated with the GSK3 selective inhibitors BIO (1 ??M), LiCl (10 mM), 1-Azakenpaullone (Aza, 7.5 ??M) for 1 h. Proteins were isolated 24 h after transfection and detected by Western blotting. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":795,
            "y2":2784
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Cells were transfected with expression vectors for USF2 and GSK3?? and the cell extract was incubated with calf intestinal phosphatase (CIP) or only with buffer (Mock). Proteins were detected by Western blotting."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":795,
            "y2":2784
          }
        ]
      }
    }
  },
  "1178937":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Decreased copper content in erythrocytes of ms/??? mice. Values are expressed as the means ?? S.D. for erythrocyte samples obtained from 15 control (+/???) and 15 mutant (ms/???) males. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1660,
            "y2":1533
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) left-hand panel, the activity of SOD was measured after resolution by gel electrophoresis using the Nitroblue Tetrazolium (NBT)/riboflavin method as described in the Experimental section. The analyses were performed using erythrocyte total extracts obtained from ms/??? and +/??? males and representative results are shown. ",
          "(B,C) right-hand panels, the intensity of the SOD bands was quantified with a molecular Imager using Quantity One software (Bio-Rad) and is plotted in arbitrary units to present activity ",
          "(B) and protein level "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1660,
            "y2":1533
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) left-hand panel, SOD1 levels in erythrocytes were analyzed by western blotting as described in the Experimental section. The analyses were performed using erythrocyte total extracts obtained from ms/??? and control (+/???) males, and representative results are shown. The blot was reprobed with monoclonal anti-actin antibody as a loading control. ",
          "(B,C) right-hand panels, the intensity of the SOD bands was quantified with a molecular Imager using Quantity One software (Bio-Rad) and is plotted in arbitrary units to present activity ",
          "(C). Results are expressed as the mean ?? S.D. for 5 mice of both the ms/??? and +/??? genotypes. Significant differences are indicated (* ??? P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1660,
            "y2":1533
          }
        ]
      }
    }
  },
  "1181546":{
    
  },
  "1182421":{
    
  },
  "11840":{
    
  },
  "1188195":{
    
  },
  "1191255":{
    
  },
  "1193849":{
    
  },
  "1197451":{
    
  },
  "1199093":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          ". A) Negative controls: EDTA (10 mM), -ATP (No ATP and ATP-Regeneration)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1009,
            "y2":300
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) ER as a function of UVC dose and inhibition of ER in light. Plasmid DNA (pGLGAP) was damaged with various doses of UVC (0???1000 J/m2 as indicated), followed by standard repair reactions performed in either light or dark incubation for 1 or 3 h (as specified)."
        ],
        "rois":[
          {
            "x":0,
            "y":301,
            "x2":1009,
            "y2":1695
          }
        ]
      }
    }
  },
  "1199094":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) Repair incorporation in linear vs supercoiled plasmid substrate was compared in standard repair reaction. A mixture of plasmids, pBR322 (UV damaged, 500 J/m2) and pGLGAP (undamaged control), was used in ER reaction. Supercoiled plasmid was linearized post repair to assess and compare the repair incorporation"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1001,
            "y2":1068
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Repair incorporation in supercoiled DNA. Undamaged or UVC damaged non-linearized plasmid DNA was incubated in dark for specified duration of time for standard repair reaction. Plasmid was not linearized post repair to evaluate repair labelling in different forms of plasmid. Bio-dUTP incorporation efficiency is expressed as a normalized ratio only for supercoiled DNA (marked by arrow). [Nicked Circle "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1001,
            "y2":1068
          }
        ]
      },
      "NC":{
        "descriptions":[
          "(NC); Supercoiled "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1001,
            "y2":1068
          }
        ]
      },
      "SC":{
        "descriptions":[
          "(SC)]. In A & B, top and bottom panels depict EtBr stained gels (loading controls) and ECL detection blots, respectively."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1199097":{
    
  },
  "1199169":{
    
  },
  "1200000":{
    "tmph-2013-0708-File027.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3685,
            "y2":2387
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0708-File030.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":19,
            "y":10,
            "x2":378,
            "y2":264
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          {
            "x":19,
            "y":10,
            "x2":378,
            "y2":264
          }
        ]
      }
    },
    "tmph-2013-0708-File025.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3685,
            "y2":2388
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0708-File034.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3685,
            "y2":2388
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0708-File026.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":179,
            "y":92,
            "x2":3546,
            "y2":2224
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0708-File031.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":213,
            "y":118,
            "x2":3665,
            "y2":3630
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0708-File028.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3685,
            "y2":2389
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          
        ]
      }
    },
    "tmph-2013-0642-File005.png":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          {
            "x":93,
            "y":20,
            "x2":1182,
            "y2":2069
          }
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          {
            "x":36,
            "y":2077,
            "x2":1113,
            "y2":3134
          }
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          {
            "x":93,
            "y":20,
            "x2":1182,
            "y2":2069
          }
        ]
      }
    },
    "tmph-2013-0708-File032.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          {
            "x":157,
            "y":29,
            "x2":3751,
            "y2":3633
          }
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          {
            "x":157,
            "y":29,
            "x2":3751,
            "y2":3633
          }
        ]
      }
    },
    "tmph-2013-0708-File033.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          {
            "x":102,
            "y":39,
            "x2":3550,
            "y2":2228
          }
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          {
            "x":102,
            "y":39,
            "x2":3550,
            "y2":2228
          }
        ]
      }
    },
    "tmph-2013-0708-File029.tif":{
      "5":{
        "descriptions":[
          ": 5.0???6.2??eV; ADE"
        ],
        "rois":[
          
        ]
      },
      "4":{
        "descriptions":[
          ": 4.5???5.5??eV) than halogens (F"
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          ": 3.4??eV; Cl",
          ": 3.6??eV). Thus, we recommended that the oxyfluorides in the form of XO2F20,??? and XOF40,??? should be considered as potential superhalogens, which have not been considered previously. Surprisingly, we showed that BiO3 and BiO2F2, in superhalogen formulae, possess a high vertical detachment energy (VDE) yet a low adiabatic detachment energy (ADE). This is in marked contrast to the previously reported superhalogens, which generally contain both the high VDE and high ADE values. It is the first report about exceptions of superhalogen formulae. These findings revealed that for the analogous main-group compounds with the same structural formula, the difference in the metallic property of the core element could lead to the significant difference in the ground structures of either the anionic or neutral structures, which would result in the much differed superhalogen features."
        ],
        "rois":[
          {
            "x":19,
            "y":10,
            "x2":377,
            "y2":262
          }
        ]
      }
    }
  },
  "1202914":{
    
  },
  "1205858":{
    
  },
  "1211049":{
    
  },
  "1213535":{
    "Figure_6.tif":{
      "e":{
        "descriptions":[
          "(e) and P. subcapitata cells exposed to 0.075 mgL???1 ",
          "(e). "
        ],
        "rois":[
          {
            "x":1088,
            "y":7,
            "x2":2056,
            "y2":1739
          }
        ]
      },
      "j":{
        "descriptions":[
          "(i, j) XEDS spectra of the insets in b and d, respectively. Fe is the main constituent; Ni and Cu intense signals in the XEDS spectra (when present), are artifacts due to the metallic grid supporting the samples, and of the sample holder of the TEM instrument, respectively."
        ],
        "rois":[
          {
            "x":1061,
            "y":1726,
            "x2":2056,
            "y2":2750
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f), 0.5 mgL???1, "
        ],
        "rois":[
          {
            "x":1088,
            "y":7,
            "x2":2056,
            "y2":1739
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a), and P. subcapitata cells exposed to 0.075 mgL???1 "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":964,
            "y2":2752
          }
        ]
      },
      "i":{
        "descriptions":[
          "(i, j) XEDS spectra of the insets in b and d, respectively. Fe is the main constituent; Ni and Cu intense signals in the XEDS spectra (when present), are artifacts due to the metallic grid supporting the samples, and of the sample holder of the TEM instrument, respectively."
        ],
        "rois":[
          {
            "x":1061,
            "y":1726,
            "x2":2056,
            "y2":2750
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b), 0.5 mgL???1 ",
          "(b) and ",
          "(b) and "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":964,
            "y2":2752
          }
        ]
      },
      "g":{
        "descriptions":[
          "(g) and 2.5 mgL???1 "
        ],
        "rois":[
          {
            "x":1088,
            "y":7,
            "x2":2056,
            "y2":1739
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) and 2.5 mgL???1 "
        ],
        "rois":[
          {
            "x":1088,
            "y":7,
            "x2":2056,
            "y2":1739
          }
        ]
      },
      "h":{
        "descriptions":[
          "(h) of nZVI during 72 h. Wavenumber (cm???1) of absorption peaks vibrations analyzed in the study are marked in "
        ],
        "rois":[
          {
            "x":1061,
            "y":1726,
            "x2":2056,
            "y2":2750
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) of nZVI during 72 h. EM: external microenvironment, CW: Cell wall, CP: Cytoplasm. Black arrows show the CW-EM interface and red arrows the nZVI attached to the outer region of the algal CW in ",
          "(d). Insets in ",
          "(d) show CW-EM interfacial regions where surface-bound nZVI accumulations were observed on the CW and where nZVI particles were identified. nZVI particles showed round shapes and near squared lattices. Interplanar spaces (2.8 A?? and 3.2 A??) are consistent with those of hematite and iron (III) oxide-hydroxide. Fast Fourier Transform (FFT) pattern of the nanoparticle in inset of ",
          "(d) revealed a truncated octahedral tridimensional structure [56]. Representative FTIR transmission profile of untreated P. subcapitata control cells "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1220522":{
    
  },
  "1222473":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) Bio-informatics revealing the presence of miR-101 binding site at 3???UTR of UBE2N and SMARCA4, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1922,
            "y2":1162
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) activity of Luc gene showing a significant decrease in Luciferase activity when miR-101 was over-expressed in cells expressing Luc with 3???UTR of either (i & ii) UBE2N or (iii & iv) SMARCA4, in MCF7 and Hela cells. (c & d) Real-Time PCR showing a change in expression using Sybergreen and UBE2N and SMARCA4 specific primers, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1922,
            "y2":1162
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) under miR-101 and anti-miR-101 transfected conditions, showing decrease & increase, respectively, and "
        ],
        "rois":[
          {
            "x":0,
            "y":1163,
            "x2":1922,
            "y2":2548
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) after 12 hrs exposure to 1uM, 5 uM and 10 uM etoposide, in MCF7 cells, confirming UBE2N and SMARCA4 as targets of miR-101, which is induced to 10 fold with 1 uM etoposide. At the higher concentrations of etoposide miR-101 expression is reduced leading to increased expression of UBE2N and SMARCA4, again confirming the relationship between miR-101 and the two novel targets."
        ],
        "rois":[
          {
            "x":0,
            "y":1163,
            "x2":1922,
            "y2":2548
          }
        ]
      }
    }
  },
  "1223253":{
    "Figure_1.tif":{
      "a":{
        "descriptions":[
          "(a) The cardiomyogenic differentiation protocol and cardiomyocyte purification process are illustrated. "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2907,
            "y2":3859
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) IPSC-CMs stained with anti-??-actinin antibody (Alexa Fluor 488), anti-troponin I (Alexa Fluor 594) and DAPI, were analyzed with a confocal laser scanning microscopy. Abbreviations: EB, embryonic body; MEM, Modified Eagle's Medium; DMEM, Dulbecco's Modified Eagle's Medium; BIO, 6-bromoindirubin-3???-oxime."
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":2907,
            "y2":3859
          }
        ]
      }
    }
  },
  "1223993":{
    
  },
  "1225192":{
    "Figure_1.tif":{
      "4":{
        "descriptions":[
          "; 4) affinity enrichment of the biotin-tagged proteins on streptavidin-conjugated beads"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2664,
            "y2":1239
          }
        ]
      },
      "5":{
        "descriptions":[
          "; 5) on-beads trypsin digestion of affinity-captured sialoglycoproteins"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2664,
            "y2":1239
          }
        ]
      },
      "6":{
        "descriptions":[
          "; 6) identification using high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis using a nano-LC-LTQ Orbitrap mass spectrometer platform and sequence database searching, and quantitative differential analysis of the sialoglycoproteins using label-free analysis with DIFFTAL (DIFferential Fourier-Transform AnaLysis) software algorithm."
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          ": 1) metabolic labeling of cells with Ac4ManNAz"
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          "; 2) chemoselective conjugation of azide-labeled glycans with a biotin-linked phosphine"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2664,
            "y2":1239
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3) cell lysis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2664,
            "y2":1239
          }
        ]
      }
    }
  },
  "1228830":{
    
  },
  "1232091":{
    
  },
  "1234746":{
    
  },
  "1234932":{
    
  },
  "1238898":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(a), total Akt "
        ],
        "rois":[
          {
            "x":25,
            "y":14,
            "x2":1682,
            "y2":1115
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b), phosphorylated MEK1 "
        ],
        "rois":[
          {
            "x":1622,
            "y":37,
            "x2":3122,
            "y2":1111
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c), and total MEK1 "
        ],
        "rois":[
          {
            "x":14,
            "y":1175,
            "x2":1691,
            "y2":2350
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) were quantified using the Bio-Plex Suspension Array System. Data are mean ?? SEM (n???=???4). The values were expressed as the percentage of the mean value of the DMSO+Medium. Mann-Whitney test: *P"
        ],
        "rois":[
          {
            "x":1629,
            "y":1215,
            "x2":3127,
            "y2":2353
          }
        ]
      }
    }
  },
  "124065":{
    "Figure_S1.tif":{
      "TB":{
        "descriptions":[
          "(TB) remains a major health problem worldwide, especially in developing countries. Lack of concrete immune markers is still the obstacle to properly evaluate active TB. Therefore, identification of more validated biomarkers and phenotypic signatures is imperative. In particular, T cell-related biomarkers are more significant. MethodologyTo understand the nature of CD4+ T cell-derived signatures involved in infection and disease development, we examined and analyzed whole genome expression profiles of purified CD4+ T cells from healthy individuals "
        ],
        "rois":[
          
        ]
      },
      "HD":{
        "descriptions":[
          "(HD), two distinct populations with latent infection (with low or high IFN-?? levels, LTBL/LTBH) and untreated TB patients. Following, we validated the expression profiles of genes in the peripheral CD4+ T cells from each group and examined secretion levels of distinct cytokines in serum and pleural effusion. Principal FindingsOur bio-informatic analyses indicate that the two latent populations and clinical TB patients possess distinct CD4+ T cell gene expression profiles. Furthermore, The mRNA and protein expression levels of B cell activating factor (BAFF), which belongs to the TNF family, and a proliferation-inducing ligand (APRIL) were markedly up-regulated at the disease stage. In particular, the dramatic enhancement of BAFF and APRIL in the pleural effusion of patients with tuberculosis pleurisy suggests that these proteins may present disease status. In addition, we found that the BAFF/APRIL system was closely related to the Th1 immune response. Our study delineates previously unreported roles of BAFF and APRIL in the development of tuberculosis, and these findings have implications for the diagnosis of the disease. Our study also identifies a number of transcriptional signatures in CD4+ T cells that have the potential to be utilized as diagnostic and prognostic tools to combat the tuberculosis epidemic. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":2249
          }
        ]
      }
    }
  },
  "1243947":{
    
  },
  "1244761":{
    "Figure_3.tif":{
      "76":{
        "descriptions":[
          "(c-f) Possible proposed pictorial mechanism."
        ],
        "rois":[
          {
            "x":7,
            "y":483,
            "x2":625,
            "y2":886
          },
          {
            "x":15,
            "y":7,
            "x2":981,
            "y2":468
          }
        ]
      },
      "86":{
        "descriptions":[
          "(c-f) Possible proposed pictorial mechanism."
        ],
        "rois":[
          {
            "x":101,
            "y":505,
            "x2":984,
            "y2":1287
          }
        ]
      },
      "96":{
        "descriptions":[
          "(c-f) Possible proposed pictorial mechanism."
        ],
        "rois":[
          
        ]
      },
      "07":{
        "descriptions":[
          "(c-f) Possible proposed pictorial mechanism."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1245214":{
    
  },
  "1245215":{
    
  },
  "1247721":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":1358,
            "y":912,
            "x2":1772,
            "y2":1334
          },
          {
            "x":7,
            "y":7,
            "x2":1785,
            "y2":848
          }
        ]
      },
      "B":{
        "descriptions":[
          " 5??105 of DCs (in white) and M?? (in gray) were incubated for 24 h with concentrated culture supernatants as in Figure 2. (B)"
        ],
        "rois":[
          {
            "x":1378,
            "y":1839,
            "x2":1779,
            "y2":2299
          },
          {
            "x":932,
            "y":1839,
            "x2":1310,
            "y2":2300
          },
          {
            "x":22,
            "y":907,
            "x2":881,
            "y2":2768
          },
          {
            "x":915,
            "y":912,
            "x2":1305,
            "y2":1781
          }
        ]
      },
      "C":{
        "descriptions":[
          " 5??105 of DCs (in white) and M?? (in gray) were incubated for 24 h with concentrated culture supernatants as above and, in addition, the cells were pre-incubated with an anti-TLR4 antibody (Ab+) followed by treatment with HS or LPS. (C)"
        ],
        "rois":[
          {
            "x":937,
            "y":2304,
            "x2":1314,
            "y2":2768
          }
        ]
      },
      "HS":{
        "descriptions":[
          " Shed GP induces secretion of cytokines from DCs and M?? in a dose-dependent manner. 5??105 of DCs (in white) and M?? (in gray) were incubated for 24 h with concentrated culture supernatants, or LPS as above. Decreasing quantities of shed GP (HS)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1247723":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1445,
            "y2":1026
          }
        ]
      },
      "B":{
        "descriptions":[
          " Concentrated culture supernatants of 293T cells expressing GP-HS were treated either with inactivated deglycosylation enzymes (lane 1) or a mix of deglycosylases (lane 2). Samples were analyzed by Western blot under non-reducing conditions. Deglycosylated EBOV GP is indicated as *GP1,2??. (B)"
        ],
        "rois":[
          
        ]
      },
      "HS":{
        "descriptions":[
          " 5??105 DCs (in white) and M?? (in gray) were incubated for 24 h with concentrated culture supernatants of 293T cells expressing GP-HS (HS)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1445,
            "y2":1026
          }
        ]
      },
      "LS":{
        "descriptions":[
          ", GP-LS (LS)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1445,
            "y2":1026
          }
        ]
      }
    }
  },
  "1248344":{
    
  },
  "1248460":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Time-dependent phosphorylation of MyBP using PknQkd. Relative phosphorylation (normalized to protein amounts) is plotted and corresponding autoradiogram (top) and SDS-PAGE images (bottom) are shown. The quantification of phosphorylation intensity was done as described earlier (Fig. 1C). The experiment was repeated three times and error bars show S.D. of three values."
        ],
        "rois":[
          {
            "x":1423,
            "y":15,
            "x2":2761,
            "y2":2287
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Homology modeling showing the structure of the PknQ kinase domain (PknQkd). The structure shows a ribbon diagram (left) and surface-filled model (right) of PknQkd, highlighting the N- and C-terminal regions. "
        ],
        "rois":[
          {
            "x":2828,
            "y":156,
            "x2":4021,
            "y2":1817
          },
          {
            "x":16,
            "y":15,
            "x2":1493,
            "y2":2019
          },
          {
            "x":2604,
            "y":2202,
            "x2":4036,
            "y2":4349
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SDS-PAGE analysis of His6-tagged PknQkd. PknQkd was purified to near homogeneity as observed on SDS-PAGE. "
        ],
        "rois":[
          {
            "x":1423,
            "y":15,
            "x2":2761,
            "y2":2287
          },
          {
            "x":16,
            "y":15,
            "x2":1493,
            "y2":2019
          },
          {
            "x":1432,
            "y":2374,
            "x2":2593,
            "y2":4375
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Time-dependent autophosphorylation of PknQ. PknQ was allowed to phosphorylate itself for 0???30 minutes. Relative phosphorylation (normalized to protein amounts) is plotted and corresponding autoradiogram (top) and SDS-PAGE images (bottom) are shown. The intensity of phosphorylation on protein bands was calculated using Personal Molecular Imager (Bio-Rad) using quantification software Quantity One (Bio-Rad). The phosphorylation after 30 min was taken as 100% (signal saturation) and relative phosphorylation was calculated. The experiment was repeated thrice and error bars show S.D. of three values. "
        ],
        "rois":[
          {
            "x":16,
            "y":15,
            "x2":1493,
            "y2":2019
          },
          {
            "x":26,
            "y":2202,
            "x2":1401,
            "y2":4339
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Autophosphorylation of PknQkd and phosphorylation of Myelin basic protein (MyBP). Autoradiogram (top) and corresponding SDS-PAGE images (bottom) are shown. No phosphorylation was observed in the presence of the kinase-dead mutant PknQK41M. "
        ],
        "rois":[
          {
            "x":1423,
            "y":15,
            "x2":2761,
            "y2":2287
          }
        ]
      }
    }
  },
  "1249134":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Left ventricles obtained from the exercised and control groups were submitted to qRT-PCR, Western blotting "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1344,
            "y2":750
          }
        ]
      },
      "WB":{
        "descriptions":[
          "(WB), histochemical (Histo), and biochemical (Bio) analyses and TTC staining. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Left ventricles obtained from the non-selective (naloxone) and selective OR antagonist (naltrindole, ??-funaltrexamine and nor-binalthorphimine) groups were submitted to TTC staining."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1344,
            "y2":750
          }
        ]
      }
    }
  },
  "1250308":{
    
  },
  "1251517":{
    
  },
  "1251519":{
    "Figure_4.tif":{
      "1":{
        "descriptions":[
          "(1); DM solution of MBP-apocytochrome b6 added for reconstitution "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":691,
            "y2":164
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2); untreated proteoliposomes "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":691,
            "y2":164
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3); proteoliposomes treated with proteinase K "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":691,
            "y2":164
          }
        ]
      },
      "4":{
        "descriptions":[
          "(4). Lanes 3 and 4 contain the same amount of proteoliposomes."
        ],
        "rois":[
          {
            "x":695,
            "y":7,
            "x2":833,
            "y2":128
          }
        ]
      }
    }
  },
  "125239":{
    
  },
  "1255913":{
    
  },
  "1260299":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Alignment of L. infantum and human MRE11 proteins showing the conserved catalytic residue "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4130,
            "y2":1286
          }
        ]
      },
      "SA":{
        "descriptions":[
          "(SA) substrates with increasing concentration of the proteins (0, 5, 10, 15 nM). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4130,
            "y2":1286
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) LiMRE11WT and mutant H210Y can bind various DNA structures. Competition electrophoretic mobility shift assays were performed with LiMRE11WT (lanes 2???4) and LiMRE11H210Y (lanes 5???7) and 25 nM of ssDNA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4130,
            "y2":1286
          }
        ]
      },
      "SS":{
        "descriptions":[
          "(SS), dsDNA "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantification of the DNA binding signals of panel B."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4130,
            "y2":1286
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) that has been mutated in LiMRE11 (H210Y) to generate the LiMRE11H210Y mutated version and purification of LiMRE11WT and LiMRE11H210Y followed by SDS???PAGE separation. Purified proteins (150 ng) were loaded on an 8% SDS-PAGE, run then stained with Coomassie blue (GE Healthcare). Lane 1: molecular weight markers (Bio-Rad Laboratories); lane 2: purified LiMRE11WT; lane 3: purified LiMRE11H210Y. "
        ],
        "rois":[
          
        ]
      },
      "DS":{
        "descriptions":[
          "(DS) and splayed arm "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1260442":{
    "Figure_1.tif":{
      "N":{
        "descriptions":[
          "(N) and the kinetoplast "
        ],
        "rois":[
          {
            "x":593,
            "y":871,
            "x2":1191,
            "y2":1598
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Multiple bands corresponding to SUMO conjugated proteins are reduced upon TbSUMO knockdown. Western blot analysis of SUMOylated proteins with a monoclonal antibody generated against TbSUMO (mAb 1C9H8). Whole cell extracts from bloodstream trypanosomes were prepared in the presence of 20 mM NEM and separated in 4???20% precast polyacrylamide gels (Bio-Rad). (5??106 cells/lane); Parental, uninduced (???) and induced 48 h (+). Anti-tubulin was used as a loading control. "
        ],
        "rois":[
          {
            "x":593,
            "y":1657,
            "x2":1191,
            "y2":2209
          },
          {
            "x":13,
            "y":7,
            "x2":621,
            "y2":797
          }
        ]
      },
      "BF":{
        "descriptions":[
          "(BF) and insect procyclic form "
        ],
        "rois":[
          {
            "x":652,
            "y":15,
            "x2":1176,
            "y2":798
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Expression pattern of SUMOylated proteins in two developmental forms of T. brucei. Bloodstream form "
        ],
        "rois":[
          {
            "x":593,
            "y":1657,
            "x2":1191,
            "y2":2209
          },
          {
            "x":652,
            "y":15,
            "x2":1176,
            "y2":798
          }
        ]
      },
      "PF":{
        "descriptions":[
          "(PF) total cell extracts were prepared in the presence of 20 mM NEM and analyzed by Western blot using the mAb 1C9H8. "
        ],
        "rois":[
          {
            "x":652,
            "y":15,
            "x2":1176,
            "y2":798
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) SUMO conjugated proteins are diffusely distributed in the nucleoplasm including a Highly SUMOylated Focus (HSF) (arrowhead) in the bloodstream form of the parasite. Double indirect three-dimensional immunofluorescence (3D-IF) analysis was carried out using the anti-TbSUMO mAb 1C9H8 (green). (C???) Higher magnification of the nucleus showing anti-SUMO and DAPI fluorescence signals. DNA in the nucleus "
        ],
        "rois":[
          {
            "x":593,
            "y":1657,
            "x2":1191,
            "y2":2209
          },
          {
            "x":7,
            "y":871,
            "x2":588,
            "y2":1598
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K) was stained with DAPI (blue). Statistical analysis showed the presence of a highly SUMOylated focus in 74.9% of the cells (Figure S2B). "
        ],
        "rois":[
          {
            "x":593,
            "y":871,
            "x2":1191,
            "y2":1598
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) SUMOylated proteins in the nucleus of procyclic form are diffusely distributed in many foci. 3D-IF analysis was carried out using the anti-TbSUMO mAb (green). (D???) Higher magnification of the nucleus showing anti-SUMO and DAPI fluorescence signals. DNA was stained with DAPI (blue). Scale bars 1 ??m. Maximum intensity projections of deconvolved two-channel 3D stack are shown."
        ],
        "rois":[
          {
            "x":593,
            "y":1657,
            "x2":1191,
            "y2":2209
          },
          {
            "x":7,
            "y":1609,
            "x2":589,
            "y2":2209
          }
        ]
      }
    }
  },
  "1263007":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Non-dimensionalised pressures against non-dimensionalised impact durations at the coup, and "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":984,
            "y2":1502
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) at the contre-coup. Solid lines represent results of the parametric study conducted using the simpler two-phase head model, and bold markers represent three case studies utilising the full bio-fidelic model."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1269647":{
    
  },
  "1270002":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "(a) A simplified reduction of the TFP processing bio-system into an axi-symmetric structure with a sliced view of TFP-protein/periplasm interfaces. The cylindrical retraction apparatus(RA) sits below the TFP base on the cytoplasmic part of the cell and the shallow cylindrical polar complex at the end of the TFP(shown in dotted red lines) is an electrostatic complex which is essential for recruiting pilins for elongation [18], [31] "
        ],
        "rois":[
          {
            "x":532,
            "y":511,
            "x2":989,
            "y2":974
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) the top part of the RA (only PilT shown) forming the RA-plane is responsible for the binding regime of the retraction process and is assumed to be very closely packed with PilT units sitting close to the base of the TFP. Note that the empty space surrounding the TFP and above the RA plane in this figure is actually filled by PilQ, enclosing periplasm and embedded minor proteins. "
        ],
        "rois":[
          {
            "x":7,
            "y":3,
            "x2":776,
            "y2":485
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) binding energy at zero deformation as a function of size of the RA-plane indicating three distinct zones and a strongly saturating characteristic assuming a van-derWalls type binding. The x axis is RA radius normalized by the pilus radius and y-axis is current binding energy normalized by that of an infinite plane. (Inserts: White circle indicates the size of RA plane and black the TFP cross section). "
        ],
        "rois":[
          {
            "x":3,
            "y":22,
            "x2":986,
            "y2":972
          },
          {
            "x":7,
            "y":3,
            "x2":776,
            "y2":485
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d)Normalized force-radius characteristic of TFP. The numbers on the loading curve (green) represent  (Insert: Free body diagram of loaded TFP,  is binding force due to RA)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1273306":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "A. GD-1 was treated onto NK-92 cells at 1 to 100 ng/ml concentrations, and several down-stream targets for PKC signaling were analyzed by Western blotting. The phosphorylation of IKK was detected with the concomitant degradation of I??B. ERK and MEK were also phosphorylated by GD-1 treatment. The bands were quantified using Quantity One 1-D Analysis Software (Bio-Rad Laboratories) and p-IKK and I??B expression normalized to control their protein expression. And p-ERK and p-MEK expressions normalized to total their protein expression. The values are given above the blots"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2021,
            "y2":1600
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Inhibitors of NF-??B, Bay11-7082, was treated with a serial dilution from 100 ??M with 10 0 ng/ml GD-1, and IFN-?? production was analyzed by ELISA. The addition of Bay11-7082 has showed an inhibitory effect on GD-1 activity to increase IFN-?? production. All ELISA data are representative of at least three independent experiments. Triplicate samples in each time were tested and averaged. Error bars indicate standard deviation. *PC. The nuclear translocation of p65 (an NF-??B subunit) was observed in GD-1-stimulated NK-92 cells. The modulation of cytoskeleton was observed through Phase contrast images and DAPI was used to visualize nuclei. GD-1 treatment onto NK-92 cells induced nuclear localization of cytosolic p65 transcription factor, which was inhibited by the co-addition of Rottlerin or Bay11-7082."
        ],
        "rois":[
          
        ]
      }
    }
  }
,
  "127427":{
    
  },
  "1274442":{
    "Figure_1.tif":{
      "4":{
        "descriptions":[
          "(4) and vurtoxin "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":989,
            "y2":1071
          }
        ]
      },
      "11":{
        "descriptions":[
          "(11) are indicated by horizontal bars."
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":989,
            "y2":1071
          }
        ]
      }
    }
  },
  "1276608":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A: After starvation overnight, bladder cancer T24 cells were treated with SFN at the concentrations indicated for 24 h, cell migration was measured by a cell migration assay using the ThinCert cell culture inserts (Greiner Bio-One Ltd.). Each bar represents the mean ?? SD of 3 replicates"
        ],
        "rois":[
          {
            "x":8,
            "y":6,
            "x2":1001,
            "y2":780
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: Effect of pre-treatment of 3-MA on cell migration. DMSO (0.1% was used as a control). Statistical significance from the control, *p"
        ],
        "rois":[
          {
            "x":1150,
            "y":6,
            "x2":2212,
            "y2":746
          }
        ]
      }
    }
  },
  "1278134":{
    "Figure_2.tif":{
      "a":{
        "descriptions":[
          "a) Fluorescent microarray scanner measuring relative abundance of initiator prior to polymerization labeling. Scale bar???=???1 mm"
        ],
        "rois":[
          {
            "x":5,
            "y":1323,
            "x2":1078,
            "y2":2112
          }
        ]
      },
      "b":{
        "descriptions":[
          ". b) Relative initiator concentration on surface for spots printed from the indicated concentration of biotinylated-BSA and reacted with the SA-initiator complex. Measurements based on initiator fluorescence (ex/em???=???525/545 nm)"
        ],
        "rois":[
          {
            "x":6,
            "y":583,
            "x2":1084,
            "y2":1291
          }
        ]
      },
      "c":{
        "descriptions":[
          ". c) Thickness of spots of indicated Bio-BSA concentration. Data are mean ?? standard deviation. n???=???16."
        ],
        "rois":[
          {
            "x":5,
            "y":1323,
            "x2":1078,
            "y2":2112
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":824,
            "y2":598
          }
        ]
      }
    }
  },
  "1278139":{
    "Figure_3.tif":{
      "a":{
        "descriptions":[
          "a) Greyscale image from optical document scanner after Polymer Dye Labeling with Evans Blue dye"
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":773,
            "y2":1203
          }
        ]
      },
      "b":{
        "descriptions":[
          ". b) Greyscale image from optical document scanner after Polymer Dye Labeling with eosin dye. Scale bars???=???1 mm"
        ],
        "rois":[
          {
            "x":675,
            "y":3,
            "x2":1353,
            "y2":704
          }
        ]
      },
      "c":{
        "descriptions":[
          ". c) darkness of Evans Blue dyed spots of indicated Bio-BSA concentration"
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":773,
            "y2":1203
          }
        ]
      },
      "D":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":718,
            "y":722,
            "x2":1346,
            "y2":1208
          }
        ]
      },
      "d":{
        "descriptions":[
          ". d) Darkness of eosin dyed spots of indicated Bio-BSA concentration. Data in c) and d) are mean ?? standard deviation. n???=???12."
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":773,
            "y2":1203
          }
        ]
      }
    }
  },
  "127999":{
    
  },
  "128175":{
    
  },
  "1282838":{
    
  },
  "1282976":{
    
  },
  "1286277":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) BLI curves generated with a panel of CD4bs-directed antibodies immobilized on anti-human IgG Fc sensors and a serial dilution (200 nM???6.25 nM) of negatively selected SOSIP trimers in solution as the analyte. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3861,
            "y2":5017
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Similar BLI curves obtained with glycan-directed bNAbs."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3861,
            "y2":5017
          }
        ]
      }
    }
  },
  "1288654":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Inhibiting GSK3 activity by expression of dominant-negative GSK3 (dnGSK3), or treating explants with a GSK3 inhibitor BIO one hour prior to observation, led to extensive aggregation of PAPC in the cytoplasm in animal cap cells (arrowheads). A putative phosphorylation-mimic mutant PAPC-SD, which carries S816 and S820 to aspartic acid mutations, was resistant to dnGSK3 expression and remained on the plasma membrane. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) PAPC was not efficiently degraded in DMZ explants expressed with dominant-negative GSK3 (dnGSK3) at stage 15 and formed cytoplasmic aggregates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":980,
            "y2":397
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) GST-tagged PAPC was expressed in the dorsal marginal zone. When embryos reached the gastrula stage, PAPC-GST was partially purified with Glutathione Sepharose 4B. Phosphorylated PAPC (pPAPC) was detected by anti-phosopho-PAPC antibody, raised against phosphorylated DSR peptide as an antigen. The pPAPC signal was abolished by treating the extract with lambda protein phosphatase (PPase). The recombinant C-terminal domain of PAPC was phosphorylated in vitro in the presence of recombinant GSK3, as confirmed by a Western blot using anti-pPAPC antibody. Total input of PAPC was estimated by anti-GST antibody."
        ],
        "rois":[
          {
            "x":12,
            "y":519,
            "x2":920,
            "y2":742
          }
        ]
      }
    }
  },
  "1290007":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Infection profile 42 dpi for FVB/N mice infected orally with107 CFUs of wt Y. pseudotuberculosis (n = 20) and indicated mutant strains (each group n = 16). The infections were monitored by IVIS at certain intervals up to 42 dpi. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":960,
            "y2":527
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Heatmap showing differences in clearance (by p-value) between wt and indicated mutant strains at different time points during the 42 day infection period. Heatmap color scale, from green to yellow, was adjusted according to p-values from 1 to 0. p-values were calculated with 2??2 contingency table by Fisher???s Exact Test, see also S6 Table. "
        ],
        "rois":[
          {
            "x":2,
            "y":541,
            "x2":938,
            "y2":1033
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Motility profile of wt Y. pseudotuberculosis and indicated mutant strains under anaerobic conditions at 26??C. Images were captured by the ChemiDoc XRS System (Bio-Rad), showing the bioluminescent signal produced by Y. pseudotuberculosis YPIII/pIBX."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1294491":{
    
  },
  "1296623":{
    
  },
  "1296632":{
    
  },
  "1300495":{
    
  },
  "1302824":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          ". E. DNA sequences of 39 cloned Pax3-Foxo1 PCR fragments from CRISPR-Cas9 treated fore limb (6 different) and of 34 cloned Pax3-Foxo1 PCR fragments from CRISPR-Cas9 treated hind limb (3 different) myoblasts"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2453,
            "y2":2640
          }
        ]
      },
      "F":{
        "descriptions":[
          ". F. Co-localization frequencies of Pax3 and Foxo1 in Foxo1-inv+/+ fore limb, hind limb, and MEFs used in B"
        ],
        "rois":[
          {
            "x":836,
            "y":2312,
            "x2":2453,
            "y2":2640
          },
          {
            "x":0,
            "y":2641,
            "x2":2453,
            "y2":3246
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Schematic representation of the position of the Pax3 forward (P-F) and reverse (P-R) PCR primers upstream and downstream of the Pax3 breakpoint in intron 7 (DSB) and of the Foxo1 forward (F-F) and reverse (F-R) PCR primers upstream and downstream of the Foxo1 breakpoint in intron 1 (DSB). The P-F and F-R primer pair amplify the Pax3-Foxo1 fusion"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2453,
            "y2":2640
          }
        ]
      },
      "G":{
        "descriptions":[
          ". G. Agarose gel and DNA sequence of a partial Pax3-Foxo1 fusion cDNA fragment showing the correctly spliced Pax3 exon7-Foxo1 exon2 fusion after RT-PCR of RNA from CRISPR-Cas9 treated Foxo1-inv+/+ fore limb myoblasts."
        ],
        "rois":[
          {
            "x":0,
            "y":2641,
            "x2":2453,
            "y2":3246
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Agarose gel showing the PCR products obtained using the P-F/F-R primer pair and DNA from Foxo1-inv+/+ hind limb DNA without (lane 1) and with (lane 2) CRISPR-Cas9 treatment, form Foxo1-inv+/+ fore limb DNA without (lane 3) and with (lane 4) CRISPR-Cas9 treatment, from wild type fore limb DNA with CRISPR-Cas9 treatment (lane 5), and from Foxo1-inv+/+ MEF DNA with CRISPR-Cas9 treatment (lane 6). M is 100 bp ladder molecular weight marker. The position of the expected size of the cleanly ligated Pax3-Foxo1 fusion fragment is indicated on the right (251 bp)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2453,
            "y2":2640
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Agarose gel showing the Pax3 PCR fragments containing the RH30-like Pax3 breakpoint from Foxo1-inv+/+ fore limb myoblast DNA not treated with CRISPR-Cas9 without (lane1) and with (lane 2) MaeIII digest, treated with CRISPR-Cas9 without (lane 3) and with (lane 4) MaeIII digest and Foxo1-inv+/+ MEF DNA treated with CRISPR-Cas9 without (lane 5) and with (lane 6) MaeIII digest. Expected fragment sizes are indicated on the right. Fully modified CRISPR-Cas9/NHEJ DSBs do not cut with MaeIII. Beneath the gel is a table with the relative fragment intensities as measured with a BIO-RAD ChemiDoc imaging system. Underneath the table is a histogram giving a graphic representation of the relative band intensities"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2453,
            "y2":2640
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Same analysis as in C but for the Foxo1 fragment containing the RH30-like breakpoint digested with DdeI. The table underneath shows the relative fragment intensities as measured with a BIO-RAD ChemiDoc imaging system. Underneath the table is histogram giving a graphic representation of the relative band intensities"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2453,
            "y2":2640
          }
        ]
      }
    }
  },
  "1305081":{
    
  },
  "1310915":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) or centrifuged for detecting micronemal proteins secreted in the medium and present in sporozoites (pellet) by western blotting ",
          "(A) Effect of SB203580 on micronemal protein distribution onto the surface E. tenella. This was determined by immunofluorescence. Sporozoites in PBS at 4??C were used as a negative control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2021,
            "y2":890
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). ",
          "(B) Effect of SB203580 on micronemal protein secretion. This was evaluated by western blotting in the supernatants and parasite lysates. Profilin was used as a control of the number of sporozoites. Quantification of secreted micronemal proteins in supernatants was performed using Bio-Profil Bio-1D++ software and is represented by histograms compared to the micronemal protein content in sporozoites. Data are representative of 2 experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":891,
            "x2":2021,
            "y2":4799
          }
        ]
      }
    }
  },
  "1315533":{
    
  },
  "1316703":{
    "Fig_10.tif":{
      "12":{
        "descriptions":[
          "(12), hexamers "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":959,
            "y2":1839
          }
        ]
      },
      "5":{
        "descriptions":[
          ", 5-, or 10-fold molar excess of the 22-peptide NWVSAAKFESTDGSTDYGIYQV (2.5 ??, 5 ??, or 10 ??, respectively) or without ligand "
        ],
        "rois":[
          
        ]
      },
      "6":{
        "descriptions":[
          "(6), and trimers "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":959,
            "y2":1839
          }
        ]
      },
      "0":{
        "descriptions":[
          "(0), subjected to cross-linking with bis[sulfosuccinimidyl] suberate (BS3), and then analyzed using size exclusion chromatography as described in ???Materials and Methods???. The void volume (V0) and elution volumes of molecular weight standards (Bio-Rad) used for column calibration are shown as vertical dotted lines. The positions of HtrA dodecamers "
        ],
        "rois":[
          
        ]
      },
      "3":{
        "descriptions":[
          "(3) are indicated with arrows. A representative elution profile is shown; a.u., arbitrary units."
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":959,
            "y2":1839
          }
        ]
      }
    }
  },
  "1318337":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) LiCl, "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1596,
            "y2":644
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) BIO, and "
        ],
        "rois":[
          {
            "x":25,
            "y":644,
            "x2":1546,
            "y2":1333
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Wnt antagonist sFRP4 (* piiiiiiivviv"
        ],
        "rois":[
          {
            "x":23,
            "y":1380,
            "x2":1552,
            "y2":2082
          }
        ]
      }
    }
  },
  "1318340":{
    "Fig_3.tif":{
      "vi":{
        "descriptions":[
          "(vi) 1ng/mL sFRP4 in both (A) and (B). Scale bar = 10??M."
        ],
        "rois":[
          
        ]
      },
      "i":{
        "descriptions":[
          "(i) non-induced control media, "
        ],
        "rois":[
          {
            "x":1058,
            "y":2,
            "x2":2048,
            "y2":855
          }
        ]
      },
      "v":{
        "descriptions":[
          "(v) 100pg/mL sFRP4, and "
        ],
        "rois":[
          {
            "x":2,
            "y":8,
            "x2":998,
            "y2":855
          }
        ]
      },
      "iv":{
        "descriptions":[
          "(iv) 0.5??M BIO, "
        ],
        "rois":[
          
        ]
      },
      "ii":{
        "descriptions":[
          "(ii) adipogenic control, (iii) 10mM LiCl, "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1318342":{
    "Fig_4.tif":{
      "II":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":1468,
            "y2":1083
          }
        ]
      },
      "vi":{
        "descriptions":[
          "(vi) 1ng/mL sFRP4. Scale bar = 250??M (B) Quantification of the stained lipid droplets were performed using the eluted Oil red O stain via measuring absorbance at 510nm. The readings were normalised to background values of non-induced control ADSCs. The values of all treatment conditions were compared to the adipogenic control group (* p"
        ],
        "rois":[
          
        ]
      },
      "IV":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":47,
            "y":1098,
            "x2":1496,
            "y2":1911
          },
          {
            "x":5,
            "y":4,
            "x2":1468,
            "y2":1083
          }
        ]
      },
      "i":{
        "descriptions":[
          "(i) non-induced control, "
        ],
        "rois":[
          
        ]
      },
      "v":{
        "descriptions":[
          "(v) 100pg/mL sFRP4, and "
        ],
        "rois":[
          
        ]
      },
      "V":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":47,
            "y":1098,
            "x2":1496,
            "y2":1911
          }
        ]
      },
      "iv":{
        "descriptions":[
          "(iv) 0.5??M BIO, "
        ],
        "rois":[
          
        ]
      },
      "ii":{
        "descriptions":[
          "(ii) adipogenic control, (iii) 10mM LiCl, "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1318344":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) PPAR??, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1229,
            "y2":300
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) C/EBP??, and "
        ],
        "rois":[
          {
            "x":1230,
            "y":0,
            "x2":2049,
            "y2":300
          },
          {
            "x":0,
            "y":301,
            "x2":2049,
            "y2":1616
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Acetyl CoA carboxylase adipogenic marker proteins. All values were compared to the adipogenic media control (*p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1229,
            "y2":300
          }
        ]
      }
    }
  },
  "1318347":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) Before and ",
          "(A) and ",
          "(A) and 250??M in "
        ],
        "rois":[
          {
            "x":3,
            "y":2,
            "x2":2048,
            "y2":472
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) after Oil red O staining. Treatment conditions were (i) non-induced control media, (ii) adipogenic control, (iii) 0.5??M BIO, (iv) 1ng/mL sFRP4, and (v) 0.5??M BIO + 1ng/mL sFRP4 in both ",
          "(B). Scale bar = 10??M in ",
          "(B). "
        ],
        "rois":[
          {
            "x":4,
            "y":486,
            "x2":2032,
            "y2":967
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantification of the stained lipid droplets were performed using the eluted Oil red O stain via measuring absorbance at 510nm. The readings were normalised to background values of non-induced control ADSCs. The values of all treatment conditions were compared to the adipogenic control group (** p"
        ],
        "rois":[
          {
            "x":576,
            "y":999,
            "x2":1697,
            "y2":1543
          },
          {
            "x":4,
            "y":486,
            "x2":2032,
            "y2":967
          }
        ]
      }
    }
  },
  "1318349":{
    
  },
  "1319834":{
    "Fig_4.tif":{
      "E":{
        "descriptions":[
          "(E) Capacity of fiber containing fractions in inhibition of Ad5-GFP infection in A549 cells. The fractions containing fiber molecule (B10, B12, C5 and D7) were first concentrated by a factor of 5 and subsequently diluted as indicated with fresh cell culture media, 200 ??l of each dilution were applied to each well of A549 cells cultured in 24-well plates for 30 min at 37??C. Following two washes with fresh media, cells were infected with Ad5-GFP virus at a MOI of 100 for 1 hr at 37??C. The percentage of infected cells was analyzed with FACS assay as GFP positive cells at 24 hpi"
        ],
        "rois":[
          {
            "x":54,
            "y":1847,
            "x2":933,
            "y2":2250
          },
          {
            "x":892,
            "y":25,
            "x2":1459,
            "y2":491
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) and penton base "
        ],
        "rois":[
          {
            "x":892,
            "y":25,
            "x2":1459,
            "y2":491
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Elution profile of gel filtration chromatography. One ml of concentrated Ad5 CM was separated by Superdex 200 column at a flow rate of 0.5 ml/min. Protein concentration of each fraction was monitored with absorbance at 280 nm (Y axis). The indicated fractions (arrow), named according to their positions on the collection rack, were selected for the analyses performed in panels B to E. ",
          "(A); lower panel: SimplyBlue staining in the corresponding SDS-PAGE gel. Fiber molecules were abundant in B12 and C5 fractions, penton base mainly in B12 fraction. "
        ],
        "rois":[
          {
            "x":523,
            "y":1263,
            "x2":1456,
            "y2":1439
          },
          {
            "x":835,
            "y":1441,
            "x2":1144,
            "y2":1590
          },
          {
            "x":1189,
            "y":872,
            "x2":1446,
            "y2":1124
          }
        ]
      },
      "PC":{
        "descriptions":[
          "; PC: positive control samples (infection without pre-treatment with Ad5 CM)."
        ],
        "rois":[
          
        ]
      },
      "PB":{
        "descriptions":[
          "(PB) in the fractions from "
        ],
        "rois":[
          {
            "x":892,
            "y":25,
            "x2":1459,
            "y2":491
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Upper panel: western-blot analysis for the detection of fiber "
        ],
        "rois":[
          {
            "x":1147,
            "y":1441,
            "x2":1456,
            "y2":1590
          },
          {
            "x":523,
            "y":1440,
            "x2":832,
            "y2":1590
          },
          {
            "x":37,
            "y":867,
            "x2":1182,
            "y2":1201
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Identification of Ad structure proteins in fiber-containing fractions by cell surface binding assay. A549 cells were incubated with 200 ??l of the indicated fractions for 15 min on ice. Cells were then washed and incubated with the 4D2 anti-fiber mAb in combination with rabbit anti-penton base antibody, followed by staining with Alexa Flour 647 conjugated goat anti-mouse IgG and Alexa Flour 488 conjugated goat anti-rabbit antibody. Parallel samples stained with 4D2 mAb in combination with FITC-conjugated goat anti-hexon antibody were then stained with Alexa Flour 647 conjugated goat anti-mouse IgG. The cells were analyzed in FACS Calibur for the double stained cells. The dot-plots shown are representative of three independent experiments. Fiber, penton base and hexon were detected in B12 fraction, whereas only hexon and fiber were detected in C5 fraction. ",
          "(C). The membrane was scanned by a PharosFX Plus system (Bio-Rad) using 3-laser channels for the visualization of specific binding bands for different antigens. SimplyBlue protein staining of the native PAGE gel (left panel) depicts that B12 and C5 fraction contain protein complexes of about 720 kDa and 440 kDa, respectively. The area on the gel corresponding to the western-blot data shown in the right panel is indicated by the rectangle. Fiber, hexon and penton base were detected in the B12 fraction, whereas fiber and hexon were detected in the C5 fraction. "
        ],
        "rois":[
          {
            "x":523,
            "y":1592,
            "x2":1457,
            "y2":1745
          },
          {
            "x":4,
            "y":1231,
            "x2":510,
            "y2":1832
          },
          {
            "x":2,
            "y":510,
            "x2":1450,
            "y2":856
          }
        ]
      },
      "NC":{
        "descriptions":[
          ". NC: negative control samples (mock infection)"
        ],
        "rois":[
          {
            "x":892,
            "y":25,
            "x2":1459,
            "y2":491
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Characterization of structural protein complexes by native PAGE and western-blot analysis. Proteins in different fractions were separated by pre-casted 4???20% native PAGE gel and blotted onto PVDF membrane. The membrane was probed with anti-fiber, anti-penton base and anti-hexon antibodies simultaneously and then further probed with the secondary antibodies used in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":837,
            "y2":438
          }
        ]
      }
    }
  },
  "1320080":{
    
  },
  "1326103":{
    "Fig_3.tif":{
      "E":{
        "descriptions":[
          "(E) Detection of 6-FAM labeled siRNA distribution by fluorescence microscopy in liver 4 h after intravenous injection. The microvasculature was visualized with red signals by intravenous injection of Texas Red conjugated dextran. Left, 6-FAM labeled siRNA; right, merged images of the left panel and Texas Red stained blood vessels with DAPI. Scale bar, 50 ??m. "
        ],
        "rois":[
          {
            "x":1005,
            "y":3289,
            "x2":1602,
            "y2":3826
          },
          {
            "x":1839,
            "y":2952,
            "x2":3554,
            "y2":3926
          },
          {
            "x":3429,
            "y":2533,
            "x2":3725,
            "y2":2792
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Quantitative analysis of fluorescence intensity at 4 and 12 h. Fluorescence of 6-FAM was calculated as fluorescence intensity/area and normalized against that of control sections. Data represent mean ?? SEM. Liver: n = 12???15 fields of view (FOV) from 4 mice; Spleen: n = 12???20 FOV from 4 mice; Kidney: n = 8???16 FOV from 4 mice; HCT116: n = 21???24 FOV of 6 tumors; HT29: n = 8???24 FOV of 6 tumors (Wilcoxon rank test)."
        ],
        "rois":[
          {
            "x":1005,
            "y":3846,
            "x2":1602,
            "y2":4295
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) CT imaging of Alexa Fluor 750 labeled siRNA in FaDu tumors at 4 and 12 h. The red dashed circles indicate tumors. "
        ],
        "rois":[
          {
            "x":2088,
            "y":4056,
            "x2":3547,
            "y2":4922
          },
          {
            "x":93,
            "y":0,
            "x2":1514,
            "y2":499
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Ex vivo imaging at 9 and 16 h comparing sCA with IF and Atelo. "
        ],
        "rois":[
          {
            "x":2088,
            "y":4056,
            "x2":3547,
            "y2":4922
          },
          {
            "x":1838,
            "y":0,
            "x2":3641,
            "y2":1388
          },
          {
            "x":984,
            "y":931,
            "x2":1513,
            "y2":1245
          },
          {
            "x":984,
            "y":558,
            "x2":1513,
            "y2":871
          }
        ]
      },
      "IF":{
        "descriptions":[
          "(IF), AteloGene (Atelo), or sCA by intravenous administration via tail vein. Left panel: whole mouse imaging; right panel: CT scan images of lung and liver. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Detection of siRNA in HCT116 tumor at 4 h by light sheet fluorescence microscopy. The microvasculature was visualized as red signals by intravenous injection of Texas Red conjugated dextran. Green: 6-FAM labeled siRNA. Scale bar, 10 ??m. "
        ],
        "rois":[
          {
            "x":60,
            "y":3846,
            "x2":928,
            "y2":4763
          },
          {
            "x":2088,
            "y":4056,
            "x2":3547,
            "y2":4922
          },
          {
            "x":3429,
            "y":1518,
            "x2":3726,
            "y2":1846
          },
          {
            "x":1846,
            "y":1498,
            "x2":3752,
            "y2":2884
          },
          {
            "x":2677,
            "y":1439,
            "x2":2976,
            "y2":2881
          },
          {
            "x":1838,
            "y":0,
            "x2":3641,
            "y2":1388
          },
          {
            "x":984,
            "y":931,
            "x2":1513,
            "y2":1245
          },
          {
            "x":0,
            "y":1502,
            "x2":1594,
            "y2":2497
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IVIS spectrum CT imaging 12 h after treatment. Mice were treated with 40 ??g of Alexa Fluor 750 labeled siRNA delivered with Invivofectamine 2.0 "
        ],
        "rois":[
          {
            "x":90,
            "y":3114,
            "x2":1050,
            "y2":3826
          },
          {
            "x":1005,
            "y":4314,
            "x2":1602,
            "y2":4763
          },
          {
            "x":3429,
            "y":2533,
            "x2":3725,
            "y2":2792
          },
          {
            "x":3429,
            "y":1518,
            "x2":3726,
            "y2":1846
          },
          {
            "x":3032,
            "y":1518,
            "x2":3330,
            "y2":2791
          },
          {
            "x":1846,
            "y":1498,
            "x2":3752,
            "y2":2884
          },
          {
            "x":142,
            "y":557,
            "x2":931,
            "y2":1244
          }
        ]
      }
    }
  },
  "1329173":{
    
  },
  "1329176":{
    
  },
  "1330593":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          ". A. Cellular compromise, cellular function and maintenance (score = 45). Red, upregulated proteins; green, significantly downregulated proteins; white, proteins known to be in the network but not identified in this study. The color depth indicates the magnitude of the change in protein expression levels. The shape is indicative of the molecular class (i.e protein family). Lines connecting the molecules indicate molecular relationships. Dashed lines indicate indirect interactions, and solid lines indicate direct interactions. The arrow styles indicate specific molecular relationships and the directionality of the interaction"
        ],
        "rois":[
          {
            "x":24,
            "y":23,
            "x2":3163,
            "y2":4760
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Network build up from the three most significant bio-functions (activation Z score >2 or "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1332811":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) Experimental scheme for Rad52 knockdown experiments. Rad52 knockdown was achieved by an initial siRNA treatment followed by a subsequent siRNA treatment in conjunction with transfection of an I-SceI expression plasmid. Following treatment and I-SceI-induced DSB formation, cells were either harvested for Western blot detection of Rad52 or selected with media containing puromycin for 10 days to assay Alu-mediated deletions. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1224,
            "y2":1487
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot showing Rad52 siRNA knockdown compared to control siRNA treatment. M???Precision Plus Protein WesternC Standards (Bio-Rad). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1224,
            "y2":1487
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The average number of puror colonies is plotted for the indicated AARP HEK293FRT cells treated with control or Rad52 siRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1224,
            "y2":1487
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The percentage of Alu/Alu recombination or NHEJ as determined by PCR and sequence analysis of DNA repair products from isolated puror colonies that were treated with control (Ctrl) or Rad52 siRNA is shown."
        ],
        "rois":[
          {
            "x":0,
            "y":1488,
            "x2":1224,
            "y2":2258
          }
        ]
      }
    }
  },
  "1336665":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) Probes with a fold change ??? 1.8 between CTRL and MT1 cells in at least 1 point in the time course were selected and displayed as a heat map based on unsupervised hierarchical clustering. Red colour indicates genes that were up-regulated and green colour indicates genes that were down-regulated. Black indicates genes whose expression is unchanged in MT1 cells as compared to CTRL cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":828,
            "y2":1659
          },
          {
            "x":898,
            "y":0,
            "x2":1894,
            "y2":2208
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Venn diagram showing the overlap of modulated genes at the three time points. Numbers in italics, red, and underlined represent up-, contra-, and down-regulated genes, respectively. Numbers in brackets refer to the numbers of genes modulated at each time point. Venn analyses were performed using gene symbols. "
        ],
        "rois":[
          {
            "x":4,
            "y":1677,
            "x2":858,
            "y2":2358
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bio-function analysis of the dataset of genes differentially regulated upon MT1-MMP expression was performed in IPA. The significance is expressed as a negative log of p-value, which was calculated using the right-tailed Fisher's Exact Test. The orange line represents the threshold p value of 0.05."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1336667":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) Probes with a fold change ??? 1.8 between CTRL and MT1 cells in at least 1 point in the time course were selected and displayed as a heat map based on unsupervised hierarchical clustering. Red colour indicates genes that were up-regulated and green colour indicates genes that were down-regulated. Black indicates genes whose expression is unchanged in MT1 cells as compared to CTRL cells. "
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":809,
            "y2":1815
          },
          {
            "x":882,
            "y":1,
            "x2":1878,
            "y2":2117
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Venn diagram showing the overlap of modulated genes at the three time points. Numbers in italics, red, and underlined represent up-, contra-, and down-regulated genes, respectively. Numbers in brackets refer to the numbers of genes modulated at each time point. Venn analyses were performed using gene symbols. "
        ],
        "rois":[
          {
            "x":4,
            "y":1823,
            "x2":920,
            "y2":2466
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bio-function analysis of the dataset of genes differentially regulated upon MT1-MMP expression was performed in IPA. The significance is expressed as a negative log of p-value, which was calculated using the right-tailed Fisher's Exact Test. The orange line represents the threshold p value of 0.05."
        ],
        "rois":[
          {
            "x":882,
            "y":1,
            "x2":1878,
            "y2":2117
          }
        ]
      }
    }
  },
  "1341732":{
    
  },
  "1341734":{
    
  },
  "1343482":{
    "Fig_4.tif":{
      "a":{
        "descriptions":[
          "(a) SPR transmission spectra, normalized to the air spectrum, for different pOBP concentrations in the case of sensor with gold layer with bio-receptor. Inset: Zoom of the resonance wavelengths region. "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":1795,
            "y2":961
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Resonance wavelength variation as a function of pOBP concentrations [??M]."
        ],
        "rois":[
          {
            "x":299,
            "y":1070,
            "x2":1431,
            "y2":2071
          }
        ]
      }
    }
  },
  "1343484":{
    
  },
  "1343487":{
    "Fig_6.tif":{
      "a":{
        "descriptions":[
          "(a) SPR transmission spectra, normalized to the air spectrum, for different concentration in solution of butanal and with a fixed concentrations of pOBP (1.27 ??M), in the case of sensor with gold layer with bio-receptor. Inset: Zoom of the resonance wavelengths region. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1894,
            "y2":1030
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Resonance wavelength variation as a function of butanal concentration, obtained with binding of a fixed concentration of pOBP in presence of increasing concentration of butanal during pre-incubation time."
        ],
        "rois":[
          {
            "x":236,
            "y":1159,
            "x2":1645,
            "y2":2357
          }
        ]
      }
    }
  },
  "1351060":{
    
  },
  "1352128":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Construction of the CFA/I/II/IV MEFA. The most antigenic epitopes of the CS1, CS2, CS3, CS4, CS5 and CS6 major structural subunits were embedded into CFA/I major subunit by replacing the CfaB surface-exposed but less antigenic epitopes. "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":4094,
            "y2":2413
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Construction of the 3xSTaN12S-dmLT toxoid fusion. Three copies of the STa toxoid STaN12S gene were genetically fused to the monomeric dmLT (LTR192G/L211A) gene using SOE (splicing overlap extension) PCRs. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Construction of CFA/I/II/IV-STaN12S-dmLT MEFA. A substitution of the first 150 amino acids of the 3xSTaN12S-dmLT (the N-terminal STaN12S and the first 131 amino acids of LT-A subunit) with the CFA/I/II/IV MEFA created the CFA/I/II/IV-STaN12S-dmLT MEFA. Four linkers: LGA, GPVD, Gly-Pro linker GPGP, and L-linker were used for the construction. "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":4094,
            "y2":2413
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Western blot to detect the CFA/I/II/IV-STaN12S-dmLT MEFA protein with anti-CFA/I, anti-CS1, -CS2, -CS3, -CS4, -CS5, and anti-CS6 MAb hybridoma supernatant (1:100; provided by Dr. AM Svennerholm), and rabbit anti-CT (1:3300; Sigma) and anti-STa antiserum (1:3300; provided by Dr. DC Robertson). Extracted MEFA proteins separated in 12% PAGE gel were detected with each anti-adhesin MAb, anti-CT and anti-STa antiserum and IRDye-labeled goat anti-mouse IgG or anti-rabbit IgG (1:5000; LI-COR). Lane (+) indicated the CFA/I/II/IV-STaN12S-dmLT MEFA proteins, whereas lane (-) of extracted total proteins of E. coli BL21 host strain as the negative control. Lane M is the protein marker (in kilo Daltons; Precision Plus Protein pre-stained standards; Bio-Rad)."
        ],
        "rois":[
          {
            "x":290,
            "y":2435,
            "x2":3695,
            "y2":3035
          }
        ]
      }
    }
  },
  "1352296":{
    
  },
  "1352297":{
    
  },
  "1353677":{
    "Fig_4.tif":{
      "D":{
        "descriptions":[
          "(D, E) were added and plates were developed using phosphatase substrates. Optical density "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1999,
            "y2":970
          }
        ]
      },
      "E":{
        "descriptions":[
          "(D, E) were added and plates were developed using phosphatase substrates. Optical density "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1999,
            "y2":970
          }
        ]
      },
      "OD":{
        "descriptions":[
          "(OD) was measured at 405 nm on a Bio-Tek Powerwave XS plate reader."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1354727":{
    
  },
  "1354731":{
    
  },
  "1355155":{
    "Fig_7.tif":{
      "PD":{
        "descriptions":[
          ": The Annexin A2 expression level was over-expressed by constructing and transfecting expression plasmid. Values are mean??SE, N = 3; *, PD"
        ],
        "rois":[
          {
            "x":717,
            "y":241,
            "x2":1204,
            "y2":812
          }
        ]
      },
      "A":{
        "descriptions":[
          "A2 = Annexin A2; Mock = control group, only empty plasmid transfected; NC = Negative control group, only control siRNA transfected; A2 siRNA = Annexin A2 knockdown group transfected with silence siRNA; A2 over = Annexin A2 overexpression group transfected with Annexin A2 expression plasmid; GAS5 down = lncRNA-GAS5 knockdown group transfected with silence siRNA. A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":750,
            "y2":1074
          },
          {
            "x":1223,
            "y":0,
            "x2":1720,
            "y2":814
          }
        ]
      },
      "PC":{
        "descriptions":[
          ": The Annexin A2 expression level was knockdowned in HSVSMCs effectively by siRNA. Values are mean??SE, N = 3; *, PC"
        ],
        "rois":[
          {
            "x":717,
            "y":241,
            "x2":1204,
            "y2":812
          }
        ]
      },
      "B":{
        "descriptions":[
          ":Silver stains for protein gels obtained by lncRNA-GAS5 RNA Pulldown. Bio-GAS5 (sense): treatment group; Bio-GAS5 (antisense): control groups; GAS5 (sense): negative control groups. The GAS5- specific-binding protein gels (in Red box) was identified by MALDI-TOF-MS. Results show that Annexin A2 isoform 2 is a direct binding protein to lncRNA-GAS5. N = 2. B"
        ],
        "rois":[
          {
            "x":892,
            "y":1025,
            "x2":1609,
            "y2":1868
          },
          {
            "x":717,
            "y":241,
            "x2":1204,
            "y2":812
          }
        ]
      },
      "P":{
        "descriptions":[
          ": The proliferation abilities of HSVSMCs were reflected indirectly by the OD450 values measured using CCK-8 kit when Annexin A2 and lncRNA-GAS5 expression levels were knockdowned or over-expressed simultaneously in HSVSMCs. Firstly Annexin A2 siRNA or expression plasmid were transfected into the HSVSMCs, six hours later, the cell culture medium were changed and then lncRNA-GAS5 siRNA were transfected into the HSVSMCs. Another 48 hours later, the OD450 values were measured by CCK-8 kit. Values are mean??SE, N = 3; *, P"
        ],
        "rois":[
          {
            "x":62,
            "y":1139,
            "x2":712,
            "y2":1806
          },
          {
            "x":717,
            "y":241,
            "x2":1204,
            "y2":812
          }
        ]
      },
      "PE":{
        "descriptions":[
          ": The proliferation abilities of HSVSMCs were reflected indirectly by the OD450 values measured using CCK-8 kit when Annexin A2 expression level were knockdowned or over-expressed in HSVSMCs. Values are mean??SE, N = 3; *, PE"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1357703":{
    
  },
  "1359174":{
    
  },
  "1365857":{
    
  },
  "1366422":{
    
  },
  "1366596":{
    
  },
  "1369241":{
    "Fig_7.tif":{
      "a":{
        "descriptions":[
          "(a) and with high VDR expression (score 8) "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b). Scale bar 30 ??. "
        ],
        "rois":[
          {
            "x":3,
            "y":2,
            "x2":1350,
            "y2":454
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) The MCA graph demonstrated that phenotype AA is located in the quadrant containing the most aggressive parameters (T3 tumours, HER2 positive, ER negative and G3 in contrast to phenotype GG which is associated to more favorable bio-pathological parameters [T1 tumours, N0, G1, ki67 (-)]."
        ],
        "rois":[
          {
            "x":339,
            "y":509,
            "x2":969,
            "y2":1029
          }
        ]
      }
    }
  },
  "1372804":{
    "Fig_1.tif":{
      "1":{
        "descriptions":[
          "(1) and ~28 kDa "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2149,
            "y2":1374
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) were chosen for subsequent N-terminal sequencing. B. Limited proteolysis of PBX1 with trypsin. Lane M, Bio-Rad size standard; band 3 is the proteolysis fragment chosen for mass spectrometry analysis. C and D. Identification of PREP1 and PBX1 fragments by MALDI-TOF mass spectrometry analysis. Peptides of PREP1 and PBX1 were identified by MALDI-TOF analysis after digestion of fragments 1???3 with trypsin. Fragment 1 contained PREP1 and the matching peptides (red) covered 52.5% starting from the N-terminus and ending at residue 344. Fragment 2 contains the N-terminal part of PREP1 excluding the homeodomain. Fragment 3 contains PBX1, and the peptides (blue) covered 40.2% of the sequence, from residue 7 to 308."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2149,
            "y2":1374
          }
        ]
      }
    }
  },
  "1372807":{
    "Fig_2.tif":{
      "E":{
        "descriptions":[
          ". E. Co-expression and purification of GST-PBX11???430PREP11???436. Lane M, Bio-Rad size standard; Lane 1, total lysate before IPTG induction; Lane 2, total lysate after IPTG induction; Lane 3, pellet; Lane 4, cleared lysate; Lane 5, flow-through after incubation with glutathione beads; Lane 6, first wash (Tris-buffer with 0.5 M NaCl); Lane 7, second wash (Tris-buffer with 0.3 M NaCl); Lane 8, third wash (Tris-buffer with 0.3 M NaCl); Lane 9, glutathione beads before elution; Lane 10, glutathione beads after elution; Lane 11, supernatant containing the eluted proteins."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1702
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Expression and purification of full-length PREP1. SDS PAGE analysis of proteins at different purification stages. Lane M, Bio-Rad size standard; Lane 1, total lysate before IPTG induction; Lane 2, total lysate after IPTG induction; Lane 3, pellet; Lane 4, cleared lysate; Lane 5,empty; Lane 6, first wash after incubation with glutathione beads (Tris-buffer with 0.5 M NaCl); Lane 7, second wash (Tris-buffer with 0.3 M NaCl); Lane 8, third wash (Tris-buffer with 0.3 M NaCl); Lane 9, glutathione beads before elution; Lane 10; glutathione beads after elution; Lane 11, supernatant from glutathione beads, containing the eluted protein"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1702
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Expression and purification of full-length PBX1. Lane M, Bio-Rad size standard; Lane 1, total lysate before IPTG induction; Lane 2, total lysate after IPTG induction; Lane 3, cleared lysate; Lane 4, flow-through after incubation with glutathione beads; Lane 5, first wash (Tris-buffer with 0.5 M NaCl); Lane 6, second wash (Tris-buffer with 0.3 M NaCl); Lane 7, glutathione beads before elution; Lane 8; glutathione beads after elution; Lane 9, empty; Lane 10, supernatant from glutathione beads, containing the eluted protein"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1702
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Expression and purification of PREP11???344. Lane M, Bio-Rad size standard; Lane 1, total lysate before IPTG induction; Lane 2, total lysate after IPTG induction; Lane 3, cleared lysate; Lane 4, flow-through after incubation with glutathione beads; Lane 5, first wash (Tris-buffer with 0.5 M NaCl); Lane 6, second wash (Tris-buffer with 0.3 M NaCl); Lane 7, third wash (Tris-buffer with 0.3 M NaCl); Lane 8, empty; Lane 9; glutathione beads before elution; Lane 10, glutathione beads after elution; Lane 11, empty; Lane 12, supernatant from glutathione beads, containing the eluted protein"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1702
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Expression and purification of PBX11???317. Lane M, Bio-Rad size standard; Lane 1, total lysate before IPTG induction; Lane 2, total lysate after IPTG induction; Lane 3, pellet; Lane 4, cleared lysate; Lane 5, flow-through after incubation with glutathione beads; Lane 6, first wash (Tris-buffer with 0.5 M NaCl); Lane 7, second wash (Tris-buffer with 0.3 M NaCl); lane 8, third wash (Tris-buffer with 0.3 M NaCl); Lane 9, glutathione beads before elution; Lane 10, glutathione beads after elution; Lane 11, empty; Lane 12, supernatant from glutathione beads, containing the eluted protein"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1702
          }
        ]
      }
    }
  },
  "1372808":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "A. Co-expressed and purified full-length PBX1:PREP1 complex was loaded onto a Res Q anion exchange column and eluted with a 0.1???1 M NaCl gradient"
        ],
        "rois":[
          {
            "x":3,
            "y":5,
            "x2":1657,
            "y2":1066
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. SDS PAGE of fractions from anion exchange of full-length PBX1:PREP1. Lane M, Bio-Rad size standard; lanes 1???13, fractions indicated in cyan in the above chromatogram; fraction volume was 1.5 ml, and on SDS PAGE were loaded 10 ??l of each fraction C. SDS PAGE of fractions from anion exchange column of PBX11???308:PREP11???344. Lane M, Bio-Rad size standard; lanes 1???5, fractions indicated in cyan in the chromatogram below; fraction volume was 1.5 ml, and on SDS PAGE were loaded 10 ??l of each fraction D. Co-expressed and purified PBX11???308:PREP11???344 complex was loaded onto a Res S cation exchange column and eluted with a 0.1???1 M NaCl gradient."
        ],
        "rois":[
          {
            "x":343,
            "y":723,
            "x2":1996,
            "y2":1975
          },
          {
            "x":3,
            "y":5,
            "x2":1657,
            "y2":1066
          }
        ]
      }
    }
  },
  "1372811":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "A. Size exclusion chromatography on a Superose 6 10/300 column of the full-length PBX1:PREP1 complex purified by anion exchange chromatography. Markers were thyroglobulin (Mr 670,000), bovine gamma globulin (Mr 158,000), chicken ovalbumin (Mr 44,000), equine myoglobin (Mr 17,000), and vitamin B12 (Mr 1,350)"
        ],
        "rois":[
          {
            "x":3,
            "y":4,
            "x2":1897,
            "y2":1835
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. SDS PAGE of fractions from full-length PBX1:PREP1 gel filtration. Lane M, Bio-Rad size standard; lanes 1???7, fractions indicated in cyan in the above chromatogram; fractions volume was 0.5 ml, and on SDS PAGE were loaded 10 ??l of each fraction C. SDS PAGE of fractions from PBX1 1???308:PREP1 1???344 gel filtration. Lane M, Bio-Rad size standard; lanes 1???7, fractions indicated in cyan in the chromatogram below; fractions volume was 0.5 ml, and on SDS PAGE were loaded 10 ??l of each fraction D. Size exclusion chromatography on a Superose 6 10/300 column of the truncated PBX11???308:PREP11???344 complex purified by cation exchange chromatography. Markers were as in panel A."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1374292":{
    "Fig_4.tif":{
      "E":{
        "descriptions":[
          "(E) GSK3?? binds Dzip1 in a kinase-substrate interaction manner. Wild-type "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Phosphorylation of Dzip1 is coordinated with GSK3?? activation. The kinase activity of GSK3?? was negatively correlated with serum stimulation in NIH 3T3 cells. Note that the up-shifted bands (arrowheads) of Dzip1 became evident after serum depletion for 24???48 h, and disappeared after serum restimulation. ??-Tubulin was set as a loading control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), and endogenous Dzip1 was immunoprecipitated with GFP-GSK3?? in HEK 293T cells "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT) GFP-GSK3?? and the mutants S9A, K85R, and R96A were each co-expressed with Myc-Dzip1 in G0-phase HEK 293T cells, and treated with the CK1 inhibitor D4476 or the CK2 inhibitor CX4945. Note that treatment with CX4945 but not D4476 led to a significant decrease in the extent of the up-shifted Dzip1 bands, although the binding of Dzip1 to the GFP-GSK3?? variants showed no difference. The extent of the up-shifting of the Dzip1 bands was decreased in K85R-expressing cells. "
        ],
        "rois":[
          
        ]
      },
      "I":{
        "descriptions":[
          "(I) Inhibition of GSK3 by BIO causes loss of phospho-S520 in Dzip1."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) GSK3?? phosphorylates Dzip1 in vivo. In resting mouse embryo fibroblast (MEFs) treated versus not treated with GSK3 and CK2 inhibitors, the Dzip1 bands were up-shifted less in GSK3- and CK2-inhibited cells. The protein levels of total ??-Catenin and GSK3?? were steady, but the phosphorylated (S33/37/T41) ??-Catenin specifically disappeared from GSK3-inhibited cells. ??-Tubulin was set as a loading control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). (C and D) Dzip1 is co-localized with GSK3?? at the basal body. G0-phase NIH 3T3 cells expressing GFP-GSK3?? were immunostained for Dzip1 and AcTub "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), or cells expressing BFP-Centrin2 were immunostained with GSK3?? and Dzip1 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) GSK3?? phosphorylates Dzip1 in vitro. Auto-phosphorylation of GSK3?? (55 kD), and the phosphorylated bands of the middle (28 kD), C-terminus (36 kD), and N- terminus (50 kD) of Dzip1 are shown (left panel). Coomassie blue staining of the gel shows the loaded amounts of Dzip1 fragments (right panel). Note that the S520A mutation resulted in decreased phosphorylation of Dzip1 by GSK3??. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Scale bar: 5 ??m. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2240,
            "y2":2114
          }
        ]
      }
    }
  },
  "1374294":{
    "Fig_5.tif":{
      "E":{
        "descriptions":[
          "(E). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Expression of Dzip1S520A leads to increased binding of Rab8 to GDI2. The GFP-Dzip1 mutants and endogenous Rab8 were pulled down from G0-phase HEK 293T cells by increasing amounts of GST-GDI2. The maximum amounts of the pulled-down proteins were defined as having a binding affinity of 1.0, and the amounts of the indicated proteins at each point were normalized to the maximum amounts. The results represent two independent assays. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) The binding of Dzip1 with GDI2 is prevented by inhibition of GSK3. G0-phase NIH 3T3 cells were treated or not treated with the GSK3 inhibitor BIO, and endogenous Dzip1 and GDI2 were analyzed. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT) GFP-Dzip1 or S520 mutants were co-expressed with Myc-GDI2 in G0-phase HEK 293T cells, followed by IP assay. White asterisks indicate the heavy chain of IgG."
        ],
        "rois":[
          
        ]
      },
      "G":{
        "descriptions":[
          "(G) Phosphorylation of Dzip1S520 increases its binding to GDI2. GFP alone or wild-type "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The binding of Rab8GDP with GDI2 is increased by inhibition of GSK3. G0-phase HEK 293T cells expressing GFP-Rab8T22N were treated or not treated with the GSK3 inhibitors BIO or CHIR99021 (CHIR), and endogenous GDI2 was analyzed. The quantified band intensities are labeled. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The binding of GDI2 to Dzip1 is decreased, but to Rab8 is increased, by inhibition of GSK3. Endogenous Dzip1 and Rab8 were pulled down from G0-phase NIH 3T3 cells treated with the GSK3 inhibitor or from control (Con) cells by increasing amounts of GST-GDI2. The maximum amounts of the pulled-down proteins were defined as having a binding affinity of 1.0, and the amounts of the indicated proteins at each point were normalized to the maximum amounts. The results represent two independent assays. (D and E) The amount of free Rab8GDP at the basal body is decreased by inhibition of GSK3. G0-phase NIH 3T3 cells expressing the fusion protein CFP-RBD-YFP were treated with the GSK3 inhibitors BIO or CHIR99021 or not treated (control). The values shown are mean ?? SD, from 20 cells for each group "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). The calculated region was manually selected at the cilium base based on strong accumulation of the CFP-RBD-YFP signal. *p CFP distributions in quantitative analysis. The FECFP was highest around the basal body (labeled by AcTub staining) in the control cell, but was largely eliminated in GSK3-inhibited cells. The rainbow indicator in the heat map shows the FECFP, and each colored dot in the image represents the appearance of FECFP. The red boxes indicate the areas selected for calibrating background "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2177,
            "y2":2493
          }
        ]
      }
    }
  },
  "1374297":{
    "Fig_6.tif":{
      "E":{
        "descriptions":[
          "(E). (F and G) The kinase activity of GSK3?? is required for ciliogenesis. GSK3?????/??? MEFs were transfected with wild-type GFP-GSK3?? or mutant GFP-GSK3?? S9A, K85R, or R96A and immunostained with AcTub. The DNA was stained with DAPI. Representative images are shown in ",
          "(E), "
        ],
        "rois":[
          {
            "x":488,
            "y":938,
            "x2":610,
            "y2":1060
          },
          {
            "x":1665,
            "y":872,
            "x2":2214,
            "y2":1393
          },
          {
            "x":1473,
            "y":938,
            "x2":1595,
            "y2":1060
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), and the percentage ciliation ratios are shown in "
        ],
        "rois":[
          {
            "x":4,
            "y":1397,
            "x2":485,
            "y2":1829
          },
          {
            "x":488,
            "y":938,
            "x2":610,
            "y2":1060
          },
          {
            "x":1473,
            "y":938,
            "x2":1595,
            "y2":1060
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schematic model of the acquisition of synchronized mitosis???G0 phase NIH 3T3 cells, treated with double thymidine block, nocodazole (Noc), and the indicated GSK3 inhibitors. (B and C) Inhibition of GSK3 impairs ciliogenesis. Representative images of ciliated cells during the mitosis???G0 phase transition without (Con) or with BIO or CHIR99021 treatment. Cells were immunostained for ??-Tubulin and AcTub. The DNA was stained with DAPI. Ciliation ratios for "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2216,
            "y2":791
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT), GSK3?????/???, and GSK3?????/??? MEFs during the mitosis???G0 phase transition were immunostained with ??-Tubulin and AcTub. The DNA was stained with DAPI. Ciliation percentage ratios for "
        ],
        "rois":[
          {
            "x":4,
            "y":1397,
            "x2":485,
            "y2":1829
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I). The values in ",
          "(I) are mean ?? SD; 50 pairs of daughter cells were counted in each of three independent experiments. ***p "
        ],
        "rois":[
          {
            "x":488,
            "y":1061,
            "x2":610,
            "y2":2076
          },
          {
            "x":615,
            "y":1893,
            "x2":978,
            "y2":2317
          },
          {
            "x":616,
            "y":877,
            "x2":1101,
            "y2":1302
          },
          {
            "x":616,
            "y":1402,
            "x2":1101,
            "y2":1830
          },
          {
            "x":980,
            "y":1181,
            "x2":1101,
            "y2":1302
          },
          {
            "x":1664,
            "y":1888,
            "x2":2214,
            "y2":2360
          },
          {
            "x":1107,
            "y":1893,
            "x2":1470,
            "y2":2317
          },
          {
            "x":1473,
            "y":938,
            "x2":1595,
            "y2":1060
          },
          {
            "x":1473,
            "y":1181,
            "x2":1595,
            "y2":1830
          },
          {
            "x":0,
            "y":0,
            "x2":2216,
            "y2":791
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G). Note that the wild-type and S9A fully, and R96A partially, rescued the ciliogenesis defect, whereas K85R did not. (H and I) A phosphorylation-mimicking mutant of Dzip1 rescues the ciliogenesis defect in GSK3?????/??? cells. GSK3?????/??? MEFs were transfected with wild-type Myc-Dzip1, mutant S520A, or S520D, and immunostained with AcTub. The DNA was stained with DAPI. Representative images are shown in ",
          "(G), and "
        ],
        "rois":[
          {
            "x":488,
            "y":938,
            "x2":610,
            "y2":1060
          },
          {
            "x":616,
            "y":877,
            "x2":1101,
            "y2":1302
          },
          {
            "x":1662,
            "y":1383,
            "x2":2214,
            "y2":1850
          },
          {
            "x":1108,
            "y":1402,
            "x2":1471,
            "y2":1830
          },
          {
            "x":1473,
            "y":938,
            "x2":1595,
            "y2":1060
          },
          {
            "x":1473,
            "y":1061,
            "x2":1595,
            "y2":1180
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) are shown in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2216,
            "y2":791
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). (D and E) Knockout ",
          "(C), "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2216,
            "y2":791
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H), and the percentage ciliation ratios are shown in "
        ],
        "rois":[
          {
            "x":4,
            "y":1888,
            "x2":485,
            "y2":2317
          },
          {
            "x":616,
            "y":877,
            "x2":1101,
            "y2":1302
          },
          {
            "x":980,
            "y":1061,
            "x2":1101,
            "y2":1180
          },
          {
            "x":1473,
            "y":938,
            "x2":1595,
            "y2":1060
          }
        ]
      },
      "KO":{
        "descriptions":[
          "(KO) of GSK3??, but not GSK3??, abolishes ciliogenesis. Wild-type "
        ],
        "rois":[
          {
            "x":488,
            "y":2077,
            "x2":610,
            "y2":2317
          },
          {
            "x":1473,
            "y":2196,
            "x2":1592,
            "y2":2317
          },
          {
            "x":980,
            "y":1954,
            "x2":1592,
            "y2":2317
          },
          {
            "x":1110,
            "y":877,
            "x2":1471,
            "y2":1302
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) are shown in "
        ],
        "rois":[
          {
            "x":3,
            "y":872,
            "x2":485,
            "y2":1302
          }
        ]
      }
    }
  },
  "1376556":{
    "Fig_1.tif":{
      "13":{
        "descriptions":[
          "[13,34], except for microtubule-binding of Z555??N (*), which is based on results described below. CC1, CC2: coiled coil predicted with high and low propensity, respectively; C1: C1 domain; RhoGAP: Rho-family GTPase-activating protein domain; Kinesin: kinesin motor domain; ARFB: ARF6-binding domain "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4156,
            "y2":4016
          }
        ]
      },
      "34":{
        "descriptions":[
          "[13,34], except for microtubule-binding of Z555??N (*), which is based on results described below. CC1, CC2: coiled coil predicted with high and low propensity, respectively; C1: C1 domain; RhoGAP: Rho-family GTPase-activating protein domain; Kinesin: kinesin motor domain; ARFB: ARF6-binding domain "
        ],
        "rois":[
          
        ]
      },
      "9":{
        "descriptions":[
          "[9,10], BIO: 20 aa biotinylation tag. (B???E) Protein preparations used in this study were run on SDS-PAGE gels and visualized with Coomassie stain. Note that the version of Z601 used in Z601/C120, which lacks the biotinylation tag, showed a slightly larger mobility than those used alone or in a complex with C40G."
        ],
        "rois":[
          
        ]
      },
      "10":{
        "descriptions":[
          "[9,10], BIO: 20 aa biotinylation tag. (B???E) Protein preparations used in this study were run on SDS-PAGE gels and visualized with Coomassie stain. Note that the version of Z601 used in Z601/C120, which lacks the biotinylation tag, showed a slightly larger mobility than those used alone or in a complex with C40G."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4156,
            "y2":4016
          }
        ]
      }
    }
  },
  "1381576":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "A: analysis of amplification products obtained from qRT-PCR reactions with template (cDNA) amounts of 100 ng, 10 ng, 1 ng and 0.1 ng by agarose gel electrophoresis. The efficiency of the primer pair ???pomB fwd??? / ???pomB rev??? was 115% with R2 = 0.998, as calculated using the CFX Manager software (Bio-Rad). A 100 bp DNA ladder (GeneRuler, Thermo Scientific) served as molecular size marker"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2499,
            "y2":3183
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B: The correct size (134 bp) of the products from the qRT-PCR reactions (technical triplicates, I???III) was confirmed by agarose gel electrophoresis"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2499,
            "y2":3183
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C: Relative transcription level of pomB in the V. cholerae reference strain and in V. cholerae ??pomAB pAB induced with 10 mM L-arabinose. For both strains, qRT-PCR reactions were performed in technical triplicates. Transcription levels of pomB were calculated using the CFX Manager software (Bio-Rad, version 2.1.1022.0523), and the transcription level of the chromosomally encoded pomB (reference strain) was set to 1."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1382275":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "A) PAX3 protein levels relative to ??-actin. Each sample was run in duplicate on separate gels and the density of each band was assessed by densitometric scanning using the GS-800 Calibrated Densitometer (Bio-Rad). The density of each PAX3 band was compared to that of ??-actin for each lane on the same membrane and the fold change calculated and graphed. The error bars represent the standard deviation between duplicate samples"
        ],
        "rois":[
          {
            "x":4,
            "y":25,
            "x2":1087,
            "y2":900
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I)) human epidermal melanocytes as well as six primary (MM200, MM229, MM329, MM540, MM622 and WM115) and five metastatic (A2058, M14, SKMEL2, SKMEL5 and UACC62) melanoma cell lines. The level of PAX3 expression was calculated as fold-change relative to GAPDH expression levels. All PCRs were performed in triplicate and average values were used to calculate fold change over GAPDH for each sample. All samples were run in biological duplicates and the error bars represent the standard deviation of the biological replicates"
        ],
        "rois":[
          {
            "x":1152,
            "y":1263,
            "x2":1448,
            "y2":1501
          },
          {
            "x":1152,
            "y":1019,
            "x2":1747,
            "y2":1501
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) PAX3 mRNA expression in neonatal and adult normal human epidermal melanocytes and primary and metastatic melanoma cell lines. RT-qPCR was performed using RNA from neonatal (NHEM-n) and adult (NHEM-a "
        ],
        "rois":[
          {
            "x":4,
            "y":25,
            "x2":1087,
            "y2":900
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) and NHEM-a "
        ],
        "rois":[
          {
            "x":1152,
            "y":1507,
            "x2":1747,
            "y2":1747
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Immunocytochemistry of neonatal and adult human epidermal melanocytes, five metastatic melanoma cell lines and six primary melanoma cell lines. Nuclear PAX3 protein expression (red) is observed in all melanoma cell lines and primary melanocytes. Cell nuclei are stained with DAPI (blue). The scale measures 100 ??M. A negative control was included with each experimental run and proved negative in each instance."
        ],
        "rois":[
          {
            "x":60,
            "y":945,
            "x2":1086,
            "y2":1770
          },
          {
            "x":1453,
            "y":1019,
            "x2":1747,
            "y2":1258
          },
          {
            "x":1103,
            "y":4,
            "x2":1747,
            "y2":243
          },
          {
            "x":1152,
            "y":265,
            "x2":1747,
            "y2":996
          }
        ]
      }
    }
  },
  "1385587":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Top panel???Profiles of total extracellular protein (ECP) from P. aeruginosa PAO1 WT and morA KO culture supernatants. Samples were loaded based on protein secreted from equal number of cells. Protein bands were identified by MALDI-ToF-ToF. Bottom panel???Immunoblot of RNA polymerase (loading control) from cellular fractions of respective cultures. L-Protein ladder (Bio-Rad). "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1728,
            "y2":1962
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Percentage increase in levels of secreted proteins in morA KO compared to WT. Error bars represent mean +SE (n = 3). Student???s t-test, p-value"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1728,
            "y2":1962
          },
          {
            "x":1790,
            "y":141,
            "x2":4007,
            "y2":1981
          }
        ]
      }
    }
  },
  "1385589":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Top panel???Total extracellular protein (ECP) from culture supernatants of P. aeruginosa strains loaded based on protein secreted from equal number of cells. Black arrow indicates the position of elastase (LasB) band. Bottom panel???Immunoblot of RNA polymerase (loading control) on cellular fractions of respective cultures in top panel. L-Ladder (Bio-Rad). "
        ],
        "rois":[
          {
            "x":10,
            "y":11,
            "x2":2355,
            "y2":1853
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Percentage increase in levels of secreted LasB based on protein band quantification by densitometry. Band intensity values of MorA insertion (morA KO) and deletion (??morA) mutants are compared with wildtype "
        ],
        "rois":[
          {
            "x":10,
            "y":11,
            "x2":2355,
            "y2":1853
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT) while those of strains expressing MorA with mutations in GGDEF and EAL motifs (represented as ??morA???pUG* and ??morA???pUE* respectively) are compared with complementation strain (??morA-pU) containing full length morA expressed in ??morA background. Error bars represent mean +SE (n = 5). Student???s t-test, p-value"
        ],
        "rois":[
          {
            "x":2369,
            "y":150,
            "x2":4011,
            "y2":1611
          }
        ]
      }
    }
  },
  "1386166":{
    
  },
  "139390":{
    "Figure_S1.tif":{
      "i":{
        "descriptions":[
          "(i) rationally design microbial biosensors for chemicals of interest based on substrate auxotrophy that would enable their high-throughput screening; "
        ],
        "rois":[
          {
            "x":1282,
            "y":28,
            "x2":2277,
            "y2":999
          }
        ]
      },
      "ii":{
        "descriptions":[
          "(ii) predict engineering strategies for coupling the synthesis of a chemical of interest with the production of a proxy metabolite for which high-throughput screening is possible via a designed bio-sensor. The biosensor design method is validated based on known genetic modifications in an array of E. coli strains auxotrophic to various amino-acids. Predicted chemical production rates achievable via the biosensor-based approach are shown to potentially improve upon those predicted by current rational strain design approaches. (A Matlab implementation of the biosensor design method is available via http://www.cs.technion.ac.il/~tomersh/tools). "
        ],
        "rois":[
          {
            "x":30,
            "y":28,
            "x2":1052,
            "y2":999
          }
        ]
      }
    }
  },
  "1395036":{
    
  },
  "1395038":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) nanoparticle-streptavidin, "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":989,
            "y2":847
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) bio-TurboNuclease, "
        ],
        "rois":[
          {
            "x":1127,
            "y":10,
            "x2":2090,
            "y2":843
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) FLOS and "
        ],
        "rois":[
          {
            "x":11,
            "y":945,
            "x2":1019,
            "y2":1810
          },
          {
            "x":1127,
            "y":10,
            "x2":2090,
            "y2":843
          }
        ]
      },
      "NC":{
        "descriptions":[
          "(NC) contained all components except what was to be optimized. Each of the component was analyzed in five repeats and were performed in two independent experiments. Means ?? SD are shown."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) diameters of the nanoparticles. Both nanoparticle-streptavidin and bio-TurboNuclease were prepared at 1:10 serial dilutions between 10???8 -10-13 M. The FLOS oligos were prepared at 1:2 serial dilutions between 400???3.1 ??10???8 M. Four different diameter sizes (13, 30, 40 and 50 nm) were analyzed for nanoparticles. Negative control "
        ],
        "rois":[
          {
            "x":1127,
            "y":10,
            "x2":2090,
            "y2":843
          },
          {
            "x":1118,
            "y":946,
            "x2":2083,
            "y2":1814
          }
        ]
      }
    }
  },
  "1396639":{
    
  },
  "1397740":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Modular domain structure of LuxR-type regulators, with a N-terminal signal-binding domain (SBD) and a C-terminal DNA-binding domain (DBD) [8], containing the helix-turn-helix \"HTH LUXR\" motif (SMART00421) [25]. "
        ],
        "rois":[
          {
            "x":0,
            "y":17,
            "x2":865,
            "y2":432
          },
          {
            "x":80,
            "y":1039,
            "x2":2221,
            "y2":1622
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Comparison of the protein sequence identity of PluR from P. luminescens, PauR from P. asymbiotica and TraR from A. tumefaciens. The identity was compared either of the full-length protein sequence, only the signal-binding domain (SBD) and only the DNA-binding domain (DBD). To calculate identity of the protein sequences the LALIGN software from SIB (Swiss Institute of Bioinformatics) was used [26]. "
        ],
        "rois":[
          {
            "x":970,
            "y":0,
            "x2":2085,
            "y2":653
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Sequence alignment of the protein sequences of PauR from P. asymbiotica (P.a.), PluR from P. luminescens (P.l.), QscR from Pseudomonas aeruginosa (P.a.), SdiA from Escherichia coli (E.c.), TraR from Agrobacterium tumefaciens (A.t.) and LuxR from Vibrio fischeri (V.f.). The SBD is depicted with a blue bar and the DBD with a green bar. Within the SBD the six conserved amino acids, displaying the WYDPWG-motif of AHL-sensors, are marked with red asterisks and the three conserved amino acids in the DBD are marked with blue asterisks. Amino acids with a consensus of 60???100% are shown, positions with a lower coverage are marked with a dot. The RasMol colouring of the amino acids and the alignment was generated with CLC Mainworkbench 7 (CLC Bio Qiagen, Hilden, Germany)."
        ],
        "rois":[
          {
            "x":1,
            "y":737,
            "x2":2205,
            "y2":1046
          }
        ]
      }
    }
  },
  "1398279":{
    
  },
  "1399683":{
    "Fig_7.tif":{
      "e":{
        "descriptions":[
          "(e) Bar graphs showing the averaged values of 46 probes of Integrin members, 24 probes of Laminins, 8 probes of cytokines and 8 probes of receptors of cytokines extracted from normalized microarray data of CD34+CD38- double-selected TF-1a cells treated as in A. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "j":{
        "descriptions":[
          "(j) conducted on TF-1a cells treated with D9 (100 nM), SAHA (100 nM) or DAC (100 nM) with or without Ara-C (100 nM). Data are mean ?? SEM; N = 3; *P "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f) Bar graphs showing qRT-PCR validation of microarray expression data of 15 representative genes as indicated. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) Heat map of 720 genesets induced by both Ara-C and ADR which were suppressed by D9. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "i":{
        "descriptions":[
          "(i) and adhesion assay "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) The diagram showing the top five Bio Functions of commonly upregulated 720 genes by Ara-C and ADR suggested by IPA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "g":{
        "descriptions":[
          "(g) Representative phase-contrast images of TF-1a cells treated with D9 (100 nM), Ara-C (50 nM) alone or combination. Bar graphs showing transwell migration assay "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) The diagram showing the top ten canonical pathways of commonly upregulated 720 genes by Ara-C and ADR suggested by IPA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "h":{
        "descriptions":[
          "(h), invasion assays "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) The diagrams showing Integrins and AKT are highly associated networks of commonly upregulated 720 genes by Ara-C and ADR suggested by IPA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":2441
          }
        ]
      }
    }
  },
  "1402606":{
    "Fig_7.tif":{
      "IL":{
        "descriptions":[
          ": IL: interleukin"
        ],
        "rois":[
          
        ]
      },
      "KC":{
        "descriptions":[
          ", KC: keratinocyte chemoattractant, G-CSF: granulocyte-colony stimulating factor, IFN??: interferon gamma, TNF??: tumor necrosis factor alpha, MCP-1 (CCL2): monocyte chemoattractant protein-1 (CCL3 or 4), MIP: macrophage inflammatory protein, RANTES (CCL5): regulated on activation, normal T cell expressed and secreted, GM-CSF: granulocyte/macrophage-colony stimulating factor. * P"
        ],
        "rois":[
          {
            "x":278,
            "y":2144,
            "x2":1417,
            "y2":2541
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and chemokines "
        ],
        "rois":[
          {
            "x":26,
            "y":1,
            "x2":1632,
            "y2":1573
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were quantified from a panel of 23 cytokines using a multiplex bead assay (Bio-Rad, Hercules"
        ],
        "rois":[
          {
            "x":0,
            "y":1636,
            "x2":477,
            "y2":2086
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA) following the manufacturer???s protocols. Results shown are pooled from two separate experiments Cytokine abbreviations are as follows"
        ],
        "rois":[
          {
            "x":555,
            "y":1697,
            "x2":1594,
            "y2":2093
          }
        ]
      }
    }
  },
  "1406012":{
    
  },
  "1408103":{
    
  },
  "140877":{
    "Figure_S1.tif":{
      "4":{
        "descriptions":[
          "(4) and coelonin "
        ],
        "rois":[
          
        ]
      },
      "5":{
        "descriptions":[
          "(5). Stilbenoids (1???3) were the most concentrated in crude hydro-alcoholic stem extract and were considered as Vanda coerulea stem biomarkers. Dihydro-phenanthropyran "
        ],
        "rois":[
          {
            "x":129,
            "y":147,
            "x2":3247,
            "y2":2552
          }
        ]
      },
      "1":{
        "descriptions":[
          "(1) methoxycoelonin ",
          "(1) and dihydro-phenanthrene ",
          "(1) and ",
          "(1) and ",
          "(1) and methoxycoelonin "
        ],
        "rois":[
          {
            "x":129,
            "y":147,
            "x2":3247,
            "y2":2552
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) gigantol ",
          "(2) displayed the best DPPH/???OH radical scavenging activities as well as HaCaT intracellular antioxidant properties (using DCFH-DA probe: IC50 8.8 ??M and 9.4 ??M, respectively) compared to bibenzyle ",
          "(2) (IC50 12.2 ??M and 19.3 ??M, respectively). Western blot analysis revealed that stilbenoids (1???3) inhibited COX-2 expression at 23 ??M. Interestingly, stilbenoids ",
          "(2) but not ",
          "(2) were also able to inhibit COX-2 activity in a concentration-dependent manner thereby reducing PGE-2 production from irradiated HaCaT cells. Our studies suggest that stilbenoids (1???3) could be potentially used for skin protection against the damage caused by UVB exposure."
        ],
        "rois":[
          {
            "x":129,
            "y":147,
            "x2":3247,
            "y2":2552
          }
        ]
      },
      "3":{
        "descriptions":[
          "(3) flavidin ",
          "(3) (IC50 20.6 ??M). In turn, the latter showed a constant inhibition of PGE-2 production, stronger than stilbenoids ",
          "(3) were able to inhibit human recombinant COX-2 activity.ConclusionsMajor antioxidant stilbenoids (1???3) from Vanda coerulea stems displayed an inhibition of UVB-induced COX-2 expression. Imbricatin "
        ],
        "rois":[
          {
            "x":129,
            "y":147,
            "x2":3247,
            "y2":2552
          }
        ]
      }
    }
  },
  "1410578":{
    
  },
  "1413206":{
    
  },
  "1413316":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic depiction of bio-orthogonal labeling of proteins with alk-16 and an azido-reporter (tag, azido-rhodamine for fluorescence detection or azido-biotin for affinity purification). "
        ],
        "rois":[
          {
            "x":14,
            "y":10,
            "x2":2037,
            "y2":590
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Total proteins from wild-type and mutant cells labeled ?? alk-16, resolved by SDS-PAGE, and analyzed by Coomassie stain or in-gel fluorescence. MW standards (in kDa) are indicated on the right. "
        ],
        "rois":[
          {
            "x":12,
            "y":674,
            "x2":2072,
            "y2":3662
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Localization of Chs3-mCherry expressed in the strain indicated and visualized by fluorescence (left, shown as a negative image for clarity) or brightfield microscopy (right). Scale bar, 5 ??m."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1415285":{
    "Fig_2.tif":{
      "AO":{
        "descriptions":[
          "[AO]7:GALT5 reaction product before and after base hydroylysis. Permeablized microsomal membranes from the Pichia C5 line expressing 6x His-GALT5 served as the enzyme source in the ",
          "[AO]7:GALT5 reaction. Elution profiles of the reaction product before and after base hydrolysis are shown. The column was calibrated with high-Mr dextran (V0), galactose (Vt), xylo-oligosaccharides with degree of polymerization "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":2104,
            "y2":2321
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Bio-gel P2 fractionation of the RP-HPLC purified "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":2104,
            "y2":2321
          }
        ]
      },
      "DP":{
        "descriptions":[
          "(DP) 2 to 5 and xyloglucan-oligosaccharides (DP6-9); their elution positions are indicated with arrows at the top of the figure. The elution position of free Hyp amino acid (corresponding to DP3) is shown with an arrow in the panel. Base hydrolysis produces a radioactive peak eluting at DP4, which corresponds to Hyp-Gal. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) HPAEC profile of a chemically synthesized Hyp-Gal standard detected as a PAD response. "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":2104,
            "y2":2321
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The radioactive peak eluting at DP4 coelutes with the chemically synthesized Hyp-Gal standard following HPAEC. Both the Hyp-Gal standard and the radioactive peak eluting at DP4 were fractionated in 5 mM NaOH elution buffer on a CarboPac PA-20 column."
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":2104,
            "y2":2321
          }
        ]
      }
    }
  },
  "14167":{
    
  },
  "1421649":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          "(E) PLS-DA plot of ERIC-PCR data from fecal microbiota of nonxenograft and xenograft nude mice at Day 10. Black square: nonxenograft nude mice; Red dot: xenograft nude mice. "
        ],
        "rois":[
          {
            "x":23,
            "y":1901,
            "x2":895,
            "y2":2568
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Correlation coefficients of fecal microbiota of nonxenograft and xenograft nude mice. All data were expressed as the percentage change over the Day 0 control of each mouse, and presented as the mean ?? SEM (* P "
        ],
        "rois":[
          {
            "x":894,
            "y":1901,
            "x2":1812,
            "y2":2529
          },
          {
            "x":150,
            "y":717,
            "x2":1595,
            "y2":1399
          },
          {
            "x":979,
            "y":49,
            "x2":1798,
            "y2":665
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Tumor growth curve. "
        ],
        "rois":[
          {
            "x":3,
            "y":23,
            "x2":1788,
            "y2":1852
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Body wight. "
        ],
        "rois":[
          {
            "x":3,
            "y":23,
            "x2":1788,
            "y2":1852
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Representative ERIC-PCR DNA fingerprints of the fecal microbiota of individual nonxenograft and xenograft nude mice. Fecal samples were collected before xenograft (Day 0), and 5 & 10 d upon saline or tumor cells injection. "
        ],
        "rois":[
          {
            "x":3,
            "y":23,
            "x2":1788,
            "y2":1852
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Digitization of ERIC-PCR DNA fingerprints. Gel images were digitized by Image Lab 3.0 system (Bio-Rad). The peak area corresponded to the intensity of ERIC-PCR band shown in the gel image. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1422321":{
    
  },
  "1423680":{
    
  },
  "142542":{
    
  },
  "1426351":{
    
  },
  "1426433":{
    
  },
  "1427075":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) mRNA was prepared from the left ventricle "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1537,
            "y2":705
          }
        ]
      },
      "LV":{
        "descriptions":[
          "(LV) of WT mice 1 h after reperfusion, and real-time PCR analyses for cytokines were performed. Values normalized to GAPDH are expressed as fold change from the values of sham mice (n = 5 per group). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Serum samples were collected from WT mice at 1 h after reperfusion, and we performed Bio-Plex analysis for cytokines (n = 5 per group). *P "
        ],
        "rois":[
          {
            "x":0,
            "y":706,
            "x2":1537,
            "y2":1934
          }
        ]
      }
    }
  },
  "143144":{
    
  },
  "1432456":{
    
  },
  "1432777":{
    
  },
  "1433087":{
    "Fig_1.tif":{
      "e":{
        "descriptions":[
          "(e), MNLM-HP-SWI "
        ],
        "rois":[
          
        ]
      },
      "f":{
        "descriptions":[
          "(f), and MIR-SWI "
        ],
        "rois":[
          {
            "x":6,
            "y":1266,
            "x2":2680,
            "y2":2537
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a), SWI "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":3069,
            "y2":1259
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b), NLM-SWI "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":3069,
            "y2":1259
          }
        ]
      },
      "g":{
        "descriptions":[
          "(g) images. The number of phase mask multiplications is set to 4. Enhanced visibility of venous structures without loss of tissue contrast is evident in ",
          "(g) compared to (b-f)."
        ],
        "rois":[
          {
            "x":6,
            "y":1266,
            "x2":2680,
            "y2":2537
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c), IR-SWI "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":3069,
            "y2":1259
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d), MNLM-SWI "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":3069,
            "y2":1259
          }
        ]
      }
    }
  },
  "1434160":{
    
  },
  "1435440":{
    
  },
  "1437963":{
    
  },
  "1440224":{
    
  },
  "1440235":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A) and T. citrina "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2204,
            "y2":1599
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) at the indicated rearing times. MMP-2 and MMP-9 were identified by their apparent molecular mass of 67 and 92 kDa, respectively, using pre-stained molecular weight markers (Bio Rad). Histograms in C and D represent results, expressed as mean ?? SD, after scanning densitometry and computerized analysis of gels from at least three independent experiments with different cell populations. Asterisks represent values statistically different from LPS-treated astrocytes (positive control) (One-way Anova followed by Tukey test; * = p"
        ],
        "rois":[
          
        ]
      }
    }
  }
,
  "1440895":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A). Melting profile was analyzed using the fast ???Graph-1click??? method by selecting the melting peaks corresponding to the negative and unwanted product containing reactions "
        ],
        "rois":[
          {
            "x":13,
            "y":2192,
            "x2":2500,
            "y2":3481
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) in order to exclude them and thus map the remaining positive reaction profiles on the plate "
        ],
        "rois":[
          {
            "x":13,
            "y":1320,
            "x2":2475,
            "y2":2046
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2500,
            "y2":1240
          }
        ]
      }
    }
  },
  "1444194":{
    
  },
  "1445506":{
    
  },
  "1449649":{
    "Fig_9.tif":{
      "A":{
        "descriptions":[
          "(A) E12.5 embryonic kidneys were treated with various inhibitors for 7 days in organ culture. qRT-PCR results show the effect of Notch signal inhibitor (DAPT) in suppressing the expression of MM differentiation marker genes (Podxl1, Nkcc2 and Slc5a1, but not Slc12a3). No effects were seen with Wnt signal inhibitor (IWP2), GSK3?? inhibitor (BIO), JNK inhibitor (SP600125) or BMP signal inhibitor (Dorsomorphin). Data were normalized by Gapdh expression levels and presented as fold changes from DMSO treated embryonic kidneys as control. (N.D: not detected). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":977,
            "y2":676
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) E12.5 embryonic kidneys were treated with different inhibitors for 7 days in organ culture. Cells were then dispersed from these embryonic kidneys to reconstitute aggregates and cultured for another 7 days without respective inhibitors. Immuno-staining of representative aggregates for NPC marker, Six2 (green), and UB marker, DBA (red), shows the presence of Six2+-NPC only in aggregates derived from DAPT-pretreated embryonic kidneys. (Scale bars = 500 ??m)"
        ],
        "rois":[
          {
            "x":104,
            "y":681,
            "x2":897,
            "y2":1270
          },
          {
            "x":0,
            "y":0,
            "x2":977,
            "y2":676
          }
        ]
      }
    }
  },
  "1449650":{
    "Fig_10.tif":{
      "e":{
        "descriptions":[
          "(e,j), shows increased abundance of Six2+ NPC"
        ],
        "rois":[
          {
            "x":861,
            "y":582,
            "x2":1112,
            "y2":827
          },
          {
            "x":1162,
            "y":734,
            "x2":1938,
            "y2":1020
          },
          {
            "x":8,
            "y":829,
            "x2":458,
            "y2":1028
          }
        ]
      },
      "j":{
        "descriptions":[
          "(e,j), shows increased abundance of Six2+ NPC",
          "(j) epithelial structures in DAPT-treated aggregates as compared to DMSO-treated aggregates. White arrowheads indicate structures that are positive for respective markers. (Scale bar = 500??m). (C) Immuno-staining of representative P1 aggregates that were treated with either DMSO or DAPT during P0 and P1 periods for NPC marker, Six2 (green), and UB marker, DBA (red), shows that DAPT-treatment during P0 period alone increased the abundance of NPC in P1 aggregates (b vs"
        ],
        "rois":[
          
        ]
      },
      "J":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":426,
            "y":1163,
            "x2":996,
            "y2":1541
          }
        ]
      },
      "f":{
        "descriptions":[
          "(a,f); renal vesicle marker, Lef1 (green) ",
          "(f), with reduced laminin+- "
        ],
        "rois":[
          
        ]
      },
      "a":{
        "descriptions":[
          "(a,f); renal vesicle marker, Lef1 (green) ",
          ". a). The number of NPC was further expanded by continuing DAPT treatment during both P0 and P1 periods (c vs. a&b). (Scale bar = 500??m). (D) Six2+-NPC number increased by 20-fold in aggregates without passage after 21 days in culture as compared to that in the E12.5 embryonic kidneys at day 0. This was further increased to 35- and 65-fold by passage with DAPT treatment during P0 period alone and during both P0 and P1 periods, respectively. (n = 3, ** p (E) Aggregates from Six2-TGC mouse E12.5 embryonic kidneys were treated with DAPT during both P0 and P1 periods, and the Six2-GFP+ cells from these P1 aggregates were collected by FACS sorting and used to reconstitute aggregates for another 24 hour incubation with either DMSO or BIO. After being cultured for another 5 days without treatment, these aggregates were immuno-stained for epithelial cell marker, E-cadherin (green). Results from two representative aggregates show that treatment with BIO (b, b???), but not DMSO ",
          "(a), induced E-cadherin expression, indicating that Six2+ NPC from these P1 aggregates retained their potential to respond to Wnt signal to become epithelial cells. (b???) is a higher power view of "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1114,
            "y2":496
          }
        ]
      },
      "i":{
        "descriptions":[
          "(d,i); podocyte marker, pdocalyxin (green) ",
          "(i) and podocalyxin+- "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1114,
            "y2":496
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b,g); epithelial marker laminin (green)/UB marker, DBA (red) ",
          "(b) showing the induced E-cadherin+-epithelial structures by BIO treatment. (Scale bar = 20 ??m)"
        ],
        "rois":[
          {
            "x":7,
            "y":542,
            "x2":859,
            "y2":827
          }
        ]
      },
      "g":{
        "descriptions":[
          "(b,g); epithelial marker laminin (green)/UB marker, DBA (red) "
        ],
        "rois":[
          {
            "x":460,
            "y":829,
            "x2":1060,
            "y2":1028
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c,h); proximal tubule marker, LTL (red) "
        ],
        "rois":[
          {
            "x":27,
            "y":1160,
            "x2":425,
            "y2":1544
          }
        ]
      },
      "h":{
        "descriptions":[
          "(c,h); proximal tubule marker, LTL (red) ",
          "(h), LTL+- "
        ],
        "rois":[
          {
            "x":1140,
            "y":36,
            "x2":1939,
            "y2":559
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d,i); podocyte marker, pdocalyxin (green) "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1114,
            "y2":496
          }
        ]
      }
    }
  },
  "1449772":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Whole mount images of inguinal mammary gland from (a) 129SvEv WT and (b) Stat1-null (see S2 Fig for low power images of mammary gland whole mounts). Scale bar is 2 mm. "
        ],
        "rois":[
          {
            "x":4,
            "y":2,
            "x2":974,
            "y2":721
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Total ductal length and branching points were measured on photo images of whole mount mammary glands stained with either hematoxylin or carmine red. For measuring total ductal length, images were analyzed with IMARIS imaging software using the filament tracing feature. Branching points were manually counted on ducts within 2 mm of end buds. "
        ],
        "rois":[
          {
            "x":2,
            "y":725,
            "x2":977,
            "y2":1439
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantitative analyses for total ductal length (left) and the number of branches (right) shows that Stat1-null "
        ],
        "rois":[
          {
            "x":111,
            "y":1800,
            "x2":466,
            "y2":2292
          },
          {
            "x":493,
            "y":1412,
            "x2":888,
            "y2":1730
          },
          {
            "x":12,
            "y":1413,
            "x2":491,
            "y2":1795
          }
        ]
      },
      "KO":{
        "descriptions":[
          "(KO) glands have significantly (***P = 0.0003) shorter total ductal length. The number of branching points within 2 mm ductal ends was not significantly different between 129SvEv WT and Stat1-null glands. Data are mean ? SEM (n = 6)."
        ],
        "rois":[
          {
            "x":562,
            "y":1799,
            "x2":861,
            "y2":2289
          }
        ]
      }
    }
  },
  "1450963":{
    
  },
  "1451058":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A, B) Representative mouse from untreated and combination therapy group showing growing and shrinking tumor respectively. All bio-luminescent images were analyzed under the same scale."
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":191,
            "y2":1010
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Representative mouse from untreated and combination therapy group showing growing and shrinking tumor respectively. All bio-luminescent images were analyzed under the same scale."
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":191,
            "y2":1010
          },
          {
            "x":201,
            "y":62,
            "x2":785,
            "y2":522
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C, D) Irradiated Id2 knock down Neuro2a (IR-Id2kdN2a, n = 5) and wild type Neuro2a (IR-wtN2a, n = 5) were compared as whole tumor cell vaccine antigen source in combination with ??-CTLA-4 antibody against AgN2a (see Fig 3A). IR-Id2kdN2a vaccine was able to eradicate 60% of tumors in comparison to IR-wtN2a cells which had no effect on growth of the AgN2a tumors. All mice in ",
          "(C) were sacrificed on day 20 due to large tumor burden. The parenthesis indicates number of mice that survived tumor free."
        ],
        "rois":[
          {
            "x":805,
            "y":0,
            "x2":1596,
            "y2":476
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C, D) Irradiated Id2 knock down Neuro2a (IR-Id2kdN2a, n = 5) and wild type Neuro2a (IR-wtN2a, n = 5) were compared as whole tumor cell vaccine antigen source in combination with ??-CTLA-4 antibody against AgN2a (see Fig 3A). IR-Id2kdN2a vaccine was able to eradicate 60% of tumors in comparison to IR-wtN2a cells which had no effect on growth of the AgN2a tumors. All mice in "
        ],
        "rois":[
          {
            "x":201,
            "y":554,
            "x2":791,
            "y2":1003
          },
          {
            "x":801,
            "y":498,
            "x2":1422,
            "y2":1003
          },
          {
            "x":805,
            "y":0,
            "x2":1596,
            "y2":476
          },
          {
            "x":1552,
            "y":75,
            "x2":2214,
            "y2":538
          }
        ]
      }
    }
  },
  "1451494":{
    
  },
  "1454670":{
    
  },
  "1456393":{
    "Fig_3.tif":{
      "a":{
        "descriptions":[
          "(a) and "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b) represent the 1:1 line. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) Boxplot of J???bio/J???cell and 2Ebio/2Ecell. The upper and lower lines of the box represent the 75% and 25% values. The middle line in the box and circle represents the median and average of the ratios. Crosses represent maximum and minimum values. The ratio = 1 (dotted line), has the same meaning as the 1:1 line shown in Fig 3a and 3b."
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1,
            "y":8,
            "x2":2176,
            "y2":734
          }
        ]
      }
    }
  },
  "1457686":{
    "Fig_3.tif":{
      "12":{
        "descriptions":[
          "(12), "
        ],
        "rois":[
          
        ]
      },
      "13":{
        "descriptions":[
          "(13) and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2869,
            "y2":5223
          }
        ]
      },
      "14":{
        "descriptions":[
          "(14) with no measurement error. In simulations Rmax was 31.5 RU, A0 was 30nM, ka values varied between 1x105 and 3x108/M/s, kd values were adjusted so that KD was constant 1nM and kM was 3.15x107 RU/M/s. The mass transport limiting coefficients (MTLC) of these responses varied between 0.1 (little/no mass transport effect) and 300 (high/full mass transport effect). (B), same as in A, but measurement error with a constant standard deviation of 1.5 RUs was added to the simulated data. The level of noise was chosen based on empirical data obtained from the Bio-Rad Proteon XPR36 biosensor in our lab through a variety of antibody-antigen interactions (1~3 RUs in our experiments)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1461038":{
    
  },
  "1463671":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) Top row: raw lateral force profiles for the +FF and ?FF subgroups (darker and lighter colors, respectively, with experiment 1 in red, experiment 2 in blue, mean ? SEM). The +FF and ?FF subgroups display differently-shaped force profiles but similar overall force levels during training, corresponding to similar average endpoint errors (not shown). The ?FF subgroup data are well-captured by the adaptation coefficient measure (black line), which is a regression onto the ideal force profile, while the +FF data are not. This explains why learning and decay appear attenuated in the +FF subgroup in Fig 3. We performed a control experiment consisting of a 0-FF \u201ctraining\u201d block and a zEC retention block (experiment 3) to provide a baseline reference for adaptation and decay. Considering the force profiles (colored traces in top row) relative to this baseline reference (gray traces in top row) reveals symmetric adaptation and decay between +FF and ?FF conditions for both training and retention (colored traces in second row). Note that the control experiment force profiles increase substantially during the retention period, indicating that the unreferenced shooting movement decay data in Fig 3 are confounded by a tendency to produce more positive force during an extended EC block. Without control-referencing, this tendency causes the +FF decay to be underestimated and the ?FF decay to be overestimated, as it was in Fig 3. Since the control-referenced retention data is still not always well explained by the shape of the adaptation coefficient measure, we quantified adaptation using an integrated lateral force measure that is agnostic to the shape of the force profile. "
        ],
        "rois":[
          {
            "x":18,
            "y":0,
            "x2":2169,
            "y2":752
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Like Fig 3, the control-referenced vEC and zEC learning and decay appear similar (red vs blue), but here we also see symmetric learning and decay across +FF and ?FF conditions in both experiments. The strong decay apparent in both the +FF and ?FF arms of the vEC experiment is in contrast to reports of the vEC manipulation eliminating decay. "
        ],
        "rois":[
          {
            "x":0,
            "y":823,
            "x2":875,
            "y2":1484
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Consistent with the unreferenced adaptation coefficients in Fig 3, the analysis based on control-referenced integrated lateral forces shows similar learning and decay for the analogous vEC and zEC experiments, but it displays much greater symmetry across +FF vs ?FF conditions. For point-to-point movements, the vEC condition (red) actually seems to increase the decay somewhat over the corresponding zEC data (blue). These data fail to support the prediction that vEC-based retention will reduce or eliminate decay. For point-to-point movements, the hatched bars are experiment 4 (vECopp) in the 90? direction, which is opposite to the zEC movement direction. The red and blue solid bars represent experiments 4 and 5 (vEC and zEC) in the 270? direction. Error bars show SEM."
        ],
        "rois":[
          {
            "x":20,
            "y":1524,
            "x2":585,
            "y2":1980
          },
          {
            "x":610,
            "y":836,
            "x2":2117,
            "y2":1980
          }
        ]
      }
    }
  },
  "1465755":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A, B) Effects of volume on estimated MP, respectively Bioscreen (n = 10) and BioTek (n = 12)"
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":1415,
            "y2":1007
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) Effects of volume on estimated MP, respectively Bioscreen (n = 10) and BioTek (n = 12)"
        ],
        "rois":[
          {
            "x":1609,
            "y":10,
            "x2":2858,
            "y2":1054
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. coli WT in glucose-limited (blue) and LB (Red). Mean and standard error: Bioscreen LB F(2,27) = 820.5, pS. aureus in MHII. (D and E), respectively for wild type E. coli and Pseudomonas aeruginosa in LB broth (black bar) and minimal media (red bar)."
        ],
        "rois":[
          {
            "x":9,
            "y":1048,
            "x2":4411,
            "y2":2113
          }
        ]
      }
    }
  },
  "1465818":{
    
  },
  "1465970":{
    "Fig_1.tif":{
      "CY":{
        "descriptions":[
          "(CY) is metabolized to 4-hydroxy-cyclophosphamide (HCY) in the hepatic cytochrome P-450 enzyme (CYP) system (CYP2B6 and/or CYP2C19). HCY enters cells as tautomer aldocyclophosphamide (AldoCY). Through ??-elimination, AldoCY can be converted to phosphoramide mustard "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":978,
            "y2":570
          }
        ]
      },
      "PM":{
        "descriptions":[
          "(PM) and acrolein. Alternatively, AldoCY can also be oxidized to the inactive metabolite o-carboxyethylphosphoramide mustard (CEPM) by aldehyde dehydrogenase 1 (ALDH1). Other metabolites include chloroacetaldehyde (CAA), deschloroethyl-cyclophosphamide (DCCY), 4-keto-cyclophosphamide (KetoCY), hydroxypropyl-phosphoramide mustard (HPPM), imino-cyclophosphamide (IminoCY), and glutathionyl-cyclophosphamide (GSCY)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1465972":{
    
  },
  "1465973":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) CY, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":914,
            "y2":431
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HCY, and "
        ],
        "rois":[
          {
            "x":3,
            "y":408,
            "x2":946,
            "y2":879
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CEPM. Underlying diseases were acute mixed lineage leukemia (male, 8 y.o.; open square) and granulocytic sarcoma (male, 17 y.o.; open circle), and acute myeloid leukemia (male, 1 y.o.; open triangle)."
        ],
        "rois":[
          {
            "x":2,
            "y":856,
            "x2":978,
            "y2":1329
          }
        ]
      }
    }
  },
  "1465975":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) 24-hour and "
        ],
        "rois":[
          {
            "x":530,
            "y":690,
            "x2":964,
            "y2":1238
          },
          {
            "x":0,
            "y":689,
            "x2":488,
            "y2":1238
          },
          {
            "x":1,
            "y":0,
            "x2":978,
            "y2":633
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 48-hour exposure to CY alone and CY metabolized by S9 fraction of rat liver homogenate mixed with co-factors (CYS9) was assessed by MTT assay (mean + SD from 3 independent experiments). "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) The changes of CY and its metabolites HCY and CEPM concentration in H9c2 cell culture media exposed to CYS9 (mean + SD from 3 independent experiments). "
        ],
        "rois":[
          {
            "x":530,
            "y":690,
            "x2":964,
            "y2":1238
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Fluorescence intensities, corresponding to levels of H2O2, in control samples or cells exposed to 250 ??M CY, S9, CYS9 for 1 hour (mean + SD from 3 independent experiments). Fluorescence intensity is shown in arbitrary units. *p "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1465977":{
    
  },
  "1465980":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) CY and its metabolites "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":911,
            "y2":440
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HCY and "
        ],
        "rois":[
          {
            "x":3,
            "y":465,
            "x2":945,
            "y2":895
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CEPM was evaluated using LC/MS/MS. (mean + SD from 3 independent experiments). *p "
        ],
        "rois":[
          {
            "x":2,
            "y":890,
            "x2":978,
            "y2":1361
          }
        ]
      }
    }
  },
  "1465982":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A) H9c2 cells were exposed for 1 and 2 hours to CYS9 with and without NAC. The changes of acrolein in culture media was measured using HPLC. (mean + SD from 3 independent experiments). Effect of NAC on ROS generated by CYS9, as shown by fluorescence intensity of "
        ],
        "rois":[
          {
            "x":11,
            "y":0,
            "x2":475,
            "y2":519
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) DCFH, "
        ],
        "rois":[
          {
            "x":485,
            "y":0,
            "x2":978,
            "y2":492
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) APF, and "
        ],
        "rois":[
          {
            "x":0,
            "y":600,
            "x2":505,
            "y2":1109
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) HPF in cells exposed for 1 hour to CYS9 or CYS9 plus NAC. Fluorescence intensity is shown in arbitrary units. (mean + SD from 3 independent experiments). *p "
        ],
        "rois":[
          {
            "x":528,
            "y":600,
            "x2":958,
            "y2":1109
          }
        ]
      }
    }
  },
  "1465984":{
    
  },
  "1465986":{
    "Fig_10.tif":{
      "A":{
        "descriptions":[
          "(A) 24-hour and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":978,
            "y2":1231
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 48-hour exposure to acrolein (Acr) with or without NAC was assessed by MTT assay (mean + SD from 2 independent experiments conducted in duplicate). *p p "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1465988":{
    "Fig_11.tif":{
      "E":{
        "descriptions":[
          "(A, C, E) or 48 hours "
        ],
        "rois":[
          {
            "x":521,
            "y":931,
            "x2":978,
            "y2":1377
          },
          {
            "x":507,
            "y":0,
            "x2":968,
            "y2":437
          }
        ]
      },
      "F":{
        "descriptions":[
          "(B, D, F). *p "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A, C, E) or 48 hours "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":456,
            "y2":436
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, D, F). *p "
        ],
        "rois":[
          {
            "x":519,
            "y":460,
            "x2":978,
            "y2":908
          },
          {
            "x":1,
            "y":459,
            "x2":471,
            "y2":914
          }
        ]
      },
      "C":{
        "descriptions":[
          "(A, C, E) or 48 hours "
        ],
        "rois":[
          {
            "x":521,
            "y":931,
            "x2":978,
            "y2":1377
          },
          {
            "x":1,
            "y":459,
            "x2":471,
            "y2":914
          },
          {
            "x":9,
            "y":931,
            "x2":462,
            "y2":1375
          }
        ]
      },
      "D":{
        "descriptions":[
          "(B, D, F). *p "
        ],
        "rois":[
          {
            "x":521,
            "y":931,
            "x2":978,
            "y2":1377
          },
          {
            "x":9,
            "y":931,
            "x2":462,
            "y2":1375
          }
        ]
      }
    }
  },
  "1466585":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) RAGE and angiotensin II expression in MCs was investigated by Western blotting (RAGE) and RT-PCR (ACE"
        ],
        "rois":[
          {
            "x":106,
            "y":935,
            "x2":1687,
            "y2":1741
          },
          {
            "x":106,
            "y":935,
            "x2":621,
            "y2":1315
          },
          {
            "x":0,
            "y":0,
            "x2":1836,
            "y2":908
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantification of the Western blotting and RT-PCR results. Western blots were quantified by densitometry and are expressed as fold changes relative to controls. RT-PCR results were quantified by densitometric analysis using Quantity One 1-D Analysis Software (Bio-Rad, USA). Target mRNA expression was calculated by normalizing with respect to ??-actin mRNA expression. Data are expressed as mean ?? SEM (n = 9). apbpcp"
        ],
        "rois":[
          {
            "x":1190,
            "y":1361,
            "x2":1687,
            "y2":1744
          }
        ]
      }
    }
  },
  "1466786":{
    
  },
  "1471326":{
    
  },
  "1472140":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          ". E"
        ],
        "rois":[
          {
            "x":3,
            "y":400,
            "x2":1361,
            "y2":1017
          }
        ]
      },
      "F":{
        "descriptions":[
          ". The protein level of Hcp4 in relevant Yptb strains. Lysates from bacteria were resolved by SDS-PAGE, and Hcp4 was detected by immunoblotting. The metabolic protein phosphoglucose isomerase (Pgi) was probed as a loading control. F"
        ],
        "rois":[
          {
            "x":3,
            "y":400,
            "x2":1361,
            "y2":1017
          }
        ]
      },
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":541,
            "y2":385
          }
        ]
      },
      "B":{
        "descriptions":[
          ". OxyR binds the T6SS-4 promoter. Biotin-labeled probe or its mutant was incubated with OxyR. The protein-DNA complexes were detected by streptavidin-conjugated HRP and chemiluminescent substrate. Unlabeled promoter was added to determine the binding specificity of OxyR. Bio-T6SS-4p: biotin-labeled T6SS-4 promoter. Bio-T6SS-4pM: biotin-labeled T6SS-4 promoter mutant. B"
        ],
        "rois":[
          {
            "x":3,
            "y":400,
            "x2":1361,
            "y2":1017
          }
        ]
      },
      "C":{
        "descriptions":[
          ". Identification of the OxyR protected region in T6SS-4 promoter region. Complexes formed between FAM dye-labeled probes and His6-OxyR were subjected to DNase I digestion. DNA was sequenced and the 4 nucleotides marked in different colors were merged. The electropherograms were aligned using GeneScan-LIZ500. C-D. OxyR activates the expression of T6SS-4. ??-galactosidase activity (C)"
        ],
        "rois":[
          {
            "x":558,
            "y":8,
            "x2":850,
            "y2":395
          }
        ]
      },
      "D":{
        "descriptions":[
          " or relative expression measured by quantitative RT-PCR in indicated bacterial strains was determined. Relative levels of transcripts were presented as the mean values ?? SD calculated from three sets of independent experiments (D)"
        ],
        "rois":[
          {
            "x":891,
            "y":8,
            "x2":1358,
            "y2":333
          }
        ]
      }
    }
  },
  "1472544":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          "(E) PET blot analysis to show PK-resistant PrP-res deposition in the brain of a mouse received i.p. rec-Prion inoculation."
        ],
        "rois":[
          {
            "x":1278,
            "y":547,
            "x2":2201,
            "y2":938
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Survival curves of wild-type CD-1 mice that received i.p. inoculations of rec-Prion or control inocula. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":991,
            "y2":800
          },
          {
            "x":1676,
            "y":1065,
            "x2":2236,
            "y2":1366
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunoblot analysis of PK-resistant PrP in the brain of all 10 mice that received i.p. inoculation of rec-Prion. C, undigested brain homogenate prepared from a rec-Prion inoculated mouse as a control. C1, PK digested brain homogenate prepared from an age-matched, un-inoculated CD-1 mice. PrP was detected by the POM1 monoclonal anti-PrP antibody and a peroxidase conjugated goat anti-mouse IgG (Bio Rad). "
        ],
        "rois":[
          {
            "x":4,
            "y":887,
            "x2":877,
            "y2":1425
          },
          {
            "x":1676,
            "y":1065,
            "x2":2236,
            "y2":1366
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The spleen homogenates prepared from all 10 mice that received i.p. inoculation of rec-Prion were digested with or without PK as indicated. The PrP in the spleen homogenates was detected by the polyclonal M20 anti-PrP antibody (Santa Cruz Biotech. Inc.) and a peroxidase conjugated donkey anti-goat IgG (Santa Cruz Biotech. Inc.). C, homogenate prepared from a spleen of an un-inoculated CD-1 mouse as a control. "
        ],
        "rois":[
          {
            "x":1676,
            "y":1065,
            "x2":2236,
            "y2":1366
          },
          {
            "x":1185,
            "y":0,
            "x2":2201,
            "y2":547
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) H&E stain of the frontal cortical region of a mouse i.p. challenged with rec-Prion. "
        ],
        "rois":[
          {
            "x":939,
            "y":887,
            "x2":1556,
            "y2":1409
          }
        ]
      }
    }
  },
  "1472658":{
    "Fig_3.tif":{
      "WT":{
        "descriptions":[
          "(WT), Hppmt1??? (???1), and Hppmt4??? (???4) mutant strains, which were grown to early exponential phase and then treated for 2 hr with 20 mM caffeine, 0.2 mg/mL CFW, 10 mg/mL CR, 2 ??g/mL CAS, 0.05% SDS, or 2.5 ??g/mL TM. The phosphorylated HpMpk1p was detected using the anti-phospho-p44/42 MAPK antibody, and the protein loading was monitored using an anti-??-actin antibody. The relative values of HpMpk1p phosphorylation to the basal level value of the wild-type were indicated, which were obtained by measuring the signal intensity of western blots with Quantity One 4.6.6 software (Bio-Rad). Error bars represent standard deviation of duplicate measurements. ",
          "(WT), Hppmt1??? (???1), and Hppmt4??? (???4) mutant strains, which were grown to early exponential phase in YPD containing 0.5 M NaCl for 2 hr. Immunoblotting was conducted using anti-phospho-p38 antibody to detect phospho-Hog1p and with anti-Hog1 antibody as a loading control. The strains used were wild-type 1BQ-LA ",
          "(WT) and the Hppmt1??? (???1) and Hppmt4??? (???4) mutants."
        ],
        "rois":[
          {
            "x":0,
            "y":511,
            "x2":1533,
            "y2":969
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Analysis of HpHog1 MAP kinase activation. The total soluble protein samples were obtained from the wild-type "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1533,
            "y2":510
          },
          {
            "x":0,
            "y":970,
            "x2":1533,
            "y2":2553
          }
        ]
      }
    }
  },
  "1473884":{
    "Fig_2.tif":{
      "c":{
        "descriptions":[
          "(c) Citrus inoculated with 10 ??L conidial suspension of Penicillium digitatum at 105 conidia/mL without treatment. "
        ],
        "rois":[
          {
            "x":0,
            "y":687,
            "x2":1048,
            "y2":1168
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Citrus inoculated with 10 ??L conidial suspension of P. digitatum at 105 conidia/mL and treated by the VOCs from C. fimbriata. "
        ],
        "rois":[
          {
            "x":1054,
            "y":0,
            "x2":2129,
            "y2":1604
          }
        ]
      },
      "e":{
        "descriptions":[
          "(e) Comparison among the positive control (CK+), negative control (CK-) and treated by C. fimbriata volatiles (T). "
        ],
        "rois":[
          {
            "x":0,
            "y":1174,
            "x2":1048,
            "y2":1604
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f) Pathogenicity test of the treated and recovered P. digitatum. T (treated) = the citrus inoculated with 10 ??L conidial suspension of P. digitatum at 105 conidia/mL with the treatment by the VOCs form C. fimbriata. CK+ (positive control) = the citrus inoculated with 10 ??L conidial suspension of P. digitatum at 105 conidia/mL without treatment. CK- (negative control) = the citrus inoculated with 10 ??L sterile water without treatment. IT = inoculation with treated 2 mm plug of P. digitatum. IR = inoculation with recovered 2 mm plug of P. digitatum."
        ],
        "rois":[
          {
            "x":1054,
            "y":0,
            "x2":2129,
            "y2":1604
          },
          {
            "x":0,
            "y":0,
            "x2":1048,
            "y2":681
          }
        ]
      }
    }
  },
  "1474499":{
    
  },
  "1474712":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) Fold changes were calculated for the various genes using the -??????Ct method relative to the CTR condition. The values represent means ?? SEM of four independent experiments. "
        ],
        "rois":[
          {
            "x":1,
            "y":0,
            "x2":1026,
            "y2":997
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Heat map of average gene expression represented as log10 of Ct values. An increase in gene expression is depicted in red, whereas a decrease in gene expression is represented by the green color. No differences in expression are depicted in black. Clustering was performed using the CFX manager software by Bio-Rad. * "
        ],
        "rois":[
          {
            "x":1128,
            "y":0,
            "x2":1985,
            "y2":1082
          }
        ]
      }
    }
  },
  "1475470":{
    
  },
  "1475570":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) MCF-7 and MDA-MB-231 breast cancer cell lines were treated with the indicated concentrations of A-366 or UNC0638 for 14 days before assessing colony formation. "
        ],
        "rois":[
          {
            "x":6,
            "y":5,
            "x2":1590,
            "y2":646
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) MCF-7 and MDA-MB-231 cells were treated with the indicated concentrations of A-366 or UNC0638 for 3 days and subjected to western blot analysis of global H3K9me2 and total histone H3."
        ],
        "rois":[
          {
            "x":7,
            "y":671,
            "x2":1590,
            "y2":2131
          }
        ]
      }
    }
  },
  "1476363":{
    
  },
  "1477176":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Growth curves of strains that expressed RpoAint (SMS05, blue line), RpoAdel (SMS06, pink line) and RplQ without RpoA (SMS07, green line), upon xylose induction. (B and C) Pull-down assays of RpoA assembled in RNAP complexes. RNAP complexes were purified using His-tagged RpoC as bait, separated by SDS-PAGE and detected by fluorescent staining with Flamingo dye (Bio-Rad), which is characterized by a high sensitivity and a low background, allowing accurate quantification [32]. The band positions corresponding to RpoB and C, RpoAint and RpoAdel in the SDS-PAGE gel are indicated by arrows (right). The duration of cultivation in LBxyl is shown at the bottom of each panel. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4360,
            "y2":4004
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Time course of alteration in the relative amounts of RpoAint and RpoAdel in the RNAP complexes of rpoAint- and rpoAdel-expressing cells grown in LBxyl. The blue line indicates the relative ratio (see below) of the amount of RpoAint in the RNAP complexes of rpoAint-expressing cells at each time point. For normalization, the amount of RpoAint was divided by that of RpoB, C in each lane as follows: normalized signal intensity of RpoA = [signal intensity of the RpoA band] / [signal intensity of the RpoB, C band]. The amount of RpoAint at each time point was then divided by the amount of RpoAint at time 0 as follows: relative ratio (RpoAint (X hour)) = [normalized signal intensity of RpoAint (X hour)] / [normalized signal intensity of RpoAint (0 hour)]. The orange line represents the relative ratios of RpoAint in the RNAP complexes of rpoAdel-expressing cells at each time point, calculated as described above. The black line shows the relative ratios of the amount of RpoAdel in the RNAP complexes of rpoAdel-expressing cells at each time point against to the amount of RpoAdel at 6 hours after the beginning of the RpoAdel induction. Here, the relative ratio was calculated as: relative ratio (RpoAdel (X hour)) = [normalized signal intensity of RpoAdel (X hour)] / [normalized signal intensity of RpoAdel (6 hour)]. Each relative ratio was calculated using the average values obtained from triplicate experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4360,
            "y2":4004
          }
        ]
      }
    }
  },
  "1478370":{
    
  },
  "1480248":{
    
  },
  "1480335":{
    
  },
  "1482294":{
    
  },
  "1482336":{
    "Fig_1.tif":{
      "a":{
        "descriptions":[
          "(a) and TqPCR",
          "(a). The standard curves were established with scatter plot "
        ],
        "rois":[
          {
            "x":5,
            "y":10,
            "x2":1988,
            "y2":1426
          },
          {
            "x":0,
            "y":0,
            "x2":971,
            "y2":691
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b). (B) Cq value comparison between conventional qPCR and TqPCR reactions. Mean Cq values were obtained for both qPCR and TqPCR using the same dilution series of pUC19 DNA ",
          "(b). Triplicate was performed for each assay condition. ???**???, indicating the Cq difference between qPCR and TqPCR groups is significant with p"
        ],
        "rois":[
          {
            "x":1073,
            "y":703,
            "x2":2025,
            "y2":1426
          }
        ]
      }
    }
  },
  "1482338":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) and TqPCR "
        ],
        "rois":[
          {
            "x":4,
            "y":553,
            "x2":970,
            "y2":1213
          },
          {
            "x":0,
            "y":0,
            "x2":1907,
            "y2":532
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) protocols using CFX-Connect qPCR unit (Bio-Rad). The qPCR SYBR Green fluorescence history vs. cycle numbers (a) and the qPCR efficiencies of Gapdh(b) were analyzed and presented. The mean Cq value comparison of the two procedures was further graphed "
        ],
        "rois":[
          {
            "x":4,
            "y":553,
            "x2":970,
            "y2":1213
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Note that the qPCR protocol did not yield reliable results for the two most diluted cDNA samples. ???**???, indicating the Cq difference between qPCR and TqPCR groups is significant with p"
        ],
        "rois":[
          {
            "x":159,
            "y":599,
            "x2":1915,
            "y2":1760
          },
          {
            "x":4,
            "y":553,
            "x2":970,
            "y2":1213
          }
        ]
      }
    }
  },
  "1482341":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) and TqPCR "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1984,
            "y2":531
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) protocols using CFX-Connect qPCR unit (Bio-Rad). The qPCR SYBR Green fluorescence history vs. cycle numbers (a) and the qPCR efficiencies of Rps13(b) were analyzed and presented. The mean Cq value comparison of the two procedures was further graphed "
        ],
        "rois":[
          {
            "x":6,
            "y":557,
            "x2":910,
            "y2":1213
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). ???**???, indicating the Cq difference between qPCR and TqPCR groups is significant with p"
        ],
        "rois":[
          {
            "x":186,
            "y":602,
            "x2":1985,
            "y2":1712
          },
          {
            "x":6,
            "y":557,
            "x2":910,
            "y2":1213
          }
        ]
      }
    }
  },
  "1482344":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) and TqPCR "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1022,
            "y2":612
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) protocols using CFX-Connect qPCR unit (Bio-Rad). The qPCR SYBR Green fluorescence history vs. cycle numbers (a) and the qPCR efficiencies of Hprt1(b) were analyzed and presented. The mean Cq value comparison of the two procedures was further graphed "
        ],
        "rois":[
          {
            "x":216,
            "y":680,
            "x2":2197,
            "y2":1936
          },
          {
            "x":1047,
            "y":24,
            "x2":2186,
            "y2":590
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Note that the qPCR protocol did not yield reliable results for the two most diluted cDNA samples. ???**???, indicating the Cq difference between qPCR and TqPCR groups is significant with p"
        ],
        "rois":[
          {
            "x":7,
            "y":640,
            "x2":1021,
            "y2":1405
          }
        ]
      }
    }
  },
  "1482346":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic representation of the sizes and locations of the PCR primers (also see S2 Table). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1523,
            "y2":677
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Comparison and correlation analyses of mean Cq value differences between Bio-Rad???s RQ1 and RQ2 primers (BRQ1 and BRQ2) and customized RQ primers (e.g., MRQ1 through MRQ6). The mean Cq values were obtained by performing TqPCR assay. Possible correlations between BRQ1/2 and MRQ primers were further analyzed statistically."
        ],
        "rois":[
          {
            "x":75,
            "y":688,
            "x2":1523,
            "y2":2259
          }
        ]
      }
    }
  },
  "1482349":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A), MRQ2/4 "
        ],
        "rois":[
          {
            "x":1,
            "y":0,
            "x2":867,
            "y2":631
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), MRQ2/5 "
        ],
        "rois":[
          {
            "x":925,
            "y":0,
            "x2":1797,
            "y2":631
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), MRQ2/6 "
        ],
        "rois":[
          {
            "x":0,
            "y":681,
            "x2":868,
            "y2":1309
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), as well as MRQ2/1 (data not shown), were all statistically positively correlated. The correlation between BRQ1/2 and MRQ2/3 is the largest, while the BRQ1/2 and MQR2/1 is the least (data not shown)."
        ],
        "rois":[
          {
            "x":926,
            "y":679,
            "x2":1796,
            "y2":1309
          }
        ]
      }
    }
  },
  "1482742":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "Levels of CXCR2 ligands KC (A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2194,
            "y2":1857
          }
        ]
      },
      "B":{
        "descriptions":[
          ", MIP-2 (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2194,
            "y2":1857
          }
        ]
      },
      "C":{
        "descriptions":[
          ", and LIX (C)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2194,
            "y2":1857
          }
        ]
      }
    }
  },
  "1485097":{
    
  },
  "1486631":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) IBA1 and "
        ],
        "rois":[
          {
            "x":55,
            "y":9,
            "x2":1984,
            "y2":2405
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) TLR4 mRNAs were significantly increased up to 15 fold on day 5 and returned to control levels on day 10 post-stroke. "
        ],
        "rois":[
          {
            "x":2132,
            "y":9,
            "x2":4013,
            "y2":2421
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CB1R expression was slightly ("
        ],
        "rois":[
          {
            "x":10,
            "y":2512,
            "x2":3988,
            "y2":4771
          }
        ]
      }
    }
  },
  "1490153":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) The AcPA peptide was adsorbed to a microtiter plate and incubated with a constant amount of C1q in the presence of varying amounts of NaCl. Bound C1q was detected with a goat polyclonal anti-C1q sera followed by HRP-conjugated anti-goat sera. Data represent the means of three independent experiments. Error bars denote SEM. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1284,
            "y2":2331
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) C1q and biotinylated PA in the absence or presence of the crosslinker BS3 were loaded onto a 4???12% SDS-PAGE gel, (left panel) transferred to nitrocellulose and probed with antibody to detect C1q (green) and streptavidin conjugate to detect PA (red). An identical gel was stained with bio-safe Coomassie blue, and visualized by Odyssey imaging (right panel). Molecular size markers (in kDa) are indicated to the left and chains of C1q "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1284,
            "y2":2331
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Interactions between AcPA and the CLR of C1q as measured by surface plasmon resonance (SPR). The CLR of C1q was immobilized onto the surface of a dextran sensor chip and AcPA was injected at the indicated concentrations. Data analysis consisted of globally fitting the SPR sensorgrams for different peptide concentrations with a 1:1 model taking into account mass transport. KD values were calculated from koff/kon for each experiment and were averaged from at least two separate experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1284,
            "y2":2331
          }
        ]
      }
    }
  },
  "1492531":{
    "Fig_9.tif":{
      "E":{
        "descriptions":[
          "(E), IL12 p40 "
        ],
        "rois":[
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          },
          {
            "x":17,
            "y":671,
            "x2":520,
            "y2":1244
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N)) in DLN were measured by ELISA. Data are presented as mean + SEM and reflects a total of 6 to 8 mice for each group from two independent experiments. Asterisks indicate statistical significance (*, P P P P "
        ],
        "rois":[
          {
            "x":523,
            "y":1956,
            "x2":989,
            "y2":2550
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J), MIP-1?? "
        ],
        "rois":[
          {
            "x":523,
            "y":1312,
            "x2":996,
            "y2":1889
          },
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F)"
        ],
        "rois":[
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          },
          {
            "x":17,
            "y":671,
            "x2":520,
            "y2":1244
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), IL-1?? "
        ],
        "rois":[
          {
            "x":19,
            "y":0,
            "x2":465,
            "y2":604
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) and CCL21 "
        ],
        "rois":[
          {
            "x":18,
            "y":1956,
            "x2":474,
            "y2":2551
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I), MIP-1?? "
        ],
        "rois":[
          {
            "x":0,
            "y":1312,
            "x2":479,
            "y2":1892
          },
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G), and IFN-?? "
        ],
        "rois":[
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          },
          {
            "x":524,
            "y":671,
            "x2":1062,
            "y2":1252
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L)) in DLN were measured by Bio-Plex assay. M-N. Levels of chemokines (CXCL13 "
        ],
        "rois":[
          {
            "x":1537,
            "y":1313,
            "x2":2009,
            "y2":1898
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), IL-2 "
        ],
        "rois":[
          {
            "x":524,
            "y":0,
            "x2":964,
            "y2":604
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), IL-6 "
        ],
        "rois":[
          {
            "x":1010,
            "y":0,
            "x2":1459,
            "y2":606
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H)) and chemokines (MCP-1 "
        ],
        "rois":[
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          },
          {
            "x":1087,
            "y":671,
            "x2":1553,
            "y2":1246
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K), and RANTES "
        ],
        "rois":[
          {
            "x":1031,
            "y":1312,
            "x2":1501,
            "y2":1897
          },
          {
            "x":1537,
            "y":684,
            "x2":1984,
            "y2":1246
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), IL-10 "
        ],
        "rois":[
          {
            "x":1517,
            "y":0,
            "x2":1982,
            "y2":607
          }
        ]
      }
    }
  },
  "1493281":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1734,
            "y2":2214
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Time-course activity of ABCA1-mediated cholesterol efflux to lipid-free CS-6253 (30 ??g/ml) and apo A-I (10 ??g/ml), using BHK cells expressing ABCA1, and control cells (unstimulated BHK-ABCA1 and BHK-mock cells). Cholesterol efflux from either ABCA1 cells or control cells to apo A-I (closed circles), and CS-6253 (closed triangles) was determined at the indicated time points. B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1734,
            "y2":2214
          }
        ]
      },
      "C":{
        "descriptions":[
          ". Dose dependent ABCA1 mediated cholesterol efflux in BHK-ABCA1 induced with mifepristone. Kinetic parameters for ABCA1-mediated cholesterol efflux from BHK-ABCA1 cells to apo A-I: Km = 4.53??0.67 ??g/ml (0.15??0.02 ??M), Vmax = 14.85??0.02% efflux/4h, and relative catalytic efficiency: Vmax/Km = 3.27. CS-6253: Km = 2.27??0.16 ??g/ml (0.73??0.05 ??M), Vmax = 15.25??0.05% efflux/4h, and relative catalytic efficiency: Vmax/Km = 6.71. ATI-5261: Km = 1.04 ?? 0.16 ??g/ml (0.37 ?? 0.04 ??M), Vmax = 14.48 ?? 0.29% efflux/ h, and relative catalytic efficiency: Vmax/Km = 13.92. Apo E: Km = 10.30??2.84 ??g/ml (0.21??0.05 ??M), Vmax = 11.45??1.16% efflux/4h, and relative catalytic efficiency: Vmax/Km = 1.11. C"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1734,
            "y2":2214
          }
        ]
      },
      "P":{
        "descriptions":[
          ". Ability of CS-6253 to stimulate cholesterol efflux from human macrophages THP-1. Foam cells were incubated with CS-6253 or apoA-I at equimolar ratio (0.96 ??M) for 4h. Cholesterol efflux induced by CS-6253 and apoA-I were compared to control cells incubated alone. P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1493295":{
    
  },
  "1493434":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          ". E. Spine l/w ratio changes are presented as cumulative histograms of the l/w ratio at 3 time points."
        ],
        "rois":[
          {
            "x":0,
            "y":834,
            "x2":2111,
            "y2":1721
          }
        ]
      },
      "A":{
        "descriptions":[
          "A. Efficiency of GSK3??/?? chemical inhibition. The level of phosphorylation for glycogen synthase Ser 641 at time points after GSK3??/?? inhibition with Ch98 and BIO. Lysates from hippocampal neurons on DIV18. Tubulin was the loading control"
        ],
        "rois":[
          {
            "x":0,
            "y":9,
            "x2":988,
            "y2":461
          },
          {
            "x":1529,
            "y":1761,
            "x2":2105,
            "y2":2498
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Pharmacological inhibition of GSK3??/?? does not affect basal fluctuations of dendritic spine morphology. Experimental outline with 4 time points for microscopy and quantitative analysis of spine width; ## indicates pTable 3. Data are presented as the mean spine width per cell ?? s.e.m. The curve between time points is extrapolated"
        ],
        "rois":[
          {
            "x":1010,
            "y":8,
            "x2":2093,
            "y2":812
          },
          {
            "x":1529,
            "y":1761,
            "x2":2105,
            "y2":2498
          },
          {
            "x":848,
            "y":1761,
            "x2":1541,
            "y2":2594
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Experimental outline with 3 time points for microscopy: baseline, LatrB treatment, end of recovery period. Representative micrographs of DIV18 cultured murine hippocampal neurons. Scale bar = 2.5 ??m"
        ],
        "rois":[
          {
            "x":0,
            "y":834,
            "x2":2111,
            "y2":1721
          },
          {
            "x":1529,
            "y":1761,
            "x2":2105,
            "y2":2498
          },
          {
            "x":848,
            "y":1761,
            "x2":1541,
            "y2":2594
          },
          {
            "x":31,
            "y":1758,
            "x2":832,
            "y2":2586
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Quantitative analysis of spine shape changes; *** and ### indicates pTable 3. Data are presented as mean spine width per cell ?? s.e.m. The curve between time points is extrapolated"
        ],
        "rois":[
          {
            "x":0,
            "y":834,
            "x2":2111,
            "y2":1721
          },
          {
            "x":31,
            "y":1758,
            "x2":832,
            "y2":2586
          }
        ]
      }
    }
  },
  "1493435":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "A. chLTD activates GSK3??/?? in synaptoneurosomes isolated from murine hippocampi. Representative immunoblots, scanned with a Li-Cor Odyssey imager, for phospho-GSK3?? (Ser21)/?? (Ser9), total GSK3??/??, phospho-GluA1 (Ser845; LTD control) and GAPDH (loading control)"
        ],
        "rois":[
          {
            "x":0,
            "y":28,
            "x2":1048,
            "y2":272
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Quantitative analysis of phospho-GSK3??/?? to the total-GSK3??/?? ratio at the time points indicated, expressed as % values of an untreated control. Data (n = 3 experiments) are presented as means ?? s.e.m. * indicates a pp p p Table 3. Data are presented as mean spine width per cell ?? s.e.m. The curve between time points is extrapolated"
        ],
        "rois":[
          {
            "x":0,
            "y":28,
            "x2":1048,
            "y2":272
          },
          {
            "x":1043,
            "y":129,
            "x2":1555,
            "y2":633
          },
          {
            "x":1581,
            "y":129,
            "x2":2092,
            "y2":633
          },
          {
            "x":0,
            "y":277,
            "x2":990,
            "y2":1224
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. Spine l/w ratio changes are presented as cumulative histograms of the length/width ratio at 3 time points."
        ],
        "rois":[
          {
            "x":999,
            "y":673,
            "x2":2090,
            "y2":1521
          },
          {
            "x":0,
            "y":1244,
            "x2":2103,
            "y2":2564
          }
        ]
      }
    }
  },
  "1494994":{
    
  },
  "1495240":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) 12% SDS-PAGE of the expression fractions and IMAC samples of Est16 from E. coli BL21 (DE3) cells carrying the pET28a-est16 vector, which contained the est16 gene"
        ],
        "rois":[
          {
            "x":1,
            "y":2,
            "x2":1717,
            "y2":1410
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. coli cells were grown in LB up to O.D.600nm = 0.5 at 37??C and then induced with 0.1 mM IPTG at 28??C for 20 hours. Lane 1: non-induced cells; Lane 2: induced cells; Lane 3: molecular weight marker (the kDa values are indicated in the picture); Lane 4: soluble extracts; Lane 5: flow-through fraction from the IMAC purification; Lane 6: 10 mM imidazole wash fraction; Lanes 7, 8 and 9: 50 mM, 100 mM and 1 M imidazole elution fractions, respectively. "
        ],
        "rois":[
          {
            "x":1888,
            "y":3,
            "x2":3898,
            "y2":1615
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The chromatogram obtained after the size-exclusion chromatography using a HiLoad 16/60 Superdex 200 column (GE Healthcare Bio-Sciences). The insets show the samples related to the peaks loaded into the 12% SDS-PAGE polyacrylamide gels. Lane 1, molecular weight standards; Lane 2: sample before SEC; Lanes 3???4: fractions from the first peak; Lanes 5???12: fractions from the second peak, which were concentrated for further spectroscopic and biochemical analyses."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1495977":{
    
  },
  "1496067":{
    "Fig_3.tif":{
      "T":{
        "descriptions":[
          ", T. weissflogii"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          ", A. fundyense"
        ],
        "rois":[
          
        ]
      },
      "I":{
        "descriptions":[
          ", I. galbana, Chlorella sp."
        ],
        "rois":[
          
        ]
      },
      "P":{
        "descriptions":[
          ", P. donghaiense"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ", C. muelleri"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":977,
            "y2":889
          }
        ]
      },
      "H":{
        "descriptions":[
          ", H. akashiwo, respectively. Lane M, DL2000 DNA Marker (Takara Bio, Japan)."
        ],
        "rois":[
          
        ]
      },
      "K":{
        "descriptions":[
          ", K. mikimotoi"
        ],
        "rois":[
          
        ]
      },
      "S":{
        "descriptions":[
          ", S. costatum"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1496082":{
    
  },
  "1496418":{
    "Fig_9.tif":{
      "E":{
        "descriptions":[
          "(E) The synthesized (+)RNA products from the experiments in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) The RdRP reactions were conducted as in ",
          "(F) were measured as in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schematic of the experimental procedures. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) The synthesized (+)RNA products from the experiments in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The in vitro transcribed EV71 3???-end (-)RNA template (10 pmol) and an excessive amount of primers (50 pmol) were preannealed and reacted with recombinant His-tagged EV71 3Dpol and DIG RNA labeling mix in the absence or presence of 5 pmol (upper panel) or 10 pmol (lower panel) MBP-2CATPase at 22??C for 30, 60, and 90 min as indicated. The reaction products were analyzed via electrophoresis on a denaturing formaldehyde-agarose gel. ",
          "(B) were measured via Bio-Rad Quantity One software, and the relative RNA production was determined by comparing the RNA product level in the presence of the indicated amount of MBP-2CATPase at each time point with the RNA product level in the absence of MBP-2CATPase at 30 min. ",
          "(B). Under either template- or primer-excessive conditions, the relative RNA production was determined by comparing the RNA product level in the presence of the indicated amount of MBP-2CATPase with the RNA product level in the absence of MBP-2CATPase. ",
          "(B) under different conditions as indicated. ",
          "(B). Under each condition, the relative RNA production was determined by comparing the RNA product level in the presence of the indicated protein with the RNA product level in the absence of MBP-2CATPase (F, lane 5). For (C, E, and G), error bars represent SD values from three separate experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The synthesized (+)RNA (DIG-labeled) products from the experiments in ",
          "(C) were measured as in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1901,
            "y2":2423
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The in vitro transcribed (-)RNA template and primers were preannealed and reacted with recombinant 3Dpol and DIG RNA labeling mix in the absence or presence of increasing amounts (1???10 pmol) of MBP-2CATPase at 22??C for 60 min as indicated. Upper panel: the amount of template (50 pmol) exceeded that of primer (10 pmol); lower panel: the amount of primer (50 pmol) exceeded that of template (10 pmol). "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1496751":{
    "Fig_3.tif":{
      "a":{
        "descriptions":[
          "a) Bacteria"
        ],
        "rois":[
          {
            "x":78,
            "y":44,
            "x2":1840,
            "y2":1260
          }
        ]
      },
      "b":{
        "descriptions":[
          ", b) Fungi and Viridiplantae"
        ],
        "rois":[
          {
            "x":65,
            "y":1296,
            "x2":1729,
            "y2":2522
          }
        ]
      },
      "us":{
        "descriptions":[
          ". us: Untreated stone; 5ts: Five months after the bio-consolidation treatment; 12ts: Twelve months after the bio-consolidation treatment; 30ts: Thirty months after the bio-consolidation treatment."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1496835-n":{
    "Fig_2.tif":{
      "4":{
        "descriptions":[
          ". 4. Placement of double-wrapped payload in the fuselage"
        ],
        "rois":[
          {
            "x":0,
            "y":1301,
            "x2":967,
            "y2":1930
          },
          {
            "x":0,
            "y":649,
            "x2":967,
            "y2":1280
          }
        ]
      },
      "5":{
        "descriptions":[
          ". 5. Covered, secured, and labeled fuselage"
        ],
        "rois":[
          {
            "x":0,
            "y":1301,
            "x2":967,
            "y2":1930
          }
        ]
      },
      "6":{
        "descriptions":[
          ". 6. Launch with hand toss."
        ],
        "rois":[
          
        ]
      },
      "1":{
        "descriptions":[
          "1. Custom-cut foam block"
        ],
        "rois":[
          {
            "x":988,
            "y":1302,
            "x2":1956,
            "y2":1930
          }
        ]
      },
      "2":{
        "descriptions":[
          ". 2. Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment"
        ],
        "rois":[
          {
            "x":0,
            "y":1301,
            "x2":967,
            "y2":1930
          },
          {
            "x":988,
            "y":0,
            "x2":1956,
            "y2":630
          }
        ]
      },
      "3":{
        "descriptions":[
          ". 3. Placement of first bio-hazard bag inside the second bio-hazard bag"
        ],
        "rois":[
          {
            "x":0,
            "y":1301,
            "x2":967,
            "y2":1930
          },
          {
            "x":0,
            "y":0,
            "x2":967,
            "y2":630
          },
          {
            "x":988,
            "y":649,
            "x2":1956,
            "y2":1280
          }
        ]
      }
    }
  },
  "1496937":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A), IL-6 "
        ],
        "rois":[
          {
            "x":0,
            "y":55,
            "x2":1181,
            "y2":1494
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), and TNF?? "
        ],
        "rois":[
          {
            "x":3,
            "y":0,
            "x2":657,
            "y2":380
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), and chemokine IL-8 "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) were determined by real-time RT-PCR analysis. Expression levels of each gene were normalized with respect to the housekeeping gene HPRT or GAPDH. Data represent the means ?? SD of 3???4 experiments. aP aP "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1498472":{
    "Fig_2.tif":{
      "RA":{
        "descriptions":[
          "; RA: rheumatoid arthritis"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":3571,
            "y2":1556
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), Expression of mPGES-1 "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":3571,
            "y2":1556
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and COX-1 "
        ],
        "rois":[
          {
            "x":265,
            "y":1566,
            "x2":1747,
            "y2":2736
          },
          {
            "x":9,
            "y":9,
            "x2":3571,
            "y2":1556
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) is increased in SpA patients"
        ],
        "rois":[
          {
            "x":265,
            "y":1566,
            "x2":1747,
            "y2":2736
          },
          {
            "x":9,
            "y":9,
            "x2":3571,
            "y2":1556
          }
        ]
      },
      "UA":{
        "descriptions":[
          "; UA: unclassified arthritis; SpA: spondyloarthritis; mPGES-1: microsomal prostaglandin E synthase-1; COX: cyclooxygenase; IOD: integrated optical density."
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":3571,
            "y2":1556
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) A trend towards increased expression of COX-2 is observed in SpA patients; values expressed as median (IQR) on a logaritmic scale"
        ],
        "rois":[
          {
            "x":2071,
            "y":1426,
            "x2":3560,
            "y2":2763
          }
        ]
      }
    }
  },
  "1498748":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) and TNF-?? "
        ],
        "rois":[
          {
            "x":1195,
            "y":4,
            "x2":2218,
            "y2":924
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) in the sera of mice infected with 2.7 x 108 PFU of DV2 at 1???2 day-old via intraperitoneal injection. There were 24 mice in each time point (12 DV2-infected and 12 mock-infected, 12 wild-type mice and 12 TLR6-/- mice). Using Kruskal-Wallis test, the amount of IL-6 and TNF-?? detected in the sera of DV2-infected wild-type and TLR6-/- mice were significantly different among the respondents. Wild-type "
        ],
        "rois":[
          {
            "x":1195,
            "y":4,
            "x2":2218,
            "y2":924
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and TLR6-/- "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":992,
            "y2":925
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) mice at 1???2 day-old were infected with 2.7 x 108 PFU of DV2 strain 16681. DV NS1 protein in the sera of the mice was assayed using Bio-rad Platelia Dengue NS1 Antigen detection kit."
        ],
        "rois":[
          {
            "x":108,
            "y":1067,
            "x2":2174,
            "y2":1768
          },
          {
            "x":1195,
            "y":4,
            "x2":2218,
            "y2":924
          }
        ]
      }
    }
  },
  "1501324":{
    
  },
  "150396":{
    
  },
  "1506245":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          ". A: The shared top 10 canonical signaling pathways between RA and T2D"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":956,
            "y2":885
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B: The shared top 10 bio-functions between RA and T2D."
        ],
        "rois":[
          {
            "x":957,
            "y":0,
            "x2":2011,
            "y2":885
          }
        ]
      }
    }
  },
  "1507839":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Unigenes assembled from Trinity and Oases, "
        ],
        "rois":[
          {
            "x":19,
            "y":9,
            "x2":2742,
            "y2":1263
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) unigenes refined from CLC Genomics Workbench, and "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) the distribution of top-hit species."
        ],
        "rois":[
          {
            "x":9,
            "y":1308,
            "x2":2790,
            "y2":4989
          },
          {
            "x":19,
            "y":9,
            "x2":2742,
            "y2":1263
          }
        ]
      }
    }
  },
  "1508089":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "A. The effect of LTBP-2 on the bio-activity of FGF-2 was tested in a cell proliferation assay (see experimental). Human foreskin fibroblasts were treated with FGF-2 with and without follistatin (white columns), or FGF-2 and follistatin pre-incubated with 5 or 10 fold molar excess of full length LTBP-2 or fragment LTBP-2C F2 (cross-hatched). Negative controls (black columns), included cells only and cells incubated with follistatin, LTBP-2 or fragment LTBP-2C F2. Mean values ?? S.D. from triplicate determinations. Note 5 fold molar excess of full-length LTBP-2 completely blocked FGF-2 induced cell proliferation (p = 0.0001) and 5-fold molar excess of fragment LTBP-2C F2 partially blocked the activity (p = 0.0001)"
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":2704,
            "y2":1889
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Immunoblot analysis FGF receptor (FGFR1) phosphorylation. Human foreskin fibroblasts were treated for 2 hours with FGF-2 (10 ng / ml) only or with FGF-2 plus 10-fold molar excess of full length LTBP-2 (LTBP-2 FL) or fragment F2 (LTBP-2C F2). Control cells had no FGF-2 or LTBP-2 added. Cellular proteins were extracted and duplicate samples were analysed by SDS-PAGE and immunoblotting with anti-phospho-FGFR1 antibody, and anti-total FGFR1 antibody. Bands were visualised using the LI-COR Odyssey Infrared Imaging System"
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":2704,
            "y2":1889
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. The band intensity was measured using ImageJ 1.48 software [National Institutes of Health (NIH), Bethesda"
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":2704,
            "y2":1889
          }
        ]
      },
      "MD":{
        "descriptions":[
          ", MD] and normalised to the internal ?? actin signal. The ratio of the phospho-FGFR1 to total FGFR1 value for each sample is expressed relative to the average FGF-2 only control value (= 100%). Note the strong FGFR1 activation by FGF-2 was substantially blocked by both LTBP-2 C and LTBP-2C F2 fragments. Mean values ?? S.D. of duplicate lanes."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "150888":{
    
  },
  "1513548":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "A. Heatmap of Bio-Plex Pro Mouse Cytokine 23-Plex Assay results"
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":1514,
            "y2":578
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. The individual expression levels of structural cytokines, IL-1??, IL-1??, IL-10, and IL17"
        ],
        "rois":[
          {
            "x":815,
            "y":629,
            "x2":1648,
            "y2":1227
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. The individual expression levels of chemokines, Cxcl1, Ccl2, Ccl3, and Ccl5."
        ],
        "rois":[
          {
            "x":2,
            "y":629,
            "x2":800,
            "y2":1227
          }
        ]
      }
    }
  },
  "1515246":{
    
  },
  "1522900":{
    
  },
  "1522903":{
    
  },
  "1522905":{
    
  },
  "1522918":{
    
  },
  "1523154":{
    
  },
  "1525666":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A) and NuOss "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":916,
            "y2":1120
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) explant showing CaP grains of the scaffold material (light grey) and newly formed bone (dark grey, indicated with white arrow) combined with 3D visualization of the processed images showing the newly formed bone (right top). Scale bar is 500??m. "
        ],
        "rois":[
          {
            "x":974,
            "y":0,
            "x2":2071,
            "y2":1120
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) ??CT based quantification of bone formed in the explants after the respective implantation periods normalized to the available volume in the scaffold. 3D expanded cells were recovered using a 880 U/ml collagenase IV solution for 7 hours at a flow rate of 4 ml/min. Scale bar is 100 ??m. n = 3 for Bio-Oss constructs, n = 4 for NuOss constructs. * p"
        ],
        "rois":[
          {
            "x":28,
            "y":1132,
            "x2":2062,
            "y2":2121
          }
        ]
      }
    }
  },
  "1526725":{
    
  },
  "1532341":{
    
  },
  "1532343":{
    
  },
  "1533398":{
    "Fig_2.tif":{
      "B":{
        "descriptions":[
          "(B) P-selectin (CD62) expression was assessed by flow cytometry (up panel: C57BL/6; down panel: apoE-/-). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1008,
            "y2":305
          },
          {
            "x":4,
            "y":924,
            "x2":1029,
            "y2":1774
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Circulating CCL5 levels were measured in apoE-/- male mice were left untreated or exposed to 200 ppb arsenic for 8 or 13 weeks using an immunoassay kit (multiplex bead-based) on a Bio-Plex 200 (Bio-Rad Laboratories, ON, Canada). Each sample (n = 4) was analyzed in duplicate (technical replicate). (D-E) The platelet/monocyte aggregates (CD14+/CD41+"
        ],
        "rois":[
          {
            "x":1160,
            "y":22,
            "x2":2019,
            "y2":831
          },
          {
            "x":106,
            "y":308,
            "x2":1008,
            "y2":562
          },
          {
            "x":0,
            "y":1804,
            "x2":1010,
            "y2":2555
          }
        ]
      },
      "D":{
        "descriptions":[
          "; D) and the platelet/neutrophil aggregates (Ly6G+/CD41+"
        ],
        "rois":[
          {
            "x":564,
            "y":578,
            "x2":2156,
            "y2":1633
          },
          {
            "x":107,
            "y":581,
            "x2":549,
            "y2":867
          },
          {
            "x":0,
            "y":1804,
            "x2":1010,
            "y2":2555
          }
        ]
      },
      "E":{
        "descriptions":[
          "; E) were followed from day 14 to 28 in the circulation of mice exposed to 200 ppb arsenic. One mouse, as positive control, was treated with LPS for 18 hours before the blood collection. Values are expressed as mean ?? S.D., n ??? 3 animals."
        ],
        "rois":[
          {
            "x":1164,
            "y":1774,
            "x2":2019,
            "y2":2425
          }
        ]
      }
    }
  },
  "1534615":{
    "Fig_11.tif":{
      "E":{
        "descriptions":[
          "(D, E, F) BALB/c mice were infected as in ",
          "(E), and the viral titers in lungs were determined by plaque assay "
        ],
        "rois":[
          {
            "x":127,
            "y":630,
            "x2":857,
            "y2":1149
          }
        ]
      },
      "F":{
        "descriptions":[
          "(D, E, F) BALB/c mice were infected as in ",
          "(F). Data presented in (A-F) are from one representative experiment (n = 2) and results are expressed as the average ? SEM. Statistical analysis in all panels was performed using a two-tailed Student\u2019s t-test, * p ? 0.05, ** p ? 0.01."
        ],
        "rois":[
          {
            "x":966,
            "y":659,
            "x2":1786,
            "y2":1997
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) BALB/c mice (n = 5) were infected i.n. with 5 ? 103 PFU of the indicated purified viruses and the weight change and signs of illness were monitored daily (Methods). ",
          "(A) and at the indicated times groups of mice (n = 5) were killed. Then the weights of the lungs were determined "
        ],
        "rois":[
          {
            "x":0,
            "y":1,
            "x2":856,
            "y2":581
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, C) BALB/c mice (n = 5) were mock treated or infected i.n. with 5 ? 103 PFU of the purified viruses and 24 h p.i. the mice were killed and cytokines ",
          "(B) and chemokines "
        ],
        "rois":[
          {
            "x":87,
            "y":1179,
            "x2":941,
            "y2":1865
          }
        ]
      },
      "C":{
        "descriptions":[
          "(B, C) BALB/c mice (n = 5) were mock treated or infected i.n. with 5 ? 103 PFU of the purified viruses and 24 h p.i. the mice were killed and cytokines ",
          "(C) in BAL fluids were assessed by ELISA. "
        ],
        "rois":[
          {
            "x":74,
            "y":1835,
            "x2":938,
            "y2":2550
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D, E, F) BALB/c mice were infected as in ",
          "(D), BAL fluids were collected and the total number of cells in these fluids were counted "
        ],
        "rois":[
          {
            "x":949,
            "y":0,
            "x2":1784,
            "y2":649
          }
        ]
      }
    }
  },
  "1535748":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) Trajectories of the first three principal components (PC1-3) indicate a clear odor separation by the population activity of the 100 AL-units. PC1, PC2 and PC3 explained 43%, 11% and 6% of the variation, respectively. The spontaneous activity before odor onset is shown in grey (Pre-stim). The three second of stimulation are plotted in an odor dependent color code (cp. caption). Note that the population activity for all odors settled in a \u2018fixed point\u2019 at around one second after odor onset (cp. PC1-3 time resolved; right three panels), which is separated from the spontaneous activity. The population activity in response to farnesol shows the most separated trajectory, which is also illustrated separately for each of the first three PCs on the right. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2024,
            "y2":1963
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The factor loadings (left panel) were used to rank the recorded single units with respect to their contribution to the variation in PC1 starting with the most contributing units at the top. The color coded mean firing rate of the single units illustrates that PC1 contrasted units being excited (positive loadings) by the odor stimuli from a few units being inhibited (negative loadings). Furthermore, the colored matrix suggests a spatial code, e.g. unit 5, 14 and 20 were responding only to farnesol and none of the other stimuli. To further analyze odor induced activity, we set a threshold and extracted all units showing factor loadings >0.05."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1535755":{
    "Fig_5.tif":{
      "E":{
        "descriptions":[
          "(E) p53-dependent up-regulation of p21 in INO80-knockdown cells. p53+/+ HCT116 cells were transfected with pBS-shINO80 or pBS-Vector. 24 hrs after transfection, cells were treated with 0.5??M doxorubicin (Dox) for 24 hours. WCE was then prepared and indicated proteins were measured by WB with specific antibodies. Representative results from three independent experiments are shown. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Quantified proteins. Western blot images (n = 3) were quantified with densitometry using Quantity One Basic software. **p p t test)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Clarification of p53 expression in p53+/+ or p53-/- HCT116 cell lines by PCR. Reversed cDNA as template, the p53 gene was amplified by PCR with p53 N-terminal or p53 C-terminal specific primer sets (See Table 1). BCCIP is the PCR control, and p53 plasmid is the positive control of the PCR product. No template in the reaction is the negative control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot analysis. Both cell lines were cultured in IMDM medium containing 5??M CPT for 8 hours. WCE was then prepared, and the proteins were detected with indicated antibodies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) High expression of p21 gene in three consecutive INO80-knockdown cells. Both HCT116 cells were transfected with 20pmol INO80 and NT (as control) siRNAs three times every 48 hours. Then, 48 hours after each transfection, cells were harvested for RT-qPCR to assess indicated gene expression. Bar graphs show ratios of RT-qPCR signals to GAPDH (all signals normalized to siNT). (n = 3) "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Obvious up-regulation of p21 in INO80-knockdown p53+/+ HCT116 cells. HCT116 cells were transfected with 2??g pBS-shINO80 (well/6-well plate) and pBS-Vector (as control). 48 hours later, indicated proteins were detected by WB with specific antibodies. Representative results from three independent experiments are shown in the upper panel. Western blot images (n = 3) were quantified with densitometry using Quantity One Basic software (Bio-Rad). *p p t test). (lower panel). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2161,
            "y2":1628
          }
        ]
      }
    }
  },
  "1537132":{
    "Fig_10.tif":{
      "E":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":467,
            "y":964,
            "x2":1324,
            "y2":1847
          }
        ]
      },
      "e":{
        "descriptions":[
          "(e) Error statistics for the four methods in the occluded areas."
        ],
        "rois":[
          {
            "x":12,
            "y":9,
            "x2":2624,
            "y2":902
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) \u201cTsukuba\u201d, "
        ],
        "rois":[
          {
            "x":1363,
            "y":954,
            "x2":2242,
            "y2":1847
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) \u201cTeddy\u201d, "
        ],
        "rois":[
          {
            "x":1363,
            "y":954,
            "x2":2242,
            "y2":1847
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) \u201cVenus\u201d, and "
        ],
        "rois":[
          
        ]
      },
      "d":{
        "descriptions":[
          "(d) \u201cCones\u201d, including all pixels, pixels in non-occluded areas, pixels in textured areas, pixels in textureless areas and pixels in discontinuous areas. "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1539774":{
    
  },
  "1539835":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "A. Cell extracts prepared in Fig 2A were analyzed by Western blot for expression of T-Ag, Cas9, and ??-tubulin (loading control)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1166,
            "y2":2220
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. The Western blots in Fig 2B were quantified using Bio-Rad Quantity One software and shown as a histogram normalized to T-Ag alone (lane 2)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1166,
            "y2":2220
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. TC620 cells were transfected with JCVL-LUC reporter plasmid and expression plasmid for Cas9 with and without expression plasmids for T-Ag and each of the gRNAs shown in Fig 1 alone or in combination as indicated. Cells were harvested and luciferase activity was assayed as described in Materials and Methods. Activities were normalized to cells transfected with reporter plasmid alone (lane 1)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1166,
            "y2":2220
          }
        ]
      }
    }
  },
  "1541263":{
    
  },
  "1547703":{
    
  },
  "1548950":{
    
  },
  "1549016":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Each magnetic nanoparticle, bio-functionalized with antibodies against target proteins, oscillates with the applied alternating current "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2248,
            "y2":1428
          }
        ]
      },
      "AC":{
        "descriptions":[
          "(AC) magnetic field before binding with ICP11. ??ac,0: the original multiple-frequency AC magnetic susceptibility of the magnetic nanoparticles "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) When these magnetic nanoparticles bind to target proteins, they become larger, and some even form clusters. This reduces the AC magnetic susceptibility of the reagent. ??ac,??: the resulting magnetic susceptibility of magnetic nanoparticles after binding with the target proteins."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2248,
            "y2":1428
          }
        ]
      }
    }
  },
  "1549610":{
    "Fig_5.tif":{
      "E":{
        "descriptions":[
          "(E). The aggregates were incubated for up to 6 (A???C) or 10 ",
          "(D, E) days. Scale bars indicate 200 ??m. F, GFP-positive aggregates were counted in 12 wells. Values represent the mean ?? S.E. from five independent experiments. G, After 6 or 10 days of culture, the aggregates were dissociated to single cells in 0.25% trypsin-EDTA. The single cell suspensions were plated onto poly-L-ornithine-coated coverslips and incubated for 30 min to allow adhesion. The percentages of GFP-positive cells were then determined. Values represent the mean ?? S.E. from five independent experiments. H, Comparison of GSK-3?? inhibitors CHIR99021 and BIO for differentiation of P/G-iPSCs into GFP-positive cells. After 10 days of culture in the presence of 10 ??M CHIR99021 or 1 ??M BIO, the percentages of GFP-positive cells were determined. Values represent the mean ?? S.E. from five independent experiments. ***PPPP>0.05). LDN, LDN193189. SB, SB431542. CHIR, CHIR99021. DIV, days in vitro."
        ],
        "rois":[
          {
            "x":9,
            "y":300,
            "x2":786,
            "y2":1335
          },
          {
            "x":846,
            "y":7,
            "x2":2115,
            "y2":514
          },
          {
            "x":849,
            "y":500,
            "x2":2050,
            "y2":992
          },
          {
            "x":853,
            "y":1046,
            "x2":1853,
            "y2":1561
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), 10 ??M SB431542 "
        ],
        "rois":[
          {
            "x":14,
            "y":42,
            "x2":786,
            "y2":299
          },
          {
            "x":846,
            "y":7,
            "x2":2115,
            "y2":514
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), 10 ??M CHIR99021 "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C, D), or 1 ??M BIO "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(C, D), or 1 ??M BIO ",
          "(D, E) days. Scale bars indicate 200 ??m. F, GFP-positive aggregates were counted in 12 wells. Values represent the mean ?? S.E. from five independent experiments. G, After 6 or 10 days of culture, the aggregates were dissociated to single cells in 0.25% trypsin-EDTA. The single cell suspensions were plated onto poly-L-ornithine-coated coverslips and incubated for 30 min to allow adhesion. The percentages of GFP-positive cells were then determined. Values represent the mean ?? S.E. from five independent experiments. H, Comparison of GSK-3?? inhibitors CHIR99021 and BIO for differentiation of P/G-iPSCs into GFP-positive cells. After 10 days of culture in the presence of 10 ??M CHIR99021 or 1 ??M BIO, the percentages of GFP-positive cells were determined. Values represent the mean ?? S.E. from five independent experiments. ***PPPP>0.05). LDN, LDN193189. SB, SB431542. CHIR, CHIR99021. DIV, days in vitro."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1552348":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          "(E) SMILIGN "
        ],
        "rois":[
          {
            "x":4,
            "y":524,
            "x2":520,
            "y2":1034
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Smith-Waterman "
        ],
        "rois":[
          {
            "x":565,
            "y":524,
            "x2":1084,
            "y2":1034
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Structure of 17 ceramide molecules consisting of a C-16 sphingoid base (light green) and an amide-linked hydroxy fatty acid. The carbon atom number of the hydroxyl group position at the fatty acid chain (red) is used for naming individual molecules. "
        ],
        "rois":[
          {
            "x":10,
            "y":19,
            "x2":1037,
            "y2":477
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) and Levenshtein distance "
        ],
        "rois":[
          {
            "x":1127,
            "y":501,
            "x2":1646,
            "y2":1034
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SMILES representation of first and last molecules. Colour coding of atoms is identical in SMILES- and structure- representations. (C-H) Heat map of pairwise distances calculated using Open Babel\u2019s FP2 Fingerprint "
        ],
        "rois":[
          {
            "x":10,
            "y":19,
            "x2":1037,
            "y2":477
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) LINGO "
        ],
        "rois":[
          {
            "x":1126,
            "y":6,
            "x2":1648,
            "y2":519
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) algorithms. Bioisosteric method uses CACTVS canonical SMILES, whereas for all other methods template-based SMILES were used. Colour bars in each panel indicate range of distances values of the particular method. Black pixels denote a distance of zero, indicating identical molecules. Numbers in rows and columns represent 1) the molecule name and 2) the position of hydroxyl group in fatty acid moiety."
        ],
        "rois":[
          {
            "x":1702,
            "y":501,
            "x2":2221,
            "y2":1034
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Bioisosteric "
        ],
        "rois":[
          {
            "x":1701,
            "y":4,
            "x2":2220,
            "y2":494
          }
        ]
      }
    }
  },
  "1553053":{
    
  }
,
  "1555659":{
    "Fig_9.tif":{
      "A":{
        "descriptions":[
          "(A) J774A.1 (5 ?? 105) were treated with approximately 4 ?? 108 purified L3 stage ELVs, live L3 stage parasites (10 worms) or na??ve culture media (control) and supernatents collected after 48 hr. The presence of 32 cytokines/chemokines was simultaneously assayed using the Milliplex MAP Mouse Cytokine/Chemokine kit (EDM Millipore) interfaced with a Bio-Plex System (Bio-Rad) utilizing Luminex xMAP technology (Luminex). The quantification of identified cytokines is presented. The cytokine profile generated by ELV treatment is consistent with a classically activated phenotype. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1530,
            "y2":2611
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cytokine response to ELV treatment is compared to LPS (200 ng/mL). The close correlation of responses indicates ELV treatment generates a classically activated phenotype. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1530,
            "y2":2611
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) J774A.1 (5 ?? 105) were treated with high dose LPS (200 ng/mL), low dose LPS (0.003 ng/mL), ELV or na??ve culture media (control) for 24 hr, supernatant collected and assayed for G-CSF using a Mouse G-CSF Quantikine ELISA kit (R&D Systems). The absence of response to low dose LPS suggests the classically activated response is not due to LPS-like contamination."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1530,
            "y2":2611
          }
        ]
      }
    }
  },
  "1557248":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) Intracellular levels of c-di-GMP were measured using LC-MS. "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":977,
            "y2":1158
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Transcripts of cabA were determined using qRT-PCR. Relative levels of the c-di-GMP and cabA mRNA were presented as those levels in JN111 grown without arabinose as 1, respectively. *, PPcabA mRNA levels in JN111 grown without arabinose. Error bars represent the SD. "
        ],
        "rois":[
          {
            "x":1048,
            "y":4,
            "x2":2035,
            "y2":1158
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Protein samples were resolved on SDS-PAGE and immunoblotted using the rabbit anti-CabA antibody. The protein size markers (Precision Plus Protein Standards; Bio-Rad Laboratories) and CabA (arrows) are shown in kDa. CMCP6, wild type; JN111, parent strain; cabA, cabA mutant."
        ],
        "rois":[
          {
            "x":1048,
            "y":4,
            "x2":2035,
            "y2":1158
          }
        ]
      }
    }
  },
  "1557253":{
    
  },
  "1557264":{
    "Fig_7.tif":{
      "A":{
        "descriptions":[
          "(A) Biofilm development of JN111 and the cabA mutant with VFMG-CF containing 10 mM of CaCl2 and 0.01% of arabinose was monitored using CV staining. Total RNAs and proteins were prepared from the JN111 biofilms (that is, from the cells and matrices) harvested at different stages as indicated by vertical arrows. *, PPcabA, cabA mutant. "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1356,
            "y2":944
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The cabA mRNA levels were determined by qRT-PCR analyses, and the cabA mRNA level in the biofilms harvested after 2 h incubation was set as 1. **, PcabA mRNA level in the biofilms harvested after 2 h incubation. Error bars represent the SD. "
        ],
        "rois":[
          {
            "x":6,
            "y":982,
            "x2":1446,
            "y2":1910
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Protein samples were resolved on SDS-PAGE and immunoblotted using the rabbit anti-CabA antibody. The protein size markers (Precision Plus Protein Standards; Bio-Rad Laboratories) and CabA (horizontal arrow) are shown in kDa."
        ],
        "rois":[
          {
            "x":6,
            "y":982,
            "x2":1446,
            "y2":1910
          }
        ]
      }
    }
  },
  "1557512":{
    
  },
  "1557897":{
    
  },
  "1563094":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) Unique mAb 1G6-specific phages after three rounds of bio-panning. The binding of isolated phage clones to 1G6 was examined by ELISA. Data represent the mean ?? S.D. of duplicate measurements. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1896,
            "y2":1094
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Peptide insert sequences (single letter code) enriched after three rounds of selection. Selected peptide sequences are aligned for the consensus motif which is highlighted in bold letters. Binding of 1G6 to control phage clone and binding of control mAb 6E1 with 1G6-specific phage particles were included as specificity controls. Absolute frequency means the times that a specific phage-displayed peptide was identified; while relative frequency means the proportion of a specific phage-displayed peptide normalized by the total number of phage clones. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1896,
            "y2":1094
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Schematic of generating truncated rED3 proteins. "
        ],
        "rois":[
          {
            "x":0,
            "y":1095,
            "x2":1896,
            "y2":1323
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Western blot of purified wild type and DENV4 rED3 truncations. The polyclonal antibody anti-GST was used as a positive control."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1566526":{
    
  },
  "1566606":{
    
  },
  "1567419":{
    
  },
  "1567953":{
    
  },
  "1573733":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic illustration of the in vivo biotinylation of ubiquitin [21]. The construct is expressed as a polyubiquitin chain fused to the E.coli BirA enzyme, which is digested by the endogenous deubiquitinating enzymes (DUBs). While this clearly indicates that DUB enzymes are capable of deconstructing linear bioUb chains, we have no evidence to support that E2/E3 enzymes are actually capable of constructing those linear bioUb chains the same way they would do with the more abundant endogenous ubiquitin. Afterwards, the BirA enzyme recognizes the short motif incorporated at the N-terminus of each ubiquitin (sequence is indicated) and attaches a biotin molecule to its lysine residue (red). The biotinylated ubiquitins are then conjugated to the target proteins. "
        ],
        "rois":[
          {
            "x":3,
            "y":4,
            "x2":1158,
            "y2":803
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot with anti-BirA antibody using total Drosophila head extracts confirmed the full digestion of the bioUb precursor by endogenous DUBs. No undigested forms of the precursor were found above the expected molecular size of BirA (35 kDa). "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Anti-biotin Western blot on the same total extracts confirmed the biotinylation and conjugation of the GMRGAL4???driven expressed ubiquitin. An endogenous protein known to be biotinylated (CG1516) appeared in all the samples (arrowhead). The expected smear corresponding to biotinylated ubiquitin conjugates was only present in the bioUb sample"
        ],
        "rois":[
          {
            "x":1462,
            "y":29,
            "x2":1796,
            "y2":691
          },
          {
            "x":1132,
            "y":114,
            "x2":1433,
            "y2":691
          }
        ]
      },
      "WT":{
        "descriptions":[
          ". WT: Oregon R; BirA: GMRGAL4/CyO;UASBirA/TM6; bioUb: GMRGAL4,UAS(bioUb)6-BirA/CyO."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1573734":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic illustration of the strategy applied to purify ubiquitinated material from Drosophila embryo nervous system and adult eye. Both embryo and adult samples, expressing either the UAS(bioUb)6-BirA or the UASBirA (control) constructs, were homogenized, clarified and incubated with High Capacity NeutrAvidin agarose resin. Beads were then subjected to stringent washes to remove the non-biotinylated proteins. Afterwards, material bound to beads was eluted by applying a heat treatment. "
        ],
        "rois":[
          {
            "x":5,
            "y":23,
            "x2":933,
            "y2":1420
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Silver staining of the eluted material revealed no protein in the BirA samples except for the endogenously biotinylated proteins, particularly the most abundant (CG1516) (arrows), while in the bioUb samples the typical smear of ubiquitinated material was detected (brackets). Monomer, dimer and tetramer forms of NeutrAvidin molecules leaking from the beads were also found in all the samples (arrowheads). Mass spectrometry analysis performed with embryo samples identified 37 and 234 proteins in the control and experimental samples, respectively. In adult the analysis identified 80 proteins in the control and 369 in the experimental samples. "
        ],
        "rois":[
          {
            "x":5,
            "y":23,
            "x2":933,
            "y2":1420
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Venn diagram showing the distribution of the identified ubiquitin conjugates. Identified ubiquitin carriers are listed in Table 1. Only 90 ubiquitin conjugates were found to be present in both data sets. The top 20 ubiquitin conjugates found only in embryo, only in adult and those found in both samples are listed below the Venn diagram. All peptides and intensities of the different analysis are shown in S1 and S2 Tables."
        ],
        "rois":[
          {
            "x":1000,
            "y":4,
            "x2":1700,
            "y2":1448
          }
        ]
      }
    }
  },
  "1573825":{
    "Fig_2.tif":{
      "E":{
        "descriptions":[
          "(E) Calcein dye flux experiments showing increased fluorescence intensity (indicating decreased MDR flux) in the presence of lapatinib or control MDR inhibitor verapamil (both at 5?M); quantitation of cell grey values shown at left. Error bars represent s.d. of measurement replicates (n = 4, > 200 cells per replicate). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) MDR1 knockdown by siRNA causes a synergistic effect on cell viability in the presence of 5nM vincristine. Error bars represent s.d. of measurement replicates (n = 7). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Screening results showing the effects at both concentrations of vincristine and lapatinib, individually, and as a combination, showing strong synergy across most melanoma cell lines as indicated by high Bliss synergy scores. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Overexpression of MDR1 (compared to GFP control) in WM451Lu decreases sensitivity to vincristine, an effect reversible with 5?M lapatinib. Error bars represent s.d. of measurement replicates (n = 4)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Confirmation of the synergistic effect of the combination of lapatinib (5?M) in A375 (n = 19) but not WM451Lu (n = 14) cells. Error bars represent s.d. of measurement replicates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Representative flow cytometry data showing lapatinib potentiates G2/M shift of A375 cell population consistent with increased vincristine effect. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Log2 relative expression of the given multi-drug resistance transporter in A375 versus WM451Lu cells, showing increased MDR1 expression in A375 cells. Error bars represent s.d. of measurement replicates (n = 9). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2239,
            "y2":1620
          }
        ]
      }
    }
  },
  "1578156":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Concentration-response curves showing the activity of elisidepsin after 30 min and 72 h in HCT-116 (?) and HCT-116-Irv cells (?); results represent the mean?SD of at least three different experiments. "
        ],
        "rois":[
          {
            "x":4,
            "y":5,
            "x2":746,
            "y2":391
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Stability of elisidepsin resistance in HCT-116-Irv cells determined by concentration-response curves after 2 (?) and 15 (?) culture passages in absence of the compound. HCT-116 cells (?) are also depicted in the graph. Results represent the mean?SD of three different experiments. "
        ],
        "rois":[
          {
            "x":5,
            "y":507,
            "x2":2071,
            "y2":1350
          },
          {
            "x":955,
            "y":956,
            "x2":1520,
            "y2":1378
          },
          {
            "x":955,
            "y":4,
            "x2":1545,
            "y2":893
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Elisidepsin accumulation (pmol/mg protein) in HCT-116 (white bars) and HCT-116-Irv cells (black bars). Both cell lines were treated with elisidepsin 7 ?M at different time points and the accumulated compound was quantified by HPLC/MS. Results represent the mean?SD of three different samples. Comparisons between different samples were analyzed by Student\u2019s t test. Differences were considered significant at *PPPD) Representative images of HCT-116 and HCT-116-Irv cells exposed to elisidepsin 10 ?M for 5 min. Phase contrast microscopy images show morphological alterations and giant vesicles formation only in the wild-type cells (white arrows). Fluorescence microscopy shows PI stained nuclei only in the parental cells. "
        ],
        "rois":[
          {
            "x":1555,
            "y":1378,
            "x2":2077,
            "y2":1744
          },
          {
            "x":1557,
            "y":40,
            "x2":2071,
            "y2":483
          },
          {
            "x":4,
            "y":1258,
            "x2":892,
            "y2":1760
          },
          {
            "x":964,
            "y":1401,
            "x2":1510,
            "y2":1744
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E) Electrophysiological effects of elisidepsin 1 ?M on HCT-116 and HCT-116-Irv cells. Left panels show original records after applying a ramp pulse protocol from -100 mV to +120 mV during 500 ms. Right panels show the amplitude of the maximum current at the end of the ramp together with the exponential fit of the process. HCT-116-Irv cells are completely insensitive to the elisidepsin effects as shown in the current records. Holding potential was maintained at -80 mV."
        ],
        "rois":[
          {
            "x":144,
            "y":407,
            "x2":758,
            "y2":820
          }
        ]
      }
    }
  },
  "1578212":{
    
  },
  "1579043":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Declined global H4K16ac in As2O3-exposed HeLa cells. Global acetylation of histone H4K16 and hMOF protein expression in As2O3-treated HeLa cells were measured with immunofluorescence and indicated antibodies. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2009,
            "y2":1434
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) A significant reduction of H4K16ac in As2O3-exposed 293T cells occurred. Representative results from three independent experiments are shown. hMOF and H4K16ac were measured with anti-hMOF and anti-H4K16ac antibodies and final protein signals were visualized with ChemiScope5000 (CLINX, China). (C-D) Quantified protein. Error bars represent standard error of means of 3 independent experiments. Blot images were scanned and signals were densitometrically quantified using Quantity One Basic software (Bio-Rad). Signals of hMOF and H4K16ac were normalized to GAPDH. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2009,
            "y2":1434
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E) No changes of hMOF mRNA levels and hMOF transactivation in As2O3-exposed HEK293T cells. Cells were cultured in DMEM medium containing 0.2, 0.4 or 0.8 ??M As2O3 for 48 hours. Relative mRNA levels of hMOF and GAPDH (as control) were measured with qRT-PCR (left panel). In addition, luciferase activity of pGL4-hMOF in As2O3-exposed 293T cells was measured and firefly values were normalized by renilla values (right panel)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2009,
            "y2":1434
          }
        ]
      }
    }
  },
  "1579045":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic of As-immobilized agarose preparation. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2009,
            "y2":1468
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) As-immobilized agarose pulled down hMOF. (C&D) Competitive inhibition between As and hMOF. H2B protein is as negative control. Western blot images were scanned and signals were densitometrically quantified with Quantity One Basic software (Bio-Rad). The percentage of bound hMOF in the flow through appears in D."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2009,
            "y2":1468
          }
        ]
      }
    }
  },
  "1580594":{
    
  },
  "1584425":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) is the result from the FBP algorithm with ramp filter; "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":2493,
            "y2":1868
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) is the result from the NCG algorithm with ? = 1.0 ? 105; "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) is the result from the SB-NCG algorithm with ? = 25, ? = 29; and "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) is the result from the ALM-ANAD algorithm with ? = 25, ? = 29. The zoomed ROIs indicated by the rectangle are also displayed for visual appealing. All images are displayed with the same window [0.0017 0.024] mm?1."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1585204":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) Both QBC939 and HuCCT1 cells were treated with BIO and combination with or without miR-221 inhibitor to evaluate cell invasion and migration activities by transwell chambers. Representative images of cells migrated into the lower chamber were shown (left panel, original magnification: X100), and quantitative data were also presented (right panel). (right panel, ?????????Pvs"
        ],
        "rois":[
          {
            "x":840,
            "y":555,
            "x2":1208,
            "y2":744
          },
          {
            "x":16,
            "y":10,
            "x2":1239,
            "y2":532
          }
        ]
      },
      "NC":{
        "descriptions":[
          ". NC. $$$Pvs. miR-221 inhibitor). The average numbers of cells per field of view from three different experiments are plotted. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Representative images of morphological investigations of QBC939 and HuCCT1 cells (original magnification: ??200). "
        ],
        "rois":[
          {
            "x":10,
            "y":552,
            "x2":838,
            "y2":744
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Both of the QBC939 and HuCCT1 cells were treated with BIO and treated with or without miR-221 inhibitor and then the cells lysate were examined with indicated antibodies by Western blot. ??-actin was used as loading control. Negative control 1: negative control for BIO with only 0.1% DMSO; Negative control 2: negative control for miR-221 inhibitor."
        ],
        "rois":[
          {
            "x":9,
            "y":766,
            "x2":1225,
            "y2":1545
          }
        ]
      }
    }
  },
  "1585206":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) PTEN protein level with c-Jun siRNA or BIO treatments detected by western blot. Antibodies include: PTEN and ??-actin. Negative control 1: mock control for siRNA containing only transfection reagent; Negative control 2: mock control for BIO with only 0.1% DMSO. "
        ],
        "rois":[
          {
            "x":8,
            "y":14,
            "x2":1224,
            "y2":697
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Both of the QBC939 and HuCCT1 cells were transfected c-Jun siRNAs and treated with or without BIO for desired time. Then the relative expression of miR-221 was determined by qRT-PCR. U6 was used as the internal control. (?????????Pvs"
        ],
        "rois":[
          {
            "x":13,
            "y":765,
            "x2":1146,
            "y2":1572
          }
        ]
      },
      "NC":{
        "descriptions":[
          ". NC. $$$Pvs. BIO)"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1585915":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Wild-type drosocrystallin "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1074,
            "y2":1766
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT) or the KR mutant "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1074,
            "y2":1766
          }
        ]
      },
      "KR":{
        "descriptions":[
          "(KR) was incubated with TG, and subjected to SDS-PAGE in 10% TGX FastCast gels (Bio-Rad Laboratories). These recombinants were detected by Western blotting with a horseradish peroxidase-conjugated anti-6 ?? His tag antibody. Monodansylcadaverine (MDC) was used as an inhibitor of protein-protein crosslinking. Data are representative of at least three independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1074,
            "y2":1766
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gut extracts from systemic TG-RNAi flies (Da>TG IR) and their counterparts (Da>+) were subjected to SDS-PAGE in 12% slab gels. Native drosocrystallin in the extracts was detected by Western blotting with an anti-drosocrystallin antibody (Anti-Dcy). Asterisks indicate unknown cross-reacted proteins. Data are representative of three independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1074,
            "y2":1766
          }
        ]
      }
    }
  },
  "1586286":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A) and BSNT_09444 "
        ],
        "rois":[
          {
            "x":16,
            "y":12,
            "x2":1599,
            "y2":1244
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). A large nucleotide deletion in bioF and a nonsense mutation in bioW are found in BEST195. All eight B. subtilis strains have the same deletions in bioF as BEST195, while the nonsense mutation in bioW was not found in strains LaoA1 and MyaA2. "
        ],
        "rois":[
          {
            "x":16,
            "y":12,
            "x2":1599,
            "y2":1244
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The number of mapped reads of the non-Japanese strains against BSNT_09438, bioI and bioB of BEST195. For only strain ThaB, no read was mapped to the end of BSNT_09438 and most of bioI. ",
          "(C) was deleted in the genome sequence of strain ThaB."
        ],
        "rois":[
          {
            "x":16,
            "y":12,
            "x2":1599,
            "y2":1244
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The pairwise sequence alignment of the draft genome of strain ThaB and BEST195. An unmapped region in "
        ],
        "rois":[
          {
            "x":16,
            "y":12,
            "x2":1599,
            "y2":1244
          }
        ]
      }
    }
  },
  "158792":{
    "Figure_1.tif":{
      "B":{
        "descriptions":[
          "(Panel B). Optical density at 650 nm was measured for 36 h at 37??C. Growth curves were obtained using an ELx808 Ultra Microplate reader (Bio-Tek Instruments). Each growth curve was performed in triplicate, and error bars of one standard deviation are indicated. Panels C and D show aerobic growth of S. enterica strain JE2119 (S. enterica metE205 ara-9 cobC1175::Tn10d[tet+]) carrying pBAD24 (vector-only, open circles), pBluB9(Rr) (R. rubrum bluB+; black squares), pBluB25(Bm) (B. megaterium bluB+; black triangles), and pCbiY6(Bm) (B. megaterium cbiY+; black diamonds) in NCE minimal medium containing 11 mM glucose, 1 mM MgSO4, 1?? trace minerals (Balch and Wolfe 1976), 50 ??g ??l???1 ampicillin, and 15 nM dicyanocobinamide. Where indicated, dicyanocobinamide was replaced with cyanocobalamin (open diamonds), DMB was added at 30 ??M (open triangles), and arabinose was added at 500 ??M "
        ],
        "rois":[
          {
            "x":24,
            "y":2867,
            "x2":3542,
            "y2":3193
          },
          {
            "x":24,
            "y":24,
            "x2":3542,
            "y2":1443
          }
        ]
      },
      "D":{
        "descriptions":[
          "(Panel D). Aerobic growth of JE2119 derivatives took place in 5 ml volumes in 125 ml sidearm flasks which were shaken at 280 rpm at 37??C. Growth was monitored with a Summerson colorimeter (Klett). Each growth curve was performed in triplicate, and error bars of one standard deviation are indicated."
        ],
        "rois":[
          {
            "x":24,
            "y":1446,
            "x2":3542,
            "y2":2864
          }
        ]
      }
    }
  },
  "158870":{
    
  },
  "1589522":{
    
  },
  "1590895":{
    
  },
  "1591454":{
    "Fig_1.tif":{
      "a":{
        "descriptions":[
          "(a) A 57-year-old women with right breast cancer underwent 18F\u2013FDG PET/CT. Mild 18F\u2013FDG uptake (inferior to the liver) resulted in her being classified into the low uptake group. Her BMI was 20.0, and triglyceride level was 45 mg/dL. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":765
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) A 64-year-old women with left breast cancer underwent 18F\u2013FDG PET/CT. Intense 18F\u2013FDG uptake along the intestine was classified into the high uptake group. Her BMI was 27.3, and triglyceride level was 393 mg/dL."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":765
          }
        ]
      }
    }
  },
  "1593036":{
    
  },
  "1593984":{
    
  },
  "1595004":{
    "Fig_4.tif":{
      "E":{
        "descriptions":[
          "(E) eNOS mRNA, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":772,
            "y2":1849
          },
          {
            "x":773,
            "y":1099,
            "x2":2025,
            "y2":1849
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) iNOS mRNA and "
        ],
        "rois":[
          {
            "x":773,
            "y":1099,
            "x2":2025,
            "y2":1849
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) portal pressure, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":772,
            "y2":1849
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) CAV-1. Results are the mean ? SE of 4\u20138 mice per group. *p+/+ mice. #p+/+ mice fed methionine. ?p-/- mice. ??p-/- mice fed methionine."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":772,
            "y2":1849
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) ET-1 mRNA, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":772,
            "y2":1849
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CBS mRNA, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":772,
            "y2":1849
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) CSE mRNA, "
        ],
        "rois":[
          {
            "x":773,
            "y":0,
            "x2":2025,
            "y2":1098
          }
        ]
      }
    }
  },
  "1596691":{
    
  },
  "159788":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E, F)."
        ],
        "rois":[
          {
            "x":1170,
            "y":1996,
            "x2":2210,
            "y2":2355
          },
          {
            "x":10,
            "y":1620,
            "x2":1053,
            "y2":2599
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E, F)."
        ],
        "rois":[
          {
            "x":1208,
            "y":1701,
            "x2":2212,
            "y2":1964
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). Values represent means ?? S.D. from 5 independent experiments. Dorsal skins of SD rats at different hair cycle stages were homogenized and solubilized in RIPA buffer. After immunoprecipitation with an anti-NEP antibody, western blotting was performed. Blots were visualized using ECL detection reagents "
        ],
        "rois":[
          {
            "x":18,
            "y":10,
            "x2":1074,
            "y2":816
          },
          {
            "x":17,
            "y":844,
            "x2":1043,
            "y2":1607
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). The loading control is shown by CBB staining "
        ],
        "rois":[
          {
            "x":1170,
            "y":1996,
            "x2":2210,
            "y2":2355
          },
          {
            "x":17,
            "y":844,
            "x2":1043,
            "y2":1607
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and chemiluminescence was determined using a Molecular Imager System "
        ],
        "rois":[
          {
            "x":1170,
            "y":1996,
            "x2":2210,
            "y2":2355
          },
          {
            "x":1056,
            "y":414,
            "x2":2200,
            "y2":823
          },
          {
            "x":17,
            "y":844,
            "x2":1043,
            "y2":1607
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Northern blotting was performed with a specific probe for rat NEP labeled with 32P-dCTP, radioactivity was measured using a BAS2000 bio-image analyzer "
        ],
        "rois":[
          {
            "x":1170,
            "y":1996,
            "x2":2210,
            "y2":2355
          },
          {
            "x":1208,
            "y":810,
            "x2":2193,
            "y2":1492
          }
        ]
      }
    }
  },
  "1599961":{
    
  },
  "1599993":{
    "Fig_6.tif":{
      "a":{
        "descriptions":[
          "(a) clean sediment, "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2335,
            "y2":323
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) 5 days, "
        ],
        "rois":[
          {
            "x":2,
            "y":339,
            "x2":2731,
            "y2":1459
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) 10 days and "
        ],
        "rois":[
          {
            "x":2,
            "y":339,
            "x2":2731,
            "y2":1459
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) 15 days of biofilm growth."
        ],
        "rois":[
          {
            "x":2,
            "y":339,
            "x2":2731,
            "y2":1459
          }
        ]
      }
    }
  },
  "1600081":{
    
  },
  "16004":{
    
  },
  "16005":{
    
  },
  "16023":{
    "Gkl1113f3.jpg":{
      "FL":{
        "descriptions":[
          "(FL) (lane 2) and 2?????g of pSG5-T antigen (lane 3) and comparative ChIP analysis were performed in parallel with the same number of cells using antibodies that specifically recognize acetylated histone H3 (K 9 and 14) and poly-acetylated histone H4. The immunoprecipitates were analyzed by quantitative PCR using specific primers for the TK promoter. PCR products were resolved in agarose gels and quantified with QuantityOne software (Bio-Rad). A schematic representation of the TK-luciferase promoter and the position of the primers used for ChIP are shown at the bottom of the figure.  Quantification of PCR products from "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) was conducted as described in Materials and Methods. The values on the  axis represent the amount of immunoprecipitated DNA as a percentage of the 1% input sample. Relative histone modification levels were calculated from three independent experiments.  Comparative ChIP analysis performed in parallel with the same number of CV1 and CV1COS cells using antibodies that specifically recognize acetylated histone H3 (K 9 and 14) and poly-acetylated histone H4. The immunoprecipitates were analyzed by quantitative PCR using specific primers for the PDGF ??-receptor promoter. PCR products were resolved in agarose gels and quantified as described in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":446,
            "y2":701
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Relative histone modification levels were calculated from two independent experiments."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1602326":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Schema of the glycogen assay based on the protocol from BioVision Inc.: glycogen was hydrolyzed "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Determination of glycogen content in hPSCs grown under various growth conditions. Column 1: MCF7 breast cancer cells used control (Cont) for the assessment of glycogen levels; Column 2: H1 colonies grown on MEF as previously descried in Materials and Methods. The glycogen content was measured at cell passage number 38. Column 3: H1 colonies initially grown on MEF for 35 passages followed by growing on 2.5% BD Matrigel "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) to produce color products. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) into glucose, then glucose developed "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      },
      "MG":{
        "descriptions":[
          "(MG) in mTeSR1 for 5 passages. Column 4: H9 cells were initially grown on MEF for 32 passages followed by passaging on 2.5% BD Matrigel ",
          "(MG) in mTeSR1 medium for 9 passages. Column 5: BC1 human iPSCs were initially grown on MEF for 50 passages followed by passaging on 2.5% BD Matrigel ",
          "(MG) in mTeSR1 medium for 26 passages."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) into an intermediate and reduce probe "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1499,
            "y2":1105
          }
        ]
      }
    }
  },
  "1602333":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) Glycogen body formation in untreated H1 cells (control). ",
          "(A, B) represent 2 ??m; and scale bars in "
        ],
        "rois":[
          {
            "x":2,
            "y":9,
            "x2":882,
            "y2":849
          },
          {
            "x":901,
            "y":7,
            "x2":1792,
            "y2":849
          }
        ]
      },
      "GB":{
        "descriptions":[
          "(GB) in the cytoplasm of the cell. The plus signs (+) in the plots indicate the location of mean values. Abbreviations: GB, glycogen bodies with defined boundaries; Nu, the nucleus of the cells. Scale bars in "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Glycogen body formation in BMP-4 treated H1 cells. ",
          "(A, B) represent 2 ??m; and scale bars in "
        ],
        "rois":[
          {
            "x":4,
            "y":866,
            "x2":884,
            "y2":1696
          },
          {
            "x":2,
            "y":9,
            "x2":882,
            "y2":849
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Glycogen body formation in GSK3i (CHIR99021)-treated H1cells. The asterisk sign indicates a glycogen defect region in the glycogen body, which likely resulted from dissociation of glycogen aggregates when the specimens were floating in solution during sample preparation. Additional TEM micrographs are available in Supporting Information S1 Fig and S2 Fig. ",
          "(C) represent 1 ??m."
        ],
        "rois":[
          {
            "x":4,
            "y":866,
            "x2":884,
            "y2":1696
          },
          {
            "x":2,
            "y":9,
            "x2":882,
            "y2":849
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Box-and-Whisker plots of glycogen to cell ratios (with 10???90% percentile) in hESC control (n = 49 cells), BMP-4 treated cells (n = 29), and GSK3i treated cells (n = 22). The statistics included both H1 and H9 cells to increase statistical power. All hESC (i.e., H1 and H9) cells were grown as a non-colony type monolayer (mc) on 2.5% BD Matrigel in meTeSR1 medium and then treated with 100 ng/mL of BMP-4 and 3 ??M GSK3i for 48 hours. The red-colored arrowheads indicate the formation of glycogen bodies "
        ],
        "rois":[
          {
            "x":2,
            "y":9,
            "x2":882,
            "y2":849
          },
          {
            "x":904,
            "y":865,
            "x2":1791,
            "y2":1696
          }
        ]
      }
    }
  },
  "1602336":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A), H1 cells treated with 100 ng/mL of BMP-4 "
        ],
        "rois":[
          {
            "x":30,
            "y":1282,
            "x2":1620,
            "y2":1933
          },
          {
            "x":25,
            "y":4,
            "x2":1728,
            "y2":453
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), and H1 cells treated with 3 ??M GSK3i (CHIR99021) for 48 hours "
        ],
        "rois":[
          {
            "x":29,
            "y":463,
            "x2":1727,
            "y2":851
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). The cellular genomic DNAs were stained by the Hoechst 33342 dye (Hoechst). The images were collected with a fluorescence microscope (Zeiss). (D and E) Box-and-Whisker plots of Oct-4 expression (with 5???95% percentile) in both H1 and BC1 cells under the indicated treatments. Control 2 (Cont2) in D is an additionally untreated control of H1 cells. The plus signs (+) in the plots indicate the location of the mean values determined from 116 to 150 individual cells by the ImageJ program. One of two independent experiments is shown. Scale bars represent 50 ??m."
        ],
        "rois":[
          {
            "x":28,
            "y":861,
            "x2":1728,
            "y2":1253
          }
        ]
      }
    }
  },
  "1602341":{
    "Fig_5.tif":{
      "E":{
        "descriptions":[
          "(E) Quantitative analysis of 2-NBDG accumulation in Fig 5B. "
        ],
        "rois":[
          {
            "x":1414,
            "y":2880,
            "x2":4203,
            "y2":4006
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Quantitative analysis of 2-NBDG retention and glycogen labeling by counting 2-NBDG loci as presented in Fig 5C. Columns represent mean fluorescence intensity measured from at least 4 random colonies and bar standard deviations. Abbreviations (depicted sequentially): BIO, 2 ??M GSK3i (BIO); 2i, 2 ??M BIO + 1 ??M MEKi; 3i, 2i + 1 ??M BMP4i; 2iL, 2i + 10 ng/mL LIF; 3iL, 3i + 10 ng/mL LIF; 2-NBDG, (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose), a fluorescent glucose derivative, overlapping with EGFP signals. Scale bars represent 100 ??m."
        ],
        "rois":[
          {
            "x":6,
            "y":1687,
            "x2":1401,
            "y2":2737
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schema of 2-NBDG accumulation and retention (glycogen labeling) experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4334,
            "y2":1019
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) 2-hour 2-NBDG accumulation in the presence of 10 mM D-glucose. Upper panel: green fluorescence intensity (Fluor) images that include signals from both Oct4-EGFP and 2-NBDG. These images were obtained (immediately after replacing with fresh mTeSR1 medium) by non-saturated time-exposure guided by an autoexposure software (Zeiss Inc.). No 2-NBDG indicates fluorescence background images produced from Oct4-EGFP signal without the use of 2-NBDG. The fluorescence intensity was determined by the signal/noise ratio between cellular fluorescence (signal) and background (noise). The fluorescent background in the 2-NBDG control was due to non-saturated auto exposure using the Zeiss Axiovert imaging system. Lower panel: the corresponding phase images of the upper panel. Only brightness was adjusted in phase images (presented in both B and C) to enhance the image presentation in this figure. "
        ],
        "rois":[
          {
            "x":10,
            "y":2880,
            "x2":1346,
            "y2":4009
          },
          {
            "x":0,
            "y":0,
            "x2":4334,
            "y2":1019
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) 2-NBDG retention and glycogen labeling carried out in the presence of 10 mM D-glucose and absence of 2-NBDG. Upper panel: unique fluorescence loci (dots) were derived from 2-NBDG signals as indicated by arrows in the inset of Fig 5C4. Lower panel: the corresponding phase images of the upper panel. "
        ],
        "rois":[
          {
            "x":10,
            "y":2880,
            "x2":1346,
            "y2":4009
          },
          {
            "x":795,
            "y":1020,
            "x2":4334,
            "y2":1526
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Quantitative analysis of Oct4-EGFP signals without the addition of 2-NBDG. "
        ],
        "rois":[
          {
            "x":10,
            "y":2880,
            "x2":1346,
            "y2":4009
          },
          {
            "x":148,
            "y":1020,
            "x2":690,
            "y2":1526
          },
          {
            "x":3641,
            "y":1825,
            "x2":4334,
            "y2":2737
          },
          {
            "x":3063,
            "y":1825,
            "x2":3596,
            "y2":2736
          },
          {
            "x":1376,
            "y":1696,
            "x2":3021,
            "y2":2737
          }
        ]
      }
    }
  },
  "1602349":{
    "Fig_6.tif":{
      "E":{
        "descriptions":[
          "(E, F) Quantitative analysis of 2-NBDG retention and glycogen labeling by measuring mean fluorescence intensity (FI, arbitrary units) from at least 4 random colonies ",
          "(E) and by counting 2-NBDG loci "
        ],
        "rois":[
          {
            "x":2626,
            "y":2931,
            "x2":3947,
            "y2":4119
          },
          {
            "x":162,
            "y":2278,
            "x2":2011,
            "y2":2830
          },
          {
            "x":2694,
            "y":2278,
            "x2":3258,
            "y2":2829
          },
          {
            "x":3310,
            "y":1030,
            "x2":4041,
            "y2":2276
          }
        ]
      },
      "F":{
        "descriptions":[
          "(E, F) Quantitative analysis of 2-NBDG retention and glycogen labeling by measuring mean fluorescence intensity (FI, arbitrary units) from at least 4 random colonies ",
          "(F). Columns represent mean fluorescence intensity measured from at least 4 random colonies and bar standard deviations. Scale bars represent 100 ??m."
        ],
        "rois":[
          {
            "x":1405,
            "y":3097,
            "x2":2599,
            "y2":4119
          },
          {
            "x":2060,
            "y":2278,
            "x2":2649,
            "y2":2830
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schema of 2-NBDG accumulation and retention (glycogen labeling) experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4041,
            "y2":1027
          }
        ]
      },
      "FI":{
        "descriptions":[
          "(FI) in Fig 6B. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) 2-hour 2-NBDG accumulation in the presence of 10 mM D-glucose. Upper panel: green fluorescence intensity (Fluor) images from 2-NBDG alone. These images were obtained (immediately after replacing with fresh mTeSR1 medium) by non-saturated time-exposure guided by an autoexposure software (Zeiss Inc.). Lower panel: the corresponding phase images of the upper panel. Only brightness was adjusted in phase images (presented in both B and C) to enhance the image presentation in this figure. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4041,
            "y2":1027
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) 2-NBDG retention and glycogen labeling carried out in the presence of 10 mM D-glucose and absence of 2-NBDG. Upper panel: unique fluorescence loci (dots) were derived from 2-NBDG signals as detailed in Fig 5. "
        ],
        "rois":[
          {
            "x":6,
            "y":1030,
            "x2":2040,
            "y2":2276
          },
          {
            "x":1471,
            "y":1030,
            "x2":2049,
            "y2":1557
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Quantitative analysis of mean fluorescence intensity "
        ],
        "rois":[
          {
            "x":10,
            "y":2925,
            "x2":1406,
            "y2":4119
          },
          {
            "x":1471,
            "y":1030,
            "x2":2049,
            "y2":1557
          },
          {
            "x":3311,
            "y":2278,
            "x2":4018,
            "y2":2830
          },
          {
            "x":2059,
            "y":1030,
            "x2":3303,
            "y2":2276
          }
        ]
      }
    }
  },
  "1602351":{
    
  },
  "1602356":{
    "Fig_8.tif":{
      "A":{
        "descriptions":[
          "(A), H1 cells treated with 100 ng/mL of BMP-4 "
        ],
        "rois":[
          {
            "x":1988,
            "y":516,
            "x2":2639,
            "y2":946
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), and 3 ??M GSK3i (CHIR99021) "
        ],
        "rois":[
          {
            "x":155,
            "y":506,
            "x2":1987,
            "y2":947
          },
          {
            "x":153,
            "y":952,
            "x2":1411,
            "y2":1388
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) for 48 hours. The cellular genomic DNAs were stained by the Hoechst 33342 dye (Hoechst). The images were collected with a fluorescence microscope (Zeiss). (D and E) Box-and-Whisker plots (with 5???95% percentile) of H1 cells under the indicated treatments: Control 2 (i.e., Cont 2) in both D and E is an additionally untreated control of H1 cells. The plus signs (+) in the plots indicate the location of mean values determined from 116 to 150 individual cells by the ImageJ program. One of two independent experiments is shown. Scale bars in the images represent 50 ??m. (F-H) Simple Western experiments: H1 Oct4-EGFP (abbreviated as H1) cells were cultured under the monolayer culture condition for 2 passages and treated with na??ve growth conditions as indicated for 48 hours. Simple Western was carried out in H1 Oct4-EGFP cell lysates using specific antibodies against GSK-3??, glycogen synthase (C-terminal), and phospho-glycogen synthase at Ser641 (pGS-Ser641). Protein expression was normalized to GAPDH protein control run in the same capillary (lane). Fold changes "
        ],
        "rois":[
          {
            "x":1412,
            "y":958,
            "x2":2640,
            "y2":1389
          },
          {
            "x":149,
            "y":0,
            "x2":2640,
            "y2":501
          }
        ]
      },
      "FC":{
        "descriptions":[
          "(FC) of protein expression related to untreated controls were labeled beneath each lane. The lanes marked by asterisk signs (in Fig 8F) were the results obtained from a separate experiment."
        ],
        "rois":[
          {
            "x":156,
            "y":1448,
            "x2":2638,
            "y2":2929
          }
        ]
      }
    }
  },
  "1602357":{
    "Fig_9.tif":{
      "E":{
        "descriptions":[
          "(E) The mechanism by which the GSK3i CHIR modulates the synthesis of glycogen is likely through the inhibition of GSK-3 activity, thereby altering glycogen synthase activity. "
        ],
        "rois":[
          {
            "x":1931,
            "y":216,
            "x2":2241,
            "y2":1701
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Concomitantly, GSK-3 inhibitors (e.g., CHIR99021 and BIO) may promote hPSC differentiation by activation of the ??-catenin-WNT pathway. "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) In this model, glucose transporter-mediated uptake of glucose is activated by an insulin-receptor signaling pathway. "
        ],
        "rois":[
          {
            "x":0,
            "y":216,
            "x2":1930,
            "y2":1701
          },
          {
            "x":1931,
            "y":216,
            "x2":2241,
            "y2":1701
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) The function of aggregated glycogen bodies is unclear and may be associated with response to extracellular stress and differentiation signals such as BMP-4. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2241,
            "y2":215
          }
        ]
      },
      "GS":{
        "descriptions":[
          "(GS). Thus, activation of the PI3K-AKT pathway increases glycogen synthesis. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Glucose takes part in aerobic glycolysis in the cytoplasm and oxidative phosphorylation in mitochondria to produce energy for hESC proliferation and self-renewal. Presumably, excessive glucose is converted to glycogen by activated glycogen synthase (GSa) upon stress and differentiation signaling to enhance hPSC survival. Glycogen can be decomposed in the presence of phosphorylated glycogen phorsphoylase (pGP) whenever necessary. "
        ],
        "rois":[
          {
            "x":1931,
            "y":216,
            "x2":2241,
            "y2":1701
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The insulin signaling pathway also activates the PI3K-AKT pathway, which phosphorylates GSK-3. The GSK-3 phosphorylation leads to its inactivation and subsequently inhibits the phosphorylation of glycogen synthase "
        ],
        "rois":[
          {
            "x":1931,
            "y":216,
            "x2":2241,
            "y2":1701
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Under sustained Oct-4 expression conditions, GSK3i-mediated glycogen accumulation concomitant with Wnt activation and other na??ve growth components enhances the transition from the primed pluripotent to the na??ve state in hPSCs. The proposed mechanisms in this model supported by this study are color-highlighted. The ??????? symbols indicate inconclusive observations. The abbreviations are: 2iL, the na??ve pluripotent growth condition that include GSK3i, MEKi, and LIF; 3iL, the na??ve pluripotent growth condition that include GSK3i, MEKi, BMP4i, and LIF; AKT, the serine-threonine protein kinase encoded by v-akt murine thymoma viral oncogene homolog; CHIR, CHIR99021; GPi, dephosphorylated glycogen phosphorylase (inactive form); GSa, dephosphorylated glycogen synthase (active form); GSK-3, glycogen synthase kinase 3; pGPa, phosphorylated glycogen phosphorylase (active form); pGSi, phosphorylated glycogen synthase (inactive form); PI3K, the phosphoinositide 3-kinase; and ??-cat, ??-catenin."
        ],
        "rois":[
          {
            "x":0,
            "y":216,
            "x2":1930,
            "y2":1701
          },
          {
            "x":0,
            "y":1702,
            "x2":2241,
            "y2":1982
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The mechanism of BMP-4-induced glycogen body formation is likely through the inhibition of GSK-3 by the putative Smad pathways. "
        ],
        "rois":[
          {
            "x":1931,
            "y":216,
            "x2":2241,
            "y2":1701
          }
        ]
      }
    }
  },
  "160656":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) WT iMEFs were treated with MG132 at 1 ??M or with DMSO for 10 h, or were heat shocked 20 min at 45??C and allowed to recover during 6 h. The relative quantity of Hsf2?? and Hsf2?? transcripts was assessed by RT-PCR using primers flanking the alternative exon. Gapdh RT-PCR served as control for efficient retrotranscritpion and amplification. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1805,
            "y2":2470
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) WT iMEFs were treated during 2 h, 4 h, 6 h or 10 h with MG132 at 1 ??M or with DMSO before being harvested. In addition, WT iMEFs exposed to MG132 during 10 h were allowed to recover during 1 h, 6 h or 24 h before collection. Relative quantity of Hsf2?? and Hsf2?? was assessed by RT-PCR, as described above. Quantity one software (Bio Rad) was used to assess band intensity. Results were expressed in mean of percentage of each isoform +/??? SD from four independent experiments. ",
          "(B) were harvested for protein analysis. Protein extracts were loaded on 12% polyacrylamide gel and submitted to a long migration to separate efficiently HSF2 isoforms. HSF2 was revealed by immunoblotting. Ponceau staining was used to verify the equal loading."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1805,
            "y2":2470
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) WT iMEFs treated as described in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1805,
            "y2":2470
          },
          {
            "x":0,
            "y":2471,
            "x2":1805,
            "y2":2772
          }
        ]
      }
    }
  },
  "1612049":{
    
  },
  "1615127":{
    "Fig_1.tif":{
      "B":{
        "descriptions":[
          "; B. Newly excysted metacercariae (NEM)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1349,
            "y2":1470
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. CYP mRNA level after in vitro treatment of O. felineus for 20 h with hemoglobin (DDPCR). CYP gene expression levels were quantified and values were simultaneously normalized to reference gene MrpL16 expression using QuantaLife (Bio-Rad, USA). The data are shown as the normalized ratio of CYP to MrpL16 ?? S.D. Each run was made in duplex. Results of three independent experiments are presented."
        ],
        "rois":[
          {
            "x":0,
            "y":1471,
            "x2":1349,
            "y2":2308
          }
        ]
      }
    }
  },
  "1616338":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A) Size exclusion chromatography of 400 ??l crude venom from C. salei on a Bio-Gel P-60 column (2 x 100 cm, flow-rate: 0.7 ml/min) in 0.2 M NH4Ac buffer, pH 5.5. "
        ],
        "rois":[
          {
            "x":21,
            "y":17,
            "x2":1011,
            "y2":614
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cation exchange chromatography of Hyal-active fractions on a MonoS column (HR 10/10, flow-rate: 2 ml/min) with 50 mM NH4Ac buffer, pH 5. Fractions were eluted in 60 min by applying a gradient of 0???50% of the same buffer containing 2 M NaCl. "
        ],
        "rois":[
          {
            "x":1123,
            "y":17,
            "x2":2131,
            "y2":612
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) RP-HPLC of Hyal-active fractions on a Nucleosil 300 butyl column (4.6 x 250 mm, 5 ??m, flow-rate: 1 ml/min) equilibrated with 0.1% TFA (v/v) in water. Fractions were eluted in 80 min by applying a gradient of 20???100% solvent B 0.1% TFA (v/v) in ACN. "
        ],
        "rois":[
          {
            "x":21,
            "y":756,
            "x2":1079,
            "y2":1350
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Purity of chromatographic fractions after the different separation steps was controlled by SDS PAGE (12.5%). Lanes: 1 and 6, low molecular mass markers (14.4???94 kDa, GE Healthcare); 2, crude venom; 3, gel filtration fraction 2; 4, MonoS fraction 5; 5, RP-HPLC fraction 1."
        ],
        "rois":[
          {
            "x":1259,
            "y":765,
            "x2":1884,
            "y2":1245
          }
        ]
      }
    }
  },
  "161882":{
    
  },
  "1620187":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Bioluminescence images of rat at day 1, 2, 7, 14, 28, 35 and 64 after a subconjunctival or intravenous injection of Ad-Luci (1x1010 GC/eye). "
        ],
        "rois":[
          {
            "x":4,
            "y":5,
            "x2":1053,
            "y2":1053
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Luciferase activity was measured in unit of photons by bioluminescence analysis. Data are presented as the means ?? SEM (n = 5)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1621688":{
    "Fig 7.tif":{
      "A":{
        "descriptions":[
          "(A) and 24h "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1769,
            "y2":822
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), mice were euthanized and blood samples were recovered by cardiac puncture followed centrifugation. The resulting plasma samples from each group were pooled and analyzed using a mouse multi-cytokine array (n = 1). Mean pixel densities were quantified by Image Lab 4.1 (Bio-Rad Laboratories, Berkeley, CA, USA)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1622038":{
    
  },
  "1622823":{
    "Fig_1.tif":{
      "9":{
        "descriptions":[
          ": 9.92 ? 0.56 vs"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1514,
            "y2":1144
          }
        ]
      },
      "11":{
        "descriptions":[
          ". 11.27 ? 0.07, P "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "162327":{
    "Figure_13.tif":{
      "A":{
        "descriptions":[
          "A, B: PBMCs treated with 100 ng/ml interferon (IFN) ?? for 4 d were used as a positive control ",
          ". A: OAS1"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":183,
            "y2":464
          },
          {
            "x":1004,
            "y":0,
            "x2":1589,
            "y2":464
          },
          {
            "x":0,
            "y":465,
            "x2":1589,
            "y2":685
          }
        ]
      },
      "B":{
        "descriptions":[
          "A, B: PBMCs treated with 100 ng/ml interferon (IFN) ?? for 4 d were used as a positive control ",
          ". B: STAT1. Data are given as mean ??1 standard deviation (n???=???3)."
        ],
        "rois":[
          {
            "x":184,
            "y":0,
            "x2":1003,
            "y2":464
          },
          {
            "x":0,
            "y":465,
            "x2":1589,
            "y2":685
          }
        ]
      },
      "PC":{
        "descriptions":[
          "(PC), and PBMCs treated with buffer alone was used as a negative control "
        ],
        "rois":[
          
        ]
      },
      "NC":{
        "descriptions":[
          "(NC). PBMCs were infected (MOI, 0.5) with wtHHV-6 or recombinant HHV-6s, total RNA from transduced PBMCs was isolated at 5 d after infection, and mRNA levels of OAS1 and STAT1 (interferon response genes) were quantified by real-time RT-PCR using IFN Response Watcher (Takara Bio)"
        ],
        "rois":[
          {
            "x":0,
            "y":465,
            "x2":1589,
            "y2":685
          }
        ]
      }
    }
  },
  "1623930":{
    
  },
  "1624562":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A) the addition of fibril samples (30 ?g/ml) increased the infectivity of R5-tropic HIV-1JR-FL Env-pseudotyped viruses in target cells. The fibril samples promoted the infectivity of different infectious HIV clones, including R5-tropic "
        ],
        "rois":[
          {
            "x":3,
            "y":1025,
            "x2":1022,
            "y2":1822
          },
          {
            "x":1125,
            "y":1012,
            "x2":2103,
            "y2":1816
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), X4-tropic "
        ],
        "rois":[
          {
            "x":3,
            "y":1025,
            "x2":1022,
            "y2":1822
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and dual-tropic infectious HIV-1 clones "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":959,
            "y2":947
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). The means (? standard deviations) of triplicate samples are shown. RLU/s, relative light units/second. One-way ANOVA and Dunnett\u2019s post hoc multiple comparisons test were used to statistically analyze differences between the group of viruses treated with PAP248-286 amyloid fibrils and the group of viruses treated with amyloid fibrils plus EP2 (*p"
        ],
        "rois":[
          {
            "x":1106,
            "y":0,
            "x2":2119,
            "y2":947
          }
        ]
      }
    }
  },
  "1624838":{
    
  },
  "1625249":{
    "Fig 6.TIF":{
      "a":{
        "descriptions":[
          "(a) Segregation following integration. "
        ],
        "rois":[
          {
            "x":1148,
            "y":9,
            "x2":2128,
            "y2":1255
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Integration following segregation. (c-d) Histograms of normalized phase durations. The number of phases is indicated in the title. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) Integration. "
        ],
        "rois":[
          {
            "x":2210,
            "y":36,
            "x2":3209,
            "y2":1239
          }
        ]
      },
      "D":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":9,
            "y":36,
            "x2":1185,
            "y2":1255
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Segregation. The mean phase durations were 36.1 input elements for integration and 36.2 for segregation."
        ],
        "rois":[
          {
            "x":3301,
            "y":9,
            "x2":4300,
            "y2":1239
          }
        ]
      }
    }
  },
  "1625363":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) The three most powerful automated biomedical-tagging engines, BioIE, Whatizit and MEDIE have specific limitations. BioIE only tags relationships between biomedical entities, and Whatizit only tags bio-entities. MEDIE tags both bio-entities and their relationships. In the given example, all three search engines failed to tag the bio-entities ???ROS??? and ???A(2)R??? (circled), which are obvious to a human reader. Red circles denote terms that the automated text mining algorithms failed to recognise. "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":3725,
            "y2":1070
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The hybrid data processing pipeline combines automated text mining (BioIE, Whatizit and MEDIE) and manual text collection. Bio-entities are annotated with BioIE, Whatizit, MEDIE and PubTator."
        ],
        "rois":[
          {
            "x":15,
            "y":1149,
            "x2":3727,
            "y2":1995
          }
        ]
      }
    }
  },
  "1625366":{
    
  },
  "1625367":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) Complete pathway map for foreskin fibroblasts. A total of 81 bio-entities and 63 bio-relations were collected from ~900 PubMed articles. "
        ],
        "rois":[
          {
            "x":1505,
            "y":7,
            "x2":2990,
            "y2":1485
          },
          {
            "x":6,
            "y":7,
            "x2":1477,
            "y2":1483
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Overlap of proteins in CARFMAP and ???foreskin fibroblasts???, with common nodes and edges highlighted in red. "
        ],
        "rois":[
          {
            "x":1505,
            "y":7,
            "x2":2990,
            "y2":1485
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Overlap of proteins in CARFMAP and a complete mouse pathway map from the REACTOME database, with common nodes and edges highlighted in yellow."
        ],
        "rois":[
          {
            "x":3023,
            "y":7,
            "x2":4494,
            "y2":1485
          }
        ]
      }
    }
  },
  "162663":{
    "Figure 7.tif":{
      "A":{
        "descriptions":[
          "(A) Western blotting analysis of the samples and the probe, using a streptavidin horse radish peroxidase (HRP) conjugate. Lane 1: blank; lane 2: a sample of the anti-human interferon-gamma mIgG1 mAb biotinylated using a conventional amine reactive sulfo-NHS-ester-biotin reagent resulting in \"global\" biotinylation of both heavy (ca. 50 kDa) and light chains (ca. 25 kDa); lane 3: the ZF5I-Q32C-MBP-BIO probe alone, biotinylated using the same amine reactive sulfo-NHS-ester-biotin reagent; lane 4: a sample of the anti-human interferon-gamma mIgG1 mAb after photoconjugation to the ZF5I-Q32C-MBP-BIO probe (ca. 8 kDa) showing a selective biotinylation of only the heavy chains (ca. 50 + 8 kDa). A small amount of unreacted probe is also visible. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2122,
            "y2":1228
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Biosensor analysis of the relative antigen binding potency of the biotinylated antibody preparations. Using a streptavidin coated biosensor chip, the biotinylated antibody proteins were selectively immobilized onto separate sensor chip surfaces, followed by injection over both surfaces of a common 7.5 nM solution of the antigen human interferon-gamma. This allowed for direct comparison of the effect on the antigen binding potency from the different biotinylation strategies. Sample (i): the anti-human interferon-gamma mIgG1 mAb biotinylated using a conventional amine reactive sulfo-NHS-ester-biotin reagent; sample (ii): the anti-human interferon-gamma mIgG1 mAb biotinylated via photoconjugation using the ZF5I-Q32C-MBP-BIO probe."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1629032":{
    "Fig_5.tif":{
      "a":{
        "descriptions":[
          "(a) The OE1 leaves were smaller and greener than the WT leaves. "
        ],
        "rois":[
          {
            "x":4,
            "y":6,
            "x2":1051,
            "y2":728
          },
          {
            "x":1195,
            "y":827,
            "x2":2192,
            "y2":1174
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) The OE1 roots were longer than the WT roots. "
        ],
        "rois":[
          {
            "x":1156,
            "y":6,
            "x2":2192,
            "y2":731
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) The OE1 plants showed lower rates of water loss at each time point than the WT after leaf detachment and incubation at 30?C and 40% relative humidity. The significantly different values between the WT and OE1 plants are indicated by asterisks (n = 3). A single asterisk indicates a significant difference at P .05 and two asterisks indicates a significant difference at P .01. "
        ],
        "rois":[
          {
            "x":1192,
            "y":1192,
            "x2":1716,
            "y2":1539
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) The leaf discs were cultured in 1/2MS nutrient solution for about a month. The discs from WT plants became yellow and senescence was more obvious than on the transgenic tobacco OE1 leaf discs. The top line is the leaf discs before culturing, and the bottom line is the leaf discs after 1 month\u2019s culturing."
        ],
        "rois":[
          {
            "x":1730,
            "y":1192,
            "x2":2193,
            "y2":1540
          },
          {
            "x":15,
            "y":825,
            "x2":1188,
            "y2":1540
          }
        ]
      }
    }
  },
  "1629162":{
    "S1_Fig.tif":{
      "OR":{
        "descriptions":[
          "(OR) and 95% confidence intervals (95% CI) were calculated by using fixed- or random-effects models.ResultsThe data from 27 of all the studies mentioned above was used in the Meta analysis. Through the meta-analysis, we found that the parameter of blood urea nitrogen, serum creatinine and urinary protein levels of the AL group was significant higher than that of the CR group, which are 4.11 mg/dl, 0.08mg/dl and 33.20mg/kg/24h, respectively. The incidence of the nephropathy in the caloric restriction "
        ],
        "rois":[
          {
            "x":47,
            "y":22,
            "x2":2927,
            "y2":1922
          }
        ]
      },
      "CR":{
        "descriptions":[
          "(CR) group was significantly lower than that in the ad libitum???fed "
        ],
        "rois":[
          
        ]
      },
      "AL":{
        "descriptions":[
          "(AL) group. We further introduced the subgroup analysis and found that the effect of caloric restriction on the occurrence of kidney disease was only significant with prolonged intervention; the beneficial effects of CR on the 60%-caloric-restriction group were greater than on the less-than-60%-caloric-restriction group, and caloric restriction did not show obvious protective effects in genetically modified strains. Moreover, survival rate of the caloric restriction group is much higher than that of the ad libitum???fed ",
          "(AL) group.ConclusionsOur findings demonstrate for the first time that compared with the AL group, the caloric restriction indeed decreased urea nitrogen, creatinine, urine protein, incidence of kidney diseases and increased the survival rate on 700~800 days."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1629546":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "A) Fibrotic protein expression in kidney. Rats were fed the standard Lieber-deCarli liquid ethanol diet, or its isomaltose control, for 28 days before kidneys were excised, perfused with saline, fixed and sectioned as described in ???Methods.??? Sections were rehydrated and stained with anti-TGF-??1, anti- ??-smooth muscle actin, anti-collagen IV or anti-collagen 1 antibodies, and SP-streptavidin-conjugated secondary antibody for anti-TGF-??1, or fluorescent secondary antibodies for the other sections as stated in ???Methods.??? TGF-?? sections were developed with horseradish peroxidase and DAB/metal chromogenic solution"
        ],
        "rois":[
          {
            "x":24,
            "y":81,
            "x2":2070,
            "y2":2550
          },
          {
            "x":0,
            "y":0,
            "x2":992,
            "y2":566
          },
          {
            "x":0,
            "y":600,
            "x2":994,
            "y2":1055
          },
          {
            "x":599,
            "y":1235,
            "x2":959,
            "y2":1912
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) mRNAs encoding fibrotic proteins were induced in kidneys of rats ingesting ethanol. Total RNA was isolated from ethanol and pair-fed kidneys from rats at the end of the feeding trial, and mRNA was quantified by SYBR Green one-step Reverse Transcription-PCR for the stated mRNAs and ribosomal 18S with the Bio-Rad MyiQ real-time PCR detection system. mRNA expression was normalized to 18S RNA content and 2-????CT was used to calculate the fold changes. Data are expressed as mean??SEM (n = 4), and p"
        ],
        "rois":[
          {
            "x":29,
            "y":1146,
            "x2":437,
            "y2":1915
          }
        ]
      }
    }
  },
  "1629579":{
    
  },
  "1629582":{
    
  },
  "1631179":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A), the white, gray, and black circles indicate 2, 5, and 10 ng/??l (final concentrations) of proteins, respectively. For OlTGK2 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2250,
            "y2":819
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), the white, gray, and black circles indicate 2, 5, and 20 ng/??l of proteins, respectively. Time course reactions (0 to 60 min) with 2 ng/??l of enzyme proteins in the absence (black) and presence (white) of EDTA were shown (B: OlTGK1"
        ],
        "rois":[
          {
            "x":7,
            "y":841,
            "x2":1083,
            "y2":1658
          }
        ]
      },
      "D":{
        "descriptions":[
          ", D: OlTGK2)."
        ],
        "rois":[
          {
            "x":1141,
            "y":847,
            "x2":2235,
            "y2":1679
          }
        ]
      }
    }
  },
  "1631629":{
    "Fig_1.tif":{
      "E":{
        "descriptions":[
          "(E), Western blot analysis of the selected clones for interaction with FvTox1. Selected clones in D were reinvestigated for interaction with FvTox1, adsorbed onto a nitrocellulose membranes and detecting the interaction of individual clones to FvTox1 with an anti-M13 antibody (Details are presented in S2 Fig). "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2057,
            "y2":2406
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), Electropherogram of a nucleotide molecule encoding an FvTox1-intearcting peptide is presented."
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2057,
            "y2":2406
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), Bio-panning of the phage display libraries on plastic surface of a microtiter plates coated with 1.5 ml FvTox1 (30 ng/??l). Unbound phage particles were washed off; and M13 phage particles bound to FvTox1 were used to infect E. coli for starting a second round of panning. The process was repeated once more. "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2057,
            "y2":2406
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), Plating of candidate M13 phage clones displaying FvTox1-interacting peptides. An eluate from the last panning in A was plated on X-gal/IPTG agar plates. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C), Identification of candidate M13 phage clones displaying FvTox1-interacting peptides. Phage clones were adsorbed onto nitrocellulose paper and hybridized to the His-tagged purified FvTox1 proteins. FvTox1-interacting clones were identified by detecting FvTox1 with the anti-His antibody. "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2057,
            "y2":2406
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), Western blot analysis of the selected phage clones for interaction with FvTox1. Selected M13 phage particles from plates in C were transferred to nitrocellulose filters and hybridized to FvTox1, which was detected with an anti-His antibody. "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":2057,
            "y2":2406
          }
        ]
      }
    }
  },
  "1632038":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "(A) Growth curve of the isolated strain Cupriavidus sp. CY-1 with 2,4-D as carbon source; "
        ],
        "rois":[
          {
            "x":5,
            "y":6,
            "x2":1461,
            "y2":615
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Degradation of 2,4-D using isolated strain Cupriavidus sp"
        ],
        "rois":[
          {
            "x":6,
            "y":637,
            "x2":1487,
            "y2":1291
          }
        ]
      }
    }
  },
  "1632041":{
    "Fig 5.tif":{
      "A":{
        "descriptions":[
          "(A) Degradation of 2,4-D with MMIT campus soil and forest soil under non-bioaugmentation and bio-augmentation conditions. Soils were contaminated with 100 mg/kg of 2,4-D. For bio-augmentation experiments, 4 ml of CY-1 culture solution was inoculated into soils. Samples were collected at different time intervals and residual concentration of 2,4-D in the medium were analyzed by HPLC. "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1474,
            "y2":1069
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) CFU and MPN of forest soil under non-bioaugmentation and bio-augmentation conditions."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1632042":{
    "Fig 6.tif":{
      "M":{
        "descriptions":[
          "M: Marker; FS: Forest soil; PC: Pure culture"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1414,
            "y2":1123
          }
        ]
      },
      "D":{
        "descriptions":[
          "; D: 2,4-D contaminated soil; CY1: 2,4-D contaminated soil bio-augmented with CY-1 strain."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1414,
            "y2":1123
          }
        ]
      }
    }
  },
  "1632043":{
    "Fig 7.tif":{
      "A":{
        "descriptions":[
          "(A) non-bioaugmentation (2,4-D + soil sample); "
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":3066,
            "y2":3517
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) bio-augmentation (2,4-D + soil + CY-1 sample) conditions using forest soil samples."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1632794":{
    
  },
  "1633883":{
    
  },
  "1634155":{
    "Fig_5.tif":{
      "E":{
        "descriptions":[
          "(E) Graphical representation of the results of the cobalt affinity pull-down assays performed in the presence of 150 or 300 mM NaCl, plotted as the ratio of the optical densities of the eIF4GI HEAT-1 band to that of the His-MNV VPg band in eluted fractions (lanes 9???16 in panel D). Band densities were quantified using ImageJ (http://imagej.nih.gov/ij/) and the ratios were normalised to the wild-type control."
        ],
        "rois":[
          {
            "x":1,
            "y":807,
            "x2":2119,
            "y2":2443
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Superposition of the 1H15N TROSY HSQC spectra of 15N-labelled eIF4GI HEAT-1 (748???993) obtained in the absence (black) and presence (green) of 0.35 molar equivalents of unlabelled MNV VPg(104???124) peptide. (1H15N TROSY NMR spectra for all of the points in the titration are given in S3 Fig). The residues for which the intensity of amide 1H15N signals exhibit the greatest reductions as the MNV VPg(104???124) peptide concentration is increased are indicated by their residue number. The assignments were taken from the Bio Magnetic Resonance Database (BMRB id 18738). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":888,
            "y2":823
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Plot of the ratio of the absolute values of non-overlapping peak volumes for assigned residues obtained at 0 and 0.35 molar equivalents of the MNV VPg(104???124) peptide. High values of the ratios indicate the residues in eIF4GI HEAT-1 most affected by MNV VPg binding. The red dashed line indicates the expected volume ratio (Rv) for unperturbed residues: 0.76, based on the relative number of scans performed in each HSQC experiment. Points above the green dashed line indicate residues for which the peak volume ratio was at least six times higher than the baseline for unperturbed amides. "
        ],
        "rois":[
          {
            "x":979,
            "y":0,
            "x2":2114,
            "y2":833
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Model of the complex of eIF4GI HEAT-1 (grey, surface representation) and eIF4A (cyan, cartoon representation) indicating the predicted location of the VPg binding site. Surface residues in eIF4GI HEAT-1 that exhibit the greatest changes in Rv in the presence of the MNV VPg(104???124) peptide are coloured yellow. The model of eIF4GI HEAT-1 was generated using SWISS-MODEL [46]; the complex was created by superposing this model on the eIF4G HEAT-1 component of the yeast eIF4G-eIF4A co-crystal structure [47]. "
        ],
        "rois":[
          {
            "x":1,
            "y":807,
            "x2":2119,
            "y2":2443
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) SDS PAGE analysis of pull-down assays to test the effect of mutations in the putative VPg-binding site on eIF4G HEAT-1 on binding to the viral protein. His-tagged MNV VPg(1???124) was used as bait; eIF4GI HEAT-1 wild-type or mutant proteins were used as prey, and the pull-down buffer contained 150 mM NaCl (top panel) or 300 mM NaCl (bottom panel). Lanes 1???8 (blue labels): input protein mixtures; lanes 9???16 (red labels): eluted proteins. "
        ],
        "rois":[
          {
            "x":2,
            "y":1453,
            "x2":500,
            "y2":2022
          },
          {
            "x":9,
            "y":2039,
            "x2":500,
            "y2":2443
          }
        ]
      }
    }
  },
  "1634193":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          ". A. Six-day-old sporocyst in a compatible interaction"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2197,
            "y2":713
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Encapsulated sporocyst 48 h after primary infection in an incompatible interaction"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ". C. Six-day-old sporocyst in a primed snail. Primed BgBRE are 100% protected against a secondary challenge with SmBRE. Sporocysts from secondary challenge were neutralized by immune humoral factors."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1634604":{
    "Fig_1.tif":{
      "e":{
        "descriptions":[
          "(e)- and GAPDH "
        ],
        "rois":[
          {
            "x":70,
            "y":757,
            "x2":362,
            "y2":1065
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f), PPAR?? "
        ],
        "rois":[
          {
            "x":379,
            "y":37,
            "x2":681,
            "y2":339
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) hMSCs morphology in standard culture conditions. ",
          "(a), BMAL1 ",
          "(a), BMAL1 "
        ],
        "rois":[
          {
            "x":373,
            "y":434,
            "x2":980,
            "y2":750
          },
          {
            "x":1087,
            "y":534,
            "x2":2476,
            "y2":1004
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Day 21 adipogenic differentiation, assessed by oil red O staining. ",
          "(b), PER1 ",
          "(b), PER1 "
        ],
        "rois":[
          {
            "x":379,
            "y":1458,
            "x2":991,
            "y2":1760
          }
        ]
      },
      "g":{
        "descriptions":[
          "(g) and OSTEOCALCIN "
        ],
        "rois":[
          {
            "x":71,
            "y":1074,
            "x2":364,
            "y2":1390
          }
        ]
      },
      "H":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":371,
            "y2":744
          },
          {
            "x":689,
            "y":37,
            "x2":991,
            "y2":339
          },
          {
            "x":1833,
            "y":56,
            "x2":2476,
            "y2":504
          },
          {
            "x":1033,
            "y":12,
            "x2":1736,
            "y2":484
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Osteogenic differentiation after 21 days, evaluated by alizarin red staining. Scale bar = 200 ??m (B) hMSCs antigen expression characterization CD105, CD73, CD90, CD44, CD34, CD45 and CD31 by flow cytometry. The percentage of markers expression is given compared to isotype control. (C) Quantitative RT-PCR showing temporal expression profiles of clock-associated genes -CLOCK ",
          "(c), PER2 ",
          "(c) and only PER2 "
        ],
        "rois":[
          {
            "x":69,
            "y":1767,
            "x2":371,
            "y2":2069
          }
        ]
      },
      "h":{
        "descriptions":[
          "(h) genes. Data, obtained during a 36 hours period, are expressed as the mean of ??Ct ?? SEM calculated from the Ct value of each gene at T0 (serum shock). Bars represent means of 3 independent experiments. (D) Immunofluorescence analysis of circadian proteins -CLOCK "
        ],
        "rois":[
          
        ]
      },
      "d":{
        "descriptions":[
          "(d), GSK-3?? ",
          "(d)- in hMSCs, 36 hours after starvation. Cell nuclei were visualized by DAPI (blue), circadian protein by FITC (green) or Cy3 staining (red). Scale bar = 20 ??m."
        ],
        "rois":[
          {
            "x":12,
            "y":1427,
            "x2":372,
            "y2":1760
          },
          {
            "x":380,
            "y":753,
            "x2":977,
            "y2":1069
          },
          {
            "x":1091,
            "y":1038,
            "x2":2481,
            "y2":1969
          }
        ]
      }
    }
  },
  "1634609":{
    "Fig_3.tif":{
      "e":{
        "descriptions":[
          "(e)- and GAPDH "
        ],
        "rois":[
          {
            "x":14,
            "y":1001,
            "x2":1987,
            "y2":1595
          }
        ]
      },
      "f":{
        "descriptions":[
          "(f), PPAR?? "
        ],
        "rois":[
          {
            "x":1054,
            "y":1655,
            "x2":1940,
            "y2":2204
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a), BMAL1 "
        ],
        "rois":[
          {
            "x":14,
            "y":15,
            "x2":1018,
            "y2":774
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b), PER1 "
        ],
        "rois":[
          {
            "x":61,
            "y":1641,
            "x2":951,
            "y2":2204
          }
        ]
      },
      "g":{
        "descriptions":[
          "(g) and OSTEOCALCIN "
        ],
        "rois":[
          {
            "x":1043,
            "y":2270,
            "x2":1940,
            "y2":2813
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c), PER2 "
        ],
        "rois":[
          {
            "x":56,
            "y":2261,
            "x2":951,
            "y2":2814
          }
        ]
      },
      "h":{
        "descriptions":[
          "(h) in WT, shClock and shPer2 hMSCs (T0 = serum shock). Data are expressed as the mean of ??Ct ?? SEM calculated from the Ct value of each gene T0. Bars represent means of 2 independent experiments."
        ],
        "rois":[
          {
            "x":1046,
            "y":2865,
            "x2":1945,
            "y2":3436
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d), GSK-3?? "
        ],
        "rois":[
          {
            "x":54,
            "y":2860,
            "x2":956,
            "y2":3437
          }
        ]
      }
    }
  },
  "1634610":{
    "Fig_4.tif":{
      "e":{
        "descriptions":[
          " and shGapdh (e)"
        ],
        "rois":[
          {
            "x":83,
            "y":428,
            "x2":945,
            "y2":776
          }
        ]
      },
      "a":{
        "descriptions":[
          "(A) Influence of circadian genes inhibition on hMSCs adipogenic differentiation. WT (a)",
          " hMSCs were stained with oil red O after 21 days of differentiation. Scale bar = 200 ??m. (B) Mean area (??m??) of each lipid droplets, determined with ImageJ?? software. (C) qPCR analysis of adipogenic differentiation markers: (a)"
        ],
        "rois":[
          {
            "x":18,
            "y":860,
            "x2":722,
            "y2":1341
          }
        ]
      },
      "b":{
        "descriptions":[
          ", shGFP (b)",
          " FABP4, (b)"
        ],
        "rois":[
          {
            "x":719,
            "y":1384,
            "x2":1309,
            "y2":2063
          }
        ]
      },
      "p":{
        "descriptions":[
          " C/EBP??. Data are expressed as mean of 2(???????Ct) ?? SEM and normalized to shGFP cells. Endogenous gene: HMBS. Bars represent means of 3 independent experiments. **: p"
        ],
        "rois":[
          {
            "x":1386,
            "y":1423,
            "x2":1985,
            "y2":2051
          },
          {
            "x":15,
            "y":15,
            "x2":945,
            "y2":403
          }
        ]
      },
      "c":{
        "descriptions":[
          ", shClock (c)",
          " PPAR?? and (c)"
        ],
        "rois":[
          {
            "x":18,
            "y":1370,
            "x2":659,
            "y2":2051
          }
        ]
      },
      "d":{
        "descriptions":[
          ", shPer2 (d)"
        ],
        "rois":[
          {
            "x":970,
            "y":54,
            "x2":1388,
            "y2":403
          }
        ]
      }
    }
  },
  "1634613":{
    "Fig_5.tif":{
      "e":{
        "descriptions":[
          "(e) hMSCs. Scale bar = 200 ??m. (B) qPCR analysis of osteogenic differentiation markers: "
        ],
        "rois":[
          {
            "x":81,
            "y":423,
            "x2":494,
            "y2":768
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a), shGFP ",
          "(a) ALP, "
        ],
        "rois":[
          {
            "x":15,
            "y":839,
            "x2":675,
            "y2":1497
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b), shClock ",
          "(b) OSTEOCALCIN and "
        ],
        "rois":[
          {
            "x":721,
            "y":853,
            "x2":1318,
            "y2":1496
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c), shPer2 ",
          "(c) RUNX2. Data are expressed as mean of 2(???????Ct) ?? SEM and normalized to shGFP cells. Endogenous gene: HMBS. Bars represent means of 3 independent experiments."
        ],
        "rois":[
          {
            "x":1394,
            "y":875,
            "x2":1986,
            "y2":1497
          },
          {
            "x":954,
            "y":53,
            "x2":1367,
            "y2":398
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d), and shGapdh "
        ],
        "rois":[
          {
            "x":12,
            "y":15,
            "x2":493,
            "y2":398
          },
          {
            "x":515,
            "y":53,
            "x2":929,
            "y2":768
          }
        ]
      }
    }
  },
  "1634617":{
    "Fig_6.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1990,
            "y2":522
          }
        ]
      },
      "WT":{
        "descriptions":[
          " Expression of adhesion molecule CD54, CD106, CD49a and CD49d on hMSCs cultured without (WT)"
        ],
        "rois":[
          {
            "x":11,
            "y":647,
            "x2":1905,
            "y2":1890
          }
        ]
      }
    }
  },
  "1634618":{
    "Fig_7.tif":{
      "a":{
        "descriptions":[
          "(A) Cell cycle studies and BIO treatment. (a)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2175,
            "y2":1355
          }
        ]
      },
      "p":{
        "descriptions":[
          " Histograms represent DNA contents according to the cell cycle phase G0/G1phase, S phase and G2/M phase for WT and BIO-treated hMSCs. Data are expressed as the mean of percentage ?? SEM. Histograms represent means of 3 independent experiments. *: p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1634620":{
    
  },
  "1635402":{
    "Fig_2.tif":{
      "A":{
        "descriptions":[
          "(A) Structure of deguelin arrow indicates the binding of deguelin on Bcl-2 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1979,
            "y2":982
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The docking of deguelin on BH3 domain of hydrophobic group of anti-apoptotic protein Bcl-xl "
        ],
        "rois":[
          {
            "x":2128,
            "y":10,
            "x2":3258,
            "y2":1178
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Binding of deguelin on MCL-1 "
        ],
        "rois":[
          {
            "x":3337,
            "y":10,
            "x2":4500,
            "y2":1178
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Binding of deguelin molecule on ERK-1 near the ATP binding site. Docking was carried out using bio-informative tools as described in materials and methods."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "1635406":{
    
  },
  "1635708":{
    "Fig_3.tif":{
      "A":{
        "descriptions":[
          "(A) Schematic of the PI3K-Akt-mTOR pathway and the three inhibitors used in this experiment (black boxes). All of the results shown in this Figure are from WSSV-infected shrimp, i.e. the controls were not treated with the various inhibitors, but they were infected. "
        ],
        "rois":[
          {
            "x":4,
            "y":33,
            "x2":199,
            "y2":337
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Real-time PCR (qPCR) analysis shows that the PI3K/mTORC1 inhibitor LY294002 had no significant effect on WSSV-induced GDH expression at 12 hpi. Gene expression was measured in 10 individual hemocyte samples for each group at each time point. (The number of data points shown may be less than 10 because any sample that failed to produce a sufficiently specific Bio-Rad amplification plot was rejected.) Bars represent the mean ?? SD. Asterisks indicate statistically significant differences in WSSV-infected shrimp between the drug treatment groups and the corresponding vehicle-only control. The Mann-Whitney U test was used to test the non-normal LY294002 12 hpi GLS group data against the DMSO control. Student???s t-test was used for all other comparisons (** ppppp"
        ],
        "rois":[
          {
            "x":7,
            "y":345,
            "x2":2220,
            "y2":1356
          },
          {
            "x":784,
            "y":5,
            "x2":2220,
            "y2":900
          }
        ]
      }
    }
  },
  "1638726":{
    "Fig_1.tif":{
      "A":{
        "descriptions":[
          "(A,B) PFCs were cultured in the presence of medium alone, with E/C peptides or with PMA plus ionomycin for 12 h, after which IL-21 and GAPDH mRNA levels were determined by RT-PCR (upper panel). The graph (lower panel) shows the ratio of IL-21 over GAPDH, calculated according to the relative intensities of the bands revealed under UV illumination with Bio-1D software. Data are representative of five separate experiments with similar results. "
        ],
        "rois":[
          {
            "x":1534,
            "y":1100,
            "x2":2914,
            "y2":2011
          },
          {
            "x":1819,
            "y":646,
            "x2":3260,
            "y2":1070
          },
          {
            "x":9,
            "y":16,
            "x2":3186,
            "y2":763
          },
          {
            "x":1689,
            "y":16,
            "x2":2150,
            "y2":299
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A,B) PFCs were cultured in the presence of medium alone, with E/C peptides or with PMA plus ionomycin for 12 h, after which IL-21 and GAPDH mRNA levels were determined by RT-PCR (upper panel). The graph (lower panel) shows the ratio of IL-21 over GAPDH, calculated according to the relative intensities of the bands revealed under UV illumination with Bio-1D software. Data are representative of five separate experiments with similar results. "
        ],
        "rois":[
          {
            "x":1819,
            "y":330,
            "x2":2150,
            "y2":614
          },
          {
            "x":9,
            "y":802,
            "x2":1267,
            "y2":1842
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) A representative data of ELISPOT results is shown. Data are representative of five separate experiments with similar results. "
        ],
        "rois":[
          {
            "x":2189,
            "y":330,
            "x2":2519,
            "y2":614
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The frequency of IL-21-producing cells was enumerated by ELISPOT assay (n = 5). Each dot represents one donor. Horizontal bars represent the mean value. *ppp"
        ],
        "rois":[
          {
            "x":1534,
            "y":1100,
            "x2":2914,
            "y2":2011
          }
        ]
      }
    }
  },
  "1639280":{
    "Fig_8.tif":{
      "a":{
        "descriptions":[
          "(a) Percentage of events with total efficiency H(%) > 0.9. "
        ],
        "rois":[
          {
            "x":8,
            "y":6,
            "x2":1056,
            "y2":617
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Percentage of events with final utility U(%)>0.9. Behavior of H(%)>0.9 and U(%)>0.9 as a function of Aw, for Kn = 1 and NLev = 20. The case of a random consumer is also considered."
        ],
        "rois":[
          {
            "x":1146,
            "y":14,
            "x2":2194,
            "y2":619
          }
        ]
      }
    }
  },
  "1639420":{
    
  },
  "164000":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Whole cell lysates from mid-exponential phase cultures of the indicated S. flexneri strains were subjected to Western immunoblotting with anti-IcsA antibody. S???=???S-LPS; R???=???R-LPS. IcsA??????=???IcsA deletion control. The 120 kDa band corresponds to the full length IcsA and the 85 kDa band corresponds to the cleaved form (IcsA???). "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":1175,
            "y2":894
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HeLa cells were infected with mid-exponential phase S. flexneri ??icsA expressing the IcsA mutants and formalin fixed. HeLa cells and bacteria nuclei were labelled with DAPI (blue), F-actin was labelled with Alexa Fluor 488-phalloidin (green), and N-WASP was labelled with anti-N-WASP antibody and Alexa Fluor 594-conjugated donkey anti-rabbit antibody (red) as detailed in Materials and Methods. IF images were observed at 100??magnification. Arrows indicate N-WASP recruitment and F-actin comet tail formation. Insert shows an enlargement of the indicated region. Strains were assessed in two independent experiments. Scale bar???=???10 ??m. "
        ],
        "rois":[
          {
            "x":169,
            "y":901,
            "x2":1175,
            "y2":1984
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Plaque assay by S. flexneri ??icsA strains expressing IcsA::BIO, IcsA::BIO G331W or IcsA::BIO V382R. Confluent HeLa cell monolayers were infected with mid-exponential phase S. flexneri strains for 2 h, and plaques were observed 48 h post-infection as detailed in Materials and Methods. 30 plaques were measured from each experiment. Data are represented as mean ?? SEM of three independent experiments. ***, Pt test)."
        ],
        "rois":[
          {
            "x":12,
            "y":2095,
            "x2":690,
            "y2":2713
          }
        ]
      }
    }
  },
  "1640110":{
    
  },
  "1640284":{
    
  },
  "1640700":{
    "Fig_5.tif":{
      "A":{
        "descriptions":[
          "(A) Lanes 1???2 are NB462, serving as a negative control for Cph8 protein. Lanes 3???4 contains wild-type Cph8, lanes 5???6 contains kinase dead and lane 7???8 is T541S mutant. Lane 9 "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":512,
            "y2":295
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L) contains a Kaleidoscope ladder (Bio-Rad, Hercules, CA, USA). Lane 10 (+) is a truncated EnvZ protein tagged with His6, which serves as a positive control. "
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":512,
            "y2":295
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) ImageJ densitometric analysis was used to calculate the relative darkness of sample bands through normalization to the optical intensity of the WT strains. This analysis resulted in quantitative approximations of the relative amounts of Cph8 protein produced per cell for each strain, as shown in the table."
        ],
        "rois":[
          {
            "x":542,
            "y":6,
            "x2":995,
            "y2":294
          }
        ]
      }
    }
  },
  "1641820":{
    
  },
  "164307":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) HeLa cells were infected with mid-exponential phase S. flexneri ??icsA (S-LPS) or S. flexneri ??icsA ??rmlD (R-LPS) having an empty vector or expressing IcsA::BIO, IcsA::BIO Y716F, IcsA::BIO Y716G or IcsA::BIO D717G, and then formalin fixed. HeLa cells and bacteria nuclei were labelled with DAPI (blue), F-actin was labelled with Alexa Fluor 488-phalloidin (green), and N-WASP was labelled with anti-N-WASP antibody and Alexa Fluor 594-conjugated donkey anti-rabbit antibody (red) as detailed in Materials and Methods. IF images were observed at 100??magnification. Arrows indicate N-WASP recruitment and F-actin comet tail formation. Enlargements of relevant region shown for clarity. Strains were assessed in two independent experiments. Scale bar???=???10 ??m. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1032,
            "y2":536
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Plaque assay of S. flexneri ??icsA strains expressing IcsA::BIO, IcsA::BIO Y716F, IcsA::BIO Y716G or IcsA::BIO D717G. Confluent HeLa cell monolayers were infected with mid-exponential phase S. flexneri strains for 2 h, and plaques were observed 48 h post-infection as detailed in Materials and Methods. 30 plaques were measured from each experiment. Data are represented as mean ?? SEM of three independent experiments. ***, Pt test)."
        ],
        "rois":[
          {
            "x":11,
            "y":540,
            "x2":2061,
            "y2":2761
          },
          {
            "x":1071,
            "y":115,
            "x2":2061,
            "y2":535
          }
        ]
      }
    }
  }
,
  "1643225":{
    "Fig_6.tif":{
      "E":{
        "descriptions":[
          "(E) KC and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1677,
            "y2":1083
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) MIP-2 were measured using Bio-Rad Bio-Plex assay. n = 6???8 in each group and P"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) IL-6, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1677,
            "y2":1083
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IL-10, "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) TNF-??, "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) IFN-??, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1677,
            "y2":1083
          }
        ]
      }
    }
  },
  "1643227":{
    "Fig_8.tif":{
      "E":{
        "descriptions":[
          "(E) KC and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) MIP-2 were measured using Bio-Rad Bio-Plex assay. n = 6???8 in each group and P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) IL-6, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IL-10, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) TNF-??, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IFN-??, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1674,
            "y2":1057
          }
        ]
      }
    }
  },
  "1643704":{
    "Fig_4.tif":{
      "A":{
        "descriptions":[
          "(A).The visualization is a hierarchical heat-map generated from edgeR analysis with filtered data where the major boxes represent a family (or category) of related functions. Each individual colored rectangle is a particular biological function or disease and the color indicates its predicted state: Increasing (orange), or decreasing (blue). Darker colors indicate higher absolute Z-scores. In this view the size of the rectangle is correlated with increasing overlap significance (p-value). The image has been cropped for better readability. "
        ],
        "rois":[
          {
            "x":10,
            "y":0,
            "x2":4295,
            "y2":1728
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Heat-map comparison of Diseases and Biofunctions affected across all 4 analysis (edgeR 0.1 cpm/all, edgeR 0.1cpm/ 22, DESEq2, TSPM). Similarly color represents predicted state. "
        ],
        "rois":[
          {
            "x":0,
            "y":1878,
            "x2":1556,
            "y2":3007
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Individual Z-scores and mean Z-scores per each Bio Function affected. The Z-score algorithm is designed to reduce the chance that random data will generate significant predictions. Negative Z-scores indicate a down-regulation of Biofunction, positives Z-scores indicate an up-regulation of function. Absolute Z-score values higher than 2.0 can be used to make biological predictions."
        ],
        "rois":[
          {
            "x":1927,
            "y":2311,
            "x2":4267,
            "y2":3006
          }
        ]
      }
    }
  },
  "164453":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A, B) IF microscopy to detect N-WASP, Arp3 recruitment and F-actin comet tail formation by intracellular S. flexneri strains. HeLa cells were infected with mid-exponential phase S. flexneri ??icsA ??rmlD (R-LPS) strains expressing either IcsA::BIO only or co-expressing IcsA::BIO V382R (N-WASP IR II) and IcsA::BIO Y716G D717G (N-WASP IR III), and formalin fixed. HeLa cells and bacteria nuclei were labelled with DAPI (blue), and N-WASP was labelled with anti-N-WASP antibody and either ",
          "(A) Alex Fluor 488-conjugated donkey anti-rabbit antibody (green) or ",
          "(A) Arp3 was labelled with anti-Arp3 monoclonal antibody and an Alex Fluor 594-conjugated donkey anti-mouse antibody (red). "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":1731,
            "y2":882
          }
        ]
      },
      "B":{
        "descriptions":[
          "(A, B) IF microscopy to detect N-WASP, Arp3 recruitment and F-actin comet tail formation by intracellular S. flexneri strains. HeLa cells were infected with mid-exponential phase S. flexneri ??icsA ??rmlD (R-LPS) strains expressing either IcsA::BIO only or co-expressing IcsA::BIO V382R (N-WASP IR II) and IcsA::BIO Y716G D717G (N-WASP IR III), and formalin fixed. HeLa cells and bacteria nuclei were labelled with DAPI (blue), and N-WASP was labelled with anti-N-WASP antibody and either ",
          "(B) Alex Fluor 594-conjugated donkey anti-rabbit antibody (red). ",
          "(B) F-actin was labelled with Alexa Fluor-488-phalloidin (green). IF images were observed at 100??magnification. Arrows indicate N-WASP, Arp3 recruitment and F-actin tail formation. Enlargements of relevant region shown for clarity. Strains were assessed in two independent experiments. Scale bar???=???10 ??m. "
        ],
        "rois":[
          {
            "x":12,
            "y":1087,
            "x2":1727,
            "y2":1533
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantification of N-WASP/Arp3 recruitment, and ",
          "(C), or recruited N-WASP and formed F-actin comet tail/capping ",
          "(C); and, as percentage of N-WASP recruitment/F-actin tail or capping formation ?? SEM of two independent experiments "
        ],
        "rois":[
          {
            "x":1088,
            "y":2057,
            "x2":2060,
            "y2":2744
          },
          {
            "x":128,
            "y":1541,
            "x2":1727,
            "y2":1926
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) N-WASP/F-actin tail or capping formation, by intracellular S. flexneri ??icsA ??rmlD strains expressing IcsA::BIO only or co-expressing IcsA::BIO V382R (N-WASP IR II) and IcsA::BIO Y716G D717G (N-WASP IR III). Bacteria that either recruited both N-WASP and Arp3 ",
          "(D), were scored from infected HeLa cells (n???=???20 HeLa cells; ???250???350 bacteria). Data are represented as percentage of N-WASP/Arp3 recruitment ?? SEM of two independent experiments ",
          "(D). **, 0.001PPt test). IR II & III???=???Interacting region II and III (S. flexneri co-expressing IcsA::BIO V382R and IcsA::BIO Y716G D717G)."
        ],
        "rois":[
          {
            "x":17,
            "y":2056,
            "x2":988,
            "y2":2735
          }
        ]
      }
    }
  },
  "1645127":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "(A) After purification steps, different concentrations of purified rgD5 protein (55 kDa) were separated by SDS-PAGE in a 12% gel and stained overnight with Coomassie Blue R-250. Lane kDa: Unstained Protein MW Marker (Fermentas/Thermo Fisher Scientific); Lane 10: 10 ??g rgD5; Lane 5: 5 ??g rgD5; Lane 2: 2 ??g of rgD5; "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":1828,
            "y2":1044
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot was performed with mouse monoclonal antibody (MAb) Anti-6xHis HRP conjugated (Anti-6xHis) or with polyclonal antibodies (PAb) from bovine immunized with inactivated BoHV-5 (Anti-BoHV-5). Lane M: Prestained Low Range Protein MW Standard (Bio-Rad); Lane 1: Purified rgD5; Lane 2: KM71H supernatant of non-transformed yeast cells after methanol induction used as negative control."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "166143":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          ". A. ???Batch Query??? was run either using Gene symbol or JGI transcript ID and NCBI RefSeq"
        ],
        "rois":[
          {
            "x":37,
            "y":37,
            "x2":3813,
            "y2":7182
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. ???Probe Match??? found probes that identically match AQP-coding sequences"
        ],
        "rois":[
          {
            "x":37,
            "y":37,
            "x2":3813,
            "y2":7182
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. AQP-targeting probe sets were identified through BLASTN alignment of target sequence and Populus trichocarpa genome sequences (v1.1 and v2.0). Venn diagram exhibits the number of probe sets retrieved from each procedure."
        ],
        "rois":[
          {
            "x":37,
            "y":37,
            "x2":3813,
            "y2":7182
          }
        ]
      }
    }
  },
  "167134":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) or gelatin-zymography "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":998,
            "y2":1270
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). The negative control (CTRL) was represented by non-activated and untreated cells. CANP-2 present in lysates was identified by comigration with 0.5 ??g of CANP-2 standard. MMP-2 and MMP-9 were identified by their apparent molecular mass of 67 and 92 kDa, respectively, using pre-stained molecular weight markers (Bio Rad). Histograms show the quantitation of CANP-2, MMP-2 and MMP-9 levels, expressed as optical density "
        ],
        "rois":[
          {
            "x":1029,
            "y":7,
            "x2":1952,
            "y2":1270
          }
        ]
      },
      "OD":{
        "descriptions":[
          "(OD) ?? mm2, calculated after scanning densitometry and computerized analysis of gels. Results represent the mean ?? SD of three separate experiments performed with different cell populations. Statistically significant values different from positive control, represented by lysates or supernatants from LPS-activated astrocytes (LPS), are indicated with * (One-way Anova followed by Student ??? Newman ??? Keuls post hoc test; *P2, pH 7.4) in the absence (Control) or in the presence of IFN-?? (500 U/ml). E-64 (20 ??M), IA (10 mM) or PA (4 mM) were used as positive controls. Staining and destaining of the gels revealed that IFN-?? was not able to inhibit the activity of CANP-2 as well as MMP-2 and MMP-9 as already observed for E-64 and IA or PA. The percentages of inhibition, calculated in comparison to control, are reported in the lower part of Figure 4C and D."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "167564":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A. At the end of the study, various organs including tumor, liver, kidney and spleen were isolated from five individual mice and tissues were digested using microwave as described in method. Level of NCe was measured using ICP-MS. Data represents mean+SEM of 5 tissues of individual mouse"
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":1743,
            "y2":1970
          },
          {
            "x":1743,
            "y":13,
            "x2":3147,
            "y2":1948
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Agglomeration of NCe localized in vacuole in ovarian cancer tumor examined by TEM as described in Method in detail."
        ],
        "rois":[
          {
            "x":1743,
            "y":13,
            "x2":3147,
            "y2":1948
          }
        ]
      }
    }
  },
  "168296":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Trypan blue staining of cell death in N. benthamiana leaves. Pto-FLAG, pto mutant-FLAG, AvrPto, AvrPtoB, and prfD1416V-3HA constructs were transiently expressed in ProPrf:Prf-5Myc or wild-type N. benthamiana as indicated and the tissue was stained 2 days post infiltration. The bar indicates 0.5 mm. Dead cells stain dark blue in this qualitative assay. Each row is derived from a single leaf, within which relative amounts of cell death were comparable, and is representative of six replicates. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":521,
            "y2":687
          },
          {
            "x":1093,
            "y":20,
            "x2":2027,
            "y2":242
          },
          {
            "x":560,
            "y":20,
            "x2":1051,
            "y2":242
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP) using anti-HA antibodies. Immunoblots "
        ],
        "rois":[
          {
            "x":829,
            "y":744,
            "x2":2021,
            "y2":1814
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The slow-migrating form of Pto requires kinase activity and double phosphorylation. Pto-FLAG, pto mutant-FLAG, AvrPto, and Prf-3HA constructs were transiently expressed in wild-type N. benthamiana as indicated, Prf-3HA was immunoprecipitated "
        ],
        "rois":[
          {
            "x":829,
            "y":519,
            "x2":1053,
            "y2":687
          },
          {
            "x":12,
            "y":519,
            "x2":788,
            "y2":998
          },
          {
            "x":560,
            "y":298,
            "x2":1852,
            "y2":687
          }
        ]
      },
      "IB":{
        "descriptions":[
          "(IB) were performed with the antibodies indicated on the left. "
        ],
        "rois":[
          {
            "x":30,
            "y":1042,
            "x2":821,
            "y2":1627
          },
          {
            "x":1095,
            "y":744,
            "x2":1852,
            "y2":912
          },
          {
            "x":1361,
            "y":744,
            "x2":1586,
            "y2":912
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Quantification of the relative abundance of slow- and fast-migrating forms of Pto under elicitation conditions as described in B with Quantity One, Bio-Rad (adjusted volume???=???[CNT*mm2] data counts/mm2). Error bars are standard deviation of relative abundance between the same samples in independent immunoblots, probed with anti-Pto antibody."
        ],
        "rois":[
          {
            "x":829,
            "y":744,
            "x2":2021,
            "y2":1814
          }
        ]
      }
    }
  },
  "168398":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) In trans inhibition of Pto S198 and T199 phosphorylation. The slower migrating from of Pto is suppressed in trans by prfK1128A and ptoD164N, but not ptoS189A/T199A, ptoS189A and ptoT199A. Pto-5Myc, Pto-FLAG, pto mutant-FLAG, AvrPto, Prf-3HA, prfK1128A-3HA constructs were transiently expressed in wild-type N. benthamiana as indicated, Prf-3HA and prfK1128A-3HA were immunoprecipitated "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1638,
            "y2":304
          }
        ]
      },
      "IP":{
        "descriptions":[
          "(IP) using anti-HA antibodies. Immunoblots "
        ],
        "rois":[
          
        ]
      },
      "IB":{
        "descriptions":[
          "(IB) were performed with the antibodies indicated on the left. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) The slower migrating from of Pto was suppressed in trans by prfK1128A and ptoD164N, but not by ptoS189A ptoT199A and ptoS189A/T199A. Pto-5Myc, Pto-FLAG, pto mutant-FLAG, AvrPto, Prf-3HA, prfK1128A-3HA constructs were transiently expressed in wild-type N. benthamiana as indicated. Prf-3HA and prfK1128A-3HA were immunoprecipitated using anti-HA antibodies. The relative abundance of slow- and fast-migrating forms of Pto-5Myc after AvrPto recognition was quantified two days post infiltration, from anti-Myc immunoblots using Quantity One, Bio-Rad (adjusted volume???=???[CNT*mm2] data counts/mm2)."
        ],
        "rois":[
          {
            "x":0,
            "y":305,
            "x2":1638,
            "y2":1648
          }
        ]
      }
    }
  },
  "169425":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) and others."
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1317,
            "y2":841
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) and melatonin "
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) are down regulated due to the increase of pro-inflammatory cytokines and then up-regulated under the effects of cortisol rhythms. These behaviors result in the circadian variation of bio-energetic proteins "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1317,
            "y2":841
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M), which in turn drive the patterns of other components in the system. Pro-inflammatory cytokines "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1317,
            "y2":841
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P), driven by melatonin secretion, are up-regulated to peak around ???4:00AM whereas anti-inflammatory cytokines "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "171011":{
    
  },
  "171200":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Number of phage clones analyzed from each selection. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3021,
            "y2":2832
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bar graph shows the redundancy of the sequences that were identified. The 10 sequences containing T7-10B in-frame fusions are labelled with their TAIR accession on the top of the corresponding bars."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3021,
            "y2":2832
          },
          {
            "x":0,
            "y":2833,
            "x2":3021,
            "y2":3183
          }
        ]
      }
    }
  },
  "171378":{
    
  },
  "171992":{
    
  },
  "172144":{
    
  },
  "172311":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) The analysis identified 3 sets of genes: 101, 153 and 318 genes were selected after bio-panning against Pa, Pst(avrRpt2) (avr) and Pst strains respectively. The sets are represented as overlapping Venn diagrams and the number of shared genes is shown in the intersections. The union of the 3 sets produces a total of 472 genes as candidate MAMP/effector ligands. The positions of At1g66740 (AtSP7), At1g67090 (RBCS1A) and At5g47220 (ATERF-2) are shown in each set. Gene products that produced immune interactions in PPIN-1 are represented by coloured dots. "
        ],
        "rois":[
          {
            "x":20,
            "y":21,
            "x2":4005,
            "y2":2854
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Genes in the 472-gene set were annotated according to the GO categories for Biological Process and the percentage of annotations falling in each category (in bold) was compared to the percentage produced by the 26,303 genes spotted on the microarray (in brackets). Categories with significant (p"
        ],
        "rois":[
          {
            "x":21,
            "y":2902,
            "x2":4246,
            "y2":5960
          }
        ]
      }
    }
  },
  "172458":{
    
  },
  "176600":{
    
  },
  "176614":{
    
  },
  "176833":{
    
  },
  "177075":{
    
  },
  "181762":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A, C) and b12 "
        ],
        "rois":[
          {
            "x":10,
            "y":10,
            "x2":1459,
            "y2":507
          }
        ]
      },
      "C":{
        "descriptions":[
          "(A, C) and b12 "
        ],
        "rois":[
          {
            "x":10,
            "y":563,
            "x2":2039,
            "y2":1061
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B, D) to immobilized JR-CSF gp120. Two normal rabbit sera are used as non-immune controls. The results shown are representative of three independent experiments. The dashed horizontal line (???) corresponds to the half-maximal signal (EC50). HIVIG: HIV immune globulin provided by J. Mascola (VRC); DEN3: a mAb to dengue virus envelope provided by D. Burton (TSRI)."
        ],
        "rois":[
          {
            "x":1500,
            "y":70,
            "x2":2017,
            "y2":418
          },
          {
            "x":10,
            "y":10,
            "x2":1459,
            "y2":507
          }
        ]
      },
      "D":{
        "descriptions":[
          "(B, D) to immobilized JR-CSF gp120. Two normal rabbit sera are used as non-immune controls. The results shown are representative of three independent experiments. The dashed horizontal line (???) corresponds to the half-maximal signal (EC50). HIVIG: HIV immune globulin provided by J. Mascola (VRC); DEN3: a mAb to dengue virus envelope provided by D. Burton (TSRI)."
        ],
        "rois":[
          {
            "x":10,
            "y":563,
            "x2":2039,
            "y2":1061
          }
        ]
      }
    }
  },
  "182422":{
    
  },
  "183148":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(a). Whole worm extract was subjected to SDS-PAGE (T???=???10%) and transferred onto Hybond C membranes. Membrane strips containing the fractionated extract were incubated with fluorescein-labeled P40 (50 ??g; 1125 pmoles)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1778,
            "y2":4149
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) and P26 (40 ??g; 1520 pmoles) "
        ],
        "rois":[
          {
            "x":1779,
            "y":0,
            "x2":3741,
            "y2":1849
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c). After extensive washing, the bound recombinant fluorescein-labeled polypeptides were detected using an anti-fluorescein antibody labeled with peroxidase. The peroxidase activity was detected using chemiluminescence. The chemiluminescence reaction was exposed to Hyperfilm ECL (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) for 30 s in both experiments."
        ],
        "rois":[
          {
            "x":1779,
            "y":1850,
            "x2":3741,
            "y2":3636
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1779,
            "y":3637,
            "x2":3741,
            "y2":4149
          }
        ]
      }
    }
  },
  "184842":{
    
  },
  "186806":{
    
  },
  "187231":{
    
  },
  "187371":{
    
  },
  "187457":{
    
  },
  "187617":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A) Sequence of protein layering in the Bio Layer Interferometry antibody competition assay: 1) a strepatavidin-coated biosensor is loaded to saturation with 2) biotinylated recombinant human Endoglin (10 ??g/ml), then with 3) a negative control IgG1k or the M999 anti-Endoglin rat IgG2 antibodies (10 ??g/ml) prior to the addition of 4) M999, TRC105, SN6, or SN6h (10 ??g/ml). "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":759,
            "y2":620
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Wavelength shifts ",
          "(B) Wavelength shifts "
        ],
        "rois":[
          {
            "x":854,
            "y":7,
            "x2":1872,
            "y2":611
          }
        ]
      },
      "WS":{
        "descriptions":[
          "(WS) triggered by the addition of the individual anti-ENG antibodies to ENG in the presence of a ctrl antibody (blue bars), or in the presence of the anti-ENG antibody M999 (red bars). Competition with M999, calculated as (WSCTRL-WSM999)/WSCTRL*100 is indicated at the bottom of the graph. ",
          "(WS) triggered by the addition of BMP9 in addition to the individual anti-ENG antibodies. BMP9 binding inhibition, calculated as [1-(WSENGAB/WSCTRLAB)]*100, is indicated at the bottom of the graph. Results are the mean +/??? standard deviation of technical triplicates."
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Sequence of protein layering in the Bio Layer Interferometry BMP9 binding assay: 1) a strepatavidin-coated biosensor is loaded to saturation with 2) biotinylated recombinant human Endoglin (10 ??g/ml), then with 3) a negative control IgG1k or the tested anti-ENG antibodies (M999, TRC105, SN6, SN6h) (10 ??g/ml) prior to the addition of 4) BMP9 (10 ??g/ml). "
        ],
        "rois":[
          {
            "x":12,
            "y":621,
            "x2":1895,
            "y2":1501
          }
        ]
      }
    }
  },
  "187968":{
    
  },
  "188583":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) Wortmannin, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) JNK or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) phospo-AKT [p-AKT Ser473], "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) SB 203580 for 15 min before incubation alone, with IL-2 (200 U/ml), HSP70 (10 ??g/ml) or both for 2 h. Cells were then co-cultured with CD4+CD25??? T cells (E???T ratio 1???5) on 96-well plates coated with anti-CD3 antibodies (OKT3, 1 ??g/ml) in serum-free medium for 48 h. Supernatants were analyzed for IFN-??, TNF-??, IL-10 and TGF-??. Results of four independent experiments, expressed as mean fold increases or decreases in comparison to results obtained for experiments without preactivation of Tregs and without inhibitor treatment (control)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) phospo-JNK [p-JNK Thr183/Tyr185], "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) phospo-p38 MAPK [p-p38 MAPK Thr180/Tyr182] and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) phospo-ERK1/2 [p-ERK1/2 Thr202/Tyr204/Thr185/Tyr187] was determined by the bead-based multiplex assay (Luminex xMAP technology). Untreated CD4+CD25+ T cells were adjusted to 1.00 by the use of the Bio-Plex Manager 6.0 software and used to calculate the ratios. Furthermore, CD4+CD25+ T cells were treated with 5 ??M of the following intracellular signal transduction inhibitors: "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4680,
            "y2":5359
          }
        ]
      }
    }
  },
  "188892":{
    
  },
  "190398":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A), Tuto ",
          ". A) Bio-A: Collagen (Col) 1: *, vs. 90 days (PPPPTuto (PSt (PPPPPTuto (PSt (PTuto: Col 1: ???, vs. 30 days (PPSt: Col 1: ??, vs. Bio-A and Tuto at 14 days (P"
        ],
        "rois":[
          {
            "x":31,
            "y":47,
            "x2":2848,
            "y2":650
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and St "
        ],
        "rois":[
          {
            "x":2914,
            "y":47,
            "x2":5295,
            "y2":650
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) after 14, 30, 90 and 180 days post-implantation. The results are expressed as the mean ?? SEM of three experiments. Gene expression was normalized with the GAPDH gene"
        ],
        "rois":[
          {
            "x":198,
            "y":665,
            "x2":7875,
            "y2":3113
          },
          {
            "x":5364,
            "y":39,
            "x2":7726,
            "y2":650
          }
        ]
      }
    }
  },
  "191368":{
    "Figure_8.tif":{
      "96":{
        "descriptions":[
          "(E-H) and St (I???L). Percentage of positive cells for the RAM-11 antibody in the different prostheses after 14, 30, 90 and 180 days post-implantation (bottom panel). The results were expressed as the mean ?? SEM. A) Bio-A: *, vs. 14 days and 90 days (PPSt (PTuto and St (PTuto and St (PTuto and St (PTuto: ??, vs. 30 days (PPPPSt: ??, vs. 90 days (PPTuto (PTuto (PTuto (P"
        ],
        "rois":[
          
        ]
      },
      "07":{
        "descriptions":[
          "(E-H) and St (I???L). Percentage of positive cells for the RAM-11 antibody in the different prostheses after 14, 30, 90 and 180 days post-implantation (bottom panel). The results were expressed as the mean ?? SEM. A) Bio-A: *, vs. 14 days and 90 days (PPSt (PTuto and St (PTuto and St (PTuto and St (PTuto: ??, vs. 30 days (PPPPSt: ??, vs. 90 days (PPTuto (PTuto (PTuto (P"
        ],
        "rois":[
          
        ]
      },
      "17":{
        "descriptions":[
          "(E-H) and St (I???L). Percentage of positive cells for the RAM-11 antibody in the different prostheses after 14, 30, 90 and 180 days post-implantation (bottom panel). The results were expressed as the mean ?? SEM. A) Bio-A: *, vs. 14 days and 90 days (PPSt (PTuto and St (PTuto and St (PTuto and St (PTuto: ??, vs. 30 days (PPPPSt: ??, vs. 90 days (PPTuto (PTuto (PTuto (P"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1233,
            "y2":853
          }
        ]
      },
      "27":{
        "descriptions":[
          "(E-H) and St (I???L). Percentage of positive cells for the RAM-11 antibody in the different prostheses after 14, 30, 90 and 180 days post-implantation (bottom panel). The results were expressed as the mean ?? SEM. A) Bio-A: *, vs. 14 days and 90 days (PPSt (PTuto and St (PTuto and St (PTuto and St (PTuto: ??, vs. 30 days (PPPPSt: ??, vs. 90 days (PPTuto (PTuto (PTuto (P"
        ],
        "rois":[
          {
            "x":40,
            "y":15,
            "x2":2164,
            "y2":2257
          },
          {
            "x":1248,
            "y":1565,
            "x2":2164,
            "y2":2257
          },
          {
            "x":467,
            "y":2404,
            "x2":3849,
            "y2":3428
          },
          {
            "x":2183,
            "y":15,
            "x2":4032,
            "y2":2257
          }
        ]
      }
    }
  },
  "191545":{
    
  },
  "191580":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          ". Caspase-3 activity were determined using the specific substrate Ac-DEVDPNA; HepG2 cells were treated with 10 ??M ABT-737, 1.25 ??M Celastrol and the combination for 24 h. E"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "F":{
        "descriptions":[
          ". Bel-7402 and HepG2 cells were stained with JC-1, then observed by Leica DMI 400B Xuorescence microscope; F"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "G":{
        "descriptions":[
          ". protein levels of Bax, Bcl-2, Bcl-xL and Mcl-1 in HepG2 and Bel-7402 cells were detected by western blotting analysis. The density of the protein band was determined by using Bio-Rad Quantity One imaging software; G"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Cells were treated with 10 ??M ABT-737, 1.25 ??M Celastrol and the combination for 24, 48, 72 hours and apoptosis was tested by propidium iodide staining of lysed cell nuclei, analyzed by Flow Cytometry. B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "C":{
        "descriptions":[
          ". After treatment 10 ??M ABT-737, 1.25 ??M Celastrol and the combination for 72 hours, cells were stained with DAPI and observed by Leica DMI 400B Xuorescence microscope. Cells were treated with 10 ??M ABT-737, 1.25 ??M Celastrol and the combination for 24 h; C"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      },
      "D":{
        "descriptions":[
          ". lysates were harvested and immunobloted with caspase-3, cleaved caspase-3 and PARP antibodies; D"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2372,
            "y2":3207
          }
        ]
      }
    }
  },
  "191769":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          ". The ratios of cleaved-PARP/Actin. The density of the protein band was determined by using Bio-Rad Quantity One imaging software. E"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2273,
            "y2":2159
          }
        ]
      },
      "A":{
        "descriptions":[
          "HepG2 cells were transfected with NOXA siRNA according to manufacturer???s recommendations. Forty-eight hours after transfection, cells were treated with10 ??M ABT-737, 1.25 ??M Celastrol and the combination for 48 h. A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2273,
            "y2":2159
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Lysates were harvested and immunobloted with NOXA antibody. B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2273,
            "y2":2159
          }
        ]
      },
      "C":{
        "descriptions":[
          ". Lysates were harvested and immunobloted with cleaved caspase-3 and PARP antibodies. C"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2273,
            "y2":2159
          }
        ]
      },
      "D":{
        "descriptions":[
          ". The ratios of cleaved-caspase 3/??-Actin. D"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2273,
            "y2":2159
          }
        ]
      }
    }
  },
  "199743":{
    
  },
  "2015607":{
    
  },
  "2015613":{
    
  },
  "2015619":{
    
  },
  "2022090":{
    
  },
  "202939":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Daily changes in GSH levels in wild type CS males. Data represents average values ?? SEM obtained from 4 independent bio-replicates (total N???=???8). Data were analyzed by a 1-way ANOVA and Bonferroni's post-tests where an asterisk marks significantly lower values relative to ZT 0 (pper01 and cyc01 mutants such that no statistical difference was detected between time points where control CS flies showed a peak (ZT 0) and a trough (ZT 8). Bars represent average values ?? SEM obtained from 3???4 independent bio-replicates (?? SEM). Data in "
        ],
        "rois":[
          {
            "x":14,
            "y":924,
            "x2":1507,
            "y2":1770
          },
          {
            "x":13,
            "y":13,
            "x2":1163,
            "y2":848
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) were analyzed by a 2-way ANOVA and Bonferroni's post-tests. Different subscript letters indicate significant difference between treatment groups. ZT???=???Zeitgeber Time."
        ],
        "rois":[
          {
            "x":14,
            "y":924,
            "x2":1507,
            "y2":1770
          }
        ]
      }
    }
  },
  "202994":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) The non-functionalized micro-fabricated Si force sensor with a flat probe and with known force-deflection relation is manipulated by a high-resolution x-y-z Piezo-stage to contact cell islands' lateral convex surface (on x-y plane). "
        ],
        "rois":[
          {
            "x":7,
            "y":96,
            "x2":683,
            "y2":538
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Confocal microscopy of cell islands show the height of islands is on the order of 30???50 ??m. The vertical height of bio-MEMS probe is 5???10 ??m. "
        ],
        "rois":[
          {
            "x":7,
            "y":626,
            "x2":721,
            "y2":1101
          },
          {
            "x":667,
            "y":7,
            "x2":1824,
            "y2":604
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) After a 2-minute contact, force sensor is horizontally pulled away at a constant speed of 2.1??0.4 ??m/s. While the cell adhesion between the probe and cell surface hinders retraction of the sensor, the sensor beams deform by ??, giving the force F. Note that the probe is not functionalized. The 2-minute contact between the probe and cells prevents the activation of cell integrins and the formation of any cell focal adhesion, which takes >30 minutes to form."
        ],
        "rois":[
          {
            "x":769,
            "y":636,
            "x2":1963,
            "y2":1101
          }
        ]
      }
    }
  },
  "203045":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) is abolished while GS mRNA is not affected "
        ],
        "rois":[
          {
            "x":1457,
            "y":1190,
            "x2":1991,
            "y2":1656
          },
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":871,
            "y":7,
            "x2":1438,
            "y2":537
          },
          {
            "x":11,
            "y":620,
            "x2":846,
            "y2":1110
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F). In per01 mutants, the trough-to-peak differences in Gclc "
        ],
        "rois":[
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":9,
            "y":1174,
            "x2":843,
            "y2":1666
          },
          {
            "x":871,
            "y":7,
            "x2":1438,
            "y2":537
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and Gclm "
        ],
        "rois":[
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":8,
            "y":28,
            "x2":848,
            "y2":551
          },
          {
            "x":1465,
            "y":17,
            "x2":2000,
            "y2":535
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I). Different subscript letters in (D???I) indicate a significant difference between treatment groups. All graphs are average values obtained from 3???5 independent bio-replicates (?? SEM) and normalized to ZT 0 or ZT 4 as appropriate."
        ],
        "rois":[
          
        ]
      },
      "G":{
        "descriptions":[
          "(G) and Gclm "
        ],
        "rois":[
          {
            "x":9,
            "y":1174,
            "x2":843,
            "y2":1666
          },
          {
            "x":871,
            "y":7,
            "x2":1438,
            "y2":537
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) mRNA but not in GS mRNA profile "
        ],
        "rois":[
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":1457,
            "y":578,
            "x2":1998,
            "y2":1101
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Data for (A???C) were analyzed by a 1-way ANOVA and Bonferroni's post-tests, and an asterisk marks significantly higher values relative to the lowest value (pcyc01 mutants, the peak in Gclc "
        ],
        "rois":[
          {
            "x":1457,
            "y":1190,
            "x2":1991,
            "y2":1656
          },
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":9,
            "y":1174,
            "x2":843,
            "y2":1666
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) are abolished while GS is not changed "
        ],
        "rois":[
          {
            "x":864,
            "y":607,
            "x2":1435,
            "y2":1101
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) and Gclm "
        ],
        "rois":[
          {
            "x":1457,
            "y":1190,
            "x2":1991,
            "y2":1656
          },
          {
            "x":864,
            "y":1168,
            "x2":1415,
            "y2":1656
          },
          {
            "x":8,
            "y":28,
            "x2":848,
            "y2":551
          }
        ]
      }
    }
  },
  "203085":{
    
  },
  "203153":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) total Gclc mRNA levels were also significant when "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":998,
            "y2":618
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gclc-RA and "
        ],
        "rois":[
          {
            "x":12,
            "y":691,
            "x2":998,
            "y2":1301
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Gclc-RB isoforms were measured separately using isoform-specific primers. The two isoforms share the same coding regions, but have distinct 5??? UTR regions. All graphs are average values obtained from 3 independent bio-repeats each normalized to the time point with the lowest expression. An asterisk indicates significant difference from the trough based on a 1-way ANOVA and Bonferroni's post-tests (p"
        ],
        "rois":[
          {
            "x":10,
            "y":1382,
            "x2":998,
            "y2":2055
          }
        ]
      }
    }
  },
  "203187":{
    
  },
  "203234":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) tim and "
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":1193,
            "y2":753
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Gclm mRNA expression show a circadian rhythm in heads of CS flies on the second day of constant darkness. An asterisk indicates a significant difference in the expression level between the trough of each gene and the peak (pGclc mRNA levels in wild type flies. Data represents average values obtained from 3 independent bio-replicates (?? SEM) and normalized to ZT 0. Significance was calculated by a 1-way ANOVA and Bonferroni's multiple comparison post-tests. CT???=???Circadian Time. Shaded horizontal bars indicate subjective day."
        ],
        "rois":[
          {
            "x":12,
            "y":774,
            "x2":1196,
            "y2":2397
          }
        ]
      }
    }
  },
  "2032818":{
    
  },
  "203322":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) GCLm and "
        ],
        "rois":[
          {
            "x":9,
            "y":8,
            "x2":1113,
            "y2":736
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) GCLc protein levels based on average densitometry of signals obtained on Western blots with anti-GCLc or anti-GCLm antibodies normalized to signals obtained with anti-actin antibodies. Each replicate was normalized to the time point with the lowest expression. "
        ],
        "rois":[
          {
            "x":15,
            "y":809,
            "x2":1113,
            "y2":1542
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Ratio of GCLc to GCLm protein over the circadian day in wild type CS males. (A???C) Data represent average values ?? SEM obtained from 8 immunoblots performed with 4 independent bio-replicates. Statistical significance was determined by a 1-way ANOVA and Dunnett's post-test as denoted by asterisks (p"
        ],
        "rois":[
          {
            "x":11,
            "y":1592,
            "x2":1109,
            "y2":2420
          }
        ]
      }
    }
  },
  "203427":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "(A) Daily profile of GCL activity in heads of CS flies as measured by the formation of the GCL product, ??-GC. Data represents average values ?? SEM obtained from 4 independent bio-replicates (total N???=???16). An asterisk indicates a significant difference between the peak and trough time points calculated by 1-way ANOVA and Bonferroni post-tests. "
        ],
        "rois":[
          {
            "x":10,
            "y":8,
            "x2":930,
            "y2":644
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) GCL activity was altered in per01 and cyc01 mutants such that no statistical difference was detected between time points where control CS flies showed peak at (ZT 0) and trough (ZT 8). Bars show average values ?? SEM obtained from 4???5 independent bio-replicates (total N???=???16). Data in ",
          "(B) are analyzed by 2-way ANOVA and Bonferroni's post-tests. Different subscript letters indicate significant differences between treatment groups (p"
        ],
        "rois":[
          {
            "x":8,
            "y":726,
            "x2":1130,
            "y2":1312
          }
        ]
      }
    }
  },
  "203505":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) A circadian rhythm in GstD1 mRNA levels was detected in wild type "
        ],
        "rois":[
          {
            "x":29,
            "y":12,
            "x2":1550,
            "y2":1092
          }
        ]
      },
      "CS":{
        "descriptions":[
          "(CS) flies with a peak at ZT 8 significantly different from the trough at ZT 20 (pper01 and cyc01 flies while the difference was observed in CS heads (p"
        ],
        "rois":[
          {
            "x":12,
            "y":1141,
            "x2":1552,
            "y2":2177
          }
        ]
      }
    }
  },
  "203983":{
    
  },
  "205583":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A). Analysis of ADAADiK on silica 60A plate by TLC after purification using Bio-Rex 70 followed by G-15 desalting column. Kanamycin (lanes 1-6), ADAADiK (lanes 7???9), and phosphokanamycin (lanes 18???19) migrate with different mobilities and thus can be separated on these plates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2058,
            "y2":1432
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Inhibition profile of fractions eluted from G-15 column. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C). Purification of ADAAD using TSK gel SP-5PW column. The ninhydrin sensitive spots (fractions 15???20) correspond to phosphokanamycin and kanamycin, while the ADAADiK concentration (fractions 9???14) is too low to be detected by ninhydrin. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2058,
            "y2":1432
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Inhibition profile of fractions eluted from SP column."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2058,
            "y2":1432
          }
        ]
      }
    }
  },
  "2063853":{
    
  },
  "207641":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-function analysis and comparison; "
        ],
        "rois":[
          {
            "x":6,
            "y":7,
            "x2":2058,
            "y2":157
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Tox-function analysis and comparison."
        ],
        "rois":[
          {
            "x":4,
            "y":194,
            "x2":2058,
            "y2":332
          }
        ]
      }
    }
  },
  "207745":{
    "Figure_10.tif":{
      "A":{
        "descriptions":[
          "(A) Bio-function analysis; "
        ],
        "rois":[
          {
            "x":15,
            "y":18,
            "x2":1752,
            "y2":5026
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Tox-function analysis."
        ],
        "rois":[
          {
            "x":2221,
            "y":18,
            "x2":3950,
            "y2":4215
          }
        ]
      }
    }
  },
  "2081416":{
    
  },
  "208653":{
    "Figure_3.tif":{
      "CA":{
        "descriptions":[
          "Human lung slices were exposed to 6??106 PFU/ml of PR8 or OK/09 for 4 h, 8 h, 12 h, 16 h, 24 h, and 32 h. Total RNA was then isolated from lung slices. Quantitative RT-PCR was performed using 100 ng sample RNA and SYBR Green (Quanta Biosciences) in a BIO-RAD iCycler IQ instrument (Hercules, CA)"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          ". Transcript levels of RIG-1 (A)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          " and IFN-?? (B)"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1892,
            "y2":1967
          }
        ]
      }
    }
  },
  "209598":{
    
  },
  "209695":{
    "Figure_2.tif":{
      "6":{
        "descriptions":[
          ", 6.48 and 5.9 respectively); the curves represent a quadratic link between mean and variance ( with ???=???4.4"
        ],
        "rois":[
          {
            "x":10,
            "y":9,
            "x2":2362,
            "y2":2320
          },
          {
            "x":11,
            "y":9,
            "x2":1105,
            "y2":1062
          }
        ]
      },
      "8":{
        "descriptions":[
          ", 8.9 and 1.1 respectively)."
        ],
        "rois":[
          {
            "x":1268,
            "y":1264,
            "x2":2362,
            "y2":2331
          }
        ]
      }
    }
  },
  "209820":{
    
  },
  "209940":{
    
  },
  "211357":{
    
  },
  "211577":{
    
  },
  "211668":{
    
  },
  "213686":{
    
  },
  "215448":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "E. coli and P. aeruginosa both contain bioH but P. aeruginosa has bioH within its bio operon upstream of bioC whereas the E. coli bioH is located elsewhere on the chromosome"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2346,
            "y2":1217
          },
          {
            "x":0,
            "y":1218,
            "x2":2346,
            "y2":1476
          }
        ]
      },
      "H":{
        "descriptions":[
          ". H. influenzae and C. jejuni have bioG within their bio operons upstream of bioC"
        ],
        "rois":[
          {
            "x":0,
            "y":1218,
            "x2":2346,
            "y2":1476
          },
          {
            "x":0,
            "y":1477,
            "x2":2346,
            "y2":1854
          }
        ]
      },
      "N":{
        "descriptions":[
          ". N. meningitidis has both bioH and bioG upstream of separate copies of bioC"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". B. fragilis encodes a fusion of BioC and BioG. In place of BioG or BioH, most BioC-containing cyanobacteria carrying, such as Synechococcus spp. and P. marinus, have bioK upstream of bioC."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "215651":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "E. coli strain STL24 (??bioH) was transformed with derivative of pBAD322 carrying various bioG or bioK genes. The transformants were streaked on M9 agar plates in the pattern shown on the plate diagram containing the carbon source shown in either the presence or absence of biotin (bio). All plates were incubated at 37??C except those expressing P. marinus bioK which were incubated at 25??C. To prevent cross-feeding plates divided into three zones by plastic walls were used"
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          ". Panel A. Arabinose as carbon source, STL24 ??bioH transformed with pBAD322 carrying no insert (lower left third), expressing bioG or bioK (top third of each plate) and the wild type strain transformed with pBAD322 (lower right of each plate)"
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":478,
            "y2":786
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B. The inoculation pattern was the same as Panel A and glycerol was the carbon source in place of arabinose"
        ],
        "rois":[
          {
            "x":9,
            "y":900,
            "x2":455,
            "y2":1312
          },
          {
            "x":523,
            "y":8,
            "x2":869,
            "y2":429
          },
          {
            "x":545,
            "y":449,
            "x2":875,
            "y2":828
          },
          {
            "x":882,
            "y":425,
            "x2":1702,
            "y2":1305
          },
          {
            "x":908,
            "y":8,
            "x2":1239,
            "y2":429
          },
          {
            "x":1293,
            "y":9,
            "x2":1612,
            "y2":410
          }
        ]
      },
      "C":{
        "descriptions":[
          ". Panel C. The streaking pattern is given by the plate diagram. Arabinose was the carbon source and the test strain was E. coli strain STL25 (??bioC??bioH) transformed with pBAD322 carrying no insert (lower left third), bioGC (top third) or the wild type strain transformed with the vector pBAD322 (lower right third)."
        ],
        "rois":[
          {
            "x":483,
            "y":906,
            "x2":804,
            "y2":1311
          },
          {
            "x":1359,
            "y":940,
            "x2":1668,
            "y2":1240
          }
        ]
      }
    }
  },
  "2161657":{
    
  },
  "217212":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A. Structural comparison of biological models (top panels) with bio-inspired vehicles (bottom) used for experimental comparisons (both are 16.4 cm diameter). Only flap versions of the robotic vehicles are shown"
        ],
        "rois":[
          {
            "x":11,
            "y":12,
            "x2":1326,
            "y2":751
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Comparison of the maximum normalized swimming speeds of jellyfish vehicles with representative values for their natural counterparts, Aurelia aurita (14.7 cm diameter) and Cyanea capillata (10 cm diameter)"
        ],
        "rois":[
          {
            "x":18,
            "y":718,
            "x2":1338,
            "y2":2001
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Comparison of the normalized swimming speed averaged over the swimming cycle. The Reynolds numbers (Re) shown are averages over 3 swimming cycles. We examined a flap and a no-flap version of both the A. aurita and C. capillata vehicle models (icons illustrate each version). Bars are the mean values over 3 consecutive swimming cycles (?? st.dev.)"
        ],
        "rois":[
          {
            "x":18,
            "y":718,
            "x2":1338,
            "y2":2001
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Bell kinematics at of no-flap and flap vehicles and live Aurelia during bell contraction. Scale represents 1 cm."
        ],
        "rois":[
          {
            "x":24,
            "y":2037,
            "x2":1296,
            "y2":2662
          }
        ]
      }
    }
  },
  "219800":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Sepharcyl S100 ??KTA FPLC of purified hep-ATIII. A 9???14 ml fraction was separated, termed as hep-ATIII and used for our experiments. Detection at 260 nm for protein detection and 280 nm for heparin detection is shown. "
        ],
        "rois":[
          {
            "x":15,
            "y":27,
            "x2":2073,
            "y2":2335
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Hep-ATIII purity and molecular weight were also determined by SDS-PAGE and silver staining (Bio-Rad kit) of a 15% slab gel. For molecular weight determination a low-range protein molecular weight marker (Bio-Rad) was used. Lane 1???2 ??g hep-ATIII; lane 2: phosphorylase B (97 kDa), serum albumin (69 kDa), carbonic anhydrase (31 kDa), trypsin inhibitor (21.5 kDa), aprotinin (6.5 kDa)."
        ],
        "rois":[
          {
            "x":2393,
            "y":13,
            "x2":3426,
            "y2":1556
          }
        ]
      }
    }
  },
  "220987":{
    
  },
  "221879":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) female gill and "
        ],
        "rois":[
          {
            "x":12,
            "y":12,
            "x2":1695,
            "y2":677
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) penis from a threshold of 10???8 M. No activity on "
        ],
        "rois":[
          {
            "x":19,
            "y":750,
            "x2":1892,
            "y2":1225
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) rectum. ??3-induced contraction on "
        ],
        "rois":[
          {
            "x":16,
            "y":1368,
            "x2":1866,
            "y2":2667
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) penis from a threshold of 10???9 M."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "224708":{
    
  },
  "226917":{
    
  },
  "229196":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "Panel A: 10???20% SDS-PAGE gel stained with Bio-Safe Coomassie. Lane 1, molecular mass markers; lane 2, 10 ??g Pdu MCPs purified from wild-type Salmonella; lane 3, 10 ??g Pdu MCPs purified from a pduQ deletion mutant BE903"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1682,
            "y2":1808
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B: Western blot with antisera against PduQ peptide (51???64). Lane 1, 10 ??g Pdu MCPs purified from wild-type Salmonella; lane 2, 10 ??g Pdu MCPs purified from ??pduQ mutant BE903."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "231455":{
    "Figure_8.tif":{
      "E":{
        "descriptions":[
          "(E) STMN1 protein level in miR-101 mimics or inhibitor-treated T47D cells was detected by western blot. The bands were analyzed using the Quantity One analyzing system (Bio-Rad Laboratory inc.). The expression of ??-ACTIN served as an internal control. The black histogram represents the optical densities of the signals quantified by densitometric analysis and represented as STMN1 intensity/??-ACTIN intensity to normalize for gel loading and transfer. "
        ],
        "rois":[
          {
            "x":0,
            "y":555,
            "x2":2223,
            "y2":2395
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) The expression of Stmn1 mRNA in miR-101 mimics and inhibitor-treated T47D cells were detected by qRT-PCR. ??-actin serves as an internal reference among different samples and helps normalize for experimental error. The y-axis displays the relative log2 ratio of Stmn1 normalized by ??-actin. *PP"
        ],
        "rois":[
          {
            "x":0,
            "y":555,
            "x2":2223,
            "y2":2395
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) MiR-101 binding sites in the 3???-UTR region of Stmn1 in cross-species. "
        ],
        "rois":[
          {
            "x":800,
            "y":262,
            "x2":1165,
            "y2":554
          },
          {
            "x":1166,
            "y":0,
            "x2":2223,
            "y2":554
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Schematic diagram for constructing the miR-101 binding site into pGL3 control vector. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1165,
            "y2":554
          },
          {
            "x":800,
            "y":262,
            "x2":1165,
            "y2":554
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Confirmation of the target gene of miR-101. T47D cells were co-transfected with pre-miR control, miR-101 mimics, anti-miR control or miR-101 inhibitor and Stmn1-pGL3 for dual-luciferase assay. PRL-TK containing Renilla luciferase was co-transfected with 3???-UTR of Stmn1 for data normalization. "
        ],
        "rois":[
          {
            "x":800,
            "y":262,
            "x2":1165,
            "y2":554
          },
          {
            "x":0,
            "y":555,
            "x2":2223,
            "y2":2395
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Mutation analysis of the miR-101 binding site. When the binding site of miR-101 in the 3???-UTR of Stmn1 was completely deleted (Stmn1-pGL3-Mutant), the luciferase activity was significantly decreased in T47D cells co-transfected with miR-101 mimics and Stmn1-pGL3 compared with Stmn1-pGL3-Mutant or pGL3. "
        ],
        "rois":[
          {
            "x":800,
            "y":262,
            "x2":1165,
            "y2":554
          },
          {
            "x":0,
            "y":555,
            "x2":2223,
            "y2":2395
          }
        ]
      }
    }
  },
  "231560":{
    "Figure_9.tif":{
      "A":{
        "descriptions":[
          "(A) The protein level of STMN1 in human breast cancer tissues was detected by western blot. The bands were analyzed using the Quantity One analyzing system (Bio-Rad Laboratory inc.). The expression of ??-ACTIN served as an internal control. The black histograms represent the expression level of STMN1 in breast cancer tissues of all (A1), ER/PR???,HER2???(A2), ER/PR+, HER2+ (A3), ER/PR+, HER2??? (A4) and ER/PR???,HER2+(A5) and expressed as STMN1 intensity/??-ACTIN intensity to normalize for gel loading and transfer. N represents non-tumor tissues, and T represents tumor tissues. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2229,
            "y2":1720
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The mRNA level of Stmn1 in human breast cancer tissues and adjacent normal breast tissues was detected by qRT-PCR. The expression level of Stmn1 was obviously increased in 83.33% individual sample. Statistical analyses were performed to analyze the overall trend of Stmn1 in human breast cancer tissues of all (B1), ER/PR???,HER2??? (B2), ER/PR+, HER2+ (B3), ER/PR+, HER2??? (B4) and ER/PR???, HER2+ (B5). ??-actin serves as an internal reference. The y-axis displays the relative log2 ratio of Stmn1 normalized to ??-actin. *PP"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2229,
            "y2":1720
          },
          {
            "x":0,
            "y":1721,
            "x2":2229,
            "y2":2367
          }
        ]
      }
    }
  },
  "233228":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(C,E) This strain panel was plated on Pseudomonas Isolation Agar (PIA) and "
        ],
        "rois":[
          {
            "x":15,
            "y":1454,
            "x2":787,
            "y2":1873
          }
        ]
      },
      "F":{
        "descriptions":[
          "(D,F) LB and incubated at 37??C for 2 days. Bioluminescence was detected in Bio-Rad XRS Chemidoc Imaging system. The colonies are depicted using epi white illumination (left panel) and corresponding exoS-lux expression using bioluminescence imaging (lower panel). Each experiment was performed at least three times and representative values and images are shown."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) Mucoid (FRD1, PAO1mucA22) and non-mucoid (FRD2, PAO1) P. aeruginosa strains encoding a chromosomal exoS-lux fusion as a reporter for the T3SS were grown in LB and "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":837,
            "y2":561
          },
          {
            "x":809,
            "y":608,
            "x2":1585,
            "y2":2306
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) BM2 (0.5 mM Mg2+, 0.2 mM Ca2+) planktonic cultures. Gene expression was measured every 20 minutes for 18 hours and the maximal gene expression is shown. The values shown are the means from experiments done in triplicate and the error bars represent the standard deviation. All values from mucoid strains (FRD1, mucA22) differ significantly (pt-test) from the corresponding non-mucoid controls (FRD2, PAO1). "
        ],
        "rois":[
          {
            "x":802,
            "y":7,
            "x2":1580,
            "y2":566
          },
          {
            "x":17,
            "y":1893,
            "x2":785,
            "y2":2306
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,E) This strain panel was plated on Pseudomonas Isolation Agar (PIA) and "
        ],
        "rois":[
          {
            "x":13,
            "y":609,
            "x2":789,
            "y2":1017
          },
          {
            "x":17,
            "y":1893,
            "x2":785,
            "y2":2306
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D,F) LB and incubated at 37??C for 2 days. Bioluminescence was detected in Bio-Rad XRS Chemidoc Imaging system. The colonies are depicted using epi white illumination (left panel) and corresponding exoS-lux expression using bioluminescence imaging (lower panel). Each experiment was performed at least three times and representative values and images are shown."
        ],
        "rois":[
          {
            "x":17,
            "y":1893,
            "x2":785,
            "y2":2306
          },
          {
            "x":10,
            "y":1032,
            "x2":789,
            "y2":1438
          }
        ]
      }
    }
  },
  "233557":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A) Copper "
        ],
        "rois":[
          {
            "x":29,
            "y":28,
            "x2":585,
            "y2":1156
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I)-catalyzed cycloaddition (CCCA) reaction between azide and alkyne incorporated to GFPhs-r5M resulted in the formation of triazole-linked protein-protein dimer bio-conjugation. "
        ],
        "rois":[
          {
            "x":38,
            "y":1575,
            "x2":1455,
            "y2":2333
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) SDS-PAGE analysis of CCCA reaction between GFPhs-r5M proteins incorporated with Hpg (alkyne) and Aha (azide group). Lane 1: CCCA reaction without catalysis agents, CuSO4 and L-ascorbic acid; lane 2: CCCA reaction with catalysis agents, CuSO4 and L-ascorbic acid. This result shows the formation of triazole-linked protein-protein bio-conjugation of GFPhs-r5M dimer. M is molecular weight marker, thick arrow indicates the protein-protein conjugated GFPhs-r5M dimer of 55.2 kDa and grey arrow indicates the 27.6 kDa monomer of GFPhs-r5M containing Hpg and Aha respectively."
        ],
        "rois":[
          {
            "x":1432,
            "y":29,
            "x2":2729,
            "y2":2411
          },
          {
            "x":23,
            "y":1116,
            "x2":1389,
            "y2":1549
          },
          {
            "x":704,
            "y":343,
            "x2":1447,
            "y2":1120
          }
        ]
      }
    }
  },
  "233722":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A)",
          " HEK293 reporter cells were incubated with CGK062 in the presence of 0.75 ??M BIO. In (A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":244,
            "y2":801
          }
        ]
      },
      "B":{
        "descriptions":[
          " HEK293 reporter cells were incubated with CGK062 in the presence of 20 mM LiCl. (B)",
          " and (B)"
        ],
        "rois":[
          {
            "x":245,
            "y":0,
            "x2":2012,
            "y2":801
          },
          {
            "x":0,
            "y":802,
            "x2":2012,
            "y2":1918
          }
        ]
      },
      "P":{
        "descriptions":[
          ", after 15 h, luciferase activities were determined and reported as relative light unit (RLU) normalized to cell titer. The results are the average of three experiments, and the bars indicate standard deviations. *, P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "234722":{
    
  },
  "237308":{
    
  },
  "237748":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) 5??? 32P-labelled CopT RNA was incubated for 2 min at 37??C in the presence of Kid or CcdB prior to separation on 8% polyacrylamide gels in the presence of urea. Tracks: 1, C???, untreated full-length ",
          "(A): Total RNA (uncleaved and cleaved products) was calculated for each track scanning the different bands using the Quantity One?? program (Bio-Rad). RNase activity was calculated as the percentage of full length RNA substrate. The average value for each condition was calculated from three independent experiments. The 100% value indicates absence of RNase activity. The standard deviation is indicated above the different bars. A Student's t-test indicated that the differences between values in lanes 2 and 3, linked with a bracket, were significant (p-value???=???0.0067). ** Represents a p-value???0.01."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1038,
            "y2":1139
          }
        ]
      },
      "FL":{
        "descriptions":[
          "(FL) RNA; 2, RNA treated with 0.2 ??M Kid; 3, RNA treated with 0.2 ??M Kid and 0.2 ??M Kis; 4, RNA treated with 0.2 ??M Kid and 0.2 ??M CcdA; 5, RNA treated with 0.2 ??M CcdA; 6, RNA treated with 0.2 ??M CcdB; 7, RNA treated with 0.2 ??M CcdA and 0.2 ??M CcdB; 8, RNA treated with 0.2 ??M Kid and 1.5 ??M BSA; 9, RNA treated with 0.2 ??M Kid and 0.2 ??M CcdB. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bar graph representation and quantitative analysis of data in "
        ],
        "rois":[
          {
            "x":1032,
            "y":237,
            "x2":2020,
            "y2":1169
          }
        ]
      }
    }
  },
  "237799":{
    "Figure_8.tif":{
      "E":{
        "descriptions":[
          ", FYJ105 (??fadR), FYJ133 (??arcA), FYJ134 (??crp), FYJ141 (??arcA ??fadR), FYJ142 (??crp ??fadR), FYJ169 (??crp ??arcA), and FYJ170 (??crp ??arcA ??fadR), respectively. E"
        ],
        "rois":[
          {
            "x":8,
            "y":1954,
            "x2":1319,
            "y2":2689
          }
        ]
      },
      "A":{
        "descriptions":[
          "A"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1179,
            "y2":806
          }
        ]
      },
      "WT":{
        "descriptions":[
          ". Modulation of LacZ activity of the fadBA-lacZ transcriptional fusion by different regulatory proteins under anaerobic conditions. The fadBA-lacZ strains were SI203 (WT)",
          ". Transcriptional control of the fadH-lacZ fusion by different regulatory proteins under anaerobic conditions. The fadH-lacZ fusion strains were FYJ55 (WT)",
          ". Effect on fadL transcriptional levels by different regulatory proteins under anaerobic conditions. The fadL-lacZ were FYJ104 (WT)",
          ". Regulation of fadD transcription by different regulatory proteins under anaerobic conditions. The fadD-lacZ fusion strains were FYJ159 (WT)"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ". Alignments of the ArcA-P binding sites of with those of other fad regulon genes. Red background indicates strictly conserved bases whereas yellow background denotes less conserved bases. B"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1179,
            "y2":806
          }
        ]
      },
      "P":{
        "descriptions":[
          ", FYJ161 (??fadR), FYJ162 (??arcA), FYJ163 (??crp), FYJ164 (??arcA ??fadR), FYJ165 (??crp ??fadR), FYJ166 (??crp ??arcA), and FYJ167 (??crp ??arcA ??fadR), respectively. The strains were grown on LB agar plates supplemented with 5 mM nitrate (KNO3) as the electron receptor. Anaerobic environments were generated using Bio-Bag environmental chamber type A as described [17]. beta-Galactosidase activities were recorded from at least six independent assays and are expressed as means ?? standard deviations. *, P"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          ", SI207 (??fadR), FYJ82 (??arcA), FYJ83 (??crp), FYJ84 (??arcA ??fadR), FYJ85 (??crp ??fadR), FYJ86 (??crp ??arcA) and FYJ87 (??crp ??arcA ??fadR), respectively. C"
        ],
        "rois":[
          {
            "x":7,
            "y":820,
            "x2":1178,
            "y2":1364
          }
        ]
      },
      "D":{
        "descriptions":[
          ", FYJ56 (??fadR), FYJ64 (??arcA), FYJ65 (??crp), FYJ68 (??arcA ??fadR), FYJ81 (??crp ??fadR), FYJ79 (??crp ??arcA) and FYJ80 (??crp ??arcA ??fadR), respectively. D"
        ],
        "rois":[
          {
            "x":9,
            "y":1382,
            "x2":1177,
            "y2":1932
          }
        ]
      }
    }
  },
  "238677":{
    "Figure_5.tif":{
      "a":{
        "descriptions":[
          "(a) Dependency network of changes from baseline to the end of the low calorie diet. "
        ],
        "rois":[
          {
            "x":8,
            "y":15,
            "x2":815,
            "y2":848
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Dependency network of changes from baseline to the end of the weight maintenance diet."
        ],
        "rois":[
          {
            "x":873,
            "y":7,
            "x2":1628,
            "y2":765
          }
        ]
      }
    }
  },
  "2389504":{
    
  },
  "2395216":{
    
  },
  "239831":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Measurement of protein phosphorylation in intestinal tissue lysates by Bio-Plex. The heat map is organized such that the columns represent the phospho-signal time courses, while the rows represent the experimental conditions. Different doses, regions, and genotypes are color-coded. Each phospho-signal is arranged sequentially as a function of time (left to right, 0 to 4 h). The intensity of the heat map represents the average of technical duplicates of the median fluorescence intensity (normalized to the highest value of each signal) resulting from each assay. Data are compiled from three independent experiments for each condition. "
        ],
        "rois":[
          {
            "x":0,
            "y":4,
            "x2":2041,
            "y2":676
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) A three-dimensional PLSDA model constructed using signaling time courses obtained from the different conditions and their correlating apoptotic phenotypes. Each data point represents scores generated by the model, composed of all signaling time courses of a particular experimental condition mapped onto the three-dimensional latent variable space. The three orthogonal latent variable axes separate the scores by apoptotic phenotype: LV1 by the presence or absence of apoptosis, LV2 by the magnitude of apoptosis, and LV3 by the timing of apoptosis. The percentages on the axes represent the percent variance in the dataset captured by a particular LV. "
        ],
        "rois":[
          {
            "x":0,
            "y":4,
            "x2":2041,
            "y2":676
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Loadings on LV2, the latent variable that correlates the magnitude of TNF-??-induced apoptosis. The y-axis quantifies the positive or negative contribution of a particular signal to LV2."
        ],
        "rois":[
          {
            "x":31,
            "y":639,
            "x2":2049,
            "y2":1497
          }
        ]
      }
    }
  },
  "239925":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) Measurement of cytokine protein levels in intestinal tissue lysates by Bio-Plex. The heat map is organized in a similar manner as Figure 2A. Data are compiled from three independent experiments for each condition. "
        ],
        "rois":[
          {
            "x":94,
            "y":651,
            "x2":1989,
            "y2":1396
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) A two-dimensional PLSDA model constructed using early cytokine data (0, 0.5, 1 h) obtained from the different conditions and their correlating apoptotic phenotypes. Each data point represents scores generated by the model, composed of the early time points of all cytokines measured of a particular experimental condition mapped onto the two-dimensional latent variable space. The dotted gray line represents the 95% confidence limit of the distribution of the scores. The two orthogonal latent variable axes separate the scores by apoptotic phenotype: LV1 by the magnitude of apoptosis and LV2 by the timing of apoptosis. The percentages on the axes represent the percent variance in the dataset captured by a particular LV. "
        ],
        "rois":[
          {
            "x":1,
            "y":3,
            "x2":2043,
            "y2":675
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Loadings for the PLSDA model plotted on LV1 and LV2. MCP-1 clusters most significantly with the lowest degree of apoptotic phenotype (low magnitude, late timing)."
        ],
        "rois":[
          {
            "x":1,
            "y":3,
            "x2":2043,
            "y2":675
          }
        ]
      }
    }
  },
  "240103":{
    
  },
  "240475":{
    
  },
  "241571":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(a) free DOX, "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1890,
            "y2":1448
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b)PEG-hyd-DOX; cumulative accumulation of DOX in "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1890,
            "y2":1448
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) tumor and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1890,
            "y2":1448
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) heart assayed by LC/MS/MS. (n???=???5, mean ?? SD)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1890,
            "y2":1448
          }
        ]
      }
    }
  },
  "242827":{
    "Figure_1.tif":{
      "e":{
        "descriptions":[
          "(d, e, f). In normal glucose conditions ANXA1 protein is highly expressed in WS1 fibroblast cells and accumulates at the plasma membrane and at lamellipodial extrusions (arrows). An increase of glucose levels leads to a reduction of ANXA1 expression and inhibits the relocation of the protein to the plasma membrane ",
          "(e). The data are representative of 5 experiments with similar results. Bar???=???25 ??m."
        ],
        "rois":[
          {
            "x":222,
            "y":565,
            "x2":733,
            "y2":991
          }
        ]
      },
      "f":{
        "descriptions":[
          "(d, e, f). In normal glucose conditions ANXA1 protein is highly expressed in WS1 fibroblast cells and accumulates at the plasma membrane and at lamellipodial extrusions (arrows). An increase of glucose levels leads to a reduction of ANXA1 expression and inhibits the relocation of the protein to the plasma membrane "
        ],
        "rois":[
          
        ]
      },
      "F":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":49,
            "y":7,
            "x2":639,
            "y2":524
          },
          {
            "x":914,
            "y":40,
            "x2":1243,
            "y2":528
          },
          {
            "x":1363,
            "y":40,
            "x2":1982,
            "y2":991
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a, b, c) and HG conditions "
        ],
        "rois":[
          {
            "x":769,
            "y":565,
            "x2":1331,
            "y2":982
          }
        ]
      },
      "b":{
        "descriptions":[
          "(a, b, c) and HG conditions "
        ],
        "rois":[
          {
            "x":50,
            "y":1076,
            "x2":1367,
            "y2":1721
          }
        ]
      },
      "c":{
        "descriptions":[
          "(a, b, c) and HG conditions "
        ],
        "rois":[
          {
            "x":1375,
            "y":1080,
            "x2":1956,
            "y2":1719
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d, e, f). In normal glucose conditions ANXA1 protein is highly expressed in WS1 fibroblast cells and accumulates at the plasma membrane and at lamellipodial extrusions (arrows). An increase of glucose levels leads to a reduction of ANXA1 expression and inhibits the relocation of the protein to the plasma membrane "
        ],
        "rois":[
          {
            "x":48,
            "y":1725,
            "x2":1956,
            "y2":2305
          }
        ]
      }
    }
  },
  "2444011":{
    
  },
  "24641":{
    
  }
,
  "24642":{
    
  },
  "2477407":{
    
  },
  "248116":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(panel a) from HepG2 cells after incubation with medium alone (controls), TNF-?? (10 ng/ml) and remifentanil (50 and 500 ng/ml) for 24 h or preincubation with remifentanil (50 and 500 ng/ml, 1 h incubation) followed by incubation with TNF-?? (10 ng/ml) for an additional 24 h (n???=???5) (The polyclonal antibody used is specific to recognize both the precursor procaspase-3 ???36 kDa and the mature active enzymes of 17???20 kDa following cleavage by upstream caspases) (C: control, R50: remifentanil 50 ng/ml, R500: remifentanil 500 ng/ml). Densitometric analysis of cleaved caspase protein levels "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(panel b): the protein bands were analyzed and quantified densitometrically using Quantity One software from Bio-Rad. The relative levels of cleaved caspase 3 expression were normalized to actin and the results are expressed as arbitrary units and are means+/???SD for five independent experiments. Statistical analysis for cleaved caspase 3 levels was performed by one-way analysis of variance (ANOVA): # p???=???0.002. Afterwards, all groups were divided into subgroups and subsequent one-way ANOVA was performed in the subgroups (subgroup 1: control, TNF-??, R50 and R500 (p???=???0.006); subgroup 2: TNF-??, R50+TNF-?? and R500+TNF-??; p&???=???independent t-test R500+TNF- ?? vs. TNF-?? (p???=???0.02)."
        ],
        "rois":[
          {
            "x":150,
            "y":0,
            "x2":1427,
            "y2":821
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":149,
            "y2":821
          }
        ]
      }
    }
  },
  "249142":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          ", E: strong C-type; panels B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1953,
            "y2":544
          }
        ]
      },
      "F":{
        "descriptions":[
          ", F: weak C-type; panels C"
        ],
        "rois":[
          {
            "x":0,
            "y":545,
            "x2":1953,
            "y2":2621
          }
        ]
      },
      "G":{
        "descriptions":[
          ", G: H-type; panels D"
        ],
        "rois":[
          {
            "x":0,
            "y":545,
            "x2":1953,
            "y2":2621
          }
        ]
      },
      "H":{
        "descriptions":[
          ", H: L-type. All the weak C type water dilutions series tested negative with Bio-Rad?? TeSeE??? SAP (notably, the optical densities were for all the three replicates of the 1???2 dilution just under the cut-off value), thereby, the odd ratio could not be calculated (Subfigure B)."
        ],
        "rois":[
          {
            "x":0,
            "y":545,
            "x2":1953,
            "y2":2621
          }
        ]
      }
    }
  },
  "249362":{
    
  },
  "24968":{
    
  },
  "250023":{
    "Figure_5.tif":{
      "I":{
        "descriptions":[
          ", I). MA-MADS5 was detected using anti-MA-MADS5 IgG coupled to FITC (green images) (Second row"
        ],
        "rois":[
          {
            "x":547,
            "y":7,
            "x2":1856,
            "y2":725
          }
        ]
      },
      "II":{
        "descriptions":[
          ", II). Nuclear localization of MA-MADS5 (yellow fluorescence) has been shown in the merged pictures of I and II of b to e respectively (third row, III). Fourth rows "
        ],
        "rois":[
          {
            "x":7,
            "y":741,
            "x2":2079,
            "y2":2705
          },
          {
            "x":630,
            "y":1754,
            "x2":1111,
            "y2":2229
          },
          {
            "x":640,
            "y":738,
            "x2":1107,
            "y2":1265
          },
          {
            "x":638,
            "y":1274,
            "x2":1112,
            "y2":1744
          },
          {
            "x":1606,
            "y":1274,
            "x2":2083,
            "y2":1744
          },
          {
            "x":1115,
            "y":1754,
            "x2":1600,
            "y2":2230
          },
          {
            "x":1119,
            "y":1272,
            "x2":1596,
            "y2":1748
          },
          {
            "x":1123,
            "y":732,
            "x2":1589,
            "y2":1265
          }
        ]
      },
      "IV":{
        "descriptions":[
          "(IV) of b???e indicate difference interference contrast pictures."
        ],
        "rois":[
          {
            "x":1612,
            "y":732,
            "x2":2078,
            "y2":1265
          }
        ]
      }
    }
  },
  "250178":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Study 1. The response score was the proportion of ???yes??? responses (range 0???1.0). Score 0 means that children did not regard the item as an agent, whereas score 1 means that children attributed the item with biological and psychological properties. BIO???=???Biological, PSY???=???Psychological, PER???=???Perceptual. "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":1891,
            "y2":903
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Study 2."
        ],
        "rois":[
          {
            "x":136,
            "y":1036,
            "x2":1658,
            "y2":1880
          }
        ]
      }
    }
  },
  "2510914":{
    
  },
  "25126":{
    
  },
  "25127":{
    
  },
  "25132":{
    
  },
  "25133":{
    
  },
  "25134":{
    
  },
  "25135":{
    
  },
  "25136":{
    
  },
  "252376":{
    "Figure_7.tif":{
      "B":{
        "descriptions":[
          "; B) fluorescent light and DIC"
        ],
        "rois":[
          {
            "x":9,
            "y":9,
            "x2":1774,
            "y2":1072
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C) fluorescent light and polarized DIC and D) polarized DIC. White arrows indicate lysosomes visualized by DIC with overlapping glo-1::GFP signal, red ovals outline the shell of the embryo."
        ],
        "rois":[
          {
            "x":9,
            "y":1086,
            "x2":1774,
            "y2":2150
          }
        ]
      }
    }
  },
  "252975":{
    
  },
  "2534728":{
    
  },
  "2539":{
    
  },
  "254011":{
    
  },
  "2558260":{
    
  },
  "2575273":{
    
  },
  "2584144":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          "(A) and SP-GNP "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1324,
            "y2":668
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). SEM micrographs showed both blank GNP and SP-GNP were uniform in shape, and the dynamic light scattering demonstrated that both blank GNP and SP-GNP were uniform in size."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "2585329":{
    
  },
  "258745":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) DNA sequence traces of DNA methylated with M.CbeI (top panel) or M.HaeIII (bottom panel). Differences in the G residue signals between M.HaeIII and M.CbeI pUC18 are shown in the middle panel."
        ],
        "rois":[
          {
            "x":55,
            "y":2024,
            "x2":1724,
            "y2":4279
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) The region of the C. bescii chromosome containing CbeI and M.CbeI. "
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1810,
            "y2":2011
          }
        ]
      },
      "M":{
        "descriptions":[
          ", M.CbeI methylated pDCW70 digested with purified CbeI"
        ],
        "rois":[
          {
            "x":31,
            "y":4381,
            "x2":1734,
            "y2":5161
          }
        ]
      },
      "MW":{
        "descriptions":[
          ", MW: 1 kb DNA ladder (NEB). "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) Diagram of pDCW73 used to produce a His-tagged version of M.CbeI in E. coli. "
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1810,
            "y2":2011
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Purified M.CbeI displayed on a 10???20% Tris-HCl gradient gel (CriterionTM Precast Gel, Bio-Rad Laboratories, Hercules"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1810,
            "y2":2011
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA) stained with coomassie blue. lane 1: protein molecular weight standards (BioRad); lane 2: 15 ng of purified M.CbeI protein. "
        ],
        "rois":[
          {
            "x":31,
            "y":4381,
            "x2":1734,
            "y2":5161
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) lane 1, undigested unmethylated pDCW70; lane 2, undigested M.CbeI methylated pDCW70; lane 3, unmethylated pDCW70 digested with purified CbeI; lane 4"
        ],
        "rois":[
          {
            "x":55,
            "y":2024,
            "x2":1724,
            "y2":4279
          }
        ]
      }
    }
  },
  "259053":{
    
  },
  "259153":{
    
  },
  "2592253":{
    "Fig 1.TIF":{
      "E":{
        "descriptions":[
          "(E), oleoylethanolamide "
        ],
        "rois":[
          {
            "x":8,
            "y":1260,
            "x2":722,
            "y2":1760
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), linoleoylethanolamide "
        ],
        "rois":[
          {
            "x":966,
            "y":1260,
            "x2":1613,
            "y2":1761
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), anandamide "
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":724,
            "y2":503
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G), and palmitoylethanolamide "
        ],
        "rois":[
          {
            "x":938,
            "y":637,
            "x2":1610,
            "y2":1130
          },
          {
            "x":8,
            "y":1886,
            "x2":732,
            "y2":2387
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), 2-linoleoylglycerol "
        ],
        "rois":[
          {
            "x":938,
            "y":5,
            "x2":1610,
            "y2":504
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), docosahexaenoylethanolamide "
        ],
        "rois":[
          {
            "x":7,
            "y":636,
            "x2":739,
            "y2":1131
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) of subjects from each of the body mass index (BMI) sub-groups. The median is represented as a line within the box plot and the mean is represented as a + sign. Significant differences (p"
        ],
        "rois":[
          {
            "x":959,
            "y":1886,
            "x2":1627,
            "y2":2388
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), 2-oleoylglycerol "
        ],
        "rois":[
          {
            "x":938,
            "y":637,
            "x2":1610,
            "y2":1130
          }
        ]
      }
    }
  },
  "259915":{
    "Figure_5.tif":{
      "E":{
        "descriptions":[
          "(E) Gelatin zymography and casein zymography were used to quantify MMP2, MMP9 and MMP7 activity, respectively, in cell-free conditioned media from OVCAR-3/CD157, OV-90/CD157 and the corresponding mock cells (left panel). Zymographic bands from all samples were quantified by densitometry (right panel). The enzyme activities are expressed as arbitrary units. Results are from one representative experiment performed in triplicate and are expressed as the mean ?? SD."
        ],
        "rois":[
          {
            "x":1545,
            "y":853,
            "x2":2085,
            "y2":1258
          },
          {
            "x":1207,
            "y":60,
            "x2":2044,
            "y2":767
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Ovarian cancer cell migration through a mesothelial monolayer. Met-5A mesothelial cells were labeled with CellBrite??? Red and grown to confluence on fibronectin-coated coverslips. CFSE-stained tumor cells were plated onto the monolayer. After 6 h (OVCAR-3 cells) or 2.5 h (OV-90 cells) at 37??C, sample were fixed and analyzed using an Olympus FV300 laser scanning confocal microscope by sequential scanning of the XY planes recorded along the Z-axis (step size: 1.25 ??M). Series of confocal optical XY images were processed using a 3D reconstruction program (bioView3D software, Bio-Image Informatics, University of California, Santa Barbara"
        ],
        "rois":[
          {
            "x":1545,
            "y":1275,
            "x2":1943,
            "y2":1562
          },
          {
            "x":1012,
            "y":851,
            "x2":1460,
            "y2":1046
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Mesothelial layer integrity was verified by confocal microscopy analysis in CellBrite??? Red-labeled samples. Samples were analyzed with an Olympus FV300 laser scanning confocal microscope and by Nomarski differential interference contrast (DIC) optics. Scale bars : 50 ??M. "
        ],
        "rois":[
          {
            "x":1545,
            "y":853,
            "x2":2085,
            "y2":1258
          },
          {
            "x":1012,
            "y":851,
            "x2":1460,
            "y2":1046
          },
          {
            "x":90,
            "y":7,
            "x2":905,
            "y2":440
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Transmesothelial migration of OVCAR-3 and OV-90 cells. Where indicated, OVCAR-3/CD157, OV-90/CD157 and the corresponding mock cells were treated for 1 h with GM6001 (25 ??g/ml) before seeding onto Met-5A mesothelial cell monolayer. Results are expressed in terms of percent of transmigrated cells calculated as the ratio of cells that crossed the mesothelial layer to the total number of cells in the field. At least ten fields have been counted for each sample. Results are expressed as the mean ?? SEM of three independent experiments. P values were derived from analysis of variance (ANOVA) with Dunnett correction. **Pns, not significant. "
        ],
        "rois":[
          {
            "x":1545,
            "y":853,
            "x2":2085,
            "y2":1258
          },
          {
            "x":1012,
            "y":1047,
            "x2":1460,
            "y2":1144
          },
          {
            "x":35,
            "y":1054,
            "x2":1460,
            "y2":1566
          },
          {
            "x":555,
            "y":61,
            "x2":1161,
            "y2":1047
          },
          {
            "x":923,
            "y":512,
            "x2":1159,
            "y2":881
          },
          {
            "x":1012,
            "y":851,
            "x2":1460,
            "y2":1046
          },
          {
            "x":1207,
            "y":60,
            "x2":2044,
            "y2":767
          },
          {
            "x":7,
            "y":447,
            "x2":905,
            "y2":766
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA). Top, orthogonal and bottom views are shown (scale bar: 50 ??M). "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) sqRT-PCR expression of MMP2, MMP7, MMP9 and TIMP3 in engineered OVCAR-3 (left panel) and OV-90 cells (right panel). Densitometry quantifies the levels of expression of MMP compared with GADPH. "
        ],
        "rois":[
          {
            "x":1545,
            "y":853,
            "x2":2085,
            "y2":1258
          },
          {
            "x":74,
            "y":837,
            "x2":529,
            "y2":1047
          }
        ]
      }
    }
  },
  "2602135":{
    "Fig 5.tif":{
      "a":{
        "descriptions":[
          "(a) Viral titers in nasal washes of untreated infected controls (Ctr) and mice that received 6.0 mg/kg HB36.6 either 1 day before (Prophylaxis, Pro) or 1 day after (Therapeutic, Ther) infection with 10 MLD50 CA09 virus. Nasal washes collected on days 2, 4 and 6 post-infection were measured by determining the 50% tissue culture infectious dose (TCID50) (bars indicate mean viral titer ??SD, n = 18 mice per group, three replicate experiments). "
        ],
        "rois":[
          {
            "x":1391,
            "y":0,
            "x2":2992,
            "y2":1252
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) IHC staining of intracellular influenza NP (H1N1) of representative lung sections from uninfected (Na??ve) and untreated infected controls (Control) and HB36.6-treated mice (Prophylactic and Therapeutic) at 4 days post-infection with 10 MLD50 CA09 virus. Mouse lungs were not inflated with formalin and consequently resulted in lung collapse and a more hypercellular appearance in the uninfected control. Images selected show representative staining of influenza (NP) positive cells for each group. "
        ],
        "rois":[
          {
            "x":1391,
            "y":0,
            "x2":2992,
            "y2":1252
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Quantification of influenza positive cells in lung tissues was performed by measuring the area of positive staining compared to the total tissue on the slide (uniform random sampling of 50% lung tissue). "
        ],
        "rois":[
          {
            "x":0,
            "y":1193,
            "x2":1315,
            "y2":2241
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Inflammatory cytokines were assayed by Bio-Plex using supernatants from lung homogenates obtained from BALB/c mice on day 2 following infection with 10 MLD50 CA09 virus (n = 8 mice per group). The fold change over na??ve-uninfected mice is shown. For a, c and d, significant differences between the Pro and Ther groups to the Ctr group are shown: *P "
        ],
        "rois":[
          {
            "x":0,
            "y":17,
            "x2":2954,
            "y2":2244
          }
        ]
      }
    }
  },
  "2602138":{
    
  },
  "2602561":{
    
  },
  "260341":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Western blot analysis of expression of E-cadherin and vimentin in SW620-mock and SW620-shRNA-SOX2 cells. GAPDH was used as a loading control. The right panel showed the right panel quantified by the Quantity One software (Bio-Rad). GAPDH was used for normalization. "
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":4116,
            "y2":762
          },
          {
            "x":3187,
            "y":216,
            "x2":3647,
            "y2":762
          },
          {
            "x":2723,
            "y":216,
            "x2":3183,
            "y2":762
          },
          {
            "x":17,
            "y":871,
            "x2":1671,
            "y2":2159
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Immunofluorescence images of SW620-mock and SW620-shRNA-SOX2 cells stained with antibodies against E-cadherin, vimentin and SOX2. Secondary antibody was conjugated with FITC and Cy3. Cell nuclei were stained with Hoechest 33258. "
        ],
        "rois":[
          {
            "x":989,
            "y":36,
            "x2":1942,
            "y2":764
          },
          {
            "x":1861,
            "y":212,
            "x2":2719,
            "y2":762
          },
          {
            "x":1780,
            "y":769,
            "x2":4118,
            "y2":2277
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Semi-quantitative RT-PCR analysis of EMT-related regulatory factors. GAPDH was used as a loading control."
        ],
        "rois":[
          {
            "x":989,
            "y":36,
            "x2":1942,
            "y2":764
          }
        ]
      }
    }
  },
  "260471":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(E) Quantitative real time PCR analysis of c-Myc gene in SW620-mock and SW620-shRNA-SOX2 cells. "
        ],
        "rois":[
          {
            "x":2137,
            "y":1470,
            "x2":2765,
            "y2":2119
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) Quantitative real time PCR analysis of cyclin D1 expression in SW620-mock and SW620-shRNA-SOX2 cells."
        ],
        "rois":[
          {
            "x":2262,
            "y":2124,
            "x2":2586,
            "y2":2278
          },
          {
            "x":3402,
            "y":1959,
            "x2":4019,
            "y2":2233
          },
          {
            "x":2137,
            "y":1470,
            "x2":2765,
            "y2":2119
          },
          {
            "x":1478,
            "y":1629,
            "x2":1987,
            "y2":2207
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Immunofluorescence images of SW620-mock and SW620-shRNA-SOX2 cells stained with anti-beta-catenin antibody. Secondary antibody was conjugated with CY3. Cell nuclei were stained with Hoechest 33258. The top 6 panels are in 100?? magnification and the lower 6 panels are in 400?? magnification. "
        ],
        "rois":[
          {
            "x":2813,
            "y":1494,
            "x2":3237,
            "y2":2276
          },
          {
            "x":959,
            "y":1141,
            "x2":1465,
            "y2":1616
          },
          {
            "x":1478,
            "y":637,
            "x2":2145,
            "y2":1127
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Western blot analysis of beta-catenin expression using cytoplasmic and nuclear fractions of SW620-mock and SW620-shRNA-SOX2 cells. Alpha-tubulin and Lamin B were used as loading controls for the cytoplasmic and nuclear fractions respectively. The right panel showed the band intensities (left panel) quantified by the Quantity One software (Bio-Rad). "
        ],
        "rois":[
          {
            "x":71,
            "y":1629,
            "x2":943,
            "y2":2243
          },
          {
            "x":114,
            "y":1141,
            "x2":943,
            "y2":1616
          },
          {
            "x":3480,
            "y":1011,
            "x2":4078,
            "y2":1682
          },
          {
            "x":3361,
            "y":1775,
            "x2":4019,
            "y2":1926
          },
          {
            "x":1478,
            "y":63,
            "x2":2152,
            "y2":608
          },
          {
            "x":15,
            "y":63,
            "x2":1465,
            "y2":608
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) LEF1/TCF1-luciferase activity in SW620-mock and SW620-shRNA-SOX2 cells. "
        ],
        "rois":[
          {
            "x":71,
            "y":1629,
            "x2":943,
            "y2":2243
          },
          {
            "x":959,
            "y":1627,
            "x2":1467,
            "y2":2200
          },
          {
            "x":3496,
            "y":20,
            "x2":4114,
            "y2":894
          },
          {
            "x":63,
            "y":637,
            "x2":1465,
            "y2":1127
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Quantitative real time PCR (upper panel) and western blot (lower panel) analyses of LEF1 in SW620-mock and SW620-shRNA-SOX2 cells. GAPDH was used as a loading control. "
        ],
        "rois":[
          {
            "x":959,
            "y":1627,
            "x2":1467,
            "y2":2200
          },
          {
            "x":2107,
            "y":180,
            "x2":3380,
            "y2":1418
          },
          {
            "x":1480,
            "y":1141,
            "x2":1987,
            "y2":1616
          }
        ]
      }
    }
  },
  "262329":{
    
  },
  "2623850":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          ". A) Cullin 1"
        ],
        "rois":[
          {
            "x":44,
            "y":433,
            "x2":504,
            "y2":498
          },
          {
            "x":19,
            "y":5,
            "x2":589,
            "y2":419
          }
        ]
      },
      "B":{
        "descriptions":[
          "; B) SKP1 (antibody 4E11)"
        ],
        "rois":[
          {
            "x":577,
            "y":63,
            "x2":1110,
            "y2":401
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C) RBX1. The data were processed using Quantity One software (Bio-Rad). 100% represents the sum of the trace quantities of all bands; relative abundance (y-axis) represents the percentage of each band. Bars show mean ?? S.D. a,bValues with different superscripts indicate statistical significance (P"
        ],
        "rois":[
          {
            "x":607,
            "y":409,
            "x2":1080,
            "y2":506
          },
          {
            "x":10,
            "y":542,
            "x2":985,
            "y2":1055
          }
        ]
      }
    }
  },
  "262477":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) CHRF-288-11 cells or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1127,
            "y2":2550
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) HeLa cells were serum starved for 12 h and incubated with W7 (150 ??M) for 10 min followed by addition of thrombin to CHRF-288-11 cells and EGF to HeLa cells for 1 min or 3 min. At the end of the incubation cells were lysed using RIPA buffer. After centrifugation, 60 ??l of the supernatant was suspended in 20 ??l 4X Laemmli's sample buffer to determine level of endogenous Rac1 in various samples by western blotting. The rest of the supernatant was incubated with GST-PAK1 for 2 h at 4??C. After incubation, the beads were washed three times with Rac1 washing buffer. The final bead pellet was suspended in 30 ??l of Laemmli's sample buffer and heated at 100??C for 5 min. Western blotting was performed using mouse anti-Rac1 antibody. Quantification (adjusted for endogenous level of Rac1) was carried out using Bio-Rad ???quantity one??? program and *p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1127,
            "y2":2550
          }
        ]
      }
    }
  },
  "262564":{
    
  },
  "262776":{
    
  },
  "2634010":{
    "Fig 8.tif":{
      "E":{
        "descriptions":[
          "(E) conditions for ND. See Table 1 for parameter descriptions."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":1227
          }
        ]
      },
      "DF":{
        "descriptions":[
          "(DF) or endemic "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":1227
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) homogeneous and ",
          "(A), the root node rule is the duration of the acute infectious stage (D?) less than 11.08 days; the subset of simulations satisfying this rule partitioned to the left daughter node and consecutively down the nodes. The terminal nodes represent disease-free "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":1227
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) age-structured populations of white-winged parakeets. The rule for data partitioning is on top of each node. For example, in panel "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2999,
            "y2":1227
          }
        ]
      },
      "ND":{
        "descriptions":[
          "(ND) in "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "263416":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          ", E. coli cells were removed by centrifugation, supernatants were analyzed with SDS-PAGE (Panel A and Panel B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1469,
            "y2":1146
          }
        ]
      },
      "A":{
        "descriptions":[
          ". Panel A: Lane 1, YebF-ACP expressed extracellularly; Lane 2, YebF-ACP expressed extracellularly and coexpressed with cytosolic modification enzyme AcpS; Lane 3, YebF-ACP expressed extracellularly and coexpressed with cytosolic modification enzyme AcpS, and with addition of 1 mM sodium azide in culture medium"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1469,
            "y2":1146
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B: Lane 1, YebF-BCCP87 expressed extracellularly; Lane 2, YebF-BCCP87 expressed extracellularly and coexpressed with cytosolic modification enzyme BirA; Lane 3, YebF-BCCP87 expressed extracellularly and coexpressed with cytosolic modification enzyme BirA, and with addition of 1 mM sodium azide in culture medium. Panel C, Target proteins was quantified by Quantity Tools (Image Lab??? software, Version 2.0, BIO-RAD). The densitometric value of the band of YebF-ACP or YebF-BCCP87 expressed extracellularly was set to be 1. Each bar represented the mean ?? standard error, three replicates. Open bars: fusion proteins expressed extracellularly; Filled bars: fusion proteins expressed extracellularly and coexpressed with corresponding cytosolic modification enzymes; Hatched bars: fusion proteins expressed extracellularly and coexpressed with corresponding cytosolic modification enzymes, and with addition of 1 mM sodium azide in culture medium."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1469,
            "y2":1146
          }
        ]
      }
    }
  },
  "2644375":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "(A) Bioluminescence images of rat at day 1, 2, 7, 14, 28, 35 and 64 after a subconjunctival or intravenous injection of Ad-Luci (1x1010 GC/eye). "
        ],
        "rois":[
          {
            "x":4,
            "y":5,
            "x2":1053,
            "y2":1053
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Luciferase activity was measured in unit of photons by bioluminescence analysis. Data are presented as the means ?? SEM (n = 5)."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "266566":{
    
  },
  "2667754":{
    
  },
  "2667772":{
    "Fig 4.tif":{
      "CL":{
        "descriptions":[
          "(CL) and drag coefficients "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1639,
            "y2":1363
          }
        ]
      },
      "CD":{
        "descriptions":[
          "(CD) for the bio-realistic (bio) and simple wings against angle of attack (????). Both wings share very similar performance trends. The lift is noted to plateau at about 15??. The flat wing presents a higher lift value regardless of Reynolds number. At large angles of attack the drag values match very well between the two wings due to the large degree of separation which minimizes the effects of the corrugations."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1639,
            "y2":1363
          }
        ]
      }
    }
  },
  "2667781":{
    
  },
  "2667793":{
    
  },
  "2667805":{
    
  },
  "2667820":{
    
  },
  "2667832":{
    
  },
  "2667847":{
    
  },
  "266945":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) Graph showing proportion of ??-gal expressing cells in specific regions of cultured cerebellum slices. Statistical comparisons were made between each of the treatment groups and the DMSO control group for each region by a Student's T-test. "
        ],
        "rois":[
          {
            "x":7,
            "y":388,
            "x2":339,
            "y2":728
          },
          {
            "x":385,
            "y":388,
            "x2":1087,
            "y2":809
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) qRT-PCR analysis of Axin2 expression in cultured slices. Each treated group was compared to the DMSO control group by a Student's T-test. For each test, n???=???3, error bars???=???SEM, *???=???p"
        ],
        "rois":[
          {
            "x":1101,
            "y":389,
            "x2":1668,
            "y2":807
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":124,
            "y":8,
            "x2":602,
            "y2":365
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) or 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":7,
            "y":388,
            "x2":339,
            "y2":728
          },
          {
            "x":612,
            "y":8,
            "x2":1091,
            "y2":366
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). "
        ],
        "rois":[
          {
            "x":7,
            "y":388,
            "x2":339,
            "y2":728
          },
          {
            "x":1100,
            "y":7,
            "x2":1578,
            "y2":364
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Schematic drawing of cerebellum slice indicating regions used for quantitation. "
        ],
        "rois":[
          {
            "x":7,
            "y":388,
            "x2":339,
            "y2":728
          },
          {
            "x":385,
            "y":388,
            "x2":1087,
            "y2":809
          }
        ]
      }
    }
  },
  "267032":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          "(B,E,H) OR 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":768,
            "y":439,
            "x2":1285,
            "y2":826
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "N":{
        "descriptions":[
          "(N,O) qRT-PCR analysis of expression of Sox9 ",
          "(N) and Gfap "
        ],
        "rois":[
          {
            "x":763,
            "y":1695,
            "x2":1402,
            "y2":2147
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "F":{
        "descriptions":[
          "(C,F,I) and analysed by immunohistochemistry for the expression of Sox9 (A???C), GFAP (D???F), Pax2 (G???I) and Calbindin (J???L). "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":1292,
            "y":438,
            "x2":1812,
            "y2":1614
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A,D,G), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":769,
            "y":834,
            "x2":1286,
            "y2":1221
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) Graph showing the proportion of Sox9+ cells in specific regions of cultured slices. "
        ],
        "rois":[
          {
            "x":6,
            "y":1695,
            "x2":720,
            "y2":2149
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "I":{
        "descriptions":[
          "(C,F,I) and analysed by immunohistochemistry for the expression of Sox9 (A???C), GFAP (D???F), Pax2 (G???I) and Calbindin (J???L). "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":768,
            "y":1226,
            "x2":1287,
            "y2":1615
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "G":{
        "descriptions":[
          "(A,D,G), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":1436,
            "y":1692,
            "x2":2057,
            "y2":2148
          },
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "Q":{
        "descriptions":[
          "(Q) Graph showing the proportion of Calbindin+ cells in the dorsal region of each slice. In all cases, direct comparisons were made by comparing each treatment group with the relevant DMSO control with a Student's T-test. For each test, n???=???3, error bars???=???SEM, *???=???p"
        ],
        "rois":[
          {
            "x":1104,
            "y":2189,
            "x2":1733,
            "y2":2653
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B,E,H) OR 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":767,
            "y":8,
            "x2":1284,
            "y2":433
          }
        ]
      },
      "P":{
        "descriptions":[
          "(P) Graph showing the proportion of Pax2+ cells in specific regions of cultured slices. "
        ],
        "rois":[
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":244,
            "y":833,
            "x2":761,
            "y2":1220
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,F,I) and analysed by immunohistochemistry for the expression of Sox9 (A???C), GFAP (D???F), Pax2 (G???I) and Calbindin (J???L). "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":244,
            "y":833,
            "x2":761,
            "y2":1220
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          }
        ]
      },
      "H":{
        "descriptions":[
          "(B,E,H) OR 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          },
          {
            "x":769,
            "y":834,
            "x2":1286,
            "y2":1221
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          },
          {
            "x":242,
            "y":7,
            "x2":760,
            "y2":432
          }
        ]
      },
      "O":{
        "descriptions":[
          "(N,O) qRT-PCR analysis of expression of Sox9 ",
          "(O) expression, relative to EIF4A2 control. "
        ],
        "rois":[
          {
            "x":1104,
            "y":2189,
            "x2":1733,
            "y2":2653
          },
          {
            "x":1290,
            "y":6,
            "x2":1808,
            "y2":432
          }
        ]
      },
      "D":{
        "descriptions":[
          "(A,D,G), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":374,
            "y":2190,
            "x2":983,
            "y2":2649
          },
          {
            "x":242,
            "y":440,
            "x2":760,
            "y2":827
          },
          {
            "x":241,
            "y":1226,
            "x2":761,
            "y2":1615
          }
        ]
      }
    }
  },
  "267164":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(B,E) or 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":973,
            "y":406,
            "x2":1447,
            "y2":761
          },
          {
            "x":490,
            "y":406,
            "x2":964,
            "y2":762
          }
        ]
      },
      "F":{
        "descriptions":[
          "(C,F) and analysed by immunohistochemistry for the retention of a BrdU label administered two hours prior to fixation (A???C) or apoptotic marker Caspase3 (D???F). "
        ],
        "rois":[
          {
            "x":973,
            "y":406,
            "x2":1447,
            "y2":761
          },
          {
            "x":490,
            "y":406,
            "x2":964,
            "y2":762
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A,D), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":481,
            "y2":399
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Graph showing proportion of BrdU+ cells in specific areas of cultured slices. "
        ],
        "rois":[
          {
            "x":45,
            "y":809,
            "x2":757,
            "y2":1222
          },
          {
            "x":490,
            "y":406,
            "x2":964,
            "y2":762
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B,E) or 50 ??M CHIR "
        ],
        "rois":[
          {
            "x":489,
            "y":6,
            "x2":963,
            "y2":399
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,F) and analysed by immunohistochemistry for the retention of a BrdU label administered two hours prior to fixation (A???C) or apoptotic marker Caspase3 (D???F). "
        ],
        "rois":[
          {
            "x":974,
            "y":8,
            "x2":1449,
            "y2":399
          },
          {
            "x":490,
            "y":406,
            "x2":964,
            "y2":762
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) Graph showing density of Caspase3 labelled cells per unit area in specific regions of cultured slices. In all cases statistical comparisons were made by comparing each treatment group with the appropriate DMSO control using a Student's T-test. For each test, n???=???3, error bars???=???SEM, *???=???p"
        ],
        "rois":[
          {
            "x":809,
            "y":811,
            "x2":1387,
            "y2":1219
          }
        ]
      },
      "D":{
        "descriptions":[
          "(A,D), 20 ??M BIO "
        ],
        "rois":[
          {
            "x":7,
            "y":408,
            "x2":481,
            "y2":763
          },
          {
            "x":490,
            "y":406,
            "x2":964,
            "y2":762
          }
        ]
      }
    }
  },
  "267271":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Layout of biotin IgM indirect EIA (Bio-EIA). "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":344,
            "y2":648
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The distribution of EIA absorbance values of 612 adults??? serum samples of Group 1 and Group 2. Five-pointed star: HRP conjugates."
        ],
        "rois":[
          {
            "x":359,
            "y":8,
            "x2":1000,
            "y2":703
          }
        ]
      }
    }
  },
  "267520":{
    "Figure_4.tif":{
      "I":{
        "descriptions":[
          "(I) Biotinylated MCVLPs (at concentrations of 100 ng, 10 ng, 5 ng, 1 ng/100 ??L), "
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1487,
            "y2":1413
          }
        ]
      },
      "II":{
        "descriptions":[
          "(II) Biotinylated BSA (at concentrations of 20 ??g, 10 ??g, 1 ??g, 100 ng/100 ??L) or (III) Soluble biotin (at concentrations of 20 ??g, 10 ??g, 1 ??g, 100 ng/100 ??L). The reactivities were plotted in boxplot. Five-pointed star: HRP conjugates. P: positive group comprising nine Bio-IgM positive sera. N: negative group comprising nine Bio-IgM-negative sera."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "267602":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) In inhouse MCV IgM EIA, biotinylated MCV VLPs (10 ng/100 ??L) were mixed with increasing concentrations of either unbiotinylated MCV VLPs or soluble biotin and added onto the ??-capture plates (100 ??L/well). "
        ],
        "rois":[
          {
            "x":9,
            "y":12,
            "x2":499,
            "y2":186
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The upper figures show two serum samples positive for biotin IgM; the lower figures show two serum samples positive for MCV IgM. (C and D) In Bio-EIA, four samples positive for biotin IgM were coincubated with avidin and applied to the assay. Five-pointed star: HRP conjugates."
        ],
        "rois":[
          {
            "x":533,
            "y":9,
            "x2":1615,
            "y2":2271
          },
          {
            "x":9,
            "y":12,
            "x2":499,
            "y2":186
          },
          {
            "x":23,
            "y":1324,
            "x2":407,
            "y2":2252
          },
          {
            "x":41,
            "y":212,
            "x2":459,
            "y2":1085
          }
        ]
      }
    }
  },
  "267712":{
    
  },
  "267791":{
    
  },
  "2680261":{
    
  },
  "270130":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) PCR for detecting TG mice. Two pairs of primers were used to amplify the 489 bp and 282 bp inserts. M, 100 bp DNA ladder; 10???37, TG founders; N, genomic DNA from WT mouse as a negative control; P, circular BAC DNA as a positive control. "
        ],
        "rois":[
          {
            "x":9,
            "y":7,
            "x2":941,
            "y2":182
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Southern blot analysis of integrated pFSH transgenes. Purified genomic DNA (10 ??g) from each TG founder was digested by BamHI overnight at 37??C and analyzed by Southern blotting using probes specific for pFSH?? and pFSH??. 10???37, TG founders; P, porcine genomic DNA as positive control; N, genomic DNA from a WT mouse as a negative control. Band intensity was quantified by densitometry using Quantity-One software (Bio-Rad). (C???D) The two ends of both the BAC412H8 and BAC183O11 transgenes were amplified separately from TG mouse genomic DNA using 5???- or 3???-specific primers."
        ],
        "rois":[
          {
            "x":7,
            "y":230,
            "x2":2059,
            "y2":1258
          },
          {
            "x":1058,
            "y":7,
            "x2":1996,
            "y2":180
          }
        ]
      }
    }
  },
  "271267":{
    "Figure_3.tif":{
      "kd":{
        "descriptions":[
          "(kd) rate constants. "
        ],
        "rois":[
          {
            "x":20,
            "y":1841,
            "x2":990,
            "y2":2557
          }
        ]
      },
      "ka":{
        "descriptions":[
          "(ka) and dissociation "
        ],
        "rois":[
          {
            "x":20,
            "y":1841,
            "x2":990,
            "y2":2557
          }
        ]
      },
      "a":{
        "descriptions":[
          "(a) Equilibrium dissociation constant (KD) for P12/P41 interaction. Serial dilutions of recP41-Cd4d3/4-6H were injected through flow cells containing Cd4d3/4 (as a reference) and recP12-Cd4d3/4-bio captured on a streptavidin-coated sensor chip until equilibrium had been reached (see inset). Reference-subtracted binding data were plotted as a binding curve and an equilibrium dissociation constant calculated using non-linear regression fitting of a simple Langmuir binding isotherm to the data (solid line). "
        ],
        "rois":[
          {
            "x":102,
            "y":9,
            "x2":1717,
            "y2":905
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Kinetic data for the P12/P41 interaction. Serial two-fold dilutions of 3.6 ??M purified recP41-Cd4d3/4-6H were injected at high flow rates (100 ??L min???1) over recP12 and a reference flow cell. Sensorgrams showed excellent fits to a simple 1???1 binding model (shown in red) and were used to derive association "
        ],
        "rois":[
          {
            "x":9,
            "y":981,
            "x2":982,
            "y2":1797
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c, d) P12 and P41 do not interact homophilically. ",
          "(c) Injection (solid bar) of purified 2.5 ??M recP12-CD4d3/4-6H over recP41-Cd4d3/4-bio (blue line) and recP12-Cd4d3/4-bio (red dotted line) immobilised on a streptavidin-coated sensor chip. The reciprocal experiment using purified P41 is shown in "
        ],
        "rois":[
          {
            "x":1081,
            "y":1074,
            "x2":1977,
            "y2":1793
          }
        ]
      },
      "d":{
        "descriptions":[
          "(c, d) P12 and P41 do not interact homophilically. ",
          "(d)."
        ],
        "rois":[
          {
            "x":1086,
            "y":1841,
            "x2":1972,
            "y2":2557
          }
        ]
      }
    }
  },
  "272030":{
    
  },
  "272043":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          ". A. Colonies (+) were counted using a Bio-Rad ChemiDoc XRS + imager in biological triplicate"
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":1527,
            "y2":912
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Representative wells showing IPTG and ICI 182780 and vehicle (control) treated colonies at week 4"
        ],
        "rois":[
          {
            "x":73,
            "y":984,
            "x2":1851,
            "y2":2204
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. IPTG treated cells at week 12."
        ],
        "rois":[
          {
            "x":98,
            "y":2242,
            "x2":1866,
            "y2":2626
          }
        ]
      }
    }
  },
  "272427":{
    
  },
  "2730421":{
    
  },
  "2732860":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "A. Scanning electron microscopy (SEM) images of COOH-functionalized Au-labeled Thiol-Carbon derived bionanofluids, at two different magnifications. Au particles have defined spherical structures, highlighted by the arrowhead"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2249,
            "y2":1891
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. EDC-NHS coupling chemistry to attach bio-affinity molecules, whether antibody or protein/mitogen to the Thiol-PEG-CNT. PEGylation of the Thiol-CNT is described in the Materials and Methods."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "278346":{
    "Figure_1.tif":{
      "a":{
        "descriptions":[
          "(a) Cell viability quantified by Syto60 after 72 hours of AZ-628, CI-1040 or BAY61-3606 treatment in HCT-116 (K-RASG13D/+, red) or HKe-3 (K-RAS???/+, blue) cell lines. Relative cell viability was normalized to DMSO vehicle treated control for each cell line. Error bars represent SEM for 3 independent experiments. Cells expressing mutant K-RAS were relatively sensitive to AZ-628 and BAY61-3606, but not CI-1040. "
        ],
        "rois":[
          {
            "x":10,
            "y":7,
            "x2":2050,
            "y2":551
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Cell cycle profiles, as determined by propidium iodide staining, of colorectal cancer cells with mutant B-RAF (HT-29) treated with CI-1040 or mutant K-RAS (DLD-1) treated with BAY61-3606. While inhibition of MEK induces G1 arrest in HT-29 cells, as evidenced by the loss of the 4N peak, BAY61-3606 did not appear to alter the profile of DLD-1 cells. "
        ],
        "rois":[
          {
            "x":11,
            "y":609,
            "x2":1213,
            "y2":1181
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Cell viability of colorectal cancer cells expressing mutant B-RAF (V600E) after 72 hours of treatment with BAY61-3606 and/or CI-1040. Cells expressing mutant B-RAF (HT-29 ??? solid outline and RKO ??? dotted outline) were sensitive to both BAY61-3606 and CI-1040 and these two inhibitors cooperated to produce an enhanced response. "
        ],
        "rois":[
          {
            "x":1357,
            "y":609,
            "x2":2035,
            "y2":1196
          }
        ]
      },
      "D":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":742,
            "y":1253,
            "x2":1813,
            "y2":1789
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Phospho-MEK1 (Ser217/Ser221) and phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187) levels in K-RAS wild-type and mutant cells after 45 minute exposure to 1 ??M AZ-628, 1 ??M BAY61-3606, or vehicle control. Signals were measured using Bio-Plex assays. Relative signal was normalized to a master control lysate. AZ-628 treatment reduced the level of phospho-MEK and phospho-ERK, but BAY61-3606 did not."
        ],
        "rois":[
          {
            "x":7,
            "y":1246,
            "x2":689,
            "y2":1789
          }
        ]
      }
    }
  },
  "278772":{
    "Figure_6.tif":{
      "a":{
        "descriptions":[
          "(a) Time course of phospho-I?????? (Ser32/Ser36) activation after 1 ??M AZ-628 treatment in HCT-116 (red lines) or HKe-3 (blue line) cells with MAP4K2 knock down, as measured via Bio-Plex. Relative signal was normalized to a master control lysate. Error bars represent SEM for 3 independent experiments. NF???? signaling was enhanced in HKe-3 cells after exposure to AZ-628 and this was dependent upon MAP4K2. "
        ],
        "rois":[
          {
            "x":7,
            "y":12,
            "x2":657,
            "y2":584
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Cell viability quantified by Syto60 after 72 hours of combinatorial treatment with IKK inhibitor VII and 1 ??M AZ-628. Relative cell viability was normalized to DMSO vehicle treated control for each cell line. Like BAY61-3606, IKK inhibitor VII enhanced the effect of AZ-628 specifically in K-RAS wild-type cells. "
        ],
        "rois":[
          {
            "x":678,
            "y":7,
            "x2":1402,
            "y2":584
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Cell viability after 72 hours of combinatorial treatment of 1 ??M IKK inhibitor VII and 1 ??M AZ-628 (shaded) or 1 ??M AZ-628 alone (clear) in HKe3 cells with MAP4K2 knockdown. Relative cell viability was normalized to 1 ??M AZ-628 treated samples. Loss of MAP4K2 abrogated the ability of IKK inhibitor VII to sensitize HKe-3 cells to AZ-628."
        ],
        "rois":[
          {
            "x":678,
            "y":7,
            "x2":1402,
            "y2":584
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1399,
            "y":9,
            "x2":2051,
            "y2":574
          }
        ]
      }
    }
  },
  "282492":{
    "Figure_5.tif":{
      "1":{
        "descriptions":[
          "(1) 5-kbp ladder (Bio-Rad) and "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1007,
            "y2":2463
          }
        ]
      },
      "2":{
        "descriptions":[
          "(2) supercoiled DNA ladder (Promega). The outer CD region probe is designed to detect the normal 16.5-kb circular mtDNA and the deleted 11.7-kb circular mtDNA, if the deletion is present. (B) Quantitative analysis of mtDNA lacking the 4977-bp region. The levels of mtDNA lacking the 4977-bp region were estimated from the ratio of the 11.7-kb circular mtDNA (indicated by arrow) to nuclear DNA (represented by ??-actin), and normalized to the value for control cells. Data are shown as the mean ?? standard error of the mean (SEM) from five independent measurements (n???=???5). Statistical significance of the difference as calculated by Student???s t-test is with p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1007,
            "y2":2463
          }
        ]
      }
    }
  },
  "282577":{
    
  },
  "285099":{
    
  },
  "286582":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) CD97 small isoforms in CD97/EGF1,2,5 knockdown group as compared with corresponding controls (*p"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3444,
            "y2":3152
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) CD97 expression on gastric carcinoma cell lines SGC-7901, AGS, BGC-823 and MGC-801. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3444,
            "y2":3152
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Expression of CD97 isoforms in SGCwt, SGC-NS and CD97/EGF1,2,5 knockdown groups. Semi-quantitative RT-PCR analysis, performed with the Bio 1D software, revealed differentially expressed "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3444,
            "y2":3152
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CD97 small and "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) big isoforms of the four cell lines, and significantly decreased levels of "
        ],
        "rois":[
          
        ]
      }
    }
  },
  "286774":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E) The biological activity of mouse recombinant chemerin was measured on mouse ChemR23-expressing CHO-K1 cells using the aequorin-based intracellular Ca2+ mobilization assay. Results are expressed as the percentage of the response to ATP and represent the mean ?? SD of duplicated data points. One representative experiment out of 3 is shown."
        ],
        "rois":[
          {
            "x":113,
            "y":1295,
            "x2":847,
            "y2":1899
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Peritoneal macrophages from WT or ChemR23???/??? mice, collected following i.p. Bio-Gel injection, were stimulated for 15 h by 100 ng/ml LPS or left unstimulated. Cells were harvested, and expression of ChemR23 was determined by quantitative RT-PCR. Data are expressed as mean ?? SEM for 3 independent experiments performed in duplicate. "
        ],
        "rois":[
          {
            "x":941,
            "y":1300,
            "x2":1674,
            "y2":1904
          },
          {
            "x":8,
            "y":7,
            "x2":530,
            "y2":719
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Peritoneal cells from WT or ChemR23???/??? mice, collected following i.p. Bio-Gel injection, were analysed by flow cytometry, directly or after selection by adherence to plates. Cells were stained for leukocyte markers (F4-80 and Gr1) and expression of ChemR23 on F4-80+ Gr1??? (M??) and F4-80??? Gr1+ (PMN) cells was evaluated using flow cytometry. Histograms represent the fluorescence observed following ChemR23 staining on peritoneal cells from WT (black histogram) or ChemR23???/??? (white histogram) mice, compared to the isotype-matched control (dotted line). One representative experiment out of 3 is shown. "
        ],
        "rois":[
          {
            "x":590,
            "y":7,
            "x2":1371,
            "y2":742
          },
          {
            "x":1396,
            "y":59,
            "x2":1901,
            "y2":715
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Total peritoneal cells from WT and ChemR23???/??? mice, collected following i.p. Bio-Gel injection, were incubated with increasing concentrations of radiolabeled chemerin (???). Non-specific binding was determined in the presence of a 100-fold excess of unlabeled chemerin (*), and specific binding (???) was calculated as the difference. One representative experiment out of 3 is shown. "
        ],
        "rois":[
          {
            "x":10,
            "y":729,
            "x2":579,
            "y2":1280
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Peritoneal macrophages from WT or ChemR23???/??? mice, collected following i.p. Bio-Gel injection, were tested for their ability to migrate in response to recombinant mouse chemerin. In the left panel (mean ?? SEM for 3 independent experiments performed in quadruplicate), the whole populations of cells recovered was used. In the right panel (mean ?? SD for an experiment performed in triplicate), macrophages selected by overnight adherence were used. Results are expressed as migration index. "
        ],
        "rois":[
          {
            "x":14,
            "y":1957,
            "x2":1760,
            "y2":2611
          },
          {
            "x":699,
            "y":734,
            "x2":1216,
            "y2":1218
          },
          {
            "x":1378,
            "y":727,
            "x2":1895,
            "y2":1218
          }
        ]
      }
    }
  },
  "286931":{
    
  },
  "287066":{
    
  },
  "288622":{
    
  },
  "291286":{
    "Figure_10.tif":{
      "1":{
        "descriptions":[
          ". 1) While the spatial statistical (SS) model identified 6 disease clusters (the 6 epidemic nodes, of which two partially overlapped, which are seen, within the red pentagon, as 4 circles or ovals, of different colors), because the SS approach does not offer information on directionality, control measures should consider every epidemic node, i.e., the overall ???cost??? of an intervention would be equal to the sum of the areas of the 6 original epidemic nodes included in the red pentagon"
        ],
        "rois":[
          {
            "x":20,
            "y":29,
            "x2":3407,
            "y2":4310
          }
        ]
      },
      "2":{
        "descriptions":[
          ". 2) If a Network Theory (NT) perspective were considered, only a single cluster would be observed (the area included within the red pentagon, which is defined by nodes and edges [road segments]). The NT model may generate several cost-benefit metrics"
        ],
        "rois":[
          {
            "x":20,
            "y":29,
            "x2":3407,
            "y2":4310
          }
        ]
      },
      "3":{
        "descriptions":[
          ". 3) A bio-geo-temporal analysis can integrate both SS advantages (a small area) and NT advantages (identification of the most influential node, based on analysis of network properties). The bio-geo-temporal model can generate the lowest ???cost??? (smallest area to be intervened per each prevented case). Calculations are reported in the text."
        ],
        "rois":[
          {
            "x":20,
            "y":29,
            "x2":3407,
            "y2":4310
          }
        ]
      }
    }
  },
  "29207":{
    
  },
  "29208":{
    
  },
  "294217":{
    "Figure_4.tif":{
      "C":{
        "descriptions":[
          "(C) but not PP cells "
        ],
        "rois":[
          {
            "x":14,
            "y":14,
            "x2":1789,
            "y2":674
          },
          {
            "x":14,
            "y":682,
            "x2":896,
            "y2":1455
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). "
        ],
        "rois":[
          {
            "x":842,
            "y":1443,
            "x2":1325,
            "y2":2813
          },
          {
            "x":25,
            "y":1443,
            "x2":829,
            "y2":2812
          },
          {
            "x":904,
            "y":682,
            "x2":1788,
            "y2":2813
          }
        ]
      },
      "E":{
        "descriptions":[
          "(E) Immunoblot profiles showing that anti-PP and anti-PRT antibodies specifically recognize parapinopsin and parietopsin expressed in cultured cells. Monoclonal antibody rho 1D4 stains iguana parapinopsin (arrowhead) and parietopsin (asterisk) tagged with rho 1D4 epitope, in SDS-extracts form PP and PRT cells (lanes 3 and 4) but not from mock transfected cells (lane 2). Anti-PP specifically stained ???38 k peptide (lane 6, arrowhead), which is the same as the band stained by rho 1D4 (lane 3), in PP cells but not in mock cells (lane 5) or PRT cells (lane 7). Anti-PRT antibodies recognize specifically ???39 k peptide (lane 10, asterisk), which is identical to the stained band by rho 1D4 (lane 4) in PRT cells, but not in mock cells (lane 8) or PP cells (lane 9). M indicates Molecular weight standard markers (lane 1) (Bio-Rad Laboratories)."
        ],
        "rois":[
          {
            "x":14,
            "y":682,
            "x2":896,
            "y2":1455
          }
        ]
      }
    }
  },
  "296301":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) and ??-galactosidase activity ",
          "(A) A small amount of RraA protein expressed from the lacZ promoter of the pTrc-rraA plasmid was sufficient to suppress the SOS response; the level mediating such suppression was compared to the level of RraA protein expressed in stationary phase (after 24 h growth) by untreated SY2 cells harboring pTrc-99A (empty plasmid). Aliquots were assayed by Western blot at various times with and without MTC addition (samples were separated by Criterion 12% Bis-Tris gel electrophoresis using XT-MOPS buffer and were immunoblotted using anti-RraA and anti-S1 antibodies. Specific protein bands were imaged by VersaDoc 1000 (Bio-Rad) and quantified by Quantity One (Bio-Rad). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1972,
            "y2":2127
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). ",
          "(B) Repression of SOS response by leaky expression of RraA from pTrc-rraA plasmid in SY2 cells cultured in the absence of IPTG. SOS response was induced at 0 time in SY2 cells harboring pTrc99A (???, empty plasmid) or pTrc-rraA (???) by addition of MTC (0.1 ??g/ml)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1972,
            "y2":2127
          }
        ]
      }
    }
  },
  "298122":{
    
  },
  "298511":{
    
  },
  "299285":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A. Fluorogenic assay. RT activity was measured by detection of RNA:DNA heteroduplex by fluorescence of EvaGreen binding. Oligo dT primed poly A was incubated at 37??C and 65??C in the presence of indicated Pol enzymes in manufacturer recommended buffers and dTTP. Fluorescence measurements were obtained every 6 seconds for 10 minutes. The initial slopes from a plot of RFU vs. time in seconds were determined by linear least square regression from 30 to 150 seconds at 37??C and from 30 to 90 seconds at 65??C. Error bars are standard error of regression slope"
        ],
        "rois":[
          {
            "x":144,
            "y":1749,
            "x2":661,
            "y2":2743
          },
          {
            "x":8,
            "y":8,
            "x2":878,
            "y2":773
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. RT primer extension assay. HEX-labeled dT20 primed poly A was incubated 10 minutes at 37??C and then 10 minutes at 65??C in the presence of indicated Pol enzymes and dTTP in manufacturer recommended buffers. Primer extension products were resolved by 10% denaturing PAGE and imaged on a Molecular Imager FX (Bio-Rad). Left facing triangle indicates migration of unextended dT20 primer and asterisk indicates bromophenol blue dye front"
        ],
        "rois":[
          {
            "x":12,
            "y":784,
            "x2":873,
            "y2":1750
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. RT MS2-specific primer extension. 5???-labeled primer was annealed to MS2 RNA and incubated 10 minutes at 37??C and then 30 minutes at 65??C in the presence of indicated Pol enzymes with dNTPS (N???=???A,C,G,T) in manufacturer recommended buffers. Primer extension products were resolved by 5% denaturing PAGE. Lane 1 No RNA+MMLV RT; Lane 2: MS2 RNA No RT; Lane 3 MS2 RNA+MMLV RT, Lane 3 MS2 RNA+3173 Pol. Molecular weight in bases indicted. Red Arrow: ???650 base MMLV extension product. Blue Arrow: ???715 base PyroScript extension product. Green arrow: Non-templated MMLV reaction product."
        ],
        "rois":[
          {
            "x":12,
            "y":784,
            "x2":873,
            "y2":1750
          }
        ]
      }
    }
  },
  "30038":{
    
  },
  "30040":{
    
  },
  "30041":{
    
  },
  "300693":{
    "Figure_4.tif":{
      "E":{
        "descriptions":[
          "(E) Primers specific for the overlapping regions bb0685-bb0686 (5 and 8), bb0686-bb0687 (7 and 10) and bb0687-bb0688 (9 and 12) amplified genomic DNA (lane 4) but not cDNA (lane 3), indicating that the ORFs are not co-transcribed The images were generated using the Versadoc imaging system (Bio-Rad Laboratories, Hercules"
        ],
        "rois":[
          {
            "x":802,
            "y":862,
            "x2":2086,
            "y2":1351
          },
          {
            "x":23,
            "y":848,
            "x2":852,
            "y2":1339
          },
          {
            "x":11,
            "y":11,
            "x2":2024,
            "y2":210
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Schematic representation of the borrelial mevalonate pathway that extends from bb0683 to bb0688. The arrows with numbers refer to primers used for the RT-PCR amplicons (depicted in B-E) separated on a 1% agarose gel stained with ethidium bromide. (B-E) The templates used in PCR amplification (B-E) are from B. burgdorferi strain B31 clonal isolate MSK5 and are as follows: Lane 1, PCR master mix with no template (double-distilled H2O control); Lane 2, total RNA (-RT control); Lane 3, cDNA (+RT); Lane 4, total genomic DNA. Lanes M and M2, molecular size markers in kilobases "
        ],
        "rois":[
          
        ]
      },
      "M":{
        "descriptions":[
          "(M) or base pairs (M2) as indicated on the left and right sides, respectively. "
        ],
        "rois":[
          {
            "x":802,
            "y":862,
            "x2":2086,
            "y2":1351
          },
          {
            "x":23,
            "y":293,
            "x2":770,
            "y2":791
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Primers specific for bb0683 (1 and 2) and bb0684 (3 and 4) amplified cDNA (lane 3) and genomic DNA (lane 4). "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2024,
            "y2":210
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Primers specific for bb0685 (5 and 6), bb0686 (7 and 8), bb0687 (9 and 10) and bb0688 (11 and 12) amplified cDNA (lane 3), and genomic DNA (lane 4) indicating active transcription of these ORFs. "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2024,
            "y2":210
          },
          {
            "x":804,
            "y":298,
            "x2":2087,
            "y2":786
          }
        ]
      },
      "CA":{
        "descriptions":[
          ", CA)."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) Primers specific for the overlapping regions bb0683-bb0684 (1 and 4), bb0684-bb0685 (3 and 6) amplified genomic DNA (lane 4), but not cDNA (lane 3) indicating that the ORFs are not co-transcribed. "
        ],
        "rois":[
          {
            "x":802,
            "y":862,
            "x2":2086,
            "y2":1351
          },
          {
            "x":11,
            "y":11,
            "x2":2024,
            "y2":210
          }
        ]
      }
    }
  },
  "302232":{
    
  },
  "3024061":{
    
  },
  "3024370":{
    "Fig 2.tif":{
      "A":{
        "descriptions":[
          "A. Relative abundance of five genera, which were the most abundant among those that changed during time"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3899,
            "y2":1911
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Akkermansia abundance"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3899,
            "y2":1911
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C. Relative abundance of all KEGG pathways that changed during whole study",
          ", C: over the six time points), or the Wilcoxon test (B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3899,
            "y2":1911
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Metabolic pathways that changed from baseline to T3. Abbreviations: bios, biosynthesis; met, metabolism. Statistics: Relative abundances are expressed in percent (abundance at T0 is 100%). Each dot is the mean at a given time point. Relative abundances at different time points were compared using the Friedman test (A",
          ", D, *p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3899,
            "y2":1911
          }
        ]
      }
    }
  },
  "3024412":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          "(A). The binding protein was analyzed by MALDI-TOF MS after in-gel digestion, and found to be eEF1A2 "
        ],
        "rois":[
          {
            "x":4,
            "y":4,
            "x2":590,
            "y2":597
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Western blotting with anti-eEF1A2 antibody confirmed the identity of the binding protein "
        ],
        "rois":[
          {
            "x":714,
            "y":5,
            "x2":1916,
            "y2":980
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Confocal microscopy revealed co-localization of FITC-labeled MLIF (green) and eEF1A2 (labeled with rabbit anti-eEF1A2; red) in SH-SY5Y cells "
        ],
        "rois":[
          {
            "x":9,
            "y":1106,
            "x2":1108,
            "y2":1480
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D)."
        ],
        "rois":[
          {
            "x":9,
            "y":1106,
            "x2":1108,
            "y2":1480
          },
          {
            "x":1109,
            "y":1177,
            "x2":1968,
            "y2":1480
          }
        ]
      }
    }
  },
  "3024718":{
    "Fig 6.tif":{
      "A":{
        "descriptions":[
          "A: Bio 1 (annual mean temperature)"
        ],
        "rois":[
          {
            "x":1151,
            "y":46,
            "x2":2246,
            "y2":960
          }
        ]
      },
      "B":{
        "descriptions":[
          ", B: Bio 2 (precipitation of seasonality (coefficient of variation)"
        ],
        "rois":[
          {
            "x":1152,
            "y":1107,
            "x2":2264,
            "y2":2011
          },
          {
            "x":9,
            "y":11,
            "x2":1143,
            "y2":948
          }
        ]
      },
      "C":{
        "descriptions":[
          ", C: Bio 16 (Precipitation of Wettest Quarter)"
        ],
        "rois":[
          {
            "x":15,
            "y":1059,
            "x2":1141,
            "y2":2010
          },
          {
            "x":1152,
            "y":1107,
            "x2":2264,
            "y2":2011
          }
        ]
      },
      "D":{
        "descriptions":[
          ", D: Bio 19 (Precipitation of Coldest Quarter). Populations in the northern region represented by open circles and in the southern region represented by red circles."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "304574":{
    "Figure_4.tif":{
      "a":{
        "descriptions":[
          "(a) Detection of DSBs by PFGE. After 10 Gy IR exposure CCDC6-depleted (shCCDC6) and CCDC6-proficient (shCTRL) HeLa cells have been collected at different time points (1, 2, 4, 24 hours). Densitometric analysis of DSBs bands were plotted as percentage of total DNA. "
        ],
        "rois":[
          
        ]
      },
      "b":{
        "descriptions":[
          "(b) The percentages of GFP positive cells, compared to controls, have been plotted on the histograms that are representative of three independent experiments. Error bars indicate the standard error mean. The anti-HA-I-Sce1 and anti-tubulin immunoblots are shown at bottom of the figure. "
        ],
        "rois":[
          
        ]
      },
      "c":{
        "descriptions":[
          "(c) HeLa cells, bearing the doxycycline-inducible I-Sce1 DNA repair construct, have been transfected with control shRNAs (shCTRL) or sh-CCDC6 by Microporator MP-100 transfection system (Digital Bio, Korea). The CCDC6 protein depletion was assessed by western blot analysis for every rate of transfection (#1, #2, #3, #4). The percentages of protein expression, compared to controls, have been plotted on the histogram below."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3031,
            "y2":3216
          }
        ]
      }
    }
  },
  "304891":{
    
  },
  "307446":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1704,
            "y2":1408
          }
        ]
      },
      "B":{
        "descriptions":[
          " Cells were exposed to Ad.TERT.LacZ (10 MOI), Ad.TERT.T??10 (10 MOI), and actin polymerization inhibitor (cytochalasin D, 1 ??g/ml) for 48 hr, and then a mitochondrial membrane potential (MMP) assay was performed. The MMP assay was performed using the MMP assay kit protocol (Thermo), and the results were imaged using a Thermo Scientific Cellomics ArrayScan high-content screening (HCS) reader. (B)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1704,
            "y2":1408
          },
          {
            "x":0,
            "y":1409,
            "x2":1704,
            "y2":1778
          }
        ]
      },
      "P":{
        "descriptions":[
          " Cells were exposed to Ad.TERT.LacZ (10 MOI), Ad.TERT.T??10 (10 MOI) with or without anti-cancer agents, such as paclitaxel (taxol, 5 ??g/ml) and cisplatin (platinum, 10 ??g/ml), for 48 hr. The results were compared to those from other treatments, for example, each anti-cancer agent or actin polymerization inhibitor (cytochalasin D, 1 ??g/ml). The levels of intracellular reactive oxygen species (ROS) were detected by a fluorescence ELISA system with the oxidation-sensitive fluorescent probe 2, 7-dichlorofluorescein diacetate (DCF-DA). In addition to the ROS assay, an MTT-bio assay was also performed under the same conditions. The all results are expressed as a percentage of the vehicle control and are mean ?? SE (bars) of three experiments.??Significant differences from vehicle control group are denoted by an asterisk (*), P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3078787":{
    "Fig 3.tif":{
      "a":{
        "descriptions":[
          "(a) Switch off in C3 and D2 on LD2 and LD4 respectively; Hypothesis of partial switch on when regulatory region of LD2 is absent, as evidenced in C2. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2325,
            "y2":1219
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Concentration calibration curves depicting binding of constructs B2, C35, ???54???189???, ???79???189???, ???105???189??? with GST-FAT. The data is representative of a single experiment. Each experiment was performed at-least thrice. "
        ],
        "rois":[
          {
            "x":0,
            "y":1220,
            "x2":878,
            "y2":1623
          },
          {
            "x":0,
            "y":0,
            "x2":2325,
            "y2":1219
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Illustrations of C35, C35_1, C35_2 and C35_3."
        ],
        "rois":[
          {
            "x":879,
            "y":1220,
            "x2":1193,
            "y2":1623
          }
        ]
      },
      "C":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1194,
            "y":1220,
            "x2":2325,
            "y2":1623
          },
          {
            "x":0,
            "y":1624,
            "x2":2325,
            "y2":3199
          }
        ]
      }
    }
  },
  "3080182":{
    
  }
,
  "3085819":{
    
  },
  "3090979":{
    
  },
  "3094306":{
    
  },
  "309438":{
    
  },
  "309461":{
    
  },
  "3094822":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          "(A) Gel retardation assay indicating the formation of CPP/DNA complexes. Various amounts of L6 or L5a were mixed with DNA at molecular N/P ratios of 0 (DNA only), 3, 6, 9, 12, 15, and 18. These complexes were analyzed by electrophoresis on a 0.5% agarose gel, followed by SYBR Safe staining. DNA images were captured using a ChemiDoc XRS+ Gel Imaging System (Bio-Rad). "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":587,
            "y2":532
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The relative mobility of CPP/DNA complexes. The mobility of CPP/DNA complexes is indicated. Data are presented as mean ?? SD from five independent experiments in each treatment group."
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":587,
            "y2":532
          },
          {
            "x":56,
            "y":536,
            "x2":1149,
            "y2":996
          },
          {
            "x":621,
            "y":69,
            "x2":1177,
            "y2":450
          }
        ]
      }
    }
  },
  "3094825":{
    "Fig 4.tif":{
      "A":{
        "descriptions":[
          "(A) Final RT-PCR products of EGFP and 18S rRNA genes from the cells after uptake of the peptide/DNA complexes. Cells were not treated (negative control, NCtl) or were treated with DNA alone, CPP alone, Lipofectamine 2000/DNA (Lip/DNA) or CPP/DNA complexes for 24 h. Real-time PCR for the detection of EGFP gene expression was conducted using a Bio-Rad iQ5 Real-Time PCR Detection System. Human18S rRNA gene expression was analyzed as an internal control. Negative control (NTC) represents real-time PCR signal in the absence of a DNA template. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1180,
            "y2":376
          },
          {
            "x":0,
            "y":377,
            "x2":1180,
            "y2":1501
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Real-time PCR analysis of EGFP gene expression. EGFP gene expression recorded in panel A was normalized to 18S rRNA expression. Statistical comparisons were performed by ANOVA. Data are presented as mean ?? SD from three independent experiments in each treatment group. Significant differences from cells without any treatments (negative control) at P"
        ],
        "rois":[
          {
            "x":0,
            "y":377,
            "x2":1180,
            "y2":1501
          }
        ]
      }
    }
  },
  "3097066":{
    "Fig 3.tif":{
      "E":{
        "descriptions":[
          "(E): ??-catenin elevates Klf4 expression in the absence of LIF. J1 mESCs were transfected with ??-catenin expression vector pCDNA3.1-??-catenin s37a and the negative control pCDNA3.1 in the presence or absence of LIF. At 48 h of incubation, Klf4 expression level was analyzed by western blot. Gapdh was used to normalize template levels."
        ],
        "rois":[
          {
            "x":321,
            "y":881,
            "x2":1054,
            "y2":1300
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A): CHIR promotes Klf4 mRNA expression. J1 mESCs were cultured in LIF-containing medium with or without 3 ??M CHIR for 24 h, and Klf4 expression level was analyzed by RT-qPCR using the comparative Ct method. Gapdh was used to normalize template levels. Data are presented as the mean ?? SD of three independent experiments (*p "
        ],
        "rois":[
          {
            "x":4,
            "y":27,
            "x2":568,
            "y2":969
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B): CHIR promotes Klf4 expression. Representative western blot analysis of Klf4 in J1 mESCs in the presence of 1,000 U/ml LIF, with or without 3 ??M CHIR. Small molecule BIO (1 ??M) was used as control. Cell lysates were extracted and analyzed by western blot, the experiments were repeated for three times. The graph presents Klf4 levels normalized to corresponding Gapdh levels, error bar indicates standard deviation (*p "
        ],
        "rois":[
          {
            "x":15,
            "y":971,
            "x2":316,
            "y2":1137
          },
          {
            "x":591,
            "y":200,
            "x2":1055,
            "y2":282
          },
          {
            "x":534,
            "y":5,
            "x2":1022,
            "y2":196
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C): CHIR partly rescued the colony morphology changes without LIF. J1 mESCs were treated with 3 ??M CHIR or DMSO with or without LIF for 24 h, cell morphology was detected under phase contrast microscopy. Scale bars represent 50 ??m. "
        ],
        "rois":[
          {
            "x":15,
            "y":709,
            "x2":316,
            "y2":969
          },
          {
            "x":15,
            "y":971,
            "x2":316,
            "y2":1137
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D): The expression of Klf4 is downregulated without LIF. Western blot analysis of Klf4 in J1 mESCs in the presence or absence of 1,000 U/ml LIF for 24 h. "
        ],
        "rois":[
          {
            "x":15,
            "y":971,
            "x2":316,
            "y2":1137
          },
          {
            "x":546,
            "y":299,
            "x2":1008,
            "y2":879
          }
        ]
      }
    }
  },
  "3097084":{
    "Fig 6.tif":{
      "E":{
        "descriptions":[
          "(E): CHIR and BIO inhibit miR-7a expression. J1 mESCs were cultured in LIF-containing medium with or without CHIR/BIO for 24 h, and miR-7a expression level was analyzed by RT-qPCR. U6 was used to normalize template levels. Data are presented as the mean ?? SD of three independent experiments (*p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F): ??-catenin does not influence miR-7a expression. J1 mESCs were transfected with ??-catenin expression vector pCDNA3.1-??-catenin s37a and the negative control pCDNA3.1. At 48 h of incubation, miR-7a expression level was analyzed by RT-qPCR. Gapdh was used to normalize template levels. Data are presented as the mean ?? SD of three independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A): Schematic of miRNA binding sites in the Klf4 gene. Presentation of miR-7a, miR-125, miR-152, and miR-363 target sites in the 3???-UTR of Klf4. The lines represent sequence alignment of predicted miRNA binding sites on Klf4 3???-UTR. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G): miR-7a represses Klf4 expression. J1 mESCs were transfected with miR-7a expression vector pCDH-mir-7a and the negative control pCDH-GFP. At 48 h of incubation, Klf4 expression level was analyzed by western blot. Gapdh was used to normalize template levels."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B): miRNAs regulate Klf4 expression. J1 mESCs were transfected with pCDH-CMV-pre-miRNA-EF1-coGFP or pCDH-CMV-MCS-EF1-coGFP control plasmid. After 24 h of incubation, Klf4 expression level was analyzed by RT-qPCR. Gapdh was used to normalize template levels. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C): miR-7a mimics regulate Klf4 expression in a post-transcriptional regulation manner. Schematic representation of the 3???-UTR reporter constructs in the upper panel. Abbreviations TK, hluc+, SV40 and hRluc represent HSV-TK promoter, firefly luciferase gene, SV40 early enhancer/promoter, and Renilla luciferase gene, respectively. In the lower panel, psiCHECK2-Klf4-3???UTR or psiCHECK2 control plasmids were co-transfected with mimics NC or miR-7a mimics/inhibitor into 293FT cells. At 36 h after incubation, luciferase activity was expressed relative to that of psiCHECK2. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D): miR-7a mimics regulates Klf4 expression. J1 mESCs were transfected with mimics NC or miR-7a mimics/inhibitor. At 36 h of incubation, Klf4 expression level was analyzed by RT-qPCR. Gapdh was used to normalize template levels. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1423,
            "y2":2080
          }
        ]
      }
    }
  },
  "3108331":{
    "Fig 1.tif":{
      "A":{
        "descriptions":[
          "A. Alkaline phosphatase activity in the presence (2.5 mT/75 Hz) and absence of an applied magnetic field using the dual Helmholtz/spectrophotometer system. Enzyme activity is assayed by measuring 4-nitrophenol formation (abs. 405 nm) with time. Inset. Shows a plot of the applied field "
        ],
        "rois":[
          {
            "x":7,
            "y":6,
            "x2":1550,
            "y2":850
          }
        ]
      },
      "AF":{
        "descriptions":[
          "(AF) time course minus the no applied field "
        ],
        "rois":[
          {
            "x":7,
            "y":6,
            "x2":1550,
            "y2":850
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) time course. Conditions: [substrate] = 0.07 mM"
        ],
        "rois":[
          {
            "x":7,
            "y":6,
            "x2":1550,
            "y2":850
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Alkaline phosphatase activity in the presence (2.5 mT/75 Hz) and absence of an applied magnetic field using the Biostim system. Inset. Shows a plot of the applied field (biostim on, bioon) time course minus the no applied field (biostim off, biooff) time course. Conditions: [substrate] = 0.07 mM."
        ],
        "rois":[
          {
            "x":7,
            "y":925,
            "x2":1550,
            "y2":1799
          }
        ]
      }
    }
  },
  "3108337":{
    "Fig 3.tif":{
      "A":{
        "descriptions":[
          "A. Acetylcholinesterase activity in the presence (2.5 mT/75 Hz) and absence of an applied magnetic field using the dual Helmholtz/spectrophotometer system. Enzyme activity is assayed by measuring thionitrobenzoate formation (abs. 405 nm) with time. Inset. Shows a plot of the applied field "
        ],
        "rois":[
          {
            "x":7,
            "y":17,
            "x2":1550,
            "y2":959
          }
        ]
      },
      "AF":{
        "descriptions":[
          "(AF) time course minus the no applied field "
        ],
        "rois":[
          {
            "x":7,
            "y":17,
            "x2":1550,
            "y2":959
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) time course. Conditions: [substrate] = 0.025 mM"
        ],
        "rois":[
          {
            "x":7,
            "y":17,
            "x2":1550,
            "y2":959
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Acetylcholinesterase activity in the presence (2.5 mT/75 Hz) and absence of an applied magnetic field using the Biostim system. Inset. Shows a plot of the applied field (biostim on, bioon) time course minus the no applied field (biostim off, biooff) time course. Conditions: [substrate] = 0.10 mM."
        ],
        "rois":[
          {
            "x":6,
            "y":1012,
            "x2":1551,
            "y2":1847
          }
        ]
      }
    }
  },
  "3108802":{
    
  },
  "3110140":{
    "Fig 7.tif":{
      "29":{
        "descriptions":[
          "[29, 30]."
        ],
        "rois":[
          
        ]
      },
      "30":{
        "descriptions":[
          "[29, 30]."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2205,
            "y2":1383
          }
        ]
      }
    }
  },
  "3117286":{
    
  },
  "312298":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          ". Panel A. Nuclear and cytosolic samples were obtained as described in the Method section. As confirmed by coomassie blue staining (right panel), an equal amount of proteins (10 ??g) of the nuclear (lane N) and cytosolic (lane C) samples were loaded in each lane of a SDS-polyacrylamide 4???16 % gradient gels. After migration, the proteins were transferred on PVDF membranes that were blotted with antibody against ACBD6, ZNF23 or ANKRD7. ANKRD7 is a known nuclear protein and was used as a control [66]. The molecular mass standard (Precision Plus Protein Dual-Stained, Bio-Rad) is indicated on the right of the panels. A band of the predicted molecular mass of 32 kDa and 64 kDa was detected for ABCD6 and ZNF23 respectively, in the cytosolic and nuclear samples. A major band of the expected size of 30 kDa (asterisk) was detected for ANKRD7 in the nuclear extract"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":2179,
            "y2":1507
          }
        ]
      },
      "B":{
        "descriptions":[
          ". Panel B. ACSL3 protein was detected with the mouse anti-ACSL3 antibody in a total protein extract of HeLa cells as described in panel A."
        ],
        "rois":[
          {
            "x":2179,
            "y":15,
            "x2":2806,
            "y2":1509
          }
        ]
      }
    }
  },
  "3127594":{
    "Fig 4.tif":{
      "A":{
        "descriptions":[
          "A) EGFP-fused constructs were made containing the DPBW domain module. The NLS determined using bio-informatics is shown in an inset. For the EGFP-DPBWMUT construct the arginines ",
          "(A)"
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":995,
            "y2":555
          }
        ]
      },
      "R":{
        "descriptions":[
          "(R) of the EGFP-DPBW construct were mutated to alanines "
        ],
        "rois":[
          {
            "x":55,
            "y":562,
            "x2":996,
            "y2":1222
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Representative confocal image of N2a cells with overexpression of the EGFP-DPBW or the EGFP-DPBWMUT fusion protein. DAPI was used to stain the nucleus. Quantification of nuclear intensity was based on at least 300 transfected cells per condition. Scale represents 5??m"
        ],
        "rois":[
          {
            "x":5,
            "y":4,
            "x2":995,
            "y2":555
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Representative western blot of four experiments showing nuclear and cytoplasmic fractions of N2a cells transfected with pEGFP, pEGFP-DPBW or EGFP-DPBWMUT. For detection of the EGFP-fusion protein (170 kDa) an anti-GFP antibody was used (a-GFP). As a control for specificity for the fusion protein, no signal is seen for the unfused EGFP protein at this height, since it has a lower molecular weight of 27???30 kDa. HDAC2 and GAPDH were used as markers for nuclear and cytoplasmic fractions, respectively."
        ],
        "rois":[
          {
            "x":4,
            "y":562,
            "x2":421,
            "y2":855
          }
        ]
      }
    }
  },
  "3133975":{
    "Fig 5.tif":{
      "E":{
        "descriptions":[
          ". E) NDV neutralizing antibodies in serum of hamsters before and 6 weeks after the first NDV administration. These data are from one experiment representative of two."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1299,
            "y2":1543
          }
        ]
      },
      "A":{
        "descriptions":[
          ". A) In vivo luciferase activity was monitored at 10, 24, 48 and 72 hours after iv administration of the NDV virus. Each line represents an individual hamster"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1299,
            "y2":1543
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Image of a representative hamster before (basal) and 10 hours after the first NDV administration"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1299,
            "y2":1543
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Luciferase activity stimulation in hamsters receiving two doses of NDV-F3AA-GFP LaSota 6 weeks apart one from the other"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1299,
            "y2":1543
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) Type I IFN activity in serum of hamsters before and 24 hours after second NDV administration, measured by bio-assay"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1299,
            "y2":1543
          }
        ]
      }
    }
  },
  "313700":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Groups of CD1 mice were immunized with R4-GST or with GST, used as a negative control, and challenged with the D39 strain (1??105 CFU). Results represent cumulative data from 3 experiments; n???=???28, total number of animal per each group. "
        ],
        "rois":[
          {
            "x":20,
            "y":21,
            "x2":2129,
            "y2":1353
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Groups of CD1 mice were immunized with Spr1875-BIO or with CAT-BIO, used as a negative control, and challenged with the D39 strain (1??105 CFU). Results represent data from one experiment involving 14 animals per group. *, statistically different (p"
        ],
        "rois":[
          {
            "x":38,
            "y":1290,
            "x2":2125,
            "y2":2946
          }
        ]
      }
    }
  },
  "313885":{
    
  },
  "3139459":{
    
  },
  "314654":{
    
  },
  "314785":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) RD cells were grown in the chamber slides (Lab-tek, Rochester, USA) and incubated at room temperature for 1 hour with or without the SP40 peptide. This was followed by the incubation of the cells in the cold with EV-71 for 1 hour and washing off the unbound virions with PBS. RD cell monolayers were fixed with 4% paraformaldehyde and subsequently blocked with Image-iT??? FX Signal Enhancer (Invitrogen, San Diego, USA). The EV-71 particles were probed with anti-EV-71 monoclonal antibody (Millipore, Billerica, USA) and Alexa Fluor 488 anti-mouse IgG (Invitrogen, San Diego, USA). The nuclei were stained with DAPI for 7??minutes at room temperature. The images were obtained from the fluorescent microscopy. EV-71 viral particles and cell nuclei were shown in green and blue fluorescence, respectively. The number of virus particles that was attached to the cell surface were quantitated by "
        ],
        "rois":[
          {
            "x":7,
            "y":19,
            "x2":1224,
            "y2":389
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Cellomics HCS ArrayScan Spot Detector Bio-Application and "
        ],
        "rois":[
          {
            "x":1234,
            "y":7,
            "x2":2054,
            "y2":486
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) RT TaqMan real-time PCR assay"
        ],
        "rois":[
          {
            "x":81,
            "y":393,
            "x2":1267,
            "y2":1012
          },
          {
            "x":1234,
            "y":7,
            "x2":2054,
            "y2":486
          },
          {
            "x":1293,
            "y":520,
            "x2":2054,
            "y2":996
          }
        ]
      }
    }
  },
  "3152131":{
    "Fig 1.tif":{
      "4":{
        "descriptions":[
          ". 4. FACS was performed on a BD FACS ARIA III with single human TNFR2-specific IgG+ B cells being deposited into the well of a 96-well PCR plate"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      },
      "5":{
        "descriptions":[
          ". 5. cDNA from single B cells was prepared using Superscript III reverse transcriptase (Invitrogen) primed with oligo (dT). Antibody variable-region genes were then recovered via two rounds of PCR followed by a third round to generate transcriptionally-active PCR (TAP) products in a manner similar to that described in Clargo et al.9 employing an Aviso Onyx liquid handling robot to facilitate set-up"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      },
      "6":{
        "descriptions":[
          ". 6. Heavy and light chain TAP fragments were transiently co-transfected into Expi293 cells using ExpiFectamine (Life Technologies). After 7 days expression, supernatants were harvested for further characterisation."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      },
      "1":{
        "descriptions":[
          ": 1. Mice were immunised and a splenocyte suspension prepared"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      },
      "2":{
        "descriptions":[
          ". 2. B cells from the mouse splenocyte preparation were enriched using anti-mouse CD45R microbeads (Miltenyi Biotech) and LS MACS columns (Miltenyi Biotech) according to manufacturers??? instructions"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      },
      "3":{
        "descriptions":[
          ". 3. Following enrichment, cells were stained with the following antibodies: rat anti-mouse IgG brilliant violet 421 (BD biosciences), rat anti-mouse IgM PE-Cy7 (Bio legend), rat anti-mouse IgD APC-Cy7 (Bio legend), rat anti-mouse CD19 AF700 (BD biosciences) (2 ??g per 108 Cells), and rat anti-mouse CD4, CD8, GR1 and F4/80 FITC (BD biosciences)(dump channel). Human TNFR2 extracellular domain was labelled with PE and APC using Lightning Link PE and APC labelling kits (Innova Bioscience) and added to the cell suspension"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2389,
            "y2":3848
          }
        ]
      }
    }
  },
  "3154498":{
    
  },
  "3154510":{
    
  },
  "3154516":{
    
  },
  "3154528":{
    
  },
  "3164596":{
    
  },
  "31670":{
    "1471-2180-4-21-2.jpg":{
      "1":{
        "descriptions":[
          ", 1.5 mM MgCl2, 50 mM KCl"
        ],
        "rois":[
          {
            "x":0,
            "y":58,
            "x2":599,
            "y2":356
          }
        ]
      },
      "0":{
        "descriptions":[
          ", 0.1% Triton X-100, 200 ??M each dNTP",
          ", 0.4 ??M of each oligonucleotide primer",
          ", 0.4 ??M of the single stranded DNA, and 1.5 U of DNA polymerase (Invitrogen, Cergy-Pontoise, France). The thermocycler (Biometra, G??ttingen, Germany) profile was 5 min at 95??C, followed by 35 cycles of 30 sec at 95??C, 30 sec at 55??C, and 1 min at 72??C, and terminated by a final extension for 7 min at 72??C. PCR products were electrophorezed in 3% TAE-agarose gel containing ethidium bromide and visualized under UV transillumination. Column purification of the PCR products. PCR products of the expected size were column-purified by using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, and eluted in 50 ??l of RNase free distillated water. When two bands or more were observed by gel analysis, the band of expected size was excised from the gel and purified by glass milk extraction with the GenClean III Kit (Q-Bio-Gene, Carlsbad CA, USA). 2, assemblage was conducted by pair, seq1 with seq2 (resulting in seq1-2). Equal volumes (10 ??l) of purified seq1- and seq2-dsDNA were incubated at 37??C in the presence of . site is located at the 3' and 5' ends of seq1 and seq2, respectively. 3, the reaction product was column purified using the protocol aforementioned to discard the 15-nt DNA fragments corresponding to the 5' and 3' ends to avoid their re-ligation to their respective complementary sequences at step 5. 4, Overnight incubation at 4??C in the presence of T4 DNA ligase. Ten ??l of the reaction was incubated with T4 DNA ligase (Roche, Basel, Switzerland) according to the manufaturer's instructions. 5, PCR amplification by using the external primers (italics) was performed according to the protocol described at step 1. Then column purification using the protocol detailed at step 2 of the resulting PCR product. At this step the seq1-2 PCR product may be cloned into PGEM-T for storage. The same procedure was performed for seq3 and seq4. Ultimately, seq1-2 and seq3-4 were assembled by using the same protocol (sections 1???9). The final product cloned into PGEM-T plasmid includes seq1-2-3-4 flanked by the two Sseq and restriction sites."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":599,
            "y2":57
          }
        ]
      }
    }
  },
  "3177352":{
    
  },
  "3183835":{
    
  },
  "3195631":{
    
  },
  "3195718":{
    "Fig 3.TIF":{
      "A":{
        "descriptions":[
          ". A) SE image showing the polished shell surface. Lines of pores in the SE image ",
          "(A) correlate to low fluorescence in CLFM "
        ],
        "rois":[
          {
            "x":8,
            "y":9,
            "x2":2074,
            "y2":2376
          }
        ]
      },
      "M":{
        "descriptions":[
          ". M. Keck Laboratory for Biological Imaging at UW-Madison operated with a 40 mW laser at a wavelength of 488 nm. Images of banding within the outer prismatic layer were best expressed through an emission filter that detects visible green light (?? = 505 to 539 nm). Growth-band orientation in the prismatic layer was used to place SIMS transects."
        ],
        "rois":[
          {
            "x":8,
            "y":2424,
            "x2":2074,
            "y2":4792
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), bright portions of the band in the plain light correlate to dissecting microscope image ",
          ". B) CLFM (true color) image showing growth bands. Growth bands extend from the exterior surface of the outer prismatic layer (top of the image) to the interior boundary with the nacreous layer. Note that the banding closer to the nacreous boundary is more pronounced than the banding toward the exterior of the shell"
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) and dark portions in the long wavelength UV (~360 nm) fluorescence image ",
          ". C) Plain-light dissecting microscope image (true color) of polished shell surface. Banding is apparent but discontinuous"
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D). These cavities are the same as those intersected by some SIMS analysis pits (Fig 4)",
          ". D) UV fluorescence (true color) image of the shell. Faint banding is present with an orientation equal to that found in other imaging techniques. CLFM images on the uncoated sample mount were made using a Bio-Rad MRC-1024 scanning confocal microscope at the W"
        ],
        "rois":[
          {
            "x":2122,
            "y":8,
            "x2":4188,
            "y2":4792
          }
        ]
      }
    }
  },
  "3197494":{
    
  },
  "319812":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A)"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":2025,
            "y2":1311
          }
        ]
      },
      "IV":{
        "descriptions":[
          ": Mock or NC1 ??4(IV)"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":2025,
            "y2":1311
          }
        ]
      },
      "AU":{
        "descriptions":[
          "-overexpressing cells were incubated for 48 h without FBS. MT1-MMP expression and activation in whole cell extracts were analyzed by Western blot with an antibody directed against the hinge region of MT1-MMP. The membrane was dehybridized and reprobed with an anti-actin antibody. Quantifications were performed by densitometry using the Bio-1D software. Results were expressed as arbitrary units (AU)"
        ],
        "rois":[
          
        ]
      },
      "NS":{
        "descriptions":[
          ". NS"
        ],
        "rois":[
          {
            "x":11,
            "y":1324,
            "x2":2027,
            "y2":2217
          },
          {
            "x":8,
            "y":8,
            "x2":2025,
            "y2":1311
          }
        ]
      }
    }
  },
  "3202858":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) Maps showing the localities of penguin fossils NMV P221273, NMV P232062 and NMV P251637, plus measured stratigraphic sections (Port 1???4) at Portland, Victoria, Australia. "
        ],
        "rois":[
          {
            "x":15,
            "y":12,
            "x2":1935,
            "y2":1572
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The stratigraphy of the Portland outcrop. The vertical scale is in metres, the coordinates of each section are: Port 1, 38??20???14???S, 141??36???35???E; Port 2, 38??20???29???S, 141??36???27???E; Port 3, 38??20???18???S, 141??36???32???E; Port 4, 38??20???04???S, 141??36???33???E. The occurrence of Gr. conomiozea in Port 2 is from [27]. Coarser cross-bedded calcarenite units are indicated. The blue arrows are microfossil samples, the purple arrows are brachiopods samples for Sr analyses. "
        ],
        "rois":[
          {
            "x":15,
            "y":12,
            "x2":1935,
            "y2":1572
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Sr ages of brachiopods (see also Tables 1 and 2). Results of replicate analyses of the seven brachiopods from the horizon denoted (4mBRACH) at log level 4 metres are in Table 1. The black circle and red line are the preferred ages with +/- error; the surrounding grey box shows the total age range of each sample. The green shading is the most likely age range of the outcrop; the light blue incorporates the full error of the Sr dates. "
        ],
        "rois":[
          {
            "x":15,
            "y":12,
            "x2":1935,
            "y2":1572
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The bio-chronostratigraphy of the Mio-Pliocene [after 35] showing the most likely age of the vertebrate fossils from the Port Campbell Limestone at Portland. Abbreviations: km, kilometres; m, metres; Ma, million years ago; Port, geological section; Sr, strontium."
        ],
        "rois":[
          {
            "x":15,
            "y":12,
            "x2":1935,
            "y2":1572
          }
        ]
      }
    }
  },
  "320637":{
    
  },
  "320749":{
    
  },
  "3209347":{
    
  },
  "3211975":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A,B) Adult female Aphidius ervi and aphid mummy. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(A,B) Adult female Aphidius ervi and aphid mummy. "
        ],
        "rois":[
          {
            "x":0,
            "y":702,
            "x2":893,
            "y2":1396
          },
          {
            "x":0,
            "y":0,
            "x2":892,
            "y2":701
          },
          {
            "x":1393,
            "y":0,
            "x2":1802,
            "y2":501
          },
          {
            "x":893,
            "y":430,
            "x2":1802,
            "y2":701
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C,D) Adult female Praon pequodorum and aphid mummy."
        ],
        "rois":[
          {
            "x":893,
            "y":0,
            "x2":1392,
            "y2":429
          }
        ]
      },
      "D":{
        "descriptions":[
          "(C,D) Adult female Praon pequodorum and aphid mummy."
        ],
        "rois":[
          {
            "x":894,
            "y":702,
            "x2":1802,
            "y2":1396
          }
        ]
      }
    }
  },
  "3215023":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) Cell homogenates ",
          "(A). ",
          "(A). Bar represents the mean ? standard deviation of the amount of immunoblot signal normalized with the signal for ?-actin, and also for the total amount of protein in each fraction (for more details see S1 Table). *** P ns, not statistically significant."
        ],
        "rois":[
          {
            "x":3,
            "y":2583,
            "x2":1598,
            "y2":3880
          },
          {
            "x":0,
            "y":0,
            "x2":1830,
            "y2":1301
          }
        ]
      },
      "M":{
        "descriptions":[
          "(M) fractions. Equivalent amounts of each fraction (10 ?g of proteins) were subjected to SDS-PAGE and immunoblotting using antibodies to the proteins indicated on the right. The position of molecular mass markers is indicated on the left. ",
          "(M) fractions as shown in "
        ],
        "rois":[
          {
            "x":387,
            "y":1272,
            "x2":1337,
            "y2":2556
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Densitometric quantification of the immunoblot signal of the levels of GOLPH3 in the cell homogenates as shown in "
        ],
        "rois":[
          {
            "x":3,
            "y":2583,
            "x2":1598,
            "y2":3880
          },
          {
            "x":0,
            "y":0,
            "x2":1830,
            "y2":1301
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and membrane ",
          "(C) Densitometric quantification of the immunoblot signal of the levels of GOLPH3 in cytosolic ",
          "(C) and membrane "
        ],
        "rois":[
          {
            "x":3,
            "y":2583,
            "x2":1598,
            "y2":3880
          },
          {
            "x":0,
            "y":0,
            "x2":1830,
            "y2":1301
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) from the indicated cell lines were used to prepare cytosolic "
        ],
        "rois":[
          {
            "x":3,
            "y":2583,
            "x2":1598,
            "y2":3880
          },
          {
            "x":0,
            "y":0,
            "x2":1830,
            "y2":1301
          }
        ]
      }
    }
  },
  "3217792":{
    
  },
  "3218239":{
    "Fig 4.TIF":{
      "A":{
        "descriptions":[
          "(panel A) and propagation "
        ],
        "rois":[
          {
            "x":7,
            "y":12,
            "x2":620,
            "y2":1253
          }
        ]
      },
      "B":{
        "descriptions":[
          "(panel B) toughness in diabetic OVE26 (n = 6) vs wildtype FVB (n = 6) mice. Reference point indentation showed increased IDI (indentation distance increase"
        ],
        "rois":[
          {
            "x":652,
            "y":9,
            "x2":1166,
            "y2":1253
          }
        ]
      },
      "C":{
        "descriptions":[
          "; panel C) and a tendency toward increased TID (total indentation distance"
        ],
        "rois":[
          {
            "x":1216,
            "y":5,
            "x2":1721,
            "y2":1253
          }
        ]
      },
      "D":{
        "descriptions":[
          "; panel D). The mean value is indicated by the grey diamond; the median by the horizontal line; the 25% and 75% by the boxes and the 95% confidence interval by the bars."
        ],
        "rois":[
          {
            "x":1216,
            "y":5,
            "x2":1721,
            "y2":1253
          },
          {
            "x":1773,
            "y":4,
            "x2":2218,
            "y2":1253
          }
        ]
      }
    }
  },
  "3219067":{
    
  },
  "322925":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "A: The gene organization of MT-B mitochondrial genome"
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          ": B: RT-PCR results of Sh ble gene and the mitochondrial genes with rrnL7 as internal control"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1344,
            "y2":1526
          }
        ]
      },
      "C":{
        "descriptions":[
          "; C: Relative mRNA levels analysis using BIO-RAD image software."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1344,
            "y2":1526
          }
        ]
      }
    }
  },
  "32321":{
    "1471-2180-8-18-7.jpg":{
      "3":{
        "descriptions":[
          ", 3, 5) and D7SS-p (lanes 2"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":599,
            "y2":118
          },
          {
            "x":0,
            "y":119,
            "x2":599,
            "y2":226
          }
        ]
      },
      "5":{
        "descriptions":[
          ", 3, 5) and D7SS-p (lanes 2"
        ],
        "rois":[
          {
            "x":0,
            "y":119,
            "x2":599,
            "y2":226
          }
        ]
      },
      "4":{
        "descriptions":[
          ", 4, 6). WCP; whole cell protein."
        ],
        "rois":[
          {
            "x":0,
            "y":119,
            "x2":599,
            "y2":226
          }
        ]
      },
      "6":{
        "descriptions":[
          ", 4, 6). WCP; whole cell protein."
        ],
        "rois":[
          {
            "x":0,
            "y":119,
            "x2":599,
            "y2":226
          }
        ]
      }
    }
  },
  "32351":{
    "1472-6750-4-18-4.jpg":{
      "8":{
        "descriptions":[
          ", 8). Cells represented in lanes 1, 3, 5 and 7 were transfected with pMT/V5-His/lacZ and those represented in lanes 2, 4, 6 and 8 were transfected with pMT/V5-His/lacZ and dsRNA. The line to the right indicates the position of GFP specific siRNAs produced in plants as described by Canto et al. "
        ],
        "rois":[
          {
            "x":0,
            "y":506,
            "x2":427,
            "y2":998
          }
        ]
      },
      "4":{
        "descriptions":[
          ", 4), DS2-2b cells (lanes 5"
        ],
        "rois":[
          {
            "x":0,
            "y":12,
            "x2":600,
            "y2":536
          }
        ]
      },
      "6":{
        "descriptions":[
          ", 6) and DS2-16k cells (lanes 7"
        ],
        "rois":[
          {
            "x":0,
            "y":506,
            "x2":427,
            "y2":998
          },
          {
            "x":0,
            "y":12,
            "x2":600,
            "y2":536
          }
        ]
      },
      "47":{
        "descriptions":[
          "(47). The lower panel shows the RNA species detected by staining of the gel before electroblotting."
        ],
        "rois":[
          
        ]
      },
      "2":{
        "descriptions":[
          ", 2), DS2-HC-Pro cells (lanes 3"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "32352":{
    
  },
  "3236":{
    
  },
  "327522":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Microphotograph of a typical bio-patterned network aligned with the electrode array. "
        ],
        "rois":[
          {
            "x":14,
            "y":1206,
            "x2":966,
            "y2":1996
          },
          {
            "x":1006,
            "y":99,
            "x2":2014,
            "y2":1695
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Raster plot of basal extracellular activity (time window, 150 s) on random (upper panel) and printed (bottom panel) cultures. On the right (B1), a close-up (time window, 2 s) of the firing electrodes. (B2) representative traces of two synchronously firing channels. "
        ],
        "rois":[
          {
            "x":13,
            "y":13,
            "x2":1081,
            "y2":1136
          },
          {
            "x":1006,
            "y":99,
            "x2":2014,
            "y2":1695
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Comparison of electrophysiological features of two sample groups (Red, Patterned n???=???5; Black Random n???=???5) at 14 and 21 DIV. While the MFR did not significantly change, the number of active channels (threshold???=???0.1 spike/s) was significantly increased and the MBR was significantly higher at 14 DIV in patterned samples. "
        ],
        "rois":[
          {
            "x":2048,
            "y":13,
            "x2":2927,
            "y2":742
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Example of the migration of neuronal somas to the grid's nodes, favouring cell localization in close proximity to the electrodes in mature networks. Scale bars: 200 ??m."
        ],
        "rois":[
          {
            "x":2087,
            "y":859,
            "x2":2927,
            "y2":2504
          },
          {
            "x":1006,
            "y":99,
            "x2":2014,
            "y2":1695
          },
          {
            "x":1069,
            "y":1724,
            "x2":2017,
            "y2":2430
          },
          {
            "x":78,
            "y":2018,
            "x2":970,
            "y2":2505
          }
        ]
      }
    }
  },
  "328035":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          ". E) U87MG astrocytes were transfected with negative control siRNA (siNEG) or GSK-3?? siRNA (siGSK3) at 50 nM. Forty-eight hours post-transfection, cells were infected with VEEV TC-83 at MOI 0.1. Viral supernatants were collected 24 hours post-infection and assayed for viral replication by plaque assays. Western blot results are displayed below the graph, indicating that GSK-3?? expression was decreased following siRNA treatment."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4461,
            "y2":2019
          }
        ]
      },
      "A":{
        "descriptions":[
          "A) U87MG astrocytes were treated with BIO (10, 5, 2.5, or 1.25 ??M) and cell viability assayed 24 hours later by CellTiter Glo Assay (Promega). DMSO treated cells are displayed at 100% viability and all treatments compared to those values"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4461,
            "y2":2019
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) U87MG astrocytes were pretreated for 2 hours with DMSO, or BIO (5, 2.5, or 1.25 ??M), infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by plaque assays"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4461,
            "y2":2019
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) U87MG astrocytes were treated with DMSO, SB 415286 (50, 10, or 2 ??M), or SB 216763 (50, 10, or 2 ??M) and cell viability assayed 24 hours later by CellTiter Glo Assay (Promega). DMSO treated cells are displayed at 100% viability and all treatments compared to those values"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4461,
            "y2":2019
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) U87MG astrocytes were pretreated for 2 hours with DMSO, SB 415286 (50, or 10 ??M), or SB 216763 (50 or 10 ??M), infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by plaque assays"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4461,
            "y2":2019
          }
        ]
      }
    }
  },
  "328181":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) U87MG astrocytes were pretreated for 2 hours with DMSO or various BIO derivatives at 1 ??M, infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by q-RT-PCR. Compounds with an asterisk displayed greater than 1 log inhibition of viral replication. The horizontal bar indicates the level of viral replication displayed by the DMSO control"
        ],
        "rois":[
          {
            "x":2676,
            "y":21,
            "x2":5350,
            "y2":1241
          },
          {
            "x":21,
            "y":21,
            "x2":2651,
            "y2":1338
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) U87MG astrocytes were treated with DMSO or various BIO derivatives at 1 ??M. Forty-eight hours post infection cell viability was measured by CellTiter Glo luminescence cell viability assay. The horizontal bar indicates the cell viability displayed by the DMSO control (set to 100%)"
        ],
        "rois":[
          {
            "x":2676,
            "y":21,
            "x2":5350,
            "y2":1241
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) U87MG astrocytes were pretreated for 2 hours with DMSO, BIO, #6, #8, #10, or #19 at 1 ??M, infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by plaque assays"
        ],
        "rois":[
          {
            "x":24,
            "y":1561,
            "x2":1716,
            "y2":2057
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) BIO derivatives were assayed for their ability to inhibit VEEV induced CPE. U87MG astrocytes were pretreated for 2 hours with DMSO or various BIO derivatives at 1 ??M, infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Forty-eight hours post infection CPE was measured by MTT assay. Mock infected cells are displayed at 100% viability. The horizontal bar indicates the cell viability displayed by the VEEV infected and DMSO control. Compound #6 has an asterisk as cells treated with it displayed the greatest cell viability following VEEV infection."
        ],
        "rois":[
          {
            "x":2722,
            "y":1264,
            "x2":5194,
            "y2":2654
          }
        ]
      }
    }
  },
  "328333":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) Structure of BIO: 6-bromoindirubin-3???-oxime and BIOder (#6): 6-bromo-5-methyl-1H-indole-2,3-dione 3"
        ],
        "rois":[
          {
            "x":16,
            "y":16,
            "x2":3913,
            "y2":2372
          },
          {
            "x":1113,
            "y":640,
            "x2":1631,
            "y2":986
          },
          {
            "x":2296,
            "y":1274,
            "x2":4025,
            "y2":2342
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) U87MG astrocytes were pretreated for 2 hours with DMSO or BIOder (10, 1.0, and 0.1 ??M), infected with VEEV TC-83 at MOI 0.1, and post-treated. Twenty-four hours post-infection, supernatants were collected and analyzed by plaque assay to determine the amount of infectious virus released"
        ],
        "rois":[
          {
            "x":1282,
            "y":189,
            "x2":1807,
            "y2":639
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) U87MG astrocytes were pretreated for 2 hours with DMSO or BIOder (10, 1.0, and 0.1 ??M), infected with VEEV TC-83 at MOI 0.1, and post-treated. Seventy hours post infection, CPE was measured by MTT assay. Mock infected cells are displayed at 100% viability"
        ],
        "rois":[
          {
            "x":1282,
            "y":189,
            "x2":1807,
            "y2":639
          }
        ]
      },
      "UT":{
        "descriptions":[
          "(UT) cells are displayed at 100% viability."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          ". D) Uninfected U87MG astrocytes were treated with BIOder (10, 1.0, and 0.1 ??M), and cell viability determined by MTT assay. Untreated "
        ],
        "rois":[
          {
            "x":1282,
            "y":189,
            "x2":1807,
            "y2":639
          }
        ]
      }
    }
  },
  "328441":{
    
  },
  "328538":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "A) Samples from both infected and uninfected cells were loaded on a sizing column and separated in presence of a 500 mM salt buffer. No detergents were used during the chromatography steps. Each fraction (over a range of 60 fractions) contained 500 ??L and only 250 ??L samples were precipitated, resuspend in low volume of TNE50 and 0.1% NP-40 (10 ??L) and ran on a gel for western blotting. Samples were western blotted for presence of GSK-3?? and actin"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4931,
            "y2":1712
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) GSK-3?? IPs from fractions 31, 41, 51 (100 ??L each) were mixed with GSK-3?? Ab (5 ??g) overnight and washed next day first with RIPA buffer (1??) and then TNE50 and 0.1% NP-40 (2??) followed by kinase buffer (3??) prior to addition of substrate and 32P-ATP. Samples were ran on a gel, stained, destained (over 4 hrs), dried and then exposed to phosphoImager cassette. Control immunoprecipitation from these fraction (50 uL each) were mixed and used for IP/Kinase using IgG (5 ??g)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4931,
            "y2":1712
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) IP/kinase reactions were treated with either BIO or BIOder (0.1 uM or 1 ??M) in vitro during the kinase reaction. Samples were ran on a gel and exposed to phosphoImager cassette."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":4931,
            "y2":1712
          }
        ]
      }
    }
  },
  "328643":{
    "Figure_6.tif":{
      "A":{
        "descriptions":[
          "A) U87MGs were treated with 1 ??M BIO, 1 ??M BIOder, or DMSO and infected with VEEV TC-83. RNA was harvested from infected cells 24 hours post infection and analyzed by RT-PCR for expression of the indicated anti- and pro-apoptotic genes"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2211,
            "y2":1854
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Band intensities corresponding to triplicate samples were quantified and represented as fold change in gene expression over the DMSO control, with the DMSO control being set as a fold change of 1.0."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2211,
            "y2":1854
          },
          {
            "x":2212,
            "y":0,
            "x2":3950,
            "y2":1854
          }
        ]
      }
    }
  },
  "328781":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          "A) Female C3H/HeN mice were treated subcutaneously with either DMSO or various concentration of BIOder (10 mg/kg, 20 mg/kg, 40 mg/kg) every day for 5 days. Mice were weighed daily and the average % of the mouse weight is plotted in panel A"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3818,
            "y2":2459
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) and C) Female C3H/HeN mice were infected intranasally with 5??LD50 (2??107 pfu) of VEEV TC-83. Groups of 10 mice were treated SQ with vehicle, BIO (50 mg/kg) or BIOder (20 mg/kg) on days ???1, 1, 3, and 5 and were monitored for survival for 14 days. Kaplan-Meier curves for survival between DMSO and BIO ",
          "(panel B). Kaplan-Meier curves for survival between DMSO and BIOder "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3818,
            "y2":2459
          }
        ]
      },
      "C":{
        "descriptions":[
          "(panel C). Significance was determined using Mantel-Cox Log-rank test. P-value of 0.057 between control and BIOder. This experiment was performed one time."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "331355":{
    
  },
  "331400":{
    
  },
  "332357":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "A) Wnt3a and Dkk1 inhibit sphere formation by tumorsphere- and mammosphere-derived cells, compared to bovine serum albumin (BSA) and stem cell media (SCM) controls"
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":3853,
            "y2":3799
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) BIO stimulates tumorsphere and mammosphere formation. C???D) Sphere formation in the presence of increasing concentrations of PKF118???310, PKF115???584, and CGP049090. E???F) Colony formation in the presence of increasing concentrations of PKF118???310, PKF115???584, and CGP049090."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "332730":{
    
  },
  "333385":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Total protein extracts from placental tissue lysates were generated and used in Western blot analysis with an antibody specific for total PDGF??-R and a phosphospecific PDGF??-R antibody that recognized p-PDGF??-R phosphorylated at Tyr770. Lanes 1???2: healthy animals. Lanes 3???4: placental tissue from two of the four cows with papillomavirus-associated tumors of the urinary bladder. Actin protein levels were detected to ensure equal protein loading. "
        ],
        "rois":[
          {
            "x":8,
            "y":7,
            "x2":1334,
            "y2":553
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Quantitative densitometric analysis of the gels was performed with Image Lab software (ChemiDoc; Bio-Rad Laboratories) and significance determined by the Student T-test (P???0.01)."
        ],
        "rois":[
          {
            "x":80,
            "y":623,
            "x2":1239,
            "y2":1931
          }
        ]
      }
    }
  },
  "333740":{
    "Figure_8.tif":{
      "1":{
        "descriptions":[
          ". 1) 3D reconstruction of ??CT studies. Red arrows indicate bone height"
        ],
        "rois":[
          {
            "x":22,
            "y":22,
            "x2":3714,
            "y2":2139
          },
          {
            "x":2822,
            "y":752,
            "x2":3722,
            "y2":1431
          },
          {
            "x":1870,
            "y":758,
            "x2":2683,
            "y2":1414
          }
        ]
      },
      "2":{
        "descriptions":[
          ". 2) Representative ??CT slices. Dotted lines indicate scaffold location"
        ],
        "rois":[
          {
            "x":1869,
            "y":1463,
            "x2":2699,
            "y2":2114
          }
        ]
      },
      "3":{
        "descriptions":[
          ". 3) Macroscopic appearance of histological samples. Dotted lines indicate scaffold location. Squares indicate the area observed in provided histological details "
        ],
        "rois":[
          {
            "x":1869,
            "y":1463,
            "x2":2699,
            "y2":2114
          }
        ]
      },
      "4":{
        "descriptions":[
          "(4)."
        ],
        "rois":[
          {
            "x":2822,
            "y":1452,
            "x2":3722,
            "y2":2131
          }
        ]
      }
    }
  },
  "333900":{
    
  },
  "335330":{
    
  },
  "3365437":{
    "Fig 7.TIF":{
      "E":{
        "descriptions":[
          "(E) ChIP followed by quantitative PCR revealed that BIO treatment reduced Gata-a binding to the Efna.d upstream region. Error bars indicate standard errors of three independent experiments."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1668,
            "y2":1375
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Gata.a protein produced in vitro specifically recognized the Gata site critical for Efna.d expression. As a negative control, we used a rabbit reticulocyte lysate that did not contain template plasmids (NT control). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1668,
            "y2":1375
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Co-incubation of Gata.a with either ??-catenin or Tcf7 did not affect the binding activity of Gata.a for the proximal Gata site (Gata site 1) in the upstream sequence of Efna.d, whereas co-incubation of Gata.a with ??-catenin and Tcf7 reduced the binding activity of Gata.a. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1668,
            "y2":1375
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Co-incubation of Gata.a with ??-catenin and Tcf7 reduced the binding activity of Gata.a for Gata sites in the upstream sequences of Efna.d and Gdf1/3-r. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1668,
            "y2":1375
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Expression of Efna.d was suppressed in embryos injected with ??-catenin mRNA. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1668,
            "y2":1375
          }
        ]
      }
    }
  },
  "3368848":{
    "Fig 6.TIF":{
      "A":{
        "descriptions":[
          "(A) Percentage mortality of insects after feeding of various concentration of BtA1VgR siRNA at different time interval. "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1390,
            "y2":750
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Light microscope imaging of cotton leaf after 20 days of releasing of control and BtA1VgR siRNA fed insects. The different letters above each bar indicates significantly different data as per DMRT, preceded by a one-way ANOVA having p-value"
        ],
        "rois":[
          {
            "x":15,
            "y":733,
            "x2":1405,
            "y2":1320
          }
        ]
      }
    }
  },
  "336923":{
    
  },
  "3372334":{
    
  },
  "3375439":{
    
  },
  "3389059":{
    "Fig 1.TIF":{
      "a":{
        "descriptions":[
          "(a) Cells were seeded onto nitinol-foils (control), and nitinol-foils coated with star-PEG, or star-PEG-coated foils bio-functionalized with RGD or RGD/CXCL1. Adherent cells were quantified after 12 hours (n = 10???12). *Pvs. controls, #Pvs. star-PEG, and ??Pvs. star-PEG+RGD-coated foils. One-way-ANOVA with Tukey???s multiple comparison test. "
        ],
        "rois":[
          {
            "x":793,
            "y":13,
            "x2":1494,
            "y2":603
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Cell proliferation was assessed by BrdU-incorporation (n = 9 each) after indicated stimulation, expressed relative to untreated cells (control). *Pvs. controls and #Pvs. RGD. One-way-ANOVA with Tukey???s multiple comparison test."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2250,
            "y2":1123
          }
        ]
      },
      "B":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":1535,
            "y":13,
            "x2":2250,
            "y2":603
          }
        ]
      }
    }
  },
  "3389089":{
    "Fig 3.TIF":{
      "a":{
        "descriptions":[
          "(a) Representative Giemsa-stained sections (scale bars, 200??m) from apoE-/- mice. Quantification of in-stent intima formation "
        ],
        "rois":[
          {
            "x":0,
            "y":41,
            "x2":592,
            "y2":318
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) and thrombus formation "
        ],
        "rois":[
          {
            "x":1462,
            "y":795,
            "x2":2157,
            "y2":1523
          },
          {
            "x":94,
            "y":351,
            "x2":1158,
            "y2":693
          },
          {
            "x":1218,
            "y":36,
            "x2":2157,
            "y2":773
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c). "
        ],
        "rois":[
          {
            "x":0,
            "y":792,
            "x2":780,
            "y2":1554
          }
        ]
      },
      "D":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":850,
            "y":841,
            "x2":1413,
            "y2":1340
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) Representative images of vWF-staining (red); cell nuclei were counterstained by DAPI (L, lumen; x, stent struts; scale bar, 50??m); quantification of re-endothelialization. *P"
        ],
        "rois":[
          {
            "x":642,
            "y":6,
            "x2":1137,
            "y2":339
          }
        ]
      }
    }
  },
  "339275":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A) Hepatocyte-restricted eGFP expression in the liver of rats injected with AAV2/8-TBG-eGFP. Wild-type rats were injected at P4 (upper pictures), or at P30 (lower pictures) with 4??10e13 gc/kg of AAV2/8-TBG-eGFP vectors. Animals were sacrificed at P15 (those injected at P4) or at P90 (those injected at P30). The identity of eGFP expressing cells in the liver from injected rats was confirmed by confocal microscopy analysis on sections after immuno-fluorescence with anti-albumin (left panels), anti-CD163 (middle panels, white arrows) or anti CD-31 (right panels, white arrows) antibodies. Representative pictures from rats in each group are shown. Magnification: 63??"
        ],
        "rois":[
          {
            "x":49,
            "y":10,
            "x2":1722,
            "y2":1113
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B, C) Analysis of vector bio-distribution and eGFP expression in tissues from rats injected with AAV2/8-TBG-eGFP",
          ". B) AAV vector genome copies/molecule of diploid genome (gc/mdg) were measured in tissues (reported under each bar) from rats injected at P4 (left, for spleen, kidney, muscle, heart and gonads data are pooled from tissues harvested at P15, P30 and P90) or at P30 (right, all tissues harvested at P90) by Real-time PCR. Results are reported as mean ?? SE. The number of animals analyzed in each group is reported in the corresponding bar"
        ],
        "rois":[
          {
            "x":9,
            "y":1178,
            "x2":1813,
            "y2":1763
          }
        ]
      },
      "C":{
        "descriptions":[
          ". B, C) Analysis of vector bio-distribution and eGFP expression in tissues from rats injected with AAV2/8-TBG-eGFP",
          ". C) eGFP expression was assessed by Western blot analysis on the spleen (70 ??g of proteins) , kidney (70 ??g of proteins) and heart (150 ??g of proteins). Representative animals from each group are shown. ???: tissues from uninjected rats; +: liver lysate from a rat injected at P4 with AAV2/8-TBG-eGFP and collected at P15 used as eGFP-positive control (10 ug of proteins)."
        ],
        "rois":[
          {
            "x":14,
            "y":1797,
            "x2":1924,
            "y2":2639
          }
        ]
      }
    }
  },
  "339772":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "A,B, Representative traces of PER2::LUC rhythms from lung fibroblasts treated with increasing doses of lithium (A)"
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":716,
            "y2":686
          }
        ]
      },
      "B":{
        "descriptions":[
          " or the GSK3 inhibitor BIO (B)"
        ],
        "rois":[
          {
            "x":29,
            "y":920,
            "x2":2060,
            "y2":1498
          },
          {
            "x":1517,
            "y":486,
            "x2":2050,
            "y2":891
          },
          {
            "x":810,
            "y":7,
            "x2":2050,
            "y2":680
          }
        ]
      }
    }
  },
  "3402709":{
    
  },
  "3415900":{
    "Fig 2.TIF":{
      "E":{
        "descriptions":[
          "(E) or prefusion F "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":0,
            "y":0,
            "x2":784,
            "y2":421
          },
          {
            "x":756,
            "y":1002,
            "x2":1445,
            "y2":1469
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J) and MPE8 "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":754,
            "y":1507,
            "x2":1438,
            "y2":2011
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F), respectively. To determine steady-state affinity, response levels at equilibrium were plotted over concentration of pre- "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":756,
            "y":1002,
            "x2":1445,
            "y2":1469
          },
          {
            "x":1,
            "y":476,
            "x2":726,
            "y2":966
          },
          {
            "x":2,
            "y":1002,
            "x2":716,
            "y2":1469
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) and 3B1 IgG "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":0,
            "y":0,
            "x2":784,
            "y2":421
          }
        ]
      },
      "I":{
        "descriptions":[
          "(I), D25 "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":782,
            "y":11,
            "x2":1481,
            "y2":459
          },
          {
            "x":756,
            "y":1002,
            "x2":1445,
            "y2":1469
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) protein. 50 nM of post- "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":1,
            "y":1507,
            "x2":714,
            "y2":2011
          },
          {
            "x":756,
            "y":1002,
            "x2":1445,
            "y2":1469
          }
        ]
      },
      "L":{
        "descriptions":[
          "(L) Bio-Layer Interferometry (BLI) based competition experiment of 3B1 IgG against site I antibody 131-2a. Palivizumab (blue) is able to bind to postfusion F protein in an Octet sandwich competition assay using 131-2a as the capture antibody, but antibody 3B1 (red) does not bind."
        ],
        "rois":[
          {
            "x":1483,
            "y":1507,
            "x2":2160,
            "y2":2011
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) binding to RSV pre- (red circle) and postfusion F (blue square) proteins. (C-H) Surface plasmon resonance (SPR) analysis of 2E1 and 3B1 Fabs binding to pre- and postfusion RSV F proteins. RU = Resonance Units. Monovalent Fab antibody fragments were captured on the surface of a Series S Sensor Chip CM5 previously functionalized with Human Fab Binder. Prefusion or postfusion F protein diluted 2-fold serially starting at 100 nM or 200 nM was then injected over captured 2E1 "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":0,
            "y":0,
            "x2":784,
            "y2":421
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) or 3B1 "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":1,
            "y":476,
            "x2":726,
            "y2":966
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) was injected to demonstrate the specificity of 2E1 binding to prefusion F and 3B1 to postfusion F. (I-K) SPR based competition analysis of 2E1 and 3B1 against palivizumab "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":1483,
            "y":476,
            "x2":2166,
            "y2":1469
          },
          {
            "x":756,
            "y":1002,
            "x2":1445,
            "y2":1469
          }
        ]
      },
      "K":{
        "descriptions":[
          "(K) in binding to RSV prefusion F protein. RU = Resonance Units. Palivizumab and D25 were amine coupled to the surface of separate flow channels of a CM5 chip. A third flow channel was subjected to amine coupling activation without an antibody and used for reference subtraction. Prefusion F (40 ??g/mL) was then injected over all surfaces. After a brief stabilization period, 2E1, 3B1, or running buffer was injected to measure binding to sites not occupied by the capturing antibody (palivizumab or D25). To assess competition to MPE8, the MPE8 antibody was captured (6000 RU, not shown) to flow channel 2 of a Biacore Sensor Chip Protein A. Prefusion F (40 ??g/mL) was passed over channels 1 and 2 followed by 2E1 Fab, 3B1 Fab, D25 Fab and buffer to measure binding to sites not occupied by MPE8. "
        ],
        "rois":[
          {
            "x":1483,
            "y":1507,
            "x2":2160,
            "y2":2011
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) or postfusion F "
        ],
        "rois":[
          {
            "x":40,
            "y":2022,
            "x2":1246,
            "y2":2550
          },
          {
            "x":757,
            "y":476,
            "x2":1454,
            "y2":966
          }
        ]
      }
    }
  },
  "342450":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) VHB genotype A, Abbott ?????=???0.44, p???=???0.02; Diasorin ?????=???0.49, p???=???0.01; Bio-Rad ?????=???0.46, p???=???0.02; Roche ?????=???0.47, p???=???0.02; "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1669,
            "y2":621
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) genotype D, Abbott ?????=???0.29, p???=???0.15; Diasorin ?????=???0.05, p???=???0.81; Bio-Rad ?????=???0.30, p???=???0.14; Roche ?????=???0.38, p???=???0.05."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3430157":{
    "Fig 1.TIF":{
      "E":{
        "descriptions":[
          "(E) Representative confocal images of EPS in the biofilms. Values followed by the same letters are not significantly different from each other (P > 0.05)."
        ],
        "rois":[
          {
            "x":1234,
            "y":1302,
            "x2":3021,
            "y2":2509
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Bacterial adhesion. "
        ],
        "rois":[
          {
            "x":12,
            "y":6,
            "x2":1122,
            "y2":848
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Bio-volume. "
        ],
        "rois":[
          {
            "x":6,
            "y":919,
            "x2":1093,
            "y2":1693
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Mean thickness. "
        ],
        "rois":[
          {
            "x":1,
            "y":1778,
            "x2":1094,
            "y2":2553
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Representative confocal images of bacteria in the biofilms. "
        ],
        "rois":[
          {
            "x":1221,
            "y":0,
            "x2":3015,
            "y2":1209
          }
        ]
      }
    }
  },
  "3430205":{
    "Fig 3.TIF":{
      "A":{
        "descriptions":[
          "(A) bio-volume and mean thickness "
        ],
        "rois":[
          {
            "x":1,
            "y":1555,
            "x2":991,
            "y2":2353
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) roughness coefficient, and "
        ],
        "rois":[
          {
            "x":6,
            "y":793,
            "x2":991,
            "y2":1570
          },
          {
            "x":3,
            "y":27,
            "x2":1060,
            "y2":795
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) surface to volume ratio of 46-h S. mutans biofilm. "
        ],
        "rois":[
          {
            "x":6,
            "y":793,
            "x2":991,
            "y2":1570
          },
          {
            "x":3,
            "y":27,
            "x2":1060,
            "y2":795
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Representative 3-D images (isosurface rendering) of bacterial cells. Values followed by the same letters are not significantly different from each other (P > 0.05)."
        ],
        "rois":[
          {
            "x":1135,
            "y":0,
            "x2":2804,
            "y2":2350
          }
        ]
      }
    }
  },
  "3430226":{
    "Fig 4.TIF":{
      "A":{
        "descriptions":[
          "(A) bio-volume and mean thickness "
        ],
        "rois":[
          {
            "x":1,
            "y":1584,
            "x2":983,
            "y2":2378
          },
          {
            "x":6,
            "y":809,
            "x2":984,
            "y2":1597
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) roughness coefficient, and "
        ],
        "rois":[
          {
            "x":1,
            "y":1584,
            "x2":983,
            "y2":2378
          },
          {
            "x":6,
            "y":809,
            "x2":984,
            "y2":1597
          },
          {
            "x":2,
            "y":46,
            "x2":1032,
            "y2":821
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) surface to volume ratio of 46-h S. mutans biofilm. "
        ],
        "rois":[
          {
            "x":1,
            "y":1584,
            "x2":983,
            "y2":2378
          },
          {
            "x":2,
            "y":46,
            "x2":1032,
            "y2":821
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Representative 3-D images (isosurface rendering) of bacterial cells (green) and EPS (red). Values followed by the same letters are not significantly different from each other (P > 0.05)."
        ],
        "rois":[
          {
            "x":1100,
            "y":0,
            "x2":2798,
            "y2":2350
          }
        ]
      }
    }
  },
  "3433457":{
    
  },
  "3440249":{
    
  },
  "344409":{
    
  },
  "3448472":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "(A) Serial dilutions of recombinant human IgG1 (???) or IgG4 (???) variants of mAbs (F706 against Dsg3 in upper left, F779 against Dsg3 in upper right, Px43 against Dsg3 in lower left and Px43 against Dsg1 in lower right) were incubated with Dsg3- coated ELISA plates. Bound antibody was detected using HRP conjugated mouse anti-human (H+L) Ab. Results are the mean of duplicate wells and are representative of 2???3 independent experiments. The relative affinity of each mAb was calculated by Lineweaver-Burk plot. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1859,
            "y2":927
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IgG1 and IgG4 variants of F706 and F779 mAbs show comparable immunoreactivity to the Dsg3+ human oropharynx tumor cell line SCC-47. F71 IgG1 and b12 IgG4 served as isotype controls. Other negative controls included HRP substrate OPD added alone or with secondary reagents only (secondary (2nd) biotinylated anti-human Fc Ab (Biotin Ab) or 2nd Ab with HRP-conjugated streptavidin Ab (Bio + SA Abs) in absence of tested PV mAbs. OPD: o-phenylenediamine dihydrochloride. "
        ],
        "rois":[
          {
            "x":1897,
            "y":11,
            "x2":3372,
            "y2":927
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Px43 IgG1 and IgG4 demonstrate different relative affinities by ELISA but comparable affinity by IIF binding of human skin"
        ],
        "rois":[
          {
            "x":1110,
            "y":3815,
            "x2":1864,
            "y2":4486
          },
          {
            "x":101,
            "y":3815,
            "x2":1097,
            "y2":4483
          },
          {
            "x":53,
            "y":960,
            "x2":3363,
            "y2":3812
          },
          {
            "x":1897,
            "y":11,
            "x2":3372,
            "y2":927
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D: dermal part of skin. Results are representative of 1???2 experiments."
        ],
        "rois":[
          {
            "x":101,
            "y":3815,
            "x2":3393,
            "y2":5100
          }
        ]
      }
    }
  },
  "3448724":{
    "Fig 4.TIF":{
      "E":{
        "descriptions":[
          "(E) DnaA???DnaD and "
        ],
        "rois":[
          {
            "x":638,
            "y":534,
            "x2":1212,
            "y2":1023
          },
          {
            "x":1275,
            "y":14,
            "x2":1850,
            "y2":498
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) DnaA???DnaD1-195 were analyzed using SPR. SaPriA and SaDnaA were individually immobilized on Series S sensor chips CM5, and the binding experiments were carried out using a Biacore T200 (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). Control samples were used to monitor the sensor chip surface stability, demonstrating reproducibility throughout the duration of the experiments. The estimated Kd values were derived by fitting the association and dissociation signals with a 1:1 (Langmuir) model using the Biacore T200 Evaluation Software. The residual plots for SPR fitting were shown in S3 Fig."
        ],
        "rois":[
          {
            "x":1267,
            "y":535,
            "x2":1841,
            "y2":1023
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) PriA???DnaD, "
        ],
        "rois":[
          {
            "x":4,
            "y":13,
            "x2":580,
            "y2":498
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) PriA???DnaD1-204, "
        ],
        "rois":[
          {
            "x":632,
            "y":4,
            "x2":1206,
            "y2":498
          },
          {
            "x":1275,
            "y":14,
            "x2":1850,
            "y2":498
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) PriA???DnaD1-200, "
        ],
        "rois":[
          {
            "x":1275,
            "y":14,
            "x2":1850,
            "y2":498
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) PriA???DnaD1-195, "
        ],
        "rois":[
          {
            "x":4,
            "y":534,
            "x2":579,
            "y2":1023
          },
          {
            "x":1275,
            "y":14,
            "x2":1850,
            "y2":498
          }
        ]
      }
    }
  },
  "3449441":{
    "Fig 4.TIF":{
      "CV":{
        "descriptions":[
          "(CV) mortality. NRI and IDI values were reported when CRP was added to the clinical model in combination with high BCN value. NRI: net reclassification index; IDI: integrated discrimination index; BCN: Barcelona bio-heart failure risk calculator (BCN Bio-HF calculator)."
        ],
        "rois":[
          {
            "x":46,
            "y":36,
            "x2":4488,
            "y2":3144
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Correlation analysis with survival rate, "
        ],
        "rois":[
          {
            "x":46,
            "y":36,
            "x2":4488,
            "y2":3144
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Adjusted hazard ratio of death according to combined criteria as median of ST2 and Barcelona score "
        ],
        "rois":[
          {
            "x":46,
            "y":36,
            "x2":4488,
            "y2":3144
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Kaplan Meier curves for all-cause mortality according to combination of median of ST2 and Barcelona score and "
        ],
        "rois":[
          {
            "x":46,
            "y":36,
            "x2":4488,
            "y2":3144
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Reclassification of two years risk of death for all cause or cardiovascular "
        ],
        "rois":[
          {
            "x":46,
            "y":36,
            "x2":4488,
            "y2":3144
          }
        ]
      }
    }
  },
  "344966":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) A schematic diagram of the pig INS gene showing the relative positions of promoter, exon 1 and CpG islands. The black arrow indicates the location of the primer set. The striped box indicates the putative DMR. The horizontal line indicates the CpG site. The PCR product was digested with BstUI. "
        ],
        "rois":[
          
        ]
      },
      "B":{
        "descriptions":[
          "(B) The putative DMR of the maternally imprinted INS gene in cloned pigs and wild-type pigs was analyzed by COBRA. The numbers under the figure in the WT panel indicate the average methylation percentage of three wild-type pigs. ",
          "; B: blood"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5120,
            "y2":3238
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Bisulfite sequencing of the INS putative DMR in WT ear, CP4 liver, and CP3 ear. Open and closed circles indicate unmethylated and methylated CpG sites, respectively. The top number indicates the CpG site position of the analyzed INS putative DMR. The bottom line indicates the BstUI recognition site. Fourteen clones of each tissue were sequenced. The methylation percentage calculations were divided into three parts: CpG sites 1 to 20 (all), CpG sites 15 to 20, and CpG sites 13 to 20. For example, WT ear showed a total methylation percentage of 75.7 (212 methylated CpG sites/20 CpG sites ??14 clones???=???75.7%). M1: Bio 100 DNA ladder; M2: 500 bp DNA ladder; Br: brain; Ea: ear; He: heart; Ki: kidney; Li: liver; Lu: lung; Mu: muscle; Pl: placenta; Um: umbilical cord"
        ],
        "rois":[
          
        ]
      },
      "W":{
        "descriptions":[
          "; W: ddH2O."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5120,
            "y2":3238
          }
        ]
      },
      "S":{
        "descriptions":[
          "; S: blood treated with SssI"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":5120,
            "y2":3238
          }
        ]
      }
    }
  },
  "3450638":{
    
  },
  "3458618":{
    "Fig 9.TIF":{
      "A":{
        "descriptions":[
          "(A) The graph generated with the CLC Genomics Workbench 7.5 software (CLC bio) shows the ChIP-seq read distribution in the genomic region containing ros1 in output DNA from the sample where maize was infected with FB1??ros1-Ros1HA x FB2??ros1-Ros1HA (Output Ros1HA) and in the control sample where the infection was done with FB1??ros1-Ros1 x FB2??ros1-Ros1 (output Ros1) Open reading frames are represented by yellow arrows. Peaks with significant peak shape scores are indicated in the ChIP peaks lane by dark red arrows. The location of the fragment (WT-probe) used as a probe for EMSA is indicated by a black arrow. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3011,
            "y2":1754
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Sequence of the probe fragment used for EMSA assays. Putative binding sites (m1, m2 and m3) for Ros1 are boxed and mutations introduced in the respective sites are indicated (mut-m1, mut-m2). "
        ],
        "rois":[
          {
            "x":0,
            "y":1755,
            "x2":3011,
            "y2":3112
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) In vitro binding of Ros1WOPR-His to the ros1 promoter. Ros1WOPR-His expressed and purified from E. coli was used in EMSA assays with the probe shown in B (WT-probe). When incubated with Ros1WOPR-His, the WT-probe was shifted and this could be competed by addition of a non-labeled WT-probe (competitor). Ros1WOPR-His did not bind a probe of the same length corresponding to a part of the ros1 coding sequence (ORF-probe). Probes mut-m1 and mut-m2 harboring mutations in motifs 1 and 2 are also bound by Ros1WOPR-His, but the interaction results in a less pronounced shift than observed for the WT-probe and an even smaller shift when both motifs are mutated (mut-m1+2). Binding to mutated probes could also be efficiently competed by adding a non-labeled WT-probe."
        ],
        "rois":[
          {
            "x":0,
            "y":1755,
            "x2":3011,
            "y2":3112
          },
          {
            "x":0,
            "y":3113,
            "x2":3011,
            "y2":3888
          }
        ]
      }
    }
  },
  "3462182":{
    "Fig 1.TIF":{
      "a":{
        "descriptions":[
          "(a) Data record numbers for Plants, Compounds and Bio-targets. "
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":4149,
            "y2":1826
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Data record reference quantities for Plants-Compounds and Compounds-Targets."
        ],
        "rois":[
          {
            "x":9,
            "y":10,
            "x2":4149,
            "y2":1826
          }
        ]
      }
    }
  },
  "346575":{
    "Figure_1.tif":{
      "0":{
        "descriptions":[
          ", 0.5"
        ],
        "rois":[
          {
            "x":2403,
            "y":154,
            "x2":3411,
            "y2":846
          }
        ]
      },
      "1":{
        "descriptions":[
          ", 1.0",
          ", 1.5"
        ],
        "rois":[
          {
            "x":18,
            "y":856,
            "x2":3432,
            "y2":2499
          },
          {
            "x":14,
            "y":14,
            "x2":2407,
            "y2":819
          }
        ]
      },
      "2":{
        "descriptions":[
          ", 2.0 ??M); D, The number of iPMSCs colonies; E, Expression of PDX1, PCNA, Ngn3, TERT and C-Myc were analysed at mRNA level in the absence and presence of 1.0 and 1.5 ??M BIO; F, The growth curves of iPMSCs cultured in the absence and presence of BIO (1 ??M). Bar???=???20 ??m. * P"
        ],
        "rois":[
          {
            "x":1778,
            "y":1809,
            "x2":3405,
            "y2":2498
          }
        ]
      }
    }
  },
  "346779":{
    
  },
  "346964":{
    
  },
  "347120":{
    
  },
  "347231":{
    
  },
  "347448":{
    
  },
  "347710":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "A) Collection of environmental samples is realized using the Airborne Sample Analysis Platform (ASAP) equipment. Aerosolized particulates stick to a filter, and the content is extracted and analyzed. In contrast to protein detection, detection of nucleic acids requires preparation of the filter content prior to exposure to the molecular procedures. The molecular procedures detect the target molecules using dedicated probes and reacted probes are then amplified. The amplification products are analyzed using a dedicated prototype instrument"
        ],
        "rois":[
          {
            "x":20,
            "y":20,
            "x2":4264,
            "y2":7002
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) The molecular procedures of DNA (left) and protein (right) detection. Detection of nucleic acids is achieved by padlock probes that are specifically circularized if correctly hybridized to the correct target in the presence of DNA ligase. Padlock and capture probes are added to the samples along with DNA ligase (5 min). Reacted padlock probes are captured on magnetic beads and excess probes are eliminated by washing (3 min). Detection of proteins is initiated by capture of the target protein using magnetic beads equipped with antibodies. The addition of a pair of PLA probes, which are antibodies with attached oligonucleotides (3 min), forms a DNA circle guided by two connector oligonucletides, and a DNA ligase (5 min). Unreacted probes are eliminated by washing the circles, and from this step the magnetic beads are treated identically in both the genetic and PLA assays. A first RCA is initiated either by an extra primer or the target itself on the beads to replicate the DNA circles (11 min). The products are then restriction digested (2 min), and the monomers are collected. The monomers can then bind head-to-tail to the excess amount of replication oligonucleotides and formed new DNA circles. The new circles are amplified and labeled with fluorescence-tagged detection probes. The ligation, amplification and labeling are performed in one reaction (8 min). The RCPs are therefore ready for analysis in the detection instrument."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "347821":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) or CdV ",
          "(A) after BaV treatment (50 ??g/ml) or "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2005,
            "y2":1179
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). The protein concentrations were determined and 2.5 ??g of total proteins were loaded in each lane. Western blots depicting the time course of Cyt c release ",
          "(B) after CdV (50 ug/ml) and the same volume of vehicle as control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2005,
            "y2":1179
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) The graphs report the quantitative analysis of the kinetics of Cyt c release induced by venoms (black lines) and controls (dotted lines). The intensity of each band was determined using the software Quantity One (Bio-Rad) The blots and their quantification show one representative experiment (n???3)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2005,
            "y2":1179
          },
          {
            "x":0,
            "y":1180,
            "x2":2005,
            "y2":1311
          }
        ]
      }
    }
  },
  "348059":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) Western blots depicting the time course of Cyt c release after injection of either BaV (5 mg/kg) or CdV (0.15 mg/kg), or the same volume of vehicle as control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":996,
            "y2":985
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The graphs report the relative quantification analysis of the kinetics of Cyt c release induced by venoms, as compared to the control. The intensity of each band was determined using the software Quantity One (Bio-Rad). The blot and its quantification show one representative experiment."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":996,
            "y2":985
          }
        ]
      }
    }
  },
  "3482348":{
    
  }
,
  "3483737":{
    
  },
  "3483767":{
    
  },
  "3501428":{
    "Fig 2.TIF":{
      "E":{
        "descriptions":[
          "(E) IL-1?? protein and "
        ],
        "rois":[
          {
            "x":1851,
            "y":2003,
            "x2":3556,
            "y2":3127
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) TNF-?? protein was determined using Griess assay (for NO) or Bio-Plex Suspension Array (For IL-1?? and TNF-??) in cell lysates from WT (n = 5) and miR-155 KO (n = 5) bone marrow-derived macrophages in vitro activated in M1 or M2 conditions for 24 hours. Individual protein concentrations expressed as fraction of total protein concentration in either M0 or M1 condition. "
        ],
        "rois":[
          {
            "x":1851,
            "y":2003,
            "x2":3556,
            "y2":3127
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Inducible nitric oxide synthase (Nos2), "
        ],
        "rois":[
          {
            "x":3,
            "y":0,
            "x2":1676,
            "y2":976
          }
        ]
      },
      "NO":{
        "descriptions":[
          "(NO), "
        ],
        "rois":[
          
        ]
      },
      "G":{
        "descriptions":[
          "(G) IL1b expression was determined by Real-Time PCR in WT and KO bone marrow-derived macrophages transfected with a scrambled miR control (n = 5) or a miR-155 oligonucleotide mimic (n = 5) and activated in M0 (untreated), M1 (LPS+IFN-??) or M2"
        ],
        "rois":[
          {
            "x":4,
            "y":3163,
            "x2":1692,
            "y2":4286
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) IL1b, "
        ],
        "rois":[
          {
            "x":6,
            "y":1019,
            "x2":1680,
            "y2":1959
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Tumor Necrosis Factor-?? (Tnfa) "
        ],
        "rois":[
          {
            "x":0,
            "y":2003,
            "x2":1676,
            "y2":3127
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) and Arginase-1 (Arg1) expression was determined by Real-Time PCR in wild-type (WT, n = 8???11) and miR-155 knockout (KO n = 8???12) bone marrow-derived macrophages in vitro activated in M1 or M2 conditions for 24 hours in three independent experiments. Gene expression is expressed as a percentage +/- SEM of the WT M1 condition. Unpaired t-test, *p"
        ],
        "rois":[
          {
            "x":1852,
            "y":3164,
            "x2":3565,
            "y2":4187
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) nitric oxide "
        ],
        "rois":[
          {
            "x":1849,
            "y":0,
            "x2":3556,
            "y2":1950
          }
        ]
      }
    }
  },
  "350894":{
    "Figure_7.tif":{
      "A":{
        "descriptions":[
          ". A. Immunoblot for PIK3CA expression in transfected BEAS-2B cells"
        ],
        "rois":[
          {
            "x":947,
            "y":9,
            "x2":2048,
            "y2":848
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B. Heat map showing fold change patterns of DEGs induced by constitutive PI3K signalling. The heat map was generated in Matlab (Mathworks), and compares fold change patterns of DEGs in BEAS-2B-PI3K-E545K cells compared to parental BEAS-2B (pC. The top 11 functional categories determined by IPA, that were significantly up-regulated or down-regulated in BEAS-2B-PI3K-E545K cells compared to parental BEAS-2B are shown. The 2126 DEGs in BEAS-2B-PI3K-E545K were mapped to the IPA-defined network. The significance p-values that determine the probability that the association between the genes in the dataset and the canonical pathway is by chance alone were calculated by Fisher's exact test, and are expressed as ???log (p-value)"
        ],
        "rois":[
          {
            "x":935,
            "y":951,
            "x2":1969,
            "y2":2462
          },
          {
            "x":10,
            "y":11,
            "x2":836,
            "y2":1803
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D. Bio-functions identified by IPA in the 2126 DEGs from BEAS-2B-PI3K-E545K compared with BEAS-2B"
        ],
        "rois":[
          {
            "x":935,
            "y":951,
            "x2":1969,
            "y2":2462
          },
          {
            "x":10,
            "y":11,
            "x2":836,
            "y2":1803
          }
        ]
      },
      "E":{
        "descriptions":[
          ". E. Sub-Categories and Functions identified through IPA showing the genes associated to lung cancer in the 2126 DEGs from BEAS-2B-PI3K-E545K compared with BEAS-2B."
        ],
        "rois":[
          {
            "x":17,
            "y":2410,
            "x2":1568,
            "y2":3443
          }
        ]
      }
    }
  },
  "351838":{
    
  },
  "352949":{
    
  },
  "353956":{
    "Figure_4.tif":{
      "12":{
        "descriptions":[
          "; 12: MLH1-GFP-N/PMS2-Red-C"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "8":{
        "descriptions":[
          "; 8: MLH1-GFP-C/PMS2"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "4":{
        "descriptions":[
          "; 4: MLH1/PMS2-GFP-C"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "15":{
        "descriptions":[
          "; 15: MLH1-Red-N/PMS2-GFP-N"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "11":{
        "descriptions":[
          "; 11: MLH1-GFP-N/PMS2-Red-N"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "9":{
        "descriptions":[
          "; 9: MLH1-Red-N/PMS2"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "13":{
        "descriptions":[
          "; 13: MLH1-GFP-C/PMS2-Red-N"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "16":{
        "descriptions":[
          "; 16: MLH1-Red-N/PMS2-GFP-C"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "5":{
        "descriptions":[
          "; 5: MLH1/PMS2-Red-N"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "10":{
        "descriptions":[
          "[10]. In vitro repair was scored on a 2-kb circular DNA substrate that contains an EcoRV site which is destroyed by a G-T mismatch. Upon repair of the G-T mismatch to an A-T base pair the intact EcoRV site together with an AseI site gives rise to a 0.8- and a 1.2-kb fragment, whereas unrepaired DNA is only linearized by AseI to a 2-kb fragment. Repair efficiency was assessed by measuring the signal intensities of linearized and digested vector with Bio-Rad Quantity One software using the ???rolling ball??? baseline correction. The signal intensity of the repair bands was divided by the intensity of all three bands. Repair efficiency of unlabeled MutL?? was set at 100 percent and repair of fluorescent tagged MutL?? was determined in relation to the wild-type sample that was expressed, processed and tested in parallel. Average repair values and standard deviations (??) were determined from four independent experiments. Single PMS2 tagged MutL??s, single MLH1-GFP-N tagged MutL??s as well as MLH1-GFP-N coexpressed with PMS2-Red-N or MLH1-Red-N coexpressed with PMS2-GFP-N were MMR proficient while all other tagged variants showed MMR deficiency",
          "; 10: MLH1-Red-C/PMS2"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "6":{
        "descriptions":[
          "; 6: MLH1/PMS2-Red-C"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "1":{
        "descriptions":[
          ". 1: mock control (untransfected)"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "17":{
        "descriptions":[
          "; 17: MLH1-Red-C/PMS2-GFP-N"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          }
        ]
      },
      "14":{
        "descriptions":[
          "; 14: MLH1-GFP-C/PMS2-Red-C"
        ],
        "rois":[
          {
            "x":13,
            "y":550,
            "x2":3253,
            "y2":866
          },
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "2":{
        "descriptions":[
          ". 2: MLH1/PMS2 unlabeled (positive control)"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "18":{
        "descriptions":[
          "; 18: MLH1-Red-C/PMS2-GFP-C. Symbols see Figure 1."
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "7":{
        "descriptions":[
          "; 7: MLH1-GFP-N/PMS2"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      },
      "3":{
        "descriptions":[
          "; 3: MLH1/PMS2-GFP-N"
        ],
        "rois":[
          {
            "x":306,
            "y":13,
            "x2":3433,
            "y2":491
          }
        ]
      }
    }
  },
  "3545829":{
    
  },
  "355111":{
    
  },
  "3560115":{
    
  },
  "3577536":{
    
  },
  "357922":{
    
  },
  "358196":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Model of the cytokinin signaling pathway in Arabidopsis. Arrows indicate positive interactions, bar indicates a negative interaction. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":951,
            "y2":2528
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Heat map of gene expression of two-component elements in Arabidopsis following pathogen or elicitor treatment. Microarray data was obtained from AtGenExpress (http://www.uni-tuebingen.de/plantphys/AFGN/atgenex.htm) and analyzed using the e-northern tool of the Bio-Array Resource for Arabidopsis Functional Genomics (http://bar.utoronto.ca/). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":951,
            "y2":2528
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Susceptibility of cytokinin-treated Arabidopsis to Hpa Noco2. Two-week-old wild-type plants were sprayed with the indicated concentrations of BA or DMSO control 48 hours prior to inoculation with Hpa Noco2. Spore production was measured as described in Methods. Error bars represent SE (n???=???6). Asterisks indicate statistically significant differences from wild-type plants (p-value"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":951,
            "y2":2528
          }
        ]
      }
    }
  },
  "360353":{
    "Figure_4.tif":{
      "HY":{
        "descriptions":[
          "(HY) were measured. The data represent the percentage variation in alkaline phosphatase "
        ],
        "rois":[
          {
            "x":7,
            "y":1013,
            "x2":1752,
            "y2":2557
          }
        ]
      },
      "AP":{
        "descriptions":[
          "(AP) positive colonies compared with the DMSO treated control. The average values ?? SEM are shown from three independent experiments. Two-tailed paired t-test: ***???=???pC iPSCs were cultured in KO SR without LIF and supplemented with 10% (v/v) HY. The total numbers of colonies generated are shown and are compared with the total number of colonies generated by ESCs and iPSCs in KO SR plus LIF plus serum. The percentage of alkaline phosphatase positive colonies are shown in histogram D."
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1618,
            "y2":905
          }
        ]
      }
    }
  },
  "3608298":{
    
  },
  "361797":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          ". E: eosinophils"
        ],
        "rois":[
          {
            "x":8,
            "y":8,
            "x2":1079,
            "y2":2761
          },
          {
            "x":1148,
            "y":8,
            "x2":2134,
            "y2":1776
          }
        ]
      },
      "F":{
        "descriptions":[
          "; F: dermal fibroblasts"
        ],
        "rois":[
          {
            "x":1206,
            "y":1858,
            "x2":2180,
            "y2":2748
          }
        ]
      },
      "EF":{
        "descriptions":[
          "; EF: co-culture of eosinophils and dermal fibroblasts *p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "361965":{
    "Figure_3.tif":{
      "E":{
        "descriptions":[
          ". E: unfixed eosinophils; E???: fixed eosinophils"
        ],
        "rois":[
          {
            "x":46,
            "y":1859,
            "x2":1087,
            "y2":2721
          },
          {
            "x":8,
            "y":8,
            "x2":2180,
            "y2":1782
          }
        ]
      },
      "F":{
        "descriptions":[
          "; F: unfixed dermal fibroblasts; F???: fixed dermal fibroblasts *p"
        ],
        "rois":[
          {
            "x":1183,
            "y":1861,
            "x2":2174,
            "y2":2714
          }
        ]
      }
    }
  },
  "362047":{
    
  },
  "362208":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Enzymes and intermediates in the steroid bio-synthetic pathway leading from cholesterol to the formation of testosterone and DHT. LDLR and SR-B1 mediate cholesterol uptake; STAR and STARD3 mediate transport of cholesterol across the mitochondrial membrane where steroidogenesis is initiated. CYB5A is an important cofactor for the lyase activity of CYP17A. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1278,
            "y2":663
          }
        ]
      },
      "CT":{
        "descriptions":[
          "(CT) for detection of each transcript was normalized to expression of the housekeeping gene RPL13A in the same sample (delta or dCT). "
        ],
        "rois":[
          {
            "x":0,
            "y":664,
            "x2":3100,
            "y2":1999
          }
        ]
      },
      "AR":{
        "descriptions":[
          "(AR), the androgen regulate gene PSA, and genes involved in cholesterol transport. "
        ],
        "rois":[
          {
            "x":2346,
            "y":0,
            "x2":3100,
            "y2":663
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Transcript profiling of tumors from all 4 treatment groups by qRT-PCR for the androgen receptor "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1278,
            "y2":663
          },
          {
            "x":2346,
            "y":0,
            "x2":3100,
            "y2":663
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Transcript profiling for the expression of steroidogenic genes and the CYB5 cofactor. The mean cycle threshold "
        ],
        "rois":[
          {
            "x":1279,
            "y":0,
            "x2":2345,
            "y2":663
          },
          {
            "x":2346,
            "y":0,
            "x2":3100,
            "y2":663
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) The correlation of serum cholesterol levels with transcript expression of CYP17A as measured by qRT-PCR. Correlation coefficients and p values from linear regression analysis."
        ],
        "rois":[
          {
            "x":2346,
            "y":0,
            "x2":3100,
            "y2":663
          },
          {
            "x":0,
            "y":664,
            "x2":3100,
            "y2":1999
          }
        ]
      }
    }
  },
  "362406":{
    "Figure_7.tif":{
      "LY":{
        "descriptions":[
          ", LY: LY294002"
        ],
        "rois":[
          
        ]
      },
      "U":{
        "descriptions":[
          ", U: U0126"
        ],
        "rois":[
          
        ]
      },
      "SB":{
        "descriptions":[
          ", SB: SB203580"
        ],
        "rois":[
          {
            "x":1202,
            "y":24,
            "x2":2283,
            "y2":915
          },
          {
            "x":8,
            "y":954,
            "x2":1095,
            "y2":1978
          },
          {
            "x":11,
            "y":8,
            "x2":1093,
            "y2":910
          }
        ]
      },
      "SP":{
        "descriptions":[
          ", SP: SP600125 *p"
        ],
        "rois":[
          {
            "x":54,
            "y":954,
            "x2":2383,
            "y2":2946
          }
        ]
      }
    }
  },
  "362744":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) Wound healing assay of DU145 cells infected with EZH2-specific shRNA (sh1) or control shRNA "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Western blot analysis of EZH2 expression in the benign prostate cell line RWPE-1 and the malignant prostate cancer cell lines LNCaP, DU145, and PC3 (top). Actin was used as an internal control. The protein bands were quantified using Quantity One software (Bio-Rad) (bottom). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      },
      "WT":{
        "descriptions":[
          "(WT) and mutant (H689A, enzymatically inactive) EZH2 proteins in RWPE-1 cells infected with EZH2 ",
          "(WT)-GFP, EZH2 (H689A)-GFP, or control (GFP vector) lentivirus. EZH2 proteins were expressed from the CMV promoter (left). Invasion assay of RWPE-1 cells infected with EZH2 ",
          "(WT)-GFP, EZH2 (H689A)-GFP, or control (GFP vector) lentivirus (right). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Invasion assay of RWPE-1, PC3 and DU145 cells. Cell invasiveness was assessed by the invasion of cells through BME-coated inserts in the Transwell Boyden chamber (top). The invasion rate was determined by counting the cells that migrated through the inserts and expressed as the percentage relative to control (RWPE-1, set to 100%) (bottom). Each bar represents the mean ?? s.e of five fields counted. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Western blot analysis of EZH2 expression in PC3 and DU145 cells after an infection with EZH2-specific shRNA lentivirus (sh1 or sh2; two different EZH2-specific shRNAs) or with non-treated shRNA (NT, control) lentivirus (top). Invasion assay of PC3 or DU145 cells after an infection with EZH2-specific shRNA (sh1 or sh2) or control "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      },
      "NT":{
        "descriptions":[
          "(NT) lentivirus (middle). Representative fields of invaded and stained cells are shown (middle). Each bar represents the mean ?? s.e of five fields counted (bottom). ",
          "(NT) lentivirus. Images were taken before (0 h) and after wound (24 h) (top). The results were expressed as the percentage of the remaining area determined by normalizing the area of wound after 24 h to the initial wound area at 0 h (set to 100%). Each bar represents the mean ?? s.e of five fields measured (bottom).* P, ** p (as compared with control values)."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Western blot analysis of overexpression of wild-type "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2066,
            "y2":1402
          }
        ]
      }
    }
  },
  "363045":{
    
  },
  "363357":{
    "Figure_8.tif":{
      "A":{
        "descriptions":[
          "(A) Western blot analysis of EZH2 and TIMP3 expression in RWPE-1 cells after an infection with the indicated combinations of lentivirus expressing EZH2, TIMP3 and control virus. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1668
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Invasion assay of RWPE-1 cells after an infection with the indicated combinations of lentivirus expressing EZH2, TIMP3 and control virus. Top: a, EZH2(???)/TIMP3(???); b, EZH2(???)/TIMP3(+); c, EZH2(+)/TIMP3(???); d, EZH2(+)/TIMP3(+). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1668
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Gelatin zymographic assay for MMP-2 and MMP-9 activity in PC3 and DU145 cells infected with EZH2-specific shRNA (sh1) or control shRNA virus "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1668
          }
        ]
      },
      "NT":{
        "descriptions":[
          "(NT). The upper and lower bands indicate active MMP-9 (92 kDa) and active MMP-2 (62 kDa), respectively. Zymographic band intensities were quantified by densitometry using Quantity One software (Bio-Rad). Each bar represents the mean ?? s.e of three fields counted. * P, ** p, *** p (as compared with control ",
          "(NT))."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1849,
            "y2":1668
          }
        ]
      }
    }
  },
  "36384":{
    
  },
  "364475":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) Spatial pattern of the Pearson correlation coefficients between the mode 1 and the OC4v4-chl time series of the lake-sections. "
        ],
        "rois":[
          {
            "x":12,
            "y":13,
            "x2":1103,
            "y2":1081
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Spatial pattern of Pearson correlation coefficients between the mode 2 and the OC4v4-chl time series. "
        ],
        "rois":[
          {
            "x":1133,
            "y":16,
            "x2":2223,
            "y2":1082
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Contour lines were obtained by kriging interpolation. Spatial distribution of the most representative mode (highest R) for each lake-section. "
        ],
        "rois":[
          {
            "x":10,
            "y":1119,
            "x2":2225,
            "y2":2191
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Classification of Lake Victoria in regions sharing similar bio-optical co-variation. The Transitional Region between North and South Regions is delimited by dotted lines. The topography of the study area is also shown through the contour heights (in meters) interpolated from a 10' dataset."
        ],
        "rois":[
          
        ]
      }
    }
  },
  "364600":{
    
  },
  "364680":{
    
  },
  "365870":{
    "Figure_3.tif":{
      "A":{
        "descriptions":[
          "(A) and quantitated by using Bio-Rad Quantity One program. The y-axis was normalized for the loading control. B7-H4 treatment significantly inhibited AKT phosphorylation at 10 min to a similar degree on different T-cell subsets "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1496,
            "y2":758
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Data represent 3 independent experiments and are expressed as means ?? SD from 3???4 mice per group."
        ],
        "rois":[
          {
            "x":306,
            "y":862,
            "x2":1466,
            "y2":1768
          }
        ]
      }
    }
  },
  "365962":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A) or IL-2 secretion ",
          "(A). Culture supernatant was collected and tested by ELISA "
        ],
        "rois":[
          {
            "x":533,
            "y":10,
            "x2":1282,
            "y2":667
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) or CD69 ",
          "(G)"
        ],
        "rois":[
          {
            "x":69,
            "y":1447,
            "x2":2558,
            "y2":3588
          },
          {
            "x":1034,
            "y":762,
            "x2":1783,
            "y2":1403
          },
          {
            "x":1834,
            "y":1117,
            "x2":2566,
            "y2":1403
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), or stained with anti-IL-2 (C, D, E, and F) or anti-CD25 ",
          "(B). Representative dot plot of the expression of IL-2 secretion on CD3+, CD4+, CD8+ population and percentage of double positive IL-2 on three different subsets was shown "
        ],
        "rois":[
          {
            "x":1409,
            "y":50,
            "x2":2103,
            "y2":653
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). The average expression level of IL-2 on CD3+, CD4+, and CD8+ was shown in D, E, and F, respectively. Representative dot plot of CD25 expression and average expression level was shown "
        ],
        "rois":[
          {
            "x":10,
            "y":706,
            "x2":994,
            "y2":1403
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) at the indicated time points. Relative expression of IL-2 mRNA was detected by real-time PCR ",
          ". H. Representative histogram of the expression of CD69 was plotted and the average expression level was quantitated using Bio-Rad Quantity One program ",
          "(H). 20,000 of Living cells were analyzed by flow cytometry. Data represent 3 independent experiments and are expressed as means ?? SD. One star (*) indicates p"
        ],
        "rois":[
          {
            "x":1829,
            "y":762,
            "x2":2577,
            "y2":1102
          }
        ]
      }
    }
  },
  "366066":{
    
  },
  "366289":{
    
  },
  "367485":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) Effects of CART on AMVN-induced fluorescence decay in mitochondria isolated from human SHSY cells. AMVN 1.5 mM was added to the reaction medium (0.2 ml) containing mitochondria 50 ??g, cis PA 12 ??M in 0.1 M KCl and phosphate buffer (50 mM, pH 7.4 at 40??C). CART (1 nM) was added 20 min later. The fluorescence intensity was monitored by using a BIO-TEK spectrofluorometer. "
        ],
        "rois":[
          {
            "x":7,
            "y":8,
            "x2":819,
            "y2":830
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Radical scavenging activity of CART in mitochondria isolated from HEK293 cells. The reaction containing 50 ??g mitochondria, cisPA 6 ??M, CART peptides and AMVM 2 mM in 0.1 M KCI and phosphate buffer was performed at 40??C for 20 min, and the fluorescence intensity was measured after continued incubation at RT for 90 min. *, PPP"
        ],
        "rois":[
          {
            "x":923,
            "y":7,
            "x2":1611,
            "y2":830
          }
        ]
      }
    }
  },
  "368484":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) RNA sequence map of the 3???-UTR of CHD5 (Gene ID 26038) mRNA with the complementary site (3???-UTR 130???136) for the seed region of miRNA-211. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1903,
            "y2":1241
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) miR-211 levels in RKO, HCT-116, RKO-S, and RKO-AS cell lines by quantitative RT-PCR based on miR-211/U6 expression fold values. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1903,
            "y2":1241
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) CHD5 protein levels in two colon cancer cell lines (RKO and HCT-116) and two established cell lines (RKO-S and RKO-AS) with enforced CHD5-S expression were analyzed by Western blot and semi-quantified based on CHD5/??-actin relative intensities. Bio-Rad Quantity One software was used for densitometric analysis of the Western blots. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1903,
            "y2":1241
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Comparison of CHD5 and miR-211 expression levels in HCT-116 and RKO cell lines. * indicated as P"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1903,
            "y2":1241
          }
        ]
      }
    }
  },
  "369355":{
    
  },
  "371672":{
    "Figure_2.tif":{
      "E":{
        "descriptions":[
          "(E)."
        ],
        "rois":[
          
        ]
      },
      "A":{
        "descriptions":[
          "(A) or down-regulated "
        ],
        "rois":[
          {
            "x":14,
            "y":7,
            "x2":1128,
            "y2":607
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) in oocytes aged for 24 hours, but their expression was restored to the normal level under caffeine stimulation. On the other side, the expression of proteins was not changed in oocytes aging for 24 hours, but was up-regulated "
        ],
        "rois":[
          {
            "x":14,
            "y":7,
            "x2":1128,
            "y2":607
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) or down-regulated "
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D) with caffeine stimulation. Some protein expressions were not affected by caffeine "
        ],
        "rois":[
          {
            "x":7,
            "y":575,
            "x2":917,
            "y2":1691
          },
          {
            "x":14,
            "y":7,
            "x2":1128,
            "y2":607
          },
          {
            "x":1191,
            "y":78,
            "x2":2058,
            "y2":1098
          }
        ]
      }
    }
  },
  "373608":{
    "Figure_5.tif":{
      "e":{
        "descriptions":[
          "(e), and the ventricular expression expands into the MZ (e???, white bar). Treatment of embryos with the Wnt signaling agonist BIO from 16 hpf to 48 hpf leads to an expansion of pchd10b expression into the pretectum (f, white arrow), however the expanded VZ is not detectable (f???, white bar). Although the gross morphology is altered, pcdh10b expression shows similar broadening in axin1 mutant embryos (g, g???). Consequently, blocking of Wnt signaling by IWR-1 treatment from 16 hpf to 48 hpf leads to a severe downregulation of pcdh10b (h, h???). Embryos with ubiquitous expression of the Wnt inhibitor Dkk1 after heat shock activation at 10 hpf leads to a downregulation of pcdh10 expression at 48 hpf (i, i???). Knock-down of Wnt3a in the Lhx2/Lhx9-double-deficient embryos leads to a rescue of the expansion into the pretectum "
        ],
        "rois":[
          {
            "x":1115,
            "y":120,
            "x2":1752,
            "y2":577
          },
          {
            "x":450,
            "y":19,
            "x2":1311,
            "y2":107
          },
          {
            "x":1322,
            "y":705,
            "x2":1534,
            "y2":1145
          },
          {
            "x":885,
            "y":1165,
            "x2":1313,
            "y2":1253
          },
          {
            "x":1542,
            "y":691,
            "x2":1752,
            "y2":1145
          },
          {
            "x":1321,
            "y":1165,
            "x2":1753,
            "y2":1253
          },
          {
            "x":1115,
            "y":692,
            "x2":1311,
            "y2":1145
          },
          {
            "x":449,
            "y":590,
            "x2":1753,
            "y2":1724
          },
          {
            "x":449,
            "y":1165,
            "x2":877,
            "y2":1253
          }
        ]
      },
      "j":{
        "descriptions":[
          "(j), however the lateral expansion of the VZ is still detectable (j???). Canonical Wnt signaling???that is, Wnt3a???is required for induction of pcdh10b expression in the thalamic ventricular zone, whereas Lhx2/Lhx9 inhibits pcdh10b expression in the mantle zone of the cTh "
        ],
        "rois":[
          {
            "x":13,
            "y":21,
            "x2":441,
            "y2":109
          },
          {
            "x":885,
            "y":1269,
            "x2":1106,
            "y2":1722
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) shown in a dorsal view (c???). Overexpression of lhx2 DNA via electroporation leads to a unilateral downregulation of pcdh10b expression (dorsal view, d; d???). Control embryos show pcdh10b expression in the cTh (d, d???). In lhx2 mutant embryo knocked-down for lhx9, pcdh10b expression expands into the pretectum "
        ],
        "rois":[
          {
            "x":13,
            "y":121,
            "x2":441,
            "y2":678
          },
          {
            "x":449,
            "y":126,
            "x2":671,
            "y2":576
          },
          {
            "x":680,
            "y":122,
            "x2":1106,
            "y2":576
          },
          {
            "x":245,
            "y":695,
            "x2":439,
            "y2":1145
          },
          {
            "x":14,
            "y":1165,
            "x2":443,
            "y2":1722
          },
          {
            "x":681,
            "y":1282,
            "x2":876,
            "y2":1720
          },
          {
            "x":245,
            "y":1268,
            "x2":440,
            "y2":1721
          },
          {
            "x":450,
            "y":1269,
            "x2":671,
            "y2":1722
          },
          {
            "x":884,
            "y":692,
            "x2":1106,
            "y2":1146
          },
          {
            "x":680,
            "y":692,
            "x2":874,
            "y2":1145
          },
          {
            "x":449,
            "y":692,
            "x2":670,
            "y2":1146
          }
        ]
      },
      "k":{
        "descriptions":[
          "(k)."
        ],
        "rois":[
          
        ]
      },
      "d":{
        "descriptions":[
          "(d). Asterisks mark the thalamic territory. pcdh10b expression abuts the expression domain of lhx9 in the mantle zone (MZ, black bar; a, a???). The roof plate marker, wnt3a, is adjacently expressed to the pcdh10b expression in the thalamus (b, b???). Expression of pcdh10b in the thalamus abuts posteriorly the expression domain of gsx1 and therefore respects the border to the pretecum "
        ],
        "rois":[
          {
            "x":15,
            "y":694,
            "x2":234,
            "y2":1145
          }
        ]
      }
    }
  },
  "373914":{
    
  },
  "3748773":{
    "Fig 3.TIF":{
      "A":{
        "descriptions":[
          "(A) A549 was co-cultured with NFs-Scr, NFs-TM, or CAFs-Scr for 48 h. The levels of various factors in the cell-free culture supernatants were measured by Bio-Plex cytokine array. All cytokines levels were normalized to the levels of IL-1?? in the CM of NFs-Scr-A549 co-culture. The relative levels of each cytokine were compared to the particular cytokine. Date is shown as fold induction of triplicates. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1999,
            "y2":1552
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B,C) Cell migration assay and Colony formation assay was performed to determine LCCs cell migration and colony formation ability when treated with indicated secreted factor(s). *p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1999,
            "y2":1552
          }
        ]
      },
      "C":{
        "descriptions":[
          "(B,C) Cell migration assay and Colony formation assay was performed to determine LCCs cell migration and colony formation ability when treated with indicated secreted factor(s). *p "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1999,
            "y2":1552
          }
        ]
      }
    }
  },
  "375584":{
    "Figure_1.tif":{
      "A":{
        "descriptions":[
          "(A) or LPS (10 ??g/ml) ",
          "(A) and "
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":2915,
            "y2":1593
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Negative and positive control supernatants were obtained from unstimulated and untreated astrocytes in serum-free DMEM (control) and cells stimulated with LPS or PMA, respectively. After 24 h of incubation equal amounts of cell culture supernatants were subjected to gelatine zymography as described in the Methods section. Representative gels are reported in ",
          "(B). MMP-2 and MMP-9 were identified by their apparent molecular mass of 67 and 92 kDa, respectively, using pre-stained molecular weight markers (Bio-Rad). Histograms represent results, expressed as mean??SD, after scanning densitometry and computerized analysis of gels, from at least three independent experiments with different cell populations. Asterisk represents values statistically different from positive control (PMA-treated astrocytes) (One-way Anova followed by Student-Newman-Keuls post hoc test; *???=???p"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "3756096":{
    
  },
  "375736":{
    
  },
  "3759198":{
    
  },
  "376214":{
    
  },
  "376321":{
    
  },
  "376460":{
    
  },
  "3770229":{
    "Fig 3.TIF":{
      "E":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":0,
            "y":1902,
            "x2":1653,
            "y2":2399
          }
        ]
      },
      "e":{
        "descriptions":[
          "(e) The MITE-like transposon found within the CEN2 fragment (from 1925 to 2120 bp), named CEN2-2, was used as a query in a search through the D. bruxellensis genome (Y879 strain). 10 sequences (and their surroundings) were randomly sampled from the 51 present in the genome (S2 Table) and aligned with CEN2-2 (reference sequence) to present the ???structural??? parts of the transposon: inverted and direct repeats. The bases identical to the reference sequence are shown in grey. Inverted repeats are 7 bp long and they are at the beginning and end of the transposon; marked with red arrows only on the reference sequence, inverted repeats are present in all sequences in the genome. Direct repeats are marked with blue arrows; they are 5 bp long but have different sequences, and they immediately flank the transposon (in the genome of Y879 strain)."
        ],
        "rois":[
          
        ]
      },
      "a":{
        "descriptions":[
          "(a) The CEN1 locus has 65.6% AT content and carries the ser-tRNA gene; it carries part of a gene homologous to the RPT2 gene, the TVP15 gene, and the COPI-coated vesicle-protein encoding gene. The CEN2 locus has 62.4% AT content and it carries the gene coding for the MATE efflux family protein. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1653,
            "y2":1901
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) The AT-peaks occur at the intergenic region in CEN1 and within a 3???-region of CEN2. This subfigure was drawn using the DNA/RNA GC Content Calculator (http://www.endmemo.com/bio/gc.php). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1653,
            "y2":1901
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) The transformation efficiency of three plasmid types. (1) The plasmid with CEN1. (2) Two plasmids with CEN2, specifically the Y881 strain possessing the transposon and the Y879 strain lacking the transposon. (3) The deletion plasmids of CEN2, specifically CEN2-1, CEN2-2, CEN2-3, CEN2-4, CEN2-5; the plasmid CEN2-2 has a transposon. The P892/BI plasmid, which carried the URA3 gene and which had been linearized by BamHI (BI), was used as a control. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1653,
            "y2":1901
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) The schematic representation of the CEN1, CEN2 and CEN2 deletion-plasmids. The sequences that promote autonomous replication and stable maintenance are marked with a plus sign (+); the remaining sequences are marked with a minus sign (-). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1653,
            "y2":1901
          }
        ]
      }
    }
  },
  "3771855":{
    
  },
  "377283":{
    
  },
  "37833":{
    
  },
  "3796098":{
    
  },
  "379766":{
    "Figure_6.tif":{
      "E":{
        "descriptions":[
          "(E) IL-17, and "
        ],
        "rois":[
          {
            "x":1032,
            "y":860,
            "x2":1973,
            "y2":1630
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) IL-18 using a Bio-Plex pro cytokine assay (n???=???6 mice per group). Asterisks indicate differences that are statistically significant (*, PPP"
        ],
        "rois":[
          {
            "x":1998,
            "y":860,
            "x2":2932,
            "y2":1630
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) IFN-??, "
        ],
        "rois":[
          {
            "x":16,
            "y":15,
            "x2":983,
            "y2":806
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) TNF-??, "
        ],
        "rois":[
          {
            "x":1032,
            "y":22,
            "x2":1970,
            "y2":806
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) IL-10, "
        ],
        "rois":[
          {
            "x":1994,
            "y":29,
            "x2":2934,
            "y2":806
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) IL-12 p40, "
        ],
        "rois":[
          {
            "x":19,
            "y":851,
            "x2":983,
            "y2":1630
          }
        ]
      }
    }
  },
  "380370":{
    
  },
  "380492":{
    "Figure_3.tif":{
      "PA":{
        "descriptions":[
          "Comparative analysis of the global DNA methylation recorded as total fluorescence intensity (TFI) value in oocytes isolated from preantral (PA)"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1920,
            "y2":1428
          }
        ]
      },
      "EA":{
        "descriptions":[
          ", in vivo and in vitro grown early antral (EA)"
        ],
        "rois":[
          {
            "x":11,
            "y":11,
            "x2":1920,
            "y2":1428
          }
        ]
      },
      "P":{
        "descriptions":[
          " and preovulatory follicles. The distribution of data revealed that global DNA methylation increased during the transition from PA to EA follicles, in parallel, with the increase of the oocyte diameter (r ranged between 0.694 and 0.933; P"
        ],
        "rois":[
          
        ]
      }
    }
  },
  "380639":{
    
  },
  "3809607":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "(A) fresh (unfrozen) from the time of collection until time of testing (n = 146), and "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":2284,
            "y2":1065
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) frozen immediately after being collected from culled deer (n = 207). For the FEC test, results are recorded in eggs per gram of faeces (epg). For the cELISA, results are expressed in ELISA units "
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":2284,
            "y2":1065
          }
        ]
      },
      "EU":{
        "descriptions":[
          "(EU). Positive diagnosis by the cELISA was recorded for samples where results fell above a cut off derived using a positive reference standard."
        ],
        "rois":[
          {
            "x":3,
            "y":3,
            "x2":2284,
            "y2":1065
          }
        ]
      }
    }
  },
  "381255":{
    "Figure_4.tif":{
      "A":{
        "descriptions":[
          "(A), MSb3 "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3445,
            "y2":1191
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) and MSb13 "
        ],
        "rois":[
          {
            "x":0,
            "y":1192,
            "x2":3445,
            "y2":2303
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) we plotted the in-ward and out-ward TE for the two stimulation conditions (left and right columns). With the letters (s), (m) and (a) we are referring respectively to sender, messenger and addressee. The dynamical functional structure of effective information flows depends strongly on the two external conditions showing significant variations of bio-molecular information flows."
        ],
        "rois":[
          {
            "x":0,
            "y":2304,
            "x2":3445,
            "y2":3445
          }
        ]
      }
    }
  },
  "3814536":{
    
  },
  "3815571":{
    
  },
  "3838470":{
    
  },
  "3838809":{
    
  },
  "3845850":{
    
  },
  "3845865":{
    
  },
  "3845877":{
    
  },
  "3854157":{
    
  },
  "3855456":{
    
  },
  "3861672":{
    
  },
  "3864231":{
    "Fig 6.TIF":{
      "E":{
        "descriptions":[
          "(E) The survival ratio of wild type and pqt3 mutant germinated and grown on MS medium containing 0 ??M or 1 ??M paraquat without or with 15 ??M MG132 for 7 days were counted. DMSO was used as control. Values are mean ?? SD (n = 30 plants, *P "
        ],
        "rois":[
          {
            "x":888,
            "y":1930,
            "x2":1627,
            "y2":2508
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A)In vitro ubiquitination assay. GST-PQT3-N40 and GST-PQT3 were expressed in E. coli and purified. Nickel-HRP was used to detect His-tagged ubiquitin. The ubiquitination activity of PQT3 was observed only in the presence of E1 (from wheat), E2 (UBCh5b, from human), and 6??His-tagged ubiquitin (Ub). GST was used as negative control. The numbers on the left indicate the molecular masses of marker proteins. "
        ],
        "rois":[
          {
            "x":0,
            "y":2,
            "x2":877,
            "y2":1204
          },
          {
            "x":100,
            "y":1185,
            "x2":1743,
            "y2":1700
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) In planta ubiquitination assay. Total protein samples were isolated from the infiltrated parts of N. benthamiana leaves 1 day after agroinfiltration. The total protein was analyzed via western blot using anti-HA antibody (upper panel). Immunoprecipitated samples were analyzed using western blot with anti-ubiquitin antibody subsequently (middle panel). Ponceau S staining of the Rubisco protein was shown as a loading control (lower panel). The numbers on the left indicate the molecular masses of marker proteins. (C and D) The effect of proteasome inhibitor MG132 on the protein level of PRMT4b in wild type and pqt3-1 mutant without or with paraquat treatment in time-course. Wild type and pqt3-1 mutant were grown for 14 days, then the seedlings were treated without or with 6 ??M paraquat for 6 or 12 h in presence or absence of 50 ??M proteasome inhibitor MG132. The total proteins were extracted. Western blot was performed using anti-PRMT4b antibody "
        ],
        "rois":[
          {
            "x":101,
            "y":1962,
            "x2":789,
            "y2":2549
          },
          {
            "x":1,
            "y":1711,
            "x2":1629,
            "y2":1967
          },
          {
            "x":100,
            "y":1185,
            "x2":1743,
            "y2":1700
          },
          {
            "x":885,
            "y":4,
            "x2":1743,
            "y2":1140
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C). Ponceau S staining of the rubisco protein serves as a loading control. Band densities were quantified using Quantity One software (Bio-Rad, USA) "
        ],
        "rois":[
          {
            "x":101,
            "y":1962,
            "x2":789,
            "y2":2549
          },
          {
            "x":1,
            "y":1711,
            "x2":1629,
            "y2":1967
          },
          {
            "x":0,
            "y":2,
            "x2":877,
            "y2":1204
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D). Values are mean ?? SD (n = 3 experiments, ***P "
        ],
        "rois":[
          {
            "x":101,
            "y":1962,
            "x2":789,
            "y2":2549
          }
        ]
      }
    }
  },
  "3865110":{
    "Fig 1.TIF":{
      "a":{
        "descriptions":[
          "(a) Immunoblotting of the SMIS protein in the JE of C. pyrrhogaster. Substances present in the JE were separated through 2D-electrophoresis and transferred to a PVDF membrane. Immunoreaction was performed using an anti-SMIS monoclonal antibody (mAb)[4]. The upper and lower photographs show Coomassie brilliant blue staining of the gel and an immunoblot image, respectively. Arrowheads indicate the SMIS proteins. "
        ],
        "rois":[
          {
            "x":10,
            "y":12,
            "x2":689,
            "y2":396
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b) Amplification of SMIS cDNA through reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was purified from the indicated organs using the TRIzol?? reagent (Invitrogen), and 1 ??g of each sample was reverse-transcribed with an oligo-(dT) primer. Subsequently, PCR was performed using a primer set specific for the SMIS gene. In the control, primers specific for the ??-tubulin gene were used for PCR. "
        ],
        "rois":[
          {
            "x":733,
            "y":4,
            "x2":1518,
            "y2":496
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c) Immunoblotting of recombinant SMIS protein with an anti-SMIS mAb. Recombinant SMIS protein was produced in Escherichia coli by transfection of an expression vector (pCold TF, TaKaRa Bio, Tokyo, Japan) containing the open reading frame of SMIS cDNA. The protein was subjected to 1D-electrophoresis and immunoblotted with the anti-SMIS mAb. The left two columns show Coomassie Brilliant Blue staining of the acrylamide gel. The right shows specific binding of the anti-SMIS mAb. Arrowheads and arrows indicate the proteins produced from expression vectors with (SMIS) and without (Mock) SMIS cDNA, respectively. "
        ],
        "rois":[
          {
            "x":1553,
            "y":29,
            "x2":1686,
            "y2":399
          },
          {
            "x":733,
            "y":4,
            "x2":1518,
            "y2":496
          },
          {
            "x":10,
            "y":436,
            "x2":688,
            "y2":774
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d) A CK motif in the deduced amino acid sequence of the SMIS. The CK motif includes 6 cysteine residues at the 53rd, 62nd, 66th, 87th, 117th, 119th from N-terminus. Disulfide bonds are formed between cysteines-53 and -87, -62 and -117, and -87 and -119 to produce one ring and 3 loops (loops 1???3) that are supposed to be exposed on the outside. P1-P3 indicate the corresponding sites for preparation of the peptides for sperm motility analysis."
        ],
        "rois":[
          {
            "x":732,
            "y":510,
            "x2":1668,
            "y2":736
          }
        ]
      }
    }
  },
  "386767":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) and Tissue-specific "
        ],
        "rois":[
          {
            "x":28,
            "y":64,
            "x2":4767,
            "y2":3838
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) data series as data sources, and a threshold of 4.0. Colour scale represents Log2(transformed ratio of APL4 relative to APL3 signals)."
        ],
        "rois":[
          {
            "x":4609,
            "y":28,
            "x2":7176,
            "y2":3857
          }
        ]
      }
    }
  },
  "3868590":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "(A) Western blot of hippocampal proteins with FosB antibody reveals multiple additional bands in typical human cocaine addict HPC sample compared to a chronic cocaine-treated (15 mg/kg for 7 days) mouse HPC. Novel bands are apparent at 20 kDa, 23 kDa (white arrow), and 30 kDa (black arrow). "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":441,
            "y2":959
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Correlation and linear regression plots of protein expression for each band in the human samples with the postmortem interval (time between death and brain freezing) for each human sample. Dotted lines represent 95% confidence interval; no linear regression slope differed significantly from 0."
        ],
        "rois":[
          {
            "x":429,
            "y":0,
            "x2":2250,
            "y2":1538
          }
        ]
      }
    }
  },
  "3868611":{
    
  },
  "3868650":{
    "Fig 6.TIF":{
      "E":{
        "descriptions":[
          "(E) Western blot results showing the antigen detected in individual P60 gel fractions from patients or healthy people, probed by mAb 659."
        ],
        "rois":[
          {
            "x":0,
            "y":13,
            "x2":759,
            "y2":627
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) P10 [20 kDa], "
        ],
        "rois":[
          {
            "x":0,
            "y":13,
            "x2":759,
            "y2":627
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) P30 [40 kDa], "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) P60 [60 kDa], and "
        ],
        "rois":[
          {
            "x":894,
            "y":0,
            "x2":1554,
            "y2":618
          },
          {
            "x":905,
            "y":710,
            "x2":1562,
            "y2":1377
          },
          {
            "x":11,
            "y":709,
            "x2":671,
            "y2":1494
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) P100 [100 kDa]. OPN antigenic content determined by mAb 659 inhibition ELISA; concentration of BSA (included as control) determined by BCA. "
        ],
        "rois":[
          {
            "x":905,
            "y":710,
            "x2":1562,
            "y2":1377
          },
          {
            "x":57,
            "y":1438,
            "x2":1459,
            "y2":2564
          }
        ]
      }
    }
  },
  "3872106":{
    "Fig 4.TIF":{
      "a":{
        "descriptions":[
          "(a): ?ECS activity in the roots; "
        ],
        "rois":[
          {
            "x":17,
            "y":10,
            "x2":2177,
            "y2":1262
          }
        ]
      },
      "b":{
        "descriptions":[
          "(b): GSHS activity in the roots; "
        ],
        "rois":[
          {
            "x":11,
            "y":1261,
            "x2":2171,
            "y2":2548
          }
        ]
      },
      "c":{
        "descriptions":[
          "(c): ?ECS activity in the leaves; "
        ],
        "rois":[
          {
            "x":2178,
            "y":10,
            "x2":4290,
            "y2":1260
          }
        ]
      },
      "d":{
        "descriptions":[
          "(d): GSHS activity in the leaves. (For details see legend of Table 1)."
        ],
        "rois":[
          {
            "x":2172,
            "y":1261,
            "x2":4290,
            "y2":2548
          }
        ]
      }
    }
  },
  "3873045":{
    "Fig 6.TIF":{
      "i":{
        "descriptions":[
          "(panel i), vaso-obliterated areas are shown in white "
        ],
        "rois":[
          
        ]
      },
      "ii":{
        "descriptions":[
          "(panel ii). (B). Quantification of the vaso-obliterated area. Imaging analyses are expressed as mean ? standard error of the mean (SEM) and P values were calculated using a one-way ANOVA unpaired t-test. **P"
        ],
        "rois":[
          
        ]
      },
      "I":{
        "descriptions":[
          
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1547,
            "y2":1525
          }
        ]
      }
    }
  },
  "387355":{
    "Figure_1.tif":{
      "E":{
        "descriptions":[
          "(E) BALB/c mice were injected i.p. with 4 S. Paratyphi A isolates. Bacteria were collected from Lennox plates incubated at 37??C over-night, diluted in PBS, and mixed with hog gastric mucin. Groups of na??ve BALB/c mice, 6 mice per group were challenged and monitored twice daily for three days. Data represent percent cumulative survival curves."
        ],
        "rois":[
          {
            "x":2436,
            "y":1030,
            "x2":4084,
            "y2":1952
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Growth curves of four S. Paratyphi A isolates cultured on Lennox medium at 37??C under high aeration (250 rpm, 1???10 medium???flask volume). "
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1212,
            "y2":1039
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Final cell yields were recorded at time point of 8 h (t???=???8) by performing live counts. Average yields from two independent experiments are shown. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) Equivalent cell pellets and supernatants from t???=???8 were analysed by SDS-PAGE and stained with Coomassie (upper panels) or subjected to Western blot analysis with anti-FliC antibody (middle), along with S. Paratyphi A FliC standard (100 ??g). Estimation of FliC quantity was performed on the blots with Bio-Rad QuantityOne (lower). "
        ],
        "rois":[
          {
            "x":15,
            "y":15,
            "x2":1212,
            "y2":1039
          },
          {
            "x":1296,
            "y":152,
            "x2":2204,
            "y2":778
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Swim (0.3% agar) and swarm (0.7%) plates, following 8 h incubation at 37??C. "
        ],
        "rois":[
          {
            "x":16,
            "y":1075,
            "x2":2126,
            "y2":1972
          },
          {
            "x":1301,
            "y":783,
            "x2":1761,
            "y2":1309
          },
          {
            "x":1766,
            "y":783,
            "x2":2204,
            "y2":1309
          },
          {
            "x":2436,
            "y":16,
            "x2":4084,
            "y2":875
          }
        ]
      }
    }
  },
  "3874164":{
    "Fig 4.TIF":{
      "A":{
        "descriptions":[
          "(A) and densitometry "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2018,
            "y2":2105
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) of UCP1 levels in inguinal WAT from 12-week old R6/2 and WT littermate mice. Western blot of iBAT is shown for control purposes (SFig 2). Stain-free imaging (Bio-Rad) was used as the loading control and also for normalization. Graph shows mean % above control ?? S.E.M. for six mice of each genotype."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2018,
            "y2":2105
          }
        ]
      }
    }
  },
  "3876966":{
    
  },
  "3877185":{
    
  },
  "387735":{
    "Figure_5.tif":{
      "A":{
        "descriptions":[
          "(A) The plate was incubated at 37??C for 20 min, then, 180 ??l of a 37??C suspension of sheep erythrocytes (0.25%) in PBS pH 7.4 or 5.5 was added to each well. ",
          "(A) and "
        ],
        "rois":[
          {
            "x":7,
            "y":7,
            "x2":1057,
            "y2":1034
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) The plate was kept on ice for 20 min, then, 180 ??l of a 37??C suspension of erythrocytes (0.25%) in PBS pH 7.4 or 5.5 was added to each well. In ",
          "(B) following addition of erythrocytes, the plates were incubated at 37??C in a Power Wave 340 spectrophotometer (Bio-Tek) and absorbance (700 nm) was acquired every min [102]. Results show representative experiments (of 3), each performed in duplicate. In "
        ],
        "rois":[
          {
            "x":1044,
            "y":7,
            "x2":1967,
            "y2":1034
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and "
        ],
        "rois":[
          {
            "x":28,
            "y":1069,
            "x2":1077,
            "y2":1646
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), perforation of HepG2 cells was measured by quantitative live cell fluorescence microscopy. HepG2 cells were incubated on the microscope stage at 37??C for 40 min with ethidium homodimer and in the presence or absence of 1 mM calcium. Phase contrast and fluorescence images were recorded at regular time intervals using a 100X objective and LLO was added after 10 min of incubation. Results were expressed as the averagefluorescence intensity (in arbitrary units) in the cells ?? SEM of 5 movies for each condition. Scale bar???=???10 ??m."
        ],
        "rois":[
          {
            "x":28,
            "y":1069,
            "x2":1077,
            "y2":1646
          },
          {
            "x":1021,
            "y":1246,
            "x2":1961,
            "y2":2142
          },
          {
            "x":40,
            "y":1655,
            "x2":968,
            "y2":2165
          }
        ]
      }
    }
  },
  "3878838":{
    
  },
  "388095":{
    "Figure_5.tif":{
      "e":{
        "descriptions":[
          ", e) IL-5"
        ],
        "rois":[
          {
            "x":0,
            "y":494,
            "x2":1932,
            "y2":1537
          }
        ]
      },
      "f":{
        "descriptions":[
          ", f) IL-10 and g) IL-17. The cytokine concentrations for each mouse were calculated by subtracting the basal release of unstimulated samples from that of stimulated samples. Each bar represents mean values from six mice and error bars indicate SEM. *, ** and *** indicate statistically significant differences between groups (p"
        ],
        "rois":[
          {
            "x":0,
            "y":494,
            "x2":1932,
            "y2":1537
          }
        ]
      },
      "b":{
        "descriptions":[
          ", b) IFN-??"
        ],
        "rois":[
          {
            "x":0,
            "y":494,
            "x2":1932,
            "y2":1537
          }
        ]
      },
      "c":{
        "descriptions":[
          ", c) TNF-??"
        ],
        "rois":[
          {
            "x":0,
            "y":494,
            "x2":1932,
            "y2":1537
          }
        ]
      },
      "d":{
        "descriptions":[
          ", d) IL-4"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1932,
            "y2":493
          }
        ]
      }
    }
  },
  "3883932":{
    
  },
  "3888738":{
    
  },
  "3892971":{
    
  },
  "3893004":{
    
  },
  "3893094":{
    "Fig 6.TIF":{
      "A":{
        "descriptions":[
          "(A) SYBR GREEN I and "
        ],
        "rois":[
          {
            "x":4,
            "y":6,
            "x2":558,
            "y2":491
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B)TaqMan; Correlation of detection of copy number of ISAV in plasma samples by "
        ],
        "rois":[
          {
            "x":546,
            "y":6,
            "x2":1043,
            "y2":525
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) SYBR Green I (n = 13) and "
        ],
        "rois":[
          {
            "x":9,
            "y":468,
            "x2":529,
            "y2":1062
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) TaqMan chemistries (n = 8)."
        ],
        "rois":[
          {
            "x":539,
            "y":525,
            "x2":1044,
            "y2":1063
          }
        ]
      }
    }
  },
  "389885":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) Radiolabeled p53 (wild type and indicated mutants) and HPV16 E6 proteins produced in rabbit reticulocyte lysates were incubated together at 28??C. Aliquots were removed at the indicated times before separation by 12% SDS-PAGE and exposition to photographic film. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3586,
            "y2":2630
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Same experiment as in A, but levels of radiolabeled p53, after exposition to photographic film, were quantified by densitometry (BIO-RAD, Quantity One Software). Mean values "
        ],
        "rois":[
          
        ]
      },
      "AU":{
        "descriptions":[
          "(AU) ?? standard deviation for three independent experiments are shown. "
        ],
        "rois":[
          
        ]
      },
      "C":{
        "descriptions":[
          "(C) H1299 cells were co-transfected by vectors for transient expression of HPV16 E6 and p53 proteins. Where indicated, 4 h prior to harvesting, the medium was supplemented with the 26S proteasome inhibitor ALLN at a final concentration of 100 ??M. 24 h after transfection, extracted proteins were separated by 12% SDS-PAGE and analysed by Western-blotting using monoclonal anti-p53 antibody, polyclonal anti-actin antibody and monoclonal anti-16-E6 antibody."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":3586,
            "y2":2630
          }
        ]
      }
    }
  },
  "3900588":{
    "Fig 6.TIF":{
      "E":{
        "descriptions":[
          "(E), total chlorophyll "
        ],
        "rois":[
          {
            "x":552,
            "y":562,
            "x2":1097,
            "y2":926
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F) and carotenoid contents "
        ],
        "rois":[
          {
            "x":1106,
            "y":562,
            "x2":1651,
            "y2":926
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A), lipid peroxidation "
        ],
        "rois":[
          {
            "x":552,
            "y":562,
            "x2":1097,
            "y2":926
          },
          {
            "x":0,
            "y":0,
            "x2":724,
            "y2":545
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) of WT and transgenic plants. Graphs represent mean value ?? SE followed by different letters are significantly different at P"
        ],
        "rois":[
          {
            "x":1658,
            "y":562,
            "x2":2203,
            "y2":926
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B), proline "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":724,
            "y2":545
          },
          {
            "x":739,
            "y":0,
            "x2":1464,
            "y2":545
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C), chlorophyll a "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":724,
            "y2":545
          },
          {
            "x":1478,
            "y":0,
            "x2":2203,
            "y2":545
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D), chlorophyll b "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":724,
            "y2":545
          },
          {
            "x":0,
            "y":562,
            "x2":544,
            "y2":926
          }
        ]
      }
    }
  },
  "3902205":{
    "Fig 3.TIF":{
      "E":{
        "descriptions":[
          "(E) are shown. Mortality was recorded daily for 2 weeks "
        ],
        "rois":[
          {
            "x":631,
            "y":1023,
            "x2":1114,
            "y2":1483
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          },
          {
            "x":233,
            "y":0,
            "x2":772,
            "y2":445
          }
        ]
      },
      "J":{
        "descriptions":[
          "(J). Hemagglutination inhibition "
        ],
        "rois":[
          {
            "x":873,
            "y":1574,
            "x2":1399,
            "y2":1998
          }
        ]
      },
      "F":{
        "descriptions":[
          "(F). Oropharyngeal "
        ],
        "rois":[
          {
            "x":631,
            "y":1023,
            "x2":1114,
            "y2":1483
          },
          {
            "x":7,
            "y":1028,
            "x2":597,
            "y2":1399
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A). BPL-treated AFs were used to stimulate HD11 cells and confirm chIFN?? bio-activity through determination of nitrites as a sub-product of nitric oxide induced upon macrophage activation. Stimulated cells were incubated for 48 hrs at 37??C under a 5% CO2 atmosphere. Cell culture was used to determine nitrite concentration using the Griess method "
        ],
        "rois":[
          {
            "x":1170,
            "y":1024,
            "x2":1670,
            "y2":1484
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "AF":{
        "descriptions":[
          "(AF), rZJ1*L- and rZJ1*L/IFN??-infected AFs were inactivated with BPL for inactivated vaccine preparation and tested for chIFN?? concentration by ELISA "
        ],
        "rois":[
          
        ]
      },
      "I":{
        "descriptions":[
          "(I) and to determine T and B cell subpopulation by flow cytometric analysis "
        ],
        "rois":[
          {
            "x":210,
            "y":1568,
            "x2":755,
            "y2":1993
          },
          {
            "x":631,
            "y":1023,
            "x2":1114,
            "y2":1483
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) and cloacal "
        ],
        "rois":[
          {
            "x":210,
            "y":1568,
            "x2":755,
            "y2":1993
          },
          {
            "x":631,
            "y":1023,
            "x2":1114,
            "y2":1483
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B). Two-week-old SPF birds were vaccinated and boosted with inactivated Sham-vaccine, rZJ1*L or rZJ1*L/IFN??. Two different vaccine doses were tested and serum samples were collected before and after challenge for antibody titer determination by HI test. Pre-challenge HI titers after vaccination with an EID50/mL of 108.1 "
        ],
        "rois":[
          {
            "x":873,
            "y":8,
            "x2":1428,
            "y2":433
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) and 109.1 "
        ],
        "rois":[
          {
            "x":0,
            "y":496,
            "x2":560,
            "y2":929
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) swab samples were collected 2 and 4 dpc, viral titers were determined in 10-day-old ECEs and are expressed as EID50/mL. One week after booster vaccination, 6 birds from each vaccinated group were euthanized and the spleens were collected for the isolation of lymphocytes to be used in a proliferation assay to measure antigen-specific memory T cell response "
        ],
        "rois":[
          {
            "x":1170,
            "y":1024,
            "x2":1670,
            "y2":1484
          },
          {
            "x":631,
            "y":1023,
            "x2":1114,
            "y2":1483
          },
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          }
        ]
      },
      "HI":{
        "descriptions":[
          "(HI) antibody titers, viral shedding and cell proliferation assay results were analyzed with One-way ANOVA followed by a multiple comparisons Tukey's test. Survival curves were analyzed using the Long-Rank test. Statistical difference was considered with a P.05. Significant differences are denoted by different letters."
        ],
        "rois":[
          
        ]
      },
      "D":{
        "descriptions":[
          "(D), and post-challenge titers "
        ],
        "rois":[
          {
            "x":1177,
            "y":562,
            "x2":1665,
            "y2":909
          },
          {
            "x":611,
            "y":484,
            "x2":1188,
            "y2":922
          }
        ]
      }
    }
  },
  "3905733":{
    "Fig 1.TIF":{
      "A":{
        "descriptions":[
          "(A) Genes with significantly differential expression between young and old gingival tissues were shown as scatter plot. Blue lines represent baseline of upregulated and downregulated genes in old gingival tissues versus young gingival tissues in the range of ??? ??2 fold differences, respectively. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1488,
            "y2":1468
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Hierarchically heat map of differential expressed genes was presented for each individuals. Highly expressed genes in young or old were displayed as red, while lower expressed genes as green. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1488,
            "y2":1468
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Ingenuity Pathway Analysis (IPA) were performed among the DEGs for pathways, upstream regulators, diseases and bio functions. Top 5 ranking per each categories is shown as enrichment score (???log10 (p value)). Y, young gingival tissues; and O, old gingival tissues."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1488,
            "y2":1468
          },
          {
            "x":1489,
            "y":0,
            "x2":2106,
            "y2":1468
          }
        ]
      }
    }
  },
  "3908043":{
    
  },
  "3908094":{
    
  },
  "3913635":{
    
  },
  "391766":{
    
  },
  "3918726":{
    
  },
  "3918768":{
    "Fig 2.TIF":{
      "A":{
        "descriptions":[
          "A) The IgM and IgY containing pellet from the PEG precipitation was loaded onto a 10/30 Superdex 200HR column (GE Healthcare) and the proteins were eluted with PBS at a flow rate of 0.4 ml/min. Dual wave length absorbance monitoring, A260nm and A280nm, was used for protein detection"
        ],
        "rois":[
          {
            "x":5,
            "y":5,
            "x2":1102,
            "y2":687
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Fractions collected during the gel permeation chromatography were analysed by SDS-PAGE under non-reducing conditions, the left lane shows molecular weight marker (Precision Plus Protein Dual Color, Bio-Rad) and the subsequent lanes labelled f1-f17 represent the fractions (marked with * in the chromatogram)"
        ],
        "rois":[
          {
            "x":1185,
            "y":143,
            "x2":1884,
            "y2":593
          },
          {
            "x":5,
            "y":5,
            "x2":1102,
            "y2":687
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) The fractions (the left ???peak??? in A, corresponding to f1-f9 in B) containing IgM were pooled, concentrated using a 100 kDa centrifugal filter (Millipore), and loaded onto a 16/60 Sephacryl S-200HR column (GE Healthcare). The proteins were eluted with PBS at flow rate of 1.0 ml/min, and dual wave length absorbance monitoring, A260nm and A280nm, was used for protein detection"
        ],
        "rois":[
          {
            "x":5,
            "y":706,
            "x2":993,
            "y2":1497
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) The fractions (the second ???peak??? in A, corresponding to f10-f17 in B) containing IgY were pooled, concentrated using a 100 kDa centrifugal filter (Millipore), and loaded onto a 16/60 Sephacryl S-200HR column (GE Healthcare). The proteins were eluted with PBS at a flow rate of 1.0 ml/min, and dual wave length absorbance monitoring, A260nm and A280nm, was used for protein detection."
        ],
        "rois":[
          {
            "x":1040,
            "y":743,
            "x2":2037,
            "y2":1495
          }
        ]
      }
    }
  },
  "3918837":{
    "Fig 4.TIF":{
      "E":{
        "descriptions":[
          ". E) Immunoblots with affinity purified and HRP labelled anti-IgM. The lanes and the detection are as in D."
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2037,
            "y2":1174
          }
        ]
      },
      "A":{
        "descriptions":[
          "A) The antisera produced by immunizing rabbits with either purified IgY (Anti-IgY) or IgM (Anti-IgM) were used for immunoblotting the proteins present in the final pellet of the PEG precipitation (see lane 5 in Fig 1 for reference). The left lane in both gels shows the molecular weight marker (Precision Plus Protein Dual Color, Bio-Rad). The results were recorded using Odyssey infrared imaging system (LI-COR Biosciences)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2037,
            "y2":1174
          }
        ]
      },
      "B":{
        "descriptions":[
          ". B) Immunoblots with affinity purified anti-IgY. The left lanes show the molecular weight marker (Precision Plus Protein Dual Color, Bio-Rad), the middle lanes represent the purified IgY fraction, and the right lanes the purified IgM fraction (see Fig 3 for IgY and IgM reference). The proteins were separated on both 5% SDS-PAGE under non-reducing and 8% SDS-PAGE under reducing conditions. The results were recorded using Odyssey infrared imaging system (LI-COR Biosciences)"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2037,
            "y2":1174
          }
        ]
      },
      "C":{
        "descriptions":[
          ". C) Immunoblots with affinity purified anti-IgM. The lanes and the detection are as in B"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2037,
            "y2":1174
          }
        ]
      },
      "D":{
        "descriptions":[
          ". D) Immunoblots with affinity purified and HRP labelled anti-IgY. The left lanes represent the purified IgY fraction, and the right lanes the purified IgM fraction. The proteins were separated on both 5% SDS-PAGE under non-reducing and 8% SDS-PAGE under reducing conditions. The marker is not visible, since the results were recorded on X-ray film using enhanced chemiluminescence"
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":2037,
            "y2":1174
          }
        ]
      }
    }
  },
  "392160":{
    
  },
  "3923358":{
    "Fig 4.TIF":{
      "E":{
        "descriptions":[
          "(E) Flow cytometry analysing proliferating cells (KI67+) in CD8+CD11c+ and CD8+CD11c- T cells in the indicated groups of mice. A representative experiment of at least two independent experiments is shown, n = 3 mice per group. (F,left) Graph shows percentages of CD8+CD11c+ T cells expressing each gene and sorted from both group of untreated (119 cells) and PC61-treated (107 cells). (F,right) Graph shows percentages of CD8+CD11c+ T cells co-expressing the four genes (right). Data are obtained from two different cell-sorting "
        ],
        "rois":[
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":8,
            "y":897,
            "x2":683,
            "y2":1305
          }
        ]
      },
      "A":{
        "descriptions":[
          "(A) Representative dot plots show tumour infiltrating lymphocytes analysed by flow cytometry for cell surface CD4 and CD8? expression gated on CD3 T cells in untreated and treated tumour infiltrates (day 14). ",
          "(A) 20x magnification; scale bar: 100 ?m and "
        ],
        "rois":[
          {
            "x":4,
            "y":0,
            "x2":357,
            "y2":479
          },
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":731,
            "y":897,
            "x2":1635,
            "y2":1337
          }
        ]
      },
      "G":{
        "descriptions":[
          "(G) Frozen tumor sections obtained 14 days after tumor injection from treated and untreated mice were examined by confocal microscopy after staining with CD8? (red), CD11c (green) specific antibodies and Dapi (gray, left panels). Direct photography acquired with a 63x objective show co-staining of CD8 and CD11c antibodies on CD8 T cells. Cell surface co-expression of CD8? and CD11c (circles) and contact between CD8 T cells and dendritic cells (rectangle) are shown in white color. Data are representative of at least two independent experiments. "
        ],
        "rois":[
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":1180,
            "y":1782,
            "x2":1511,
            "y2":2111
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) Percentages of tumour infiltrating CD8 T cells in untreated (n = 4) and treated (n = 4) mice at different time points after tumour inoculation. ",
          "(B) 63x magnification; scale bar: 100 ?m. These data are representative of three independent experiments. *,p"
        ],
        "rois":[
          {
            "x":22,
            "y":470,
            "x2":674,
            "y2":855
          },
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":815,
            "y":0,
            "x2":1384,
            "y2":396
          }
        ]
      },
      "C":{
        "descriptions":[
          "(C) Representative dot plots of cell surface expression of CD8+CD11c+ gated on CD8 T cells. "
        ],
        "rois":[
          {
            "x":372,
            "y":18,
            "x2":676,
            "y2":358
          },
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":1145,
            "y":1400,
            "x2":1511,
            "y2":1780
          }
        ]
      },
      "H":{
        "descriptions":[
          "(H) The tumour vasculature was examined by confocal microscopy following staining with CD31 specific antibody. Representative tumour sections from indicated group are shown by "
        ],
        "rois":[
          {
            "x":807,
            "y":1364,
            "x2":1178,
            "y2":2111
          }
        ]
      },
      "D":{
        "descriptions":[
          "(D) Histogram shows frequencies of CD8+CD11c+ T cells in indicated groups of mice (n = 3). "
        ],
        "rois":[
          {
            "x":0,
            "y":1359,
            "x2":748,
            "y2":2107
          },
          {
            "x":815,
            "y":433,
            "x2":1385,
            "y2":863
          }
        ]
      }
    }
  },
  "392399":{
    "Figure_2.tif":{
      "A":{
        "descriptions":[
          "(A) The 586 genes (rows) were arranged using K-means clustering into six clusters shown on the left (C1 through C6). The hybridization scores shown for each gene were mean-centered and normalized to a standard deviation of one. This commonly used normalization puts each gene's fitness profile on a similar scale and facilitates comparison between the different conditions. Yellow indicates those conditions where mutants with transposons in or near the indicated gene underwent the greatest increases in abundance. Blue indicates conditions where transposons in or near the same gene were either deleterious or were slightly beneficial and resulted in a comparatively small increase in abundance. Column labels indicate the experimental condition: Bio-ND and Bio-TOB refer to transposon insertion libraries grown as biofilms and treated with no drug or tobramycin, respectively, and Pla-ND and Pla-TOB refer to libraries grown planktonically without or with tobramycin. Two biological replicates were performed in each condition and numbers indicate the repetition number. Gene names and annotations are in Dataset S3. "
        ],
        "rois":[
          {
            "x":0,
            "y":0,
            "x2":1444,
            "y2":2356
          }
        ]
      },
      "B":{
        "descriptions":[
          "(B) iPAGE was used to look for enrichment and depletion of functional categories (rows) among clusters C1 through C6 plus the set of genes not in any cluster (columns). Red (green) indicates that genes in the cluster were enriched (depleted) for the indicated category."
        ],
        "rois":[
          {
            "x":610,
            "y":427,
            "x2":1026,
            "y2":685
          },
          {
            "x":610,
            "y":686,
            "x2":1026,
            "y2":936
          },
          {
            "x":1027,
            "y":427,
            "x2":1444,
            "y2":699
          },
          {
            "x":1027,
            "y":700,
            "x2":1444,
            "y2":936
          },
          {
            "x":1029,
            "y":937,
            "x2":1444,
            "y2":1238
          },
          {
            "x":610,
            "y":937,
            "x2":1028,
            "y2":1238
          },
          {
            "x":610,
            "y":1239,
            "x2":1444,
            "y2":1517
          },
          {
            "x":610,
            "y":1518,
            "x2":1444,
            "y2":1863
          },
          {
            "x":1445,
            "y":0,
            "x2":4011,
            "y2":2356
          },
          {
            "x":610,
            "y":1864,
            "x2":1444,
            "y2":2356
          }
        ]
      }
    }
  }
}
